No O
drug O
, O
nutritional O
supplement O
, O
food O
or O
herb O
interactions O
have O
yet O
been O
reported O
. O

No O
formal O
drug O
/ O
drug O
interaction O
studies O
with O
Plenaxis B-BRAND
were O
performed O
. O
Cytochrome O
P O
- O
450 O
is O
not O
known O
to O
be O
involved O
in O
the O
metabolism O
of O
Plenaxis B-BRAND
. O
Plenaxis B-BRAND
is O
highly O
bound O
to O
plasma O
proteins O
( O
96 O
to O
99 O
% O
) O
. O
Laboratory O
Tests O
Response O
to O
Plenaxis B-BRAND
should O
be O
monitored O
by O
measuring O
serum O
total O
testosterone B-DRUG
concentrations O
just O
prior O
to O
administration O
on O
Day O
29 O
and O
every O
8 O
weeks O
thereafter O
. O
Serum O
transaminase O
levels O
should O
be O
obtained O
before O
starting O
treatment O
with O
Plenaxis B-BRAND
and O
periodically O
during O
treatment O
. O
Periodic O
measurement O
of O
serum O
PSA O
levels O
may O
also O
be O
considered O
. O

Formal O
drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
ORENCIA B-BRAND
. O
Population O
pharmacokinetic O
analyses O
revealed O
that O
MTX B-DRUG
, O
NSAIDs B-GROUP
, O
corticosteroids B-GROUP
, O
and O
TNF B-GROUP
blocking I-GROUP
agents I-GROUP
did O
not O
influence O
abatacept B-DRUG
clearance O
. O
The O
majority O
of O
patients O
in O
RA O
clinical O
studies O
received O
one O
or O
more O
of O
the O
following O
concomitant O
medications O
with O
ORENCIA B-BRAND
: O
MTX B-DRUG
, O
NSAIDs B-GROUP
, O
corticosteroids B-GROUP
, O
TNF B-GROUP
blocking I-GROUP
agents I-GROUP
, O
azathioprine B-DRUG
, O
chloroquine B-DRUG
, O
gold B-DRUG
, O
hydroxychloroquine B-DRUG
, O
leflunomide B-DRUG
, O
sulfasalazine B-DRUG
, O
and O
anakinra B-DRUG
. O
Concurrent O
administration O
of O
a O
TNF B-GROUP
antagonist I-GROUP
with O
ORENCIA B-BRAND
has O
been O
associated O
with O
an O
increased O
risk O
of O
serious O
infections O
and O
no O
significant O
additional O
efficacy O
over O
use O
of O
the O
TNF B-GROUP
antagonists I-GROUP
alone O
. O
Concurrent O
therapy O
with O
ORENCIA B-BRAND
and O
TNF B-GROUP
antagonists I-GROUP
is O
not O
recommended O
. O
There O
is O
insufficient O
experience O
to O
assess O
the O
safety O
and O
efficacy O
of O
ORENCIA B-BRAND
administered O
concurrently O
with O
anakinra B-DRUG
, O
and O
therefore O
such O
use O
is O
not O
recommended O
. O

Formal O
drug O
interaction O
studies O
with O
Abciximab B-DRUG
have O
not O
been O
conducted O
. O
Abciximab B-DRUG
has O
been O
administered O
to O
patients O
with O
ischemic O
heart O
disease O
treated O
concomitantly O
with O
a O
broad O
range O
of O
medications O
used O
in O
the O
treatment O
of O
angina O
myocardial O
infarction O
and O
hypertension O
. O
These O
medications O
have O
included O
heparin B-DRUG
, O
warfarin B-DRUG
, O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
receptor I-GROUP
blockers I-GROUP
, O
calcium B-GROUP
channel I-GROUP
antagonists I-GROUP
, O
angiotensin B-GROUP
converting I-GROUP
enzyme I-GROUP
inhibitors I-GROUP
, O
intravenous O
and O
oral O
nitrates B-GROUP
, O
ticlopidine B-DRUG
, O
and O
aspirin B-BRAND
. O
Heparin B-DRUG
, O
other O
anticoagulants B-GROUP
, O
thrombolytics B-GROUP
, O
and O
anti B-GROUP
platelet I-GROUP
agents I-GROUP
are O
associated O
with O
an O
increase O
in O
bleeding O
. O
Patients O
with O
HACA O
titers O
may O
have O
allergic O
or O
hypersensitivity O
reactions O
when O
treated O
with O
other O
diagnostic B-GROUP
or I-GROUP
therapeutic I-GROUP
monoclonal I-GROUP
antibodies I-GROUP
. O

The O
concomitant O
intake O
of O
alcohol B-DRUG
and O
Acamprosate B-DRUG
does O
not O
affect O
the O
pharmacokinetics O
of O
either O
alcohol B-DRUG
or O
acamprosate B-DRUG
. O
Pharmacokinetic O
studies O
indicate O
that O
administration O
of O
disulfiram B-DRUG
or O
diazepam B-DRUG
does O
not O
affect O
the O
pharmacokinetics O
of O
acamprosate B-DRUG
. O
Co O
- O
administration O
of O
naltrexone B-DRUG
with O
Acamprosate B-DRUG
produced O
a O
25 O
% O
increase O
in O
AUC O
and O
a O
33 O
% O
increase O
in O
the O
Cmax O
of O
acamprosate B-DRUG
. O
No O
adjustment O
of O
dosage O
is O
recommended O
in O
such O
patients O
. O
The O
pharmacokinetics O
of O
naltrexone B-DRUG
and O
its O
major O
metabolite O
6 B-DRUG_N
- I-DRUG_N
beta I-DRUG_N
- I-DRUG_N
naltrexol I-DRUG_N
were O
unaffected O
following O
co O
- O
administration O
with O
Acamprosate B-DRUG
. O
Other O
concomitant O
therapies O
: O
In O
clinical O
trials O
, O
the O
safety O
profile O
in O
subjects O
treated O
with O
Acamprosate B-DRUG
concomitantly O
with O
anxiolytics B-GROUP
, O
hypnotics B-GROUP
and O
sedatives B-GROUP
( O
including O
benzodiazepines B-GROUP
) O
, O
or O
non B-GROUP
- I-GROUP
opioid I-GROUP
analgesics I-GROUP
was O
similar O
to O
that O
of O
subjects O
taking O
placebo O
with O
these O
concomitant O
medications O
. O
Patients O
taking O
Acamprosate B-DRUG
concomitantly O
with O
antidepressants B-GROUP
more O
commonly O
reported O
both O
weight O
gain O
and O
weight O
loss O
, O
compared O
with O
patients O
taking O
either O
medication O
alone O
. O

Certain O
drugs O
tend O
to O
produce O
hyperglycemia O
and O
may O
lead O
to O
loss O
of O
blood O
glucose O
control O
. O
These O
drugs O
include O
the O
thiazides B-GROUP
and O
other O
diuretics B-GROUP
, O
corticosteroids B-GROUP
, O
phenothiazines B-GROUP
, O
thyroid B-GROUP
products I-GROUP
, O
estrogens B-GROUP
, O
oral O
contraceptives B-GROUP
, O
phenytoin B-DRUG
, O
nicotinic B-DRUG
acid I-DRUG
, O
sympathomimetics B-GROUP
, O
calcium B-GROUP
channel I-GROUP
- I-GROUP
blocking I-GROUP
drugs I-GROUP
, O
and O
isoniazid B-DRUG
. O
When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
Acarbose B-DRUG
, O
the O
patient O
should O
be O
closely O
observed O
for O
loss O
of O
blood O
glucose O
control O
. O
When O
such O
drugs O
are O
withdrawn O
from O
patients O
receiving O
Acarbose B-DRUG
in O
combination O
with O
sulfonylureas B-GROUP
or O
insulin B-DRUG
, O
patients O
should O
be O
observed O
closely O
for O
any O
evidence O
of O
hypoglycemia O
. O
Intestinal B-GROUP
adsorbents I-GROUP
( O
e O
. O
g O
. O
, O
charcoal B-DRUG
) O
and O
digestive B-GROUP
enzyme I-GROUP
preparations I-GROUP
containing O
carbohydrate O
- O
splitting O
enzymes O
( O
e O
. O
g O
. O
, O
amylase B-DRUG
, O
pancreatin B-DRUG
) O
may O
reduce O
the O
effect O
of O
Acarbose B-DRUG
and O
should O
not O
be O
taken O
concomitantly O
. O
Acarbose B-DRUG
has O
been O
shown O
to O
change O
the O
bioavailabillty O
digoxin B-DRUG
when O
they O
are O
co O
- O
administered O
, O
which O
may O
require O
digoxin B-DRUG
dose O
adjustment O
. O
Studies O
in O
healthy O
volunteers O
have O
shown O
that O
Acarbose B-DRUG
has O
no O
effect O
on O
either O
the O
pharmacokinetics O
or O
pharmacodynamics O
of O
digoxin B-DRUG
, O
nifedipine B-DRUG
, O
propranolol B-DRUG
, O
or O
ranitidine B-DRUG
. O
Acarbose B-DRUG
did O
not O
interfere O
with O
the O
absorption O
or O
disposition O
of O
the O
sulfonylurea B-DRUG
glyburide B-DRUG
in O
diabetic O
patients O
. O
Acarbose B-DRUG
may O
affect O
digoxin B-DRUG
bioavailabillty O
and O
may O
require O
dose O
adjustment O
of O
digoxin B-DRUG
by O
16 O
% O
( O
90 O
% O
confidence O
interval O
: O
8 O
- O
23 O
% O
) O
, O
decrease O
mean O
C O
max O
digoxin B-DRUG
by O
26 O
% O
( O
90 O
% O
confidence O
interval O
: O
16 O
- O
34 O
% O
) O
and O
decrease O
mean O
trough O
concentrations O
of O
digoxin B-DRUG
by O
9 O
% O
( O
90 O
% O
confidence O
limit O
: O
19 O
% O
decrease O
to O
2 O
% O
increase O
) O
. O
The O
amount O
of O
metformin B-DRUG
absorbed O
while O
taking O
Acarbose B-DRUG
was O
bioequivalent O
to O
the O
amount O
absorbed O
when O
taking O
placebo O
, O
as O
indicated O
by O
the O
plasma O
AUC O
values O
. O
However O
, O
the O
peak O
plasma O
level O
of O
metformin B-DRUG
was O
reduced O
by O
approximately O
20 O
% O
when O
taking O
Acarbose B-DRUG
due O
to O
a O
slight O
delay O
in O
the O
absorption O
of O
metformin B-DRUG
. O
There O
is O
little O
if O
any O
clinically O
significant O
interaction O
between O
Acarbose B-DRUG
and O

metformin B-DRUG
. O

Catecholamine B-GROUP
- I-GROUP
depleting I-GROUP
drugs I-GROUP
, O
such O
as O
reserpine B-DRUG
, O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
. O
Patients O
treated O
with O
acebutolol B-DRUG
plus O
catecholamine B-GROUP
depletors I-GROUP
should O
, O
therefore O
, O
be O
observed O
closely O
for O
evidence O
of O
marked O
bradycardia O
or O
hypotension O
which O
may O
present O
as O
vertigo O
, O
syncope O
/ O
presyncope O
, O
or O
orthostatic O
changes O
in O
blood O
pressure O
without O
compensatory O
tachycardia O
. O
Exaggerated O
hypertensive O
responses O
have O
been O
reported O
from O
the O
combined O
use O
of O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
antagonists I-GROUP
and O
alpha B-GROUP
- I-GROUP
adrenergic I-GROUP
stimulants I-GROUP
, O
including O
those O
contained O
in O
proprietary O
cold O
remedies O
and O
vasoconstrictive O
nasal O
drops O
. O
Patients O
receiving O
beta B-GROUP
- I-GROUP
blockers I-GROUP
should O
be O
warned O
of O
this O
potential O
hazard O
. O
Blunting O
of O
the O
antihypertensive O
effect O
of O
beta B-GROUP
- I-GROUP
adrenoceptor I-GROUP
blocking I-GROUP
agents I-GROUP
by O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
has O
been O
reported O
. O
No O
significant O
interactions O
with O
digoxin B-DRUG
, O
hydrochlorothiazide B-DRUG
, O
hydralazine B-DRUG
, O
sulfinpyrazone B-DRUG
, O
oral O
contraceptives B-GROUP
, O
tolbutamide B-DRUG
, O
or O
warfarin B-DRUG
have O
been O
observed O
. O

DIAMOX B-BRAND
modifies O
phenytoin B-DRUG
metabolism O
with O
increased O
serum O
levels O
of O
phenytoin B-DRUG
. O
This O
may O
increase O
or O
enhance O
the O
occurrence O
of O
osteomalacia O
in O
some O
patients O
receiving O
chronic O
phenytoin B-DRUG
therapy O
. O
Caution O
is O
advised O
in O
patients O
receiving O
chronic O
concomitant O
therapy O
. O
By O
decreasing O
the O
gastrointestinal O
absorption O
of O
primidone B-DRUG
, O
DIAMOX B-BRAND
may O
decrease O
serum O
concentrations O
of O
primidone B-DRUG
and O
its O
metabolites O
, O
with O
a O
consequent O
possible O
decrease O
in O
anticonvulsant O
effect O
. O
Caution O
is O
advised O
when O
beginning O
, O
discontinuing O
, O
or O
changing O
the O
dose O
of O
DIAMOX B-BRAND
in O
patients O
receiving O
primidone B-DRUG
. O
Because O
of O
possible O
additive O
effects O
with O
other O
carbonic B-GROUP
anhydrase I-GROUP
inhibitors I-GROUP
, O
concomitant O
use O
is O
not O
advisable O
. O
Acetazolamide B-DRUG
may O
increase O
the O
effects O
of O
other O
folic B-GROUP
acid I-GROUP
antagonists I-GROUP
. O
Acetazolamide B-DRUG
may O
increase O
or O
decrease O
blood O
glucose O
levels O
. O
Consideration O
should O
be O
taken O
in O
patients O
being O
treated O
with O
antidiabetic B-DRUG
agents O
. O
Acetazolamide B-DRUG
decreases O
urinary O
excretion O
of O
amphetamine B-DRUG
and O
may O
enhance O
the O
magnitude O
and O
duration O
of O
their O
effect O
. O
Acetazolamide B-DRUG
reduces O
urinary O
excretion O
of O
quinidine B-DRUG
and O
may O
enhance O
its O
effect O
. O
Acetazolamide B-DRUG
may O
prevent O
the O
urinary O
antiseptic O
effect O
of O
methenamine B-DRUG
. O
Acetazolamide B-DRUG
increases O
lithium B-DRUG
excretion O
and O
the O
lithium B-DRUG
may O
be O
decreased O
. O
Acetazolamide B-DRUG
and O
sodium B-DRUG
bicarbonate I-DRUG
used O
concurrently O
increases O
the O
risk O
of O
renal O
calculus O
formation O
. O
Acetazolamide B-DRUG
may O
elevate O
cyclosporine B-DRUG
levels O
. O

Concomitant O
use O
with O
iron B-GROUP
supplements I-GROUP
may O
result O
in O
the O
reduced O
absorption O
of O
iron B-DRUG
. O

Co O
- O
administration O
of O
probenecid B-DRUG
with O
acyclovir B-DRUG
has O
been O
shown O
to O
increase O
the O
mean O
half O
- O
life O
and O
the O
area O
under O
the O
concentration O
- O
time O
curve O
. O
Urinary O
excretion O
and O
renal O
clearance O
were O
correspondingly O
reduced O
. O
The O
clinical O
effects O
of O
this O
combination O
have O
not O
been O
studied O
. O

Ethanol B-DRUG
: O
Clinical O
evidence O
has O
shown O
that O
etretinate B-DRUG
can O
be O
formed O
with O
concurrent O
ingestion O
of O
acitretin B-DRUG
and O
ethanol B-DRUG
. O
Glibenclamide B-DRUG
: O
In O
a O
study O
of O
7 O
healthy O
male O
volunteers O
, O
acitretin B-DRUG
treatment O
potentiated O
the O
blood O
glucose O
lowering O
effect O
of O
glibenclamide B-DRUG
( O
a O
sulfonylurea B-GROUP
similar O
to O
chlorpropamide B-DRUG
) O
in O
3 O
of O
the O
7 O
subjects O
. O
Repeating O
the O
study O
with O
6 O
healthy O
male O
volunteers O
in O
the O
absence O
of O
glibenclamide B-DRUG
did O
not O
detect O
an O
effect O
of O
acitretin B-DRUG
on O
glucose O
tolerance O
. O
Careful O
supervision O
of O
diabetic O
patients O
under O
treatment O
with O
Soriatane B-BRAND
is O
recommended O
. O
Hormonal B-GROUP
Contraceptives I-GROUP
: O
It O
has O
not O
been O
established O
if O
there O
is O
a O
pharmacokinetic O
interaction O
between O
acitretin B-DRUG
and O
combined B-GROUP
oral I-GROUP
contraceptives I-GROUP
. O
However O
, O
it O
has O
been O
established O
that O
acitretin B-DRUG
interferes O
with O
the O
contraceptive O
effect O
of O
microdosed O
progestin B-DRUG
minipill O
preparations O
. O
Microdosed O
minipill O
progestin B-DRUG
preparations O
are O
not O
recommended O
for O
use O
with O
Soriatane B-DRUG
. O
It O
is O
not O
known O
whether O
other O
progestational B-GROUP
contraceptives I-GROUP
, O
such O
as O
implants O
and O
injectables O
, O
are O
adequate O
methods O
of O
contraception O
during O
acitretin B-DRUG
therapy O
. O
Methotrexate B-DRUG
: O
An O
increased O
risk O
of O
hepatitis O
has O
been O
reported O
to O
result O
from O
combined O
use O
of O
methotrexate B-DRUG
and O
etretinate B-DRUG
. O
Consequently O
, O
the O
combination O
of O
methotrexate B-DRUG
with O
acitretin B-DRUG
is O
also O
contraindicated O
. O
Phenytoin B-DRUG
: O
If O
acitretin B-DRUG
is O
given O
concurrently O
with O
phenytoin B-DRUG
, O
the O
protein O
binding O
of O
phenytoin B-DRUG
may O
be O
reduced O
. O
Tetracyclines B-GROUP
: O
Since O
both O
acitretin B-DRUG
and O
tetracyclines B-GROUP
can O
cause O
increased O
intracranial O
pressure O
, O
their O
combined O
use O
is O
contraindicated O
. O
Vitamin B-GROUP
A I-GROUP
and O
oral O
retinoids B-GROUP
: O
Concomitant O
administration O
of O
vitamin B-GROUP
A I-GROUP
and O
/ O
or O
other O
oral O
retinoids B-GROUP
with O
acitretin B-DRUG
must O
be O
avoided O
because O
of O
the O
risk O
of O
hypervitaminosis O
A O
. O
Other O
: O
There O
appears O
to O
be O
no O
pharmacokinetic O
interaction O
between O
acitretin B-DRUG
and O
cimetidine B-DRUG
, O
digoxin B-DRUG
, O
or O
glyburide B-DRUG
. O
Investigations O
into O
the O
effect O
of O
acitretin B-DRUG
on O
the O
protein O
binding O
of O
anticoagulants B-GROUP
of I-GROUP
the I-GROUP
coumarin I-GROUP
type I-GROUP
( O
warfarin B-DRUG
) O
revealed O
no O
interaction O
. O
Laboratory O
Tests O
If O
significant O

abnormal O
laboratory O
results O
are O
obtained O
, O
either O
dosage O
reduction O
with O
careful O
monitoring O
or O
treatment O
discontinuation O
is O
recommended O
, O
depending O
on O
clinical O
judgement O
. O
Blood O
Sugar O
: O
Some O
patients O
receiving O
retinoids B-GROUP
have O
experienced O
problems O
with O
blood O
sugar O
control O
. O
In O
addition O
, O
new O
cases O
of O
diabetes O
have O
been O
diagnosed O
during O
retinoid B-GROUP
therapy O
, O
including O
diabetic O
ketoacidosis O
. O
In O
diabetics O
, O
blood O
- O
sugar O
levels O
should O
be O
monitored O
very O
carefully O
. O
Lipids O
: O
In O
clinical O
studies O
, O
the O
incidence O
of O
hypertriglyceridemia O
was O
66 O
% O
, O
hypercholesterolemia O
was O
33 O
% O
and O
that O
of O
decreased O
HDL O
was O
40 O
% O
. O
Pretreatment O
and O
follow O
- O
up O
measurements O
should O
be O
obtained O
under O
fasting O
conditions O
. O
It O
is O
recommended O
that O
these O
tests O
be O
performed O
weekly O
or O
every O
other O
week O
until O
the O
lipid O
response O
to O
Soriatane B-BRAND
has O
stabilized O
. O
Liver O
Function O
Tests O
: O
Elevations O
of O
AST O
( O
SGOT O
) O
, O
ALT O
( O
SGPT O
) O
or O
LDH O
were O
experienced O
by O
approximately O
1 O
in O
3 O
patients O
treated O
with O
Soriatane B-BRAND
. O
It O
is O
recommended O
that O
these O
tests O
be O
performed O
prior O
to O
initiation O
of O
Soriatane B-BRAND
therapy O
, O
at O
1 O
- O
to O
2 O
- O
week O
intervals O
until O
stable O
and O
thereafter O
at O
intervals O
as O
clinically O
indicated O
. O

Methotrexate B-DRUG
: O
HUMIRA B-BRAND
has O
been O
studied O
in O
rheumatoid O
arthritis O
patients O
taking O
concomitant O
MTX B-DRUG
. O
The O
data O
do O
not O
suggest O
the O
need O
for O
dose O
adjustment O
of O
either O
HUMIRA B-BRAND
or O
MTX B-DRUG
. O
Anakinra B-DRUG
: O
Concurrent O
administration O
of O
anakinra B-DRUG
( O
an O
interleukin B-GROUP
- I-GROUP
1 I-GROUP
antagonist I-GROUP
) O
and O
another O
TNF B-GROUP
- I-GROUP
blocking I-GROUP
agent I-GROUP
has O
been O
associated O
with O
an O
increased O
risk O
of O
serious O
infections O
, O
an O
increased O
risk O
of O
neutropenia O
and O
no O
additional O
benefit O
compared O
to O
these O
medicinal O
products O
alone O
. O
The O
safety O
and O
efficacy O
of O
anakinra B-DRUG
used O
in O
combination O
with O
HUMIRA B-BRAND
has O
not O
been O
studied O
. O
Therefore O
the O
, O
combination O
of O
anakinra B-DRUG
with O
other O
TNF B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
, O
including O
HUMIRA B-BRAND
, O
may O
also O
result O
i O
n O
similar O
toxicities O
. O

As O
DIFFERIN B-BRAND
Gel O
has O
the O
potential O
to O
produce O
local O
irritation O
in O
some O
patients O
, O
concomitant O
use O
of O
other O
potentially O
irritating O
topical O
products O
( O
medicated O
or O
abrasive O
soaps O
and O
cleansers O
, O
soaps O
and O
cosmetics O
that O
have O
a O
strong O
drying O
effect O
, O
and O
products O
with O
high O
concentrations O
of O
alcohol O
, O
astringents O
, O
spices O
or O
lime O
) O
should O
be O
approached O
with O
caution O
. O
Particular O
caution O
should O
be O
exercised O
in O
using O
preparations O
containing O
sulfur B-DRUG
, O
resorcinol B-DRUG
, O
or O
salicylic B-DRUG
acid I-DRUG
in O
combination O
with O
DIFFERIN B-BRAND
Gel O
. O
If O
these O
preparations O
have O
been O
used O
it O
is O
advisable O
not O
to O
start O
therapy O
with O
DIFFERIN B-BRAND
Gel O
until O
the O
effects O
of O
such O
preparations O
in O
the O
skin O
have O
subsided O
. O

Before O
using O
this O
medication O
, O
tell O
your O
doctor O
or O
pharmacist O
of O
all O
prescription O
and O
nonprescription O
products O
you O
may O
use O
, O
especially O
of O
: O
aminoglycosides B-GROUP
( O
e O
. O
g O
. O
, O
gentamicin B-DRUG
, O
amikacin B-DRUG
) O
, O
amphotericin B-DRUG
B I-DRUG
, O
cyclosporine B-DRUG
, O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs O
( O
e O
. O
g O
. O
, O
ibuprofen B-DRUG
) O
, O
tacrolimus B-DRUG
, O
vancomycin B-DRUG
. O
Do O
not O
start O
or O
stop O
any O
medicine O
without O
doctor O
or O
pharmacist O
approval O
. O

Intravenous O
Adenocard B-BRAND
( O
adenosine B-DRUG
) O
has O
been O
effectively O
administered O
in O
the O
presence O
of O
other O
cardioactive O
drugs O
, O
such O
as O
quinidine B-DRUG
, O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
, O
calcium B-GROUP
channel I-GROUP
blocking I-GROUP
agents I-GROUP
, O
and O
angiotensin B-GROUP
converting I-GROUP
enzyme I-GROUP
inhibitors I-GROUP
, O
without O
any O
change O
in O
the O
adverse O
reaction O
profile O
. O
Digoxin B-DRUG
and O
verapamil B-DRUG
use O
may O
be O
rarely O
associated O
with O
ventricular O
fibrillation O
when O
combined O
with O
Adenocard B-BRAND
. O
Because O
of O
the O
potential O
for O
additive O
or O
synergistic O
depressant O
effects O
on O
the O
SA O
and O
AV O
nodes O
, O
however O
, O
Adenocard B-BRAND
should O
be O
used O
with O
caution O
in O
the O
presence O
of O
these O
agents O
. O
The O
use O
of O
Adenocard B-BRAND
in O
patients O
receiving O
digitalis B-GROUP
may O
be O
rarely O
associated O
with O
ventricular O
fibrillation O
. O
The O
effects O
of O
adenosine B-DRUG
are O
antagonized O
by O
methylxanthines B-GROUP
such O
as O
caffeine B-DRUG
and O
theophylline B-DRUG
. O
In O
the O
presence O
of O
these O
methylxanthines B-GROUP
, O
larger O
doses O
of O
adenosine B-DRUG
may O
be O
required O
or O
adenosine B-DRUG
may O
not O
be O
effective O
. O
Adenosine B-DRUG
effects O
are O
potentiated O
by O
dipyridamole B-DRUG
. O
Thus O
, O
smaller O
doses O
of O
adenosine B-DRUG
may O
be O
effective O
in O
the O
presence O
of O
dipyridamole B-DRUG
. O
Carbamazepine B-DRUG
has O
been O
reported O
to O
increase O
the O
degree O
of O
heart O
block O
produced O
by O
other O
agents O
. O
As O
the O
primary O
effect O
of O
adenosine B-DRUG
is O
to O
decrease O
conduction O
through O
the O
A O
- O
V O
node O
, O
higher O
degrees O
of O
heart O
block O
may O
be O
produced O
in O
the O
presence O
of O
carbamazepine B-DRUG
. O

Co O
- O
administration O
with O
antifungal B-GROUP
agents I-GROUP
such O
as O
ketoconazole B-DRUG
or O
itraconazole B-DRUG
is O
not O
recommended O
. O
Nafazodone B-DRUG
, O
fluvoxamine B-DRUG
, O
cimetidine B-DRUG
( O
consider O
Xanax B-BRAND
dose O
reduction O
) O
. O
Fluoxetine B-DRUG
, O
OCs B-GROUP
, O
sertraline B-DRUG
, O
diltiazem B-DRUG
, O
macrolide B-GROUP
antibiotics I-GROUP
( O
exercise O
caution O
) O
. O

No O
drug O
interaction O
studies O
were O
performed O
. O
No O
in O
vitro O
metabolism O
studies O
were O
performed O
. O

Dexamethasone B-DRUG
: O
Steady O
- O
state O
trough O
concentrations O
of O
albendazole B-DRUG
sulfoxide I-DRUG
were O
about O
56 O
% O
higher O
when O
8 O
mg O
dexamethasone B-DRUG
was O
coadministered O
with O
each O
dose O
of O
albendazole B-DRUG
( O
15 O
mg O
/ O
kg O
/ O
day O
) O
in O
eight O
neurocysticercosis O
patients O
. O
Praziquantel B-DRUG
: O
In O
the O
fed O
state O
, O
praziquantel B-DRUG
( O
40 O
mg O
/ O
kg O
) O
increased O
mean O
maximum O
plasma O
concentration O
and O
area O
under O
the O
curve O
of O
albendazole B-DRUG
sulfoxide I-DRUG
by O
about O
50 O
% O
in O
healthy O
subjects O
( O
n O
= O
10 O
) O
compared O
with O
a O
separate O
group O
of O
subjects O
( O
n O
= O
6 O
) O
given O
albendazole B-DRUG
alone O
. O
Mean O
T O
max O
and O
mean O
plasma O
elimination O
half O
- O
life O
of O
albendazole B-DRUG
sulfoxide I-DRUG
were O
unchanged O
. O
The O
pharmacokinetics O
of O
praziquantel B-DRUG
were O
unchanged O
following O
coadministration O
with O
albendazole B-DRUG
( O
400 O
mg O
) O
. O
Cimetidine B-DRUG
: O
Albendazole B-DRUG
sulfoxide I-DRUG
concentrations O
in O
bile O
and O
cystic O
fluid O
were O
increased O
( O
about O
2 O
- O
fold O
) O
in O
hydatid O
cyst O
patients O
treated O
with O
cimetidine B-DRUG
( O
10 O
mg O
/ O
kg O
/ O
day O
) O
( O
n O
= O
7 O
) O
compared O
with O
albendazole B-DRUG
( O
20 O
mg O
/ O
kg O
/ O
day O
) O
alone O
( O
n O
= O
12 O
) O
. O
Albendazole B-DRUG
sulfoxide I-DRUG
plasma O
concentrations O
were O
unchanged O
4 O
hours O
after O
dosing O
. O
Theophylline B-DRUG
: O
The O
pharmacokinetics O
of O
theophylline B-DRUG
( O
aminophylline B-DRUG
5 O
. O
8 O
mg O
/ O
kg O
infused O
over O
20 O
minutes O
) O
were O
unchanged O
following O
a O
single O
oral O
dose O
of O
albendazole B-DRUG
( O
400 O
mg O
) O
in O
6 O
healthy O
subjects O
. O

No O
information O
provided O

PROLEUKIN B-BRAND
may O
affect O
central O
nervous O
function O
. O
Therefore O
, O
interactions O
could O
occur O
following O
concomitant O
administration O
of O
psychotropic B-GROUP
drugs I-GROUP
( O
e O
. O
g O
. O
, O
narcotics B-GROUP
, O
analgesics B-GROUP
, O
antiemetics B-GROUP
, O
sedatives B-GROUP
, O
tranquilizers B-GROUP
) O
. O
Concurrent O
administration O
of O
drugs O
possessing O
nephrotoxic O
( O
e O
. O
g O
. O
, O
aminoglycosides B-GROUP
, O
indomethacin B-DRUG
) O
, O
myelotoxic O
( O
e O
. O
g O
. O
, O
cytotoxic B-GROUP
chemotherapy O
) O
, O
cardiotoxic O
( O
e O
. O
g O
. O
, O
doxorubicin B-DRUG
) O
or O
hepatotoxic O
( O
e O
. O
g O
. O
, O
methotrexate B-DRUG
, O
asparaginase B-DRUG
) O
effects O
with O
PROLEUKIN B-BRAND
may O
increase O
toxicity O
in O
these O
organ O
systems O
. O
The O
safety O
and O
efficacy O
of O
PROLEUKIN B-BRAND
in O
combination O
with O
any O
antineoplastic B-GROUP
agents I-GROUP
have O
not O
been O
established O
. O
In O
addition O
, O
reduced O
kidney O
and O
liver O
function O
secondary O
to O
PROLEUKIN B-BRAND
treatment O
may O
delay O
elimination O
of O
concomitant O
medications O
and O
increase O
the O
risk O
of O
adverse O
events O
from O
those O
drugs O
. O
Hypersensitivity O
reactions O
have O
been O
reported O
in O
patients O
receiving O
combination O
regimens O
containing O
sequential O
high O
dose O
PROLEUKIN B-BRAND
and O
antineoplastic B-GROUP
agents I-GROUP
, O
specifically O
, O
dacarbazine B-DRUG
, O
cis B-DRUG
- I-DRUG
platinum I-DRUG
, O
tamoxifen B-DRUG
and O
interferon B-DRUG
- I-DRUG
alfa I-DRUG
. O
These O
reactions O
consisted O
of O
erythema O
, O
pruritus O
, O
and O
hypotension O
and O
occurred O
within O
hours O
of O
administration O
of O
chemotherapy O
. O
These O
events O
required O
medical O
intervention O
in O
some O
patients O
. O
Myocardial O
injury O
, O
including O
myocardial O
infarction O
, O
myocarditis O
, O
ventricular O
hypokinesia O
, O
and O
severe O
rhabdomyolysis O
appear O
to O
be O
increased O
in O
patients O
receiving O
PROLEUKIN B-BRAND
and O
interferon B-DRUG
- I-DRUG
alfa I-DRUG
concurrently O
. O
Exacerbation O
or O
the O
initial O
presentation O
of O
a O
number O
of O
autoimmune O
and O
inflammatory O
disorders O
has O
been O
observed O
following O
concurrent O
use O
of O
interferon B-DRUG
- I-DRUG
alfa I-DRUG
and O
PROLEUKIN B-BRAND
, O
including O
crescentic O
IgA O
glomerulonephritis O
, O
oculo O
- O
bulbar O
myasthenia O
gravis O
, O
inflammatory O
arthritis O
, O
thyroiditis O
, O
bullous O
pemphigoid O
, O
and O
Stevens O
- O
Johnson O
syndrome O
. O
Although O
glucocorticoids B-GROUP
have O
been O
shown O
to O
reduce O
PROLEUKIN B-BRAND
- O
induced O
side O
effects O
including O
fever O
, O
renal O
insufficiency O
, O

hyperbilirubinemia O
, O
confusion O
, O
and O
dyspnea O
, O
concomitant O
administration O
of O
these O
agents O
with O
PROLEUKIN B-BRAND
may O
reduce O
the O
antitumor O
effectiveness O
of O
PROLEUKIN B-BRAND
and O
thus O
should O
be O
avoided O
. O
12 O
Beta B-GROUP
- I-GROUP
blockers I-GROUP
and O
other O
antihypertensives B-GROUP
may O
potentiate O
the O
hypotension O
seen O
with O
PROLEUKIN B-BRAND
. O
Delayed O
Adverse O
Reactions O
to O
Iodinated B-GROUP
Contrast I-GROUP
Media I-GROUP
: O
A O
review O
of O
the O
literature O
revealed O
that O
12 O
. O
6 O
% O
( O
range O
11 O
- O
28 O
% O
) O
of O
501 O
patients O
treated O
with O
various O
interleukin B-DRUG
- I-DRUG
2 I-DRUG
containing O
regimens O
who O
were O
subsequently O
administered O
radiographic B-GROUP
iodinated I-GROUP
contrast I-GROUP
media I-GROUP
experienced O
acute O
, O
atypical O
adverse O
reactions O
. O
The O
onset O
of O
symptoms O
usually O
occurred O
within O
hours O
( O
most O
commonly O
1 O
to O
4 O
hours O
) O
following O
the O
administration O
of O
contrast O
media O
. O
These O
reactions O
include O
fever O
, O
chills O
, O
nausea O
, O
vomiting O
, O
pruritus O
, O
rash O
, O
diarrhea O
, O
hypotension O
, O
edema O
, O
and O
oliguria O
. O
Some O
clinicians O
have O
noted O
that O
these O
reactions O
resemble O
the O
immediate O
side O
effects O
caused O
by O
interleukin B-DRUG
- I-DRUG
2 I-DRUG
administration O
, O
however O
the O
cause O
of O
contrast O
reactions O
after O
interleukin O
- O
2 O
therapy O
is O
unknown O
. O
Most O
events O
were O
reported O
to O
occur O
when O
contrast O
media O
was O
given O
within O
4 O
weeks O
after O
the O
last O
dose O
of O
interleukin B-DRUG
- I-DRUG
2 I-DRUG
. O
These O
events O
were O
also O
reported O
to O
occur O
when O
contrast O
media O
was O
given O
several O
months O
after O
interleukin B-DRUG
- I-DRUG
2 I-DRUG
treatment O
. O

No O
formal O
interaction O
studies O
have O
been O
performed O
. O
The O
duration O
of O
the O
period O
following O
treatment O
with O
AMEVIVE B-BRAND
before O
one O
should O
consider O
starting O
other O
immunosuppressive B-GROUP
therapy O
has O
not O
been O
evaluated O
. O
Carcinogenesis O
, O
Mutagenesis O
, O
and O
Fertility O
In O
a O
chronic O
toxicity O
study O
, O
cynomolgus O
monkeys O
were O
dosed O
weekly O
for O
52 O
weeks O
with O
intravenous O
alefacept B-DRUG
at O
1 O
mg O
/ O
kg O
/ O
dose O
or O
20 O
mg O
/ O
kg O
/ O
dose O
. O
One O
animal O
in O
the O
high O
dose O
group O
developed O
a O
B O
- O
cell O
lymphoma O
that O
was O
detected O
after O
28 O
weeks O
of O
dosing O
. O
Additional O
animals O
in O
both O
dose O
groups O
developed O
B O
- O
cell O
hyperplasia O
of O
the O
spleen O
and O
lymph O
nodes O
. O
All O
animals O
in O
the O
study O
were O
positive O
for O
an O
endemic O
primate O
gammaherpes O
virus O
also O
known O
as O
lymphocryptovirus O
( O
LCV O
) O
. O
Latent O
LCV O
infection O
is O
generally O
asymptomatic O
, O
but O
can O
lead O
to O
B O
- O
cell O
lymphomas O
when O
animals O
are O
immune O
suppressed O
. O
In O
a O
separate O
study O
, O
baboons O
given O
3 O
doses O
of O
alefacept B-DRUG
at O
1 O
mg O
/ O
kg O
every O
8 O
weeks O
were O
found O
to O
have O
centroblast O
proliferation O
in O
B O
- O
cell O
dependent O
areas O
in O
the O
germinal O
centers O
of O
the O
spleen O
following O
a O
116 O
- O
day O
washout O
period O
. O
The O
role O
of O
AMEVIVE B-BRAND
in O
the O
development O
of O
the O
lymphoid O
malignancy O
and O
the O
hyperplasia O
observed O
in O
non O
- O
human O
primates O
and O
the O
relevance O
to O
humans O
is O
unknown O
. O
Immunodeficiency O
- O
associated O
lymphocyte O
disorders O
( O
plasmacytic O
hyperplasia O
, O
polymorphic O
proliferation O
, O
and O
B O
- O
cell O
lymphomas O
) O
occur O
in O
patients O
who O
have O
congenital O
or O
acquired O
immunodeficiencies O
including O
those O
resulting O
from O
immunosuppressive B-GROUP
therapy O
. O
No O
carcinogenicity O
or O
fertility O
studies O
were O
conducted O
. O
Mutagenicity O
studies O
were O
conducted O
in O
vitro O
and O
in O
vivo O
; O
no O
evidence O
of O
mutagenicity O
was O
observed O
. O
Pregnancy O
( O
Category O
B O
) O
Women O
of O
childbearing O
potential O
make O
up O
a O
considerable O
segment O
of O
the O
patient O
population O
affected O
by O
psoriasis O
. O
Since O
the O
effect O
of O
AMEVIVE B-BRAND
on O
pregnancy O
and O
fetal O
development O
, O
including O
immune O
system O
development O
, O
is O
not O
known O
, O
health O
care O
providers O
are O
encouraged O
to O
enroll O
patients O
currently O
taking O
AMEVIVE B-BRAND
who O
become O
pregnant O
into O
the O
Biogen O
Pregnancy O
Registry O
by O
calling O
1 O
- O
866 O
- O
AMEVIVE B-BRAND
( O
1 O
- O
866 O
- O
263 O
- O
8483 O
) O

. O
Reproductive O
toxicology O
studies O
have O
been O
performed O
in O
cynomolgus O
monkeys O
at O
doses O
up O
to O
5 O
mg O
/ O
kg O
/ O
week O
( O
about O
62 O
times O
the O
human O
dose O
based O
on O
body O
weight O
) O
and O
have O
revealed O
no O
evidence O
of O
impaired O
fertility O
or O
harm O
to O
the O
fetus O
due O
to O
AMEVIVE B-BRAND
. O
No O
abortifacient O
or O
teratogenic O
effects O
were O
observed O
in O
cynomolgus O
monkeys O
following O
intravenous O
bolus O
injections O
of O
AMEVIVE B-BRAND
administered O
weekly O
during O
the O
period O
of O
organogenesis O
to O
gestation O
. O
AMEVIVE B-BRAND
underwent O
trans O
- O
placental O
passage O
and O
produced O
in O
utero O
exposure O
in O
the O
developing O
monkeys O
. O
In O
utero O
, O
serum O
levels O
of O
exposure O
in O
these O
monkeys O
were O
23 O
% O
of O
maternal O
serum O
levels O
. O
No O
evidence O
of O
fetal O
toxicity O
including O
adverse O
effects O
on O
immune O
system O
development O
was O
observed O
in O
any O
of O
these O
animals O
. O
Animal O
reproduction O
studies O
, O
however O
, O
are O
not O
always O
predictive O
of O
human O
response O
and O
there O
are O
no O
adequate O
and O
well O
- O
controlled O
studies O
in O
pregnant O
women O
. O
Because O
the O
risk O
to O
the O
development O
of O
the O
fetal O
immune O
system O
and O
postnatal O
immune O
function O
in O
humans O
is O
unknown O
, O
AMEVIVE B-BRAND
should O
be O
used O
during O
pregnancy O
only O
if O
clearly O
needed O
. O
If O
pregnancy O
occurs O
while O
taking O
AMEVIVE B-BRAND
, O
continued O
use O
of O
the O
drug O
should O
be O
assessed O
. O
Nursing O
Mothers O
It O
is O
not O
known O
whether O
AMEVIVE B-BRAND
is O
excreted O
in O
human O
milk O
. O
Because O
many O
drugs O
are O
excreted O
in O
human O
milk O
, O
and O
because O
there O
exists O
the O
potential O
for O
serious O
adverse O
reactions O
in O
nursing O
infants O
from O
AMEVIVE B-BRAND
, O
a O
decision O
should O
be O
made O
whether O
to O
discontinue O
nursing O
while O
taking O
the O
drug O
or O
to O
discontinue O
the O
use O
of O
the O
drug O
, O
taking O
into O
account O
the O
importance O
of O
the O
drug O
to O
the O
mother O
. O
Geriatric O
Use O
Of O
the O
1357 O
patients O
who O
received O
AMEVIVE B-BRAND
in O
clinical O
trials O
, O
a O
total O
of O
100 O
patients O
were O
65 O
years O
of O
age O
and O
13 O
patients O
were O
75 O
years O
of O
age O
. O
No O
differences O
in O
safety O
or O
efficacy O
were O
observed O
between O
older O
and O
younger O
patients O
, O
but O
there O
were O
not O
sufficient O
data O
to O
exclude O
important O
differences O
. O
Because O
the O
incidence O
of O
infections O
and O
certain O
malignancies O
is O
higher O
in O
the O
elderly O
population O
, O
in O
general O
, O
caution O
should O
be O
used O
in O
treating O
the O
elderly O
. O
Pediatric O
Use O
The O
safety O
and O
efficacy O
of O
AMEVIVE B-BRAND
in O
pediatric O
patients O
have O
not O
been O
studied O
. O
AMEVIVE B-BRAND
is O
not O
indicated O
for O
pediatric O
patients O
. O

Drug O
/ O
Laboratory O
Interactions O
No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
with O
Campath B-BRAND
. O
An O
immune O
response O
to O
Campath B-BRAND
may O
interfere O
with O
subsequent O
diagnostic O
serum O
tests O
that O
utilize O
antibodies B-GROUP
. O

Intravenous O
ranitidine B-DRUG
was O
shown O
to O
double O
the O
bioavailability O
of O
oral O
alendronate B-DRUG
. O
The O
clinical O
significance O
of O
this O
increased O
bioavailability O
and O
whether O
similar O
increases O
will O
occur O
in O
patients O
given O
oral O
H2 B-GROUP
- I-GROUP
antagonists I-GROUP
is O
unknown O
; O
no O
other O
specific O
drug O
interaction O
studies O
were O
performed O
. O
Products O
containing O
calcium B-DRUG
and O
other O
multivalent B-DRUG
cations I-DRUG
likely O
will O
interfere O
with O
absorption O
of O
alendronate B-DRUG
. O

Both O
the O
magnitude O
and O
duration O
of O
central O
nervous O
system O
and O
cardiovascular O
effects O
may O
be O
enhanced O
when O
ALFENTA B-BRAND
is O
administered O
in O
combination O
with O
other O
CNS B-GROUP
depressants I-GROUP
such O
as O
barbiturates B-GROUP
, O
tranquilizers B-GROUP
, O
opioids B-GROUP
, O
or O
inhalation O
general O
anesthetics B-GROUP
. O
Postoperative O
respiratory O
depression O
may O
be O
enhanced O
or O
prolonged O
by O
these O
agents O
. O
In O
such O
cases O
of O
combined O
treatment O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O
Limited O
clinical O
experience O
indicates O
that O
requirements O
for O
volatile B-GROUP
inhalation I-GROUP
anesthetics I-GROUP
are O
reduced O
by O
30 O
to O
50 O
% O
for O
the O
first O
sixty O
( O
60 O
) O
minutes O
following O
ALFENTA B-BRAND
induction O
The O
concomitant O
use O
of O
erythromycin B-DRUG
with O
ALFENTA B-BRAND
can O
significantly O
inhibit O
ALFENTA B-BRAND
clearance O
and O
may O
increase O
the O
risk O
of O
prolonged O
or O
delayed O
respiratory O
depression O
. O
Cimetidine B-DRUG
reduces O
the O
clearance O
of O
ALFENTA B-BRAND
. O
Therefore O
smaller O
ALFENTA B-BRAND
doses O
will O
be O
required O
with O
prolonged O
administration O
and O
the O
duration O
of O
action O
of O
ALFENTA B-BRAND
my O
be O
extended O
. O
Perioperative O
administration O
of O
drugs O
affecting O
hepatic O
blood O
flow O
or O
enzyme O
function O
may O
reduce O
plasma O
clearance O
and O
prolong O
recovery O
. O

Drug O
- O
Drug O
Interactions O
: O
The O
pharmacokinetic O
and O
pharmacodynamic O
interactions O
between O
UROXATRAL B-BRAND
and O
other O
alpha B-GROUP
- I-GROUP
blockers I-GROUP
have O
not O
been O
determined O
. O
However O
, O
interactions O
may O
be O
expected O
, O
and O
UROXATRAL B-BRAND
should O
NOT O
be O
used O
in O
combination O
with O
other O
alpha B-GROUP
- I-GROUP
blockers I-GROUP
. O

No O
drug O
interaction O
studies O
have O
been O
performed O
. O

Effects O
of O
Other O
Drugs O
on O
Aliskiren B-DRUG
Based O
on O
in O
- O
vitro O
studies O
, O
aliskiren B-DRUG
is O
metabolized O
by O
CYP O
3A4 O
. O
Co O
- O
administration O
of O
lovastatin B-DRUG
, O
atenolol B-DRUG
, O
warfarin B-DRUG
, O
furosemide B-DRUG
, O
digoxin B-DRUG
, O
celecoxib B-DRUG
, O
hydrochlorothiazide B-DRUG
, O
ramipril B-DRUG
, O
valsartan B-DRUG
, O
metformin B-DRUG
and O
amlodipine B-DRUG
did O
not O
result O
in O
clinically O
significant O
increases O
in O
aliskiren B-DRUG
exposure O
. O
Co O
- O
administration O
of O
irbesartan B-DRUG
reduced O
aliskiren B-DRUG
Cmax O
up O
to O
50 O
% O
after O
multiple O
dosing O
. O
Co O
- O
administration O
of O
atorvastatin B-DRUG
resulted O
in O
about O
a O
50 O
% O
increase O
in O
aliskiren B-DRUG
Cmax O
and O
AUC O
after O
multiple O
dosing O
. O
Ketoconazole B-DRUG
: O
Co O
- O
administration O
of O
200 O
mg O
twice O
- O
daily O
ketoconazole B-DRUG
with O
aliskiren B-DRUG
resulted O
in O
an O
approximate O
80 O
% O
increase O
in O
plasma O
levels O
of O
aliskiren B-DRUG
. O
A O
400 O
mg O
once O
- O
daily O
dose O
was O
not O
studied O
but O
would O
be O
expected O
to O
increase O
aliskiren B-DRUG
blood O
levels O
further O
. O
Effects O
of O
Aliskiren B-DRUG
on O
Other O
Drugs O
Aliskiren B-DRUG
does O
not O
inhibit O
the O
CYP450 O
isoenzymes O
( O
CYP1A2 O
, O
2C8 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
2E1 O
, O
and O
CYP O
3A O
) O
or O
induce O
CYP O
3A4 O
. O
Co O
- O
administration O
of O
aliskiren B-DRUG
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
lovastatin B-DRUG
, O
digoxin B-DRUG
, O
valsartan B-DRUG
, O
amlodipine B-DRUG
, O
metformin B-DRUG
, O
celecoxib B-DRUG
, O
atenolol B-DRUG
, O
atorvastatin B-DRUG
, O
ramipril B-DRUG
or O
hydrochlorothiazide B-DRUG
. O
Warfarin B-DRUG
: O
The O
effects O
of O
aliskiren B-DRUG
on O
warfarin B-DRUG
pharmacokinetics O
have O
not O
been O
evaluated O
in O
a O
well O
- O
controlled O
clinical O
trial O
. O
Furosemide B-DRUG
: O
When O
aliskiren B-DRUG
was O
co O
- O
administered O
with O
furosemide B-DRUG
, O
the O
AUC O
and O
Cmax O
of O
furosemide B-DRUG
were O
reduced O
by O
about O
30 O
% O
and O
50 O
% O
, O
respectively O
. O

Patients O
who O
are O
applying O
Panretin B-BRAND
gel O
should O
not O
concurrently O
use O
products O
that O
contain O
DEET B-DRUG
( O
N O
, O
N B-DRUG
- I-DRUG
diethyl I-DRUG
- I-DRUG
m I-DRUG
- I-DRUG
toluamide I-DRUG
) O
, O
a O
common O
component O
of O
insect O
repellent O
products O
. O
Animal O
toxicology O
studies O
showed O
increased O
DEET B-DRUG
toxicity O
when O
DEET B-DRUG
was O
included O
as O
proof O
of O
the O
formulation O
. O
Although O
there O
was O
no O
clinical O
evidence O
in O
the O
vehicle O
- O
controlled O
studies O
of O
drug O
interactions O
with O
systemic O
antiretroviral B-GROUP
agents I-GROUP
, O
including O
protease B-GROUP
inhibitors I-GROUP
, O
macrolide B-GROUP
antibiotics I-GROUP
, O
and O
azole B-GROUP
antifungals I-GROUP
, O
the O
effect O
of O
Panretin B-BRAND
gel O
on O
the O
steady O
- O
state O
concentrations O
of O
these O
drugs O
is O
not O
known O
. O
No O
drug O
interaction O
data O
are O
available O
on O
concomitant O
administration O
of O
Panretin B-BRAND
gel O
and O
systemic O
anti O
- O
KS O
agents O
. O

The O
following O
drug O
interactions O
were O
observed O
in O
some O
patients O
undergoing O
treatment O
with O
oral O
allopurinol B-DRUG
. O
Although O
the O
pattern O
of O
use O
for O
oral O
allopurinol B-DRUG
includes O
longer O
term O
therapy O
, O
particularly O
for O
gout O
and O
renal O
calculi O
, O
the O
experience O
gained O
may O
be O
relevant O
. O
Mercaptopurine B-DRUG
/ O
Azathioprine B-DRUG
: O
Allopurinol B-DRUG
inhibits O
the O
enzymatic O
oxidation O
of O
mercaptopurine B-DRUG
and O
azathioprine B-DRUG
to O
6 B-DRUG
- I-DRUG
thiouric I-DRUG
acid I-DRUG
. O
This O
oxidation O
, O
which O
is O
catalyzed O
by O
xanthine O
oxidase O
, O
inactivates O
mercaptopurine B-DRUG
. O
In O
patients O
receiving O
mercaptopurine B-DRUG
( O
Purinethol B-BRAND
) O
or O
azathioprine B-DRUG
( O
Imuran B-BRAND
) O
, O
the O
concomitant O
administration O
of O
300 O
- O
600 O
mg O
of O
allopurinol B-DRUG
per O
day O
will O
require O
a O
reduction O
in O
dose O
to O
approximately O
one O
- O
third O
to O
one O
- O
fourth O
of O
the O
usual O
dose O
of O
mercaptopurine B-DRUG
or O
azathioprine B-DRUG
. O
Subsequent O
adjustment O
of O
doses O
of O
mercaptopurine B-DRUG
or O
azathioprine B-DRUG
should O
be O
made O
on O
the O
basis O
of O
therapeutic O
response O
and O
the O
appearance O
of O
toxic O
effects O
. O
Dicumarol B-DRUG
: O
It O
has O
been O
reported O
that O
allopurinol B-DRUG
prolongs O
the O
half O
- O
life O
of O
the O
anticoagulant B-GROUP
, O
dicumarol B-DRUG
. O
The O
clinical O
basis O
of O
this O
drug O
interaction O
has O
not O
been O
established O
but O
should O
be O
noted O
when O
allopurinol B-DRUG
is O
given O
to O
patients O
already O
on O
dicumarol B-DRUG
therapy O
. O
Consequently O
, O
prothrombin O
time O
should O
be O
reassessed O
periodically O
in O
patients O
receiving O
both O
drugs O
. O
Uricosuric B-GROUP
Agents I-GROUP
: O
Since O
the O
excretion O
of O
oxipurinol B-DRUG
is O
similar O
to O
that O
of O
urate O
, O
uricosuric B-GROUP
agents I-GROUP
, O
which O
increase O
the O
excretion O
of O
urate O
, O
are O
also O
likely O
to O
increase O
the O
excretion O
of O
oxipurinol B-DRUG
and O
thus O
lower O
the O
degree O
of O
inhibition O
of O
xanthine O
oxidase O
. O
The O
concomitant O
administration O
of O
uricosuric B-GROUP
agents I-GROUP
and O
allopurinol B-DRUG
has O
been O
associated O
with O
a O
decrease O
in O
the O
excretion O
of O
oxypurines O
( O
hypoxanthine O
and O
xanthine O
) O
and O
an O
increase O
in O
urinary O
uric O
acid O
excretion O
compared O
with O
that O
observed O
with O
allopurinol B-DRUG
alone O
. O
Although O
clinical O
evidence O
to O
date O
has O
not O
demonstrated O
renal O
precipitation O
of O
oxypurines O
in O
patients O
either O
on O
allopurinol B-DRUG
alone O
or O
in O
combination O
with O
uricosuric B-GROUP

agents I-GROUP
, O
the O
possibility O
should O
be O
kept O
in O
mind O
. O
Thiazide B-GROUP
Diuretics I-GROUP
: O
The O
reports O
that O
the O
concomitant O
use O
of O
allopurinol B-DRUG
and O
thiazide B-GROUP
diuretics I-GROUP
may O
contribute O
to O
the O
enhancement O
of O
allopurinol B-DRUG
toxicity O
in O
some O
patients O
have O
been O
reviewed O
in O
an O
attempt O
to O
establish O
a O
cause O
- O
and O
- O
effect O
relationship O
and O
a O
mechanism O
of O
causation O
. O
Review O
of O
these O
case O
reports O
indicates O
that O
the O
patients O
were O
mainly O
receiving O
thiazide B-GROUP
diuretics I-GROUP
for O
hypertension O
and O
that O
tests O
to O
rule O
out O
decreased O
renal O
function O
secondary O
to O
hypertensive O
nephropathy O
were O
not O
often O
performed O
. O
In O
those O
patients O
in O
whom O
renal O
insufficiency O
was O
documented O
, O
however O
, O
the O
recommendation O
to O
lower O
the O
dose O
of O
allopurinol B-DRUG
was O
not O
followed O
. O
Although O
a O
causal O
mechanism O
and O
a O
cause O
- O
and O
- O
effect O
relationship O
have O
not O
been O
established O
, O
current O
evidence O
suggests O
that O
renal O
function O
should O
be O
monitored O
in O
patients O
on O
thiazide B-GROUP
diuretics I-GROUP
and O
allopurinol B-DRUG
even O
in O
the O
absence O
of O
renal O
failure O
, O
and O
dosage O
levels O
should O
be O
even O
more O
conservatively O
adjusted O
in O
those O
patients O
on O
such O
combined O
therapy O
if O
diminished O
renal O
function O
is O
detected O
. O
. O
Ampicillin B-DRUG
/ O
Amoxicillin B-DRUG
: O
An O
increase O
in O
the O
frequency O
of O
skin O
rash O
has O
been O
reported O
among O
patients O
receiving O
ampicillin B-DRUG
or O
amoxicillin B-DRUG
concurrently O
with O
allopurinol B-DRUG
compared O
to O
patients O
who O
are O
not O
receiving O
both O
drugs O
. O
The O
cause O
of O
the O
reported O
association O
has O
not O
been O
established O
. O
Cytotoxic B-GROUP
Agents I-GROUP
: O
Enhanced O
bone O
marrow O
suppression O
by O
cyclophosphamide B-DRUG
and O
other O
cytotoxic B-GROUP
agents I-GROUP
has O
been O
reported O
among O
patients O
with O
neoplastic O
disease O
, O
except O
leukemia O
, O
in O
the O
presence O
of O
allopurinol B-DRUG
. O
However O
, O
in O
a O
well O
- O
controlled O
study O
of O
patients O
with O
lymphoma O
on O
combination O
therapy O
, O
allopurinol B-DRUG
did O
not O
increase O
the O
marrow O
toxicity O
of O
patients O
treated O
with O
cyclophosphamide B-DRUG
, O
doxorubicin B-DRUG
, O
bleomycin B-DRUG
, O
procarbazine B-DRUG
and O
/ O
or O
mechlorethamine B-DRUG
. O
Chlorpropamide B-DRUG
: O
Chlorpropamides B-DRUG
plasma O
half O
- O
life O
may O
be O
prolonged O
by O
allopurinol B-DRUG
, O
since O
allopurinol B-DRUG
and O
chlorpropamide B-DRUG
may O
compete O
for O
excretion O
in O
the O
renal O
tubule O
. O
The O
risk O
of O
hypoglycemia O
secondary O
to O
this O
mechanism O
may O
be O
increased O
if O
allopurinol B-DRUG
and O
chlorpropamide B-DRUG
are O
given O

concomitantly O
in O
the O
presence O
of O
renal O
insufficiency O
. O
Cyclosporin B-DRUG
: O
Reports O
indicate O
that O
cyclosporine B-DRUG
levels O
may O
be O
increased O
during O
concomitant O
treatment O
with O
allopurinol B-DRUG
sodium I-DRUG
for O
injection O
. O
Monitoring O
of O
cyclosporine B-DRUG
levels O
and O
possible O
adjustment O
of O
cyclosporine B-DRUG
dosage O
should O
be O
considered O
when O
these O
drugs O
are O
co O
- O
administered O
. O
Tolbutamides B-DRUG
conversion O
to O
inactive O
metabolites O
has O
been O
shown O
to O
be O
catalyzed O
by O
xanthine O
oxidase O
from O
rat O
liver O
. O
The O
clinical O
significance O
, O
if O
any O
, O
of O
these O
observations O
is O
unknown O
. O

Ergot B-GROUP
- I-GROUP
Containing I-GROUP
Drugs I-GROUP
: O
These O
drugs O
have O
been O
reported O
to O
cause O
prolonged O
vasospastic O
reactions O
. O
Because O
there O
is O
a O
theoretical O
basis O
that O
these O
effects O
may O
be O
additive O
, O
use O
of O
ergotamine B-DRUG
- O
containing O
or O
ergot B-GROUP
- I-GROUP
type I-GROUP
medications I-GROUP
( O
like O
dihydroergotamine B-DRUG
or O
methysergide B-DRUG
) O
and O
AXERT B-BRAND
within O
24 O
hours O
of O
each O
other O
should O
be O
avoided O
. O
Monoamine B-GROUP
Oxidase I-GROUP
Inhibitors I-GROUP
: O
Coadministration O
of O
moclobemide B-DRUG
resulted O
in O
a O
27 O
% O
decrease O
in O
almotriptan B-DRUG
clearance O
and O
an O
increase O
in O
Cmax O
of O
approximately O
6 O
% O
. O
No O
dose O
adjustment O
is O
necessary O
. O
Other O
5 B-GROUP
- I-GROUP
HT1B I-GROUP
/ I-GROUP
1D I-GROUP
Agonists I-GROUP
Concomitant O
use O
of O
other O
5 B-GROUP
- I-GROUP
HT1B I-GROUP
/ I-GROUP
1D I-GROUP
agonists I-GROUP
within O
24 O
hours O
of O
treatment O
with O
AXERT B-BRAND
is O
contraindicated O
. O
Propanolol B-DRUG
: O
The O
pharmacokinetics O
of O
almotriptan B-DRUG
were O
not O
affected O
by O
coadministration O
of O
propranolol B-DRUG
. O
Selective B-GROUP
Serotonin I-GROUP
Reuptake I-GROUP
Inhibitors I-GROUP
( O
SSRIs B-GROUP
) O
: O
SSRIs B-GROUP
( O
e O
. O
g O
. O
, O
fluoxetine B-DRUG
, O
fluvoxamine B-DRUG
, O
paroxetine B-DRUG
, O
sertraline B-DRUG
) O
have O
been O
rarely O
reported O
to O
cause O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
when O
coadministered O
with O
5 B-GROUP
- I-GROUP
HT1 I-GROUP
agonists I-GROUP
. O
If O
concomitant O
treatment O
with O
AXERT B-BRAND
and O
an O
SSRI B-GROUP
is O
clinically O
warranted O
, O
appropriate O
observation O
of O
the O
patient O
is O
advised O
. O
Verapamil B-DRUG
: O
Coadministration O
of O
almotriptan B-DRUG
and O
verapamil B-DRUG
resulted O
in O
a O
24 O
% O
increase O
in O
plasma O
concentrations O
of O
almotriptan B-DRUG
. O
No O
dose O
adjustment O
is O
necessary O
. O
Coadministration O
of O
almotriptan B-DRUG
and O
the O
potent O
CYP3A4 O
inhibitor O
ketoconazole B-DRUG
( O
400 O
mg O
q O
. O
d O
. O
for O
3 O
days O
) O
resulted O
in O
an O
approximately O
60 O
% O
increase O
in O
the O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
and O
maximal O
plasma O
concentrations O
of O
almotriptan B-DRUG
. O
Although O
the O
interaction O
between O
almotriptan B-DRUG
and O
other O
potent O
CYP3A4 O
inhibitors O
( O
e O
. O
g O
. O
, O
itraconazole B-DRUG
, O
ritonavir B-DRUG
, O
and O
erythromycin B-DRUG
) O
has O
not O
been O
studied O
, O
increased O
exposures O
to O
almotriptan B-DRUG
may O
be O
expected O
when O
almotriptan B-DRUG
is O
used O
concomitantly O
with O
these O
medications O
. O
AXERT B-BRAND
is O
not O
known O
to O
interfere O
with O
commonly O
employed O

clinical O
laboratory O
tests O
. O

Because O
alosetron B-DRUG
is O
metabolized O
by O
a O
variety O
of O
hepatic O
CYP O
drug O
- O
metabolizing O
enzymes O
, O
inducers O
or O
inhibitors O
of O
these O
enzymes O
may O
change O
the O
clearance O
of O
alosetron B-DRUG
. O
Fluvoxamine B-DRUG
is O
a O
known O
strong O
inhibitor O
of O
CYP1A2 O
and O
also O
inhibits O
CYP3A4 O
, O
CYP2C9 O
, O
and O
CYP2C19 O
. O
In O
a O
pharmacokinetic O
study O
, O
40 O
healthy O
female O
subjects O
received O
fluvoxamine B-DRUG
in O
escalating O
doses O
from O
50 O
to O
200 O
mg O
per O
day O
for O
16 O
days O
, O
with O
coadministration O
of O
alosetron B-DRUG
1 O
mg O
on O
the O
last O
day O
. O
Fluvoxamine B-DRUG
increased O
mean O
alosetron B-DRUG
plasma O
concentrations O
( O
AUC O
) O
approximately O
6 O
- O
fold O
and O
prolonged O
the O
half O
- O
life O
by O
approximately O
3 O
- O
fold O
. O
Concomitant O
administration O
of O
alosetron B-DRUG
and O
fluvoxamine B-DRUG
is O
contraindicated O
. O
Concomitant O
administration O
of O
alosetron B-DRUG
and O
moderate O
CYP1A2 O
inhibitors O
, O
including O
quinolone B-GROUP
antibiotics I-GROUP
and O
cimetidine B-DRUG
, O
has O
not O
been O
evaluated O
, O
but O
should O
be O
avoided O
unless O
clinically O
necessary O
because O
of O
similar O
potential O
drug O
interactions O
. O
Ketoconazole B-DRUG
is O
a O
known O
strong O
inhibitor O
of O
CYP3A4 O
. O
In O
a O
pharmacokinetic O
study O
, O
38 O
healthy O
female O
subjects O
received O
ketoconazole B-DRUG
200 O
mg O
twice O
daily O
for O
7 O
days O
, O
with O
coadministration O
of O
alosetron B-DRUG
1 O
mg O
on O
the O
last O
day O
. O
Ketoconazole B-DRUG
increased O
mean O
alosetron B-DRUG
plasma O
concentrations O
( O
AUC O
) O
by O
29 O
% O
. O
Caution O
should O
be O
used O
when O
alosetron B-DRUG
and O
ketoconazole B-DRUG
are O
administered O
concomitantly O
. O
Coadministration O
of O
alosetron B-DRUG
and O
strong O
CYP3A4 O
inhibitors O
, O
such O
as O
clarithromycin B-DRUG
, O
telithromycin B-DRUG
, O
protease B-GROUP
inhibitors I-GROUP
, O
voriconazole B-DRUG
, O
and O
itraconazole B-DRUG
has O
not O
been O
evaluated O
but O
should O
be O
undertaken O
with O
caution O
because O
of O
similar O
potential O
drug O
interactions O
. O
The O
effect O
of O
induction O
or O
inhibition O
of O
other O
pathways O
on O
exposure O
to O
alosetron B-DRUG
and O
its O
metabolites O
is O
not O
known O
. O
In O
vitro O
human O
liver O
microsome O
studies O
and O
an O
in O
vivo O
metabolic O
probe O
study O
demonstrated O
that O
alosetron B-DRUG
did O
not O
inhibit O
CYP O
enzymes O
2D6 O
, O
3A4 O
, O
2C9 O
, O
or O
2C19 O
. O
In O
vitro O
, O
at O
total O
drug O
concentrations O
27 O
- O
fold O
higher O
than O
peak O
plasma O
concentrations O
observed O
with O
the O
1 O
- O
mg O
dosage O
, O

alosetron B-DRUG
inhibited O
CYP O
enzymes O
1A2 O
( O
60 O
% O
) O
and O
2E1 O
( O
50 O
% O
) O
. O
In O
an O
in O
vivo O
metabolic O
probe O
study O
, O
alosetron B-DRUG
did O
not O
inhibit O
CYP2E1 O
but O
did O
produce O
30 O
% O
inhibition O
of O
both O
CYP1A2 O
and O
N O
- O
acetyltransferase O
. O
Although O
not O
studied O
with O
alosetron B-DRUG
, O
inhibition O
of O
N O
- O
acetyltransferase O
may O
have O
clinically O
relevant O
consequences O
for O
drugs O
such O
as O
isoniazid B-DRUG
, O
procainamide B-DRUG
, O
and O
hydralazine B-DRUG
. O
The O
effect O
on O
CYP1A2 O
was O
explored O
further O
in O
a O
clinical O
interaction O
study O
with O
theophylline B-DRUG
and O
no O
effect O
on O
metabolism O
was O
observed O
. O
Another O
study O
showed O
that O
alosetron B-DRUG
had O
no O
clinically O
significant O
effect O
on O
plasma O
concentrations O
of O
the O
oral O
contraceptive B-GROUP
agents I-GROUP
ethinyl B-DRUG
estradiol I-DRUG
and O
levonorgestrel B-DRUG
( O
CYP3A4 O
substrates O
) O
. O
A O
clinical O
interaction O
study O
was O
also O
conducted O
with O
alosetron B-DRUG
and O
the O
CYP3A4 O
substrate O
cisapride B-DRUG
. O
No O
significant O
effects O
on O
cisapride B-DRUG
metabolism O
or O
QT O
interval O
were O
noted O
. O
The O
effect O
of O
alosetron B-DRUG
on O
monoamine O
oxidases O
and O
on O
intestinal O
first O
pass O
secondary O
to O
high O
intraluminal O
concentrations O
have O
not O
been O
examined O
. O
Based O
on O
the O
above O
data O
from O
in O
vitro O
and O
in O
vivo O
studies O
, O
it O
is O
unlikely O
that O
alosetron B-DRUG
will O
inhibit O
the O
hepatic O
metabolic O
clearance O
of O
drugs O
metabolized O
by O
the O
major O
CYP O
enzyme O
3A4 O
, O
as O
well O
as O
the O
CYP O
enzymes O
2D6 O
, O
2C9 O
, O
2C19 O
, O
2E1 O
, O
or O
1A2 O
. O
Alosetron B-DRUG
does O
not O
appear O
to O
induce O
the O
major O
cytochrome O
P450 O
( O
CYP O
) O
drug O
metabolizing O
enzyme O
3A O
. O
Alosetron B-DRUG
also O
does O
not O
appear O
to O
induce O
CYP O
enzymes O
2E1 O
or O
2C19 O
. O
It O
is O
not O
known O
whether O
alosetron B-DRUG
might O
induce O
other O
enzymes O
. O

The O
benzodiazepines B-GROUP
, O
including O
alprazolam B-DRUG
, O
produce O
additive O
CNS O
depressant O
effects O
when O
co O
- O
administered O
with O
other O
psychotropic B-GROUP
medications I-GROUP
, O
anticonvulsants B-GROUP
, O
antihistaminics B-GROUP
, O
ethanol B-DRUG
, O
and O
other O
drugs O
which O
themselves O
produce O
CNS O
depression O
. O
The O
steady O
state O
plasma O
concentrations O
of O
imipramine B-DRUG
and O
desipramine B-DRUG
have O
been O
reported O
to O
be O
increased O
an O
average O
of O
31 O
% O
and O
20 O
% O
, O
respectively O
, O
by O
the O
concomitant O
administration O
of O
alprazolam B-DRUG
tablets O
in O
doses O
up O
to O
4 O
mg O
/ O
day O
. O
The O
clinical O
significance O
of O
these O
changes O
is O
unknown O
. O
Drugs O
That O
Inhibit O
Alprazolam B-DRUG
Metabolism O
Via O
Cytochrome O
P450 O
3A O
: O
The O
initial O
step O
in O
alprazolam B-DRUG
metabolism O
is O
hydroxylation O
catalyzed O
by O
cytochrome O
P450 O
3A O
( O
CYP O
3A O
) O
. O
Drugs O
which O
inhibit O
this O
metabolic O
pathway O
may O
have O
a O
profound O
effect O
on O
the O
clearance O
of O
alprazolam B-DRUG
. O
Drugs O
Demonstrated O
to O
be O
CYP O
3A O
Inhibitors O
of O
Possible O
Clinical O
Significance O
on O
the O
Basis O
of O
Clinical O
Studies O
Involving O
Alprazolam B-DRUG
( O
caution O
is O
recommended O
during O
coadministration O
with O
alprazolam B-DRUG
) O
: O
Coadministration O
of O
fluoxetine B-DRUG
with O
alprazolam B-DRUG
increased O
the O
maximum O
plasma O
concentration O
of O
alprazolam B-DRUG
by O
46 O
% O
, O
decreased O
clearance O
by O
21 O
% O
, O
increased O
half O
- O
life O
by O
17 O
% O
, O
and O
decreased O
measured O
psychomotor O
performance O
. O
Coadministration O
of O
propoxyphene B-DRUG
decreased O
the O
maximum O
plasma O
concentration O
of O
alprazolam B-DRUG
by O
6 O
% O
, O
decreased O
clearance O
by O
38 O
% O
, O
and O
increased O
half O
- O
life O
by O
58 O
% O
. O
Coadministration O
of O
oral O
contraceptives B-GROUP
increased O
the O
maximum O
plasma O
concentration O
of O
alprazolam B-DRUG
by O
18 O
% O
, O
decreased O
clearance O
by O
22 O
% O
, O
and O
increased O
half O
- O
life O
by O
29 O
% O
. O
Drugs O
and O
other O
substances O
demonstrated O
to O
be O
CYP O
3A O
inhibitors O
on O
the O
basis O
of O
clinical O
studies O
involving O
benzodiazepines B-GROUP
metabolized O
similarly O
to O
alprazolam B-DRUG
or O
on O
the O
basis O
of O
in O
vitro O
studies O
with O
alprazolam B-DRUG
or O
other O
benzodiazepines B-GROUP
( O
caution O
is O
recommended O
during O
coadministration O
with O
alprazolam B-DRUG
) O
: O
Available O
data O
from O
clinical O
studies O
of O
benzodiazepines B-GROUP
other O
than O
alprazolam B-DRUG
suggest O
a O
possible O
drug O
interaction O
with O
alprazolam B-DRUG
for O
the O
following O
: O
diltiazem B-DRUG
, O
isoniazid B-DRUG
, O
macrolide B-GROUP
antibiotics I-GROUP
such O
as O

erythromycin B-DRUG
and O
clarithromycin B-DRUG
, O
and O
grapefruit O
juice O
. O
Data O
from O
in O
vitro O
studies O
of O
alprazolam B-DRUG
suggest O
a O
possible O
drug O
interaction O
with O
alprazolam B-DRUG
for O
the O
following O
: O
sertraline B-DRUG
and O
paroxetine B-DRUG
. O
Data O
from O
in O
vitro O
studies O
of O
benzodiazepines B-GROUP
other O
than O
alprazolam B-DRUG
suggest O
a O
possible O
drug O
interaction O
for O
the O
following O
: O
ergotamine B-DRUG
, O
cyclosporine B-DRUG
, O
amiodarone B-DRUG
, O
nicardipine B-DRUG
, O
and O
nifedipine B-DRUG
. O
Caution O
is O
recommended O
during O
the O
coadministration O
of O
any O
of O
these O
with O
alprazolam B-DRUG
. O

No O
drug O
interactions O
have O
been O
reported O
between O
Prostin B-BRAND
VR I-BRAND
Pediatric I-BRAND
and O
the O
therapy O
standard O
in O
neonates O
with O
restricted O
pulmonary O
or O
systemic O
blood O
flow O
. O
Standard O
therapy O
includes O
antibiotics B-GROUP
, O
such O
as O
penicillin B-DRUG
and O
gentamicin B-DRUG
; O
vasopressors B-GROUP
, O
such O
as O
dopamine B-DRUG
and O
isoproterenol B-DRUG
; O
cardiac B-GROUP
glycosides I-GROUP
; O
and O
diuretics B-GROUP
, O
such O
as O
furosemide B-DRUG
. O
Caverject B-BRAND
: O
The O
potential O
for O
pharmacokinetic O
drug O
- O
drug O
interactions O
between O
alprostadil B-DRUG
and O
other O
agents O
has O
not O
been O
formally O
studied O
. O

The O
interaction O
of O
Activase B-BRAND
with O
other O
cardioactive O
or O
cerebroactive O
drugs O
has O
not O
been O
studied O
. O
In O
addition O
to O
bleeding O
associated O
with O
heparin B-DRUG
and O
vitamin B-GROUP
K I-GROUP
antagonists I-GROUP
, O
drugs O
that O
alter O
platelet O
function O
( O
such O
as O
acetylsalicylic B-DRUG
acid I-DRUG
, O
dipyridamole B-DRUG
and O
Abciximab B-DRUG
) O
may O
increase O
the O
risk O
of O
bleeding O
if O
administered O
prior O
to O
, O
during O
, O
or O
after O
Activase B-BRAND
therapy O
. O
Use O
of O
Antithrombotics B-GROUP
Aspirin B-BRAND
and O
heparin B-DRUG
have O
been O
administered O
concomitantly O
with O
and O
following O
infusions O
of O
Activase B-BRAND
in O
the O
management O
of O
acute O
myocardial O
infarction O
or O
pulmonary O
embolism O
. O
Because O
heparin B-DRUG
, O
aspirin B-BRAND
, O
or O
Activase B-BRAND
may O
cause O
bleeding O
complications O
, O
careful O
monitoring O
for O
bleeding O
is O
advised O
, O
especially O
at O
arterial O
puncture O
sites O
. O
The O
concomitant O
use O
of O
heparin B-DRUG
or O
aspirin B-BRAND
during O
the O
first O
24 O
hours O
following O
symptom O
onset O
were O
prohibited O
in O
The O
NINDS O
t O
- O
PA O
Stroke O
Trial O
. O
The O
safety O
of O
such O
concomitant O
use O
with O
Activase B-BRAND
for O
the O
management O
of O
acute O
ischemic O
stroke O
is O
unknown O
. O

Concurrent O
administration O
of O
HEXALEN B-BRAND
and O
antidepressants B-GROUP
of I-GROUP
the I-GROUP
MAO I-GROUP
inhibitor I-GROUP
class I-GROUP
may O
cause O
severe O
orthostatic O
hypotension O
. O
Cimetidine B-DRUG
, O
an O
inhibitor O
of O
microsomal O
drug O
metabolism O
, O
increased O
altretamines B-DRUG
half O
- O
life O
and O
toxicity O
in O
a O
rat O
model O
. O
Data O
from O
a O
randomized O
trial O
of O
HEXALEN B-BRAND
and O
cisplatin B-DRUG
plus O
or O
minus O
pyridoxine B-DRUG
in O
ovarian O
cancer O
indicated O
that O
pyridoxine B-DRUG
significantly O
reduced O
neurotoxicity O
; O
however O
, O
it O
adversely O
affected O
response O
duration O
suggesting O
that O
pyridoxine B-DRUG
should O
not O
be O
administered O
with O
HEXALEN B-BRAND
and O
/ O
or O
cisplatin B-DRUG
. O
1 O

Careful O
observation O
is O
required O
when O
amantadine B-DRUG
is O
administered O
concurrently O
with O
central B-GROUP
nervous I-GROUP
system I-GROUP
stimulants I-GROUP
. O
Coadministration O
of O
thioridazine B-DRUG
has O
been O
reported O
to O
worsen O
the O
tremor O
in O
elderly O
patients O
with O
Parkinsons O
disease O
; O
however O
, O
it O
is O
not O
known O
if O
other O
phenothiazines B-GROUP
produce O
a O
similar O
response O
. O

Special O
consideration O
should O
be O
given O
to O
the O
administration O
of O
ETHYOL B-BRAND
in O
patients O
receiving O
antihypertensive B-GROUP
medications I-GROUP
or O
other O
drugs O
that O
could O
cause O
or O
potentiate O
hypotension O
. O

When O
amiloride B-DRUG
HCl O
is O
administered O
concomitantly O
with O
an O
angiotensin B-GROUP
- I-GROUP
converting I-GROUP
enzyme I-GROUP
inhibitor I-GROUP
, O
the O
risk O
of O
hyperkalemia O
may O
be O
increased O
. O
Therefore O
, O
if O
concomitant O
use O
of O
these O
agents O
is O
indicated O
because O
of O
demonstrated O
hypokalemia O
, O
they O
should O
be O
used O
with O
caution O
and O
with O
frequent O
monitoring O
of O
serum O
potassium O
. O
Lithium B-DRUG
generally O
should O
not O
be O
given O
with O
diuretics B-GROUP
because O
they O
reduce O
its O
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium O
toxicity O
. O
Read O
circulars O
for O
lithium B-DRUG
preparations O
before O
use O
of O
such O
concomitant O
therapy O
. O
In O
some O
patients O
, O
the O
administration O
of O
a O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agent I-GROUP
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop B-GROUP
, I-GROUP
potassium I-GROUP
- I-GROUP
sparing I-GROUP
and I-GROUP
thiazide I-GROUP
diuretics I-GROUP
. O
Therefore O
, O
when O
MIDAMOR B-BRAND
and O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-GROUP
is O
obtained O
. O
Since O
indomethacin B-DRUG
and O
potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
, O
including O
MIDAMOR B-BRAND
, O
may O
each O
be O
associated O
with O
increased O
serum O
potassium O
levels O
, O
the O
potential O
effects O
on O
potassium O
kinetics O
and O
renal O
function O
should O
be O
considered O
when O
these O
agents O
are O
administered O
concurrently O
. O

Drug O
Laboratory O
Test O
Interactions O
: O
Prolongation O
of O
the O
template O
bleeding O
time O
has O
been O
reported O
during O
continuous O
intravenous O
infusion O
of O
AMICAR B-BRAND
at O
dosages O
exceeding O
24 O
g O
/ O
day O
. O
Platelet O
function O
studies O
in O
these O
patients O
have O
not O
demonstrated O
any O
significant O
platelet O
dysfunction O
. O
However O
, O
in O
vitro O
studies O
have O
shown O
that O
at O
high O
concentrations O
( O
7 O
. O
4 O
mMol O
/ O
L O
or O
0 O
. O
97 O
mg O
/ O
mL O
and O
greater O
) O
EACA B-DRUG
inhibits O
ADP O
and O
collagen O
- O
induced O
platelet O
aggregation O
, O
the O
release O
of O
ATP O
and O
serotonin O
, O
and O
the O
binding O
of O
fibrinogen O
to O
the O
platelets O
in O
a O
concentration O
- O
response O
manner O
. O
Following O
a O
10 O
g O
bolus O
of O
AMICAR B-BRAND
, O
transient O
peak O
plasma O
concentrations O
of O
4 O
. O
6 O
mMol O
/ O
L O
or O
0 O
. O
60 O
mg O
/ O
mL O
have O
been O
obtained O
. O
The O
concentration O
of O
AMICAR B-BRAND
necessary O
to O
maintain O
inhibition O
of O
fibrinolysis O
is O
0 O
. O
99 O
mMol O
/ O
L O
or O
0 O
. O
13 O
mg O
/ O
mL O
. O
Administration O
of O
a O
5 O
g O
bolus O
followed O
by O
1 O
to O
1 O
. O
25 O
g O
/ O
hr O
should O
achieve O
and O
sustain O
plasma O
levels O
of O
0 O
. O
13 O
mg O
/ O
mL O
. O
Thus O
, O
concentrations O
which O
have O
been O
obtained O
in O
vivo O
clinically O
in O
patients O
with O
normal O
renal O
function O
are O
considerably O
lower O
than O
the O
in O
vitro O
concentrations O
found O
to O
induce O
abnormalities O
in O
platelet O
function O
tests O
. O
However O
, O
higher O
plasma O
concentrations O
of O
AMICAR B-BRAND
may O
occur O
in O
patients O
with O
severe O
renal O
failure O
. O

Cytadren B-BRAND
accelerates O
the O
metabolism O
of O
dexamethasone B-DRUG
; O
therefore O
, O
if O
glucocorticoid B-GROUP
replacement O
is O
needed O
, O
hydrocortisone B-DRUG
should O
be O
prescribed O
. O
Aminoglutethimide B-DRUG
diminishes O
the O
effect O
of O
coumarin B-GROUP
and O
warfarin B-DRUG
. O

Renal O
clearance O
measurements O
of O
PAH B-DRUG
cannot O
be O
made O
with O
any O
significant O
accuracy O
in O
patients O
receiving O
sulfonamides B-GROUP
, O
procaine B-DRUG
, O
or O
thiazolesulfone B-DRUG
. O
These O
compounds O
interfere O
with O
chemical O
color O
development O
essential O
to O
the O
analytical O
procedures O
. O
Probenecid B-DRUG
depresses O
tubular O
secretion O
of O
certain O
weak O
acids O
such O
as O
PAH B-DRUG
. O
Therefore O
, O
patients O
receiving O
probenecid B-DRUG
will O
have O
erroneously O
low O
ERPF O
and O
Tm O
PAH B-DRUG
values O
. O

There O
have O
been O
no O
formal O
studies O
of O
the O
interaction O
of O
LEVULAN B-BRAND
KERASTICK I-BRAND
for O
Topical O
Solution O
with O
any O
other O
drugs O
, O
and O
no O
drug O
- O
specific O
interactions O
were O
noted O
during O
any O
of O
the O
controlled O
clinical O
trials O
. O
It O
is O
, O
however O
, O
possible O
that O
concomitant O
use O
of O
other O
known O
photosensitizing B-GROUP
agents I-GROUP
such O
as O
griseofulvin B-DRUG
, O
thiazide B-GROUP
diuretics I-GROUP
, O
sulfonylureas B-GROUP
, O
phenothiazines B-GROUP
, O
sulfonamides B-GROUP
and O
tetracyclines B-GROUP
might O
increase O
the O
photosensitivity O
reaction O
of O
actinic O
keratoses O
treated O
with O
the O
LEVULAN B-BRAND
KERASTICK I-BRAND
for O
Topical O
Solution O
. O

Aminosalicylic B-DRUG
acid I-DRUG
may O
decrease O
the O
amount O
of O
digoxin B-DRUG
( O
Lanoxin B-BRAND
, O
Lanoxicaps B-DRUG
) O
that O
gets O
absorbed O
into O
your O
body O
. O
In O
the O
case O
that O
you O
are O
taking O
digoxin B-DRUG
while O
taking O
aminosalicylic B-DRUG
acid I-DRUG
, O
higher O
doses O
of O
digoxin B-DRUG
may O
be O
needed O
. O
Aminosalicylic B-DRUG
acid I-DRUG
may O
also O
decrease O
the O
absorption O
of O
vitamin B-DRUG
B12 I-DRUG
, O
which O
can O
lead O
to O
a O
deficiency O
. O
Therefore O
you O
may O
need O
to O
take O
a O
vitamin B-DRUG
B12 I-DRUG
supplement O
while O
taking O
aminosalicylic B-DRUG
acid I-DRUG
. O

Amiodarone B-DRUG
is O
metabolized O
to O
desethylamiodarone B-DRUG
by O
the O
cytochrome O
P450 O
( O
CYP450 O
) O
enzyme O
group O
, O
specifically O
cytochromes O
P450 O
3A4 O
( O
CYP3A4 O
) O
and O
CYP2C8 O
. O
The O
CYP3A4 O
isoenzyme O
is O
present O
in O
both O
the O
liver O
and O
intestines O
. O
Amiodarone B-DRUG
is O
also O
known O
to O
be O
an O
inhibitor O
of O
CYP3A4 O
. O
Therefore O
, O
amiodarone B-DRUG
has O
the O
potential O
for O
interactions O
with O
drugs O
or O
substances O
that O
may O
be O
substrates O
, O
inhibitors O
or O
inducers O
of O
CYP3A4 O
. O
While O
only O
a O
limited O
number O
of O
in O
vivo O
drug O
- O
drug O
interactions O
with O
amiodarone B-DRUG
have O
been O
reported O
, O
chiefly O
with O
the O
oral O
formulation O
, O
the O
potential O
for O
other O
interactions O
should O
be O
anticipated O
. O
This O
is O
especially O
important O
for O
drugs O
associated O
with O
serious O
toxicity O
, O
such O
as O
other O
antiarrhythmics B-GROUP
. O
If O
such O
drugs O
are O
needed O
, O
their O
dose O
should O
be O
reassessed O
and O
, O
where O
appropriate O
, O
plasma O
concentration O
measured O
. O
In O
view O
of O
the O
long O
and O
variable O
half O
- O
life O
of O
amiodarone B-DRUG
, O
potential O
for O
drug O
interactions O
exists O
not O
only O
with O
concomitant O
medication O
but O
also O
with O
drugs O
administered O
after O
discontinuation O
of O
amiodarone B-DRUG
. O
Since O
amiodarone B-DRUG
is O
a O
substrate O
for O
CYP3A4 O
and O
CYP2C8 O
, O
drugs O
/ O
substances O
that O
inhibit O
these O
isoenzymes O
may O
decrease O
the O
metabolism O
and O
increase O
serum O
concentration O
of O
amiodarone B-DRUG
. O
Reported O
examples O
include O
the O
following O
: O
Protease B-GROUP
Inhibitors I-GROUP
: O
Protease B-GROUP
inhibitors I-GROUP
are O
known O
to O
inhibit O
CYP3A4 O
to O
varying O
degrees O
. O
A O
case O
report O
of O
one O
patient O
taking O
amiodarone B-DRUG
200 O
mg O
and O
indinavir B-DRUG
800 O
mg O
three O
times O
a O
day O
resulted O
in O
increases O
in O
amiodarone B-DRUG
concentrations O
from O
0 O
. O
9 O
mg O
/ O
L O
to O
1 O
. O
3 O
mg O
/ O
L O
. O
DEA O
concentrations O
were O
not O
affected O
. O
There O
was O
no O
evidence O
of O
toxicity O
. O
Monitoring O
for O
amiodarone B-DRUG
toxicity O
and O
serial O
measurement O
of O
amiodarone B-DRUG
serum O
concentration O
during O
concomitant O
protease B-GROUP
inhibitor I-GROUP
therapy O
should O
be O
considered O
. O
Histamine B-GROUP
H2 I-GROUP
antagonists I-GROUP
: O
Cimetidine B-DRUG
inhibits O
CYP3A4 O
and O
can O
increase O
serum O
amiodarone B-DRUG
levels O
. O
Other O
substances O
: O
Grapefruit O
juice O
given O
to O
healthy O
volunteers O
increased O
amiodarone B-DRUG
AUC O
by O
50 O
% O
and O
Cmax O
by O
84 O
% O
, O
resulting O
in O
increased O
plasma O
levels O
of O
amiodarone B-DRUG
. O
Grapefruit O
juice O
should O
not O
be O
taken O
during O
treatment O
with O
oral O

amiodarone O
. O
This O
information O
should O
be O
considered O
when O
changing O
from O
intravenous O
amiodarone B-DRUG
to O
oral O
amiodarone B-DRUG
. O
Amiodarone B-DRUG
may O
suppress O
certain O
CYP450 O
enzymes O
, O
including O
CYP1A2 B-DRUG
, O
CYP2C9 B-DRUG
, O
CYP2D6 B-DRUG
, O
and O
CYP3A4 B-DRUG
. O
This O
inhibition O
can O
result O
in O
unexpectedly O
high O
plasma O
levels O
of O
other O
drugs B-DRUG
which O
are O
metabolized O
by O
those O
CYP450 O
enzymes O
. O
Reported O
examples O
of O
this O
interaction O
include O
the O
following O
: O
Immunosuppressives B-DRUG
: O
Cyclosporine B-DRUG
( O
CYP3A4 B-DRUG
substrate O
) O
administered O
in O
combination O
with O
oral O
amiodarone B-DRUG
has O
been O
reported O
to O
produce O
persistently O
elevated O
plasma O
concentrations O
of O
cyclosporine B-DRUG
resulting O
in O
elevated O
creatinine O
, O
despite O
reduction O
in O
dose O
of O
cyclosporine B-DRUG
. O
HMG B-DRUG
- I-DRUG
CoA I-DRUG
Reductase I-DRUG
Inhibitors I-DRUG
: O
Simvastatin B-DRUG
( O
CYP3A4 B-DRUG
substrate O
) O
in O
combination O
with O
amiodarone B-DRUG
has O
been O
associated O
with O
reports O
of O
myopathy O
/ O
rhabdomyolysis O
. O
Cardiovasculars O
: O
Cardiac B-DRUG
glycosides I-DRUG
: O
In O
patients O
receiving O
digoxin B-DRUG
therapy O
, O
administration O
of O
oral O
amiodarone B-DRUG
regularly O
results O
in O
an O
increase O
in O
serum O
digoxin B-DRUG
concentration O
that O
may O
reach O
toxic O
levels O
with O
resultant O
clinical O
toxicity O
. O
Amiodarone B-DRUG
taken O
concomitantly O
with O
digoxin B-DRUG
increases O
the O
serum O
digoxin B-DRUG
concentration O
by O
70 O
% O
after O
one O
day O
. O
On O
administration O
of O
oral O
amiodarone B-DRUG
, O
the O
need O
for O
digitalis B-GROUP
therapy O
should O
be O
reviewed O
and O
the O
dose O
reduced O
by O
approximately O
50 O
% O
or O
discontinued O
. O
If O
digitalis B-DRUG
treatment O
is O
continued O
, O
serum O
levels O
should O
be O
closely O
monitored O
and O
patients O
observed O
for O
clinical O
evidence O
of O
toxicity O
. O
These O
precautions O
probably O
should O
apply O
to O
digitoxin B-DRUG
administration O
as O
well O
. O
Antiarrhythmics B-DRUG
: O
Other O
antiarrhythmic B-DRUG
drugs O
, O
such O
as O
quinidine B-DRUG
, O
procainamide B-DRUG
, O
disopyramide B-DRUG
, O
and O
phenytoin B-DRUG
, O
have O
been O
used O
concurrently O
with O
amiodarone B-DRUG
. O
There O
have O
been O
case O
reports O
of O
increased O
steady O
- O
state O
levels O
of O
quinidine B-DRUG
, O
procainamide B-DRUG
, O
and O
phenytoin B-DRUG
during O
concomitant O
therapy O
with O
amiodarone B-DRUG
. O
Phenytoin B-DRUG
decreases O
serum O
amiodarone O
levels O
. O
Amiodarone B-DRUG
taken O
concomitantly O
with O
quinidine B-DRUG
increases O
quinidine B-DRUG
serum O
concentration O
by O
33 O
% O
after O
two O
days O
. O
Amiodarone B-DRUG
taken O
concomitantly O
with O
procainamide B-DRUG

for O
less O
than O
seven O
days O
increases O
plasma O
concentrations O
of O
procainamide B-DRUG
and O
n O
- O
acetyl O
procainamide B-DRUG
by O
55 O
% O
and O
33 O
% O
, O
respectively O
. O
Quinidine B-DRUG
and O
procainamide O
doses O
should O
be O
reduced O
by O
one O
- O
third O
when O
either O
is O
administered O
with O
amiodarone B-DRUG
. O
Plasma O
levels O
of O
flecainide B-DRUG
have O
been O
reported O
to O
increase O
in O
the O
presence O
of O
oral O
amiodarone B-DRUG
; O
because O
of O
this O
, O
the O
dosage O
of O
flecainide B-DRUG
should O
be O
adjusted O
when O
these O
drugs B-DRUG
are O
administered O
concomitantly O
. O
In O
general O
, O
any O
added O
antiarrhythmic B-DRUG
drug I-DRUG
should O
be O
initiated O
at O
a O
lower O
than O
usual O
dose O
with O
careful O
monitoring O
. O
Combination O
of O
amiodarone B-DRUG
with O
other O
antiarrhythmic B-DRUG
therapy O
should O
be O
reserved O
for O
patients O
with O
life O
- O
threatening O
ventricular O
arrhythmias O
who O
are O
incompletely O
responsive O
to O
a O
single O
agent O
or O
incompletely O
responsive O
to O
amiodarone B-DRUG
. O
During O
transfer O
to O
oral O
amiodarone B-DRUG
, O
the O
dose O
levels O
of O
previously O
administered O
agents O
should O
be O
reduced O
by O
30 O
to O
50 O
% O
several O
days O
after O
the O
addition O
of O
oral O
amiodarone B-DRUG
. O
The O
continued O
need O
for O
the O
other O
antiarrhythmic B-DRUG
agent O
should O
be O
reviewed O
after O
the O
effects O
of O
amiodarone B-DRUG
have O
been O
established O
, O
and O
discontinuation O
ordinarily O
should O
be O
attempted O
. O
If O
the O
treatment O
is O
continued O
, O
these O
patients O
should O
be O
particularly O
carefully O
monitored O
for O
adverse O
effects O
, O
especially O
conduction O
disturbances O
and O
exacerbation O
of O
tachyarrhythmias O
, O
as O
amiodarone B-DRUG
is O
continued O
. O
In O
amiodarone B-DRUG
- O
treated O
patients O
who O
require O
additional O
antiarrhythmic B-DRUG
therapy O
, O
the O
initial O
dose O
of O
such O
agents O
should O
be O
approximately O
half O
of O
the O
usual O
recommended O
dose O
. O
Antihypertensives B-DRUG
: O
Amiodarone B-DRUG
should O
be O
used O
with O
caution O
in O
patients O
receiving O
- O
receptor B-DRUG
blocking O
agents O
( O
e O
. O
g O
. O
, O
propranolol B-DRUG
, O
a O
CYP3A4 B-DRUG
inhibitor O
) O
or O
calcium B-DRUG
channel I-DRUG
antagonists O
( O
e O
. O
g O
. O
, O
verapamil B-DRUG
, O
a O
CYP3A4 B-DRUG
substrate O
, O
and O
diltiazem B-DRUG
, O
a O
CYP3A4 B-DRUG
inhibitor O
) O
because O
of O
the O
possible O
potentiation O
of O
bradycardia O
, O
sinus O
arrest O
, O
and O
AV O
block O
; O
if O
necessary O
, O
amiodarone B-DRUG
can O
continue O
to O
be O
used O
after O
insertion O
of O
a O
pacemaker O
in O
patients O
with O
severe O
bradycardia O
or O
sinus O
arrest O
. O
Anticoagulants B-DRUG
: O
Potentiation O
of O
warfarin B-DRUG
- O
type O
( O
CYP2C9 B-DRUG
and O
CYP3A4 B-DRUG

substrate O
) O
anticoagulant B-DRUG
response O
is O
almost O
always O
seen O
in O
patients O
receiving O
amiodarone B-DRUG
and O
can O
result O
in O
serious O
or O
fatal O
bleeding O
. O
Since O
the O
concomitant O
administration O
of O
warfarin B-DRUG
with O
amiodarone B-DRUG
increases O
the O
prothrombin O
time O
by O
100 O
% O
after O
3 O
to O
4 O
days O
, O
the O
dose O
of O
the O
anticoagulant B-DRUG
should O
be O
reduced O
by O
one O
- O
third O
to O
one O
- O
half O
, O
and O
prothrombin O
times O
should O
be O
monitored O
closely O
. O
Some O
drugs B-DRUG
/ O
substances O
are O
known O
to O
accelerate O
the O
metabolism O
of O
amiodarone B-DRUG
by O
stimulating O
the O
synthesis O
of O
CYP3A4 B-DRUG
( O
enzyme O
induction O
) O
. O
This O
may O
lead O
to O
low O
amiodarone B-DRUG
serum O
levels O
and O
potential O
decrease O
in O
efficacy O
. O
Reported O
examples O
of O
this O
interaction O
include O
the O
following O
: O
Antibiotics B-DRUG
: O
Rifampin B-DRUG
is O
a O
potent O
inducer O
of O
CYP3A4 B-DRUG
. O
Administration O
of O
rifampin B-DRUG
concomitantly O
with O
oral O
amiodarone B-DRUG
has O
been O
shown O
to O
result O
in O
decreases O
in O
serum O
concentrations O
of O
amiodarone B-DRUG
and O
desethylamiodarone B-DRUG
. O
Other O
substances O
, O
including O
herbal O
preparations O
: O
St O
. O
John O
s O
Wort O
( O
Hypericum O
perforatum O
) O
induces O
CYP3A4 O
. O
Since O
amiodarone B-DRUG
is O
a O
substrate O
for O
CYP3A4 B-DRUG
, O
there O
is O
the O
potential O
that O
the O
use O
of O
St O
. O
John O
s O
Wort O
in O
patients O
receiving O
amiodarone B-DRUG
could O
result O
in O
reduced O
amiodarone B-DRUG
levels O
. O
Other O
reported O
interactions O
with O
amiodarone B-DRUG
: O
Fentanyl B-DRUG
( O
CYP3A4 B-DRUG
substrate O
) O
in O
combination O
with O
amiodarone B-DRUG
may O
cause O
hypotension O
, O
bradycardia O
, O
and O
decreased O
cardiac O
output O
. O
Sinus O
bradycardia O
has O
been O
reported O
with O
oral O
amiodarone B-DRUG
in O
combination O
with O
lidocaine B-DRUG
( O
CYP3A4 B-DRUG
substrate O
) O
given O
for O
local O
anesthesia B-DRUG
. O
Seizure O
, O
associated O
with O
increased O
lidocaine B-DRUG
concentrations O
, O
has O
been O
reported O
with O
concomitant O
administration O
of O
intravenous O
amiodarone B-DRUG
. O
Dextromethorphan B-DRUG
is O
a O
substrate O
for O
both O
CYP2D6 B-DRUG
and O
CYP3A4 B-DRUG
. O
Amiodarone B-DRUG
inhibits O
CYP2D6 B-DRUG
. O
Cholestyramine B-DRUG
increases O
enterohepatic O
elimination O
of O
amiodarone B-DRUG
and O
may O
reduce O
its O
serum O
levels O
and O
t1 B-DRUG
/ O
2 O
. O
Disopyramide B-DRUG
increases O
QT O
prolongation O
which O
could O
cause O
arrhythmia O
. O
Fluoroquinolones B-DRUG
, O
macrolide B-DRUG
antibiotics I-DRUG
, O
and O
azoles O
are O
known O
to O
cause O
QTc O
prolongation O
. O
There O

have O
been O
reports O
of O
QTc O
prolongation O
, O
with O
or O
without O
TdP O
, O
in O
patients O
taking O
amiodarone B-DRUG
when O
fluoroquinolones B-DRUG
, O
macrolide B-DRUG
antibiotics I-DRUG
, O
or O
azoles O
were O
administered O
concomitantly O
. O
Hemodynamic O
and O
electrophysiologic O
interactions O
have O
also O
been O
observed O
after O
concomitant O
administration O
with O
propranolol B-DRUG
, O
diltiazem B-DRUG
, O
and O
verapamil B-DRUG
. O
Volatile O
Anesthetic B-DRUG
Agents O
: O
. O
In O
addition O
to O
the O
interactions O
noted O
above O
, O
chronic O
( O
2 O
weeks O
) O
oral O
Cordarone B-DRUG
administration O
impairs O
metabolism O
of O
phenytoin B-DRUG
, O
dextromethorphan B-DRUG
, O
and O
methotrexate B-DRUG
. O
Electrolyte O
Disturbances O
Patients O
with O
hypokalemia O
or O
hypomagnesemia O
should O
have O
the O
condition O
corrected O
whenever O
possible O
before O
being O
treated O
with O
Cordarone B-DRUG
I I-DRUG
. I-DRUG
V I-DRUG
. I-DRUG
, O
as O
these O
disorders O
can O
exaggerate O
the O
degree O
of O
QTc O
prolongation O
and O
increase O
the O
potential O
for O
TdP O
. O
Special O
attention O
should O
be O
given O
to O
electrolyte O
and O
acid O
- O
base O
balance O
in O
patients O
experiencing O
severe O
or O
prolonged O
diarrhea O
or O
in O
patients O
receiving O
concomitant O
diuretics B-DRUG
. O

Drugs O
Metabolized O
by O
P450 O
2D6 O
- O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
caucasian O
population O
( O
about O
7 O
- O
10 O
% O
of O
caucasians O
are O
so O
called O
poor O
metabolizers O
) O
; O
reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O
Poor O
metabolizers O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-GROUP
antidepressants I-GROUP
( O
TCAs B-GROUP
) O
when O
given O
usual O
doses O
. O
Depending O
on O
the O
fraction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8 O
- O
fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA B-GROUP
) O
. O
In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
poor O
metabolizers O
. O
An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCA B-GROUP
may O
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O
The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-DRUG
; O
cimetidine B-DRUG
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-GROUP
, O
phenothiazines B-GROUP
, O
and O
the O
Type B-GROUP
1C I-GROUP
antiarrhythmics I-GROUP
propafenone B-DRUG
and O
flecainide B-DRUG
) O
. O
While O
all O
the O
selective O
serotonin B-GROUP
reuptake I-GROUP
inhibitors I-GROUP
( O
SSRIs B-GROUP
) O
, O
e O
. O
g O
. O
, O
fluoxetine B-DRUG
, O
sertraline B-DRUG
, O
and O
paroxetine B-DRUG
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O
The O
extent O
to O
which O
SSRI B-GROUP
- O
TCA B-GROUP
interactions O
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-GROUP
involved O
. O
Nevertheless O
, O
caution O
is O
indicated O
in O
the O
coadministration O
of O
TCAs B-GROUP
with O
any O
of O
the O
SSRIs B-GROUP
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O
Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCA O
treatment O
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-DRUG
, O
given O
the O
long O
half O
- O
life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O
Concomitant O
use O
of O
tricyclic B-GROUP

antidepressants I-GROUP
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-GROUP
antidepressant I-GROUP
or O
the O
other O
drug O
. O
Furthermore O
, O
whenever O
one O
of O
these O
other O
drugs O
is O
withdrawn O
from O
co O
- O
therapy O
, O
an O
increased O
dose O
of O
tricyclic B-DRUG
antidepressant I-DRUG
may O
be O
required O
. O
It O
is O
desirable O
to O
monitor O
TCA B-GROUP
plasma O
levels O
whenever O
a O
TCA B-GROUP
is O
going O
to O
be O
coadministered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
. O
Monoamine B-DRUG
Oxidase I-DRUG
Inhibitors I-DRUG
: O
Guanethidine B-DRUG
or O
similarly O
acting O
compounds O
; O
thyroid B-DRUG
medication O
; O
alcohol B-DRUG
, O
barbiturates B-DRUG
and O
other O
CNS B-DRUG
depressants I-DRUG
; O
and O
disulfiram B-DRUG
When O
amitriptyline B-DRUG
HCl I-DRUG
is O
given O
with O
anticholinergic B-DRUG
agents O
or O
sympathomimetic B-DRUG
drugs O
, O
including O
epinephrine B-DRUG
combined O
with O
local O
anesthetics B-DRUG
, O
close O
supervision O
and O
careful O
adjustment O
of O
dosages O
are O
required O
. O
Hyperpyrexia O
has O
been O
reported O
when O
amitriptyline B-DRUG
HCl I-DRUG
is O
administered O
with O
anticholinergic B-DRUG
agents O
or O
with O
neuroleptic B-DRUG
drugs O
, O
particularly O
during O
hot O
weather O
. O
Paralytic O
ileus O
may O
occur O
in O
patients O
taking O
tricyclic B-DRUG
antidepressants I-DRUG
in O
combination O
with O
anticholinergic B-DRUG
- O
type O
drugs O
. O
Cimetidine B-DRUG
is O
reported O
to O
reduce O
hepatic O
metabolism O
of O
certain O
tricyclic B-DRUG
antidepressants I-DRUG
, O
thereby O
delaying O
elimination O
and O
increasing O
steady O
- O
state O
concentrations O
of O
these O
drugs B-DRUG
. O
Clinically O
significant O
effects O
have O
been O
reported O
with O
the O
tricyclic B-DRUG
antidepressants I-DRUG
when O
used O
concomitantly O
with O
cimetidine B-DRUG
. O
Increases O
in O
plasma O
levels O
of O
tricyclic B-DRUG
antidepressants I-DRUG
, O
and O
in O
the O
frequency O
and O
severity O
of O
side O
effects O
, O
particularly O
anticholinergic B-DRUG
, O
have O
been O
reported O
when O
cimetidine B-DRUG
was O
added O
to O
the O
drug B-DRUG
regimen O
. O
Discontinuation O
of O
cimetidine B-DRUG
in O
well O
- O
controlled O
patients O
receiving O
tricyclic B-DRUG
antidepressants I-DRUG
and O
cimetidine B-DRUG
may O
decrease O
the O
plasma O
levels O
and O
efficacy O
of O
the O
antidepressants B-DRUG
. O
Caution O
is O
advised O
if O
patients O
receive O
large O
doses O
of O
ethchlorvynol B-DRUG
concurrently O
. O
Transient O
delirium O
has O
been O
reported O
in O
patients O
who O
were O
treated O
with O
one O
gram O
of O
ethchlorvynol B-DRUG
and O
75 O
- O
150 O
mg O
of O
amitriptyline B-DRUG
HCl I-DRUG
. O

When O
administered O
concurrently O
, O
the O
following O
drugs O
may O
interact O
with O
amphotericin B-DRUG
B I-DRUG
: O
Antineoplastic B-GROUP
agents I-GROUP
: O
may O
enhance O
the O
potential O
for O
renal O
toxicity O
, O
bronchospasm O
and O
hypotension O
. O
Antineoplastic B-GROUP
agents I-GROUP
( O
e O
. O
g O
. O
, O
nitrogen B-DRUG
mustard I-DRUG
, O
etc O
. O
) O
should O
be O
given O
concomitantly O
only O
with O
great O
caution O
. O
Corticosteroids B-GROUP
and O
Corticotropin B-DRUG
( O
ACTH B-GROUP
) O
: O
may O
potentiate O
amphotericin B-DRUG
B I-DRUG
- O
induced O
hypokalemia O
which O
may O
predispose O
the O
patient O
to O
cardiac O
dysfunction O
. O
Avoid O
concomitant O
use O
unless O
necessary O
to O
control O
side O
effects O
of O
amphotericin B-DRUG
B I-DRUG
. O
If O
used O
concomitantly O
, O
closely O
monitor O
serum O
electrolytes O
and O
cardiac O
function O
. O
Digitalis B-GROUP
glycosides I-GROUP
: O
amphotericin B-DRUG
B I-DRUG
- O
induced O
hypokalemia O
may O
potentiate O
digitalis B-GROUP
toxicity O
. O
Serum O
potassium O
levels O
and O
cardiac O
function O
should O
be O
closely O
monitored O
and O
any O
deficit O
promptly O
corrected O
. O
Flucytosine B-DRUG
: O
while O
a O
synergistic O
relationship O
with O
amphotericin B-DRUG
B I-DRUG
has O
been O
reported O
, O
concomitant O
use O
may O
increase O
the O
toxicity O
of O
flucytosine B-DRUG
by O
possibly O
increasing O
its O
cellular O
uptake O
and O
/ O
or O
impairing O
its O
renal O
excretion O
. O
Imidazoles B-GROUP
( O
e O
. O
g O
. O
, O
ketoconazole B-DRUG
, O
miconazole B-DRUG
, O
clotrimazole B-DRUG
, O
fluconazole B-DRUG
, O
etc O
. O
) O
: O
in O
vitro O
and O
animal O
studies O
with O
the O
combination O
of O
amphotericin B-DRUG
B I-DRUG
and O
imidazoles B-GROUP
suggest O
that O
imidazoles B-GROUP
may O
induce O
fungal O
resistance O
to O
amphotericin B-DRUG
B I-DRUG
. O
Combination O
therapy O
should O
be O
administered O
with O
caution O
, O
especially O
in O
immunocompromised O
patients O
. O
Other O
nephrotoxic O
medications O
: O
agents O
such O
as O
aminoglycosides B-GROUP
, O
cyclosporine B-DRUG
, O
and O
pentamidine B-DRUG
may O
enhance O
the O
potential O
for O
drug O
- O
induced O
renal O
toxicity O
, O
and O
should O
be O
used O
concomitantly O
only O
with O
great O
caution O
. O
Intensive O
monitoring O
of O
renal O
function O
is O
recommended O
in O
patients O
requiring O
any O
combination O
of O
nephrotoxic O
medications O
. O
Skeletal B-GROUP
muscle I-GROUP
relaxants I-GROUP
: O
amphotericin B-DRUG
B I-DRUG
- O
induced O
hypokalemia O
may O
enhance O
the O
curariform O
effect O
of O
skeletal B-GROUP
muscle I-GROUP
relaxants I-GROUP
( O
e O
. O
g O
. O
, O
tubocurarine B-DRUG
) O
. O
Serum O
potassium O
levels O
should O
be O
monitored O
and O
deficiencies O
corrected O
. O
Leukocyte B-DRUG_N
transfusions I-DRUG_N
: O
acute O
pulmonary O
toxicity O
has O
been O
reported O
in O
patients O
receiving O

intravenous O
amphotericin B-DRUG
B I-DRUG
and O
leukocyte B-DRUG_N
transfusions I-DRUG_N
. O

When O
administered O
concurrently O
, O
the O
following O
drugs O
may O
interact O
with O
ampicillin B-DRUG
. O
Allopurinol B-DRUG
: O
Increased O
possibility O
of O
skin O
rash O
, O
particularly O
in O
hyperuricemic O
patients O
may O
occur O
. O
Bacteriostatic B-GROUP
Antibiotics I-GROUP
: O
Chloramphenicol B-DRUG
, O
erythromycins B-DRUG
, O
sulfonamides B-GROUP
, O
or O
tetracyclines B-GROUP
may O
interfere O
with O
the O
bactericidal O
effect O
of O
penicillins B-GROUP
. O
This O
has O
been O
demonstrated O
in O
view O
, O
however O
, O
the O
clinical O
significance O
of O
this O
interaction O
is O
not O
well O
documented O
. O
Oral O
Contraceptives B-GROUP
: O
May O
be O
less O
effective O
and O
increased O
breakthrough O
bleeding O
may O
occur O
. O
Probenecid B-DRUG
: O
May O
decrease O
renal O
tubular O
secretion O
of O
ampicillin B-DRUG
resulting O
in O
increased O
blood O
levels O
and O
/ O
or O
ampicillin B-DRUG
toxicity O
. O
Drug O
/ O
Laboratory O
Test O
Interaction O
After O
treatment O
with O
ampicillin B-DRUG
, O
a O
false O
- O
positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
with O
copper B-DRUG_N
sulfate I-DRUG_N
tests O
( O
Benedicts O
solution O
, O
Fehlings O
solution O
, O
or O
Clinitest O
tablets O
) O
but O
not O
with O
enzyme O
based O
tests O
such O
as O
Clinistix O
and O
Glucose O
Enzymatic O
Test O
Strip O
USP O
. O

Amprenavir B-DRUG
is O
metabolized O
in O
the O
liver O
by O
the O
cytochrome O
P450 O
enzyme O
system O
. O
Amprenavir B-DRUG
inhibits O
CYP3A4 O
. O
Caution O
should O
be O
used O
when O
coadministering O
medications O
that O
are O
substrates O
, O
inhibitors O
, O
or O
inducers O
of O
CYP3A4 O
, O
or O
potentially O
toxic O
medications O
that O
are O
metabolized O
by O
CYP3A4 O
. O
Amprenavir B-DRUG
does O
not O
inhibit O
CYP2D6 O
, O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2E1 O
, O
or O
uridine O
glucuronosyltransferase O
( O
UDPGT O
) O
. O
HIV B-GROUP
Protease I-GROUP
Inhibitors I-GROUP
: O
The O
effect O
of O
amprenavir B-DRUG
on O
total O
drug O
concentrations O
of O
other O
HIV B-GROUP
protease I-GROUP
inhibitors I-GROUP
in O
subjects O
receiving O
both O
agents O
was O
evaluated O
using O
comparisons O
to O
historical O
data O
. O
Indinavir B-DRUG
steady O
- O
state O
Cmax O
, O
A O
. O
C O
. O
and O
Cmin O
were O
decreased O
by O
22 O
% O
, O
38 O
% O
, O
and O
27 O
% O
, O
respectively O
, O
by O
concomitant O
amprenavir B-DRUG
. O
Similar O
decreases O
in O
Cmax O
and O
AUC O
were O
seen O
after O
the O
first O
dose O
. O
Saquinavir B-DRUG
steady O
- O
state O
Cmax O
, O
A O
. O
C O
. O
and O
Cmin O
were O
increased O
21 O
% O
, O
decreased O
19 O
% O
, O
and O
decreased O
48 O
% O
, O
respectively O
, O
by O
concomitant O
amprenavir B-DRUG
. O
Nelfinavir B-DRUG
steady O
- O
state O
Cmax O
, O
A O
. O
C O
. O
and O
Cmin O
were O
increased O
by O
12 O
% O
, O
15 O
% O
, O
and O
14 O
% O
, O
respectively O
, O
by O
concomitant O
amprenavir B-DRUG
. O
Methadone B-DRUG
: O
Coadministration O
of O
amprenavir B-DRUG
and O
methadone B-DRUG
can O
decrease O
plasma O
levels O
of O
methadone B-DRUG
. O
Coadministration O
of O
amprenavir B-DRUG
and O
methadone B-DRUG
as O
compared O
to O
a O
non O
- O
matched O
historicalcontrol O
group O
resulted O
in O
a O
30 O
% O
, O
27 O
% O
, O
and O
25 O
% O
decrease O
in O
serum O
amprenavir B-DRUG
AUC O
, O
Cmax O
, O
andCmin O
, O
respectively O
. O
Amprenavir B-DRUG
is O
an O
inhibitor O
of O
cytochrome O
P450 O
C O
. O
P O
. O
A O
. O
metabolism O
and O
therefore O
should O
not O
be O
administered O
concurrently O
with O
medications O
with O
narrow O
therapeutic O
windows O
that O
are O
substrates O
of O
CYP3A4 O
. O
There O
are O
other O
agents O
that O
may O
result O
in O
serious O
and O
/ O
or O
life O
- O
threatening O
drug O
interactions O
. O
Laboratory O
Tests O
: O
The O
combination O
of O
Amprenavir B-DRUG
and O
low O
- O
dose O
ritonavir B-DRUG
has O
been O
associated O
with O
elevations O
of O
cholesterol O
and O
triglycerides O
, O
SGOT O
( O
AST O

) O
, O
and O
SGPT O
( O
ALT O
) O
in O
some O
patients O
. O
Appropriate O
laboratory O
testing O
should O
be O
considered O
prior O
to O
initiating O
combination O
therapy O
with O
Amprenavir B-DRUG
and O
ritonavir B-DRUG
and O
at O
periodic O
intervals O
or O
if O
any O
clinical O
signs O
or O
symptoms O
of O
hyperlipidemia O
or O
elevated O
liver O
function O
tests O
occur O
during O
therapy O
. O
For O
comprehensive O
information O
concerning O
laboratory O
test O
alterations O
associated O
with O
ritonavir B-DRUG
, O
physicians O
should O
refer O
to O
the O
complete O
prescribing O
information O
for O
NORVIR B-BRAND
( O
ritonavir B-DRUG
) O
. O

Taking O
amyl B-DRUG
nitrite I-DRUG
after O
drinking O
alcohol B-DRUG
may O
worsen O
side O
effects O
and O
may O
cause O
severe O
hypotension O
and O
cardiovascular O
collapse O
. O

Limited O
PK O
and O
/ O
or O
PD O
studies O
investigating O
possible O
interactions O
between O
anagrelide B-DRUG
and O
other O
medicinal O
products O
have O
been O
conducted O
. O
In O
vivo O
interaction O
studies O
in O
humans O
have O
demonstrated O
that O
digoxin B-DRUG
and O
warfarin B-DRUG
do O
not O
affect O
the O
PK O
properties O
of O
anagrelide B-DRUG
, O
nor O
does O
anagrelide B-DRUG
affect O
the O
PK O
properties O
of O
digoxin B-DRUG
or O
warfarin B-DRUG
. O
Although O
additional O
drug O
interaction O
studies O
have O
not O
been O
conducted O
, O
the O
most O
common O
medications O
used O
concomitantly O
with O
anagrelide B-DRUG
in O
clinical O
trials O
were O
aspirin B-BRAND
, O
acetaminophen B-DRUG
, O
furosemide B-DRUG
, O
iron B-DRUG
, O
ranitidine B-DRUG
, O
hydroxyurea B-DRUG
, O
and O
allopurinol B-DRUG
. O
There O
is O
no O
clinical O
evidence O
to O
suggest O
that O
anagrelide B-DRUG
interacts O
with O
any O
of O
these O
compounds O
. O
An O
in O
vivo O
interaction O
study O
in O
humans O
demonstrated O
that O
a O
single O
1mg O
dose O
of O
anagrelide B-DRUG
administered O
concomitantly O
with O
a O
single O
900 O
mg O
dose O
of O
aspirin B-BRAND
was O
generally O
well O
tolerated O
. O
There O
was O
no O
effect O
on O
bleeding O
time O
, O
PT O
or O
aPTT O
. O
No O
clinically O
relevant O
pharmacokinetic O
interactions O
between O
anagrelide B-DRUG
and O
acetylsalicylic B-DRUG
acid I-DRUG
were O
observed O
. O
In O
that O
same O
study O
, O
aspirin B-BRAND
alone O
produced O
a O
marked O
inhibition O
in O
platelet O
aggregation O
ex O
vivo O
. O
Anagrelide B-DRUG
alone O
had O
no O
effect O
on O
platelet O
aggregation O
, O
but O
did O
slightly O
enhance O
the O
inhibition O
of O
platelet O
aggregation O
by O
aspirin B-BRAND
. O
Anagrelide B-DRUG
is O
metabolized O
at O
least O
in O
part O
by O
CYP1A2 O
. O
It O
is O
known O
that O
CYP1A2 O
is O
inhibited O
by O
several O
medicinal O
products O
, O
including O
fluvoxamine B-DRUG
, O
and O
such O
medicinal O
products O
could O
theoretically O
adversely O
influence O
the O
clearance O
of O
anagrelide B-DRUG
. O
Anagrelide B-DRUG
demonstrates O
some O
limited O
inhibitory O
activity O
towards O
CYP1A2 O
which O
may O
present O
a O
theoretical O
potential O
for O
interaction O
with O
other O
coadministered O
medicinal O
products O
sharing O
that O
clearance O
mechanism O
e O
. O
g O
. O
Anagrelide B-DRUG
demonstrates O
some O
limited O
inhibitory O
activity O
towards O
CYP1A2 O
which O
may O
present O
a O
theoretical O
potential O
for O
interaction O
with O
other O
coadministered O
medicinal O
products O
sharing O
that O
clearance O
mechanism O
e O
. O
g O
. O
theophylline B-DRUG
. O
Anagrelide B-DRUG
is O
an O
inhibitor O
of O
cyclic O
AMP O
PDE O
III O
. O
The O
effects O
of O
medicinal O
products O
with O
similar O
properties O
such O
as O
inotropes O
milrinone B-DRUG
, O
enoximone B-DRUG
, O
amrinone B-DRUG
, O
olprinone B-DRUG_N
and O
cilostazol B-DRUG
may O
be O
exacerbated O
by O
anagrelide B-DRUG
. O
There O

is O
a O
single O
case O
report O
, O
which O
suggests O
that O
sucralfate B-DRUG
may O
interfere O
with O
anagrelide B-DRUG
absorption O
. O
Food O
has O
no O
clinically O
significant O
effect O
on O
the O
bioavailability O
of O
anagrelide B-DRUG
. O

No O
drug O
- O
drug O
interaction O
studies O
in O
human O
subjects O
have O
been O
conducted O
. O
Toxicologic O
and O
toxicokinetic O
studies O
in O
rats O
did O
not O
demonstrate O
any O
alterations O
in O
the O
clearance O
or O
toxicologic O
profile O
of O
either O
methotrexate B-DRUG
or O
Kineret B-BRAND
when O
the O
two O
agents O
were O
administered O
together O
. O
In O
a O
study O
in O
which O
patients O
with O
active O
RA O
were O
treated O
for O
up O
to O
24 O
weeks O
with O
concurrent O
Kineret B-BRAND
and O
etanercept B-DRUG
therapy O
, O
a O
7 O
% O
rate O
of O
serious O
infections O
was O
observed O
, O
which O
was O
higher O
than O
that O
observed O
with O
etanercept B-DRUG
alone O
( O
0 O
% O
) O
. O
Two O
percent O
of O
patients O
treated O
concurrently O
with O
Kineret B-BRAND
and O
etanercept B-DRUG
developed O
neutropenia O
( O
ANC O
1 O
x O
109 O
/ O
L O
) O
. O

Anastrozole B-DRUG
inhibited O
in O
vitro O
metabolic O
reactions O
catalyzed O
by O
cytochromes O
P450 O
1A2 O
, O
2C8 O
/ O
9 O
, O
and O
3A4 O
but O
only O
at O
relatively O
high O
concentrations O
. O
Anastrozole B-DRUG
did O
not O
inhibit O
P450 O
2A6 O
or O
the O
polymorphic O
P450 O
2D6 O
in O
human O
liver O
microsomes O
. O
Anastrozole B-DRUG
did O
not O
alter O
the O
pharmacokinetics O
of O
antipyrine B-DRUG
. O
Although O
there O
have O
been O
no O
formal O
interaction O
studies O
other O
than O
with O
antipyrine B-DRUG
, O
based O
on O
these O
in O
vivo O
and O
in O
vitro O
studies O
, O
it O
is O
unlikely O
that O
co O
- O
administration O
of O
a O
1 O
mg O
dose O
of O
ARIMIDEX B-BRAND
with O
other O
drugs O
will O
result O
in O
clinically O
significant O
drug O
inhibition O
of O
cytochrome O
P450 O
- O
mediated O
metabolism O
of O
the O
other O
drugs O
. O
An O
interaction O
study O
with O
warfarin B-DRUG
showed O
no O
clinically O
significant O
effect O
of O
anastrozole B-DRUG
on O
warfarin B-DRUG
pharmacokinetics O
or O
anticoagulant O
activity O
. O
At O
a O
median O
follow O
- O
up O
of O
33 O
months O
, O
the O
combination O
of O
ARIMIDEX B-BRAND
and O
tamoxifen B-DRUG
did O
not O
demonstrate O
any O
efficacy O
benefit O
when O
compared O
with O
tamoxifen B-DRUG
in O
all O
patients O
as O
well O
as O
in O
the O
hormone O
receptor O
- O
positive O
subpopulation O
. O
This O
treatment O
arm O
was O
discontinued O
from O
the O
trial O
. O
Based O
on O
clinical O
and O
pharmacokinetic O
results O
from O
the O
ATAC O
trial O
, O
tamoxifen B-DRUG
should O
not O
be O
administered O
with O
anastrozole B-DRUG
( O
see O
CLINICAL O
PHARMACOLOGY O
Drug O
Interactions O
and O
CLINICAL O
PHARMACOLOGY O
- O
Clinical O
Studies O
- O
Adjuvant O
Treatment O
of O
Breast O
Cancer O
in O
Postmenopausal O
Women O
subsections O
) O
. O
Co O
- O
administration O
of O
anastrozole B-DRUG
and O
tamoxifen B-DRUG
resulted O
in O
a O
reduction O
of O
anastrozole B-DRUG
plasma O
levels O
by O
27 O
% O
compared O
with O
those O
achieved O
with O
anastrozole B-DRUG
alone O
. O
Estrogen B-GROUP
- O
containing O
therapies O
should O
not O
be O
used O
with O
ARIMIDEX B-BRAND
as O
they O
may O
diminish O
its O
pharmacologic O
action O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
No O
clinically O
significant O
changes O
in O
the O
results O
of O
clinical O
laboratory O
tests O
have O
been O
observed O
. O

No O
clinically O
relevant O
drug O
- O
drug O
interactions O
have O
been O
observed O
with O
drugs O
likely O
to O
be O
co O
- O
administered O
with O
anidulafungin B-DRUG
. O

Caution O
should O
be O
observed O
when O
anileridine B-DRUG
is O
coadministered O
with O
other O
opioids B-GROUP
, O
sedatives B-GROUP
, O
phenothiazines B-GROUP
, O
or O
anesthetics B-GROUP
, O
as O
these O
agents O
may O
increase O
respiratory O
and O
circulatory O
depression O
. O

Addition O
or O
deletion O
of O
any O
drug O
from O
the O
therapeutic O
regimen O
of O
patients O
receiving O
oral O
anticoagulants B-GROUP
may O
affect O
patient O
response O
to O
the O
anticoagulant B-GROUP
. O
Frequent O
determination O
of O
prothrombin O
time O
and O
close O
monitoring O
of O
the O
patient O
is O
essential O
to O
ascertain O
when O
adjustment O
of O
dosage O
of O
anticoagulant B-GROUP
may O
be O
needed O
. O
Because O
of O
the O
variability O
of O
individual O
patient O
response O
, O
multiple O
interacting O
mechanisms O
with O
some O
drugs O
, O
the O
dependency O
of O
the O
extent O
of O
the O
interaction O
on O
the O
dosage O
and O
duration O
of O
therapy O
, O
and O
the O
possible O
administration O
of O
several O
interacting O
drugs O
simultaneously O
, O
it O
is O
difficult O
to O
predict O
the O
direction O
and O
degree O
of O
the O
ultimate O
effect O
of O
concomitant O
medications O
on O
anticoagulant B-GROUP
response O
. O
For O
example O
, O
since O
cholestyramine B-DRUG
may O
reduce O
the O
gastrointestinal O
absorption O
of O
both O
the O
oral O
anticoagulants B-GROUP
and O
vitamin B-GROUP
K I-GROUP
, O
the O
net O
effects O
are O
unpredictable O
. O
Chloral B-DRUG
hydrate I-DRUG
may O
cause O
an O
increased O
prothrombin O
response O
by O
displacing O
the O
anticoagulant B-GROUP
from O
protein O
binding O
sites O
or O
a O
diminished O
prothrombin O
response O
through O
increased O
metabolism O
of O
the O
unbound O
drug O
by O
hepatic O
enzyme O
induction O
, O
thus O
leading O
to O
inter O
- O
patient O
variation O
in O
ultimate O
prothrombin O
effect O
. O
An O
interacting O
drug O
which O
leads O
to O
a O
decrease O
in O
prothrombin O
time O
necessitating O
an O
increased O
dose O
of O
oral O
anticoagulant B-GROUP
to O
maintain O
an O
adequate O
degree O
of O
anticoagulation O
may O
, O
if O
abruptly O
discontinued O
, O
increase O
the O
risk O
of O
subsequent O
bleeding O
. O
Drugs O
that O
have O
been O
reported O
to O
diminish O
oral O
anticoagulant B-GROUP
response O
, O
ie O
, O
decreased O
prothrom O
- O
bin O
time O
response O
, O
in O
man O
significantly O
include O
: O
adrenocortical B-GROUP
steroids I-GROUP
; O
alcohol B-DRUG
* O
; O
antacids B-GROUP
; O
antihistamines B-GROUP
; O
barbiturates B-GROUP
; O
carbamazepine B-DRUG
; O
chloral B-DRUG
hydrate I-DRUG
* O
; O
chlordiazepoxide B-DRUG
; O
cholestyramine B-DRUG
; O
diet O
high O
in O
vitamin B-GROUP
K I-GROUP
; O
diuretics B-GROUP
* O
; O
ethchlorvynol B-DRUG
; O
glutethimide B-DRUG
; O
griseofulvin B-DRUG
; O
haloperidol B-DRUG
; O
meprobamate B-DRUG
; O
oral O
contraceptives B-GROUP
; O
paraldehyde B-DRUG
; O
primidone B-DRUG
; O
ranitidine B-DRUG
* O
; O
rifampin B-DRUG
; O
unreliable O
prothrombin O
time O
determinations O
; O
vitamin B-DRUG
C I-DRUG
; O
Drugs O
that O
have O
been O
reported O
to O
diminish O
oral O
anticoagulant B-GROUP
response O
, O
ie O
, O
decreased O
prothrom O
- O
bin O
time O
response O
, O
in O
man O
significantly O
include O
: O
adrenocortical B-GROUP
steroids I-GROUP
; O
alcohol B-DRUG
* O
; O
antacids B-GROUP
; O
antihistamines B-GROUP

; O
barbiturates B-GROUP
; O
carbamazepine B-DRUG
; O
chloral B-DRUG
hydrate I-DRUG
* O
; O
chlordiazepoxide B-DRUG
; O
cholestyramine B-DRUG
; O
diet O
high O
in O
vitamin B-GROUP
K I-GROUP
; O
diuretics B-GROUP
* O
; O
ethchlorvynol B-DRUG
; O
glutethimide B-DRUG
; O
griseofulvin B-DRUG
; O
haloperidol B-DRUG
; O
meprobamate B-DRUG
; O
oral O
contraceptives B-GROUP
; O
paraldehyde B-DRUG
; O
primidone B-DRUG
; O
ranitidine B-DRUG
* O
; O
rifampin B-DRUG
; O
unreliable O
prothrombin O
time O
determinations O
; O
vitamin B-DRUG
C I-DRUG
; O
warfarin B-DRUG
sodium I-DRUG
under O
- O
dosage O
. O
Drugs O
that O
reportedly O
may O
increase O
oral O
anticoagulant B-GROUP
response O
, O
ie O
, O
increased O
prothrombin O
response O
, O
in O
man O
include O
: O
alcohol B-DRUG
* O
; O
allopurinol B-DRUG
; O
aminosalicylic B-DRUG
acid I-DRUG
; O
amiodarone B-DRUG
; O
anabolic B-GROUP
steroids I-GROUP
; O
antibiotics B-GROUP
; O
bromelains B-DRUG
; O
chloral B-DRUG
hydrate I-DRUG
* O
; O
chlorpropamide B-DRUG
; O
chymotrypsin B-DRUG
; O
cimetidine B-DRUG
; O
cinchophen B-DRUG
; O
clofibrate B-DRUG
; O
dextran B-DRUG
; O
dextrothyroxine B-DRUG
; O
diazoxide B-DRUG
; O
dietary O
deficiencies O
; O
diflunisal B-DRUG
; O
diuretics B-GROUP
* O
; O
disulfiram B-DRUG
; O
drugs O
affecting O
blood O
elements O
; O
ethacrynic B-DRUG
acid I-DRUG
; O
fenoprofen B-DRUG
; O
glucagon B-DRUG
; O
hepatotoxic O
drugs O
; O
ibuprofen B-DRUG
; O
indomethacin B-DRUG
; O
influenza B-GROUP
virus I-GROUP
vaccine I-GROUP
; O
inhalation O
anesthetics B-GROUP
; O
mefenamic B-DRUG
acid I-DRUG
; O
methyldopa B-DRUG
; O
methylphenidate B-DRUG
; O
metronidazole B-DRUG
; O
miconazole B-DRUG
; O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
; O
nalidixic B-DRUG
acid I-DRUG
; O
naproxen B-DRUG
; O
oxolinic B-DRUG
acid I-DRUG
; O
oxyphenbutazone B-DRUG
; O
pentoxifylline B-DRUG
; O
phenylbutazone B-DRUG
; O
phenyramidol B-DRUG_N
; O
phenytoin B-DRUG
; O
prolonged O
hot O
weather O
; O
prolonged B-GROUP
narcotics I-GROUP
; O
pyrazolones B-GROUP
; O
quinidine B-DRUG
; O
quinine B-DRUG
; O
ranitidine B-DRUG
* O
; O
salicylates B-GROUP
; O
sulfinpyrazone B-DRUG
; O
sulfonamides B-GROUP
, O
long O
acting O
; O
sulindac B-DRUG
; O
thyroid B-GROUP
drugs I-GROUP
; O
tolbutamide B-DRUG
; O
triclofos B-DRUG
sodium I-DRUG
; O
trimethoprim B-DRUG
/ O
sulfamethoxazole B-DRUG
; O
unreliable O
prothrombin O
time O
determinations O
; O
Drugs O
that O
reportedly O
may O
increase O
oral O
anticoagulant B-GROUP

response O
, O
ie O
, O
increased O
prothrombin O
response O
, O
in O
man O
include O
: O
alcohol B-DRUG
* O
; O
allopurinol B-DRUG
; O
aminosalicylic B-DRUG
acid I-DRUG
; O
amiodarone B-DRUG
; O
anabolic B-GROUP
steroids I-GROUP
; O
antibiotics B-GROUP
; O
bromelains B-DRUG
; O
chloral B-DRUG
hydrate I-DRUG
* O
; O
chlorpropamide B-DRUG
; O
chymotrypsin B-DRUG
; O
cimetidine B-DRUG
; O
cinchophen B-DRUG
; O
clofibrate B-DRUG
; O
dextran B-DRUG
; O
dextrothyroxine B-DRUG
; O
diazoxide B-DRUG
; O
dietary O
deficiencies O
; O
diflunisal B-DRUG
; O
disulfiram B-DRUG
; O
drugs O
affecting O
blood O
elements O
; O
ethacrynic B-DRUG
acid I-DRUG
; O
fenoprofen B-DRUG
; O
glucagon B-DRUG
; O
hepatotoxic O
drugs O
; O
ibuprofen B-DRUG
; O
indomethacin B-DRUG
; O
influenza B-GROUP
virus I-GROUP
vaccine I-GROUP
; O
inhalation O
anesthetics B-GROUP
; O
mefenamic B-DRUG
acid I-DRUG
; O
methyldopa B-DRUG
; O
methylphenidate B-DRUG
; O
metronidazole B-DRUG
; O
miconazole B-DRUG
; O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
; O
nalidixic B-DRUG
acid I-DRUG
; O
naproxen B-DRUG
; O
oxolinic B-DRUG
acid I-DRUG
; O
oxyphenbutazone B-DRUG
; O
pentoxifylline B-DRUG
; O
phenylbutazone B-DRUG
; O
phenyramidol B-DRUG_N
; O
phenytoin B-DRUG
; O
prolonged O
hot O
weather O
; O
prolonged B-GROUP
narcotics I-GROUP
; O
pyrazolones B-GROUP
; O
quinidine B-DRUG
; O
quinine B-DRUG
; O
ranitidine B-DRUG
* O
; O
salicylates B-GROUP
; O
sulfinpyrazone B-DRUG
; O
sulfonamides B-GROUP
, O
long O
acting O
; O
sulindac B-DRUG
; O
thyroid B-GROUP
drugs I-GROUP
; O
tolbutamide B-DRUG
; O
triclofos B-DRUG
sodium I-DRUG
; O
trimethoprim B-DRUG
/ O
sulfamethoxazole B-DRUG
; O
unreliable O
prothrombin O
time O
determinations O
; O
warfarin B-DRUG
sodium I-DRUG
overdosage O
. O
Oral O
anticoagulants B-GROUP
may O
potentiate O
the O
hypoglycemic O
action O
of O
hypoglycemic B-GROUP
agents I-GROUP
, O
eg O
, O
tolbutamide B-DRUG
and O
chlorpropamide B-DRUG
, O
by O
inhibiting O
their O
metabolism O
in O
the O
liver O
. O
Because O
oral O
anticoagulants B-GROUP
may O
interfere O
with O
the O
hepatic O
metabolism O
of O
phenytoin B-DRUG
, O
toxic O
levels O
of O
the O
anticonvulsant B-GROUP
may O
occur O
when O
an O
oral O
anticoagulant B-GROUP
and O
phenytoin B-DRUG
are O
administered O
concurrently O
. O
Drugs O
that O
reduce O
the O
number O
of O
blood O
platelets O
by O
causing O
bone O
marrow O
depression O
( O
such O
as O
antineoplastic B-GROUP
agents I-GROUP
) O
or O
drugs O
which O
inhibit O
platelet O
function O
( O
eg O
, O
aspirin B-BRAND

and O
other O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
, O
dipyridamole B-DRUG
, O
hydrochloroquine B-DRUG
, O
clofibrate B-DRUG
, O
dextran B-DRUG
) O
may O
increase O
the O
bleeding O
tendency O
produced O
by O
anticoagulants B-GROUP
without O
altering O
prothrombin O
time O
determinations O
. O
The O
beneficial O
effects O
on O
arterial O
thrombus O
formation O
from O
combined O
therapy O
with O
antiplatelet B-GROUP
and I-GROUP
anticoagulant I-GROUP
medication I-GROUP
must O
be O
weighed O
against O
an O
increased O
risk O
of O
inducing O
hemorrhage O
. O
* O
Increased O
and O
decreased O
prothrombin O
time O
responses O
have O
been O
reported O
. O
Drug O
/ O
Laboratory O
Test O
Interferences O
: O
Dicumarol B-DRUG
and O
indanedione B-GROUP
anticoagulants I-GROUP
, O
including O
anisindione B-DRUG
, O
or O
their O
metabolites O
may O
color O
alkaline O
urine O
red O
- O
orange O
, O
which O
may O
interfere O
with O
spectrophotometrically O
determined O
urinary O
laboratory O
tests O
. O
The O
color O
reverses O
when O
the O
test O
sample O
is O
acidified O
in O
vitro O
to O
a O
pH O
below O
4 O
. O

5HT3 B-GROUP
Antagonists I-GROUP
: O
Based O
on O
reports O
of O
profound O
hypotension O
and O
loss O
of O
consciousness O
when O
apomorphine B-DRUG
was O
administered O
with O
ondansetron B-DRUG
, O
the O
concomitant O
use O
of O
apomorphine B-DRUG
with O
drugs O
of O
the O
5HT3 B-GROUP
antagonist I-GROUP
class I-GROUP
( O
including O
, O
for O
example O
, O
ondansetron B-DRUG
, O
granisetron B-DRUG
, O
dolasetron B-DRUG
, O
palonosetron B-DRUG
, O
and O
alosetron B-DRUG
) O
is O
contraindicated O
. O
Antihypertensive B-GROUP
Medications I-GROUP
and O
Vasodilators B-GROUP
: O
The O
following O
adverse O
events O
were O
experienced O
more O
commonly O
in O
patients O
receiving O
concomitant O
antihypertensive B-GROUP
medications I-GROUP
or O
vasodilators B-GROUP
( O
n O
= O
94 O
) O
compared O
to O
patients O
not O
receiving O
these O
concomitant O
drugs O
( O
n O
= O
456 O
) O
: O
hypotension O
10 O
% O
vs O
4 O
% O
, O
myocardial O
infarction O
3 O
% O
vs O
1 O
% O
, O
serious O
pneumonia O
5 O
% O
vs O
3 O
% O
, O
serious O
falls O
9 O
% O
vs O
3 O
% O
, O
and O
bone O
and O
joint O
injuries O
6 O
% O
vs O
2 O
% O
. O
The O
mechanism O
underlying O
many O
of O
these O
events O
is O
unknown O
, O
but O
may O
represent O
increased O
hypotension O
. O
Dopamine B-GROUP
Antagonists I-GROUP
: O
Since O
apomorphine B-DRUG
is O
a O
dopamine B-GROUP
agonist I-GROUP
, O
it O
is O
possible O
that O
dopamine B-GROUP
antagonists I-GROUP
, O
such O
as O
the O
neuroleptics B-GROUP
( O
phenothiazines B-GROUP
, O
butyrophenones B-GROUP
, O
thioxanthenes B-GROUP
) O
or O
metoclopramide B-DRUG
, O
may O
diminish O
the O
effectiveness O
of O
APOKYN B-BRAND
. O
Patients O
with O
major O
psychotic O
disorders O
, O
treated O
with O
neuroleptics B-GROUP
, O
should O
be O
treated O
with O
dopamine B-GROUP
agonists I-GROUP
only O
if O
the O
potential O
benefits O
outweigh O
the O
risks O
. O
Drugs O
Prolonging O
the O
QT O
/ O
QTc O
Interval O
Caution O
should O
be O
exercised O
when O
prescribing O
apomorphine B-DRUG
concomitantly O
with O
drugs O
that O
prolong O
the O
QT O
/ O
QTc O
interval O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
There O
are O
no O
known O
interactions O
between O
APOKYN B-BRAND
and O
laboratory O
tests O
. O

Apraclonidine B-DRUG
should O
not O
be O
used O
in O
patients O
receiving O
MAO B-GROUP
inhibitors I-GROUP
. O
. O
Although O
no O
specific O
drug O
interactions O
with O
topical O
glaucoma O
drugs O
or O
systemic O
medications O
were O
identified O
in O
clinical O
studies O
of O
IOPIDINE B-BRAND
0 O
. O
5 O
% O
Ophthalmic O
Solution O
, O
the O
possibility O
of O
an O
additive O
or O
potentiating O
effect O
with O
CNS B-GROUP
depressants I-GROUP
( O
alcohol B-DRUG
, O
barbiturates B-GROUP
, O
opiates B-GROUP
, O
sedatives B-GROUP
, O
anesthetics B-GROUP
) O
should O
be O
considered O
. O
Tricyclic B-GROUP
antidepressants I-GROUP
have O
been O
reported O
to O
blunt O
the O
hypotensive O
effect O
of O
systemic O
clonidine B-DRUG
. O
It O
is O
not O
known O
whether O
the O
concurrent O
use O
of O
these O
agents O
with O
apraclonidine B-DRUG
can O
lead O
to O
a O
reduction O
in O
IOP O
lowering O
effect O
. O
No O
data O
on O
the O
level O
of O
circulating O
catecholamines O
after O
apraclonidine B-DRUG
withdrawal O
are O
available O
. O
Caution O
, O
however O
, O
is O
advised O
in O
patients O
taking O
tricyclic B-GROUP
antidepressants I-GROUP
which O
can O
affect O
the O
metabolism O
and O
uptake O
of O
circulating O
amines O
. O
An O
additive O
hypotensive O
effect O
has O
been O
reported O
with O
the O
combination O
of O
systemic O
clonidine B-DRUG
and O
neuroleptic B-GROUP
therapy O
. O
Systemic O
clonidine B-DRUG
may O
inhibit O
the O
production O
of O
catecholamines O
in O
response O
to O
insulin O
- O
induced O
hypoglycemia O
and O
mask O
the O
signs O
and O
symptoms O
of O
hypoglycemia O
. O
Since O
apraclonidine B-DRUG
may O
reduce O
pulse O
and O
blood O
pressure O
, O
caution O
in O
using O
drugs O
such O
as O
beta B-GROUP
- I-GROUP
blockers I-GROUP
( O
ophthalmic O
and O
systemic O
) O
, O
antihypertensives B-GROUP
, O
and O
cardiac B-GROUP
glycosides I-GROUP
is O
advised O
. O
Patients O
using O
cardiovascular O
drugs O
concurrently O
with O
IOPIDINE B-BRAND
0 O
. O
5 O
% O
Ophthalmic O
Solution O
should O
have O
pulse O
and O
blood O
pressures O
frequently O
monitored O
. O
Caution O
should O
be O
exercised O
with O
simultaneous O
use O
of O
clonidine B-DRUG
and O
other O
similar O
pharmacologic O
agents O
. O

Aprepitant B-DRUG
is O
a O
substrate O
, O
a O
moderate O
inhibitor O
, O
and O
an O
inducer O
of O
CYP3A4 O
. O
Aprepitant B-DRUG
is O
also O
an O
inducer O
of O
CYP2C9 O
. O
Effect O
of O
aprepitant B-DRUG
on O
the O
pharmacokinetics O
of O
other O
agents O
As O
a O
moderate O
inhibitor O
of O
CYP3A4 O
, O
aprepitant B-DRUG
can O
increase O
plasma O
concentrations O
of O
coadministered O
medicinal O
products O
that O
are O
metabolized O
through O
CYP3A4 O
. O
Aprepitant B-DRUG
has O
been O
shown O
to O
induce O
the O
metabolism O
of O
S B-DRUG
( I-DRUG
- I-DRUG
) I-DRUG
warfarin I-DRUG
and O
tolbutamide B-DRUG
, O
which O
are O
metabolized O
through O
CYP2C9 O
. O
Coadministration O
of O
Aprepitant B-DRUG
with O
these O
drugs O
or O
other O
drugs O
that O
are O
known O
to O
be O
metabolized O
by O
CYP2C9 O
, O
such O
as O
phenytoin B-DRUG
, O
may O
result O
in O
lower O
plasma O
concentrations O
of O
these O
drugs O
. O
Aprepitant B-DRUG
is O
unlikely O
to O
interact O
with O
drugs O
that O
are O
substrates O
for O
the O
P O
- O
glycoprotein O
transporter O
, O
as O
demonstrated O
by O
the O
lack O
of O
interaction O
of O
Aprepitant B-DRUG
with O
digoxin B-DRUG
in O
a O
clinical O
drug O
interaction O
study O
. O
5 B-GROUP
- I-GROUP
HT3 I-GROUP
antagonists I-GROUP
: O
In O
clinical O
drug O
interaction O
studies O
, O
aprepitant B-DRUG
did O
not O
have O
clinically O
important O
effects O
on O
the O
pharmacokinetics O
of O
ondansetron B-DRUG
or O
granisetron B-DRUG
. O
No O
clinical O
or O
drug O
interaction O
study O
was O
conducted O
with O
dolasetron B-DRUG
. O
Corticosteroids B-GROUP
: O
Dexamethasone B-DRUG
: O
Aprepitant B-DRUG
, O
when O
given O
as O
a O
regimen O
of O
125mg O
with O
dexamethasone B-DRUG
coadministered O
orally O
as O
20 O
mg O
on O
Day O
1 O
, O
and O
Aprepitant B-DRUG
when O
given O
as O
80 O
mg O
/ O
day O
with O
dexamethasone B-DRUG
coadministered O
orally O
as O
8 O
mg O
on O
Days O
2 O
through O
5 O
, O
increased O
the O
AUC O
of O
dexamethasone B-DRUG
, O
a O
CYP3A4 O
substrate O
by O
2 O
. O
2 O
- O
fold O
, O
on O
Days O
1 O
and O
5 O
. O
The O
oral O
dexamethasone B-DRUG
doses O
should O
be O
reduced O
by O
approximately O
50 O
% O
when O
coadministered O
with O
Aprepitant B-DRUG
, O
to O
achieve O
exposures O
of O
dexamethasone B-DRUG
similar O
to O
those O
obtained O
when O
it O
is O
given O
without O
Aprepitant B-DRUG
. O
The O
daily O
dose O
of O
dexamethasone B-DRUG
administered O
in O
clinical O
studies O
with O
Aprepitant B-DRUG
reflects O
an O
approximate O
50 O
% O
reduction O
of O
the O
dose O
of O
dexamethasone B-DRUG
. O
Methylprednisolone B-DRUG
Aprepitant B-DRUG
, O
when O
given O
as O
a O
regimen O
of O
125 O
mg O
on O
Day O
1 O
and O
80 O

mg O
/ O
day O
on O
Days O
2 O
and O
3 O
, O
increased O
the O
AUC O
of O
methylprednisolone B-DRUG
, O
a O
CYP3A4 O
substrate O
, O
by O
1 O
. O
34 O
- O
fold O
on O
Day O
1 O
and O
by O
2 O
. O
5 O
- O
fold O
on O
Day O
3 O
, O
when O
methylprednisolone B-DRUG
was O
coadministered O
intravenously O
as O
125 O
mg O
on O
Day O
1 O
and O
orally O
as O
40 O
mg O
on O
Days O
2 O
and O
3 O
. O
The O
IV O
methylprednisolone B-DRUG
dose O
should O
be O
reduced O
by O
approximately O
25 O
% O
, O
and O
the O
oral O
methylprednisolone B-DRUG
dose O
should O
be O
reduced O
by O
approximately O
50 O
% O
when O
coadministered O
with O
Aprepitant B-DRUG
to O
achieve O
exposures O
of O
methylprednisolone B-DRUG
similar O
to O
those O
obtained O
when O
it O
is O
given O
without O
Aprepitant B-DRUG
. O
Warfarin B-DRUG
: O
A O
single O
125 O
- O
mg O
dose O
of O
Aprepitant B-DRUG
was O
administered O
on O
Day O
1 O
and O
80 O
mg O
/ O
day O
on O
Days O
2 O
and O
3 O
to O
healthy O
subjects O
who O
were O
stabilized O
on O
chronic O
warfarin B-DRUG
therapy O
. O
Although O
there O
was O
no O
effect O
of O
Aprepitant B-DRUG
on O
the O
plasma O
AUC O
of O
R B-DRUG
( I-DRUG
+ I-DRUG
) I-DRUG
or I-DRUG
S I-DRUG
( I-DRUG
- I-DRUG
) I-DRUG
warfarin I-DRUG
determined O
on O
Day O
3 O
, O
there O
was O
a O
34 O
% O
decrease O
in O
S B-DRUG
( I-DRUG
- I-DRUG
) I-DRUG
warfarin I-DRUG
( O
a O
CYP2C9 O
substrate O
) O
trough O
concentration O
accompanied O
by O
a O
14 O
% O
decrease O
in O
the O
prothrombin O
time O
( O
reported O
as O
International O
Normalized O
Ratio O
or O
INR O
) O
5 O
days O
after O
completion O
of O
dosing O
with O
Aprepitant B-DRUG
. O
In O
patients O
on O
chronic O
warfarin B-DRUG
therapy O
, O
the O
prothrombin O
time O
( O
INR O
) O
should O
be O
closely O
monitored O
in O
the O
2 O
- O
week O
period O
, O
particularly O
at O
7 O
to O
10 O
days O
, O
following O
initiation O
of O
the O
3 O
- O
day O
regimen O
of O
Aprepitant B-DRUG
with O
each O
chemotherapy O
cycle O
. O
Tolbutamide B-DRUG
: O
Aprepitant B-DRUG
, O
when O
given O
as O
125 O
mg O
on O
Day O
1 O
and O
80 O
mg O
/ O
day O
on O
Days O
2 O
and O
3 O
, O
decreased O
the O
AUC O
of O
tolbutamide B-DRUG
( O
a O
CYP2C9 O
substrate O
) O
by O
23 O
% O
on O
Day O
4 O
, O
28 O
% O
on O
Day O
8 O
, O
and O
15 O
% O
on O
Day O
15 O
, O
when O
a O
single O
dose O
of O
tolbutamide B-DRUG
500 O
mg O
was O
admini O
, O
stered O
orally O
prior O
to O
the O
administration O
of O
the O
3 O
- O
day O
regimen O
of O
Aprepitant B-DRUG
and O
on O
Days O
4 O
, O
8 O
, O
and O
15 O
. O
Oral O
contraceptives B-GROUP
: O
Aprepitant B-DRUG
, O
when O
given O
once O
daily O
for O
14 O
days O
as O
a O
100 O
- O
mg O
capsule O
with O
an O
oral O
contraceptive B-GROUP
containing O
35 O
mcg O
of O
ethinyl B-DRUG

estradiol I-DRUG
and O
1 O
mg O
of O
norethindrone B-DRUG
, O
decreased O
the O
AUC O
of O
ethinyl B-DRUG
estradiol I-DRUG
by O
43 O
% O
, O
and O
decreased O
the O
AUC O
of O
norethindrone B-DRUG
by O
8 O
% O
; O
therefore O
, O
the O
efficacy O
of O
oral O
contraceptives B-GROUP
during O
administration O
of O
Aprepitant B-DRUG
may O
be O
reduced O
. O
Although O
a O
3 O
- O
day O
regimen O
of O
Aprepitant B-DRUG
given O
concomitantly O
with O
oral O
contraceptives B-GROUP
has O
not O
been O
studied O
, O
alternative O
or O
back O
- O
up O
methods O
of O
contraception O
should O
be O
used O
. O
Midazolam B-DRUG
: O
Aprepitant B-DRUG
increased O
the O
AUC O
of O
midazolam B-DRUG
, O
a O
sensitive O
CYP3A4 O
substrate O
, O
by O
2 O
. O
3 O
- O
fold O
on O
Day O
1 O
and O
3 O
. O
3 O
- O
fold O
on O
Day O
5 O
, O
when O
a O
single O
oral O
dose O
of O
midazolam B-DRUG
2 O
mg O
was O
coadministered O
on O
Day O
1 O
and O
Day O
5 O
of O
a O
regimen O
of O
Aprepitant B-DRUG
125 O
mg O
on O
Day O
1 O
and O
80 O
mg O
/ O
day O
on O
Days O
2 O
through O
5 O
. O
The O
potential O
effects O
of O
increased O
plasma O
concentrations O
of O
midazolam B-DRUG
or O
other O
benzodiazepines B-GROUP
metabolized O
via O
CYP3A4 O
( O
alprazolam B-DRUG
, O
triazolam B-DRUG
) O
should O
be O
considered O
when O
coadministering O
these O
agents O
with O
Aprepitant B-DRUG
. O
In O
another O
study O
with O
intravenous O
administration O
of O
midazolam B-DRUG
, O
Aprepitant B-DRUG
was O
given O
as O
125 O
mg O
on O
Day O
1 O
and O
80 O
mg O
/ O
day O
on O
Days O
2 O
and O
3 O
, O
and O
midazolam B-DRUG
2 O
mg O
IV O
was O
given O
prior O
to O
the O
administration O
of O
the O
3 O
- O
day O
regimen O
of O
Aprepitant B-DRUG
and O
on O
Days O
4 O
, O
8 O
, O
and O
15 O
. O
Aprepitant B-DRUG
increased O
the O
AUC O
of O
midazolam B-DRUG
by O
25 O
% O
on O
Day O
4 O
and O
decreased O
the O
AUC O
of O
midazolam B-DRUG
by O
19 O
% O
on O
Day O
8 O
relative O
to O
the O
dosing O
of O
Aprepitant B-DRUG
on O
Days O
1 O
through O
3 O
. O
These O
effects O
were O
not O
considered O
clinically O
important O
. O
The O
AUC O
of O
midazolam B-DRUG
on O
Day O
15 O
was O
similar O
to O
that O
observed O
at O
baseline O
. O
Effect O
of O
other O
agents O
on O
the O
pharmacokinefics O
of O
aprepitant B-DRUG
Aprepitant B-DRUG
is O
a O
substrate O
for O
CYP3A4 O
; O
therefore O
, O
coadministration O
of O
Aprepitant B-DRUG
with O
drugs O
that O
inhibit O
CYP3A4 O
activity O
may O
result O
in O
increased O
plasma O
concentrations O
of O
aprepitant B-DRUG
. O
Consequently O
, O
concomitant O
administration O
of O
Aprepitant B-DRUG
with O
strong O
CYP3A4 O
inhibitors O
( O
e O
. O
g O
. O
, O

ketoconazole B-DRUG
, O
itraconazole B-DRUG
, O
nefazodone B-DRUG
, O
troleandomycin B-DRUG
, O
clarithromycin B-DRUG
, O
ritonavir B-DRUG
, O
nelfinavir B-DRUG
) O
should O
be O
approached O
with O
caution O
. O
Because O
moderate O
CYP3A4 O
inhibitors O
( O
e O
. O
g O
. O
, O
diltiazem B-DRUG
) O
result O
in O
2 O
- O
fold O
increase O
in O
plasma O
concentrations O
of O
aprepitant B-DRUG
, O
concomitant O
administration O
should O
also O
be O
approached O
with O
caution O
. O
Aprepitant B-DRUG
is O
a O
substrate O
for O
CYP3A4 O
; O
therefore O
, O
coadministration O
of O
Aprepitant B-DRUG
with O
drugs O
that O
strongly O
induce O
CYP3A4 O
activity O
( O
e O
. O
g O
. O
, O
rifampin B-DRUG
, O
carbamazepine B-DRUG
, O
phenytoin B-DRUG
) O
may O
result O
in O
reduced O
plasma O
concentrations O
of O
aprepitant B-DRUG
that O
may O
result O
in O
decreased O
efficacy O
of O
Aprepitant B-DRUG
. O
Ketoconazole B-DRUG
: O
When O
a O
single O
125 O
- O
mg O
dose O
of O
Aprepitant B-DRUG
was O
administered O
on O
Day5 O
of O
a O
Ketoconazole B-DRUG
: O
When O
a O
single O
125 O
- O
mg O
dose O
of O
Aprepitant B-DRUG
was O
administered O
on O
Day5 O
of O
a O
10 O
- O
day O
regimen O
of O
400 O
mg O
/ O
day O
of O
ketoconazole B-DRUG
, O
a O
strong O
CYP3A4 O
inhibitor O
, O
the O
AUC O
of O
aprepitant B-DRUG
increased O
approximately O
5 O
- O
fold O
and O
the O
mean O
terminal O
half O
- O
life O
of O
aprepitant B-DRUG
increased O
approximately O
3 O
- O
fold O
. O
Concomitant O
administration O
of O
Aprepitant B-DRUG
with O
strong O
CYP3A4 O
inhibitors O
should O
be O
approached O
cautiously O
. O
Rifampin B-DRUG
: O
When O
a O
single O
375 O
- O
mg O
dose O
of O
Aprepitant B-DRUG
was O
administered O
on O
Day9 O
of O
a O
14 O
- O
day O
regimen O
of O
600 O
mg O
/ O
day O
of O
rifampin B-DRUG
, O
a O
strong O
CYP3A4 O
inducer O
, O
the O
AUC O
of O
aprepitant B-DRUG
decreased O
approximately O
11 O
- O
fold O
and O
the O
mean O
terminal O
half O
- O
life O
decreased O
approximately O
3 O
- O
fold O
. O
Coadministration O
of O
Aprepitant B-DRUG
with O
drugs O
that O
induce O
CYP3A4 O
activity O
may O
result O
in O
reduced O
plasma O
concentrations O
and O
decreased O
efficacy O
of O
Aprepitant B-DRUG
. O
Additional O
interactions O
Diltiazem B-DRUG
: O
In O
patients O
with O
mild O
to O
moderate O
hypertension O
, O
administration O
of O
aprepitant B-DRUG
once O
daily O
, O
as O
a O
tablet O
formulation O
comparable O
to O
230 O
mg O
of O
the O
capsule O
formulation O
, O
with O
diltiazem B-DRUG
120 O
mg O
3 O
times O
daily O
for O
5 O
days O
, O
resulted O
in O
a O
2 O
- O
fold O
increase O
of O
aprepitant B-DRUG
AUC O
and O
a O
simultaneous O
1 O
. O
7 O
- O
fold O
increase O
of O

diltiazem B-DRUG
AUC O
. O
These O
pharmacokinetic O
effects O
did O
not O
result O
in O
clinically O
meaningful O
changes O
in O
ECG O
, O
heart O
rate O
or O
blood O
pressure O
beyond O
those O
changes O
induced O
by O
diltiazem B-DRUG
alone O
. O
Paroxetine B-DRUG
: O
Coadministration O
of O
once O
daily O
doses O
of O
aprepitant B-DRUG
, O
as O
a O
tablet O
formulation O
comparable O
to O
85 O
mg O
or O
170 O
mg O
of O
the O
capsule O
formulation O
, O
with O
paroxetine B-DRUG
20 O
mg O
once O
daily O
, O
resulted O
in O
a O
decrease O
in O
AUC O
by O
approximately O
25 O
% O
and O
Cmax O
, O
by O
approximately O
20 O
% O
of O
both O
aprepitant B-DRUG
and O
paroxetine B-DRUG
. O

Beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
: O
concurrent O
use O
may O
blunt O
the O
response O
to O
arbutamine B-DRUG
. O
Beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
should O
be O
withdrawn O
at O
least O
48 O
hours O
before O
conducting O
an O
arbutamine B-DRUG
- O
mediated O
stress O
test O
. O
Antiarrhythmic B-DRUG
agents I-DRUG
, I-DRUG
class I-DRUG
I I-DRUG
( O
such O
as O
flecainide B-DRUG
, O
lidocaine B-DRUG
, O
or O
quinidine B-DRUG
) O
: O
concurrent O
use O
with O
arbutamine B-DRUG
may O
have O
a O
proarrhythmic O
effect O
. O
Antidepressants B-GROUP
( O
tricyclic B-GROUP
) O
, O
atropine B-DRUG
or O
other O
anticholinergic B-GROUP
agents I-GROUP
, O
or O
digitalis B-GROUP
glycosides I-GROUP
: O
concurrent O
use O
with O
arbutamine B-DRUG
may O
produce O
additive O
inotropic O
and O
/ O
or O
chronotropic O
effects O
. O

Anticoagulants B-GROUP
including O
coumarin O
derivatives O
, O
indandione O
derivatives O
, O
and O
platelet B-GROUP
aggregation I-GROUP
inhibitors I-GROUP
such O
as O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
( O
NSAIDs B-GROUP
) O
, O
and O
aspirin B-BRAND
may O
increase O
the O
risk O
of O
bleeding O
when O
administered O
concomitantly O
with O
ardeparin B-DRUG
. O

If O
additional O
adrenergic B-GROUP
drugs I-GROUP
are O
to O
be O
administered O
by O
any O
route O
, O
they O
should O
be O
used O
with O
caution O
because O
the O
pharmacologically O
predictable O
sympathetic O
effects O
of O
BROVANA B-BRAND
may O
be O
potentiated O
. O
When O
paroxetine B-DRUG
, O
a O
potent O
inhibitor O
of O
CYP2D6 O
, O
was O
co O
- O
administered O
with O
BROVANA B-BRAND
at O
steady O
- O
state O
, O
exposure O
to O
either O
drug O
was O
not O
altered O
. O
Dosage O
adjustments O
of O
BROVANA B-BRAND
are O
not O
necessary O
when O
the O
drug O
is O
given O
concomitantly O
with O
potent O
CYP2D6 O
inhibitors O
. O
Concomitant O
treatment O
with O
methylxanthines B-GROUP
( O
aminophylline B-DRUG
, O
theophylline B-DRUG
) O
, O
steroids B-GROUP
, O
or O
diuretics B-GROUP
may O
potentiate O
any O
hypokalemic O
effect O
of O
adrenergic B-GROUP
agonists I-GROUP
. O
The O
ECG O
changes O
and O
/ O
or O
hypokalemia O
that O
may O
result O
from O
the O
administration O
of O
non B-GROUP
- I-GROUP
potassium I-GROUP
sparing I-GROUP
diuretics I-GROUP
( O
such O
as O
loop B-GROUP
or I-GROUP
thiazide I-GROUP
diuretics I-GROUP
) O
can O
be O
acutely O
worsened O
by O
beta B-GROUP
- I-GROUP
agonists I-GROUP
, O
especially O
when O
the O
recommended O
dose O
of O
the O
beta B-GROUP
- I-GROUP
agonist I-GROUP
is O
exceeded O
. O
Although O
the O
clinical O
significance O
of O
these O
effects O
is O
not O
known O
, O
caution O
is O
advised O
in O
the O
co O
- O
administration O
of O
beta B-GROUP
- I-GROUP
agonists I-GROUP
with O
non B-GROUP
- I-GROUP
potassium I-GROUP
sparing I-GROUP
diuretics I-GROUP
. O
BROVANA B-BRAND
, O
as O
with O
other O
beta2 B-GROUP
- I-GROUP
agonists I-GROUP
, O
should O
be O
administered O
with O
extreme O
caution O
to O
patients O
being O
treated O
with O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
, O
tricyclic B-GROUP
antidepressants I-GROUP
, O
or O
drugs O
known O
to O
prolong O
the O
QTc O
interval O
because O
the O
action O
of O
adrenergic B-GROUP
agonists I-GROUP
on O
the O
cardiovascular O
system O
may O
be O
potentiated O
by O
these O
agents O
. O
Drugs O
that O
are O
known O
to O
prolong O
the O
QTc O
interval O
have O
an O
increased O
risk O
of O
ventricular O
arrhythmias O
. O
The O
concurrent O
use O
of O
intravenously O
or O
orally O
administered O
methylxanthines B-GROUP
( O
e O
. O
g O
. O
, O
aminophylline B-DRUG
, O
theophylline B-DRUG
) O
by O
patients O
receiving O
BROVANA B-BRAND
has O
not O
been O
completely O
evaluated O
. O
In O
two O
combined O
12 O
- O
week O
placebo O
controlled O
trials O
that O
included O
BROVANA B-BRAND
doses O
of O
15 O
mcg O
twice O
daily O
, O
25 O
mcg O
twice O
daily O
, O
and O
50 O
mcg O
once O
daily O
, O
54 O
of O
873 O
BROVANA B-BRAND
- O
treated O
subjects O
received O
concomitant O
theophylline B-DRUG
at O
study O
entry O
. O
In O
a O
12 O
- O
month O
controlled O
trial O
that O
included O
a O
50 O
mcg O
once O
daily O
BROVANA B-BRAND
dose O
, O
30 O
of O
the O
528 O

BROVANA B-BRAND
- O
treated O
subjects O
received O
concomitant O
theophylline B-DRUG
at O
study O
entry O
. O
In O
these O
trials O
, O
heart O
rate O
and O
systolic O
blood O
pressure O
were O
approximately O
2 O
- O
3 O
bpm O
and O
6 O
- O
8 O
mm O
Hg O
higher O
, O
respectively O
, O
in O
subjects O
on O
concomitant O
theophylline B-DRUG
compared O
with O
the O
overall O
population O
. O
Beta B-GROUP
- I-GROUP
adrenergic I-GROUP
receptor I-GROUP
antagonists I-GROUP
( O
beta B-GROUP
- I-GROUP
blockers I-GROUP
) O
and O
BROVANA B-BRAND
may O
interfere O
with O
the O
effect O
of O
each O
other O
when O
administered O
concurrently O
. O
Beta B-GROUP
- I-GROUP
blockers I-GROUP
not O
only O
block O
the O
therapeutic O
effects O
of O
beta B-GROUP
- I-GROUP
agonists I-GROUP
, O
but O
may O
produce O
severe O
bronchospasm O
in O
COPD O
patients O
. O
Therefore O
, O
patients O
with O
COPD O
should O
not O
normally O
be O
treated O
with O
beta B-GROUP
- I-GROUP
blockers I-GROUP
. O
However O
, O
under O
certain O
circumstances O
, O
e O
. O
g O
. O
, O
as O
prophylaxis O
after O
myocardial O
infarction O
, O
there O
may O
be O
no O
acceptable O
alternatives O
to O
the O
use O
of O
beta B-GROUP
- I-GROUP
blockers I-GROUP
in O
patients O
with O
COPD O
. O
In O
this O
setting O
, O
cardioselective B-GROUP
beta I-GROUP
- I-GROUP
blockers I-GROUP
could O
be O
considered O
, O
although O
they O
should O
be O
administered O
with O
caution O
. O

Heparin B-DRUG
: O
Since O
heparin B-DRUG
is O
contraindicated O
in O
patients O
with O
heparin B-DRUG
- O
induced O
thrombocytopenia O
, O
the O
co O
- O
administration O
of O
Argatroban B-DRUG
and O
heparin B-DRUG
is O
unlikely O
for O
this O
indication O
. O
However O
, O
if O
Argatroban B-DRUG
is O
to O
be O
initiated O
after O
cessation O
of O
heparin B-DRUG
therapy O
, O
allow O
sufficient O
time O
for O
heparins O
effect O
on O
the O
aPTT O
to O
decrease O
prior O
to O
initiation O
of O
Argatroban B-DRUG
therapy O
. O
Aspirin B-BRAND
/ O
Acetaminophen B-DRUG
: O
Pharmacokinetic O
or O
pharmacodynamic O
drug O
- O
drug O
interactions O
have O
not O
been O
demonstrated O
between O
Argatroban B-DRUG
and O
concomitantly O
administered O
aspirin B-BRAND
( O
162 O
. O
5 O
mg O
orally O
given O
26 O
and O
2 O
hours O
prior O
to O
initiation O
of O
Argatroban B-DRUG
1 O
g O
/ O
kg O
/ O
min O
. O
over O
4 O
hours O
) O
or O
acetaminophen B-DRUG
( O
1000 O
mg O
orally O
given O
12 O
, O
6 O
and O
0 O
hours O
prior O
to O
, O
and O
6 O
and O
12 O
hours O
subsequent O
to O
, O
initiation O
of O
Argatroban B-DRUG
1 O
. O
5 O
g O
/ O
kg O
/ O
min O
. O
over O
18 O
hours O
) O
. O
Oral O
anticoagulant B-GROUP
agents I-GROUP
: O
Pharmacokinetic O
drug O
- O
drug O
interactions O
between O
Argatroban B-DRUG
and O
warfarin B-DRUG
( O
7 O
. O
5 O
mg O
single O
oral O
dose O
) O
have O
not O
been O
demonstrated O
. O
However O
, O
the O
concomitant O
use O
of O
Argatroban B-DRUG
and O
warfarin B-DRUG
( O
5 O
- O
7 O
. O
5 O
mg O
initial O
oral O
dose O
followed O
by O
2 O
. O
5 O
- O
6 O
mg O
/ O
day O
orally O
for O
6 O
- O
10 O
days O
) O
results O
in O
prolongation O
of O
the O
prothrombin O
time O
( O
PT O
) O
and O
International O
Normalized O
Ratio O
( O
INR O
) O
. O
Thrombolytic B-GROUP
agents I-GROUP
: O
The O
safety O
and O
effectiveness O
of O
Argatroban B-DRUG
with O
thrombolytic B-GROUP
agents I-GROUP
have O
not O
been O
established O
. O
Co O
- O
administration O
: O
Concomitant O
use O
of O
Argatroban B-DRUG
with O
antiplatelet B-GROUP
agents I-GROUP
, O
thrombolytics B-GROUP
, O
and O
other O
anticoagulants B-GROUP
may O
increase O
the O
risk O
of O
bleeding O
. O
Drug O
- O
drug O
interactions O
have O
not O
been O
observed O
between O
Argatroban B-DRUG
and O
digoxin B-DRUG
or O
erythromycin B-DRUG
. O

Drug O
- O
Drug O
Interactions O
Given O
the O
primary O
CNS O
effects O
of O
aripiprazole B-DRUG
, O
caution O
should O
be O
used O
when O
ABILIFY B-BRAND
is O
taken O
in O
combination O
with O
other O
centrally B-GROUP
acting I-GROUP
drugs I-GROUP
and O
alcohol B-DRUG
. O
Due O
to O
its O
1 O
- O
adrenergic O
receptor O
antagonism O
, O
aripiprazole B-DRUG
has O
the O
potential O
to O
enhance O
the O
effect O
of O
certain O
antihypertensive B-GROUP
agents I-GROUP
. O
Potential O
for O
Other O
Drugs O
to O
Affect O
ABILIFY B-BRAND
Aripiprazole B-BRAND
is O
not O
a O
substrate O
of O
CYP1A1 O
, O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2B6 O
, O
CYP2C8 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
or O
CYP2E1 O
enzymes O
. O
Aripiprazole B-DRUG
also O
does O
not O
undergo O
direct O
glucuronidation O
. O
This O
suggests O
that O
an O
interaction O
of O
aripiprazole B-DRUG
with O
inhibitors O
or O
inducers O
of O
these O
enzymes O
, O
or O
other O
factors O
, O
like O
smoking O
, O
is O
unlikely O
. O
Both O
CYP3A4 O
and O
CYP2D6 O
are O
responsible O
for O
aripiprazole B-DRUG
metabolism O
. O
Agents O
that O
induce O
CYP3A4 O
( O
eg O
, O
carbamazepine B-DRUG
) O
could O
cause O
an O
increase O
in O
aripiprazole B-DRUG
clearance O
and O
lower O
blood O
levels O
. O
Inhibitors O
of O
CYP3A4 O
( O
eg O
, O
ketoconazole B-DRUG
) O
or O
CYP2D6 O
( O
eg O
, O
quinidine B-DRUG
, O
fluoxetine B-DRUG
, O
or O
paroxetine B-DRUG
) O
can O
inhibit O
aripiprazole B-DRUG
elimination O
and O
cause O
increased O
blood O
levels O
. O
Ketoconazole B-DRUG
: O
Coadministration O
of O
ketoconazole B-DRUG
( O
200 O
mg O
/ O
day O
for O
14 O
days O
) O
with O
a O
15 O
- O
mg O
single O
dose O
of O
aripiprazole B-DRUG
increased O
the O
AUC O
of O
aripiprazole B-DRUG
and O
its O
active O
metabolite O
by O
63 O
% O
and O
77 O
% O
, O
respectively O
. O
The O
effect O
of O
a O
higher O
ketoconazole B-DRUG
dose O
( O
400 O
mg O
/ O
day O
) O
has O
not O
been O
studied O
. O
When O
concomitant O
administration O
of O
ketoconazole B-DRUG
with O
aripiprazole B-DRUG
occurs O
, O
aripiprazole B-DRUG
dose O
should O
be O
reduced O
to O
one O
- O
half O
of O
its O
normal O
dose O
. O
Other O
strong O
inhibitors O
of O
CYP3A4 O
( O
itraconazole B-DRUG
) O
would O
be O
expected O
to O
have O
similar O
effects O
and O
need O
similar O
dose O
reductions O
; O
weaker O
inhibitors O
( O
erythromycin B-DRUG
, O
grapefruit O
juice O
) O
have O
not O
been O
studied O
. O
When O
the O
CYP3A4 O
inhibitor O
is O
withdrawn O
from O
the O
combination O
therapy O
, O
aripiprazole B-DRUG
dose O
should O

then O
be O
increased O
. O
Quinidine B-DRUG
: O
Coadministration O
of O
a O
10 O
- O
mg O
single O
dose O
of O
aripiprazole B-DRUG
with O
quinidine B-DRUG
( O
166 O
mg O
/ O
day O
for O
13 O
days O
) O
, O
a O
potent O
inhibitor O
of O
CYP2D6 O
, O
increased O
the O
AUC O
of O
aripiprazole B-DRUG
by O
112 O
% O
but O
decreased O
the O
AUC O
of O
its O
active O
metabolite O
, O
dehydroaripiprazole B-DRUG_N
, O
by O
35 O
% O
. O
Aripiprazole B-DRUG
dose O
should O
be O
reduced O
to O
one O
- O
half O
of O
its O
normal O
dose O
when O
concomitant O
administration O
of O
quinidine B-DRUG
with O
aripiprazole B-DRUG
occurs O
. O
Other O
significant O
inhibitors O
of O
CYP2D6 O
, O
such O
as O
fluoxetine B-DRUG
or O
paroxetine B-DRUG
, O
would O
be O
expected O
to O
have O
similar O
effects O
and O
, O
therefore O
, O
should O
be O
accompanied O
by O
similar O
dose O
reductions O
. O
When O
the O
CYP2D6 O
inhibitor O
is O
withdrawn O
from O
the O
combination O
therapy O
, O
aripiprazole B-DRUG
dose O
should O
then O
be O
increased O
. O
Carbamazepine B-DRUG
: O
Coadministration O
of O
carbamazepine B-DRUG
( O
200 O
mg O
BID O
) O
, O
a O
potent O
CYP3A4 O
inducer O
, O
with O
aripiprazole B-DRUG
( O
30 O
mg O
QD O
) O
resulted O
in O
an O
approximate O
70 O
% O
decrease O
in O
Cmax O
and O
AUC O
values O
of O
both O
aripiprazole B-DRUG
and O
its O
active O
metabolite O
, O
dehydro B-DRUG_N
- I-DRUG_N
aripiprazole I-DRUG_N
. O
When O
carbamazepine B-DRUG
is O
added O
to O
aripiprazole B-DRUG
therapy O
, O
aripiprazole B-DRUG
dose O
should O
be O
doubled O
. O
Additional O
dose O
increases O
should O
be O
based O
on O
clinical O
evaluation O
. O
When O
carbamazepine B-DRUG
is O
withdrawn O
from O
the O
combination O
therapy O
, O
aripiprazole B-DRUG
dose O
should O
then O
be O
reduced O
. O
No O
clinically O
significant O
effect O
of O
famotidine B-DRUG
, O
valproate B-DRUG
, O
or O
lithium B-DRUG
was O
seen O
on O
the O
pharmacokinetics O
of O
aripiprazole B-DRUG
( O
see O
CLINICAL O
PHARMACOLOGY O
: O
Drug O
- O
Drug O
Interactions O
) O
. O
Potential O
for O
ABILIFY B-BRAND
to O
Affect O
Other O
Drugs O
Aripiprazole B-DRUG
is O
unlikely O
to O
cause O
clinically O
important O
pharmacokinetic O
interactions O
with O
drugs O
metabolized O
by O
cytochrome O
P450 O
enzymes O
. O
In O
in O
vivo O
studies O
, O
10 O
- O
to O
30 O
- O
mg O
/ O
day O
doses O
of O
aripiprazole B-DRUG
had O
no O
significant O
effect O
on O
metabolism O
by O
CYP2D6 O
( O
dextromethorphan B-DRUG
) O
, O
CYP2C9 O
( O
warfarin B-DRUG
) O
, O
CYP2C19 O
( O

omeprazole B-DRUG
, O
warfarin B-DRUG
) O
, O
and O
CYP3A4 O
( O
dextromethorphan B-DRUG
) O
substrates O
. O
Additionally O
, O
aripiprazole B-DRUG
and O
dehydroaripiprazole B-DRUG_N
did O
not O
show O
potential O
for O
altering O
CYP1A2 O
- O
mediated O
metabolism O
in O
vitro O
. O
Alcohol B-DRUG
: O
There O
was O
no O
significant O
difference O
between O
aripiprazole B-DRUG
coadministered O
with O
ethanol B-DRUG
and O
placebo O
coadministered O
with O
ethanol B-DRUG
on O
performance O
of O
gross O
motor O
skills O
or O
stimulus O
response O
in O
healthy O
subjects O
. O
As O
with O
most O
psychoactive O
medications O
, O
patients O
should O
be O
advised O
to O
avoid O
alcohol B-DRUG
while O
taking O
ABILIFY B-BRAND
. O

No O
formal O
assessments O
of O
pharmacokinetic O
drug O
- O
drug O
interactions O
between O
TRISENOX B-BRAND
and O
other O
agents O
have O
been O
conducted O
. O
Caution O
is O
advised O
when O
TRISENOX B-BRAND
is O
coadministered O
with O
other O
medications O
that O
can O
prolong O
the O
QT O
interval O
( O
e O
. O
g O
. O
certain O
antiarrhythmics B-GROUP
or O
thioridazine B-DRUG
) O
or O
lead O
to O
electrolyte O
abnormalities O
( O
such O
as O
diuretics B-GROUP
or O
amphotericin B-DRUG
B I-DRUG
) O
. O

Tissue O
culture O
and O
animal O
studies O
indicate O
that O
ELSPAR B-BRAND
can O
diminish O
or O
abolish O
the O
effect O
of O
methotrexate B-DRUG
on O
malignant O
cells O
. O
14 O
This O
effect O
on O
methotrexate B-DRUG
activity O
persists O
as O
long O
as O
plasma O
asparagine O
levels O
are O
suppressed O
. O
These O
results O
would O
seem O
to O
dictate O
against O
the O
clinical O
use O
of O
methotrexate B-DRUG
with O
ELSPAR B-BRAND
, O
or O
during O
the O
period O
following O
ELSPAR B-BRAND
therapy O
when O
plasma O
asparagine O
levels O
are O
below O
normal O
. O

Uricosuric B-GROUP
Agents I-GROUP
: O
Aspirin B-BRAND
may O
decrease O
the O
effects O
of O
probenecid B-DRUG
, O
sulfinpyrazone B-DRUG
, O
and O
phenylbutazone B-DRUG
. O
Alcohol B-DRUG
: O
Has O
a O
synergistic O
effect O
with O
aspirin B-BRAND
in O
causing O
gastrointestinal O
bleeding O
. O
Corticosteroids B-GROUP
: O
Concomitant O
administration O
with O
aspirin B-BRAND
may O
increase O
the O
risk O
of O
gastrointestinal O
ulceration O
and O
may O
reduce O
serum O
salicylate O
levels O
. O
Pyrazolone B-GROUP
Derivatives I-GROUP
( O
phenylbutazone B-DRUG
, O
oxyphenbutazone B-DRUG
, O
and O
possibly O
dipyrone B-DRUG
) O
: O
Concomitant O
administration O
with O
aspirin B-DRUG
may O
increase O
the O
risk O
of O
gastrointestinal O
ulceration O
. O
Nonsteroidal B-DRUG
Antiinflammatory I-DRUG
Agents O
: O
Aspirin B-DRUG
is O
contraindicated O
in O
patients O
who O
are O
hypersensitive O
to O
nonsteroidal B-DRUG
anti I-DRUG
- I-DRUG
inflammatory I-DRUG
agents O
. O
Urinary O
Alkalinizers O
: O
Decrease O
aspirin B-BRAND
effectiveness O
by O
increasing O
the O
rate O
of O
salicylate B-GROUP
renal O
excretion O
. O
Phenobarbital B-DRUG
: O
Decreases O
aspirin B-BRAND
effectiveness O
by O
enzyme O
induction O
. O
Phenytoin B-DRUG
: O
Serum O
phenytoin B-DRUG
levels O
may O
be O
increased O
by O
aspirin B-BRAND
. O
Propranolol B-DRUG
: O
May O
decrease O
aspirins B-BRAND
anti O
- O
inflammatory O
action O
by O
competing O
for O
the O
same O
receptors O
. O
Antacids B-GROUP
: O
Enteric O
Coated O
Aspirin B-BRAND
should O
not O
be O
given O
concurrently O
with O
antacids B-GROUP
, O
since O
an O
increase O
in O
the O
pH O
of O
the O
stomach O
may O
effect O
the O
enteric O
coating O
of O
the O
tablets O
. O

Ketoconazole B-DRUG
/ O
Itraconazole B-DRUG
, O
Macrolides B-GROUP
, O
Including O
Erythromycin B-DRUG

Catecholamine O
- O
depleting O
drugs O
( O
eg O
, O
reserpine B-DRUG
) O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
. O
Patients O
treated O
with O
TENORMIN B-BRAND
plus O
a O
catecholamine O
depletor O
should O
therefore O
be O
closely O
observed O
for O
evidence O
of O
hypotension O
and O
/ O
or O
marked O
bradycardia O
which O
may O
produce O
vertigo O
, O
syncope O
, O
or O
postural O
hypotension O
. O
Calcium B-GROUP
channel I-GROUP
blockers I-GROUP
may O
also O
have O
an O
additive O
effect O
when O
given O
with O
TENORMIN B-BRAND
. O
Beta B-GROUP
blockers I-GROUP
may O
exacerbate O
the O
rebound O
hypertension O
which O
can O
follow O
the O
withdrawal O
of O
clonidine B-DRUG
. O
If O
the O
two O
drugs O
are O
coadministered O
, O
the O
beta B-GROUP
blocker I-GROUP
should O
be O
withdrawn O
several O
days O
before O
the O
gradual O
withdrawal O
of O
clonidine B-DRUG
. O
If O
replacing O
clonidine B-DRUG
by O
beta B-GROUP
- I-GROUP
blocker I-GROUP
therapy O
, O
the O
introduction O
of O
beta B-GROUP
blockers I-GROUP
should O
be O
delayed O
for O
several O
days O
after O
clonidine B-DRUG
administration O
has O
stopped O
. O
Concomitant O
use O
of O
prostaglandin O
synthase O
inhibiting O
drugs O
, O
eg O
, O
indomethacin B-DRUG
, O
may O
decrease O
the O
hypotensive O
effects O
of O
beta B-GROUP
blockers I-GROUP
. O
Information O
on O
concurrent O
usage O
of O
atenolol B-DRUG
and O
aspirin B-BRAND
is O
limited O
. O
Data O
from O
several O
studies O
, O
ie O
, O
TIMI O
- O
II O
, O
ISIS O
- O
2 O
, O
currently O
do O
not O
suggest O
any O
clinical O
interaction O
between O
aspirin B-BRAND
and O
beta B-GROUP
blockers I-GROUP
in O
the O
acute O
myocardial O
infarction O
setting O
. O
While O
taking O
beta B-GROUP
blockers I-GROUP
, O
patients O
with O
a O
history O
of O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
have O
a O
more O
severe O
reaction O
on O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
or O
therapeutic O
. O
Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-DRUG
used O
to O
treat O
the O
allergic O
reaction O
. O

Drug O
- O
Drug O
Interactions O
Albuterol B-DRUG
- O
STRATTERA B-BRAND
should O
be O
administered O
with O
caution O
to O
patients O
being O
treated O
with O
systemically O
- O
administered O
( O
oral O
or O
intravenous O
) O
albuterol B-DRUG
( O
or O
other O
beta2 B-GROUP
agonists I-GROUP
) O
because O
the O
action O
of O
albuterol B-DRUG
on O
the O
cardiovascular O
system O
can O
be O
potentiated O
resulting O
in O
increases O
in O
heart O
rate O
and O
blood O
pressure O
. O
CYP2D6 O
inhibitors O
- O
Atomoxetine B-DRUG
is O
primarily O
metabolized O
by O
the O
CYP2D6 O
pathway O
to O
4 B-DRUG_N
- I-DRUG_N
hydroxyatomoxetine I-DRUG_N
. O
In O
EMs O
, O
selective O
inhibitors O
of O
CYP2D6 O
increase O
atomoxetine B-DRUG
steady O
- O
state O
plasma O
concentrations O
to O
exposures O
similar O
to O
those O
observed O
in O
PMs O
. O
Dosage O
adjustment O
of O
STRATTERA B-BRAND
may O
be O
necessary O
when O
coadministered O
with O
CYP2D6 O
inhibitors O
, O
e O
. O
g O
. O
, O
paroxetine B-DRUG
, O
fluoxetine B-DRUG
, O
and O
quinidine B-DRUG
. O
In O
EM O
individuals O
treated O
with O
paroxetine B-DRUG
or O
fluoxetine B-DRUG
, O
the O
AUC O
of O
atomoxetine B-DRUG
is O
approximately O
6 O
- O
to O
8 O
- O
fold O
and O
Css O
, O
max O
is O
about O
3 O
- O
to O
4 O
- O
fold O
greater O
than O
atomoxetine B-DRUG
alone O
. O
In O
vitro O
studies O
suggest O
that O
coadministration O
of O
cytochrome O
P450 O
inhibitors O
to O
PMs O
will O
not O
increase O
the O
plasma O
concentrations O
of O
atomoxetine B-DRUG
. O
Pressor O
agents O
- O
Because O
of O
possible O
effects O
on O
blood O
pressure O
, O
STRATTERA B-BRAND
should O
be O
used O
cautiously O
with O
pressor O
agents O
. O

The O
risk O
of O
myopathy O
during O
treatment O
with O
drugs O
of O
this O
class O
is O
increased O
with O
concurrent O
administration O
of O
cyclosporine B-DRUG
, O
fibric B-GROUP
acid I-GROUP
derivatives I-GROUP
, O
niacin B-DRUG
( O
nicotinic B-DRUG
acid I-DRUG
) O
, O
erythromycin B-DRUG
, O
azole B-GROUP
antifungals I-GROUP
. O
Antacid B-GROUP
: O
When O
atorvastatin B-DRUG
and O
Maalox B-BRAND
TC I-BRAND
suspension O
were O
coadministered O
, O
plasma O
concentrations O
of O
atorvastatin B-DRUG
decreased O
approximately O
35 O
% O
. O
However O
, O
LDL O
- O
C O
reduction O
was O
not O
altered O
. O
Antipyrine B-DRUG
: O
Because O
atorvastatin B-DRUG
does O
not O
affect O
the O
pharmacokinetics O
of O
antipyrine B-DRUG
, O
interactions O
with O
other O
drugs B-DRUG
metabolized O
via O
the O
same O
cytochrome O
isozymes O
are O
not O
expected O
. O
Colestipol B-DRUG
: O
Plasma O
concentrations O
of O
atorvastatin B-DRUG
decreased O
approximately O
25 O
% O
when O
colestipol B-DRUG
and O
atorvastatin B-DRUG
were O
coadministered O
. O
However O
, O
LDL O
- O
C O
reduction O
was O
greater O
when O
atorvastatin B-DRUG
and O
colestipol B-DRUG
were O
coadministered O
than O
when O
either O
drug O
was O
given O
alone O
. O
Cimetidine B-DRUG
: O
Atorvastatin B-DRUG
plasma O
concentrations O
and O
LDL O
- O
C O
reduction O
were O
not O
altered O
by O
coadministration O
of O
cimetidine B-DRUG
. O
Digoxin B-DRUG
: O
When O
multiple O
doses O
of O
atorvastatin B-DRUG
and O
digoxin B-DRUG
were O
coadministered O
, O
steady O
- O
state O
plasma O
digoxin B-DRUG
concentrations O
increased O
by O
approximately O
20 O
% O
. O
Patients O
taking O
digoxin B-DRUG
should O
be O
monitored O
appropriately O
. O
Erythromycin B-DRUG
: O
In O
healthy O
individuals O
, O
plasma O
concentrations O
of O
atorvastatin B-DRUG
increased O
approximately O
40 O
% O
with O
coadministration O
of O
atorvastatin B-DRUG
and O
erythromycin B-DRUG
, O
a O
known O
inhibitor O
of O
cytochrome O
P450 O
3A4 O
. O
Oral O
Contraceptives B-GROUP
: O
Coadministration O
of O
atorvastatin B-DRUG
and O
an O
oral O
contraceptive B-GROUP
increased O
AUC O
values O
for O
norethindrone B-DRUG
and O
ethinyl B-DRUG
estradiol I-DRUG
by O
approximately O
30 O
% O
and O
20 O
% O
. O
These O
increases O
should O
be O
considered O
when O
selecting O
an O
oral O
contraceptive B-GROUP
for O
a O
woman O
taking O
atorvastatin B-DRUG
. O
Warfarin B-DRUG
: O
Atorvastatin B-DRUG
had O
no O
clinically O
significant O
effect O
on O
prothrombin O
time O
when O
administered O
to O
patients O
receiving O
chronic O
warfarin B-DRUG
treatment O
. O
Endocrine O
Function O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
interfere O
with O
cholesterol O
synthesis O
and O
theoretically O
might O
blunt O
adrenal O
and O
/ O
or O
gonadal O
steroid O
production O
. O
Clinical O
studies O
have O
shown O
that O

atorvastatin B-DRUG
does O
not O
reduce O
basal O
plasma O
cortisol O
concentration O
or O
impair O
adrenal O
reserve O
. O
The O
effects O
of O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
on O
male O
fertility O
have O
not O
been O
studied O
in O
adequate O
numbers O
of O
patients O
. O
The O
effects O
, O
if O
any O
, O
on O
the O
pituitary O
- O
gonadal O
axis O
in O
premenopausal O
women O
are O
unknown O
. O
Caution O
should O
be O
exercised O
if O
an O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitor I-GROUP
is O
administered O
concomitantly O
with O
drugs O
that O
may O
decrease O
the O
levels O
or O
activity O
of O
endogenous O
steroid O
hormones O
, O
such O
as O
ketoconazole B-DRUG
, O
spironolactone B-DRUG
, O
and O
cimetidine B-DRUG
. O
CNS O
Toxicity O
Brain O
hemorrhage O
was O
seen O
in O
a O
female O
dog O
treated O
for O
3 O
months O
at O
120 O
mg O
/ O
kg O
/ O
day O
. O
Brain O
hemorrhage O
and O
optic O
nerve O
vacuolation O
were O
seen O
in O
another O
female O
dog O
that O
was O
sacrificed O
in O
moribund O
condition O
after O
11 O
weeks O
of O
escalating O
doses O
up O
to O
280 O
mg O
/ O
kg O
/ O
day O
. O
The O
120 O
mg O
/ O
kg O
dose O
resulted O
in O
a O
systemic O
exposure O
approximately O
16 O
times O
the O
human O
plasma O
area O
- O
under O
- O
the O
- O
curve O
( O
AUC O
, O
0 O
- O
24 O
hours O
) O
based O
on O
the O
maximum O
human O
dose O
of O
80 O
mg O
/ O
day O
. O
A O
single O
tonic O
convulsion O
was O
seen O
in O
each O
of O
2 O
male O
dogs O
( O
one O
treated O
at O
10 O
mg O
/ O
kg O
/ O
day O
and O
one O
at O
120 O
mg O
/ O
kg O
/ O
day O
) O
in O
a O
2 O
- O
year O
study O
. O
No O
CNS O
lesions O
have O
been O
observed O
in O
mice O
after O
chronic O
treatment O
for O
up O
to O
2 O
years O
at O
doses O
up O
to O
400 O
mg O
/ O
kg O
/ O
day O
or O
in O
rats O
at O
doses O
up O
to O
100 O
mg O
/ O
kg O
/ O
day O
. O
These O
doses O
were O
6 O
to O
11 O
times O
( O
mouse O
) O
and O
8 O
to O
16 O
times O
( O
rat O
) O
the O
human O
AUC O
( O
0 O
- O
24 O
) O
based O
on O
the O
maximum O
recommended O
human O
dose O
of O
80 O
mg O
/ O
day O
. O
CNS O
vascular O
lesions O
, O
characterized O
by O
perivascular O
hemorrhages O
, O
edema O
, O
and O
mononuclear O
cell O
infiltration O
of O
perivascular O
spaces O
, O
have O
been O
observed O
in O
dogs O
treated O
with O
other O
members O
of O
this O
class O
. O
A O
chemically O
similar O
drug O
in O
this O
class O
produced O
optic O
nerve O
degeneration O
( O
Wallerian O
degeneration O
of O
retinogeniculate O
fibers O
) O
in O
clinically O
normal O
dogs O
in O
a O
dose O
- O
dependent O
fashion O
at O
a O
dose O
that O
produced O
plasma O
drug O
levels O
about O
30 O
times O
higher O
than O
the O
mean O
drug O
level O
in O
humans O
taking O
the O
highest O
recommended O
dose O
. O

Atovaquone B-DRUG
is O
highly O
bound O
to O
plasma O
protein O
( O
99 O
. O
9 O
% O
) O
. O
Therefore O
, O
caution O
should O
be O
used O
when O
administering O
MEPRON B-BRAND
concurrently O
with O
other O
highly O
plasma O
protein O
- O
bound O
drugs O
with O
narrow O
therapeutic O
indices O
, O
as O
competition O
for O
binding O
sites O
may O
occur O
. O
The O
extent O
of O
plasma O
protein O
binding O
of O
atovaquone B-DRUG
in O
human O
plasma O
is O
not O
affected O
by O
the O
presence O
of O
therapeutic O
concentrations O
of O
phenytoin B-DRUG
( O
15 O
mcg O
/ O
mL O
) O
, O
nor O
is O
the O
binding O
of O
phenytoin B-DRUG
affected O
by O
the O
presence O
of O
atovaquone B-DRUG
. O
Rifampin B-DRUG
: O
Coadministration O
of O
rifampin B-DRUG
and O
MEPRON B-BRAND
Suspension O
results O
in O
a O
significant O
decrease O
in O
average O
steady O
- O
state O
plasma O
atovaquone B-DRUG
concentrations O
. O
Alternatives O
to O
rifampin B-DRUG
should O
be O
considered O
during O
the O
course O
of O
PCP O
treatment O
with O
MEPRON B-BRAND
. O
Rifabutin B-DRUG
, O
another O
rifamycin B-DRUG
, O
is O
structurally O
similar O
to O
rifampin B-DRUG
and O
may O
possibly O
have O
some O
of O
the O
same O
drug O
interactions O
as O
rifampin B-DRUG
. O
No O
interaction O
trials O
have O
been O
conducted O
with O
MEPRON B-BRAND
and O
rifabutin B-DRUG
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
: O
It O
is O
not O
known O
if O
MEPRON B-BRAND
interferes O
with O
clinical O
laboratory O
test O
or O
assay O
results O
. O

Drugs O
which O
may O
enhance O
the O
neuromuscular O
blocking O
action O
of O
TRACRIUM B-BRAND
include O
: O
enflurane B-DRUG
; O
isoflurane B-DRUG
; O
halothane B-DRUG
; O
certain O
antibiotics B-GROUP
, O
especially O
the O
aminoglycosides B-GROUP
and O
polymyxins B-GROUP
; O
lithium B-DRUG
; O
magnesium B-DRUG
salts O
; O
procainamide B-DRUG
; O
Drugs O
which O
may O
enhance O
the O
neuromuscular O
blocking O
action O
of O
TRACRIUM B-BRAND
include O
: O
enflurane B-DRUG
; O
isoflurane B-DRUG
; O
halothane B-DRUG
; O
certain O
antibiotics B-GROUP
, O
especially O
the O
aminoglycosides B-GROUP
and O
polymyxins B-GROUP
; O
lithium B-DRUG
; O
magnesium B-DRUG
salts O
; O
procainamide B-DRUG
; O
and O
quinidine B-DRUG
. O
If O
other O
muscle B-GROUP
relaxants I-GROUP
are O
used O
during O
the O
same O
procedure O
, O
the O
possibility O
of O
a O
synergistic O
or O
antagonist O
effect O
should O
be O
considered O
. O
The O
prior O
administration O
of O
succinylcholine B-DRUG
does O
not O
enhance O
the O
duration O
, O
but O
quickens O
the O
onset O
and O
may O
increase O
the O
depth O
, O
of O
neuromuscular O
block O
induced O
by O
TRACRIUM B-BRAND
. O
TRACRIUM B-BRAND
should O
not O
be O
administered O
until O
a O
patient O
has O
recovered O
from O
succinylcholine B-DRUG
- O
induced O
neuromuscular O
block O
. O

When O
atropine B-DRUG
and O
pralidoxime B-DRUG
are O
used O
together O
, O
the O
signs O
of O
atropinization O
( O
flushing O
, O
mydriasis O
, O
tachycardia O
, O
dryness O
of O
the O
mouth O
and O
nose O
) O
may O
occur O
earlier O
than O
might O
be O
expected O
than O
when O
atropine B-DRUG
is O
used O
alone O
because O
pralidoxime B-DRUG
may O
potentiate O
the O
effect O
of O
atropine B-DRUG
. O
The O
following O
precautions O
should O
be O
kept O
in O
mind O
in O
the O
treatment O
of O
anticholinesterase O
poisoning O
although O
they O
do O
not O
bear O
directly O
on O
the O
use O
of O
atropine B-DRUG
and O
pralidoxime B-DRUG
. O
Since O
barbiturates B-GROUP
are O
potentiated O
by O
the O
anticholinesterases B-GROUP
, O
they O
should O
be O
used O
cautiously O
in O
the O
treatment O
of O
convulsions O
. O

Auranofin B-DRUG
should O
be O
avoided O
by O
patients O
with O
a O
history O
of O
serious O
reaction O
to O
any O
gold B-GROUP
medication I-GROUP
, O
including O
Solganal B-BRAND
and O
Myochrysine B-BRAND
. O
Auranofin B-DRUG
should O
not O
be O
used O
together O
with O
penicillamine B-DRUG
( O
Depen B-BRAND
, O
Cuprimine B-BRAND
) O
, O
another O
arthritis O
medication O
. O
It O
should O
also O
be O
avoided O
in O
patients O
with O
blood O
, O
liver O
or O
kidney O
diseases O
, O
recent O
radiation O
treatment O
, O
or O
uncontrolled O
diabetes O
. O
Patients O
should O
report O
to O
their O
practitioners O
any O
new O
rashes O
, O
itching O
, O
mouth O
sores O
, O
or O
unusual O
taste O
while O
taking O
auranofin B-DRUG
. O
Gold B-GROUP
is O
excreted O
slowly O
from O
the O
body O
. O
Safety O
and O
effectiveness O
in O
children O
has O
not O
been O
established O
. O

No O
formal O
assessments O
of O
drug O
- O
drug O
interactions O
between O
Vidaza B-BRAND
and O
other O
agents O
have O
been O
conducted O
. O

MAO B-GROUP
inhibitors I-GROUP
prolong O
and O
intensify O
the O
effects O
of O
antihistamines B-GROUP
. O
Concomitant O
use O
of O
antihistamines B-GROUP
with O
alcohol B-DRUG
, O
tricyclic B-GROUP
antidepressants I-GROUP
, O
barbiturates B-GROUP
, O
or O
other O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressants I-GROUP
may O
have O
an O
additive O
effect O
. O
When O
sympathomimetic B-GROUP
drugs I-GROUP
are O
given O
to O
patients O
receiving O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
, O
hypertensive O
reactions O
, O
including O
hypertensive O
crises O
, O
may O
occur O
. O
The O
antihypertensive O
effects O
of O
methyldopa B-DRUG
, O
mecamylamine B-DRUG
, O
reserpine B-DRUG
, O
and O
veratrum B-DRUG
alkaloids I-DRUG
may O
be O
reduced O
by O
sympathomimetics B-GROUP
. O
Beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
may O
also O
interact O
with O
sympathomimetics B-GROUP
. O
Increased O
ectopic O
pacemaker O
activity O
can O
occur O
when O
pseudoephedrine B-DRUG
is O
used O
concomitantly O
with O
digitalis B-GROUP
. O
Antacids B-GROUP
increase O
the O
rate O
of O
absorption O
of O
pseudoephedrine B-DRUG
, O
while O
kaolin B-DRUG
decreases O
it O
. O

Use O
with O
Allopurinol B-DRUG
: O
The O
principal O
pathway O
for O
detoxification O
of O
azathioprine B-DRUG
is O
inhibited O
by O
allopurinol B-DRUG
. O
Patients O
receiving O
azathioprine B-DRUG
and O
allopurinol B-DRUG
concomitantly O
should O
have O
a O
dose O
reduction O
of O
azathioprine B-DRUG
, O
to O
approximately O
1 O
/ O
3 O
to O
1 O
/ O
4 O
the O
usual O
dose O
. O
Use O
with O
Other O
Agents O
Affecting O
Myelopoesis O
: O
Drugs O
which O
may O
affect O
leukocyte O
production O
, O
including O
co B-BRAND
- I-BRAND
trimoxazole I-BRAND
, O
may O
lead O
to O
exaggerated O
leukopenia O
, O
especially O
in O
renal O
transplant O
recipients O
. O
Use O
with O
Angiotensln B-GROUP
Converting I-GROUP
Enzyme I-GROUP
Inhibitors I-GROUP
: O
The O
use O
of O
angiotensin B-GROUP
converting I-GROUP
enzyme I-GROUP
inhibitors I-GROUP
to O
control O
hypertension O
in O
patients O
on O
azathioprine B-DRUG
has O
been O
reported O
to O
induce O
severe O
leukopenia O
. O

No O
information O
provided O

Co O
- O
administration O
of O
nelfinavir B-DRUG
at O
steady O
- O
state O
with O
a O
single O
dose O
of O
azithromycin B-DRUG
. O
Co O
- O
administration O
of O
nelfinavir B-DRUG
at O
steady O
- O
state O
with O
a O
single O
dose O
of O
azithromycin B-DRUG
( O
2 O
x O
600 O
mg O
tablets O
) O
results O
in O
increased O
azithromycin B-DRUG
serum O
concentrations O
. O
Although O
a O
dose O
adjustment O
of O
azithromycin B-DRUG
is O
not O
recommended O
when O
administered O
in O
combination O
with O
nelfinavir B-DRUG
, O
close O
monitoring O
for O
known O
side O
effects O
of O
azithromycin B-DRUG
, O
such O
as O
liver O
enzyme O
abnormalities O
and O
hearing O
impairment O
, O
is O
warranted O
. O
Azithromycin B-DRUG
did O
not O
affect O
the O
prothrombin O
time O
response O
to O
a O
single O
dose O
of O
warfarin B-DRUG
. O
However O
, O
prudent O
medical O
practice O
dictates O
careful O
monitoring O
of O
prothrombin O
time O
in O
all O
patients O
treated O
with O
azithromycin B-DRUG
and O
warfarin B-DRUG
concomitantly O
. O
Concurrent O
use O
of O
macrolides B-GROUP
and O
warfarin B-DRUG
in O
clinical O
practice O
has O
been O
associated O
with O
increased O
anticoagulant O
effects O
. O
Drug O
interaction O
studies O
were O
performed O
with O
azithromycin B-DRUG
and O
other O
drugs O
likely O
to O
be O
co O
- O
administered O
. O
When O
used O
in O
therapeutic O
doses O
, O
azithromycin B-DRUG
had O
a O
modest O
effect O
on O
the O
pharmacokinetics O
of O
atorvastatin B-DRUG
, O
carbamazepine B-DRUG
, O
cetirizine B-DRUG
, O
didanosine B-DRUG
, O
efavirenz B-DRUG
, O
fluconazole B-DRUG
, O
indinavir B-DRUG
, O
midazolam B-DRUG
, O
rifabutin B-DRUG
, O
sildenafil B-DRUG
, O
theophylline B-DRUG
( O
intravenous O
and O
oral O
) O
, O
triazolam B-DRUG
, O
trimethoprim B-DRUG
/ O
sulfamethoxazole B-DRUG
or O
zidovudine B-DRUG
. O
Co O
- O
administration O
with O
efavirenz B-DRUG
or O
fluconazole B-DRUG
had O
a O
modest O
effect O
on O
the O
pharmacokinetics O
of O
azithromycin B-DRUG
. O
No O
dosage O
adjustment O
of O
either O
drug O
is O
recommended O
when O
azithromycin B-DRUG
is O
co O
administered O
with O
any O
of O
the O
above O
agents O
. O
Interactions O
with O
the O
drugs O
listed O
below O
have O
not O
been O
reported O
in O
clinical O
trials O
with O
azithromycin B-DRUG
; O
however O
, O
no O
specific O
drug O
interaction O
studies O
have O
been O
performed O
to O
evaluate O
potential O
drug O
- O
drug O
interaction O
. O
Nonetheless O
, O
they O
have O
been O
observed O
with O
macrolide B-GROUP
products I-GROUP
. O
Until O
further O
data O
are O
developed O
regarding O
drug O
interactions O
when O
azithromycin B-DRUG
and O
these O
drugs O
are O
used O
concomitantly O
, O
careful O
monitoring O
of O
patients O
is O
advised O
: O
Digoxin B-DRUG
elevated O
digoxin B-DRUG
concentrations O
. O
Ergotamine B-DRUG
or O
dihydroergotamine B-DRUG
acute O

ergot O
toxicity O
characterized O
by O
severe O
peripheral O
vasospasm O
and O
dysesthesia O
. O
Cyclosporine B-DRUG
, O
hexobarbital B-DRUG
and O
phenytoin B-DRUG
concentrations O
. O
Laboratory O
Test O
Interactions O
There O
are O
no O
reported O
laboratory O
test O
interactions O
. O
Repeat O
Treatment O
Studies O
evaluating O
the O
use O
of O
repeated O
courses O
of O
Zmax B-BRAND
have O
not O
been O
conducted O
. O

Azlocillin B-DRUG
should O
not O
be O
administered O
concomitantly O
with O
amikacin B-DRUG
, O
ciprofloxacin B-DRUG
, O
gentamicin B-DRUG
, O
netilmicin B-DRUG
, O
or O
tobramycin B-DRUG
. O

Injection O
There O
is O
inadequate O
systematic O
experience O
with O
the O
use O
of O
baclofen B-DRUG
injection O
in O
combination O
with O
other O
medications O
to O
predict O
specific O
drug O
- O
drug O
interactions O
. O
Interactions O
attributed O
to O
the O
combined O
use O
of O
baclofen B-DRUG
injection O
and O
epidural O
morphine B-DRUG
include O
hypotension O
and O
dyspnea O
. O
SIDE O
EFFECTS O
( O
KEMSTRO B-BRAND
) O
The O
most O
common O
adverse O
reaction O
during O
treatment O
with O
baclofen B-DRUG
is O
transient O
drowsiness O
( O
10 O
- O
63 O
% O
) O
. O
In O
one O
controlled O
study O
of O
175 O
patients O
, O
transient O
drowsiness O
was O
observed O
in O
63 O
% O
of O
those O
receiving O
baclofen B-DRUG
tablets O
compared O
to O
36 O
% O
of O
those O
in O
the O
placebo O
group O
. O
Other O
common O
adverse O
reactions O
are O
dizziness O
( O
5 O
- O
15 O
% O
) O
, O
weakness O
( O
5 O
- O
15 O
% O
) O
and O
fatigue O
( O
2 O
- O
4 O
% O
) O
. O
Others O
reported O
: O
Neuropsychiatric O
: O
Confusion O
( O
1 O
- O
11 O
% O
) O
, O
headache O
( O
4 O
- O
8 O
% O
) O
, O
insomnia O
( O
2 O
- O
7 O
% O
) O
; O
and O
, O
rarely O
, O
euphoria O
, O
excitement O
, O
depression O
, O
hallucinations O
, O
paresthesia O
, O
muscle O
pain O
, O
tinnitus O
, O
slurred O
speech O
, O
coordination O
disorder O
, O
tremor O
, O
rigidity O
, O
dystonia O
, O
ataxia O
, O
blurred O
vision O
, O
nystagmus O
, O
strabismus O
, O
miosis O
, O
mydriasis O
, O
diplopia O
, O
dysarthria O
, O
epileptic O
seizure O
. O
Cardiovascular O
: O
Hypotension O
( O
0 O
- O
9 O
% O
) O
. O
Rare O
instances O
of O
dyspnea O
, O
palpitation O
, O
chest O
pain O
, O
syncope O
. O
Gastrointestinal O
: O
Nausea O
( O
4 O
- O
12 O
% O
) O
, O
constipation O
( O
2 O
- O
6 O
% O
) O
; O
and O
, O
rarely O
, O
dry O
mouth O
, O
anorexia O
, O
taste O
disorder O
, O
abdominal O
pain O
, O
vomiting O
, O
diarrhea O
, O
and O
positive O
test O
for O
occult O
blood O
in O
stool O
. O
Genitourinary O
: O
Urinary O
frequency O
( O
2 O
- O
6 O
% O
) O
; O
and O
, O
rarely O
, O
enuresis O
, O
urinary O
retention O
, O
dysuria O
, O
impotence O
, O
inability O
to O
ejaculate O
, O
nocturia O
, O
hematuria O
. O
Other O
: O
Instances O
of O
rash O
, O
pruritus O
, O
ankle O
edema O
, O
excessive O
perspiration O
, O
weight O
gain O
, O
nasal O
congestion O
. O
Some O
of O
the O
CNS O
and O
genitourinary O
symptoms O
may O
be O
related O
to O
the O
underlying O
disease O
rather O
than O
to O
drug O
therapy O
. O
The O
following O
laboratory O
tests O
have O
been O
found O
to O
be O
abnormal O
in O
a O
few O
patients O

receiving O
baclofen B-DRUG
: O
increased O
SGOT O
, O
elevated O
alkaline O
phosphatase O
, O
and O
elevation O
of O
blood O
sugar O
. O
The O
adverse O
experience O
profile O
seen O
with O
KEMSTROTM B-BRAND
was O
similar O
to O
that O
seen O
with O
baclofen B-DRUG
tablets O
. O

No O
drug O
interaction O
studies O
have O
been O
conducted O
for O
COLAZAL B-BRAND
, O
however O
the O
use O
of O
orally O
administered O
antibiotics B-GROUP
could O
, O
theoretically O
, O
interfere O
with O
the O
release O
of O
mesalamine B-DRUG
in O
the O
colon O
. O

No O
dose O
adjustment O
is O
necessary O
when O
Simulect B-BRAND
is O
added O
to O
triple O
- O
immunosuppression O
regimens O
including O
cyclosporine B-DRUG
, O
corticosteroids B-GROUP
, O
and O
either O
azathioprine B-DRUG
or O
mycophenolate B-DRUG
mofetil I-DRUG
. O
Three O
clinical O
trials O
have O
investigated O
Simulect B-BRAND
use O
in O
combination O
with O
triple O
- O
therapy O
regimens O
. O
Pharmacokinetics O
were O
assessed O
in O
two O
of O
these O
trials O
. O
Total O
body O
clearance O
of O
Simulect B-BRAND
was O
reduced O
by O
an O
average O
22 O
% O
and O
51 O
% O
when O
azathioprine B-DRUG
and O
mycophenolate B-DRUG
mofetil I-DRUG
, O
respectively O
, O
were O
added O
to O
a O
regimen O
consisting O
of O
cyclosporine B-DRUG
, O
USP O
( O
MODIFIED O
) O
and O
corticosteroids B-GROUP
. O
Nonetheless O
, O
the O
range O
of O
individual O
Simulect B-BRAND
clearance O
values O
in O
the O
presence O
of O
azathioprine B-DRUG
( O
12 O
- O
57 O
mL O
/ O
h O
) O
or O
mycophenolate B-DRUG
mofetil I-DRUG
( O
7 O
- O
54 O
mL O
/ O
h O
) O
did O
not O
extend O
outside O
the O
range O
observed O
with O
dual O
therapy O
( O
10 O
- O
78 O
mL O
/ O
h O
) O
. O
The O
following O
medications O
have O
been O
administered O
in O
clinical O
trials O
with O
Simulect B-BRAND
with O
no O
increase O
in O
adverse O
reactions O
: O
ATG O
/ O
ALG O
, O
azathioprine B-DRUG
, O
corticosteroids B-GROUP
, O
cyclosporine B-DRUG
, O
mycophenolate B-DRUG
mofetil I-DRUG
, O
and O
muromonab B-DRUG
- I-DRUG
CD3 I-DRUG
. O

It O
is O
not O
known O
if O
REGRANEX B-BRAND
Gel O
interacts O
with O
other O
topical O
medications O
applied O
to O
the O
ulcer O
site O
. O
The O
use O
of O
REGRANEX B-BRAND
Gel O
with O
other O
topical O
drugs O
has O
not O
been O
studied O
. O

Albuterol B-DRUG
, O
Antihistamines B-GROUP
, O
antidiabetic B-GROUP
drugs I-GROUP
, O
diuretics B-GROUP
, O
digitalis B-GROUP
. O

Diuretics B-GROUP
: O
Patients O
on O
diuretics B-GROUP
, O
especially O
those O
in O
whom O
diuretic O
therapy O
was O
recently O
instituted O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
therapy O
with O
Lotensin B-BRAND
. O
The O
possibility O
of O
hypotensive O
effects O
with O
Lotensin B-BRAND
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-GROUP
or O
increasing O
the O
salt O
intake O
prior O
to O
initiation O
of O
treatment O
with O
Lotensin B-BRAND
. O
If O
this O
is O
not O
possible O
, O
the O
starting O
dose O
should O
be O
reduced O
. O
Potassium B-DRUG
Supplements O
and O
Potassium B-GROUP
- I-GROUP
Sparing I-GROUP
Diuretics I-GROUP
Lotensin O
can O
attenuate O
potassium O
loss O
caused O
by O
thiazide B-GROUP
diuretics I-GROUP
. O
Potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
( O
spironolactone B-DRUG
, O
amiloride B-DRUG
, O
triamterene B-DRUG
, O
and O
others O
) O
or O
potassium B-DRUG
supplements O
can O
increase O
the O
risk O
of O
hyperkalemia O
. O
Therefore O
, O
if O
concomitant O
use O
of O
such O
agents O
is O
indicated O
, O
they O
should O
be O
given O
with O
caution O
, O
and O
the O
patient O
' O
s O
serum O
potassium O
should O
be O
monitored O
frequently O
. O
Oral O
Anticoagulants B-GROUP
Interaction O
studies O
with O
warfarin B-DRUG
and O
acenocoumarol B-DRUG
failed O
to O
identify O
any O
clinically O
important O
effects O
on O
the O
serum O
concentrations O
or O
clinical O
effects O
of O
these O
anticoagulants B-GROUP
. O
Lithium B-DRUG
: O
Increased O
serum O
lithium B-DRUG
levels O
and O
symptoms O
of O
lithium B-DRUG
toxicity O
have O
been O
reported O
in O
patients O
receiving O
ACE B-GROUP
inhibitors I-GROUP
during O
therapy O
with O
lithium B-DRUG
. O
These O
drugs O
should O
be O
coadministered O
with O
caution O
, O
and O
frequent O
monitoring O
of O
serum O
lithium B-DRUG
levels O
is O
recommended O
. O
If O
a O
diuretic B-GROUP
is O
also O
used O
, O
the O
risk O
of O
lithium B-DRUG
toxicity O
may O
be O
increased O
. O
Other O
No O
clinically O
important O
pharmacokinetic O
interactions O
occurred O
when O
Lotensin B-BRAND
was O
administered O
concomitantly O
with O
hydrochlorothiazide B-DRUG
, O
chlorthalidone B-DRUG
, O
furosemide B-DRUG
, O
digoxin B-DRUG
, O
propranolol B-DRUG
, O
atenolol B-DRUG
, O
naproxen B-DRUG
, O
or O
cimetidine B-DRUG
. O
Lotensin B-BRAND
has O
been O
used O
concomitantly O
with O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
, O
calcium B-GROUP
- I-GROUP
channel I-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
, O
diuretics B-GROUP
, O
digoxin B-DRUG
, O
and O
hydralazine B-DRUG
, O
without O
evidence O
of O
clinically O
important O
adverse O
interactions O
. O
Benazepril B-DRUG
, O
like O
other O
ACE B-GROUP
inhibitors I-GROUP
, O
has O
had O
less O
than O
additive O
effects O
with O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blockers I-GROUP
, O
presumably O
because O
both O
drugs O
lower O
blood O
pressure O
by O
inhibiting O
parts O
of O
the O
renin O
- O
angiotensin O
system O
. O

May O
interact O
with O
the O
following O
: O
cholestyramine B-DRUG
, O
colestipol B-DRUG
( O
use O
with O
thiazide B-GROUP
diuretics I-GROUP
may O
prevent O
the O
diuretic B-GROUP
from O
working O
properly O
; O

Bentiromide B-DRUG
may O
interact O
with O
acetaminophen B-DRUG
( O
e O
. O
g O
. O
, O
Tylenol B-BRAND
) O
, O
chloramphenicol B-DRUG
( O
e O
. O
g O
. O
, O
Chloromycetin B-BRAND
) O
, O
local O
anesthetics B-GROUP
( O
e O
. O
g O
. O
, O
benzocaine B-DRUG
and O
lidocaine B-DRUG
) O
, O
para B-DRUG_N
- I-DRUG_N
aminobenzoic I-DRUG_N
acid I-DRUG_N
( O
PABA B-DRUG_N
) O
- O
containing O
preparations O
( O
e O
. O
g O
. O
, O
sunscreens O
and O
some O
multivitamins B-GROUP
) O
, O
procainamide B-DRUG
( O
e O
. O
g O
. O
, O
Pronestyl B-BRAND
) O
, O
sulfonamides B-GROUP
( O
sulfa O
medicines O
) O
, O
thiazide B-GROUP
diuretics I-GROUP
( O
use O
of O
these O
medicines O
during O
the O
test O
period O
will O
affect O
the O
test O
results O
) O
, O
and O
pancreatic O
supplements O
( O
use O
of O
pancreatic O
supplements O
may O
give O
false O
test O
results O
) O
. O

May O
interact O
with O
other O
creams O
, O
lotions O
, O
or O
skin O
medicines O
when O
placed O
on O
the O
same O
areas O
of O
your O
skin O
that O
you O
are O
using O
bentoquatam B-DRUG_N
. O

No O
information O
is O
available O
. O

Hypertensive O
crises O
have O
resulted O
when O
sympathomimetic B-GROUP
amines I-GROUP
have O
been O
used O
concomitantly O
within14 O
days O
following O
use O
of O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
. O
DIDREX B-BRAND
should O
not O
be O
used O
concomitantly O
with O
other O
CNS B-GROUP
stimulants I-GROUP
. O
Amphetamines B-GROUP
may O
decrease O
the O
hypotensive O
effect O
of O
antihypertensives B-GROUP
. O
Amphetamines B-GROUP
may O
enhance O
the O
effects O
of O
tricyclic B-GROUP
antidepressants I-GROUP
. O
Urinary O
alkalinizing O
agents O
increase O
blood O
levels O
and O
decrease O
excretion O
of O
amphetamines B-GROUP
. O
Urinary B-DRUG
acidifying I-DRUG
agents O
decrease O
blood O
levels O
and O
increase O
excretion O
of O
amphetamines B-GROUP
. O

Benzthiazide B-DRUG
may O
interact O
with O
alcohol B-DRUG
, O
blood B-GROUP
thinners I-GROUP
, O
decongestant B-GROUP
drugs I-GROUP
( O
allergy O
, O
cold O
, O
and O
sinus O
medicines O
) O
, O
diabetic O
drugs O
, O
lithium B-DRUG
, O
norepinephrine B-DRUG
, O
NSAIDs B-GROUP
like O
Aleve B-BRAND
or O
Ibuprofen B-DRUG
, O
and O
high O
blood O
pressure O
medications O
. O

Antipsychotic B-GROUP
drugs I-GROUP
such O
as O
phenothiazines B-GROUP
or O
haloperidol B-DRUG
; O
tricyclic B-GROUP
antidepressants I-GROUP
. O

Nitrates B-GROUP
: O
The O
concomitant O
use O
of O
Bepridil B-DRUG
with O
long O
- O
and O
short O
- O
acting O
nitrates B-GROUP
has O
been O
safely O
tolerated O
in O
patients O
with O
stable O
angina O
pectoris O
. O
Sublingual O
nitroglycerin B-DRUG
may O
be O
taken O
if O
necessary O
for O
the O
control O
of O
acute O
angina O
attacks O
during O
Bepridil B-DRUG
therapy O
. O
Beta B-GROUP
- I-GROUP
blocking I-GROUP
Agents I-GROUP
: O
The O
concomitant O
use O
of O
Bepridil B-DRUG
and O
beta B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
has O
been O
well O
tolerated O
in O
patients O
with O
stable O
angina O
. O
Available O
data O
are O
not O
sufficient O
, O
however O
, O
to O
predict O
the O
effects O
of O
concomitant O
medication O
on O
patients O
with O
impaired O
ventricular O
function O
or O
cardiac O
conduction O
abnormalities O
. O
Digoxin B-DRUG
: O
In O
controlled O
studies O
in O
healthy O
volunteers O
, O
bepridil B-DRUG
hydrochloride I-DRUG
either O
had O
no O
effect O
( O
one O
study O
) O
or O
was O
associated O
with O
modest O
increases O
, O
about O
30 O
% O
( O
two O
studies O
) O
in O
steady O
- O
state O
serum O
digoxin B-DRUG
concentrations O
. O
Limited O
clinical O
data O
in O
angina O
patients O
receiving O
concomitant O
bepridil B-DRUG
hydrochloride I-DRUG
and O
digoxin B-DRUG
therapy O
indicate O
no O
discernible O
changes O
in O
serum O
digoxin O
levels O
. O
Available O
data O
are O
neither O
sufficient O
to O
rule O
out O
possible O
increases O
in O
serum O
digoxin B-DRUG
with O
concomitant O
treatment O
in O
some O
patients O
, O
nor O
other O
possible O
interactions O
, O
particularly O
in O
patients O
with O
cardiac O
conduction O
abnormalities O
( O
Also O
see O
WARNINGS O
Congestive O
Heart O
Failure O
) O
. O
Oral O
Hypoglycemics B-GROUP
: O
Bepridil B-DRUG
has O
been O
safely O
used O
in O
diabetic O
patients O
without O
significantly O
lowering O
their O
blood O
glucose O
levels O
or O
altering O
their O
need O
for O
insulin B-DRUG
or O
oral O
hypoglycemic B-GROUP
agents I-GROUP
. O
General O
Interactions O
: O
Certain O
drugs O
could O
increase O
the O
likelihood O
of O
potentially O
serious O
adverse O
effects O
with O
bepridil B-DRUG
hydrochloride I-DRUG
. O
In O
general O
, O
these O
are O
drugs O
that O
have O
one O
or O
more O
pharmacologic O
activities O
similar O
to O
bepridil B-DRUG
hydrochloride I-DRUG
, O
including O
anti B-GROUP
- I-GROUP
arrhythmic I-GROUP
agents I-GROUP
such O
as O
quinidine B-DRUG
and O
procainamide B-DRUG
, O
cardiac B-GROUP
glycosides I-GROUP
and O
tricyclic B-GROUP
anti I-GROUP
- I-GROUP
depressants I-GROUP
. O
Anti B-GROUP
- I-GROUP
arrhythmics I-GROUP
and O
tricyclic B-GROUP
anti I-GROUP
- I-GROUP
depressants I-GROUP
could O
exaggerate O
the O
prolongation O
of O
the O
QT O
interval O
observed O
with O
bepridil B-DRUG
hydrochloride I-DRUG
. O
Cardiac B-GROUP
glycosides I-GROUP
could O
exaggerate O
the O
depression O
of O
AV O
nodal O
conduction O
observed O
with O
bepridil B-DRUG
hydrochloride I-DRUG
. O

APRD00513 O
_ O
IN O
, O
txt O

The O
following O
drugs O
have O
been O
coadministered O
with O
Kerlone B-BRAND
and O
have O
not O
altered O
its O
pharmacokinetics O
: O
cimetidine B-DRUG
, O
nifedipine B-DRUG
, O
chlorthalidone B-DRUG
, O
and O
hydrochlorothiazide B-DRUG
. O
Concomitant O
administration O
of O
Kerlone B-BRAND
with O
the O
oral O
anticoagulant B-GROUP
warfarin B-DRUG
has O
been O
shown O
not O
to O
potentiate O
the O
anticoagulant O
effect O
of O
warfarin B-DRUG
. O
Catecholamine O
- O
depleting O
drugs O
( O
e O
. O
g O
. O
, O
reserpine B-DRUG
) O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta B-DRUG
- I-DRUG
blocking I-DRUG
agents O
. O
Patients O
treated O
with O
a O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
receptor I-GROUP
blocking I-GROUP
agent I-GROUP
plus O
a O
catecholamine O
depletor O
should O
therefore O
be O
closely O
observed O
for O
evidence O
of O
hypotension O
or O
marked O
bradycardia O
, O
which O
may O
produce O
vertigo O
, O
syncope O
, O
or O
postural O
hypotension O
. O
Should O
it O
be O
decided O
to O
discontinue O
therapy O
in O
patients O
receiving O
beta B-GROUP
- I-GROUP
blockers I-GROUP
and O
clonidine B-DRUG
concurrently O
, O
the O
beta B-GROUP
- I-GROUP
blocker I-GROUP
should O
be O
discontinued O
slowly O
over O
several O
days O
before O
the O
gradual O
withdrawal O
of O
clonidine B-DRUG
. O
Literature O
reports O
suggest O
that O
oral O
calcium B-GROUP
antagonists I-GROUP
may O
be O
used O
in O
combination O
with O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
when O
heart O
function O
is O
normal O
, O
but O
should O
be O
avoided O
in O
patients O
with O
impaired O
cardiac O
function O
. O
Hypotension O
, O
AV O
conduction O
disturbances O
, O
and O
left O
ventricular O
failure O
have O
been O
reported O
in O
some O
patients O
receiving O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
when O
an O
oral O
calcium B-GROUP
antagonist I-GROUP
was O
added O
to O
the O
treatment O
regimen O
. O
Hypotension O
was O
more O
likely O
to O
occur O
if O
the O
calcium B-GROUP
antagonist I-GROUP
were O
a O
dihydropyridine B-GROUP
derivative I-GROUP
, O
e O
. O
g O
. O
, O
nifedipine B-DRUG
, O
while O
left O
ventricular O
failure O
and O
AV O
conduction O
disturbances O
, O
including O
complete O
heart O
block O
, O
were O
more O
likely O
to O
occur O
with O
either O
verapamil B-DRUG
or O
diltiazem B-DRUG
. O
Risk O
of O
Anaphylactic O
Reaction O
: O
Although O
it O
is O
known O
that O
patients O
on O
beta B-GROUP
- I-GROUP
blockers I-GROUP
may O
be O
refractory O
to O
epinephrine B-DRUG
in O
the O
treatment O
of O
anaphylactic O
shock O
, O
beta B-GROUP
- I-GROUP
blockers I-GROUP
can O
, O
in O
addition O
, O
interfere O
with O
the O
modulation O
of O
allergic O
reaction O
and O
lead O
to O
an O
increased O
severity O
and O
/ O
or O
frequency O
of O
attacks O
. O
Severe O
allergic O
reactions O
including O
anaphylaxis O
have O
been O
reported O
in O
patients O
exposed O
to O
a O
variety O
of O
allergens O
either O
by O
repeated O
challenge O
, O
or O
accidental O
contact O
, O
and O
with O
diagnostic O
or O
therapeutic O
agents O
while O
receiving O
beta B-GROUP
- I-GROUP
blockers I-GROUP
. O
Such O
patients O
may O
be O

unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-DRUG
used O
to O
treat O
allergic O
reaction O
. O

Special O
care O
is O
required O
if O
this O
drug O
is O
given O
to O
patients O
receiving O
ganglion B-GROUP
blocking I-GROUP
compounds I-GROUP
because O
a O
critical O
fall O
in O
blood O
pressure O
may O
occur O
. O
Usually O
, O
severe O
abdominal O
symptoms O
appear O
before O
there O
is O
such O
a O
fall O
in O
the O
blood O
pressure O
. O

No O
formal O
drug O
interaction O
studies O
with O
anti B-GROUP
- I-GROUP
neoplastic I-GROUP
agents I-GROUP
have O
been O
conducted O
. O
In O
Study O
1 O
, O
patients O
with O
colorectal O
cancer O
were O
given O
irinotecan B-DRUG
/ O
5 B-DRUG
- I-DRUG
FU I-DRUG
/ O
leucovorin B-DRUG
( O
bolus O
- O
IFL O
) O
with O
or O
without O
AVASTIN B-BRAND
. O
Irinotecan B-DRUG
concentrations O
were O
similar O
in O
patients O
receiving O
bolus O
- O
IFL O
alone O
and O
in O
combination O
with O
AVASTIN B-BRAND
. O
The O
concentrations O
of O
SN38 B-DRUG_N
, O
the O
active O
metabolite O
of O
irinotecan B-DRUG
, O
were O
on O
average O
33 O
% O
higher O
in O
patients O
receiving O
bolus O
- O
IFL O
in O
combination O
with O
AVASTIN B-BRAND
when O
compared O
with O
bolus O
- O
IFL O
alone O
. O
In O
Study O
1 O
, O
patients O
receiving O
bolus O
- O
IFL O
plus O
AVASTIN B-BRAND
had O
a O
higher O
incidence O
of O
Grade O
3 O
- O
4 O
diarrhea O
and O
neutropenia O
. O
Due O
to O
high O
inter O
- O
patient O
variability O
and O
limited O
sampling O
, O
the O
extent O
of O
the O
increase O
in O
SN38 B-DRUG_N
levels O
in O
patients O
receiving O
concurrent O
irinotecan B-DRUG
and O
AVASTIN B-BRAND
is O
uncertain O
. O

No O
formal O
studies O
to O
evaluate O
drug O
interactions O
with O
bexarotene B-DRUG
have O
been O
conducted O
. O
Bexarotene B-DRUG
oxidative O
metabolites O
appear O
to O
be O
formed O
by O
cytochrome O
P450 O
3A4 O
. O
On O
the O
basis O
of O
the O
metabolism O
of O
bexarotene B-DRUG
by O
cytochrome O
P450 O
3A4 O
, O
ketoconazole B-DRUG
, O
itraconazole B-DRUG
, O
erythromycin B-DRUG
, O
gemfibrozil B-DRUG
, O
grapefruit O
juice O
, O
and O
other O
inhibitors O
of O
cytochrome O
P450 O
3A4 O
would O
be O
expected O
to O
lead O
to O
an O
increase O
in O
plasma O
bexarotene B-DRUG
concentrations O
. O
Furthermore O
, O
rifampin B-DRUG
, O
phenytoin B-DRUG
, O
phenobarbital B-DRUG
, O
and O
other O
inducers O
of O
cytochrome O
P450 O
3A4 O
may O
cause O
a O
reduction O
in O
plasma O
bexarotene B-DRUG
concentrations O
. O
Concomitant O
administration O
of O
Targretin B-BRAND
capsules O
and O
gemfibrozil B-DRUG
resulted O
in O
substantial O
increases O
in O
plasma O
concentrations O
of O
bexarotene B-DRUG
, O
probably O
at O
least O
partially O
related O
to O
cytochrome O
P450 O
3A4 O
inhibition O
by O
gemfibrozil B-DRUG
. O
Under O
similar O
conditions O
, O
bexarotene B-DRUG
concentrations O
were O
not O
affected O
by O
concomitant O
atorvastatin B-DRUG
administration O
. O
Concomitant O
administration O
of O
gemfibrozil B-DRUG
with O
Targretin B-BRAND
capsules O
is O
not O
recommended O
. O

When O
Bezalip B-BRAND
or O
Bezalip B-BRAND
retard I-BRAND
is O
used O
at O
the O
same O
time O
as O
other O
medicines O
or O
substances O
the O
following O
interactions O
must O
be O
taken O
into O
account O
: O
- O
Bezalip B-BRAND
and O
Bezalip B-BRAND
retard I-BRAND
may O
enhance O
the O
action O
of O
anticoagulants B-GROUP
of I-GROUP
the I-GROUP
coumarin I-GROUP
type I-GROUP
. O
For O
this O
reason O
, O
the O
dose O
of O
the O
anticoagulant B-DRUG
should O
be O
reduced O
by O
30 O
- O
50 O
% O
at O
the O
start O
of O
treatment O
with O
Bezalip B-BRAND
or O
Bezalip B-BRAND
retard O
and O
then O
titrated O
according O
to O
the O
blood O
clotting O
parameters O
. O
- O
The O
action O
of O
sulphonylureas B-GROUP
and O
insulin B-DRUG
may O
be O
enhanced O
by O
Bezalip B-BRAND
or O
Bezalip B-BRAND
retard I-BRAND
. O
This O
may O
be O
due O
to O
an O
improved O
glucose O
utilization O
with O
simultaneous O
reduction O
in O
insulin B-DRUG
requirement O
. O
- O
In O
isolated O
cases O
, O
a O
pronounced O
though O
reversible O
, O
impairment O
of O
renal O
function O
( O
accompanied O
by O
a O
corresponding O
increase O
in O
the O
serum O
creatinine O
level O
) O
has O
been O
reported O
in O
organ O
transplant O
patients O
receiving O
immuno B-GROUP
- I-GROUP
suppressant I-GROUP
therapy O
and O
concomitant O
bezafibrate B-DRUG
. O
Accordingly O
, O
renal O
function O
should O
be O
closely O
monitored O
in O
these O
patients O
and O
, O
in O
the O
event O
of O
relevant O
significant O
changes O
in O
laboratory O
parameters O
, O
bezafibrate B-DRUG
should O
, O
if O
necessary O
, O
be O
discontinued O
. O
- O
When O
Bezalip B-BRAND
or O
Bezalip B-BRAND
retard I-BRAND
is O
used O
concurrently O
with O
anion B-GROUP
- I-GROUP
exchange I-GROUP
resins I-GROUP
( O
e O
. O
g O
. O
cholestryramine B-DRUG
) O
, O
an O
interval O
of O
at O
least O
2 O
hours O
should O
be O
maintained O
between O
the O
two O
medicines O
, O
since O
the O
absorption O
of O
Bezalip B-BRAND
or O
Bezalip B-BRAND
retard I-BRAND
is O
impaired O
. O
- O
Perhexiline B-DRUG
hydrogen I-DRUG
maleate I-DRUG
or O
MAO B-GROUP
- I-GROUP
inhibitors I-GROUP
( O
with O
hepatotoxic O
potential O
) O
must O
not O
be O
administered O
together O
with O
Bezalip B-BRAND
or O
Bezalip B-BRAND
retard I-BRAND
. O

In O
vitro O
studies O
have O
shown O
CASODEX B-BRAND
can O
displace O
coumarin B-GROUP
anticoagulants I-GROUP
, O
such O
as O
warfarin B-DRUG
, O
from O
their O
protein O
- O
binding O
sites O
. O
It O
is O
recommended O
that O
if O
CASODEX B-BRAND
is O
started O
in O
patients O
already O
receiving O
coumarin B-GROUP
anticoagulants I-GROUP
, O
prothrombin O
times O
should O
be O
closely O
monitored O
and O
adjustment O
of O
the O
anticoagulant B-GROUP
dose O
may O
be O
necessary O
. O

No O
Information O
Provided O

Drug O
Interactions O
: O
The O
central O
anticholinergic B-GROUP
syndrome O
can O
occur O
when O
anticholinergic O
agents O
such O
as O
AKINETON B-BRAND
are O
administered O
concomitantly O
with O
drugs O
that O
have O
secondary O
anticholinergic O
actions O
, O
e O
. O
g O
. O
, O
certain O
narcotic B-GROUP
analgesics I-GROUP
such O
as O
meperidine B-DRUG
, O
the O
phenothiazines B-GROUP
and O
other O
antipsychotics B-GROUP
, O
tricyclic B-GROUP
antidepressants I-GROUP
, O
certain O
antiarrhythmics B-GROUP
such O
as O
the O
quinidine B-DRUG
salts O
, O
and O
antihistamines B-GROUP
. O

ZEBETA B-BRAND
should O
not O
be O
combined O
with O
other O
beta B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
. O
Patients O
receiving O
catecholamine O
- O
depleting O
drugs O
, O
such O
as O
reserpine B-DRUG
or O
guanethidine B-DRUG
, O
should O
be O
closely O
monitored O
, O
because O
the O
added O
beta O
- O
adrenergic O
blocking O
action O
of O
ZEBETA B-BRAND
may O
produce O
excessive O
reduction O
of O
sympathetic O
activity O
. O
In O
patients O
receiving O
concurrent O
therapy O
with O
clonidine B-DRUG
, O
if O
therapy O
is O
to O
be O
discontinued O
, O
it O
is O
suggested O
that O
ZEBETA B-BRAND
be O
discontinued O
for O
several O
days O
before O
the O
withdrawal O
of O
clonidine B-DRUG
. O
ZEBETA B-BRAND
should O
be O
used O
with O
care O
when O
myocardial B-GROUP
depressants I-GROUP
or O
inhibitors O
of O
AV O
conduction O
, O
such O
as O
certain O
calcium B-GROUP
antagonists I-GROUP
( O
particularly O
of O
the O
phenylalkylamine B-GROUP
[ O
verapamil B-DRUG
] O
and O
benzothiazepine B-GROUP
[ O
diltiazem B-DRUG
] O
classes O
) O
, O
or O
antiarrhythmic B-GROUP
agents I-GROUP
, O
such O
as O
disopyramide B-DRUG
, O
are O
used O
concurrently O
. O
Concurrent O
use O
of O
rifampin B-DRUG
increases O
the O
metabolic O
clearance O
of O
ZEBETA B-BRAND
, O
resulting O
in O
a O
shortened O
elimination O
half O
- O
life O
of O
ZEBETA B-BRAND
. O
However O
, O
initial O
dose O
modification O
is O
generally O
not O
necessary O
. O
Pharmacokinetic O
studies O
document O
no O
clinically O
relevant O
interactions O
with O
other O
agents O
given O
concomitantly O
, O
including O
thiazide B-GROUP
diuretics I-GROUP
, O
digoxin B-DRUG
, O
and O
cimetidine B-DRUG
. O
There O
was O
no O
effect O
of O
ZEBETA B-BRAND
on O
prothrombin O
time O
in O
patients O
on O
stable O
doses O
of O
warfarin B-DRUG
. O
Risk O
of O
Anaphylactic O
Reaction O
: O
While O
taking O
beta B-GROUP
- I-GROUP
blockers I-GROUP
, O
patients O
with O
a O
history O
of O
severe O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
be O
more O
reactive O
to O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
, O
or O
therapeutic O
. O
Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-DRUG
used O
to O
treat O
allergic O
reactions O
. O

Use O
of O
MAO B-GROUP
inhibitors I-GROUP
may O
cause O
an O
excessive O
increase O
in O
blood O
pressure O
and O
heart O
stimulation O
. O
If O
you O
are O
also O
using O
a O
steroid B-GROUP
inhaler O
, O
take O
bitolterol B-DRUG
first O
and O
then O
wait O
about O
15 O
minutes O
before O
using O
the O
steroid B-GROUP
inhaler O
. O
This O
allows O
bitolterol B-DRUG
to O
open O
air O
passages O
, O
increasing O
the O
effectiveness O
of O
the O
steroid B-GROUP
. O

Angiomax B-BRAND
does O
not O
exhibit O
binding O
to O
plasma O
proteins O
( O
other O
than O
thrombin O
) O
or O
red O
blood O
cells O
. O
In O
clinical O
trials O
in O
patients O
undergoing O
PTCA O
/ O
PCI O
, O
co O
- O
administration O
of O
Angiomax B-BRAND
with O
heparin B-DRUG
, O
warfarin B-DRUG
, O
thrombolytics B-GROUP
or O
glycoprotein O
IIb O
/ O
IIIa O
inhibitors O
was O
associated O
with O
increased O
risks O
of O
major O
bleeding O
events O
compared O
to O
patients O
not O
receiving O
these O
concomitant O
medications O
. O
There O
is O
no O
experience O
with O
co O
- O
administration O
of O
Angiomax B-BRAND
and O
plasma O
expanders O
such O
as O
dextran B-DRUG
. O
Angiomax B-BRAND
should O
be O
used O
with O
caution O
in O
patients O
with O
disease O
states O
associated O
with O
an O
increased O
risk O
of O
bleeding O
. O
Immunogenicity O
/ O
Re O
- O
exposure O
: O
In O
in O
vitro O
studies O
, O
Angiomax B-BRAND
exhibited O
no O
platelet O
aggregation O
response O
against O
sera O
from O
patients O
with O
a O
history O
of O
HIT O
/ O
HITTS O
. O
Among O
494 O
subjects O
who O
received O
Angiomax B-BRAND
in O
clinical O
trials O
and O
were O
tested O
for O
antibodies O
, O
2 O
subjects O
had O
treatment O
- O
emergent O
positive O
bivalirudin B-DRUG
antibody O
tests O
. O
Neither O
subject O
demonstrated O
clinical O
evidence O
of O
allergic O
or O
anaphylactic O
reactions O
and O
repeat O
testing O
was O
not O
performed O
. O
Nine O
additional O
patients O
who O
had O
initial O
positive O
tests O
were O
negative O
on O
repeat O
testing O
. O

Certain O
antibiotic B-GROUP
, O
cisplatin B-DRUG
, O
cyclosporine B-DRUG
, O
diuretic B-GROUP
, O
foscarnet B-DRUG
, O
and O
vaccines B-GROUP
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
with O
VELCADE B-BRAND
. O
In O
vitro O
studies O
with O
human O
liver O
microsomes O
indicate O
that O
bortezomib B-DRUG
is O
primarily O
a O
substrate O
for O
cytochrome O
P450 O
3A4 O
, O
2C19 O
, O
and O
1A2 O
. O
Patients O
who O
are O
concomitantly O
receiving O
VELCADE B-BRAND
and O
drugs O
that O
are O
inhibitors O
or O
inducers O
of O
cytochrome O
P450 O
3A4 O
should O
be O
closely O
monitored O
for O
either O
toxicities O
or O
reduced O
efficacy O
. O
During O
clinical O
trials O
, O
hypoglycemia O
and O
hyperglycemia O
were O
reported O
in O
diabetic O
patients O
receiving O
oral O
hypoglycemics B-GROUP
. O
Patients O
on O
oral O
antidiabetic B-GROUP
agents I-GROUP
receiving O
VELCADE B-BRAND
treatment O
may O
require O
close O
monitoring O
of O
their O
blood O
glucose O
levels O
and O
adjustment O
of O
the O
dose O
of O
their O
antidiabetic B-GROUP
medication I-GROUP
. O
Drug O
Laboratory O
Test O
Interactions O
None O
known O
. O

Bosentan B-DRUG
is O
metabolized O
by O
CYP2C9 O
and O
CYP3A4 O
. O
Inhibition O
of O
these O
isoenzymes O
may O
increase O
the O
plasma O
concentration O
of O
bosentan B-DRUG
. O
Bosentan B-DRUG
is O
an O
inducer O
of O
CYP3A4 O
and O
CYP2C9 O
. O
Consequently O
, O
plasma O
concentrations O
of O
drugs O
metabolized O
by O
these O
two O
isoenzymes O
will O
be O
decreased O
when O
TRACLEER B-BRAND
is O
co O
- O
administered O
. O
Bosentan B-DRUG
had O
no O
relevant O
inhibitory O
effect O
on O
any O
CYP O
isoenzymes O
tested O
( O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
CYP3A4 O
) O
. O
Consequently O
, O
TRACLEER B-BRAND
is O
not O
expected O
to O
increase O
the O
plasma O
concentrations O
of O
drugs O
metabolized O
by O
these O
enzymes O
. O
Hormonal B-GROUP
Contraceptives I-GROUP
, O
Including O
Oral O
, O
Injectable O
, O
Transdermal O
, O
and O
Implantable O
Contraceptives B-GROUP
: O
An O
interaction O
study O
demonstrated O
that O
co O
- O
administration O
of O
bosentan B-DRUG
and O
the O
oral O
hormonal B-GROUP
contraceptive I-GROUP
Ortho B-BRAND
- I-BRAND
Novum I-BRAND
produced O
average O
decreases O
of O
norethindrone B-DRUG
and O
ethinyl B-DRUG
estradiol I-DRUG
levels O
of O
14 O
% O
and O
31 O
% O
, O
respectively O
. O
However O
, O
decreases O
in O
exposure O
were O
as O
much O
as O
56 O
% O
and O
66 O
% O
, O
respectively O
, O
in O
individual O
subjects O
. O
Therefore O
, O
hormonal B-GROUP
contraceptives I-GROUP
, O
including O
oral O
, O
injectable O
, O
transdermal O
, O
and O
implantable O
forms O
, O
may O
not O
be O
reliable O
when O
TRACLEER B-BRAND
is O
co O
- O
administered O
. O
Women O
should O
practice O
additional O
methods O
of O
contraception O
and O
not O
rely O
on O
hormonal O
contraception O
alone O
when O
taking O
TRACLEER B-BRAND
. O
Specific O
interaction O
studies O
have O
demonstrated O
the O
following O
: O
Cyclosporine B-DRUG
A I-DRUG
: O
During O
the O
first O
day O
of O
concomitant O
administration O
, O
trough O
concentrations O
of O
bosentan B-DRUG
were O
increased O
by O
about O
30 O
- O
fold O
. O
Steady O
- O
state O
bosentan B-DRUG
plasma O
concentrations O
were O
3 O
- O
to O
4 O
- O
fold O
higher O
than O
in O
the O
absence O
of O
cyclosporine B-DRUG
A I-DRUG
. O
The O
concomitant O
administration O
of O
bosentan B-DRUG
and O
cyclosporine B-DRUG
A I-DRUG
is O
contraindicated O
. O
Co O
- O
administration O
of O
bosentan B-DRUG
decreased O
the O
plasma O
concentrations O
of O
cyclosporine B-DRUG
A I-DRUG
( O
a O
CYP3A4 O
substrate O
) O
by O
approximately O
50 O
% O
. O
Tacrolimus B-DRUG
: O
Co O
- O
administration O
of O
tacrolimus B-DRUG
and O
bosentan B-DRUG
has O
not O
been O
studied O
in O
man O
. O
Co O
- O
administration O
of O
tacrolimus B-DRUG
and O

bosentan B-DRUG
resulted O
in O
markedly O
increased O
plasma O
concentrations O
of O
bosentan B-DRUG
in O
animals O
. O
Caution O
should O
be O
exercised O
if O
tacrolimus B-DRUG
and O
bosentan B-DRUG
are O
used O
together O
. O
Glyburide B-DRUG
: O
An O
increased O
risk O
of O
elevated O
liver O
aminotransferases O
was O
observed O
in O
patients O
receiving O
concomitant O
therapy O
with O
glyburide B-DRUG
. O
Therefore O
, O
the O
concomitant O
administration O
of O
TRACLEER B-BRAND
and O
glyburide B-DRUG
is O
contraindicated O
, O
and O
alternative O
hypoglycemic B-GROUP
agents I-GROUP
should O
be O
considered O
. O
Co O
- O
administration O
of O
bosentan B-DRUG
decreased O
the O
plasma O
concentrations O
of O
glyburide B-DRUG
by O
approximately O
40 O
% O
. O
The O
plasma O
concentrations O
of O
bosentan B-DRUG
were O
also O
decreased O
by O
approximately O
30 O
% O
. O
Bosentan B-DRUG
is O
also O
expected O
to O
reduce O
plasma O
concentrations O
of O
other O
oral O
hypoglycemic B-GROUP
agents I-GROUP
that O
are O
predominantly O
metabolized O
by O
CYP2C9 O
or O
CYP3A4 O
. O
The O
possibility O
of O
worsened O
glucose O
control O
in O
patients O
using O
these O
agents O
should O
be O
considered O
. O
Ketoconazole B-DRUG
: O
Co O
- O
administration O
of O
bosentan B-DRUG
125 O
mg O
b O
. O
i O
. O
d O
. O
and O
ketoconazole B-DRUG
, O
a O
potent O
CYP3A4 O
inhibitor O
, O
increased O
the O
plasma O
concentrations O
of O
bosentan B-DRUG
by O
approximately O
2 O
- O
fold O
. O
No O
dose O
adjustment O
of O
bosentan B-DRUG
is O
necessary O
, O
but O
increased O
effects O
of O
bosentan B-DRUG
should O
be O
considered O
. O
Simvastatin B-DRUG
and O
Other O
Statins B-GROUP
: O
Co O
- O
administration O
of O
bosentan B-DRUG
decreased O
the O
plasma O
concentrations O
of O
simvastatin B-DRUG
( O
a O
CYP3A4 O
substrate O
) O
, O
and O
its O
active O
- O
hydroxy O
acid O
metabolite O
, O
by O
approximately O
50 O
% O
. O
The O
plasma O
concentrations O
of O
bosentan B-DRUG
were O
not O
affected O
. O
Bosentan B-DRUG
is O
also O
expected O
to O
reduce O
plasma O
concentrations O
of O
other O
statins B-GROUP
that O
have O
significant O
metabolism O
by O
CYP3A4 O
, O
such O
as O
lovastatin B-DRUG
and O
atorvastatin B-DRUG
. O
The O
possibility O
of O
reduced O
statin B-GROUP
efficacy O
should O
be O
considered O
. O
Patients O
using O
CYP3A4 O
metabolized O
statins B-GROUP
should O
have O
cholesterol O
levels O
monitored O
after O
TRACLEER B-BRAND
is O
initiated O
to O
see O
whether O
the O
statin B-GROUP
dose O
needs O
adjustment O
. O
Warfarin B-DRUG
: O
Co O
- O
administration O
of O
bosentan B-DRUG
500 O
mg O
b O
. O
i O
. O
d O
. O
for O
6 O
days O
decreased O
the O
plasma O
concentrations O
of O
both O
S B-DRUG
- I-DRUG
warfarin I-DRUG
( O
a O
CYP2C9 O
substrate O
) O
and O
R B-DRUG
- I-DRUG
warfarin I-DRUG
( O
a O
CYP3A4 O
substrate O
) O
by O
29 O
and O
38 O
% O
, O
respectively O
. O
Clinical O
experience O
with O

concomitant O
administration O
of O
bosentan B-DRUG
and O
warfarin B-DRUG
in O
patients O
with O
pulmonary O
arterial O
hypertension O
did O
not O
show O
clinically O
relevant O
changes O
in O
INR O
or O
warfarin B-DRUG
dose O
( O
baseline O
vs O
. O
end O
of O
the O
clinical O
studies O
) O
, O
and O
the O
need O
to O
change O
the O
warfarin B-DRUG
dose O
during O
the O
trials O
due O
to O
changes O
in O
INR O
or O
due O
to O
adverse O
events O
was O
similar O
among O
bosentan B-DRUG
- O
and O
placebo O
- O
treated O
patients O
. O
Digoxin B-DRUG
, O
Nimodipine B-DRUG
and O
Losartan B-DRUG
: O
Bosentan B-DRUG
has O
no O
significant O
pharmacokinetic O
interactions O
with O
digoxin B-DRUG
and O
nimodipine B-DRUG
, O
and O
losartan B-DRUG
has O
no O
significant O
effect O
on O
plasma O
levels O
of O
bosentan B-DRUG
. O

Co O
- O
administration O
of O
BOTOX B-BRAND
and O
aminoglycosides B-GROUP
or O
other O
agents O
interfering O
with O
neuromuscular O
transmission O
( O
e O
. O
g O
. O
, O
curare B-GROUP
- I-GROUP
like I-GROUP
compounds I-GROUP
) O
should O
only O
be O
performed O
with O
caution O
as O
the O
effect O
of O
the O
toxin B-DRUG
may O
be O
potentiated O
. O
The O
effect O
of O
administering O
different O
botulinum B-GROUP
neurotoxin I-GROUP
serotypes O
at O
the O
same O
time O
or O
within O
several O
months O
of O
each O
other O
is O
unknown O
. O
Excessive O
neuromuscular O
weakness O
may O
be O
exacerbated O
by O
administration O
of O
another O
botulinum B-GROUP
toxin I-GROUP
prior O
to O
the O
resolution O
of O
the O
effects O
of O
a O
previously O
administered O
botulinum B-GROUP
toxin I-GROUP
. O

Co O
- O
administration O
of O
MYOBLOC B-BRAND
and O
aminoglycosides B-GROUP
or O
other O
agents O
interfering O
with O
neuromuscular O
transmission O
( O
e O
. O
g O
. O
, O
curare B-GROUP
- I-GROUP
like I-GROUP
compounds I-GROUP
) O
should O
only O
be O
performed O
with O
caution O
as O
the O
effect O
of O
the O
toxin B-DRUG
may O
be O
potentiated O
. O
The O
effect O
of O
administering O
different O
botulinum B-GROUP
neurotoxin I-GROUP
serotypes O
at O
the O
same O
time O
or O
within O
less O
than O
4 O
months O
of O
each O
other O
is O
unknown O
. O
However O
, O
neuromuscular O
paralysis O
may O
be O
potentiated O
by O
co O
- O
administration O
or O
overlapping O
administration O
of O
different O
botulinum B-GROUP
toxin I-GROUP
serotypes O
. O

Digitalis B-GROUP
toxicity O
may O
be O
aggravated O
by O
the O
initial O
release O
of O
norepinephrine O
caused O
by O
Bretylium B-DRUG
Tosylate I-DRUG
Injection O
. O
The O
pressor O
effects O
of O
catecholamines B-GROUP
such O
as O
dopamine B-DRUG
or O
norepinephrine B-DRUG
are O
enhanced O
by O
Bretylium B-DRUG
Tosylate I-DRUG
. O
When O
catecholamines B-GROUP
are O
administered O
, O
dilute O
solutions O
should O
be O
used O
and O
blood O
pressure O
should O
be O
monitored O
closely O
. O
Although O
there O
is O
little O
published O
information O
on O
concomitant O
administration O
of O
lidocaine B-DRUG
and O
Bretylium B-DRUG
Tosylate I-DRUG
, O
these O
drugs O
are O
often O
administered O
concurrently O
without O
any O
evidence O
of O
interactions O
resulting O
in O
adverse O
effects O
or O
diminished O
efficacy O
. O

Although O
specific O
drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
ALPHAGAN B-BRAND
P I-BRAND
, O
the O
possibility O
of O
an O
additive O
or O
potentiating O
effect O
with O
CNS B-GROUP
depressants I-GROUP
( O
alcohol B-DRUG
, O
barbiturates B-GROUP
, O
opiates B-GROUP
, O
sedatives B-GROUP
, O
or O
anesthetics B-GROUP
) O
should O
be O
considered O
. O
Alpha B-GROUP
- I-GROUP
agonists I-GROUP
, O
as O
a O
class O
, O
may O
reduce O
pulse O
and O
blood O
pressure O
. O
Caution O
in O
using O
concomitant O
drugs O
such O
as O
beta B-GROUP
- I-GROUP
blockers I-GROUP
( O
ophthalmic O
and O
systemic O
) O
, O
anti B-GROUP
- I-GROUP
hypertensives I-GROUP
and O
/ O
or O
cardiac B-GROUP
glycosides I-GROUP
is O
advised O
. O
Tricyclic B-GROUP
antidepressants I-GROUP
have O
been O
reported O
to O
blunt O
the O
hypotensive O
effect O
of O
systemic O
clonidine B-DRUG
. O
It O
is O
not O
known O
whether O
the O
concurrent O
use O
of O
these O
agents O
with O
ALPHAGAN B-BRAND
P I-BRAND
in O
humans O
can O
lead O
to O
resulting O
interference O
with O
the O
IOP O
lowering O
effect O
. O
No O
data O
on O
the O
level O
of O
circulating O
catecholamines O
after O
ALPHAGAN B-BRAND
P I-BRAND
administration O
are O
available O
. O
Caution O
, O
however O
, O
is O
advised O
in O
patients O
taking O
tricyclic B-GROUP
antidepressants I-GROUP
which O
can O
affect O
the O
metabolism O
and O
uptake O
of O
circulating O
amines O
. O

AZOPT B-BRAND
( O
brinzolamide B-DRUG
ophthalmic O
suspension O
) O
1 O
% O
contains O
a O
carbonic B-GROUP
anhydrase I-GROUP
inhibitor I-GROUP
. O
Acid O
- O
base O
and O
electrolyte O
alterations O
were O
not O
reported O
in O
the O
clinical O
trials O
with O
brinzolamide B-DRUG
. O
However O
, O
in O
patients O
treated O
with O
oral O
carbonic B-GROUP
anhydrase I-GROUP
inhibitors I-GROUP
, O
rare O
instances O
of O
drug O
interactions O
have O
occurred O
with O
high O
- O
dose O
salicylate B-DRUG
therapy O
. O
Therefore O
, O
the O
potential O
for O
such O
drug O
interaction O
should O
be O
considered O
in O
patients O
receiving O
AZOPT B-BRAND
( O
brinzolamide B-DRUG
ophthalmic O
suspension O
) O
1 O
% O
. O

The O
risk O
of O
using O
bromocriptine B-DRUG
mesylate I-DRUG
in O
combination O
with O
other O
drugs O
has O
not O
been O
systematically O
evaluated O
, O
but O
alcohol B-DRUG
may O
potentiate O
the O
side O
effects O
of O
bromocriptine B-DRUG
mesylate I-DRUG
. O
Bromocriptine B-DRUG
mesylate I-DRUG
may O
interact O
with O
dopamine B-GROUP
antagonists I-GROUP
, O
butyrophenones B-GROUP
, O
and O
certain O
other O
agents O
. O
Compounds O
in O
these O
categories O
result O
in O
a O
decreased O
efficacy O
of O
bromocriptine B-DRUG
mesylate I-DRUG
: O
phenothiazines B-GROUP
, O
haloperidol B-DRUG
, O
metoclopramide B-DRUG
, O
pimozide B-DRUG
. O
Concomitant O
use O
of O
bromocriptine B-DRUG
mesylate I-DRUG
with O
other O
ergot B-GROUP
alkaloids I-GROUP
is O
not O
recommended O
. O

Dexbrompheniramine B-DRUG
can O
interact O
with O
alcohol B-DRUG
or O
other O
CNS B-GROUP
depressants I-GROUP
( O
may O
potentiate O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
antihistamines B-GROUP
) O
, O
anticholinergics B-GROUP
or O
other O
medications O
with O
anticholinergic O
activity O
( O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
antihistamines B-GROUP
) O
, O
and O
monoamine B-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
( O
concurrent O
use O
with O
antihistamines B-GROUP
may O
prolong O
and O
intensify O
the O
anticholinergic O
and O
CNS O
depressant O
effects O
of O
antihistamines B-GROUP
) O
. O

This O
drug O
may O
interact O
with O
alcohol B-DRUG
or O
other O
CNS B-GROUP
depressants I-GROUP
( O
may O
potentiate O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
antihistamines B-GROUP
) O
, O
anticholinergics B-GROUP
or O
other O
medications O
with O
anticholinergic O
activity O
( O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
antihistamines B-GROUP
) O
, O
and O
monoamine B-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
( O
concurrent O
use O
with O
antihistamines B-GROUP
may O
prolong O
and O
intensify O
the O
anticholinergic O
and O
CNS O
depressant O
effects O
of O
antihistamines B-GROUP
) O
. O

Concomitant O
oral O
administration O
of O
ketoconazole B-DRUG
( O
a O
known O
inhibitor O
of O
CYP3A4 O
activity O
in O
the O
liver O
and O
in O
the O
intestinal O
mucosa O
) O
caused O
an O
eight O
- O
fold O
increase O
of O
the O
systemic O
exposure O
to O
oral O
budesonide B-DRUG
. O
If O
treatment O
with O
inhibitors O
of O
CYP3A4 O
activity O
( O
such O
as O
ketoconazole B-DRUG
, O
intraconazole B-DRUG
, O
ritonavir B-DRUG
, O
indinavir B-DRUG
, O
saquinavir B-DRUG
, O
erythromycin B-DRUG
, O
etc O
. O
) O
is O
indicated O
, O
reduction O
of O
the O
budesonide B-DRUG
dose O
should O
be O
considered O
. O
After O
extensive O
intake O
of O
grapefruit O
juice O
( O
which O
inhibits O
CYP3A4 O
activity O
predominantly O
in O
the O
intestinal O
mucosa O
) O
, O
the O
systemic O
exposure O
for O
oral O
budesonide B-DRUG
increased O
about O
two O
times O
. O
As O
with O
other O
drugs O
primarily O
being O
metabolized O
through O
CYP3A4 O
, O
ingestion O
of O
grapefruit O
or O
grapefruit O
juice O
should O
be O
avoided O
in O
connection O
with O
budesonide B-DRUG
administration O
. O

- O
Drugs O
with O
ototoxic O
potential O
: O
Especially O
in O
the O
presence O
of O
impaired O
renal O
function O
, O
the O
use O
of O
parenterally O
administered O
bumetanide B-DRUG
in O
patients O
to O
whom O
aminoglycoside B-GROUP
antibiotics I-GROUP
are O
also O
being O
given O
should O
be O
avoided O
, O
except O
in O
life O
- O
threatening O
conditions O
. O
- O
Drugs O
with O
nephrotoxic O
potential O
: O
There O
has O
been O
no O
experience O
on O
the O
concurrent O
use O
of O
bumetanide B-DRUG
with O
drugs O
known O
to O
have O
a O
nephrotoxic O
potential O
. O
Therefore O
, O
the O
simultaneous O
administration O
of O
these O
drugs O
should O
be O
avoided O
. O
- O
Lithium B-DRUG
: O
Lithium B-DRUG
should O
generally O
not O
be O
given O
with O
diuretics B-GROUP
( O
such O
as O
bumetanide B-DRUG
) O
because O
they O
reduce O
its O
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium B-DRUG
toxicity O
. O
- O
Probenecid B-DRUG
: O
Pretreatment O
with O
probenecid B-DRUG
reduces O
both O
the O
natriuresis O
and O
hyperreninemia O
produced O
by O
bumetanide B-DRUG
. O
This O
antagonistic O
effect O
of O
probenecid B-DRUG
on O
bumetanide B-DRUG
natriuresis O
is O
not O
due O
to O
a O
direct O
action O
on O
sodium O
excretion O
but O
is O
probably O
secondary O
to O
its O
inhibitory O
effect O
on O
renal O
tubular O
secretion O
of O
bumetanide B-DRUG
. O
Thus O
, O
probenecid B-DRUG
should O
not O
be O
administered O
concurrently O
with O
bumetanide B-DRUG
. O
- O
Indomethacin B-DRUG
: O
Indomethacin B-DRUG
blunts O
the O
increases O
in O
urine O
volume O
and O
sodium O
excretion O
seen O
during O
bumetanide B-DRUG
treatment O
and O
inhibits O
the O
bumetanide B-DRUG
- O
induced O
increase O
in O
plasma O
renin O
activity O
. O
Concurrent O
therapy O
with O
bumetanide B-DRUG
is O
thus O
not O
recommended O
. O
- O
Antihypertensives B-GROUP
: O
Bumetanide B-DRUG
may O
potentiate O
the O
effect O
of O
various O
antihypertensive B-GROUP
drugs I-GROUP
, O
necessitating O
a O
reduction O
in O
the O
dosage O
of O
these O
drugs O
. O
- O
Digoxin B-DRUG
: O
Interaction O
studies O
in O
humans O
have O
shown O
no O
effect O
on O
digoxin B-DRUG
blood O
levels O
. O
- O
Anticoagulants B-GROUP
: O
Interaction O
studies O
in O
humans O
have O
shown O
bumetanide B-DRUG
to O
have O
no O
effect O
on O
warfarin B-DRUG
metabolism O
or O
on O
plasma O
prothrombin O
activity O
. O

The O
administration O
of O
local O
anesthetic B-GROUP
solutions I-GROUP
containing O
epinephrine B-DRUG
or O
norepinephrine B-DRUG
to O
patients O
receiving O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
or O
tricyclic B-GROUP
antidepressants I-GROUP
may O
produce O
severe O
, O
prolonged O
hypertension O
. O
Concurrent O
use O
of O
these O
agents O
should O
generally O
be O
avoided O
. O
In O
situations O
in O
which O
concurrent O
therapy O
is O
necessary O
, O
careful O
patient O
monitoring O
is O
essential O
. O
Concurrent O
administration O
of O
vasopressor B-GROUP
drugs I-GROUP
and O
of O
ergot B-GROUP
- I-GROUP
type I-GROUP
oxytocic I-GROUP
drugs I-GROUP
may O
cause O
severe O
, O
persistent O
hypertension O
or O
cerebrovascular O
accidents O
. O
Phenothiazines B-GROUP
and O
butyrophenones B-GROUP
may O
reduce O
or O
reverse O
the O
pressor O
effect O
of O
epinephrine B-DRUG
. O

Buprenorphine B-DRUG
is O
metabolized O
to O
norbuprenorphine B-DRUG_N
by O
cytochrome O
CYP O
3A4 O
. O
Because O
CYP O
3A4 O
inhibitors O
may O
increase O
plasma O
concentrations O
of O
buprenorphine B-DRUG
, O
patients O
already O
on O
CYP O
3A4 O
inhibitors O
such O
as O
azole B-GROUP
antifungals I-GROUP
( O
e O
. O
g O
. O
ketoconazole B-DRUG
) O
, O
macrolide B-GROUP
antibiotics I-GROUP
( O
e O
. O
g O
. O
erythromycin B-DRUG
) O
, O
and O
HIV B-GROUP
protease I-GROUP
inhibitors I-GROUP
( O
e O
. O
g O
. O
ritonavir B-DRUG
, O
indinavir B-DRUG
and O
saquinavir B-DRUG
) O
should O
have O
their O
dose O
of O
SUBUTEX B-BRAND
or O
SUBOXONE B-BRAND
adjusted O
. O
Based O
on O
anecdotal O
reports O
, O
there O
may O
be O
an O
interaction O
between O
buprenorphine B-DRUG
and O
benzodiazepines B-GROUP
. O
There O
have O
been O
a O
number O
of O
reports O
in O
the O
post O
- O
marketing O
experience O
of O
coma O
and O
death O
associated O
with O
the O
concomitant O
intravenous O
misuse O
of O
buprenorphine B-DRUG
and O
benzodiazepines B-DRUG
by O
addicts O
. O
In O
many O
of O
these O
cases O
, O
buprenorphine B-DRUG
was O
misused O
by O
self O
- O
injection O
of O
crushed O
SUBUTEX B-BRAND
tablets O
. O
SUBUTEX B-BRAND
and O
SUBOXONE B-BRAND
should O
be O
prescribed O
with O
caution O
to O
patients O
on O
benzodiazepines B-GROUP
or O
other O
drugs O
that O
act O
on O
the O
central O
nervous O
system O
, O
regardless O
of O
whether O
these O
drugs O
are O
taken O
on O
the O
advice O
of O
a O
physician O
or O
are O
taken O
as O
drugs O
of O
abuse O
. O
Patients O
should O
be O
warned O
of O
the O
potential O
danger O
of O
the O
intravenous O
self O
- O
administration O
of O
benzodiazepines B-GROUP
while O
under O
treatment O
with O
SUBOXONE B-BRAND
or O
SUBUTEX B-BRAND
. O

Few O
systemic O
data O
have O
been O
collected O
on O
the O
metabolism O
of O
WELLBUTRIN B-BRAND
following O
concomitant O
administration O
with O
other O
drugs O
or O
, O
alternatively O
, O
the O
effect O
of O
concomitant O
administration O
of O
WELLBUTRIN B-BRAND
on O
the O
metabolism O
of O
other O
drugs O
. O
Because O
bupropion B-DRUG
is O
extensively O
metabolized O
, O
the O
coadministration O
of O
other O
drugs O
may O
affect O
its O
clinical O
activity O
. O
In O
vitro O
studies O
indicate O
that O
bupropion B-DRUG
is O
primarily O
metabolized O
to O
hydroxybupropion B-DRUG_N
by O
the O
CYP2B6 O
isoenzyme O
. O
Therefore O
, O
the O
potential O
exists O
for O
a O
drug O
interaction O
between O
WELLBUTRIN B-BRAND
and O
drugs O
that O
affect O
the O
CYP2B6 O
isoenzyme O
( O
e O
. O
g O
. O
, O
orphenadrine B-DRUG
and O
cyclophosphamide B-DRUG
) O
. O
The O
threohydrobupropion B-DRUG_N
metabolite O
of O
bupropion B-DRUG
does O
not O
appear O
to O
be O
produced O
by O
the O
cytochrome O
P450 O
isoenzymes O
. O
The O
effects O
of O
concomitant O
administration O
of O
cimetidine B-DRUG
on O
the O
pharmacokinetics O
of O
bupropion B-DRUG
and O
its O
active O
metabolites O
were O
studied O
in O
24 O
healthy O
young O
male O
volunteers O
. O
Following O
oral O
administration O
of O
two O
150 O
- O
mg O
sustained O
- O
release O
tablets O
with O
and O
without O
800 O
mg O
of O
cimetidine B-DRUG
, O
the O
pharmacokinetics O
of O
bupropion B-DRUG
and O
hydroxybupropion B-DRUG_N
were O
unaffected O
. O
However O
, O
there O
were O
16 O
% O
and O
32 O
% O
increases O
in O
the O
AUC O
and O
Cmax O
, O
respectively O
, O
of O
the O
combined O
moieties O
of O
threohydrobupropion B-DRUG_N
and O
erythrohydrobupropion B-DRUG_N
. O
While O
not O
systematically O
studied O
, O
certain O
drugs O
may O
induce O
the O
metabolism O
of O
bupropion B-DRUG
( O
e O
. O
g O
. O
, O
carbamazepine B-DRUG
, O
phenobarbital B-DRUG
, O
phenytoin B-DRUG
) O
. O
Animal O
data O
indicated O
that O
bupropion B-DRUG
may O
be O
an O
inducer O
of O
drug O
- O
metabolizing O
enzymes O
in O
humans O
. O
In O
one O
study O
, O
following O
chronic O
administration O
of O
bupropion B-DRUG
, O
100 O
mg O
3 O
times O
daily O
to O
8 O
healthy O
male O
volunteers O
for O
14 O
days O
, O
there O
was O
no O
evidence O
of O
induction O
of O
its O
own O
metabolism O
. O
Nevertheless O
, O
there O
may O
be O
the O
potential O
for O
clinically O
important O
alterations O
of O
blood O
levels O
of O
coadministered O
drugs O
. O
Drugs O
Metabolized O
by O
Cytochrome O
P450IID6 O
( O
CYP2D6 O
) O
: O
Many O
drugs O
, O
including O
most O
antidepressants B-GROUP
( O
SSRIs O
, O
many O
tricyclics B-GROUP

) O
, O
beta B-GROUP
- I-GROUP
blockers I-GROUP
, O
antiarrhythmics B-DRUG
, O
and O
antipsychotics B-GROUP
are O
metabolized O
by O
the O
CYP2D6 O
isoenzyme O
. O
Although O
bupropion B-DRUG
is O
not O
metabolized O
by O
this O
isoenzyme O
, O
bupropion B-DRUG
and O
hydroxybupropion B-DRUG_N
are O
inhibitors O
of O
the O
CYP2D6 O
isoenzyme O
in O
vitro O
. O
In O
a O
study O
of O
15 O
male O
subjects O
( O
ages O
19 O
to O
35 O
years O
) O
who O
were O
extensive O
metabolizers O
of O
the O
CYP2D6 O
isoenzyme O
, O
daily O
doses O
of O
bupropion B-DRUG
given O
as O
150 O
mg O
twice O
daily O
followed O
by O
a O
single O
dose O
of O
50 O
mg O
desipramine B-DRUG
increased O
the O
Cmax O
, O
AUC O
, O
and O
t1 O
/ O
2 O
of O
desipramine B-DRUG
by O
an O
average O
of O
approximately O
2 O
- O
, O
5 O
- O
and O
2 O
- O
fold O
, O
respectively O
. O
The O
effect O
was O
present O
for O
at O
least O
7 O
days O
after O
the O
last O
dose O
of O
bupropion B-DRUG
. O
Concomitant O
use O
of O
bupropion B-DRUG
with O
other O
drugs O
metabolized O
by O
CYP2D6 O
has O
not O
been O
formally O
studied O
. O
Therefore O
, O
co O
- O
administration O
of O
bupropion B-DRUG
with O
drugs O
that O
are O
metabolized O
by O
CYP2D6 O
isoenzyme O
including O
certain O
antidepressants B-GROUP
( O
e O
. O
g O
. O
, O
nortriptyline B-DRUG
, O
imipramine B-DRUG
, O
desipramine B-DRUG
, O
paroxetine B-DRUG
, O
fluoxetine B-DRUG
, O
sertraline B-DRUG
) O
, O
antipsychotics B-GROUP
( O
e O
. O
g O
. O
, O
haloperidol B-DRUG
, O
risperidone B-DRUG
, O
thioridazine B-DRUG
) O
, O
beta B-GROUP
- I-GROUP
blockers I-GROUP
( O
e O
. O
g O
. O
, O
metoprolol B-DRUG
) O
, O
and O
Type B-GROUP
1C I-GROUP
antiarrhythmics I-GROUP
( O
e O
. O
g O
. O
, O
propafenone B-DRUG
, O
flecainide B-DRUG
) O
, O
should O
be O
approached O
with O
caution O
and O
should O
be O
initiated O
at O
the O
lower O
end O
of O
the O
dose O
range O
of O
the O
concomitant O
medication O
. O
If O
bupropion B-DRUG
is O
added O
to O
the O
treatment O
regimen O
of O
a O
patient O
already O
receiving O
a O
drug O
metabolized O
by O
CYP2D6 O
, O
the O
need O
to O
decrease O
the O
dose O
of O
the O
original O
medication O
should O
be O
considered O
, O
particularly O
for O
those O
concomitant O
medications O
with O
a O
narrow O
therapeutic O
index O
. O
MAO B-GROUP
Inhibitors I-GROUP
: O
Studies O
in O
animals O
demonstrate O
that O
the O
acute O
toxicity O
of O
bupropion B-DRUG
is O
enhanced O
by O
the O
MAO B-GROUP
inhibitor I-GROUP
phenelzine B-DRUG
. O
Levodopa B-DRUG
and O
Amantadine B-DRUG
: O
Limited O
clinical O
data O
suggest O
a O
higher O
incidence O
of O
adverse O
experiences O
in O
patients O
receiving O
bupropion B-DRUG
concurrently O
with O
either O

levodopa B-DRUG
or O
amantadine B-DRUG
. O
Administration O
of O
WELLBUTRIN B-BRAND
Tablets O
to O
patients O
receiving O
either O
levodopa B-DRUG
or O
amantadine B-DRUG
concurrently O
should O
be O
undertaken O
with O
caution O
, O
using O
small O
initial O
doses O
and O
small O
gradual O
dose O
increases O
. O
Drugs O
that O
Lower O
Seizure O
Threshold O
: O
Concurrent O
administration O
of O
WELLBUTRIN B-BRAND
and O
agents O
( O
e O
. O
g O
. O
, O
antipsychotics B-GROUP
, O
other O
antidepressants B-GROUP
, O
theophylline B-DRUG
, O
systemic O
steroids B-GROUP
, O
etc O
. O
) O
that O
lower O
seizure O
threshold O
should O
be O
undertaken O
only O
with O
extreme O
caution O
. O
Low O
initial O
dosing O
and O
small O
gradual O
dose O
increases O
should O
be O
employed O
. O
Nicotine B-DRUG
Transdermal O
System O
: O
. O
Alcohol B-DRUG
: O
In O
post O
- O
marketing O
experience O
, O
there O
have O
been O
rare O
reports O
of O
adverse O
neuropsychiatric O
events O
or O
reduced O
alcohol B-DRUG
tolerance O
in O
patients O
who O
were O
drinking O
alcohol B-DRUG
during O
treatment O
with O
WELLBUTRIN B-BRAND
. O
The O
consumption O
of O
alcohol B-DRUG
during O
treatment O
with O
WELLBUTRIN B-BRAND
should O
be O
minimized O
or O
avoided O
( O
also O
see O
a O
href O
= O
bupropz O
_ O
od O
. O
htm O
# O
CI O
CONTRAINDICATIONS O
) O
. O

It O
is O
recommended O
that O
buspirone B-DRUG
hydrochloride I-DRUG
not O
be O
used O
concomitantly O
with O
MAO B-GROUP
inhibitors I-GROUP
Because O
the O
effects O
of O
concomitant O
administration O
of O
buspirone B-DRUG
HCl I-DRUG
with O
most O
other O
psychotropic B-GROUP
drugs I-GROUP
have O
not O
been O
studied O
, O
the O
concomitant O
use O
of O
buspirone B-DRUG
HCl I-DRUG
with O
other O
CNS O
- O
active O
drugs O
should O
be O
approached O
with O
caution O
. O
There O
is O
one O
report O
suggesting O
that O
the O
concomitant O
use O
of O
trazodone B-DRUG
hydrochloride I-DRUG
( O
Desyrel B-BRAND
) O
and O
buspirone B-DRUG
HCl I-DRUG
may O
have O
caused O
3 O
- O
to O
6 O
- O
fold O
elevations O
on O
SGPT O
( O
ALT O
) O
in O
a O
few O
patients O
. O
In O
a O
similar O
study O
, O
attempting O
to O
replicate O
this O
finding O
, O
no O
interactive O
effect O
on O
hepatic O
transaminases O
was O
identified O
. O
In O
a O
study O
in O
normal O
volunteers O
, O
concomitant O
administration O
of O
buspirone B-DRUG
HCl I-DRUG
and O
haloperidol B-DRUG
resulted O
in O
increased O
serum O
haloperidol B-DRUG
concentrations O
. O
The O
clinical O
significance O
of O
this O
finding O
is O
not O
clear O
. O
In O
vitro O
, O
buspirone B-DRUG
does O
not O
displace O
tightly O
bound O
drugs O
like O
phenytoin B-DRUG
, O
propranolol B-DRUG
, O
and O
warfarin B-DRUG
from O
serum O
proteins O
. O
However O
, O
there O
has O
been O
one O
report O
of O
prolonged O
prothrombin O
time O
when O
buspirone B-DRUG
was O
added O
to O
the O
regimen O
of O
a O
patient O
treated O
with O
warfarin B-DRUG
. O
The O
patient O
was O
also O
chronically O
receiving O
phenytoin B-DRUG
, O
phenobarbital B-DRUG
, O
digoxin B-DRUG
, O
and O
levothyroxine B-DRUG
sodium I-DRUG
. O
In O
vitro O
, O
buspirone B-DRUG
may O
displace O
less O
firmly O
bound O
drugs O
like O
digoxin B-DRUG
. O
The O
clinical O
significance O
of O
this O
property O
is O
unknown O
. O

Itraconazole B-DRUG
decreases O
busulfan B-DRUG
clearance O
by O
up O
to O
25 O
% O
, O
and O
may O
produce O
AUCs O
1500 O
M O
min O
in O
some O
patients O
. O
Fluconazole B-DRUG
, O
and O
the O
5 B-GROUP
- I-GROUP
HT3 I-GROUP
antiemetics I-GROUP
ondansetron B-DRUG
( O
Zofran B-BRAND
) O
and O
granisetron B-DRUG
( O
Kytril B-BRAND
) O
have O
all O
been O
used O
with O
BUSULFEX B-BRAND
. O
Phenytoin B-DRUG
increases O
the O
clearance O
of O
busulfan B-DRUG
by O
15 O
% O
or O
more O
, O
possibly O
due O
to O
the O
induction O
of O
glutathione O
- O
S O
- O
transferase O
. O
Since O
the O
pharmacokinetics O
of O
BUSULFEX B-BRAND
were O
studied O
in O
patients O
treated O
with O
phenytoin B-DRUG
, O
the O
clearance O
of O
BUSULFEX B-BRAND
at O
the O
recommended O
dose O
may O
be O
lower O
and O
exposure O
( O
AUC O
) O
higher O
in O
patients O
not O
treated O
with O
phenytoin B-DRUG
. O
Because O
busulfan B-DRUG
is O
eliminated O
from O
the O
body O
via O
conjugation O
with O
glutathione O
, O
use O
of O
acetaminophen B-DRUG
prior O
to O
( O
72 O
hours O
) O
or O
concurrent O
with O
BUSULFEX B-BRAND
may O
result O
in O
reduced O
busulfan B-DRUG
clearance O
based O
upon O
the O
known O
property O
of O
acetaminophen B-DRUG
to O
decrease O
glutathione O
levels O
in O
the O
blood O
and O
tissues O
. O

Interactions O
may O
occur O
with O
the O
following O
: O
adrenocorticoids O
( O
cortisone O
- O
like O
medicine O
) O
, O
anticoagulants B-GROUP
( O
blood B-GROUP
thinners I-GROUP
) O
, O
carbamazepine B-DRUG
, O
corticotropin B-DRUG
( O
barbiturates B-GROUP
may O
decrease O
the O
effects O
of O
these O
medicines O
) O
, O
central B-GROUP
nervous I-GROUP
system I-GROUP
( I-GROUP
CNS I-GROUP
) I-GROUP
depressants I-GROUP
( O
using O
these O
medicines O
with O
barbiturates B-GROUP
may O
result O
in O
increased O
CNS O
depressant O
effects O
) O
, O
divalproex B-DRUG
sodium I-DRUG
, O
valproic B-DRUG
acid I-DRUG
( O
using O
these O
medicines O
with O
barbiturates B-GROUP
may O
change O
the O
amount O
of O
either O
medicine O
that O
you O
need O
to O
take O
) O
, O
and O
oral O
contraceptives B-GROUP
containing O
estrogens B-GROUP
( O
barbiturates B-GROUP
may O
decrease O
the O
effectiveness O
of O
these O
oral O
contraceptives B-GROUP
, O
and O
you O
may O
need O
to O
change O
to O
a O
different O
type O
of O
birth O
control O
) O
. O

The O
CNS O
effects O
of O
butalbital B-DRUG
may O
be O
enhanced O
by O
monoamine B-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
. O
Butalbital B-DRUG
, O
acetaminophen B-DRUG
and O
caffeine B-DRUG
may O
enhance O
the O
effects O
of O
: O
other O
narcotic B-GROUP
analgesics I-GROUP
, O
alcohol B-DRUG
, O
general O
anesthetics B-GROUP
, O
tranquilizers B-GROUP
such O
as O
chlordiazepoxide B-DRUG
, O
sedative B-GROUP
- I-GROUP
hypnotics I-GROUP
, O
or O
other O
CNS B-GROUP
depressants I-GROUP
, O
causing O
increased O
CNS O
depression O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Acetaminophen B-DRUG
may O
produce O
false O
- O
positive O
test O
results O
for O
urinary O
5 O
- O
hydroxyindoleacetic O
acid O
. O

Potential O
drug O
interactions O
between O
Mentax B-BRAND
( O
butenafine B-DRUG
HCl I-DRUG
cream O
) O
Cream O
, O
1 O
% O
, O
and O
other O
drugs O
have O
not O
been O
systematically O
evaluated O
. O

Concurrent O
use O
of O
butorphanol B-DRUG
with O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressants I-GROUP
( O
e O
. O
g O
. O
, O
alcohol B-DRUG
, O
barbiturates B-GROUP
, O
tranquilizers B-GROUP
, O
and O
antihistamines B-GROUP
) O
may O
result O
in O
increased O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressant I-GROUP
effects O
. O
When O
used O
concurrently O
with O
such O
drugs O
, O
the O
dose O
of O
butorphanol B-DRUG
should O
be O
the O
smallest O
effective O
dose O
and O
the O
frequency O
of O
dosing O
reduced O
as O
much O
as O
possible O
when O
administered O
concomitantly O
with O
drugs O
that O
potentiate O
the O
action O
of O
opioids B-GROUP
. O
In O
healthy O
volunteers O
, O
the O
pharmacokinetics O
of O
a O
1 O
- O
mg O
dose O
of O
butorphanol B-DRUG
administered O
as O
STADOL B-BRAND
NS I-BRAND
were O
not O
affected O
by O
the O
coadministration O
of O
a O
single O
6 O
- O
mg O
subcutaneous O
dose O
of O
sumatriptan B-DRUG
. O
However O
, O
in O
another O
study O
in O
healthy O
volunteers O
, O
the O
pharmacokinetics O
of O
butorphanol B-DRUG
were O
significantly O
altered O
( O
29 O
% O
decrease O
in O
AUC O
and O
38 O
% O
decrease O
in O
Cmax O
) O
when O
a O
1 O
- O
mg O
dose O
of O
STADOL B-BRAND
NS I-BRAND
was O
administered O
1 O
minute O
after O
a O
20 O
- O
mg O
dose O
of O
sumatriptan B-DRUG
nasal O
spray O
. O
( O
The O
two O
drugs O
were O
administered O
in O
opposite O
nostrils O
. O
) O
When O
the O
STADOL B-BRAND
NS I-BRAND
was O
administered O
30 O
minutes O
after O
the O
sumatriptan B-DRUG
nasal O
spray O
, O
the O
AUC O
of O
butorphanol B-DRUG
increased O
11 O
% O
and O
Cmax O
decreased O
18 O
% O
. O
In O
neither O
case O
were O
the O
pharmacokinetics O
of O
sumatriptan B-DRUG
affected O
by O
coadministration O
with O
STADOL B-BRAND
NS I-BRAND
. O
These O
results O
suggest O
that O
the O
analgesic O
effect O
of O
STADOL B-BRAND
NS I-BRAND
may O
be O
diminished O
when O
it O
is O
administered O
shortly O
after O
sumatriptan B-DRUG
nasal O
spray O
, O
but O
by O
30 O
minutes O
any O
such O
reduction O
in O
effect O
should O
be O
minimal O
. O
The O
safety O
of O
using O
STADOL B-BRAND
NS I-BRAND
and O
IMITREX B-BRAND
( O
sumatriptan B-DRUG
) O
Nasal O
Spray O
during O
the O
same O
episode O
of O
migraine O
has O
not O
been O
established O
. O
However O
, O
it O
should O
be O
noted O
that O
both O
products O
are O
capable O
of O
producing O
transient O
increases O
in O
blood O
pressure O
. O
The O
pharmacokinetics O
of O
a O
1 O
- O
mg O
dose O
of O
butorphanol B-DRUG
administered O
as O
STADOL B-BRAND
NS I-BRAND
were O
not O
affected O
by O
the O
coadministration O
of O
cimetidine B-DRUG
( O
300 O
mg O
QID O
) O
. O
Conversely O
, O
the O
administration O
of O
STADOL B-BRAND
NS I-BRAND
( O
1 O
mg O
butorphanol B-DRUG
QID O
) O
did O
not O
alter O
the O
pharmacokinetics O
of O
a O
300 O
- O
mg O
dose O
of O
cimetidine B-DRUG
. O
It O
is O
not O
known O
if O
the O
effects O
of O

butorphanol B-DRUG
are O
altered O
by O
concomitant O
medications O
that O
affect O
hepatic O
metabolism O
of O
drugs O
( O
erythromycin B-DRUG
, O
etc O
. O
) O
, O
but O
physicians O
should O
be O
alert O
to O
the O
possibility O
that O
a O
smaller O
initial O
dose O
and O
longer O
intervals O
between O
doses O
may O
be O
needed O
. O
The O
fraction O
of O
STADOL B-BRAND
NS I-BRAND
absorbed O
is O
unaffected O
by O
the O
concomitant O
administration O
of O
a O
nasal B-GROUP
vasoconstrictor I-GROUP
( O
oxymetazoline B-DRUG
) O
, O
but O
the O
rate O
of O
absorption O
is O
decreased O
. O
Therefore O
, O
a O
slower O
onset O
can O
be O
anticipated O
if O
STADOL B-BRAND
NS I-BRAND
is O
administered O
concomitantly O
with O
, O
or O
immediately O
following O
, O
a O
nasal B-GROUP
vasoconstrictor I-GROUP
. O
No O
information O
is O
available O
about O
the O
use O
of O
butorphanol B-DRUG
concurrently O
with O
MAO B-GROUP
inhibitors I-GROUP
. O

DOSTINEX B-BRAND
should O
not O
be O
administered O
concurrently O
with O
D2 O
- O
antagonists O
, O
such O
as O
phenothiazines B-GROUP
, O
butyrophenones B-GROUP
, O
thioxanthines B-GROUP
, O
or O
metoclopramide B-DRUG
. O

Cytochrome O
P450 O
1A2 O
( O
CYP1A2 O
) O
is O
known O
to O
be O
the O
major O
enzyme O
involved O
in O
the O
metabolism O
of O
caffeine B-DRUG
. O
Therefore O
, O
caffeine B-DRUG
has O
the O
potential O
to O
interact O
with O
drugs O
that O
are O
substrates O
for O
CYP1A2 O
, O
inhibit O
CYP1A2 O
, O
or O
induce O
CYP1A2 O
. O
Few O
data O
exist O
on O
drug O
interactions O
with O
caffeine B-DRUG
in O
preterm O
neonates O
. O
Based O
on O
adult O
data O
, O
lower O
doses O
of O
caffeine B-DRUG
may O
be O
needed O
following O
coadministration O
of O
drugs O
which O
are O
reported O
to O
decrease O
caffeine B-DRUG
elimination O
( O
e O
. O
g O
. O
, O
cimetidine B-DRUG
and O
ketoconazole B-DRUG
) O
and O
higher O
caffeine B-DRUG
doses O
may O
be O
needed O
following O
coadministration O
of O
drugs O
that O
increase O
caffeine B-DRUG
elimination O
( O
e O
. O
g O
. O
, O
phenobarbital B-DRUG
and O
phenytoin B-DRUG
) O
. O
Caffeine B-DRUG
administered O
concurrently O
with O
ketoprofen B-DRUG
reduced O
the O
urine O
volume O
in O
4 O
healthy O
volunteers O
. O
The O
clinical O
significance O
of O
this O
interaction O
in O
preterm O
neonates O
is O
not O
known O
. O
Interconversion O
between O
caffeine B-DRUG
and O
theophylline B-DRUG
has O
been O
reported O
in O
preterm O
neonates O
. O
The O
concurrent O
use O
of O
these O
drugs O
is O
not O
recommended O
. O

Interactions O
for O
vitamin B-GROUP
D I-GROUP
analogues I-GROUP
( O
Vitamin B-DRUG
D2 I-DRUG
, O
Vitamin B-DRUG
D3 I-DRUG
, O
Calcitriol B-DRUG
, O
and O
Calcidiol B-DRUG
) O
: O
Cholestyramine B-DRUG
: O
Cholestyramine B-DRUG
has O
been O
reported O
to O
reduce O
intestinal O
absorption O
of O
fat B-GROUP
soluble I-GROUP
vitamins I-GROUP
; O
as O
such O
it O
may O
impair O
intestinal O
absorption O
of O
any O
of O
vitamin B-GROUP
D I-GROUP
. O
Phenytoin B-DRUG
/ O
Phenobarbital B-DRUG
: O
The O
coadministration O
of O
phenytoin B-DRUG
or O
phenobarbital B-DRUG
will O
not O
affect O
plasma O
concentrations O
of O
vitamin B-GROUP
D I-GROUP
, O
but O
may O
reduce O
endogenous O
plasma O
levels O
of O
calcitriol B-DRUG
/ O
ergocalcitriol O
by O
accelerating O
metabolism O
. O
Since O
blood O
level O
of O
calcitriol B-DRUG
/ O
ergocalcitriol O
will O
be O
reduced O
, O
higher O
doses O
of O
Rocaltrol B-BRAND
may O
be O
necessary O
if O
these O
drugs O
are O
administered O
simultaneously O
. O
Thiazides B-GROUP
: O
Thiazides B-GROUP
are O
known O
to O
induce O
hypercalcemia O
by O
the O
reduction O
of O
calcium O
excretion O
in O
urine O
. O
Some O
reports O
have O
shown O
that O
the O
concomitant O
administration O
of O
thiazides B-GROUP
with O
vitamin B-GROUP
D I-GROUP
causes O
hypercalcemia O
. O
Therefore O
, O
precaution O
should O
be O
taken O
when O
coadministration O
is O
necessary O
. O
Digitalis B-GROUP
: O
Vitamin B-GROUP
D I-GROUP
dosage O
must O
be O
determined O
with O
care O
in O
patients O
undergoing O
treatment O
with O
digitalis B-GROUP
, O
as O
hypercalcemia O
in O
such O
patients O
may O
precipitate O
cardiac O
arrhythmias O
. O
Ketoconazole B-DRUG
: O
Ketoconazole B-DRUG
may O
inhibit O
both O
synthetic O
and O
catabolic O
enzymes O
of O
vitamin B-GROUP
D I-GROUP
. O
Reductions O
in O
serum O
endogenous O
vitamin O
D O
concentrations O
have O
been O
observed O
following O
the O
administration O
of O
300 O
mg O
/ O
day O
to O
1200 O
mg O
/ O
day O
ketoconazole B-DRUG
for O
a O
week O
to O
healthy O
men O
. O
However O
, O
in O
vivo O
drug O
interaction O
studies O
of O
ketoconazole B-DRUG
with O
vitamin B-GROUP
D I-GROUP
have O
not O
been O
investigated O
. O
Corticosteroids B-GROUP
: O
A O
relationship O
of O
functional O
antagonism O
exists O
between O
vitamin B-GROUP
D I-GROUP
analogues I-GROUP
, O
which O
promote O
calcium O
absorption O
, O
and O
corticosteroids B-GROUP
, O
which O
inhibit O
calcium O
absorption O
. O
Phosphate O
- O
Binding O
Agents O
: O
Since O
vitamin B-GROUP
D I-GROUP
also O
has O
an O
effect O
on O
phosphate O
transport O
in O
the O
intestine O
, O
kidneys O
and O
bones O
, O
the O
dosage O
of O
phosphate O
- O
binding O
agents O
must O
be O
adjusted O
in O
accordance O
with O
the O
serum O
phosphate O
concentration O
. O
Vitamin B-GROUP
D I-GROUP
: O
The O
coadministration O
of O
any O
of O
the O
vitamin B-GROUP
D I-GROUP
analogues I-GROUP
should O
be O
avoided O
as O
this O
could O
create O
possible O
additive O
effects O
and O
hypercalcemia O
. O
Calcium B-DRUG
Supplements O
: O

Uncontrolled O
intake O
of O
additional O
calcium B-DRUG
- O
containing O
preparations O
should O
be O
avoided O
. O
Magnesium B-DRUG
: O
Magnesium B-DRUG
- O
containing O
preparations O
( O
eg O
, O
antacids B-GROUP
) O
may O
cause O
hypermagnesemia O
and O
should O
therefore O
not O
be O
taken O
during O
therapy O
with O
vitamin B-GROUP
D I-GROUP
by O
patients O
on O
chronic O
renal O
dialysis O
. O

Interactions O
for O
vitamin B-GROUP
D I-GROUP
analogues I-GROUP
( O
Vitamin B-DRUG
D2 I-DRUG
, O
Vitamin B-DRUG
D3 I-DRUG
, O
Calcitriol B-DRUG
, O
and O
Calcidiol B-DRUG
) O
: O
Cholestyramine B-DRUG
: O
Cholestyramine B-DRUG
has O
been O
reported O
to O
reduce O
intestinal O
absorption O
of O
fat B-GROUP
soluble I-GROUP
vitamins I-GROUP
; O
as O
such O
it O
may O
impair O
intestinal O
absorption O
of O
any O
of O
vitamin B-GROUP
D I-GROUP
. O
Phenytoin B-DRUG
/ O
Phenobarbital B-DRUG
: O
The O
coadministration O
of O
phenytoin B-DRUG
or O
phenobarbital B-DRUG
will O
not O
affect O
plasma O
concentrations O
of O
vitamin B-GROUP
D I-GROUP
, O
but O
may O
reduce O
endogenous O
plasma O
levels O
of O
calcitriol B-DRUG
/ O
ergocalcitriol O
by O
accelerating O
metabolism O
. O
Since O
blood O
level O
of O
calcitriol B-DRUG
/ O
ergocalcitriol O
will O
be O
reduced O
, O
higher O
doses O
of O
Rocaltrol B-BRAND
may O
be O
necessary O
if O
these O
drugs O
are O
administered O
simultaneously O
. O
Thiazides B-GROUP
: O
Thiazides B-GROUP
are O
known O
to O
induce O
hypercalcemia O
by O
the O
reduction O
of O
calcium B-DRUG
excretion O
in O
urine O
. O
Some O
reports O
have O
shown O
that O
the O
concomitant O
administration O
of O
thiazides B-GROUP
with O
vitamin B-GROUP
D I-GROUP
causes O
hypercalcemia O
. O
Therefore O
, O
precaution O
should O
be O
taken O
when O
coadministration O
is O
necessary O
. O
Digitalis B-GROUP
: O
Vitamin B-GROUP
D I-GROUP
dosage O
must O
be O
determined O
with O
care O
in O
patients O
undergoing O
treatment O
with O
digitalis B-GROUP
, O
as O
hypercalcemia O
in O
such O
patients O
may O
precipitate O
cardiac O
arrhythmias O
. O
Ketoconazole B-DRUG
: O
Ketoconazole B-DRUG
may O
inhibit O
both O
synthetic O
and O
catabolic O
enzymes O
of O
vitamin B-GROUP
D I-GROUP
. O
Reductions O
in O
serum O
endogenous O
vitamin O
D O
concentrations O
have O
been O
observed O
following O
the O
administration O
of O
300 O
mg O
/ O
day O
to O
1200 O
mg O
/ O
day O
ketoconazole B-DRUG
for O
a O
week O
to O
healthy O
men O
. O
However O
, O
in O
vivo O
drug O
interaction O
studies O
of O
ketoconazole B-DRUG
with O
vitamin B-GROUP
D I-GROUP
have O
not O
been O
investigated O
. O
Corticosteroids B-GROUP
: O
A O
relationship O
of O
functional O
antagonism O
exists O
between O
vitamin B-GROUP
D I-GROUP
analogues I-GROUP
, O
which O
promote O
calcium O
absorption O
, O
and O
corticosteroids B-GROUP
, O
which O
inhibit O
calcium O
absorption O
. O
Phosphate O
- O
Binding O
Agents O
: O
Since O
vitamin B-GROUP
D I-GROUP
also O
has O
an O
effect O
on O
phosphate O
transport O
in O
the O
intestine O
, O
kidneys O
and O
bones O
, O
the O
dosage O
of O
phosphate O
- O
binding O
agents O
must O
be O
adjusted O
in O
accordance O
with O
the O
serum O
phosphate O
concentration O
. O
Vitamin B-GROUP
D I-GROUP
: O
The O
coadministration O
of O
any O
of O
the O
vitamin B-GROUP
D I-GROUP
analogues I-GROUP
should O
be O
avoided O
as O
this O
could O
create O
possible O
additive O
effects O
and O
hypercalcemia O
. O
Calcium B-DRUG
Supplements O
: O

Uncontrolled O
intake O
of O
additional O
calcium B-DRUG
- O
containing O
preparations O
should O
be O
avoided O
. O
Magnesium B-DRUG
: O
Magnesium B-DRUG
- O
containing O
preparations O
( O
eg O
, O
antacids B-GROUP
) O
may O
cause O
hypermagnesemia O
and O
should O
therefore O
not O
be O
taken O
during O
therapy O
with O
vitamin B-GROUP
D I-GROUP
by O
patients O
on O
chronic O
renal O
dialysis O
. O

Concomitant O
use O
with O
other O
calcium B-DRUG
- O
containing O
medicines O
( O
including O
antacids B-GROUP
) O
may O
cause O
too O
much O
calcium B-DRUG
in O
the O
blood O
or O
urine O
, O
which O
may O
increase O
the O
chance O
of O
side O
effects O
. O
Using O
calcium B-DRUG
acetate I-DRUG
with O
digitalis B-GROUP
glycosides I-GROUP
( O
heart O
medicine O
) O
may O
cause O
hypercalcemia O
( O
too O
much O
calcium B-DRUG
in O
the O
blood O
) O
, O
which O
could O
increase O
the O
chance O
of O
developing O
an O
irregular O
heartbeat O
. O

May O
interact O
with O
cefamandole B-DRUG
naftate I-DRUG
, O
cephalothin B-DRUG
sodium I-DRUG
, O
magnesium B-DRUG
sulfate I-DRUG
, O
prednisolone B-DRUG
sodium I-DRUG
succinate I-DRUG
, O
and O
prochlorperazine B-DRUG
edisylate I-DRUG
. O

No O
significant O
drug O
interactions O
have O
been O
reported O
in O
studies O
of O
candesartan B-DRUG
cilexetil I-DRUG
given O
with O
other O
drugs O
such O
as O
glyburide B-DRUG
, O
nifedipine B-DRUG
, O
digoxin B-DRUG
, O
warfarin B-DRUG
, O
hydrochlorothiazide B-DRUG
, O
and O
oral O
contraceptives B-GROUP
in O
healthy O
volunteers O
, O
or O
given O
with O
enalapril B-DRUG
to O
patients O
with O
heart O
failure O
( O
NYHA O
class O
II O
and O
III O
) O
. O
Because O
candesartan B-DRUG
is O
not O
significantly O
metabolized O
by O
the O
cytochrome O
P450 O
system O
and O
at O
therapeutic O
concentrations O
has O
no O
effects O
on O
P450 O
enzymes O
, O
interactions O
with O
drugs O
that O
inhibit O
or O
are O
metabolized O
by O
those O
enzymes O
would O
not O
be O
expected O
. O
Lithium B-DRUG
Reversible O
increases O
in O
serum O
lithium B-DRUG
concentrations O
and O
toxicity O
have O
been O
reported O
during O
concomitant O
administration O
of O
lithium B-DRUG
with O
ACE B-GROUP
inhibitors I-GROUP
, O
and O
with O
some O
angiotensin B-GROUP
II I-GROUP
receptor I-GROUP
antagonists I-GROUP
. O
An O
increase O
in O
serum O
lithium B-DRUG
concentration O
has O
been O
reported O
during O
concomitant O
administration O
of O
lithium B-DRUG
with O
ATACAND B-BRAND
, O
so O
careful O
monitoring O
of O
serum O
lithium B-DRUG
levels O
is O
recommended O
during O
concomitant O
use O
. O

Antacid B-GROUP
: O
The O
effect O
of O
an O
aluminum B-DRUG
hydroxide I-DRUG
- O
and O
magnesium B-DRUG
hydroxide I-DRUG
- O
containing O
antacid B-GROUP
( O
Maalox B-BRAND
) O
* O
on O
the O
pharmacokinetics O
of O
capecitabine B-DRUG
was O
investigated O
in O
12 O
cancer O
patients O
. O
There O
was O
a O
small O
increase O
in O
plasma O
concentrations O
of O
capecitabine B-DRUG
and O
one O
metabolite O
( O
5 B-DRUG_N
- I-DRUG_N
DFCR I-DRUG_N
) O
; O
there O
was O
no O
effect O
on O
the O
3 O
major O
metabolites O
( O
5 B-DRUG_N
- I-DRUG_N
DFUR I-DRUG_N
, O
5 B-DRUG_N
- I-DRUG_N
FU I-DRUG_N
and O
FBAL B-DRUG_N
) O
. O
Coumarin B-GROUP
Anticoagulants I-GROUP
Altered O
coagulation O
parameters O
and O
/ O
or O
bleeding O
have O
been O
reported O
in O
patients O
taking O
capecitabine B-DRUG
concomitantly O
with O
coumarin B-GROUP
- I-GROUP
derivative I-GROUP
anticoagulants I-GROUP
such O
as O
warfarin B-DRUG
and O
phenprocoumon B-DRUG
. O
Patients O
taking O
coumarin B-GROUP
- I-GROUP
derivative I-GROUP
anticoagulants I-GROUP
concomitantly O
with O
capecitabine B-DRUG
should O
be O
monitored O
regularly O
for O
alterations O
in O
their O
coagulation O
parameters O
( O
PT O
or O
INR O
) O
. O
Leucovorin B-DRUG
: O
The O
concentration O
of O
5 B-DRUG
- I-DRUG
fluorouracil I-DRUG
is O
increased O
and O
its O
toxicity O
may O
be O
enhanced O
by O
leucovorin B-DRUG
. O
Deaths O
from O
severe O
enterocolitis O
, O
diarrhea O
, O
and O
dehydration O
have O
been O
reported O
in O
elderly O
patients O
receiving O
weekly O
leucovorin B-DRUG
and O
fluorouracil B-DRUG
. O

Hypotension O
Patients O
on O
Diuretic B-GROUP
Therapy O
: O
Patients O
on O
diuretics B-GROUP
and O
especially O
those O
in O
whom O
diuretic B-GROUP
therapy O
was O
recently O
instituted O
, O
as O
well O
as O
those O
on O
severe O
dietary O
salt O
restriction O
or O
dialysis O
, O
may O
occasionally O
experience O
a O
precipitous O
reduction O
of O
blood O
pressure O
usually O
within O
the O
first O
hour O
after O
receiving O
the O
initial O
dose O
of O
captopril B-DRUG
. O
The O
possibility O
of O
hypotensive O
effects O
with O
captopril B-DRUG
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-GROUP
or O
increasing O
the O
salt O
intake O
approximately O
one O
week O
prior O
to O
initiation O
of O
treatment O
with O
captopril B-DRUG
( O
captopril B-DRUG
tablets O
, O
USP O
) O
or O
initiating O
therapy O
with O
small O
doses O
( O
6 O
. O
25 O
or O
12 O
. O
5 O
mg O
) O
. O
Alternatively O
, O
provide O
medical O
supervision O
for O
at O
least O
one O
hour O
after O
the O
initial O
dose O
. O
If O
hypotension O
occurs O
, O
the O
patient O
should O
be O
placed O
in O
a O
supine O
position O
and O
, O
if O
necessary O
, O
receive O
an O
intravenous O
infusion O
of O
normal O
saline O
. O
This O
transient O
hypotensive O
response O
is O
not O
a O
contraindication O
to O
further O
doses O
which O
can O
be O
given O
without O
difficulty O
once O
the O
blood O
pressure O
has O
increased O
after O
volume O
expansion O
. O
Agents O
Having O
Vasodilator O
Activity O
: O
Data O
on O
the O
effect O
of O
concomitant O
use O
of O
other O
vasodilators B-GROUP
in O
patients O
receiving O
captopril B-DRUG
for O
heart O
failure O
are O
not O
available O
; O
therefore O
, O
nitroglycerin B-DRUG
or O
other O
nitrates B-GROUP
( O
as O
used O
for O
management O
of O
angina O
) O
or O
other O
drugs O
having O
vasodilator O
activity O
should O
, O
if O
possible O
, O
be O
discontinued O
before O
starting O
captopril B-DRUG
. O
If O
resumed O
during O
captopril B-DRUG
therapy O
, O
such O
agents O
should O
be O
administered O
cautiously O
, O
and O
perhaps O
at O
lower O
dosage O
. O
Agents O
Causing O
Renin O
Release O
Captopril B-DRUG
' O
s O
effect O
will O
be O
augmented O
by O
antihypertensive B-GROUP
agents I-GROUP
that O
cause O
renin O
release O
. O
For O
example O
, O
diuretics B-GROUP
( O
e O
. O
g O
. O
, O
thiazides B-GROUP
) O
may O
activate O
the O
renin O
- O
angiotensin O
- O
aldosterone O
system O
. O
Agents O
Affecting O
Sympathetic O
Activity O
The O
sympathetic O
nervous O
system O
may O
be O
especially O
important O
in O
supporting O
blood O
pressure O
in O
patients O
receiving O
captopril B-DRUG
alone O
or O
with O
diuretics B-GROUP
. O
Therefore O
, O
agents O
affecting O
sympathetic O
activity O
( O
e O
. O
g O
. O
, O
ganglionic B-GROUP
blocking I-GROUP
agents I-GROUP
or O
adrenergic B-GROUP
neuron I-GROUP
blocking I-GROUP
agents I-GROUP
) O
should O
be O
used O
with O
caution O
. O
Beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
drugs I-GROUP
add O
some O
further O
antihypertensive O
effect O
to O
captopril B-DRUG
, O
but O
the O
overall O
response O
is O
less O
than O
additive O
. O
Agents O
Increasing O
Serum O

Potassium O
Since O
captopril B-DRUG
decreases O
aldosterone O
production O
, O
elevation O
of O
serum O
potassium O
may O
occur O
. O
Potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
such O
as O
spironolactone B-DRUG
, O
triamterene B-DRUG
, O
or O
amiloride B-DRUG
, O
or O
potassium B-DRUG
supplements O
should O
be O
given O
only O
for O
documented O
hypokalemia O
, O
and O
then O
with O
caution O
, O
since O
they O
may O
lead O
to O
a O
significant O
increase O
of O
serum O
potassium O
. O
Salt O
substitutes O
containing O
potassium B-DRUG
should O
also O
be O
used O
with O
caution O
. O
Inhibitors O
Of O
Endogenous O
Prostaglandin O
Synthesis O
It O
has O
been O
reported O
that O
indomethacin B-DRUG
may O
reduce O
the O
antihypertensive O
effect O
of O
captopril B-DRUG
, O
especially O
in O
cases O
of O
low O
renin O
hypertension O
. O
Other O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
( O
e O
. O
g O
. O
, O
aspirin B-BRAND
) O
may O
also O
have O
this O
effect O
. O
Lithium B-DRUG
: O
Increased O
serum O
lithium B-DRUG
levels O
and O
symptoms O
of O
lithium B-DRUG
toxicity O
have O
been O
reported O
in O
patients O
receiving O
concomitant O
lithium B-DRUG
and O
ACE B-GROUP
inhibitor I-GROUP
therapy O
. O
These O
drugs O
should O
be O
coad O
- O
ministered O
with O
caution O
and O
frequent O
monitoring O
of O
serum O
lithium B-DRUG
levels O
is O
recommended O
. O
If O
a O
diuretic B-GROUP
is O
also O
used O
, O
it O
may O
increase O
the O
risk O
of O
lithium B-DRUG
toxicity O
. O
Cardiac B-GROUP
Glycosides I-GROUP
: O
In O
a O
study O
of O
young O
healthy O
male O
subjects O
no O
evidence O
of O
a O
direct O
pharmacokinetic O
captopril B-DRUG
- O
digoxin B-DRUG
interaction O
could O
be O
found O
. O
Loop B-GROUP
Diuretics I-GROUP
: O
Furosemide B-DRUG
administered O
concurrently O
with O
captopril B-DRUG
does O
not O
alter O
the O
pharmacokinetics O
of O
captopril B-DRUG
in O
renally O
impaired O
hypertensive O
patients O
. O
Allopurinol B-DRUG
: O
In O
a O
study O
of O
healthy O
male O
volunteers O
no O
significant O
pharmacokinetic O
interaction O
occurred O
when O
captopril B-DRUG
and O
allopurinol B-DRUG
were O
administered O
concomitantly O
for O
6 O
days O
. O
Drug O
/ O
Laboratory O
Test O
Interaction O
Captopril B-DRUG
may O
cause O
a O
false O
- O
positive O
urine O
test O
for O
acetone O
. O

Clinically O
meaningful O
drug O
interactions O
have O
occurred O
with O
concomitant O
medications O
and O
include O
, O
but O
are O
not O
limited O
to O
the O
following O
: O
Agents O
Highly O
Bound O
to O
Plasma O
Protein O
Carbamazepine B-DRUG
is O
not O
highly O
bound O
to O
plasma O
proteins O
; O
therefore O
, O
administration O
of O
EQUETROTM B-BRAND
to O
a O
patient O
taking O
another O
drug O
that O
is O
highly O
protein O
bound O
should O
not O
cause O
increased O
free O
concentrations O
of O
the O
other O
drug O
. O
Agents O
that O
Inhibit O
Cytochrome O
P450 O
Isoenzymes O
and O
/ O
or O
Epoxide O
Hydrolase O
Carbamazepine B-DRUG
is O
metabolized O
mainly O
by O
cytochrome O
P450 O
( O
CYP O
) O
3A4 O
to O
the O
active O
carbamazepine B-DRUG
10 I-DRUG
, I-DRUG
11 I-DRUG
- I-DRUG
epoxide I-DRUG
, O
which O
is O
further O
metabolized O
to O
the O
trans O
- O
diol O
by O
epoxide O
hydrolase O
. O
Therefore O
, O
the O
potential O
exists O
for O
interaction O
between O
carbamazepine B-DRUG
and O
any O
agent O
that O
inhibits O
CYP3A4 O
and O
/ O
or O
epoxide O
hydrolase O
. O
Agents O
that O
are O
CYP3A4 O
inhibitors O
that O
have O
been O
found O
, O
or O
are O
expected O
, O
to O
increase O
plasma O
levels O
of O
EQUETROTM B-BRAND
are O
the O
following O
: O
Acetazolamide B-DRUG
, O
azole B-GROUP
antifungals I-GROUP
, O
cimetidine B-DRUG
, O
clarithromycin B-DRUG
( O
1 O
) O
, O
dalfopristin B-DRUG
, O
danazol B-DRUG
, O
delavirdine B-DRUG
, O
diltiazem B-DRUG
, O
erythromycin B-DRUG
( O
1 O
) O
, O
fluoxetine B-DRUG
, O
fluvoxamine B-DRUG
, O
grapefruit O
juice O
, O
isoniazid B-DRUG
, O
itraconazole B-DRUG
, O
ketoconazole B-DRUG
, O
loratadine B-DRUG
, O
nefazodone B-DRUG
, O
niacinamide B-DRUG
, O
nicotinamide B-DRUG
, O
protease B-GROUP
inhibitors I-GROUP
, O
propoxyphene B-DRUG
, O
quinine B-DRUG
, O
quinupristin B-DRUG
, O
troleandomycin B-DRUG
, O
valproate B-DRUG
( O
1 O
) O
, O
verapamil B-DRUG
, O
zileuton B-DRUG
. O
Thus O
, O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
of O
EQUETROTM B-BRAND
, O
and O
then O
begins O
a O
course O
of O
treatment O
with O
one O
of O
these O
CYP3A4 O
or O
epoxide O
hydrolase O
inhibitors O
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
reduction O
for O
EQUETROTM B-BRAND
may O
be O
necessary O
. O
Agents O
that O
Induce O
Cytochrome O
P450 O
Isoenzymes O
Carbamazepine B-DRUG
is O
metabolized O
by O
CYP3A4 O
. O
Therefore O
, O
the O
potential O
exists O
for O
interaction O
between O

carbamazepine B-DRUG
and O
any O
agent O
that O
induces O
CYP3A4 O
. O
Agents O
that O
are O
CYP O
inducers O
that O
have O
been O
found O
, O
or O
are O
expected O
, O
to O
decrease O
plasma O
levels O
of O
EQUETROTM B-BRAND
are O
the O
following O
: O
Cisplatin B-DRUG
, O
doxorubicin B-DRUG
HCL I-DRUG
, O
felbamate B-DRUG
, O
rifampin B-DRUG
, O
phenobarbital B-DRUG
, O
Phenytoin B-DRUG
( O
2 O
) O
, O
primidone B-DRUG
, O
methsuximide B-DRUG
, O
and O
theophylline B-DRUG
Thus O
, O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
on O
EQUETROTM B-BRAND
, O
and O
then O
begins O
a O
course O
of O
treatment O
with O
one O
of O
these O
CYP3A4 O
inducers O
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
increase O
for O
EQUETROTM B-BRAND
may O
be O
necessary O
. O
Agents O
with O
Decreased O
Levels O
in O
the O
Presence O
of O
Carbamazepine B-DRUG
due O
to O
Induction O
of O
Cytochrome O
P450 O
Enzymes O
Carbamazepine B-DRUG
is O
known O
to O
induce O
CYP1A2 O
and O
CYP3A4 O
. O
Therefore O
, O
the O
potential O
exists O
for O
interaction O
between O
carbamazepine B-DRUG
and O
any O
agent O
metabolized O
by O
one O
( O
or O
more O
) O
of O
these O
enzymes O
. O
Agents O
that O
have O
been O
found O
, O
or O
are O
expected O
to O
have O
decreased O
plasma O
levels O
in O
the O
presence O
of O
EQUETROTM B-BRAND
due O
to O
induction O
of O
CYP O
enzymes O
are O
the O
following O
: O
Acetaminophen B-DRUG
, O
alprazolam B-DRUG
, O
amitriptyline B-DRUG
, O
bupropion B-DRUG
, O
buspirone B-DRUG
, O
citalopram B-DRUG
, O
clobazam B-DRUG
, O
clonazepam B-DRUG
, O
clozapine B-DRUG
, O
cyclosporin B-DRUG
, O
delavirdine B-DRUG
, O
desipramine B-DRUG
, O
diazepam B-DRUG
, O
dicumarol B-DRUG
, O
doxycycline B-DRUG
, O
ethosuximide B-DRUG
, O
felbamate B-DRUG
, O
felodipine B-DRUG
, O
glucocorticoids B-GROUP
, O
haloperidol B-DRUG
, O
itraconazole B-DRUG
, O
lamotrigine B-DRUG
, O
levothyroxine B-DRUG
, O
lorazepam B-DRUG
, O
methadone B-DRUG
, O
midazolam B-DRUG
, O
mirtazapine B-DRUG
, O
nortriptyline B-DRUG
, O
olanzapine B-DRUG
, O
oral O
contraceptives B-GROUP
( O
3 O
) O
, O
oxcarbazepine B-DRUG
, O
Phenytoin B-DRUG
( O
4 O
) O
, O
praziquantel B-DRUG
, O
protease B-GROUP
inhibitors I-GROUP
, O
quetiapine B-DRUG
, O
risperidone B-DRUG
, O
theophylline B-DRUG
, O
topiramate B-DRUG
, O
tiagabine B-DRUG
, O
tramadol B-DRUG
, O
triazolam B-DRUG
, O

valproate B-DRUG
, O
warfarin B-DRUG
( O
5 O
) O
, O
ziprasidone B-DRUG
, O
and O
zonisamide B-DRUG
. O
Thus O
, O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
on O
one O
of O
the O
agents O
in O
this O
category O
, O
and O
then O
begins O
a O
course O
of O
treatment O
with O
EQUETROTM B-BRAND
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
increase O
for O
the O
concomitant O
agent O
may O
be O
necessary O
. O
Agents O
with O
Increased O
Levels O
in O
the O
Presence O
of O
Carbamazepine B-DRUG
: O
EQUETROTM B-BRAND
increases O
the O
plasma O
levels O
of O
the O
following O
agents O
: O
Clomipramine B-DRUG
HCl I-DRUG
, O
Phenytoin B-DRUG
( O
6 O
) O
, O
and O
primidone B-DRUG
Thus O
, O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
on O
one O
of O
the O
agents O
in O
this O
category O
, O
and O
then O
begins O
a O
course O
of O
the O
treatment O
with O
EQUETROTM B-BRAND
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
decrease O
for O
the O
concomitant O
agent O
may O
be O
necessary O
. O
Pharmacological O
/ O
Pharmacodynamic O
Interactions O
with O
Carbamazepine B-DRUG
Concomitant O
administration O
of O
carbamazepine B-DRUG
and O
lithium B-DRUG
may O
increase O
the O
risk O
of O
neurotoxic O
side O
effects O
. O
Given O
the O
anticonvulsant O
properties O
of O
carbamazepine B-DRUG
, O
EQUETROTM B-BRAND
may O
reduce O
the O
thyroid O
function O
as O
has O
been O
reported O
with O
other O
anticonvulsants B-GROUP
. O
Additionally O
, O
anti B-GROUP
- I-GROUP
malarial I-GROUP
drugs I-GROUP
, O
such O
as O
chloroquine B-DRUG
and O
mefloquine B-DRUG
, O
may O
antagonize O
the O
activity O
of O
carbamazepine B-DRUG
. O
Thus O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
on O
one O
of O
the O
agents O
in O
this O
category O
, O
and O
then O
begins O
a O
course O
of O
treatment O
with O
EQUETROTM B-BRAND
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
adjustment O
may O
be O
necessary O
. O
Because O
of O
its O
primary O
CNS O
effect O
, O
caution O
should O
be O
used O
when O
EQUETROTM B-BRAND
is O
taken O
with O
other O
centrally B-GROUP
acting I-GROUP
drugs I-GROUP
and O
alcohol B-DRUG
. O

Geocillin B-BRAND
( O
carbenicillin B-DRUG
indanyl I-DRUG
sodium I-DRUG
) O
blood O
levels O
may O
be O
increased O
and O
prolonged O
by O
concurrent O
administration O
of O
probenecid B-DRUG
. O

Caution O
should O
be O
exercised O
when O
the O
following O
drugs O
are O
administered O
concomitantly O
with O
LODOSYN B-BRAND
( O
Carbidopa B-DRUG
) O
given O
with O
levodopa B-DRUG
or O
carbidopa B-DRUG
- O
levodopa B-DRUG
combination O
products O
. O
For O
patients O
receiving O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
, O
see O
CONTRAINDICATIONS O
. O
Dopamine B-GROUP
D2 I-GROUP
receptor I-GROUP
antagonists I-GROUP
( O
e O
. O
g O
. O
, O
phenothiazines B-GROUP
, O
butyrophenones B-GROUP
, O
risperidone B-DRUG
) O
and O
isoniazid B-DRUG
may O
reduce O
the O
therapeutic O
effects O
of O
levodopa B-DRUG
. O
In O
addition O
, O
the O
beneficial O
effects O
of O
levodopa B-DRUG
in O
Parkinsons O
disease O
have O
been O
reported O
to O
be O
reversed O
by O
phenytoin B-DRUG
and O
papaverine B-DRUG
. O
Patients O
taking O
these O
drugs O
with O
LODOSYN B-BRAND
and O
levodopa B-DRUG
or O
carbidopa B-DRUG
- O
levodopa B-DRUG
combination O
products O
should O
be O
carefully O
observed O
for O
loss O
of O
therapeutic O
response O
. O
Iron B-DRUG
salts O
may O
reduce O
the O
bioavailability O
of O
carbidopa B-DRUG
and O
levodopa B-DRUG
. O
The O
clinical O
relevance O
is O
unclear O
. O
Although O
metoclopramide B-DRUG
may O
increase O
the O
bioavailability O
of O
levodopa B-DRUG
by O
increasing O
gastric O
emptying O
, O
metoclopramide B-DRUG
may O
also O
adversely O
affect O
disease O
control O
by O
its O
dopamine O
receptor O
antagonistic O
properties O
. O

Iodine B-DRUG
or O
iodine B-DRUG
excess O
may O
decrease O
the O
effect O
of O
Carbimazole B-DRUG
, O
and O
an O
iodine B-DRUG
deficiency O
can O
increase O
the O
effect O
of O
Carbimazole B-DRUG
. O
Serum O
concentration O
of O
digoxin B-DRUG
and O
digitoxin B-DRUG
may O
increase O
when O
patients O
take O
antithyroid B-GROUP
agents I-GROUP
. O
A O
decrease O
of O
the O
dosage O
may O
be O
necessary O
when O
patient O
becomes O
euthyroid O
. O
Antithyroid B-GROUP
agents I-GROUP
may O
decrease O
thyroidal O
uptake O
of O
sodium B-DRUG
iodide I-DRUG
I131 I-DRUG
, O
a O
rebound O
in O
uptake O
may O
occur O
up O
to O
5 O
days O
after O
sudden O
withdrawal O
of O
Carbimazole B-DRUG
. O
Patients O
response O
to O
oral O
anticoagulants B-GROUP
may O
be O
affected O
by O
his O
/ O
her O
thyroid O
and O
metabolic O
status O
. O
An O
evaluation O
of O
prothrombin O
time O
and O
an O
adjustment O
of O
anticoagulant B-GROUP
dosage O
are O
recommended O

Antihistamines B-GROUP
may O
enhance O
the O
effects O
of O
tricyclic B-GROUP
antidepressants I-GROUP
, O
barbiturates B-GROUP
, O
alcohol B-DRUG
, O
and O
other O
CNS B-GROUP
depressants I-GROUP
. O
MAO B-GROUP
inhibitors I-GROUP
prolong O
and O
intensify O
the O
anticholinergic O
effects O
of O
antihistamines B-GROUP
. O
Sympathomimetic B-GROUP
amines I-GROUP
may O
reduce O
the O
antihypertensive O
effects O
of O
reserpine B-DRUG
, O
veratrum B-GROUP
alkaloids I-GROUP
, O
methyldopa B-DRUG
and O
mecamylamine B-DRUG
. O
Effects O
of O
sympathomimetics B-GROUP
are O
increased O
with O
MAO B-GROUP
inhibitors I-GROUP
and O
beta B-GROUP
adrenergic I-GROUP
blockers I-GROUP
. O

The O
renal O
effects O
of O
nephrotoxic O
compounds O
may O
be O
potentiated O
by O
Carboplatin B-DRUG
. O

HEMABATE B-BRAND
may O
augment O
the O
activity O
of O
other O
oxytocic B-GROUP
agents I-GROUP
. O
Concomitant O
use O
with O
other O
oxytocic B-GROUP
agents I-GROUP
is O
not O
recommended O
. O

Ocupress B-BRAND
should O
be O
used O
with O
caution O
in O
patients O
who O
are O
receiving O
a O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agent I-GROUP
orally O
because O
of O
the O
potential O
for O
additive O
effects O
on O
systemic O
beta O
- O
blockade O
. O
Close O
observation O
of O
the O
patient O
is O
recommended O
when O
a O
beta B-GROUP
- I-GROUP
blocker I-GROUP
is O
administered O
to O
patients O
receiving O
catecholamine O
- O
depleting O
drugs O
such O
as O
reserpine B-DRUG
, O
because O
of O
possible O
additive O
effects O
and O
the O
production O
of O
hypotension O
and O
/ O
or O
marked O
bradycardia O
, O
which O
may O
produce O
vertigo O
, O
syncope O
, O
or O
postural O
hypotension O
. O

Inhibitors O
of O
CYP2D6 O
; O
poor O
metabolizers O
of O
debrisoquin B-DRUG
: O
Interactions O
of O
carvedilol B-DRUG
with O
strong O
inhibitors O
of O
CYP2D6 O
( O
such O
as O
quinidine B-DRUG
, O
fluoxetine B-DRUG
, O
paroxetine B-DRUG
, O
and O
propafenone B-DRUG
) O
have O
not O
been O
studied O
, O
but O
these O
drugs O
would O
be O
expected O
to O
increase O
blood O
levels O
of O
the O
R O
( O
+ O
) O
enantiomer O
of O
carvedilol B-DRUG
. O
Retrospective O
analysis O
of O
side O
effects O
in O
clinical O
trials O
showed O
that O
poor O
2D6 O
metabolizers O
had O
a O
higher O
rate O
of O
dizziness O
during O
up O
- O
titration O
, O
presumably O
resulting O
from O
vasodilating O
effects O
of O
the O
higher O
concentrations O
of O
the O
a O
- O
blocking O
R O
( O
+ O
) O
enantiomer O
. O
Catecholamine O
- O
depleting O
Agents O
: O
Patients O
taking O
both O
agents B-GROUP
with I-GROUP
b I-GROUP
- I-GROUP
blocking I-GROUP
properties I-GROUP
and O
a O
drug O
that O
can O
deplete O
catecholamines O
( O
e O
. O
g O
. O
, O
reserpine B-DRUG
and O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
) O
should O
be O
observed O
closely O
for O
signs O
of O
hypotension O
and O
/ O
or O
severe O
bradycardia O
. O
Clonidine B-DRUG
: O
Concomitant O
administration O
of O
clonidine B-DRUG
with O
agents B-GROUP
with I-GROUP
b I-GROUP
- I-GROUP
blocking I-GROUP
properties I-GROUP
may O
potentiate O
blood O
- O
pressure O
- O
and O
heart O
- O
rate O
- O
lowering O
effects O
. O
When O
concomitant O
treatment O
with O
agents B-GROUP
with I-GROUP
b I-GROUP
- I-GROUP
blocking I-GROUP
properties I-GROUP
and O
clonidine B-DRUG
is O
to O
be O
terminated O
, O
the O
b B-GROUP
- I-GROUP
blocking I-GROUP
agent I-GROUP
should O
be O
discontinued O
first O
. O
Clonidine B-DRUG
therapy O
can O
then O
be O
discontinued O
several O
days O
later O
by O
gradually O
decreasing O
the O
dosage O
. O
Cyclosporine B-DRUG
: O
Modest O
increases O
in O
mean O
trough O
cyclosporine B-DRUG
concentrations O
were O
observed O
following O
initiation O
of O
carvedilol B-DRUG
treatment O
in O
21 O
renal O
transplant O
patients O
suffering O
from O
chronic O
vascular O
rejection O
. O
In O
about O
30 O
% O
of O
patients O
, O
the O
dose O
of O
cyclosporine B-DRUG
had O
to O
be O
reduced O
in O
order O
to O
maintain O
cyclosporine B-DRUG
concentrations O
within O
the O
therapeutic O
range O
, O
while O
in O
the O
remainder O
no O
adjustment O
was O
needed O
. O
On O
the O
average O
for O
the O
group O
, O
the O
dose O
of O
cyclosporine B-DRUG
was O
reduced O
about O
20 O
% O
in O
these O
patients O
. O
Due O
to O
wide O
interindividual O
variability O
in O
the O
dose O
adjustment O
required O
, O
it O
is O
recommended O
that O
cyclosporine B-DRUG
concentrations O
be O
monitored O
closely O
after O
initiation O
of O
carvedilol B-DRUG
therapy O
and O
that O
the O
dose O
of O
cyclosporine B-DRUG
be O
adjusted O
as O
appropriate O
. O
Digoxin B-DRUG
: O
Digoxin B-DRUG
concentrations O
are O
increased O
by O
about O
15 O
% O
when O
digoxin B-DRUG
and O
carvedilol B-DRUG
are O
administered O
concomitantly O
. O
Both O
digoxin B-DRUG
and O

COREG B-BRAND
slow O
AV O
conduction O
. O
Therefore O
, O
increased O
monitoring O
of O
digoxin B-DRUG
is O
recommended O
when O
initiating O
, O
adjusting O
, O
or O
discontinuing O
COREG B-BRAND
. O
Inducers O
and O
Inhibitors O
of O
Hepatic O
Metabolism O
: O
Rifampin B-DRUG
reduced O
plasma O
concentrations O
of O
carvedilol B-DRUG
by O
about O
70 O
% O
. O
Cimetidine B-DRUG
increased O
AUC O
by O
about O
30 O
% O
but O
caused O
no O
change O
in O
Cmax O
. O
Calcium B-GROUP
Channel I-GROUP
Blockers I-GROUP
: O
Isolated O
cases O
of O
conduction O
disturbance O
( O
rarely O
with O
hemodynamic O
compromise O
) O
have O
been O
observed O
when O
COREG B-BRAND
is O
co O
- O
administered O
with O
diltiazem B-DRUG
. O
As O
with O
other O
agents B-GROUP
with I-GROUP
b I-GROUP
- I-GROUP
blocking I-GROUP
properties I-GROUP
, O
if O
COREG B-BRAND
is O
to O
be O
administered O
orally O
with O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
of O
the O
verapamil B-DRUG
or O
diltiazem B-DRUG
type O
, O
it O
is O
recommended O
that O
ECG O
and O
blood O
pressure O
be O
monitored O
. O
Insulin B-DRUG
or O
Oral O
Hypoglycemics B-GROUP
: O
Agents B-GROUP
with I-GROUP
b I-GROUP
- I-GROUP
blocking I-GROUP
properties I-GROUP
may O
enhance O
the O
blood O
- O
sugar O
- O
reducing O
effect O
of O
insulin B-DRUG
and O
oral O
hypoglycemics B-GROUP
. O
Therefore O
, O
in O
patients O
taking O
insulin B-DRUG
or O
oral O
hypoglycemics B-GROUP
, O
regular O
monitoring O
of O
blood O
glucose O
is O
recommended O
. O

Studies O
in O
vitro O
show O
that O
caspofungin B-DRUG
acetate I-DRUG
is O
not O
an O
inhibitor O
of O
any O
enzyme O
in O
the O
cytochrome O
P450 O
( O
CYP O
) O
system O
. O
In O
clinical O
studies O
, O
caspofungin B-DRUG
did O
not O
induce O
the O
CYP3A4 O
metabolism O
of O
other O
drugs O
. O
Caspofungin B-DRUG
is O
not O
a O
substrate O
for O
P O
- O
glycoprotein O
and O
is O
a O
poor O
substrate O
for O
cytochrome O
P450 O
enzymes O
. O
Clinical O
studies O
in O
healthy O
volunteers O
show O
that O
the O
pharmacokinetics O
of O
CANCIDAS B-BRAND
are O
not O
altered O
by O
itraconazole B-DRUG
, O
amphotericin B-DRUG
B I-DRUG
, O
mycophenolate B-DRUG
, O
nelfinavir B-DRUG
, O
or O
tacrolimus B-DRUG
. O
CANCIDAS B-BRAND
has O
no O
effect O
on O
the O
pharmacokinetics O
of O
itraconazole B-DRUG
, O
amphotericin B-DRUG
B I-DRUG
, O
or O
the O
active O
metabolite O
of O
mycophenolate O
. O
CANCIDAS B-BRAND
reduced O
the O
blood O
AUC0 O
- O
12 O
of O
tacrolimus B-DRUG
by O
approximately O
20 O
% O
, O
peak O
blood O
concentration O
( O
Cmax O
) O
by O
16 O
% O
, O
and O
12 O
- O
hour O
blood O
concentration O
( O
C12hr O
) O
by O
26 O
% O
in O
healthy O
subjects O
when O
tacrolimus B-DRUG
( O
2 O
doses O
of O
0 O
. O
1 O
mg O
/ O
kg O
12 O
hours O
apart O
) O
was O
administered O
on O
the O
10th O
day O
of O
CANCIDAS B-BRAND
70 O
mg O
daily O
, O
as O
compared O
to O
results O
from O
a O
control O
period O
in O
which O
tacrolimus B-DRUG
was O
administered O
alone O
. O
For O
patients O
receiving O
both O
therapies O
, O
standard O
monitoring O
of O
tacrolimus B-DRUG
blood O
concentrations O
and O
appropriate O
tacrolimus B-DRUG
dosage O
adjustments O
are O
recommended O
. O
In O
two O
clinical O
studies O
, O
cyclosporine B-DRUG
( O
one O
4 O
mg O
/ O
kg O
dose O
or O
two O
3 O
mg O
/ O
kg O
doses O
) O
increased O
the O
AUC O
of O
caspofungin B-DRUG
by O
approximately O
35 O
% O
. O
CANCIDAS B-BRAND
did O
not O
increase O
the O
plasma O
levels O
of O
cyclosporine B-DRUG
. O
There O
were O
transient O
increases O
in O
liver O
ALT O
and O
AST O
when O
CANCIDAS B-BRAND
and O
cyclosporine B-DRUG
were O
co O
- O
administered O
. O
A O
drug O
- O
drug O
interaction O
study O
with O
rifampin B-DRUG
in O
healthy O
volunteers O
has O
shown O
a O
30 O
% O
decrease O
in O
caspofungin B-DRUG
trough O
concentrations O
. O
Patients O
on O
rifampin B-DRUG
should O
receive O
70 O
mg O
of O
CANCIDAS B-BRAND
daily O
. O
In O
addition O
, O
results O
from O
regression O
analyses O
of O
patient O
pharmacokinetic O
data O
suggest O
that O
co O
- O
administration O
of O
other O
inducers O
of O
drug O
clearance O
( O
efavirenz B-DRUG
, O
nevirapine B-DRUG
, O
phenytoin B-DRUG
, O
dexamethasone B-DRUG
, O
or O

carbamazepine B-DRUG
) O
with O
CANCIDAS B-BRAND
may O
result O
in O
clinically O
meaningful O
reductions O
in O
caspofungin B-DRUG
concentrations O
. O
It O
is O
not O
known O
which O
drug O
clearance O
mechanism O
involved O
in O
caspofungin B-DRUG
disposition O
may O
be O
inducible O
. O
When O
CANCIDAS B-BRAND
is O
co O
- O
administered O
with O
inducers O
of O
drug O
clearance O
, O
such O
as O
efavirenz B-DRUG
, O
nevirapine B-DRUG
, O
phenytoin B-DRUG
, O
dexamethasone B-DRUG
, O
or O
carbamazepine B-DRUG
, O
use O
of O
a O
daily O
dose O
of O
70 O
mg O
of O
CANCIDAS B-BRAND
should O
be O
considered O
. O

Drug O
/ O
Laboratory O
Test O
Interactions O
Positive O
direct O
Coombs O
tests O
have O
been O
reported O
during O
treatment O
with O
the O
cephalosporin B-GROUP
antibiotics I-GROUP
. O
In O
hematologic O
studies O
or O
in O
transfusion O
cross O
- O
matching O
procedures O
when O
anti O
- O
globulin O
tests O
are O
performed O
on O
the O
minor O
side O
or O
in O
Coombs O
testing O
of O
newborns O
whose O
mothers O
have O
received O
cephalosporin B-GROUP
antibiotics I-GROUP
before O
parturition O
, O
it O
should O
be O
recognized O
that O
a O
positive O
Coombs O
test O
may O
be O
due O
to O
the O
drug O
. O

Probenecid B-DRUG
may O
decrease O
renal O
tubular O
secretion O
of O
cephalosporins B-GROUP
when O
used O
concurrently O
, O
resulting O
in O
increased O
and O
more O
prolonged O
cephalosporin B-GROUP
blood O
levels O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
A O
false O
positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
with O
Benedicts O
solution O
, O
Fehlings O
solution O
or O
with O
CLINITEST O
tablets O
, O
but O
not O
with O
enzyme O
- O
based O
tests O
such O
as O
CLINISTIX O
. O
Positive O
direct O
and O
indirect O
antiglobulin O
( O
Coombs O
) O
tests O
have O
occurred O
; O
these O
may O
also O
occur O
in O
neonates O
whose O
mothers O
received O
cephalosporins B-GROUP
before O
delivery O
. O

Antacids B-GROUP
( O
aluminum B-DRUG
- O
or O
magnesium B-DRUG
- O
containing O
) O
: O
Concomitant O
administration O
of O
300 O
- O
mg O
cefdinir B-DRUG
capsules O
with O
30 O
mL O
Maalox B-BRAND
TC I-BRAND
suspension O
reduces O
the O
rate O
( O
Cmax O
) O
and O
extent O
( O
AUC O
) O
of O
absorption O
by O
approximately O
40 O
% O
. O
Time O
to O
reach O
Cmax O
is O
also O
prolonged O
by O
1 O
hour O
. O
There O
are O
no O
significant O
effects O
on O
cefdinir B-DRUG
pharmacokinetics O
if O
the O
antacid B-GROUP
is O
administered O
2 O
hours O
before O
or O
2 O
hours O
after O
cefdinir B-DRUG
. O
If O
antacids B-GROUP
are O
required O
during O
OMNICEF B-BRAND
therapy O
, O
OMNICEF B-BRAND
should O
be O
taken O
at O
least O
2 O
hours O
before O
or O
after O
the O
antacid B-GROUP
. O
Probenecid B-DRUG
: O
As O
with O
other O
b B-GROUP
- I-GROUP
lactam I-GROUP
antibiotics I-GROUP
, O
probenecid B-DRUG
inhibits O
the O
renal O
excretion O
of O
cefdinir B-DRUG
, O
resulting O
in O
an O
approximate O
doubling O
in O
A O
. O
C O
. O
a O
54 O
% O
increase O
in O
peak O
cefdinir B-DRUG
plasma O
levels O
, O
and O
a O
50 O
% O
prolongation O
in O
the O
apparent O
elimination O
half O
- O
life O
. O
Iron B-GROUP
Supplements I-GROUP
and O
Foods O
Fortified O
With O
Iron B-DRUG
Concomitant O
administration O
of O
cefdinir B-DRUG
with O
a O
therapeutic O
iron B-GROUP
supplement I-GROUP
containing O
60 O
mg O
of O
elemental O
iron B-DRUG
( O
as O
FeSO4 O
) O
or O
vitamins B-GROUP
supplemented O
with O
10 O
mg O
of O
elemental O
iron B-DRUG
reduced O
extent O
of O
absorption O
by O
80 O
% O
and O
31 O
% O
, O
respectively O
. O
If O
iron B-GROUP
supplements I-GROUP
are O
required O
during O
OMNICEF B-BRAND
therapy O
, O
OMNICEF B-BRAND
should O
be O
taken O
at O
least O
2 O
hours O
before O
or O
after O
the O
supplement O
. O
The O
effect O
of O
foods O
highly O
fortified O
with O
elemental O
iron B-DRUG_N
( O
primarily O
iron B-DRUG_N
- O
fortified O
breakfast O
cereals O
) O
on O
cefdinir B-DRUG
absorption O
has O
not O
been O
studied O
. O
Concomitantly O
administered O
iron B-DRUG_N
- O
fortified O
infant O
formula O
( O
2 O
. O
2 O
mg O
elemental O
iron B-DRUG_N
/ O
6 O
oz O
) O
has O
no O
significant O
effect O
on O
cefdinir B-DRUG
pharmacokinetics O
. O
Therefore O
, O
OMNICEF B-BRAND
for O
Oral O
Suspension O
can O
be O
administered O
with O
iron B-DRUG_N
- O
fortified O
infant O
formula O
. O
There O
have O
been O
rare O
reports O
of O
reddish O
stools O
in O
patients O
who O
have O
received O
cefdinir B-DRUG
in O
Japan O
. O
The O
reddish O
color O
is O
due O
to O
the O
formation O
of O
a O
nonabsorbable O
complex O
between O
cefdinir B-DRUG
or O
its O
breakdown O
products O
and O
iron B-DRUG
in O
the O
gastrointestinal O
tract O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
A O
false O
- O
positive O
reaction O
for O
ketones O
in O
the O
urine O
may O
occur O
with O
tests O
using O
nitroprusside B-DRUG
, O
but O
not O
with O
those O
using O
nitroferricyanide B-DRUG
. O
The O
administration O
of O
cefdinir B-DRUG
may O
result O
in O
a O
false O
- O
positive O
reaction O
for O
glucose O
in O

urine O
using O
Clinitest O
, O
Benedict O
s O
solution O
, O
or O
Fehlings O
solution O
. O
It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
( O
such O
as O
Clinistix O
or O
Tes O
- O
Tape O
) O
be O
used O
. O
Cephalosporins B-GROUP
are O
known O
to O
occasionally O
induce O
a O
positive O
direct O
Coombs O
test O
. O

Oral O
Contraceptives B-GROUP
Multiple O
doses O
of O
cefditoren B-DRUG
pivoxil I-DRUG
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
ethinyl B-DRUG
estradiol I-DRUG
, O
the O
estrogenic O
component O
in O
most O
oral O
contraceptives B-GROUP
. O
Although O
the O
clinical O
significance O
is O
not O
known O
, O
it O
is O
not O
recommended O
that O
cefditoren B-DRUG
pivoxil I-DRUG
be O
taken O
concomitantly O
with O
antacids B-GROUP
. O
H2 B-GROUP
- I-GROUP
Receptor I-GROUP
Antagonists I-GROUP
: O
Co O
- O
administration O
of O
a O
single O
dose O
of O
intravenously O
administered O
famotidine B-DRUG
( O
20 O
mg O
) O
reduced O
the O
oral O
absorption O
of O
a O
single O
400 O
mg O
dose O
of O
cefditoren B-DRUG
pivoxil I-DRUG
administered O
following O
a O
meal O
, O
as O
evidenced O
by O
a O
27 O
% O
decrease O
in O
mean O
Cmax O
and O
a O
22 O
% O
decrease O
in O
mean O
AUC O
. O
Although O
the O
clinical O
significance O
is O
not O
known O
, O
it O
is O
not O
recommended O
that O
cefditoren B-DRUG
pivoxil I-DRUG
be O
taken O
concomitantly O
with O
H2 B-GROUP
receptor I-GROUP
antagonists I-GROUP
. O
Probenecid B-DRUG
: O
As O
with O
other O
b B-GROUP
- I-GROUP
lactam I-GROUP
antibiotics I-GROUP
, O
co O
- O
administration O
of O
probenecid B-DRUG
with O
cefditoren B-DRUG
pivoxil I-DRUG
resulted O
in O
an O
increase O
in O
the O
plasma O
exposure O
of O
cefditoren B-DRUG
, O
with O
a O
49 O
% O
increase O
in O
mean O
Cmax O
, O
a O
122 O
% O
increase O
in O
mean O
AUC O
, O
and O
a O
53 O
% O
increase O
in O
half O
- O
life O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Cephalosporins B-GROUP
are O
known O
to O
occasionally O
induce O
a O
positive O
direct O
Coombs O
test O
. O
A O
false O
- O
positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
with O
copper O
reduction O
tests O
( O
Benedicts O
or O
Fehlings O
solution O
or O
with O
CLINITEST O
tablets O
) O
, O
but O
not O
with O
enzyme O
- O
based O
tests O
for O
glycosuria O
( O
e O
. O
g O
. O
, O
CLINISTIX O
, O
TES O
- O
TAPE O
) O
. O
As O
a O
false O
- O
negative O
result O
may O
occur O
in O
the O
ferricyanide O
test O
, O
it O
is O
recommended O
that O
either O
the O
glucose O
oxidase O
or O
hexokinase O
method O
be O
used O
to O
determine O
blood O
/ O
plasma O
glucose O
levels O
in O
patients O
receiving O
cefditoren B-DRUG
pivoxil I-DRUG
. O

Renal O
function O
should O
be O
monitored O
carefully O
if O
high O
doses O
of O
aminoglycosides B-GROUP
are O
to O
be O
administered O
with O
MAXIPIME B-BRAND
because O
of O
the O
increased O
potential O
of O
nephrotoxicity O
and O
ototoxicity O
of O
aminoglycoside B-GROUP
antibiotics I-GROUP
. O
Nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
other O
cephalosporins B-GROUP
with O
potent O
diuretics B-GROUP
such O
as O
furosemide B-DRUG
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
The O
administration O
of O
cefepime B-DRUG
may O
result O
in O
a O
false O
- O
positive O
reaction O
for O
glucose O
in O
the O
urine O
when O
using O
Clinitest O
tablets O
. O
It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
( O
such O
as O
Clinistix O
or O
Tes O
- O
Tape O
) O
be O
used O
. O

Carbamazepine B-DRUG
: O
Elevated O
carbamazepine B-DRUG
levels O
have O
been O
reported O
in O
postmarketing O
experience O
when O
SUPRAX B-BRAND
is O
administered O
concomitantly O
. O
Drug O
monitoring O
may O
be O
of O
assistance O
in O
detecting O
alterations O
in O
carbamazepine B-DRUG
plasma O
concentrations O
. O
Warfarin B-DRUG
and O
Anticoagulants B-GROUP
: O
Increased O
prothrombin O
time O
, O
with O
or O
without O
clinical O
bleeding O
, O
has O
been O
reported O
when O
cefixime B-DRUG
is O
administered O
concomitantly O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
A O
false O
- O
positive O
reaction O
for O
ketones O
in O
the O
urine O
may O
occur O
with O
tests O
using O
nitroprusside B-DRUG
but O
not O
with O
those O
using O
nitroferricyanide B-DRUG
. O
The O
administration O
of O
SUPRAX B-BRAND
may O
result O
in O
a O
false O
- O
positive O
reaction O
for O
glucose O
in O
the O
urine O
using O
Clinitest O
* O
* O
, O
Benedict O
s O
solution O
, O
or O
Fehling O
s O
solution O
. O
It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
( O
such O
as O
Clinistix O
* O
* O
or O
Tes O
- O
Tape O
* O
* O
) O
be O
used O
. O
A O
false O
- O
positive O
direct O
Coombs O
test O
has O
been O
reported O
during O
treatment O
with O
other O
cephalosporin B-GROUP
antibiotics I-GROUP
; O
therefore O
, O
it O
should O
be O
recognized O
that O
a O
positive O
Coombs O
test O
may O
be O
due O
to O
the O
drug O
. O

Increased O
nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
cephalosporins B-GROUP
and O
aminoglycoside B-GROUP
antibiotics I-GROUP
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Cephalosporins B-GROUP
, O
including O
cefotaxime B-DRUG
sodium I-DRUG
, O
are O
known O
to O
occasionally O
induce O
a O
positive O
direct O
Coombs O
test O
. O

Increases O
in O
serum O
creatinine O
have O
occurred O
when O
CEFOTAN B-BRAND
was O
given O
alone O
. O
If O
CEFOTAN B-BRAND
and O
an O
aminoglycoside B-GROUP
are O
used O
concomitantly O
, O
renal O
function O
should O
be O
carefully O
monitored O
, O
because O
nephrotoxicity O
may O
be O
potentiated O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
: O
The O
administration O
of O
CEFOTAN B-BRAND
may O
result O
in O
a O
false O
positive O
reaction O
for O
glucose O
in O
the O
urine O
using O
Clinitest O
, O
Benedicts O
solution O
, O
or O
Fehlings O
solution O
. O
It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
be O
used O
. O
As O
with O
other O
cephalosporins B-GROUP
, O
high O
concentrations O
of O
cefotetan B-DRUG
may O
interfere O
with O
measurement O
of O
serum O
and O
urine O
creatinine O
levels O
by O
Jaffe O
reaction O
and O
produce O
false O
increases O
in O
the O
levels O
of O
creatinine O
reported O
. O

Increased O
nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
cephalosporins B-GROUP
and O
aminoglycoside B-GROUP
antibiotics I-GROUP
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
As O
with O
cephalothin B-DRUG
, O
high O
concentrations O
of O
cefoxitin B-DRUG
( O
100 O
micrograms O
/ O
mL O
) O
may O
interfere O
with O
measurement O
of O
serum O
and O
urine O
creatinine O
levels O
by O
the O
Jaff O
reaction O
, O
and O
produce O
false O
increases O
of O
modest O
degree O
in O
the O
levels O
of O
creatinine O
reported O
. O
Serum O
samples O
from O
patients O
treated O
with O
cefoxitin B-DRUG
should O
not O
be O
analyzed O
for O
creatinine O
if O
withdrawn O
within O
2 O
hours O
of O
drug O
administration O
. O
High O
concentrations O
of O
cefoxitin B-DRUG
in O
the O
urine O
may O
interfere O
with O
measurement O
of O
urinary O
17 O
- O
hydroxy O
- O
corticosteroids O
by O
the O
Porter O
- O
Silber O
reaction O
, O
and O
produce O
false O
increases O
of O
modest O
degree O
in O
the O
levels O
reported O
. O
A O
false O
- O
positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
. O
This O
has O
been O
observed O
with O
CLINITEST O
reagent O
tablets O
. O
Registered O
trademark O
of O
Ames O
Company O
, O
Division O
of O
Miles O
Laboratories O
, O
Inc O
. O

Nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
aminoglycoside B-GROUP
antibiotics I-GROUP
and O
cephalosporin B-GROUP
antibiotics I-GROUP
. O
Concomitant O
administration O
of O
probenecid B-DRUG
doubled O
the O
AUC O
for O
cefprozil B-DRUG
. O
The O
bioavailability O
of O
the O
capsule O
formulation O
of O
cefprozil B-DRUG
was O
not O
affected O
when O
administered O
5 O
minutes O
following O
an O
antacid B-GROUP
. O

Nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
cephalosporins B-GROUP
with O
aminoglycoside B-GROUP
antibiotics I-GROUP
or O
potent O
diuretics B-GROUP
such O
as O
furosemide B-DRUG
. O
Renal O
function O
should O
be O
carefully O
monitored O
, O
especially O
if O
higher O
dosages O
of O
the O
aminoglycosides B-GROUP
are O
to O
be O
administered O
or O
if O
therapy O
is O
prolonged O
, O
because O
of O
the O
potential O
nephrotoxicity O
and O
ototoxicity O
of O
aminoglycosidic B-GROUP
antibiotics I-GROUP
. O
Nephrotoxicity O
and O
ototoxicity O
were O
not O
noted O
when O
ceftazidime B-DRUG
was O
given O
alone O
in O
clinical O
trials O
. O
Chloramphenicol B-DRUG
has O
been O
shown O
to O
be O
antagonistic O
to O
beta B-GROUP
- I-GROUP
lactam I-GROUP
antibiotics I-GROUP
, O
including O
ceftazidime B-DRUG
, O
based O
on O
in O
vitro O
studies O
and O
time O
kill O
curves O
with O
enteric O
gram O
- O
negative O
bacilli O
. O
Due O
to O
the O
possibility O
of O
antagonism O
in O
vivo O
, O
particularly O
when O
bactericidal O
activity O
is O
desired O
, O
this O
drug O
combination O
should O
be O
avoided O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
The O
administration O
of O
ceftazidime B-DRUG
may O
result O
in O
a O
false O
- O
positive O
reaction O
for O
glucose O
in O
the O
urine O
when O
using O
CLINITEST O
tablets O
, O
Benedicts O
solution O
, O
or O
Fehlings O
solution O
. O
It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
( O
such O
as O
CLINISTIX O
or O
TES O
- O
TAPE O
) O
be O
used O
. O

Theophylline B-DRUG
: O
Twelve O
healthy O
male O
volunteers O
were O
administered O
one O
200 O
- O
mg O
ceftibuten B-DRUG
capsule O
twice O
daily O
for O
6 O
days O
. O
With O
the O
morning O
dose O
of O
ceftibuten B-DRUG
on O
day O
6 O
, O
each O
volunteer O
received O
a O
single O
intravenous O
infusion O
of O
theophylline B-DRUG
( O
4 O
mg O
/ O
kg O
) O
. O
The O
pharmacokinetics O
of O
theophylline B-DRUG
were O
not O
altered O
. O
The O
effect O
of O
ceftibuten B-DRUG
on O
the O
pharmacokinetics O
of O
theophylline B-DRUG
administered O
orally O
has O
not O
been O
investigated O
. O
Antacids B-GROUP
or O
H B-GROUP
2 I-GROUP
- I-GROUP
receptor I-GROUP
antagonists I-GROUP
: O
The O
effect O
of O
increased O
gastric O
pH O
on O
the O
bioavailability O
of O
ceftibuten B-DRUG
was O
evaluated O
in O
18 O
healthy O
adult O
volunteers O
. O
Each O
volunteer O
was O
administered O
one O
400 O
- O
mg O
ceftibuten B-DRUG
capsule O
. O
A O
single O
dose O
of O
liquid O
antacid B-GROUP
did O
not O
affect O
the O
C O
max O
or O
AUC O
of O
ceftibuten B-DRUG
; O
however O
, O
150 O
mg O
of O
ranitidine B-DRUG
q12h O
for O
3 O
days O
increased O
the O
ceftibuten B-DRUG
C O
max O
by O
23 O
% O
and O
ceftibuten B-DRUG
AUC O
by O
16 O
% O
. O
The O
clinical O
relevance O
of O
these O
increases O
is O
not O
known O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
: O
There O
have O
been O
no O
chemical O
or O
laboratory O
test O
interactions O
with O
ceftibuten B-DRUG
noted O
to O
date O
. O
False O
- O
positive O
direct O
Coombs O
tests O
have O
been O
reported O
during O
treatment O
with O
other O
cephalosporins B-GROUP
. O
Therefore O
, O
it O
should O
be O
recognized O
that O
a O
positive O
Coombs O
test O
could O
be O
due O
to O
the O
drug O
. O
The O
results O
of O
assays O
using O
red O
cells O
from O
healthy O
subjects O
to O
determine O
whether O
ceftibuten B-DRUG
would O
cause O
direct O
Coombs O
reactions O
in O
vitro O
showed O
no O
positive O
reaction O
at O
ceftibuten B-DRUG
concentrations O
as O
high O
as O
40 O
g O
/ O
mL O
. O

Although O
the O
occurrence O
has O
not O
been O
reported O
with O
Cefizox B-BRAND
, O
nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
other O
cephalosporins B-GROUP
and O
aminoglycosides B-GROUP
. O

Drug O
/ O
Laboratory O
Test O
Interactions O
: O
A O
false O
- O
positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
with O
copper O
reduction O
tests O
( O
Benedict O
s O
or O
Fehling O
s O
solution O
or O
with O
Clinitest O
tablets O
) O
but O
not O
with O
enzyme O
- O
based O
tests O
for O
glycosuria O
. O
As O
a O
false O
- O
negative O
result O
may O
occur O
in O
the O
ferricyanide O
test O
, O
it O
is O
recommended O
that O
either O
the O
glucose O
oxidase O
or O
hexokinase O
method O
be O
used O
to O
determine O
blood O
plasma O
glucose O
levels O
in O
patients O
receiving O
cefuroxime B-DRUG
. O
Cefuroxime B-DRUG
does O
not O
interfere O
with O
the O
assay O
of O
serum O
and O
urine O
creatinine O
by O
the O
alkaline O
picrate O
method O
. O

General O
: O
Significant O
interactions O
may O
occur O
when O
celecoxib B-DRUG
is O
administered O
together O
with O
drugs O
that O
inhibit O
P450 O
2C9 O
. O
Celecoxib B-DRUG
metabolism O
is O
predominantly O
mediated O
via O
cytochrome O
P450 O
2C9 O
in O
the O
liver O
. O
Co O
- O
administration O
of O
celecoxib B-DRUG
with O
drugs O
that O
are O
known O
to O
inhibit O
2C9 O
should O
be O
done O
with O
caution O
. O
In O
vitro O
studies O
indicate O
that O
celecoxib B-DRUG
is O
not O
an O
inhibitor O
of O
cytochrome O
P450 O
2C9 O
, O
2C19 O
or O
3A4 O
. O
In O
vitro O
studies O
also O
indicate O
that O
celecoxib B-DRUG
, O
although O
not O
a O
substrate O
, O
is O
an O
inhibitor O
of O
cytochrome O
P450 O
2D6 O
. O
Therefore O
, O
there O
is O
a O
potential O
for O
an O
in O
vivo O
drug O
interaction O
with O
drugs O
that O
are O
metabolized O
by O
P450 O
2D6 O
. O
Clinical O
studies O
with O
celecoxib B-DRUG
have O
identified O
potentially O
significant O
interactions O
with O
fluconazole B-DRUG
and O
lithium B-DRUG
. O
Experience O
with O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
( O
NSAIDs B-GROUP
) O
suggests O
the O
potential O
for O
interactions O
with O
furosemide B-DRUG
and O
ACE B-GROUP
inhibitors I-GROUP
. O
The O
effects O
celecoxib B-DRUG
on O
the O
pharmacokinetics O
and O
/ O
or O
pharmacodynamics O
of O
glyburide B-DRUG
, O
ketoconazole B-DRUG
, O
methotrexate B-DRUG
, O
phenytoin B-DRUG
, O
tolbutamide B-DRUG
, O
and O
warfarin B-DRUG
have O
been O
studied O
in O
vivo O
and O
clinically O
important O
interactions O
have O
not O
been O
found O
. O
ACE B-GROUP
inhibitors I-GROUP
: O
Reports O
suggest O
that O
NSAIDs B-GROUP
may O
diminish O
the O
antihypertensive O
effect O
of O
Angiotensin B-GROUP
Converting I-GROUP
Enzyme I-GROUP
( I-GROUP
ACE I-GROUP
) I-GROUP
inhibitors I-GROUP
. O
This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
CELEBREX B-BRAND
concomitantly O
with O
ACE B-GROUP
- I-GROUP
inhibitors I-GROUP
. O
Furosemide B-DRUG
: O
Clinical O
studies O
, O
as O
well O
as O
post O
marketing O
observations O
, O
have O
shown O
that O
NSAIDs B-GROUP
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-DRUG
and O
thiazides B-GROUP
in O
some O
patients O
. O
This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O
Aspirin B-BRAND
: O
CELEBREX B-BRAND
can O
be O
used O
with O
low O
dose O
aspirin B-BRAND
. O
However O
, O
concomitant O
administration O
of O
aspirin B-BRAND
with O
CELEBREX B-BRAND
may O
result O
in O
an O
increased O
rate O
of O
GI O
ulceration O
or O
other O
complications O
, O
compared O
to O
use O
of O
CELEBREX B-BRAND
alone O
. O
Because O
of O
its O
lack O
of O
platelet O
effects O
, O
CELEBREX B-BRAND
is O
not O
a O
substitute O
for O
aspirin B-BRAND
for O
cardiovascular O

prophylaxis O
. O
Fluconazole B-DRUG
: O
Concomitant O
administration O
of O
fluconazole B-DRUG
at O
200 O
mg O
QD O
resulted O
in O
a O
two O
- O
fold O
increase O
in O
celecoxib B-DRUG
plasma O
concentration O
. O
This O
increase O
is O
due O
to O
the O
inhibition O
of O
celecoxib B-DRUG
metabolism O
via O
P450 O
2C9 O
by O
fluconazole B-DRUG
( O
see O
CLINICAL O
PHARMACOLOGY O
- O
Pharmacokinetics O
: O
Metabolism O
) O
. O
CELEBREX B-BRAND
should O
be O
introduced O
at O
the O
lowest O
recommended O
dose O
in O
patients O
receiving O
fluconazole B-DRUG
. O
Lithium B-DRUG
: O
In O
a O
study O
conducted O
in O
healthy O
subjects O
, O
mean O
steady O
- O
state O
lithium B-DRUG
plasma O
levels O
increased O
approximately O
17 O
% O
in O
subjects O
receiving O
lithium B-DRUG
450 O
mg O
BID O
with O
CELEBREX B-BRAND
200 O
mg O
BID O
as O
compared O
to O
subjects O
receiving O
lithium B-DRUG
alone O
. O
Patients O
on O
lithium B-DRUG
treatment O
should O
be O
closely O
monitored O
when O
CELEBREX B-BRAND
is O
introduced O
or O
withdrawn O
. O
Methotrexate B-DRUG
: O
In O
an O
interaction O
study O
of O
rheumatoid O
arthritis O
patients O
taking O
methotrexate B-DRUG
, O
CELEBREX B-BRAND
did O
not O
have O
a O
significant O
effect O
on O
the O
pharmacokinetics O
of O
methotrexate B-DRUG
. O
Warfarin B-DRUG
: O
The O
effect O
of O
celecoxib B-DRUG
on O
the O
anti O
- O
coagulant O
effect O
of O
warfarin B-DRUG
was O
studied O
in O
a O
group O
of O
healthy O
subjects O
receiving O
daily O
doses O
of O
2 O
- O
5 O
mg O
of O
warfarin B-DRUG
. O
In O
these O
subjects O
, O
celecoxib B-DRUG
did O
not O
alter O
the O
anticoagulant O
effect O
of O
warfarin B-DRUG
as O
determined O
by O
prothrombin O
time O
. O
However O
, O
caution O
should O
be O
used O
when O
administering O
CELEBREX B-BRAND
with O
warfarin B-DRUG
since O
these O
patients O
are O
at O
increased O
risk O
of O
bleeding O
complications O
. O

Metformin B-DRUG
: O
In O
healthy O
subjects O
given O
single O
500 O
mg O
doses O
of O
cephalexin B-DRUG
and O
metformin B-DRUG
, O
plasma O
metformin B-DRUG
mean O
cmax O
and O
AUC O
increased O
by O
an O
average O
of O
34 O
% O
and O
24 O
% O
, O
respectively O
, O
and O
metformin B-DRUG
mean O
renal O
clearance O
decreased O
by O
14 O
% O
. O
No O
information O
is O
available O
about O
the O
interaction O
of O
cephalexin B-DRUG
and O
metformin B-DRUG
following O
multiple O
doses O
of O
either O
drug O
. O
Although O
not O
observed O
in O
this O
study O
, O
adverse O
effects O
could O
potentially O
arise O
from O
co O
- O
administration O
of O
cephalexin B-DRUG
and O
metformin B-DRUG
by O
inhibition O
of O
tubular O
secretion O
via O
organic O
cationic O
transporter O
systems O
. O
Accordingly O
, O
careful O
patient O
monitoring O
and O
dose O
adjustment O
of O
metformin B-DRUG
is O
recommended O
in O
patients O
concomitantly O
taking O
cephalexin B-DRUG
and O
metformin B-DRUG
. O
Probenecid B-DRUG
: O
As O
with O
other O
b B-GROUP
- I-GROUP
lactams I-GROUP
, O
the O
renal O
excretion O
of O
cephalexin B-DRUG
is O
inhibited O
by O
probenecid B-DRUG
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
As O
a O
result O
of O
administration O
of O
Keflex B-BRAND
, O
a O
false O
- O
positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
. O
This O
has O
been O
observed O
with O
Benedict O
s O
and O
Fehling O
s O
solutions O
and O
also O
with O
Clinitest O
tablets O
. O

Immunosuppressive B-GROUP
Drugs I-GROUP
, O
Fibric B-GROUP
Acid I-GROUP
Derivatives I-GROUP
, O
Niacin B-DRUG
( O
Nicotinic B-DRUG
Acid I-DRUG
, O
Erythromycin B-DRUG
, O
Azole B-GROUP
Antifungals I-GROUP
: O
Skeletal O
Muscle O
. O
ANTACID B-GROUP
( O
Magnesium B-DRUG
- I-DRUG
Aluminum I-DRUG
Hydroxide I-DRUG
) O
: O
Cerivastatin B-DRUG
plasma O
concentrations O
were O
not O
affected O
by O
co O
- O
administration O
of O
antacid B-GROUP
. O
CIMETlDINE B-DRUG
: O
Cerivastatin B-DRUG
plasma O
concentrations O
were O
not O
affected O
by O
co O
- O
administration O
of O
cimetidine B-DRUG
. O
CHOLESTYRAMINE B-DRUG
: O
The O
influence O
of O
the O
bile O
- O
acidsequestering O
agent O
cholestyramine B-DRUG
on O
the O
pharmacokinetits O
of O
cerivastatin B-DRUG
sodium I-DRUG
was O
evaluated O
in O
12 O
healthy O
males O
in O
2 O
separate O
randomized O
crossover O
studies O
. O
In O
the O
first O
study O
, O
concomitant O
administration O
of O
0 O
. O
2 O
mg O
cerivastatin B-DRUG
sodium I-DRUG
and O
12 O
g O
cholestyramine B-DRUG
resulted O
in O
decreases O
of O
more O
than O
22 O
% O
for O
AUC O
and O
40 O
% O
for O
Cmax O
when O
compared O
to O
dosing O
cerivastatin B-DRUG
sodium I-DRUG
alone O
. O
However O
, O
in O
the O
second O
study O
, O
administration O
of O
12 O
g O
cholestyramine B-DRUG
1 O
hour O
before O
the O
evening O
meal O
and O
0 O
. O
3 O
mg O
cerivastatin B-DRUG
sodium I-DRUG
approximately O
4 O
hours O
after O
the O
same O
evening O
meal O
resulted O
in O
a O
decrease O
in O
the O
cerivastatin B-DRUG
AUC O
of O
less O
than O
8 O
% O
, O
and O
a O
decrease O
in O
Cmax O
of O
about O
30 O
% O
when O
compared O
to O
dosing O
cerivastatin B-DRUG
sodium I-DRUG
alone O
. O
Therefore O
, O
it O
would O
be O
expected O
that O
a O
dosing O
schedule O
of O
cerivastatin B-DRUG
sodium I-DRUG
given O
at O
bedtime O
and O
cholestyramine B-DRUG
given O
before O
the O
evening O
meal O
would O
not O
result O
in O
a O
significant O
decrease O
in O
the O
clinical O
effect O
of O
cerivastatin B-DRUG
sodium I-DRUG
. O
DIGOXIN B-DRUG
: O
Plasma O
digoxin B-DRUG
levels O
and O
digoxin B-DRUG
clearance O
at O
steady O
- O
state O
were O
not O
affected O
by O
co O
- O
administration O
of O
0 O
. O
2 O
mg O
cerivastatin B-DRUG
sodium I-DRUG
. O
Cerivastatin B-DRUG
plasma O
concentrations O
were O
also O
not O
affected O
by O
co O
- O
administration O
of O
digoxin B-DRUG
. O
WARFARIN B-DRUG
: O
Co O
- O
administration O
of O
warfarin B-DRUG
and O
cerivastatin B-DRUG
to O
healthy O
volunteers O
did O
not O
result O
in O
any O
changes O
in O
prothrombin O
time O
or O
clotting O
factor O
VII O
when O
compared O
to O
co O
- O
administration O
of O
warfarin B-DRUG
and O
placebo O
. O
The O
AUC O
and O
Cmax O
of O
both O
the O
( O
R O
) O
and O
( O
S O
) O
isomers O
of O
warfarin B-DRUG
were O
unaffected O
by O
concurrent O
dosing O
of O
0 O
. O

3 O
mg O
cerivastatin B-DRUG
sodium I-DRUG
. O
Co O
- O
administration O
of O
warfarin B-DRUG
and O
cerivastatin B-DRUG
did O
not O
alter O
the O
pharmacokinetics O
of O
cerivastatin B-DRUG
sodium I-DRUG
. O
ERYTHROMYCIN B-DRUG
: O
In O
hypercholesterolemic O
patients O
, O
steady O
- O
state O
cerivastatin B-DRUG
AUC O
and O
Cmax O
increased O
approximately O
50 O
% O
and O
24 O
% O
respectively O
after O
10 O
days O
with O
co O
- O
administration O
of O
erythromycin B-DRUG
, O
a O
known O
inhibitor O
of O
cytochrome O
P450 O
3A4 O
. O
OTHER O
CONCOMITANT O
THERAPY O
: O
Although O
specific O
interaction O
studies O
were O
not O
performed O
, O
in O
clinical O
studies O
, O
cerivastatin B-DRUG
sodium I-DRUG
was O
used O
concomitantly O
with O
angiotensin B-GROUP
- I-GROUP
converting I-GROUP
enzyme I-GROUP
( I-GROUP
ACE I-GROUP
) I-GROUP
inhibitors I-GROUP
, O
betablockers B-GROUP
, O
calcium B-GROUP
- I-GROUP
channel I-GROUP
blockers I-GROUP
, O
diuretics B-GROUP
, O
and O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
( O
NSAIDs B-GROUP
) O
without O
evidence O
of O
clinically O
significant O
adverse O
interactions O
. O

Pharmacokinetic O
interaction O
studies O
with O
cetirizine B-DRUG
in O
adults O
were O
conducted O
with O
pseudoephedrine B-DRUG
, O
antipyrine B-DRUG
, O
ketoconazole B-DRUG
, O
erythromycin B-DRUG
and O
azithromycin B-DRUG
. O
No O
interactions O
were O
observed O
. O
In O
a O
multiple O
dose O
study O
of O
theophylline B-DRUG
( O
400 O
mg O
once O
daily O
for O
3 O
days O
) O
and O
cetirizine B-DRUG
( O
20 O
mg O
once O
daily O
for O
3 O
days O
) O
, O
a O
16 O
% O
decrease O
in O
the O
clearance O
of O
cetirizine B-DRUG
was O
observed O
. O
The O
disposition O
of O
theophylline B-DRUG
was O
not O
altered O
by O
concomitant O
cetirizine B-DRUG
administration O
. O
Drug O
- O
Drug O
Interactions O
: O
No O
clinically O
significant O
drug O
interactions O
have O
been O
found O
with O
theophylline B-DRUG
at O
a O
low O
dose O
, O
azithromycin B-DRUG
, O
pseudoephedrine B-DRUG
, O
ketoconazole B-DRUG
, O
or O
erythromycin B-DRUG
. O
There O
was O
a O
small O
decrease O
in O
the O
clearance O
of O
cetirizine B-DRUG
caused O
by O
a O
400 O
- O
mg O
dose O
of O
theophylline B-DRUG
; O
it O
is O
possible O
that O
larger O
theophylline B-DRUG
doses O
could O
have O
a O
greater O
effect O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
with O
Cetrotide B-BRAND
. O

A O
drug O
interaction O
study O
was O
performed O
in O
which O
ERBITUX B-BRAND
was O
administered O
in O
combination O
with O
irinotecan B-DRUG
. O
There O
was O
no O
evidence O
of O
any O
pharmacokinetic O
interactions O
between O
ERBITUX B-BRAND
and O
irinotecan B-DRUG
. O

Cevimeline B-DRUG
should O
be O
administered O
with O
caution O
to O
patients O
taking O
beta B-GROUP
adrenergic I-GROUP
antagonists I-GROUP
, O
because O
of O
the O
possibility O
of O
conduction O
disturbances O
. O
Drugs O
with O
parasympathomimetic O
effects O
administered O
concurrently O
with O
cevimeline B-DRUG
can O
be O
expected O
to O
have O
additive O
effects O
. O
Cevimeline B-DRUG
might O
interfere O
with O
desirable O
antimuscarinic O
effects O
of O
drugs O
used O
concomitantly O
. O
Drugs O
which O
inhibit O
CYP2D6 O
and O
CYP3A3 O
/ O
4 O
also O
inhibit O
the O
metabolism O
of O
cevimeline B-DRUG
. O
Cevimeline B-DRUG
should O
be O
used O
with O
caution O
in O
individuals O
known O
or O
suspected O
to O
be O
deficient O
in O
CYP2D6 O
activity O
, O
based O
on O
previous O
experience O
, O
as O
they O
may O
be O
at O
a O
higher O
risk O
of O
adverse O
events O
. O
In O
an O
in O
vitro O
study O
, O
cytochrome O
P450 O
isozymes O
1A2 O
, O
2A6 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
2E1 O
, O
and O
3A4 O
were O
not O
inhibited O
by O
exposure O
to O
cevimeline B-DRUG
. O

There O
are O
no O
known O
drug O
/ O
drug O
interactions O
with O
chlorambucil B-DRUG
. O

Although O
clinical O
studies O
have O
not O
established O
a O
cause O
and O
effect O
relationship O
, O
physicians O
should O
be O
aware O
that O
variable O
effects O
an O
blood O
coagulation O
have O
been O
reported O
very O
rarely O
in O
patients O
receiving O
oral O
anticoagulants B-GROUP
and O
chlordiazepoxide B-DRUG
. O
The O
concomitant O
use O
of O
alcohol B-DRUG
or O
other O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressants I-GROUP
may O
have O
an O
additive O
effect O
. O

The O
administration O
of O
local O
anesthetic B-GROUP
solutions I-GROUP
containing O
epinephrine B-DRUG
or O
norepinephrine B-DRUG
to O
patients O
receiving O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
, O
tricyclic B-GROUP
antidepressants I-GROUP
or O
phenothiazines B-GROUP
may O
produce O
severe O
, O
prolonged O
hypotension O
or O
hypertension O
. O
Concurrent O
use O
of O
these O
agents O
should O
generally O
be O
avoided O
. O
In O
situations O
when O
concurrent O
therapy O
is O
necessary O
, O
careful O
patient O
monitoring O
is O
essential O
. O
Concurrent O
administration O
of O
vasopressor B-GROUP
drugs I-GROUP
( O
for O
the O
treatment O
of O
hypotension O
related O
to O
obstetric O
blocks O
) O
and O
ergot B-GROUP
- I-GROUP
type I-GROUP
oxytocic I-GROUP
drugs I-GROUP
may O
cause O
severe O
, O
persistent O
hypertension O
or O
cerebrovascular O
accidents O
. O
The O
para O
- O
aminobenzoic O
acid O
metabolite O
of O
chloroprocaine O
inhibits O
the O
action O
of O
sulfonamides B-GROUP
. O
Therefore O
, O
chloroprocaine B-DRUG
should O
not O
be O
used O
in O
any O
condition O
in O
which O
a O
sulfonamide B-GROUP
drug I-GROUP
is O
being O
employed O
. O

Antacids B-GROUP
and O
kaolin B-DRUG
: O
Antacids B-GROUP
and O
kaolin B-DRUG
can O
reduce O
absorption O
of O
chloroquine B-DRUG
; O
an O
interval O
of O
at O
least O
4 O
hours O
between O
intake O
of O
these O
agents O
and O
chloroquine B-DRUG
should O
be O
observed O
. O
Cimetidine B-DRUG
: O
Cimetidine B-DRUG
can O
inhibit O
the O
metabolism O
of O
chloroquine B-DRUG
, O
increasing O
its O
plasma O
level O
. O
Concomitant O
use O
of O
cimetidine B-DRUG
should O
be O
avoided O
. O
Ampicillin B-DRUG
: O
In O
a O
study O
of O
healthy O
volunteers O
, O
chloroquine B-DRUG
significantly O
reduced O
the O
bioavailability O
of O
ampicillin B-DRUG
. O
An O
interval O
of O
at O
least O
two O
hours O
between O
intake O
of O
this O
agent O
and O
chloroquine B-DRUG
should O
be O
observed O
. O
Cyclosporin B-DRUG
: O
After O
introduction O
of O
chloroquine B-DRUG
( O
oral O
form O
) O
, O
a O
sudden O
increase O
in O
serum O
cyclosporin B-DRUG
level O
has O
been O
reported O
. O
Therefore O
, O
close O
monitoring O
of O
serum O
cyclosporin B-DRUG
level O
is O
recommended O
and O
, O
if O
necessary O
, O
chloroquine B-DRUG
should O
be O
discontinued O
. O

When O
given O
concurrently O
the O
following O
drugs O
may O
interact O
with O
thiazide B-GROUP
diuretics I-GROUP
. O
- O
Alcohol B-DRUG
, O
barbiturates B-GROUP
, O
or O
narcotics B-GROUP
: O
Potentiation O
of O
otthostatic O
hypotension O
may O
occur O
. O
- O
Antidiabetic B-GROUP
drugs I-GROUP
: O
( O
Oral O
agents O
and O
insulin B-DRUG
) O
Dosage O
adjustment O
of O
the O
antidiabetic B-GROUP
drug I-GROUP
may O
be O
required O
. O
- O
Other O
antihypertensive B-GROUP
drugs I-GROUP
: O
Additive O
effect O
or O
potentiation O
. O
- O
Cholestyramine B-DRUG
and O
colestipol B-DRUG
resins B-GROUP
: O
Cholestytamine B-DRUG
and O
colestipol B-DRUG
resins B-GROUP
have O
the O
potential O
of O
binding O
thiazide B-GROUP
diuretics I-GROUP
and O
reducing O
diuretic B-GROUP
absorption O
from O
the O
gastrointestinal O
tract O
. O
- O
Corticosteroids B-GROUP
, O
ACTH B-DRUG
: O
Intensified O
electrolyte O
depletion O
, O
particularly O
hypokalemia O
. O
- O
Pressor O
amines O
( O
e O
. O
g O
. O
, O
norepinephrine B-DRUG
) O
: O
Possible O
decreased O
response O
to O
pressor O
amines O
but O
not O
sufficient O
to O
preclude O
their O
use O
. O
- O
Skeletal B-GROUP
muscle I-GROUP
relaxants I-GROUP
, O
nondepolarizing O
( O
e O
. O
g O
. O
, O
tubocurarine B-DRUG
) O
: O
Possible O
increased O
responsiveness O
to O
the O
muscle B-GROUP
relaxant I-GROUP
. O
- O
Lithium B-DRUG
: O
Generally O
should O
not O
be O
given O
with O
diuretics B-GROUP
. O
Diuretic B-GROUP
agents I-GROUP
reduce O
the O
renal O
clearance O
of O
lithium B-DRUG
and O
add O
a O
high O
risk O
of O
lithium B-DRUG
toxicity O
. O
Refer O
to O
the O
package O
insert O
for O
lithium B-DRUG
preparations O
before O
use O
of O
such O
preparations O
with O
chlorothiazide B-DRUG
. O
- O
Non B-GROUP
- I-GROUP
steroidal I-GROUP
Anti I-GROUP
- I-GROUP
inflammatory I-GROUP
Drugs I-GROUP
: O
In O
some O
patients O
, O
the O
administration O
of O
a O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agent I-GROUP
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop B-GROUP
, I-GROUP
potassium I-GROUP
- I-GROUP
sparing I-GROUP
and I-GROUP
thiazide I-GROUP
diuretics I-GROUP
. O
Therefore O
, O
when O
chlorothiazide B-DRUG
and O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-GROUP
is O
obtained O
. O
- O
Drug O
/ O
Laboratory O
Test O
Interactions O
: O
Thiazides B-GROUP
should O
be O
discontinued O
before O
carrying O
out O
tests O
for O
parathyroid O
function O
. O

Chlorotrianisene B-DRUG
may O
interact O
with O
antidepressants B-GROUP
, O
aspirin B-BRAND
, O
barbiturates B-GROUP
, O
bromocriptine B-DRUG
, O
calcium B-DRUG
supplements O
, O
corticosteroids B-GROUP
, O
corticotropin B-DRUG
, O
cyclosporine B-DRUG
, O
dantrolene B-DRUG
, O
nicotine B-DRUG
, O
somatropin B-DRUG
, O
tamoxifen B-DRUG
, O
and O
warfarin B-DRUG
. O

May O
interact O
with O
skin O
products O
or O
shampoos O
for O
dandruff O
or O
psoriasis O
. O

Substrate O
of O
CYP2D6 O
( O
minor O
) O
, O
3A4 O
( O
major O
) O
; O
Inhibits O
CYP2D6 O
( O
weak O
) O
. O
Increased O
toxicity O
( O
CNS O
depression O
) O
: O
CNS B-GROUP
depressants I-GROUP
, O
MAO B-GROUP
inhibitors I-GROUP
, O
tricyclic B-GROUP
antidepressants I-GROUP
, O
phenothiazines B-GROUP
. O
CYP3A4 O
inhibitors O
: O
May O
increase O
the O
levels O
/ O
effects O
of O
chlorpheniramine B-DRUG
. O
Example O
inhibitors O
include O
azole B-GROUP
antifungals I-GROUP
, O
ciprofloxacin B-DRUG
, O
clarithromycin B-DRUG
, O
diclofenac B-DRUG
, O
doxycycline B-DRUG
, O
erythromycin B-DRUG
, O
imatinib B-DRUG
, O
isoniazid B-DRUG
, O
nefazodone B-DRUG
, O
nicardipine B-DRUG
, O
propofol B-DRUG
, O
protease B-GROUP
inhibitors I-GROUP
, O
quinidine B-DRUG
, O
and O
verapamil B-DRUG
. O

The O
concurrent O
use O
of O
two O
or O
more O
drugs O
with O
anticholinergic O
activity O
- O
- O
such O
as O
an O
antipsychotic B-GROUP
drug I-GROUP
( O
eg O
, O
chlorpromazine B-DRUG
) O
, O
an O
antiparkinsonian B-GROUP
drug I-GROUP
( O
eg O
, O
trihexyphenidyl B-DRUG
) O
, O
and O
/ O
or O
a O
tricyclic B-GROUP
antidepressant I-GROUP
( O
eg O
, O
amitriptyline B-DRUG
) O
- O
- O
commonly O
results O
in O
excessive O
anticholinergic O
effects O
, O
including O
dry O
mouth O
and O
associated O
dental O
complications O
, O
blurred O
vision O
, O
and O
, O
in O
patients O
exposed O
to O
high O
temperature O
and O
humidity O
, O
hyperpyrexia O
. O
Interactions O
may O
also O
occur O
with O
the O
following O
: O
anti B-GROUP
- I-GROUP
depressants I-GROUP
/ O
anti B-GROUP
- I-GROUP
anxiety I-GROUP
drugs I-GROUP
, O
drugs O
used O
to O
treat O
an O
overactive O
thyroid O
, O
beta B-GROUP
- I-GROUP
blockers I-GROUP
( O
e O
. O
g O
. O
, O
propranolol B-DRUG
) O
, O
sparfloxacin B-DRUG
, O
grepafloxacin B-DRUG
, O
guanethidine B-DRUG
, O
guanadrel B-DRUG
, O
metrizamide B-DRUG
, O
cabergoline B-DRUG
, O
lithium B-DRUG
, O
narcotic B-GROUP
pain O
medication O
( O
e O
. O
g O
. O
, O
codeine B-DRUG
) O
, O
drugs O
used O
to O
aid O
sleep O
, O
drowsiness O
- O
causing O
antihistamines B-GROUP
( O
e O
. O
g O
. O
, O
diphenhydramine B-DRUG
) O
, O
any O
other O
drugs O
that O
may O
make O
you O
drowsy O
. O

The O
hypoglycemic O
action O
of O
sulfonylurea B-GROUP
may O
be O
potentiated O
by O
certain O
drugs O
including O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
and O
other O
drugs O
that O
are O
highly O
protein O
bound O
, O
salicylates B-GROUP
, O
sulfonamides B-GROUP
, O
chloramphenicol B-DRUG
, O
probenecid B-DRUG
, O
coumarins B-GROUP
, O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
, O
and O
beta B-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
. O
When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
DIABINESE B-BRAND
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O
When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
DIABINESE B-BRAND
, O
the O
patient O
should O
be O
observed O
closely O
for O
loss O
of O
control O
. O
Certain O
drugs O
tend O
to O
produce O
hyperglycemia O
and O
may O
lead O
to O
loss O
of O
control O
. O
These O
drugs O
include O
the O
thiazides B-GROUP
and O
other O
diuretics B-GROUP
, O
corticosteroids B-GROUP
, O
phenothiazines B-GROUP
, O
thyroid O
products O
, O
estrogens B-GROUP
, O
oral O
contraceptives B-GROUP
, O
phenytoin B-DRUG
, O
nicotinic B-DRUG
acid I-DRUG
, O
sympathomimetics B-GROUP
, O
calcium B-GROUP
channel I-GROUP
blocking I-GROUP
drugs I-GROUP
, O
and O
isoniazid B-DRUG
. O
When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
DIABINESE B-BRAND
, O
the O
patient O
should O
be O
closely O
observed O
for O
loss O
of O
control O
. O
When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
DIABINESE B-BRAND
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O
Since O
animal O
studies O
suggest O
that O
the O
action O
of O
barbiturates B-GROUP
may O
be O
prolonged O
by O
therapy O
with O
chlorpropamide B-DRUG
, O
barbiturates B-GROUP
should O
be O
employed O
with O
caution O
. O
In O
some O
patients O
, O
a O
disulfiram B-DRUG
- O
like O
reaction O
may O
be O
produced O
by O
the O
ingestion O
of O
alcohol B-DRUG
. O
A O
potential O
interaction O
between O
oral O
miconazole B-DRUG
and O
oral O
hypoglycemic B-GROUP
agents I-GROUP
leading O
to O
severe O
hypoglycemia O
has O
been O
reported O
. O
Whether O
this O
interaction O
also O
occurs O
with O
the O
intravenous O
, O
topical O
, O
or O
vaginal O
preparations O
of O
miconazole B-DRUG
is O
not O
known O
. O

Chlorprothixene B-DRUG
may O
increase O
the O
plasma O
- O
level O
of O
concomitantly O
given O
lithium B-DRUG
. O
In O
order O
to O
avoid O
lithium B-DRUG
intoxication O
, O
lithium B-DRUG
plasma O
levels O
should O
be O
monitored O
closely O
. O
If O
chlorprothixene B-DRUG
is O
given O
concomitantly O
with O
opioids B-GROUP
, O
the O
opioid B-GROUP
dose O
should O
be O
reduced O
( O
by O
approx O
. O
50 O
% O
) O
, O
because O
chlorprothixene B-DRUG
amplifies O
the O
therapeutic O
actions O
and O
side O
- O
effects O
of O
opioids B-GROUP
massively O
. O
Avoid O
the O
concomitant O
use O
of O
chlorprothixene B-DRUG
and O
tramadol B-DRUG
( O
Ultram B-BRAND
) O
. O
Massive O
seizures O
may O
be O
encountered O
with O
this O
combination O
. O
Consider O
additive O
sedative O
effects O
and O
confusional O
states O
to O
emerge O
, O
if O
chlorprothixene B-DRUG
is O
given O
with O
benzodiazepines B-GROUP
or O
barbituates B-GROUP
. O
Choose O
particular O
low O
doses O
of O
these O
drugs O
. O
Exert O
particular O
caution O
in O
combining O
chlorprothixene B-DRUG
with O
other O
anticholinergic B-GROUP
drugs I-GROUP
( O
tricyclic B-GROUP
antidepressants I-GROUP
and O
antiparkinsonian B-GROUP
agents I-GROUP
) O
: O
Particularly O
the O
elderly O
may O
develop O
delirium O
, O
high O
fever O
, O
severe O
obstipation O
, O
even O
ileus O
and O
glaucoma O
. O

Chlorthalidone B-DRUG
may O
add O
to O
or O
potentiate O
the O
action O
of O
other O
antihypertensive B-GROUP
drugs I-GROUP
. O
Potentiation O
occurs O
with O
ganglionic B-GROUP
peripheral I-GROUP
adrenergic I-GROUP
blocking I-GROUP
drugs I-GROUP
. O
Medication O
such O
as O
digitalis B-GROUP
may O
also O
influence O
serum O
electrolytes O
. O
Warning O
signs O
, O
irrespective O
of O
cause O
, O
are O
: O
dryness O
of O
mouth O
, O
thirst O
, O
weakness O
, O
lethargy O
, O
drowsiness O
, O
restlessness O
, O
muscle O
pains O
or O
cramps O
, O
muscular O
fatigue O
, O
hypotension O
, O
oliguria O
, O
tachycardia O
, O
and O
gastrointestinal O
disturbances O
such O
as O
nausea O
and O
vomiting O
. O
Insulin B-DRUG
requirements O
in O
diabetic O
patients O
may O
be O
increased O
, O
decreased O
, O
or O
unchanged O
. O
Higher O
dosage O
of O
oral O
hypoglycemic B-GROUP
agents I-GROUP
may O
be O
required O
. O
Latent O
diabetes O
mellitus O
may O
become O
manifest O
during O
chlorthalidone B-DRUG
administration O
. O
Chlorthalidone B-DRUG
and O
related O
drugs O
may O
increase O
the O
responsiveness O
to O
tubocurarine B-DRUG
. O
Chlorthalidone B-DRUG
and O
related O
drugs O
may O
decrease O
arterial O
responsiveness O
to O
norepinephrine B-DRUG
. O
This O
diminution O
is O
not O
sufficient O
to O
preclude O
effectiveness O
of O
the O
pressor O
agent O
for O
therapeutic O
use O
. O

The O
concomitant O
use O
of O
alcohol B-DRUG
or O
other O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressants I-GROUP
may O
have O
an O
additive O
effect O
. O

Interactions O
for O
vitamin B-GROUP
D I-GROUP
analogues O
( O
Vitamin B-DRUG
D2 I-DRUG
, O
Vitamin B-DRUG
D3 I-DRUG
, O
Calcitriol B-DRUG
, O
and O
Calcidiol B-DRUG
) O
: O
Cholestyramine B-DRUG
: O
Cholestyramine B-DRUG
has O
been O
reported O
to O
reduce O
intestinal O
absorption O
of O
fat B-GROUP
soluble I-GROUP
vitamins I-GROUP
; O
as O
such O
it O
may O
impair O
intestinal O
absorption O
of O
any O
of O
vitamin B-GROUP
D I-GROUP
. O
Phenytoin B-DRUG
/ O
Phenobarbital B-DRUG
: O
The O
coadministration O
of O
phenytoin B-DRUG
or O
phenobarbital B-DRUG
will O
not O
affect O
plasma O
concentrations O
of O
vitamin B-GROUP
D I-GROUP
, O
but O
may O
reduce O
endogenous O
plasma O
levels O
of O
calcitriol B-DRUG
/ O
ergocalcitriol O
by O
accelerating O
metabolism O
. O
Since O
blood O
level O
of O
calcitriol B-DRUG
/ O
ergocalcitriol O
will O
be O
reduced O
, O
higher O
doses O
of O
Rocaltrol B-BRAND
may O
be O
necessary O
if O
these O
drugs O
are O
administered O
simultaneously O
. O
Thiazides B-GROUP
: O
Thiazides B-GROUP
are O
known O
to O
induce O
hypercalcemia O
by O
the O
reduction O
of O
calcium O
excretion O
in O
urine O
. O
Some O
reports O
have O
shown O
that O
the O
concomitant O
administration O
of O
thiazides B-GROUP
with O
vitamin B-GROUP
D I-GROUP
causes O
hypercalcemia O
. O
Therefore O
, O
precaution O
should O
be O
taken O
when O
coadministration O
is O
necessary O
. O
Digitalis B-GROUP
: O
Vitamin B-GROUP
D I-GROUP
dosage O
must O
be O
determined O
with O
care O
in O
patients O
undergoing O
treatment O
with O
digitalis B-GROUP
, O
as O
hypercalcemia O
in O
such O
patients O
may O
precipitate O
cardiac O
arrhythmias O
. O
Ketoconazole B-DRUG
: O
Ketoconazole B-DRUG
may O
inhibit O
both O
synthetic O
and O
catabolic O
enzymes O
of O
vitamin B-GROUP
D I-GROUP
. O
Reductions O
in O
serum O
endogenous O
vitamin O
D O
concentrations O
have O
been O
observed O
following O
the O
administration O
of O
300 O
mg O
/ O
day O
to O
1200 O
mg O
/ O
day O
ketoconazole B-DRUG
for O
a O
week O
to O
healthy O
men O
. O
However O
, O
in O
vivo O
drug O
interaction O
studies O
of O
ketoconazole B-DRUG
with O
vitamin B-GROUP
D I-GROUP
have O
not O
been O
investigated O
. O
Corticosteroids B-GROUP
: O
A O
relationship O
of O
functional O
antagonism O
exists O
between O
vitamin B-GROUP
D I-GROUP
analogues O
, O
which O
promote O
calcium O
absorption O
, O
and O
corticosteroids B-GROUP
, O
which O
inhibit O
calcium O
absorption O
. O
Phosphate O
- O
Binding O
Agents O
: O
Since O
vitamin B-GROUP
D I-GROUP
also O
has O
an O
effect O
on O
phosphate O
transport O
in O
the O
intestine O
, O
kidneys O
and O
bones O
, O
the O
dosage O
of O
phosphate O
- O
binding O
agents O
must O
be O
adjusted O
in O
accordance O
with O
the O
serum O
phosphate O
concentration O
. O
Vitamin B-GROUP
D I-GROUP
: O
The O
coadministration O
of O
any O
of O
the O
vitamin B-GROUP
D I-GROUP
analogues O
should O
be O
avoided O
as O
this O
could O
create O
possible O
additive O
effects O
and O
hypercalcemia O
. O
Calcium B-DRUG
Supplements O
: O

Uncontrolled O
intake O
of O
additional O
calcium B-DRUG
- O
containing O
preparations O
should O
be O
avoided O
. O
Magnesium B-DRUG
: O
Magnesium B-DRUG
- O
containing O
preparations O
( O
eg O
, O
antacids B-GROUP
) O
may O
cause O
hypermagnesemia O
and O
should O
therefore O
not O
be O
taken O
during O
therapy O
with O
vitamin B-GROUP
D I-GROUP
by O
patients O
on O
chronic O
renal O
dialysis O
. O

Cholestyramine B-DRUG
resin B-GROUP
may O
delay O
or O
reduce O
the O
absorption O
of O
concomitant O
oral O
medication O
such O
as O
phenylbutazone B-GROUP
, O
warfarin B-DRUG
, O
thiazide B-GROUP
diuretics I-GROUP
( O
acidic O
) O
or O
propranolol B-DRUG
( O
basic O
) O
, O
as O
well O
as O
tetracycline B-DRUG
penicillin B-DRUG
G I-DRUG
, O
phenobarbital B-DRUG
, O
thyroid O
and O
thyroxine B-DRUG
preparations O
, O
estrogens B-GROUP
and O
progestins B-GROUP
, O
and O
digitalis B-GROUP
. O
Interference O
with O
the O
absorption O
of O
oral O
phosphate B-DRUG_N
supplements O
has O
been O
observed O
with O
another O
positively O
- O
charged O
bile O
acid O
sequestrant O
. O
Cholestyramine B-DRUG
resin B-GROUP
may O
interfere O
with O
the O
pharmacokinetics O
of O
drugs O
that O
undergo O
enterohepatic O
circulation O
, O
The O
discontinuance O
of O
cholestyramine B-DRUG
resin B-GROUP
could O
pose O
a O
hazard O
to O
health O
if O
a O
potentially O
toxic O
drug O
such O
as O
digitalis B-GROUP
has O
been O
filtrated O
to O
a O
maintenance O
level O
while O
the O
patient O
was O
taking O
cholestyramine B-DRUG
resin B-GROUP
. O
Because O
cholestyramine B-DRUG
binds O
bile O
acids O
, O
cholestyramine B-DRUG
resin B-GROUP
may O
interfere O
with O
normal O
fat O
digestion O
and O
absorption O
and O
thus O
may O
prevent O
absorption O
of O
fat B-GROUP
soluble I-GROUP
vitamins I-GROUP
such O
as O
A O
, O
D O
, O
E O
, O
and O
K O
. O
When O
cholestyramine B-DRUG
resin B-GROUP
is O
given O
for O
long O
periods O
of O
time O
, O
concomitant O
supplementation O
with O
water O
- O
miscible O
( O
or O
parenteral O
) O
forms O
of O
fat B-GROUP
- I-GROUP
soluble I-GROUP
vitamins I-GROUP
should O
be O
considered O
. O
SINCE O
CHOLESTYRAMINE B-DRUG
RESIN B-GROUP
MAY O
BIND O
OTHER O
DRUGS O
GIVEN O
CONCURRENTLY O
, O
IT O
IS O
RECOMMENDED O
THAT O
PATIENTS O
TAKE O
OTHER O
DRUGS O
AT O
LEAST O
1 O
HOUR O
BEFORE O
OR O
4 O
TO O
6 O
HOURS O
AFTER O
CHOLESTYRAMINE B-DRUG
RESIN B-GROUP
( O
OR O
AT O
AS O
GREAT O
AN O
INTERVAL O
AS O
POSSIBLE O
) O
TO O
AVOID O
IMPEDING O
THEIR O
ABSORPTION O
. O

Based O
on O
in O
vitro O
studies O
in O
human O
liver O
microsomes O
, O
des B-DRUG
- I-DRUG
ciclesonide I-DRUG
appears O
to O
have O
no O
inhibitory O
or O
induction O
potential O
on O
the O
metabolism O
of O
other O
drugs O
metabolized O
by O
CYP O
450 O
enzymes O
. O
The O
inhibitory O
potential O
of O
ciclesonide B-DRUG
on O
CYP450 O
isoenzymes O
has O
not O
been O
studied O
. O
In O
vitro O
studies O
demonstrated O
that O
the O
plasma O
protein O
binding O
of O
des B-DRUG
- I-DRUG
ciclesonide I-DRUG
was O
not O
affected O
by O
warfarin B-DRUG
or O
salicylic B-DRUG
acid I-DRUG
, O
indicating O
no O
potential O
for O
protein O
binding O
- O
based O
drug O
interactions O
. O
In O
a O
drug O
interaction O
study O
, O
co O
- O
administration O
of O
orally O
inhaled O
ciclesonide B-DRUG
and O
oral O
erythromycin B-DRUG
, O
an O
inhibitor O
of O
cytochrome O
P450 O
3A4 O
, O
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
either O
des B-DRUG
- I-DRUG
ciclesonide I-DRUG
or O
erythromycin B-DRUG
. O
In O
another O
drug O
interaction O
study O
, O
co O
- O
administration O
of O
orally O
inhaled O
ciclesonide B-DRUG
and O
oral O
ketoconazole B-DRUG
, O
a O
potent O
inhibitor O
of O
cytochrome O
P450 O
3A4 O
, O
increased O
the O
exposure O
( O
AUC O
) O
of O
des B-DRUG
- I-DRUG
ciclesonide I-DRUG
by O
approximately O
3 O
. O
6 O
- O
fold O
at O
steady O
state O
, O
while O
levels O
of O
ciclesonide B-DRUG
remained O
unchanged O
. O
Therefore O
, O
ketoconazole B-DRUG
should O
be O
administered O
with O
caution O
with O
intranasal O
ciclesonide B-DRUG
. O

Probenecid B-DRUG
: O
Probenecid B-DRUG
is O
known O
to O
interact O
with O
the O
metabolism O
or O
renal O
tubular O
excretion O
of O
many O
drugs O
( O
e O
. O
g O
. O
, O
acetaminophen B-DRUG
, O
acyclovir B-DRUG
, O
angiotensin B-GROUP
- I-GROUP
converting I-GROUP
enzyme I-GROUP
inhibitors I-GROUP
, O
aminosalicylic B-DRUG
acid I-DRUG
, O
barbiturates B-GROUP
, O
benzodiazepines B-GROUP
, O
bumetanide B-DRUG
, O
clofibrate B-DRUG
, O
methotrexate B-DRUG
, O
famotidine B-DRUG
, O
furosemide B-DRUG
, O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents O
, O
theophylline B-DRUG
, O
and O
zidovudine B-DRUG
) O
. O
Concomitant O
medications O
should O
be O
carefully O
assessed O
. O
Zidovudine B-DRUG
should O
either O
be O
temporarily O
discontinued O
or O
decreased O
by O
50 O
% O
when O
coadministered O
with O
probenecid B-DRUG
on O
the O
day O
of O
VISTIDE B-BRAND
infusion O
. O
Nephrotoxic O
agents O
: O
Concomitant O
administration O
of O
VISTIDE B-BRAND
and O
agents O
with O
nephrotoxic O
potential O
[ O
e O
. O
g O
. O
, O
intravenous O
aminoglycosides B-GROUP
( O
e O
. O
g O
. O
, O
tobramycin B-DRUG
, O
gentamicin B-DRUG
, O
and O
amikacin B-DRUG
) O
, O
amphotericin B-DRUG
B I-DRUG
, O
foscarnet B-DRUG
, O
intravenous O
pentamidine B-DRUG
, O
vancomycin B-DRUG
, O
and O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
] O
is O
contraindicated O
. O
Such O
agents O
must O
be O
discontinued O
at O
least O
seven O
days O
prior O
to O
starting O
therapy O
with O
VISTIDE B-BRAND
. O

Since O
PLETAL B-BRAND
is O
extensively O
metabolized O
by O
cytochrome O
P O
- O
450 O
isoenzymes O
, O
caution O
should O
be O
exercised O
when O
PLETAL B-BRAND
is O
coadministered O
with O
inhibitors O
of O
C O
. O
P O
. O
A O
. O
such O
as O
ketoconazole B-DRUG
and O
erythromycin B-DRUG
or O
inhibitors O
of O
CYP2C19 O
such O
as O
omeprazole B-DRUG
. O
Pharmacokinetic O
studies O
have O
demonstrated O
that O
omeprazole B-DRUG
and O
erythromycin B-DRUG
significantly O
increased O
the O
systemic O
exposure O
of O
cilostazol B-DRUG
and O
/ O
or O
its O
major O
metabolites O
. O
Population O
pharmacokinetic O
studies O
showed O
higher O
concentrations O
of O
cilostazol B-DRUG
among O
patients O
concurrently O
treated O
with O
diltiazem B-DRUG
, O
an O
inhibitor O
of O
C O
. O
P O
. O
A O
. O
. O
Pletal B-BRAND
does O
not O
, O
however O
, O
appear O
to O
cause O
increased O
blood O
levels O
of O
drugs O
metabolized O
by O
CYP3A4 O
, O
as O
it O
had O
no O
effect O
on O
lovastatin B-DRUG
, O
a O
drug O
with O
metabolism O
very O
sensitive O
to O
C O
. O
P O
. O
A O
. O
inhibition O
. O

Tagamet B-BRAND
, O
apparently O
through O
an O
effect O
on O
certain O
microsomal O
enzyme O
systems O
, O
has O
been O
reported O
to O
reduce O
the O
hepatic O
metabolism O
of O
warfarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
, O
phenytoin B-DRUG
, O
propranolol B-DRUG
, O
nifedipine B-DRUG
, O
chlordiazepoxide B-DRUG
, O
diazepam B-DRUG
, O
certain O
tricyclic B-GROUP
antidepressants I-GROUP
, O
lidocaine B-DRUG
, O
theophylline B-DRUG
and O
metronidazole B-DRUG
, O
thereby O
delaying O
elimination O
and O
increasing O
blood O
levels O
of O
these O
drugs O
. O
Clinically O
significant O
effects O
have O
been O
reported O
with O
the O
warfarin B-GROUP
anticoagulants I-GROUP
; O
therefore O
, O
close O
monitoring O
of O
prothrombin O
time O
is O
recommended O
, O
and O
adjustment O
of O
the O
anticoagulant B-GROUP
dose O
may O
be O
necessary O
when O
Tagamet B-BRAND
is O
administered O
concomitantly O
. O
Interaction O
with O
phenytoin B-DRUG
, O
lidocaine B-DRUG
and O
theophylline B-DRUG
has O
also O
been O
reported O
to O
produce O
adverse O
clinical O
effects O
. O
However O
, O
a O
crossover O
study O
in O
healthy O
subjects O
receiving O
either O
Tagamet B-BRAND
300 O
mg O
q O
. O
i O
. O
d O
. O
or O
800 O
mg O
h O
. O
s O
. O
concomitantly O
with O
a O
300 O
mg O
b O
. O
i O
. O
d O
. O
dosage O
of O
theophylline B-DRUG
( O
Theo B-BRAND
- I-BRAND
Dur I-BRAND
, O
Key O
Pharmaceuticals O
, O
Inc O
. O
) O
demonstrated O
less O
alteration O
in O
steady O
- O
state O
theophylline B-DRUG
peak O
serum O
levels O
with O
the O
800 O
mg O
h O
. O
s O
. O
regimen O
, O
particularly O
in O
subjects O
aged O
54 O
years O
and O
older O
. O
Data O
beyond O
10 O
days O
are O
not O
available O
. O
( O
Note O
: O
All O
patients O
receiving O
theophylline B-DRUG
should O
be O
monitored O
appropriately O
, O
regardless O
of O
concomitant O
drug O
therapy O
. O
) O
Dosage O
of O
the O
drugs O
mentioned O
above O
and O
other O
similarly O
metabolized O
drugs O
, O
particularly O
those O
of O
low O
therapeutic O
ratio O
or O
in O
patients O
with O
renal O
and O
/ O
or O
hepatic O
impairment O
, O
may O
require O
adjustment O
when O
starting O
or O
stopping O
concomitantly O
administered O
Tagamet B-BRAND
to O
maintain O
optimum O
therapeutic O
blood O
levels O
. O
Alteration O
of O
pH O
may O
affect O
absorption O
of O
certain O
drugs O
( O
e O
. O
g O
. O
, O
ketoconazole B-DRUG
) O
. O
If O
these O
products O
are O
needed O
, O
they O
should O
be O
given O
at O
least O
2 O
hours O
before O
cimetidine B-DRUG
administration O
. O
Additional O
clinical O
experience O
may O
reveal O
other O
drugs O
affected O
by O
the O
concomitant O
administration O
of O
Tagamet B-BRAND
. O

and O
/ O
or O
Drug O
/ O
Laboratory O
Test O
Interactions O
See O
CLINICAL O
PHARMACOLOGY O
, O
Pharmacokinetics O
and O
Drug O
Interactions O
. O
Effect O
of O
Sensipar B-BRAND
on O
other O
drugs O
: O
Drugs O
metabolized O
by O
cytochrome O
P450 O
2D6 O
( O
CYP2D6 O
) O
: O
Sensipar B-BRAND
is O
a O
strong O
in O
vitro O
inhibitor O
of O
CYP2D6 O
. O
Therefore O
, O
dose O
adjustments O
of O
concomitant O
medications O
that O
are O
predominantly O
metabolized O
by O
CYP2D6 O
and O
have O
a O
narrow O
therapeutic O
index O
( O
e O
. O
g O
. O
, O
flecainide B-DRUG
, O
vinblastine B-DRUG
, O
thioridazine B-DRUG
and O
most O
tricyclic B-GROUP
antidepressants I-GROUP
) O
may O
be O
required O
. O
Amitriptyline B-DRUG
: O
Concurrent O
administration O
of O
25 O
mg O
or O
100 O
mg O
cinacalcet B-DRUG
with O
50 O
mg O
amitriptyline B-DRUG
increased O
amitriptyline B-DRUG
exposure O
and O
nortriptyline B-DRUG_N
( O
active O
metabolite O
) O
exposure O
by O
approximately O
20 O
% O
in O
CYP2D6 O
extensive O
metabolizers O
. O
Effect O
of O
other O
drugs O
on O
Sensipar B-BRAND
: O
Sensipar B-BRAND
is O
metabolized O
by O
multiple O
cytochrome O
P450 O
enzymes O
, O
primarily O
CYP3A4 O
, O
CYP2D6 O
, O
and O
CYP1A2 O
. O
Ketoconazole B-DRUG
: O
Sensipar B-BRAND
is O
metabolized O
in O
part O
by O
CYP3A4 O
. O
Co O
- O
administration O
of O
ketoconazole B-DRUG
, O
a O
strong O
inhibitor O
of O
CYP3A4 O
, O
increased O
cinacalcet B-DRUG
exposure O
following O
a O
single O
90 O
mg O
dose O
of O
Sensipar B-BRAND
by O
2 O
. O
3 O
fold O
. O
Dose O
adjustment O
of O
Sensipar B-BRAND
may O
be O
required O
and O
PTH O
and O
serum O
calcium O
concentrations O
should O
be O
closely O
monitored O
if O
a O
patient O
initiates O
or O
discontinues O
therapy O
with O
a O
strong O
CYP3A4 O
inhibitor O
( O
e O
. O
g O
. O
, O
ketoconazole B-DRUG
, O
erythromycin B-DRUG
, O
itraconazole B-DRUG
; O
see O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

Elevated O
plasma O
levels O
of O
theophylline B-DRUG
have O
been O
reported O
with O
concomitant O
use O
of O
some O
quinolones B-GROUP
. O
There O
have O
been O
reports O
of O
theophylline B-DRUG
- O
related O
side O
- O
effects O
in O
patients O
on O
concomitant O
theophylline B-DRUG
- O
quinolone B-GROUP
therapy O
. O
Therefore O
, O
monitoring O
of O
theophylline B-DRUG
plasma O
levels O
should O
be O
considered O
and O
dosage O
of O
theophylline B-DRUG
adjusted O
as O
required O
. O
Quinolones B-GROUP
have O
also O
been O
shown O
to O
interfere O
with O
the O
metabolism O
of O
caffeine B-DRUG
. O
This O
may O
lead O
to O
reduced O
clearance O
of O
caffeine B-DRUG
and O
a O
prolongation O
of O
its O
plasma O
half O
- O
life O
. O
Although O
this O
interaction O
has O
not O
been O
reported O
with O
cinoxacin B-DRUG
, O
caution O
should O
be O
exercised O
when O
cinoxacin B-DRUG
is O
given O
concomitantly O
with O
caffeine B-DRUG
- O
containing O
products O
. O
Antacids B-GROUP
or O
sucralfate B-DRUG
substantially O
interfere O
with O
the O
absorption O
of O
some O
quinolones B-GROUP
, O
resulting O
in O
low O
urine O
levels O
. O
Also O
, O
concomitant O
administration O
of O
quinolones B-GROUP
with O
products O
containing O
iron B-DRUG
, O
multivitamins B-GROUP
containing O
zinc B-DRUG
, O
or O
Videx B-BRAND
( O
didanosine B-DRUG
) O
chewable O
/ O
buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
may O
result O
in O
low O
urine O
levels O
. O
Quinolones B-GROUP
, O
including O
cinoxacin B-DRUG
, O
may O
enhance O
the O
effects O
of O
oral O
anticoagulants B-GROUP
, O
such O
as O
warfarin B-DRUG
or O
its O
derivatives O
. O
When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
time O
or O
other O
suitable O
coagulation O
tests O
should O
be O
closely O
monitored O
. O
Seizures O
have O
been O
reported O
in O
patients O
taking O
another O
quinolone B-GROUP
class I-GROUP
antimicrobial I-GROUP
and O
the O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drug I-GROUP
fenbufen B-DRUG
concurrently O
. O
Animal O
studies O
also O
suggest O
an O
increased O
potential O
for O
seizures O
when O
these O
2 O
drugs O
are O
given O
concomitantly O
. O
Fenbufen B-DRUG
is O
not O
approved O
in O
the O
United O
States O
at O
this O
time O
. O
Physicians O
are O
provided O
this O
information O
to O
increase O
awareness O
of O
the O
potential O
for O
serious O
interactions O
when O
cinoxacin B-DRUG
and O
certain O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
are O
administered O
concomitantly O
. O
Elevated O
cyclosporine B-DRUG
serum O
levels O
have O
been O
reported O
with O
the O
concomitant O
use O
of O
quinolones B-GROUP
and O
cyclosporine B-DRUG
. O

Some O
quinolones B-GROUP
, O
including O
ciprofloxacin B-DRUG
, O
have O
also O
been O
shown O
to O
interfere O
with O
the O
metabolism O
of O
caffeine B-DRUG
. O
This O
may O
lead O
to O
reduced O
clearance O
of O
caffeine B-DRUG
and O
a O
prolongation O
of O
its O
serum O
half O
- O
life O
. O
Some O
quinolones B-GROUP
, O
including O
ciprofloxacin B-DRUG
, O
have O
been O
associated O
with O
transient O
elevations O
in O
serum O
creatinine O
in O
patients O
receiving O
cyclosporine B-DRUG
concomitantly O
. O
Glyburide B-DRUG
: O
The O
concomitant O
administration O
of O
ciprofloxacin B-DRUG
with O
the O
sulfonylurea B-GROUP
glyburide B-DRUG
has O
, O
on O
rare O
occasions O
, O
resulted O
in O
severe O
hypoglycemia O
. O
Histamine B-GROUP
H2 I-GROUP
- I-GROUP
receptor I-GROUP
antagonists I-GROUP
: O
Histamine B-GROUP
H2 I-GROUP
- I-GROUP
receptor I-GROUP
antagonists I-GROUP
appear O
to O
have O
no O
significant O
effect O
on O
the O
bioavailability O
of O
ciprofloxacin B-DRUG
. O
Methotrexate B-DRUG
Renal O
tubular O
transport O
of O
methotrexate B-DRUG
may O
be O
inhibited O
by O
concomitant O
administration O
of O
ciprofloxacin B-DRUG
, O
potentially O
leading O
to O
increased O
plasma O
levels O
of O
methotrexate B-DRUG
. O
This O
might O
increase O
the O
risk O
of O
methotrexate B-DRUG
toxic O
reactions O
. O
Therefore O
, O
patients O
under O
methotrexate B-DRUG
therapy O
should O
be O
carefully O
monitored O
when O
concomitant O
ciprofloxacin B-DRUG
therapy O
is O
indicated O
. O
Multivalent O
Cation O
- O
Containing O
Products O
: O
Concurrent O
administration O
of O
a O
quinolone B-GROUP
, O
including O
ciprofloxacin B-DRUG
, O
with O
multivalent O
cation O
- O
containing O
products O
such O
as O
magnesium B-DRUG
or O
aluminum B-DRUG
antacids B-GROUP
, O
sucralfate B-DRUG
, O
VIDEX B-BRAND
chewable O
/ O
buffered O
tablets O
or O
pediatric O
powder O
, O
or O
products O
containing O
calcium B-DRUG
, O
iron B-DRUG
, O
or O
zinc B-DRUG
may O
substantially O
decrease O
the O
absorption O
of O
ciprofloxacin B-DRUG
, O
resulting O
in O
serum O
and O
urine O
levels O
considerably O
lower O
than O
desired O
. O
Proquin B-BRAND
XR I-BRAND
should O
be O
administered O
at O
least O
4 O
hours O
before O
or O
2 O
hours O
after O
these O
products O
. O
This O
time O
window O
is O
different O
than O
for O
other O
oral O
formulations O
of O
ciprofloxacin B-DRUG
, O
which O
are O
usually O
administered O
2 O
hours O
before O
or O
6 O
hours O
after O
antacids B-GROUP
. O
Non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
( O
but O
not O
aspirin B-BRAND
) O
: O
These O
drugs O
in O
combination O
with O
very O
high O
doses O
of O
quinolones B-GROUP
have O
been O
shown O
to O
provoke O
convulsions O
in O
pre O
- O
clinical O
studies O
. O
Omeprazole B-DRUG
: O
The O
rate O
and O
extent O
of O
absorption O
of O
ciprofloxacin B-DRUG
was O
bioequivalent O
when O
Proquin B-BRAND
XR I-BRAND
was O
given O
alone O
or O
when O
Proquin B-BRAND
XR I-BRAND

was O
given O
2 O
hours O
after O
omeprazole B-DRUG
at O
the O
dose O
that O
maximally O
suppresses O
gastric O
acid O
secretion O
. O
Omeprazole B-DRUG
should O
be O
taken O
as O
directed O
and O
Proquin B-BRAND
XR I-BRAND
should O
be O
taken O
with O
a O
main O
meal O
of O
the O
day O
, O
preferably O
the O
evening O
meal O
. O
. O
Phenytoin B-DRUG
: O
Altered O
serum O
levels O
of O
phenytoin B-DRUG
( O
increased O
and O
decreased O
) O
have O
been O
reported O
in O
patients O
receiving O
concomitant O
ciprofloxacin B-DRUG
. O
Probenecid B-DRUG
: O
Probenecid B-DRUG
interferes O
with O
renal O
tubular O
secretion O
of O
ciprofloxacin B-DRUG
and O
produces O
an O
increase O
in O
the O
level O
of O
ciprofloxacin B-DRUG
in O
serum O
. O
Theophylline B-DRUG
: O
As O
with O
some O
other O
quinolones B-GROUP
, O
concurrent O
administration O
of O
ciprofloxacin B-DRUG
with O
theophylline B-DRUG
may O
lead O
to O
elevated O
serum O
concentrations O
of O
theophylline B-DRUG
and O
prolongation O
of O
its O
elimination O
half O
- O
life O
. O
This O
may O
result O
in O
increased O
risk O
of O
theophylline B-DRUG
- O
related O
adverse O
reactions O
. O
If O
concomitant O
use O
cannot O
be O
avoided O
, O
serum O
levels O
of O
theophylline B-DRUG
should O
be O
monitored O
and O
dosage O
adjustments O
made O
as O
appropriate O
. O
Warfarin B-DRUG
: O
Quinolones B-GROUP
have O
been O
reported O
to O
enhance O
the O
effects O
of O
the O
oral O
anticoagulant B-GROUP
warfarin B-DRUG
or O
its O
derivatives O
. O
When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
time O
or O
other O
suitable O
coagulation O
tests O
should O
be O
monitored O
. O

Cisapride B-DRUG
is O
metabolized O
mainly O
via O
the O
cytochrome O
P450 O
3A4 O
enzyme O
. O
In O
some O
cases O
where O
serious O
ventricular O
arrhythmias O
, O
QT O
prolongation O
, O
and O
torsades O
de O
pointes O
have O
occurred O
when O
cisapride B-DRUG
was O
taken O
in O
conjunction O
with O
one O
of O
the O
cytochrome O
P450 O
3A4 O
inhibitors O
, O
elevated O
blood O
cisapride B-DRUG
levels O
were O
noted O
at O
the O
time O
of O
the O
QT O
prolongation O
. O
Antibiotics B-GROUP
: O
In O
vitro O
and O
/ O
or O
in O
vivo O
data O
show O
that O
clarithromycin B-DRUG
, O
erythromycin B-DRUG
, O
and O
troleandomycin B-DRUG
markedly O
inhibit O
the O
metabolism O
of O
cisapride B-DRUG
, O
which O
can O
result O
in O
an O
increase O
in O
plasma O
cisapride B-DRUG
levels O
and O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O
Anticholinergics B-GROUP
: O
Concurrent O
administration O
of O
certain O
anticholinergic B-GROUP
compounds I-GROUP
, O
such O
as O
belladonna B-GROUP
alkaloids I-GROUP
and O
dicyclomine B-DRUG
, O
would O
be O
expected O
to O
compromise O
the O
beneficial O
effects O
of O
cisapride B-DRUG
. O
Anticoagulants B-GROUP
( O
Oral O
) O
: O
In O
patients O
receiving O
oral O
anticoagulants B-GROUP
, O
the O
coagulation O
times O
were O
increased O
in O
some O
cases O
. O
It O
is O
advisable O
to O
check O
coagulation O
time O
within O
the O
first O
few O
days O
after O
the O
start O
and O
discontinuation O
of O
cisapride B-DRUG
therapy O
, O
with O
an O
appropriate O
adjustment O
of O
the O
anticoagulant B-GROUP
dose O
, O
if O
necessary O
. O
Antidepressants B-GROUP
: O
In O
vitro O
data O
indicate O
that O
nefazodone B-DRUG
inhibits O
the O
metabolism O
of O
cisapride B-DRUG
, O
which O
can O
result O
in O
an O
increase O
in O
plasma O
cisapride B-DRUG
levels O
and O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O
Antifungals B-GROUP
: O
In O
vitro O
and O
/ O
or O
in O
vivo O
data O
indicate O
that O
fluconazole B-DRUG
, O
itraconazole B-DRUG
, O
and O
oral O
ketoconazole B-DRUG
markedly O
inhibit O
the O
metabolism O
of O
cisapride B-DRUG
, O
which O
can O
result O
in O
an O
increase O
in O
plasma O
cisapride B-DRUG
levels O
and O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O
Human O
pharmacokinetic O
data O
indicate O
that O
oral O
ketoconazole B-DRUG
markedly O
inhibits O
the O
metabolism O
of O
cisapride B-DRUG
, O
resulting O
in O
a O
mean O
eight O
- O
fold O
increase O
in O
AUC O
of O
cisapride B-DRUG
. O
A O
study O
in O
14 O
normal O
male O
and O
female O
volunteers O
suggests O
that O
coadministration O
of O
cisapride B-DRUG
and O
ketoconazole B-DRUG
can O
result O
in O
prolongation O
of O
the O
QT O
interval O
on O
the O

ECG O
. O
H2 B-GROUP
Receptor I-GROUP
Antagonists I-GROUP
: O
Cimetidine B-DRUG
coadministration O
leads O
to O
an O
increased O
peak O
plasma O
concentration O
and O
AUC O
of O
cisapride B-DRUG
, O
there O
is O
no O
effect O
on O
cisapride B-DRUG
absorption O
when O
it O
is O
coadministered O
with O
ranitidine B-DRUG
. O
The O
gastrointestinal O
absorption O
of O
cimetidine B-DRUG
and O
ranitidine B-DRUG
is O
accelerated O
when O
they O
are O
coadministered O
with O
cisapride B-DRUG
. O
Protease B-GROUP
Inhibitors I-GROUP
: O
In O
vitro O
data O
indicate O
that O
indinavir B-DRUG
and O
ritonavir B-DRUG
markedly O
inhibit O
the O
metabolism O
of O
cisapride B-DRUG
which O
can O
result O
in O
an O
increase O
in O
plasma O
cisapride B-DRUG
levels O
and O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O
Other O
: O
Coadministration O
of O
grapefruit O
juice O
with O
cisapride B-DRUG
increases O
the O
bioavailability O
of O
cisapride B-DRUG
and O
concomitant O
use O
should O
be O
avoided O
. O
Cisapride B-DRUG
should O
not O
be O
used O
concomitantly O
with O
other O
drugs O
known O
to O
prolong O
the O
QT O
interval O
: O
certain O
antiarrhythmics B-GROUP
, O
including O
those O
of O
Class O
IA O
( O
such O
as O
quinidine B-DRUG
and O
procainamide B-DRUG
) O
and O
Class O
III O
( O
such O
as O
sotalol B-DRUG
) O
; O
tricyclic B-GROUP
antidepressants I-GROUP
( O
such O
as O
amitriptyline B-DRUG
) O
; O
certain O
tetracyclic B-GROUP
antidepressants I-GROUP
( O
such O
as O
maprotiline B-DRUG
) O
; O
certain O
antipsychotic B-GROUP
medications I-GROUP
( O
such O
as O
sertindole B-DRUG
) O
; O
astemizole B-DRUG
, O
bepridil B-DRUG
, O
sparfloxacin B-DRUG
, O
and O
terodiline B-DRUG
. O
The O
preceding O
lists O
of O
drugs O
are O
not O
comprehensive O
. O
The O
acceleration O
of O
gastric O
emptying O
by O
cisapride B-DRUG
could O
affect O
the O
rate O
of O
absorption O
of O
other O
drugs O
. O
Patients O
receiving O
narrow O
therapeutic O
ratio O
drugs O
or O
other O
drugs O
that O
require O
careful O
titration O
should O
be O
followed O
closely O
; O
if O
plasma O
levels O
are O
being O
monitored O
, O
they O
should O
be O
reassessed O
. O

Administration O
of O
0 O
. O
1 O
- O
mg O
/ O
kg O
( O
2 O
x O
ED95 O
) O
NIMBEX B-BRAND
at O
10 O
% O
or O
95 O
% O
recovery O
following O
an O
intubating O
dose O
of O
succinylcholine B-DRUG
( O
1 O
mg O
/ O
kg O
) O
produced O
95 O
% O
neuromuscular O
block O
. O
The O
time O
to O
onset O
of O
maximum O
block O
following O
NIMBEX B-BRAND
is O
approximately O
2 O
minutes O
faster O
with O
prior O
administration O
of O
succinylcholine B-DRUG
. O
Prior O
administration O
of O
succinylcholine B-DRUG
had O
no O
effect O
on O
the O
duration O
of O
neuromuscular O
block O
following O
initial O
or O
maintenance O
bolus O
doses O
of O
NIMBEX B-BRAND
. O
Infusion O
requirements O
of O
NIMBEX B-BRAND
in O
patients O
administered O
succinylcholine B-DRUG
prior O
to O
infusions O
of O
NIMBEX B-BRAND
were O
comparable O
to O
or O
slightly O
greater O
than O
when O
succinylcholine B-DRUG
was O
not O
administered O
. O
The O
use O
of O
NIMBEX B-BRAND
before O
succinylcholine B-DRUG
to O
attenuate O
some O
of O
the O
side O
effects O
of O
succinylcholine B-DRUG
has O
not O
been O
studied O
. O
Although O
not O
studied O
systematically O
in O
clinical O
trials O
, O
no O
drug O
interactions O
were O
observed O
when O
vecuronium B-DRUG
, O
pancuronium B-DRUG
, O
or O
atracurium B-DRUG
were O
administered O
following O
varying O
degrees O
of O
recovery O
from O
single O
doses O
or O
infusions O
of O
NIMBEX B-BRAND
. O
Isoflurane B-DRUG
or O
enflurane B-DRUG
administered O
with O
nitrous B-DRUG
oxide I-DRUG
/ O
oxygen B-DRUG
to O
achieve O
1 O
. O
25 O
MAC O
[ O
Minimum O
Alveolar O
Concentration O
] O
may O
prolong O
the O
clinically O
effective O
duration O
of O
action O
of O
initial O
and O
maintenance O
doses O
of O
NIMBEX B-BRAND
and O
decrease O
the O
required O
infusion O
rate O
of O
NIMBEX B-BRAND
. O
The O
magnitude O
of O
these O
effects O
may O
depend O
on O
the O
duration O
of O
administration O
of O
the O
volatile O
agents O
. O
Fifteen O
to O
30 O
minutes O
of O
exposure O
to O
1 O
. O
25 O
MAC O
isoflurane B-DRUG
or O
enflurane B-DRUG
had O
minimal O
effects O
on O
the O
duration O
of O
action O
of O
initial O
doses O
of O
NIMBEX B-BRAND
and O
therefore O
, O
no O
adjustment O
to O
the O
initial O
dose O
should O
be O
necessary O
when O
NIMBEX B-BRAND
is O
administered O
shortly O
after O
initiation O
of O
volatile O
agents O
. O
In O
long O
surgical O
procedures O
during O
enflurane B-DRUG
or O
isoflurane B-DRUG
anesthesia O
, O
less O
frequent O
maintenance O
dosing O
, O
lower O
maintenance O
doses O
, O
or O
reduced O
infusion O
rates O
of O
NIMBEX B-BRAND
may O
be O
necessary O
. O
The O
average O
infusion O
rate O
requirement O
may O
be O
decreased O
by O
as O
much O
as O
30 O
% O
to O
40 O
% O
. O
In O
clinical O
studies O
propofol B-DRUG
had O
no O
effect O
on O
the O
duration O
of O
action O
or O
dosing O
requirements O
for O
NIMBEX B-BRAND
. O
Other O
drugs O
which O
may O
enhance O
the O
neuromuscular O
blocking O
action O
of O
nondepolarizing B-GROUP
agents I-GROUP
such O
as O
NIMBEX B-BRAND
include O
certain O
antibiotics B-GROUP
( O
e O
. O

g O
. O
, O
aminoglycosides B-GROUP
, O
tetracyclines B-GROUP
, O
bacitracin B-DRUG
, O
polymyxins B-GROUP
, O
lincomycin B-DRUG
, O
clindamycin B-DRUG
, O
colistin B-DRUG
, O
and O
sodium B-DRUG
colistemethate I-DRUG
) O
, O
magnesium B-GROUP
salts O
, O
lithium B-DRUG
, O
local O
anesthetics B-GROUP
, O
procainamide B-DRUG
, O
and O
quinidine B-DRUG
. O
Resistance O
to O
the O
neuromuscular O
blocking O
action O
of O
nondepolarizing B-GROUP
neuromuscular I-GROUP
blocking I-GROUP
agents I-GROUP
has O
been O
demonstrated O
in O
patients O
chronically O
administered O
phenytoin B-DRUG
or O
carbamazepine B-DRUG
. O
While O
the O
effects O
of O
chronic O
phenytoin B-DRUG
or O
carbamazepine B-DRUG
therapy O
on O
the O
action O
of O
NIMBEX B-BRAND
are O
unknown O
, O
slightly O
shorter O
durations O
of O
neuromuscular O
block O
may O
be O
anticipated O
and O
infusion O
rate O
requirements O
may O
be O
higher O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
None O
known O
. O

Plasma O
levels O
of O
anticonvulsant B-GROUP
agents I-GROUP
may O
become O
subtherapeutic O
during O
cisplatin B-DRUG
therapy O
. O

Central B-GROUP
nervous I-GROUP
system I-GROUP
depressant I-GROUP
( O
CNS O
) O
drugs O
including O
alcohol B-DRUG
, O
antidepressants B-GROUP
, O
antihistamines B-GROUP
, O
antipsychotics B-GROUP
, O
blood O
pressure O
medications O
( O
reserpine B-DRUG
, O
methyldopa B-DRUG
, O
beta B-GROUP
- I-GROUP
blockers I-GROUP
) O
, O
motion O
sickness O
medications O
, O
muscle B-GROUP
relaxants I-GROUP
, O
narcotics B-GROUP
, O
sedatives B-GROUP
, O
sleeping O
pills O
and O
tranquilizers B-GROUP

There O
are O
no O
known O
drug O
interactions O
with O
LEUSTATIN B-BRAND
Injection O
. O
Caution O
should O
be O
exercised O
if O
LEUSTATIN B-BRAND
Injection O
is O
administered O
before O
, O
after O
, O
or O
in O
conjunction O
with O
other O
drugs O
known O
to O
cause O
immunosuppression O
or O
myelosuppression O
. O

The O
concurrent O
administration O
of O
allopurinol B-DRUG
and O
ampicillin B-DRUG
increases O
substantially O
the O
incidence O
of O
rashes O
in O
patients O
receiving O
both O
drugs O
as O
compared O
to O
patients O
receiving O
ampicillin B-DRUG
alone O
. O
It O
is O
not O
known O
whether O
this O
potentiation O
of O
ampicillin B-DRUG
rashes O
is O
due O
to O
allopurinol B-DRUG
or O
the O
hyperuricemia O
present O
in O
these O
patients O
. O
In O
controlled O
clinical O
trials O
of O
AUGMENTIN B-BRAND
XR I-BRAND
, O
22 O
patients O
received O
concomitant O
allopurinol B-DRUG
and O
AUGMENTIN B-BRAND
XR I-BRAND
. O
No O
rashes O
were O
reported O
in O
these O
patients O
. O
However O
, O
this O
sample O
size O
is O
too O
small O
to O
allow O
for O
any O
conclusions O
to O
be O
drawn O
regarding O
the O
risk O
of O
rashes O
with O
concomitant O
AUGMENTIN B-BRAND
XR I-BRAND
and O
allopurinol B-DRUG
use O
. O
In O
common O
with O
other O
broad B-GROUP
- I-GROUP
spectrum I-GROUP
antibiotics I-GROUP
, O
AUGMENTIN B-BRAND
XR I-BRAND
may O
reduce O
the O
efficacy O
of O
oral O
contraceptives B-GROUP

Additive O
CNS O
depression O
may O
occur O
when O
antihistamines B-GROUP
are O
administered O
concomitantly O
with O
other O
CNS B-GROUP
depressants I-GROUP
including O
barbiturates B-GROUP
, O
tranquilizers B-GROUP
, O
and O
alcohol B-DRUG
. O
Patients O
receiving O
antihistamines B-GROUP
should O
be O
advised O
against O
the O
concurrent O
use O
of O
other O
CNS B-GROUP
depressant I-GROUP
drugs I-GROUP
. O
Monoamine B-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
prolong O
and O
intensify O
the O
anticholinergic O
effects O
of O
antihistamines B-GROUP
. O

Amantadine B-DRUG
, O
tricyclic B-GROUP
antidepressants I-GROUP
, O
and O
MAOIs B-GROUP
may O
increase O
anticholinergic O
effect O
of O
clidinium B-DRUG
. O
Clidinium B-DRUG
may O
decrease O
the O
effect O
of O
phenothiazines B-GROUP
, O
levodopa B-DRUG
, O
and O
ketoconazole B-DRUG
. O

Clindamycin B-DRUG
has O
been O
shown O
to O
have O
neuromuscular O
blocking O
properties O
that O
may O
enhance O
the O
action O
of O
other O
neuromuscular B-GROUP
blocking I-GROUP
agents I-GROUP
. O
Therefore O
, O
it O
should O
be O
used O
with O
caution O
in O
patients O
receiving O
such O
agents O
. O
Antagonism O
has O
been O
demonstrated O
between O
clindamycin B-DRUG
and O
erythromycin B-DRUG
in O
vitro O
. O
Because O
of O
possible O
clinical O
significance O
, O
these O
two O
drugs O
should O
not O
be O
administered O
concurrently O
. O

Alcohol B-DRUG
( O
increases O
bioavailability O
by O
50 O
% O
) O
, O
cimetidine B-DRUG
, O
and O
valproates O
. O

No O
separate O
information O
available O

Although O
no O
clinical O
drug O
- O
drug O
interaction O
studies O
have O
been O
conducted O
to O
date O
, O
on O
the O
basis O
of O
the O
in O
vitro O
studies O
, O
cytochrome O
p450 O
inhibitors O
and O
inducers O
are O
unlikely O
to O
affect O
the O
metabolism O
of O
clofarabine B-DRUG
. O
The O
effect O
of O
clofarabine B-DRUG
on O
the O
metabolism O
of O
cytochrome O
p450 O
substrates O
has O
not O
been O
studied O
. O
Drug O
/ O
Laboratory O
Tests O
Interactions O
There O
are O
no O
known O
clinically O
significant O
interactions O
of O
CLOLAR B-BRAND
with O
other O
medications O
or O
laboratory O
tests O
. O
No O
formal O
drug O
/ O
laboratory O
test O
interaction O
studies O
have O
been O
conducted O
with O
CLOLAR B-BRAND
. O

Preliminary O
data O
which O
suggest O
that O
dapsone B-DRUG
may O
inhibit O
the O
anti O
- O
inflammatory O
activity O
of O
Lamprene B-BRAND
have O
not O
been O
confirmed O
. O
If O
leprosy O
- O
associated O
inflammatory O
reactions O
develop O
in O
patients O
being O
treated O
with O
dapsone B-DRUG
and O
clofazimine B-DRUG
, O
it O
is O
still O
advisable O
to O
continue O
treatment O
with O
both O
drugs O
. O

Caution O
should O
be O
exercised O
when O
anticoagulants B-GROUP
are O
given O
in O
conjunction O
with O
Atromid B-BRAND
- I-BRAND
S I-BRAND
. O
Usually O
, O
the O
dosage O
of O
the O
anticoagulant B-GROUP
should O
be O
reduced O
by O
one O
- O
half O
( O
depending O
on O
the O
individual O
case O
) O
to O
maintain O
the O
prothrombin O
time O
at O
the O
desired O
level O
to O
prevent O
bleeding O
complications O
. O
Frequent O
prothrombin O
determinations O
are O
advisable O
until O
it O
has O
been O
determined O
definitely O
that O
the O
prothrombin O
level O
has O
been O
stabilized O
. O
Atromid B-BRAND
- I-BRAND
S I-BRAND
may O
displace O
acidic O
drugs O
such O
as O
phenytoin B-DRUG
or O
tolbutamide B-DRUG
from O
their O
binding O
sites O
. O
Caution O
should O
be O
exercised O
when O
treating O
patients O
with O
either O
of O
these O
drugs O
or O
other O
highly O
protein O
- O
bound O
drugs O
and O
Atromid B-BRAND
- I-BRAND
S I-BRAND
. O
The O
hypoglycemic O
effect O
of O
tolbutamide B-DRUG
has O
been O
reported O
to O
increase O
when O
Atromid B-BRAND
- I-BRAND
S I-BRAND
is O
given O
concurrently O
. O
Fulminant O
rhabdomyolysis O
has O
been O
seen O
as O
early O
as O
three O
weeks O
after O
initiation O
of O
combined O
therapy O
with O
another O
fibrate B-GROUP
and O
lovastatin B-DRUG
but O
may O
be O
seen O
after O
several O
months O
. O
For O
these O
reasons O
, O
it O
is O
felt O
that O
, O
in O
most O
subjects O
who O
have O
had O
an O
unsatisfactory O
lipid O
response O
to O
either O
drug O
alone O
, O
the O
possible O
benefits O
of O
combined O
therapy O
with O
lovastatin B-DRUG
and O
a O
fibrate B-GROUP
do O
not O
outweigh O
the O
risks O
of O
severe O
myopathy O
, O
rhabdomyolysis O
, O
and O
acute O
renal O
failure O
. O
While O
it O
is O
not O
known O
whether O
this O
interaction O
occurs O
with O
fibrates B-GROUP
other O
than O
gemfibrozil B-DRUG
, O
myopathy O
and O
rhabdomyolysis O
have O
occasionally O
been O
associated O
with O
the O
use O
of O
fibrates B-GROUP
alone O
, O
including O
clofibrate B-DRUG
. O
Therefore O
, O
the O
combined O
use O
of O
lovastatin B-DRUG
with O
fibrates B-GROUP
should O
generally O
be O
avoided O
. O

Drug O
interactions O
with O
clomiphene B-DRUG
citrate I-DRUG
tablets O
USP O
have O
not O
been O
documented O
. O

The O
risks O
of O
using O
Anafranil B-BRAND
in O
combination O
with O
other O
drugs O
have O
not O
been O
systematically O
evaluated O
. O
Given O
the O
primary O
CNS O
effects O
of O
Anafranil B-BRAND
, O
caution O
is O
advised O
in O
using O
it O
concomitantly O
with O
other O
CNS O
- O
active O
drugs O
. O
Anafranil B-BRAND
should O
not O
be O
used O
with O
MAO B-GROUP
inhibitors I-GROUP
. O
Close O
supervision O
and O
careful O
adjustment O
of O
dosage O
are O
required O
when O
Anafranil B-BRAND
is O
administered O
with O
anticholinergic B-GROUP
or O
sympathomimetic B-GROUP
drugs I-GROUP
. O
Several O
tricyclic B-GROUP
antidepressants I-GROUP
have O
been O
reported O
to O
block O
the O
pharmacologic O
effects O
of O
guanethidine B-DRUG
, O
clonidine B-DRUG
, O
or O
similar O
agents O
, O
and O
such O
an O
effect O
may O
be O
anticipated O
with O
CMI B-DRUG
because O
of O
its O
structural O
similarity O
to O
other O
tricyclic B-GROUP
antidepressants I-GROUP
. O
The O
plasma O
concentration O
of O
CMI B-DRUG
has O
been O
reported O
to O
be O
increased O
by O
the O
concomitant O
administration O
of O
haloperidol B-DRUG
; O
plasma O
levels O
of O
several O
closely O
related O
tricyclic B-GROUP
antidepressants I-GROUP
have O
been O
reported O
to O
be O
increased O
by O
the O
concomitant O
administration O
of O
methylphenidate B-DRUG
or O
hepatic O
enzyme O
inhibitors O
( O
e O
. O
g O
. O
, O
cimetidine B-DRUG
, O
fluoxetine B-DRUG
) O
and O
decreased O
by O
the O
concomitant O
administration O
of O
hepatic O
enzyme O
inducers O
( O
e O
. O
g O
. O
, O
barbiturates B-GROUP
, O
phenytoin B-DRUG
) O
, O
and O
such O
an O
effect O
may O
be O
anticipated O
with O
CMI B-DRUG
as O
well O
. O
Administration O
of O
CMI B-DRUG
has O
been O
reported O
to O
increase O
the O
plasma O
levels O
of O
phenobarbital B-DRUG
, O
if O
given O
concomitantly O
. O
Drugs O
Metabolized O
by O
P450 O
2D6 O
: O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
aucasian O
population O
( O
about O
7 O
% O
- O
10 O
% O
of O
Caucasians O
are O
so O
- O
called O
poor O
metabolizers O
) O
; O
reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O
Poor O
metabolizers O
have O
higher O
than O
expected O
lasma O
concentrations O
of O
tricyclic B-GROUP
antidepressants I-GROUP
( O
TCAs B-GROUP
) O
when O
given O
usual O
doses O
. O
Depending O
on O
the O
fraction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8 O
fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA B-GROUP
) O
. O
In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
poor O

metabolizers O
. O
An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCAmay B-GROUP
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O
The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-DRUG
; O
cimetidine B-DRUG
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-GROUP
, O
phenothiazines B-GROUP
, O
and O
the O
Type B-GROUP
1C I-GROUP
antiarrhythmics I-GROUP
propafenone B-DRUG
and O
flecainide B-DRUG
) O
. O
While O
all O
the O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
( O
SSRIs B-GROUP
) O
, O
e O
. O
g O
. O
, O
fluoxetine B-DRUG
, O
sertraline B-DRUG
, O
paroxetine B-DRUG
, O
and O
fluvoxamine B-DRUG
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O
Fluvoxamine B-DRUG
has O
also O
been O
shown O
to O
inhibit O
P450 O
1A2 O
, O
an O
isoform O
also O
involved O
in O
TCAmetabolism B-GROUP
. O
The O
extent O
to O
which O
SSRI B-GROUP
- O
TCAinteractions B-GROUP
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-GROUP
involved O
. O
Nevertheless O
, O
caution O
is O
indicated O
in O
the O
co O
- O
administration O
of O
TCAs B-GROUP
with O
any O
of O
the O
SSRIs B-GROUP
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O
Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCAtreatment B-GROUP
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-DRUG
, O
given O
the O
long O
half O
- O
life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O
Concomitant O
use O
of O
agents O
in O
the O
tricyclic B-GROUP
antidepressant I-GROUP
class I-GROUP
( O
which O
includes O
Anafranil B-BRAND
) O
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-GROUP
antidepressant I-GROUP
agent I-GROUP
or O
the O
other O
drug O
. O
Furthermore O
, O
whenever O
one O
of O
these O
drugs O
is O
withdrawn O
from O
co O
- O
therapy O
, O
an O
increased O
dose O
of O
tricyclic B-GROUP
antidepressant I-GROUP
agent I-GROUP
may O
be O
required O
. O
It O
is O
desirable O
to O
monitor O
TCAplasma B-GROUP
levels O
whenever O
an O
agent O
of O
the O
tricyclic B-GROUP
antidepressant I-GROUP
class I-GROUP
including O
Anafranil B-BRAND
is O
going O
to O
be O
co O
- O
administered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
( O
and O
/ O
or O
P450 O
1A2 O
) O
. O
Because O
Anafranil B-BRAND
is O
highly O
bound O
to O
serum O
protein O
, O
the O
administration O

of O
Anafranil B-BRAND
to O
patients O
taking O
other O
drugs O
that O
are O
highly O
bound O
to O
protein O
( O
e O
. O
g O
. O
, O
warfarin B-DRUG
, O
digoxin B-DRUG
) O
may O
cause O
an O
increase O
in O
plasma O
concentrations O
of O
these O
drugs O
, O
potentially O
resulting O
in O
adverse O
effects O
. O
Conversely O
, O
adverse O
effects O
may O
result O
from O
displacement O
of O
protein O
- O
bound O
Anafranil B-BRAND
by O
other O
highly O
bound O
drugs O
. O

Effect O
of O
Clonazepam B-DRUG
on O
the O
Pharmacokinetics O
of O
Other O
Drugs O
: O
Clonazepam B-DRUG
does O
not O
appear O
to O
alter O
the O
pharmacokinetics O
of O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
or O
phenobarbital B-DRUG
. O
The O
effect O
of O
clonazepam B-DRUG
on O
the O
metabolism O
of O
other O
drugs O
has O
not O
been O
investigated O
. O
Effect O
of O
Other O
Drugs O
on O
the O
Pharmacokinetics O
of O
Clonazepam B-DRUG
: O
Literature O
reports O
suggest O
that O
ranitidine B-DRUG
, O
an O
agent O
that O
decreases O
stomach O
acidity O
, O
does O
not O
greatly O
alter O
clonazepam B-DRUG
pharmacokinetics O
. O
In O
a O
study O
in O
which O
the O
2 O
mg O
clonazepam B-DRUG
orally O
disintegrating O
tablet O
was O
administered O
with O
and O
without O
propantheline B-DRUG
( O
an O
anticholinergic B-GROUP
agent I-GROUP
with O
multiple O
effects O
on O
the O
GI O
tract O
) O
to O
healthy O
volunteers O
, O
the O
AUC O
of O
clonazepam B-DRUG
was O
10 O
% O
lower O
and O
the O
Cmax O
of O
clonazepam B-DRUG
was O
20 O
% O
lower O
when O
the O
orally O
disintegrating O
tablet O
was O
given O
with O
propantheline B-DRUG
compared O
to O
when O
it O
was O
given O
alone O
. O
Fluoxetine B-DRUG
does O
not O
affect O
the O
pharmacokinetics O
of O
clonazepam B-DRUG
. O
Cytochrome O
P O
- O
450 O
inducers O
, O
such O
as O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
and O
phenobarbital B-DRUG
, O
induce O
clonazepam B-DRUG
metabolism O
, O
causing O
an O
approximately O
30 O
% O
decrease O
in O
plasma O
clonazepam B-DRUG
levels O
. O
Although O
clinical O
studies O
have O
not O
been O
performed O
, O
based O
on O
the O
involvement O
of O
the O
cytochrome O
P O
- O
450 O
3A O
family O
in O
clonazepam B-DRUG
metabolism O
, O
inhibitors O
of O
this O
enzyme O
system O
, O
notably O
oral O
antifungal B-GROUP
agents I-GROUP
, O
should O
be O
used O
cautiously O
in O
patients O
receiving O
clonazepam B-DRUG
. O
Pharmacodynamic O
Interactions O
: O
The O
CNS O
- O
depressant O
action O
of O
the O
benzodiazepine B-GROUP
class I-GROUP
of O
drugs O
may O
be O
potentiated O
by O
alcohol B-DRUG
, O
narcotics B-GROUP
, O
barbiturates B-GROUP
, O
nonbarbiturate B-GROUP
hypnotics I-GROUP
, O
antianxiety B-GROUP
agents I-GROUP
, O
the O
phenothiazines B-GROUP
, I-GROUP
thioxanthene I-GROUP
and I-GROUP
butyrophenone I-GROUP
classes I-GROUP
of I-GROUP
antipsychotic I-GROUP
agents I-GROUP
, O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
and O
the O
tricyclic B-GROUP
antidepressants I-GROUP
, O
and O
by O
other O
anticonvulsant B-GROUP
drugs I-GROUP
. O

Tablet O
If O
a O
patient O
receiving O
clonidine B-DRUG
hydrochloride I-DRUG
is O
also O
taking O
tricyclic B-GROUP
antidepressants I-GROUP
, O
the O
effect O
of O
clonidine B-DRUG
may O
be O
reduced O
, O
thus O
necessitating O
an O
increase O
in O
dosage O
. O
Clonidine B-DRUG
hydrochloride I-DRUG
may O
enhance O
the O
CNS O
- O
depressive O
effects O
of O
alcohol B-DRUG
, O
barbiturates B-GROUP
or O
other O
sedatives B-GROUP
. O
Amitriptyline B-DRUG
in O
combination O
with O
clonidine B-DRUG
enhances O
the O
manifestation O
of O
corneal O
lesions O
in O
rats O
Epidural O
Injection O
Clonidine B-DRUG
may O
potentiate O
the O
CNS O
- O
depressive O
effect O
of O
alcohol B-DRUG
, O
barbiturates B-GROUP
or O
other O
sedating B-GROUP
drugs I-GROUP
. O
Narcotic B-GROUP
analgesics I-GROUP
may O
potentiate O
the O
hypotensive O
effects O
of O
clonidine B-DRUG
. O
Tricyclic B-GROUP
antidepressants I-GROUP
may O
antagonize O
the O
hypotensive O
effects O
of O
clonidine B-DRUG
. O
The O
effects O
of O
tricyclic B-GROUP
antidepressants I-GROUP
on O
clonidines B-DRUG
analgesic O
actions O
are O
not O
known O
. O
Beta B-GROUP
blockers I-GROUP
may O
exacerbate O
the O
hypertensive O
response O
seen O
with O
clonidine B-DRUG
withdrawl O
. O
Also O
, O
due O
to O
the O
potential O
for O
additive O
effects O
such O
as O
bradycardia O
and O
AV O
block O
, O
caution O
is O
warranted O
in O
patients O
receiving O
clonidine B-DRUG
with O
agents O
known O
to O
affect O
sinus O
node O
function O
or O
AV O
nodal O
conduction O
( O
e O
. O
g O
. O
, O
digitalis B-GROUP
, O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
, O
and O
beta B-GROUP
- I-GROUP
blockers I-GROUP
. O
) O
There O
is O
one O
reported O
case O
of O
a O
patient O
with O
acute O
delirium O
associated O
with O
the O
simultaneous O
use O
of O
fluphenazine B-DRUG
and O
oral O
clonidine B-DRUG
. O
Symptoms O
resolved O
when O
clonidine B-DRUG
was O
withdrawn O
and O
recurred O
when O
the O
patient O
was O
rechallenged O
with O
clonidine B-DRUG
. O
Epidural O
clonidine B-DRUG
may O
prolong O
the O
duration O
of O
pharmacologic O
effects O
of O
epidural O
local O
anesthetics B-GROUP
, O
including O
both O
sensory O
and O
motor O
blockade O
. O

Aspirin B-BRAND
, O
warfarin B-DRUG
, O
heparin B-DRUG
, O
NSAIDs B-GROUP

If O
TRANXENE B-BRAND
is O
to O
be O
combined O
with O
other O
drugs O
acting O
on O
the O
central O
nervous O
system O
, O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
the O
agents O
to O
be O
employed O
. O
Animal O
experience O
indicates O
that O
clorazepate B-DRUG
dipotassium I-DRUG
prolongs O
the O
sleeping O
time O
after O
hexobarbital B-DRUG
or O
after O
ethyl B-DRUG
alcohol I-DRUG
, O
increases O
the O
inhibitory O
effects O
of O
chlorpromazine B-DRUG
, O
but O
does O
not O
exhibit O
monoamine O
oxidase O
inhibition O
. O
Clinical O
studies O
have O
shown O
increased O
sedation O
with O
concurrent O
hypnotic B-GROUP
medications I-GROUP
. O
The O
actions O
of O
the O
benzodiazepines B-GROUP
may O
be O
potentiated O
by O
barbiturates B-GROUP
, O
narcotics B-GROUP
, O
phenothiazines B-GROUP
, O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
or O
other O
antidepressants B-GROUP
. O
If O
TRANXENE B-BRAND
tablets O
are O
used O
to O
treat O
anxiety O
associated O
with O
somatic O
disease O
states O
, O
careful O
attention O
must O
be O
paid O
to O
possible O
drug O
interaction O
with O
concomitant O
medication O
. O
In O
bioavailability O
studies O
with O
normal O
subjects O
, O
the O
concurrent O
administration O
of O
antacids B-GROUP
at O
therapeutic O
levels O
did O
not O
significantly O
influence O
the O
bioavailability O
of O
TRANXENE B-BRAND
tablets O
. O

The O
risks O
of O
using O
Clozapine B-DRUG
in O
combination O
with O
other O
drugs O
have O
not O
been O
systematically O
evaluated O
. O
Pharmacodynamic O
- O
related O
Interactions O
: O
The O
mechanism O
of O
Clozapine B-DRUG
induced O
agranulocytosis O
is O
unknown O
; O
nonetheless O
, O
the O
possibility O
that O
causative O
factors O
may O
interact O
synergistically O
to O
increase O
the O
risk O
and O
/ O
or O
severity O
of O
bone O
marrow O
suppression O
warrants O
consideration O
. O
Therefore O
, O
Clozapine B-DRUG
should O
not O
be O
used O
with O
other O
agents O
having O
a O
well O
- O
known O
potential O
to O
suppress O
bone O
marrow O
function O
. O
Given O
the O
primary O
CNS O
effects O
of O
Clozapine B-DRUG
, O
caution O
is O
advised O
in O
using O
it O
concomitantly O
with O
other O
CNS O
- O
active O
drugs O
or O
alcohol B-DRUG
. O
Orthostatic O
hypotension O
in O
patients O
taking O
clozapine B-DRUG
can O
, O
in O
rare O
cases O
( O
approximately O
1 O
case O
per O
3 O
, O
000 O
patients O
) O
, O
be O
accompanied O
by O
profound O
collapse O
and O
respiratory O
and O
/ O
or O
cardiac O
arrest O
. O
Some O
of O
the O
cases O
of O
collapse O
/ O
respiratory O
arrest O
/ O
cardiac O
arrest O
during O
initial O
treatment O
occurred O
in O
patients O
who O
were O
being O
administered O
benzodiazepines B-GROUP
; O
similar O
events O
have O
been O
reported O
in O
patients O
taking O
other O
psychotropic B-GROUP
drugs I-GROUP
or O
even O
Clozapine B-DRUG
by O
itself O
. O
Although O
it O
has O
not O
been O
established O
that O
there O
is O
an O
interaction O
between O
Clozapine B-DRUG
and O
benzodiazepines B-GROUP
or O
other O
psychotropics B-GROUP
, O
caution O
is O
advised O
when O
clozapine B-DRUG
is O
initiated O
in O
patients O
taking O
a O
benzodiazepine B-GROUP
or O
any O
other O
psychotropic B-GROUP
drug I-GROUP
. O
Clozapine B-DRUG
may O
potentiate O
the O
hypotensive O
effects O
of O
antihypertensive B-GROUP
drugs I-GROUP
and O
the O
anticholinergic O
effects O
of O
atropine B-DRUG
- O
type O
drugs O
. O
The O
administration O
of O
epinephrine B-DRUG
should O
be O
avoided O
in O
the O
treatment O
of O
drug O
induced O
hypotension O
because O
of O
a O
possible O
reverse O
epinephrine B-DRUG
effect O
. O
Pharmacokinetic O
- O
related O
Interactions O
: O
Clozapine B-DRUG
is O
a O
substrate O
for O
many O
CYP O
450 O
isozymes O
, O
in O
particular O
1A2 O
, O
2D6 O
, O
and O
3A4 O
. O
The O
risk O
of O
metabolic O
interactions O
caused O
by O
an O
effect O
on O
an O
individual O
isoform O
is O
therefore O
minimized O
. O
Nevertheless O
, O
caution O
should O
be O
used O
in O
patients O
receiving O
concomitant O
treatment O
with O
other O
drugs O
that O
are O
either O
inhibitors O
or O
inducers O
of O
these O
enzymes O
. O
Concomitant O
administration O
of O
drugs O
known O
to O
induce O
cytochrome O
P450 O
enzymes O
may O
decrease O
the O
plasma O
levels O
of O
clozapine B-DRUG
. O
Phenytoin B-DRUG
, O
nicotine B-DRUG
, O
and O
rifampin B-DRUG
may O
decrease O
Clozapine B-DRUG
plasma O
levels O
, O
resulting O
in O
a O
decrease O
in O
effectiveness O
of O
a O

previously O
effective O
Clozapine B-DRUG
dose O
. O
Concomitant O
administration O
of O
drugs O
known O
to O
inhibit O
the O
activity O
of O
cytochrome O
P450 O
isozymes O
may O
increase O
the O
plasma O
levels O
of O
clozapine B-DRUG
. O
Cimetidine B-DRUG
, O
caffeine B-DRUG
, O
and O
erythromycin B-DRUG
may O
increase O
plasma O
levels O
of O
Clozapine B-DRUG
, O
potentially O
resulting O
in O
adverse O
effects O
. O
Although O
concomitant O
use O
of O
Clozapine B-DRUG
and O
carbamazepine B-DRUG
is O
not O
recommended O
, O
it O
should O
be O
noted O
that O
discontinuation O
of O
concomitant O
carbamazepine B-DRUG
administration O
may O
result O
in O
an O
increase O
in O
Clozapine B-DRUG
plasma O
levels O
. O
In O
a O
study O
of O
schizophrenic O
patients O
who O
received O
clozapine B-DRUG
under O
steady O
state O
conditions O
, O
fluvoxamine B-DRUG
or O
paroxetine B-DRUG
was O
added O
in O
16 O
and O
14 O
patients O
, O
respectively O
. O
After O
14 O
days O
of O
co O
- O
administration O
, O
mean O
trough O
concentrations O
of O
clozapine B-DRUG
and O
its O
metabolites O
, O
N B-DRUG_N
- I-DRUG_N
desmethylclozapine I-DRUG_N
and O
clozapine B-DRUG_N
N I-DRUG_N
- I-DRUG_N
oxide I-DRUG_N
, O
were O
elevated O
with O
fluvoxamine B-DRUG
by O
about O
three O
- O
fold O
compared O
to O
baseline O
concentrations O
. O
Paroxetine B-DRUG
produced O
only O
minor O
changes O
in O
the O
levels O
of O
clozapine B-DRUG
and O
its O
metabolites O
. O
However O
, O
other O
published O
reports O
describe O
modest O
elevations O
( O
less O
than O
two O
- O
fold O
) O
of O
clozapine B-DRUG
and O
metabolite O
concentrations O
when O
clozapine B-DRUG
was O
taken O
with O
paroxetine B-DRUG
, O
fluoxetine B-DRUG
, O
and O
sertraline B-DRUG
. O
Therefore O
, O
such O
combined O
treatment O
should O
be O
approached O
with O
caution O
and O
patients O
should O
be O
monitored O
closely O
when O
Clozapine B-DRUG
is O
combined O
with O
these O
drugs O
, O
particularly O
with O
fluvoxamine B-DRUG
. O
A O
reduced O
Clozapine B-DRUG
dose O
should O
be O
considered O
. O
A O
subset O
( O
3 O
% O
- O
10 O
% O
) O
of O
the O
population O
has O
reduced O
activity O
of O
certain O
drug O
metabolizing O
enzymes O
such O
as O
the O
cytochrome O
P450 O
isozyme O
P450 O
2D6 O
. O
Such O
individuals O
are O
referred O
to O
as O
poor O
metabolizers O
of O
drugs O
such O
as O
debrisoquin B-DRUG
, O
dextromethorphan B-DRUG
, O
the O
tricyclic B-GROUP
antidepressants I-GROUP
, O
and O
clozapine B-DRUG
. O
These O
individuals O
may O
develop O
higher O
than O
expected O
plasma O
concentrations O
of O
clozapine B-DRUG
when O
given O
usual O
doses O
. O
In O
addition O
, O
certain O
drugs O
that O
are O
metabolized O
by O
this O
isozyme O
, O
including O
many O
antidepressants B-GROUP
( O
clozapine B-DRUG
, O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
, O
and O
others O
) O
, O
may O
inhibit O
the O
activity O
of O
this O
isozyme O
, O
and O
thus O
may O
make O
normal O
metabolizers O
resemble O

poor O
metabolizers O
with O
regard O
to O
concomitant O
therapy O
with O
other O
drugs O
metabolized O
by O
this O
enzyme O
system O
, O
leading O
to O
drug O
interaction O
. O
Concomitant O
use O
of O
clozapine B-DRUG
with O
other O
drugs O
metabolized O
by O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
clozapine B-DRUG
or O
the O
other O
drug O
. O
Therefore O
, O
co O
- O
administration O
of O
clozapine B-DRUG
with O
other O
drugs O
that O
are O
metabolized O
by O
this O
isozyme O
, O
including O
antidepressants B-GROUP
, O
phenothiazines B-GROUP
, O
carbamazepine B-DRUG
, O
and O
Type B-GROUP
1C I-GROUP
antiarrhythmics I-GROUP
( O
e O
. O
g O
. O
, O
propafenone B-DRUG
, O
flecainide B-DRUG
and O
encainide B-DRUG
) O
, O
or O
that O
inhibit O
this O
enzyme O
( O
e O
. O
g O
. O
, O
quinidine B-DRUG
) O
, O
should O
be O
approached O
with O
caution O
. O

The O
risk O
of O
a O
potential O
interaction O
between O
NovoSeven B-BRAND
and O
coagulation B-GROUP
factor I-GROUP
concentrates O
has O
not O
been O
adequately O
evaluated O
in O
preclinical O
or O
clinical O
studies O
. O
Simultaneous O
use O
of O
activated B-GROUP
prothrombin I-GROUP
complex I-GROUP
concentrates I-GROUP
or O
prothrombin B-GROUP
complex I-GROUP
concentrates I-GROUP
should O
be O
avoided O
. O
Although O
the O
specific O
drug O
interaction O
was O
not O
studied O
in O
a O
clinical O
trial O
, O
there O
have O
been O
more O
than O
50 O
episodes O
of O
concomitant O
use O
of O
antifibrinolytic O
therapies O
( O
i O
. O
e O
. O
, O
tranexamic B-DRUG
acid I-DRUG
, O
aminocaproic B-DRUG
acid I-DRUG
) O
and O
NovoSeven B-BRAND
. O
NovoSeven B-BRAND
should O
not O
be O
mixed O
with O
infusion O
solutions O
until O
clinical O
data O
are O
available O
to O
direct O
this O
use O
. O

Codeine B-DRUG
in O
combination O
with O
other O
narcotic B-GROUP
analgesics I-GROUP
, O
general O
anesthetics B-GROUP
, O
phenothiazines B-GROUP
, O
tranquilizers B-GROUP
, O
sedative B-GROUP
- I-GROUP
hypnotics I-GROUP
, O
or O
other O
CNS B-GROUP
depressants I-GROUP
( O
including O
alcohol B-DRUG
) O
has O
additive O
depressant O
effects O
. O
When O
s O
. O
c O
. O
combination O
therapy O
is O
contemplated O
, O
the O
dosage O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O

Colchicine B-DRUG
is O
inhibited O
by O
acidifying B-GROUP
agents I-GROUP
. O
The O
action O
of O
colchicine B-DRUG
is O
potentiated O
by O
alkalinizing B-GROUP
agents I-GROUP
. O
Colchicine B-DRUG
may O
increase O
sensitivity O
to O
the O
CNS B-GROUP
depressants I-GROUP
. O
Response O
to O
sympathomimetic B-GROUP
agents I-GROUP
may O
be O
enhanced O
by O
colchicine B-DRUG
. O

WelChol B-BRAND
has O
been O
studied O
in O
several O
human O
drug O
interaction O
studies O
in O
which O
it O
was O
administered O
with O
a O
meal O
and O
the O
test O
drug O
. O
WelChol B-BRAND
was O
found O
to O
have O
no O
significant O
effect O
on O
the O
bioavailability O
of O
digoxin B-DRUG
, O
lovastatin B-DRUG
, O
metoprolol B-DRUG
, O
quinidine B-DRUG
, O
valproic B-DRUG
acid I-DRUG
, O
and O
warfarin B-DRUG
. O
WelChol B-BRAND
decreased O
the O
Cmax O
and O
AUC O
of O
sustained O
- O
release O
verapamil B-DRUG
( O
Calan B-BRAND
SR I-BRAND
) O
by O
approximately O
31 O
% O
and O
11 O
% O
, O
respectively O
. O
Since O
there O
is O
a O
high O
degree O
of O
variability O
in O
the O
bioavailability O
of O
verapamil B-DRUG
, O
the O
clinical O
significance O
of O
this O
finding O
is O
unclear O
. O
In O
clinical O
studies O
, O
coadministration O
of O
WelChol B-BRAND
with O
atorvastatin B-DRUG
, O
lovastatin B-DRUG
, O
or O
simvastatin B-DRUG
did O
not O
interfere O
with O
the O
lipid O
- O
lowering O
activity O
of O
the O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitor I-GROUP
. O
Other O
drugs O
have O
not O
been O
studied O
. O
When O
administering O
other O
drugs O
for O
which O
alterations O
in O
blood O
levels O
could O
have O
a O
clinically O
significant O
effect O
on O
safety O
or O
efficacy O
, O
physicians O
should O
consider O
monitoring O
drug O
levels O
or O
effects O
. O

Since O
colestipol B-DRUG
hydrochloride I-DRUG
is O
an O
anion B-GROUP
exchange I-GROUP
resin I-GROUP
, O
it O
may O
have O
a O
strong O
affinity O
for O
anions O
other O
than O
the O
bile O
acids O
. O
In O
vitro O
studies O
have O
indicated O
that O
colestipol B-DRUG
hydrochloride I-DRUG
binds O
a O
number O
of O
drugs O
. O
Therefore O
, O
COLESTlD B-BRAND
Tablets O
may O
delay O
or O
reduce O
the O
absorption O
of O
concomitant O
oral O
medication O
. O
The O
interval O
between O
the O
administration O
of O
COLESTID B-BRAND
Tablets O
and O
any O
other O
medication O
should O
be O
as O
long O
as O
possible O
. O
Patients O
should O
take O
other O
drugs O
at O
least O
one O
hour O
before O
or O
four O
hours O
after O
COLESTID B-BRAND
Tablets O
to O
avoid O
impeding O
their O
absorption O
. O
Repeated O
doses O
of O
colestipol B-DRUG
hydrochloride I-DRUG
given O
prior O
to O
a O
single O
dose O
of O
propranolol B-DRUG
in O
human O
trials O
have O
been O
reported O
to O
decrease O
propranolol B-DRUG
absorption O
. O
However O
, O
in O
a O
follow O
- O
up O
study O
in O
normal O
subjects O
, O
single O
- O
dose O
administration O
of O
colestipol B-DRUG
hydrochloride I-DRUG
and O
propranolol B-DRUG
and O
twice O
- O
a O
- O
day O
administration O
for O
5 O
days O
of O
both O
agents O
did O
not O
affect O
the O
extent O
of O
propranolol B-DRUG
absorption O
, O
but O
had O
a O
small O
yet O
statistically O
significant O
effect O
on O
its O
rate O
of O
absorption O
; O
the O
time O
to O
reach O
maximum O
concentration O
was O
delayed O
approximately O
30 O
minutes O
. O
Effects O
on O
the O
absorption O
of O
other O
beta B-GROUP
- I-GROUP
blockers I-GROUP
have O
not O
been O
determined O
. O
Therefore O
, O
patients O
on O
propranolol B-DRUG
should O
be O
observed O
when O
COLESTID B-BRAND
Tablets O
are O
either O
added O
or O
deleted O
from O
a O
therapeutic O
regimen O
. O
Studies O
in O
humans O
show O
that O
the O
absorption O
of O
chlorothiazide B-DRUG
as O
reflected O
in O
urinary O
excretion O
is O
markedly O
decreased O
even O
when O
administered O
one O
hour O
before O
colestipol B-DRUG
hydrochloride I-DRUG
. O
The O
absorption O
of O
tetracycline B-DRUG
, O
furosemide B-DRUG
, O
penicillin B-DRUG
G I-DRUG
, O
hydrochlorothiazide B-DRUG
, O
and O
gemfibrozil B-DRUG
was O
significantly O
decreased O
when O
given O
simultaneously O
with O
colestipol B-DRUG
hydrochloride I-DRUG
; O
these O
drugs O
were O
not O
tested O
to O
determine O
the O
effect O
of O
administration O
one O
hour O
before O
colestipol B-DRUG
hydrochloride I-DRUG
. O
No O
depressant O
effect O
on O
blood O
levels O
in O
humans O
was O
noted O
when O
colestipol B-DRUG
hydrochloride I-DRUG
was O
administered O
with O
any O
of O
the O
following O
drugs O
: O
aspirin B-BRAND
, O
clindamycin B-BRAND
, O
clofibrate B-DRUG
, O
methyldopa B-DRUG
, O
nicotinic B-DRUG
acid I-DRUG
( O
niacin B-DRUG
) O
, O
tolbutamide B-DRUG
, O
phenytoin B-DRUG
or O
warfarin B-DRUG
. O
Particular O
caution O
should O
be O
observed O
with O
digitalis B-GROUP
preparations I-GROUP
since O
there O
are O
conflicting O
results O
for O

the O
effect O
of O
colestipol B-DRUG
hydrochloride I-DRUG
on O
the O
availability O
of O
digoxin B-DRUG
and O
digitoxin B-DRUG
. O
The O
potential O
for O
binding O
of O
these O
drugs O
if O
given O
concomitantly O
is O
present O
. O
Discontinuing O
colestipol B-DRUG
hydrochloride I-DRUG
could O
pose O
a O
hazard O
to O
health O
if O
a O
potentially O
toxic O
drug O
that O
is O
significantly O
bound O
to O
the O
resin B-GROUP
has O
been O
titrated O
to O
a O
maintenance O
level O
while O
the O
patient O
was O
taking O
colestipol B-DRUG
hydrochloride I-DRUG
. O
Bile B-GROUP
acid I-GROUP
binding I-GROUP
resins I-GROUP
may O
also O
interfere O
with O
the O
absorption O
of O
oral O
phosphate B-DRUG
supplements O
and O
hydrocortisone B-DRUG
. O

Certain O
other O
antibiotics B-GROUP
( O
aminoglycosides B-GROUP
and O
polymyxin B-GROUP
) O
have O
also O
been O
reported O
to O
interfere O
with O
the O
nerve O
transmission O
at O
the O
neuromuscular O
junction O
. O
Based O
on O
this O
reported O
activity O
, O
they O
should O
not O
be O
given O
concomitantly O
with O
Coly B-BRAND
- I-BRAND
Mycin I-BRAND
M I-BRAND
Parenteral O
except O
with O
the O
greatest O
caution O
. O
Curariform B-BRAND
muscle I-BRAND
relaxants I-BRAND
( O
eg O
, O
tubocurarine B-DRUG
) O
and O
other O
drugs O
, O
including O
ether O
, O
succinylcholine B-DRUG
, O
gallamine B-DRUG
, O
decamethonium B-DRUG
and O
sodium B-DRUG
citrate I-DRUG
, O
potentiate O
the O
neuromuscular O
blocking O
effect O
and O
should O
be O
used O
with O
extreme O
caution O
in O
patients O
being O
treated O
with O
Coly B-BRAND
- I-BRAND
Mycin I-BRAND
M I-BRAND
Parenteral O
. O
Sodium B-DRUG
cephalothin I-DRUG
may O
enhance O
the O
nephrotoxicity O
of O
Coly B-BRAND
- I-BRAND
Mycin I-BRAND
M I-BRAND
Parenteral O
. O
The O
concomitant O
use O
of O
sodium B-DRUG
cephalothin I-DRUG
and O
Coly B-BRAND
- I-BRAND
Mycin I-BRAND
M I-BRAND
Parenteral O
should O
be O
avoided O
. O

Digoxin B-DRUG
: O
Coadministration O
of O
digoxin B-DRUG
, O
a O
P O
- O
glycoprotein O
substrate O
, O
with O
oral O
conivaptan B-DRUG
resulted O
in O
a O
reduction O
in O
clearance O
and O
an O
increase O
in O
digoxin B-DRUG
Cmax O
and O
AUC O
values O
. O
Therefore O
, O
if O
digoxin B-DRUG
is O
administered O
with O
VAPRISOL B-BRAND
, O
the O
clinician O
should O
be O
alert O
to O
the O
possibility O
of O
increases O
in O
digoxin B-DRUG
levels O
. O

DRUG O
/ O
LABORATORY O
TEST O
INTERACTIONS O
1 O
. O
Accelerated O
prothrombin O
time O
, O
partial O
thromboplastin O
time O
, O
and O
platelet O
aggregation O
time O
; O
increased O
platelet O
count O
; O
increased O
factors O
II O
, O
VII O
antigen O
, O
VIII O
antigen O
, O
VIII O
coagulant O
activity O
, O
IX O
, O
X O
, O
XII O
, O
VII O
- O
X O
complex O
, O
II O
- O
VII O
- O
X O
complex O
, O
and O
beta O
- O
thromboglobulin O
; O
decreased O
levels O
of O
anti O
- O
factor O
Xa O
and O
antithrombin B-DRUG
III I-DRUG
, O
decreased O
antithrombin B-DRUG
III I-DRUG
activity O
; O
increased O
levels O
of O
fibrinogen B-DRUG
and O
fibrinogen B-DRUG
activity O
; O
increased O
plasminogen O
antigen O
and O
activity O
. O
2 O
. O
Increased O
thyroid O
- O
binding O
globulin O
( O
TBG O
) O
levels O
leading O
to O
increased O
circulating O
total O
thyroid O
hormone O
levels O
as O
measured O
by O
protein O
- O
bound O
iodine B-DRUG
( O
PBI O
) O
, O
T4 O
levels O
( O
by O
column O
or O
by O
radioimmunoassay O
) O
or O
T3 O
levels O
by O
radioimmunoassay O
. O
T3 O
resin O
uptake O
is O
decreased O
, O
reflecting O
the O
elevated O
TBG O
. O
Free O
T4 O
and O
free O
T3 O
concentrations O
are O
unaltered O
. O
Patients O
on O
thyroid O
replacement O
therapy O
may O
require O
higher O
doses O
of O
thyroid B-GROUP
hormone I-GROUP
. O
3 O
. O
Other O
binding O
proteins O
may O
be O
elevated O
in O
serum O
, O
( O
i O
. O
e O
. O
, O
corticosteroid O
binding O
globulin O
( O
CBG O
) O
, O
sex O
hormone O
binding O
globulin O
( O
SHBG O
) O
) O
leading O
to O
increased O
total O
circulating O
corticosteroids B-GROUP
and O
sex B-GROUP
steroids I-GROUP
, O
respectively O
. O
Free O
hormone O
concentrations O
may O
be O
decreased O
. O
Other O
plasma O
proteins O
may O
be O
increased O
( O
angiotensinogen O
/ O
renin O
substrate O
, O
alpha O
- O
1 O
- O
antitrypsin O
, O
ceruloplasmin O
) O
. O
4 O
. O
Increased O
plasma O
HDL O
and O
HDL2 O
cholesterol O
subfraction O
concentrations O
, O
reduced O
LDL O
cholesterol O
concentration O
, O
increased O
triglyceride O
levels O
. O
5 O
. O
Impaired O
glucose O
tolerance O
. O
6 O
. O
Reduced O
response O
to O
metyrapone O
test O
. O

Corticotropin B-DRUG
may O
accentuate O
the O
electrolyte O
loss O
associated O
with O
diuretic B-DRUG
therapy O
. O

The O
pharmacokinetic O
interactions O
listed O
below O
are O
potentially O
clinically O
important O
. O
Drugs O
that O
induce O
hepatic O
enzymes O
such O
as O
phenobarbital B-DRUG
, O
phenytoin B-DRUG
and O
rifampin B-DRUG
may O
increase O
the O
clearance O
of O
corticosteroids B-GROUP
and O
may O
require O
increases O
in O
corticosteroid B-GROUP
dose O
to O
achieve O
the O
desired O
response O
. O
Drugs O
such O
as O
troleandomycin B-DRUG
and O
ketoconazole B-DRUG
may O
inhibit O
the O
metabolism O
of O
corticosteroids B-GROUP
and O
thus O
decrease O
their O
clearance O
. O
Therefore O
, O
the O
dose O
of O
corticosteroid B-GROUP
should O
be O
titrated O
to O
avoid O
steroid O
toxicity O
. O
Corticosteroids B-GROUP
may O
increase O
the O
clearance O
of O
chronic O
high O
dose O
aspirin B-BRAND
. O
This O
could O
lead O
to O
decreased O
salicylate B-GROUP
serum O
levels O
or O
increase O
the O
risk O
of O
salicylate B-GROUP
toxicity O
when O
corticosteroid B-DRUG
is O
withdrawn O
. O
Aspirin B-BRAND
should O
be O
used O
cautiously O
in O
conjunction O
with O
cortico B-GROUP
- I-GROUP
steroids I-GROUP
in O
patients O
suffering O
from O
hypopro O
- O
thrombinemia O
. O
The O
effect O
of O
corticosteroids B-GROUP
on O
oral O
anticoagulants B-GROUP
is O
variable O
. O
There O
are O
reports O
of O
enhanced O
as O
well O
as O
diminished O
effects O
of O
anticoagulants B-GROUP
when O
given O
concurrently O
with O
corticosteroids B-GROUP
. O
Therefore O
, O
coagulation O
indices O
should O
be O
monitored O
to O
maintain O
the O
desired O
anticoagulant O
effect O
. O

Corticotropin B-DRUG
may O
accentuate O
the O
electrolyte O
loss O
associated O
with O
diuretic B-GROUP
therapy O
. O

Drug O
Interaction O
During O
Pregnancy O
: O
Cromolyn B-DRUG
sodium I-DRUG
and O
isoproterenol B-DRUG
were O
studied O
following O
subcutaneous O
injections O
in O
pregnant O
mice O
. O
Cromolyn B-DRUG
sodium I-DRUG
alone O
in O
doses O
up O
to O
540 O
mg O
/ O
kg O
/ O
day O
( O
approximately O
340 O
times O
the O
maximum O
recommended O
daily O
inhalation O
dose O
in O
adults O
on O
a O
mg O
/ O
m2 O
basis O
) O
did O
not O
cause O
significant O
increases O
in O
resorptions O
or O
major O
malformations O
. O
Isoproterenol B-DRUG
alone O
at O
a O
dose O
of O
2 O
. O
7 O
mg O
/ O
kg O
/ O
day O
( O
approximately O
7 O
times O
the O
maximum O
recommended O
daily O
inhalation O
dose O
in O
adults O
on O
a O
mg O
/ O
m2 O
basis O
) O
increased O
both O
resorptions O
and O
malformations O
. O
The O
addition O
of O
540 O
mg O
/ O
kg O
/ O
day O
of O
cromolyn B-DRUG
sodium I-DRUG
( O
approximately O
340 O
times O
the O
maximum O
recommended O
daily O
inhalation O
dose O
in O
adults O
on O
a O
mg O
/ O
m2 O
basis O
) O
to O
2 O
. O
7 O
mg O
/ O
kg O
/ O
day O
of O
isoproterenol B-DRUG
( O
approximately O
7 O
times O
the O
maximum O
recommended O
daily O
inhalation O
dose O
in O
adults O
on O
a O
mg O
/ O
m2 O
basis O
) O
appears O
to O
have O
increased O
the O
incidence O
of O
both O
resorptions O
and O
malformations O
. O

None O
known O
. O

Persons O
taking O
most O
antibiotics B-GROUP
, O
methotrexate B-DRUG
and O
pyrimethamine B-DRUG
invalidate O
folic B-DRUG
acid I-DRUG
and O
vitamin B-DRUG
B12 I-DRUG
diagnostic O
blood O
assays O
. O
Colchicine B-DRUG
para B-DRUG
- I-DRUG
aminosalicylic I-DRUG
acid I-DRUG
and O
heavy O
alcohol B-DRUG
intake O
for O
longer O
than O
2 O
weeks O
may O
produce O
malabsorption O
of O
vitamin B-DRUG
B12 I-DRUG
. O

FLEXERIL B-BRAND
may O
have O
life O
- O
threatening O
interactions O
with O
MAO B-GROUP
inhibitors I-GROUP
. O
FLEXERIL B-BRAND
may O
enhance O
the O
effects O
of O
alcohol B-DRUG
, O
barbiturates B-GROUP
, O
and O
other O
CNS B-GROUP
depressants I-GROUP
. O
Tricyclic B-GROUP
antidepressants I-GROUP
may O
block O
the O
antihypertensive O
action O
of O
guanethidine B-DRUG
and O
similarly O
acting O
compounds O
. O
Tricyclic B-GROUP
antidepressants I-GROUP
may O
enhance O
the O
seizure O
risk O
in O
patients O
taking O
tramadol B-DRUG
. O

Cyclopentolate B-DRUG
may O
interfere O
with O
the O
anti O
- O
glaucoma O
action O
of O
carbachol B-DRUG
or O
pilocarpine B-DRUG
; O
also O
, O
concurrent O
use O
of O
this O
medication O
may O
antagonise O
the O
anti O
- O
glaucoma O
and O
miotic O
actions O
of O
ophthalmic O
cholinesterase B-GROUP
inhibitors I-GROUP
. O

The O
rate O
of O
metabolism O
and O
the O
leukopenic O
activity O
of O
cyclophosphamide B-DRUG
reportedly O
are O
increased O
by O
chronic O
administration O
of O
high O
doses O
of O
phenobarbital B-DRUG
. O
The O
physician O
should O
be O
alert O
for O
possible O
combined O
drug O
actions O
, O
desirable O
or O
undesirable O
, O
involving O
cyclophosphamide B-DRUG
even O
though O
cyclophosphamide B-DRUG
has O
been O
used O
successfully O
concurrently O
with O
other O
drugs O
, O
including O
other O
cytotoxic O
drugs O
. O
Cyclophosphamide B-DRUG
treatment O
, O
which O
causes O
a O
marked O
and O
persistent O
inhibition O
of O
cholinesterase O
activity O
, O
potentiates O
the O
effect O
of O
succinylcholine B-DRUG
chloride I-DRUG
. O
If O
a O
patient O
has O
been O
treated O
with O
cyclophosphamide B-DRUG
within O
10 O
days O
of O
general O
anesthesia O
, O
the O
anesthesiologist O
should O
be O
alerted O
. O

May O
interact O
with O
wthionamide O
( O
Trecator B-BRAND
- I-BRAND
SC I-BRAND
) O
and O
isoniazid B-DRUG
( O
Nydrazid B-BRAND
) O
. O

MAO B-GROUP
inhibitors I-GROUP
prolong O
and O
intensify O
the O
anticholinergic O
effects O
of O
antihistamines B-GROUP
. O
Antihistamines B-GROUP
may O
have O
additive O
effects O
with O
alcohol B-DRUG
and O
other O
CNS B-GROUP
depressants I-GROUP
, O
e O
. O
g O
. O
, O
hypnotics B-GROUP
, O
sedatives B-GROUP
, O
tranquilizers B-GROUP
, O
antianxiety B-GROUP
agents I-GROUP
. O

No O
drug O
interactions O
have O
been O
reported O
. O

Steady O
state O
plasma O
digitoxin B-DRUG
concentrations O
did O
not O
appear O
to O
change O
. O
Therefore O
, O
monitoring O
of O
plasma O
digoxin B-DRUG
levels O
may O
be O
indicated O
in O
patients O
receiving O
similar O
combination O
chemotherapy O
regimens O
. O
The O
utilization O
of O
digitoxin B-DRUG
for O
such O
patients O
may O
be O
considered O
as O
an O
alternative O
. O
Also O
flucytosine B-DRUG
. O

Drug O
/ O
LaboratoryTest O
Interactions O
Dactinomycin B-DRUG
may O
interfere O
with O
bioassay O
procedures O
for O
the O
determination O
of O
antibacterial B-GROUP
drug I-GROUP
levels O
. O

Dantrium B-BRAND
is O
metabolized O
by O
the O
liver O
, O
and O
it O
is O
theoretically O
possible O
that O
its O
metabolism O
may O
be O
enhanced O
by O
drugs O
known O
to O
induce O
hepatic O
microsomal O
enzymes O
. O
However O
, O
neither O
phenobarbital B-DRUG
nor O
diazepam B-DRUG
appears O
to O
affect O
Dantrium B-BRAND
metabolism O
. O
Binding O
to O
plasma O
protein O
is O
not O
significantly O
altered O
by O
diazepam B-DRUG
, O
diphenylhydantoin B-DRUG
, O
or O
phenylbutazone B-DRUG
. O
Binding O
to O
plasma O
proteins O
is O
reduced O
by O
warfarin B-DRUG
and O
clotibrate O
and O
increased O
by O
tolbutamide B-DRUG
. O
Cardiovascular O
collapse O
in O
patients O
treated O
simultaneously O
with O
varapamil O
and O
dantrolene B-DRUG
sodium I-DRUG
is O
rare O
. O
The O
combination O
of O
therapeutic O
doses O
of O
intravenous O
dantrolene B-DRUG
sodium I-DRUG
and O
verapamil B-DRUG
in O
halothane B-DRUG
a O
- O
chloralose O
anesthetized O
swine O
has O
resulted O
in O
ventricular O
fibrillation O
and O
cardiovascular O
collapse O
in O
association O
with O
marked O
hyperkalemia O
. O
It O
is O
recommended O
that O
the O
combination O
of O
intravenous O
dantrolene B-DRUG
sodium I-DRUG
and O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
, O
such O
as O
verapamil B-DRUG
, O
not O
be O
used O
together O
during O
the O
management O
of O
malignant O
hyperthermia O
crisis O
until O
the O
relevance O
of O
these O
findings O
to O
humans O
is O
established O
. O
Administration O
of O
dantrolene B-DRUG
may O
potentiate O
vecuronium B-DRUG
- O
induced O
neuromuscular O
block O
. O

A O
drug O
- O
drug O
interaction O
study O
evaluated O
the O
effect O
of O
the O
use O
of O
ACZONE B-BRAND
Gel O
, O
5 O
% O
, O
in O
combination O
with O
double O
strength O
( O
160 O
mg O
/ O
800 O
mg O
) O
trimethoprim B-DRUG
/ O
sulfamethoxazole B-DRUG
( O
TMP B-DRUG
/ O
SMX B-DRUG
) O
. O
During O
co O
- O
administration O
, O
systemic O
levels O
of O
TMP B-DRUG
and O
SMX B-DRUG
were O
essentially O
unchanged O
. O
Notably O
, O
systemic O
exposure O
( O
AUC0 O
- O
12 O
) O
of O
dapsone B-DRUG_N
hydroxylamine I-DRUG_N
( O
DHA B-DRUG_N
) O
was O
more O
than O
doubled O
in O
the O
presence O
of O
TMP B-DRUG
/ O
SMX B-DRUG
. O
Exposure O
from O
the O
proposed O
topical O
dose O
is O
about O
1 O
% O
of O
that O
from O
the O
100 O
mg O
oral O
dose O
, O
even O
when O
co O
- O
administered O
with O
TMP B-DRUG
/ O
SMX B-DRUG
. O
Certain O
concomitant O
medications O
( O
such O
as O
rifampin B-DRUG
, O
anticonvulsants B-GROUP
, O
St O
. O
John O
s O
wort O
) O
may O
increase O
the O
formation O
of O
dapsone B-DRUG_N
hydroxylamine I-DRUG_N
, O
a O
metabolite O
of O
dapsone B-DRUG
associated O
with O
hemolysis O
. O
With O
oral O
dapsone B-DRUG
treatment O
, O
folic B-GROUP
acid I-GROUP
antagonists I-GROUP
such O
as O
pyrimethamine B-DRUG
have O
been O
noted O
to O
possibly O
increase O
the O
likelihood O
of O
hematologic O
reactions O
. O

Warfarin B-DRUG
: O
Concomitant O
administration O
of O
daptomycin B-DRUG
( O
6 O
mg O
/ O
kg O
once O
every O
24 O
hours O
for O
5 O
days O
) O
and O
warfarin B-DRUG
( O
25 O
mg O
single O
oral O
dose O
) O
had O
no O
significant O
effect O
on O
the O
pharmacokinetics O
of O
either O
drug O
, O
and O
the O
INR O
was O
not O
significantly O
altered O
. O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
Reductase I-GROUP
Inhibitors I-GROUP
: O
Inhibitors B-GROUP
of I-GROUP
HMG I-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
may O
cause O
myopathy O
, O
which O
is O
manifested O
as O
muscle O
pain O
or O
weakness O
associated O
with O
elevated O
levels O
of O
CPK O
. O
There O
were O
no O
reports O
of O
skeletal O
myopathy O
in O
a O
placebo O
- O
controlled O
Phase O
I O
trial O
in O
which O
10 O
healthy O
subjects O
on O
stable O
simvastatin B-DRUG
therapy O
were O
treated O
concurrently O
with O
daptomycin B-DRUG
( O
4 O
mg O
/ O
kg O
once O
every O
24 O
hours O
) O
for O
14 O
days O
. O
Experience O
with O
co O
- O
administration O
of O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
and O
Fentanyl B-DRUG
in O
patients O
is O
limited O
, O
therefore O
, O
consideration O
should O
be O
given O
to O
temporarily O
suspending O
use O
of O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
in O
patients O
receiving O
Fentanyl B-DRUG
. O
Drug O
- O
Laboratory O
Test O
Interactions O
: O
There O
are O
no O
reported O
drug O
- O
laboratory O
test O
interactions O
. O

No O
formal O
drug O
interaction O
studies O
of O
Aranesp B-BRAND
have O
been O
performed O
. O

The O
daily O
dose O
of O
ENABLEX B-BRAND
should O
not O
exceed O
7 O
. O
5 O
mg O
when O
coadministered O
with O
potent O
CYP3A4 O
inhibitors O
( O
e O
. O
g O
. O
, O
ketoconazole B-DRUG
, O
itraconazole B-DRUG
, O
ritonavir B-DRUG
, O
nelfinavir B-DRUG
, O
clarithromycin B-DRUG
and O
nefazadone O
) O
. O
Caution O
should O
be O
taken O
when O
ENABLEX B-BRAND
is O
used O
concomitantly O
with O
medications O
that O
are O
predominantly O
metabolized O
by O
CYP2D6 O
and O
which O
have O
a O
narrow O
therapeutic O
window O
, O
such O
as O
flecainide B-DRUG
, O
thioridazine B-DRUG
and O
tricyclic B-GROUP
antidepressants I-GROUP
( O
see O
CLINICAL O
PHARMACOLOGY O
) O
. O
The O
concomitant O
use O
of O
ENABLEX B-BRAND
with O
other O
anticholinergic B-GROUP
agents I-GROUP
may O
increase O
the O
frequency O
and O
/ O
or O
severity O
of O
dry O
mouth O
, O
constipation O
, O
blurred O
vision O
and O
other O
anticholinergic O
pharmacological O
effects O
. O
Anticholinergic B-GROUP
agents I-GROUP
may O
potentially O
alter O
the O
absorption O
of O
some O
concomitantly O
administered O
drugs O
due O
to O
effects O
on O
gastrointestinal O
motility O
. O
Drug O
Laboratory O
Test O
Interactions O
Interactions O
between O
darifenacin B-DRUG
and O
laboratory O
tests O
have O
not O
been O
studied O
. O

Drugs O
that O
may O
increase O
dasatinib B-DRUG
plasma O
concentrations O
CYP3A4 O
Inhibitors O
: O
Dasatinib B-DRUG
is O
a O
CYP3A4 O
substrate O
. O
Concomitant O
use O
of O
SPRYCEL B-BRAND
and O
drugs O
that O
inhibit O
CYP3A4 O
( O
eg O
, O
ketoconazole B-DRUG
, O
itraconazole B-DRUG
, O
erythromycin B-DRUG
, O
clarithromycin B-DRUG
, O
ritonavir B-DRUG
, O
atazanavir B-DRUG
, O
indinavir B-DRUG
, O
nefazodone B-DRUG
, O
nelfinavir B-DRUG
, O
saquinavir B-DRUG
, O
telithromycin B-DRUG
) O
may O
increase O
exposure O
to O
dasatinib B-DRUG
and O
should O
be O
avoided O
. O
In O
patients O
receiving O
treatment O
with O
SPRYCEL B-BRAND
, O
close O
monitoring O
for O
toxicity O
and O
a O
SPRYCEL B-BRAND
dose O
reduction O
should O
be O
considered O
if O
systemic O
administration O
of O
a O
potent O
CYP3A4 O
inhibitor O
cannot O
be O
avoided O
. O
Drugs O
that O
may O
decrease O
dasatinib B-DRUG
plasma O
concentrations O
CYP3A4 O
Inducers O
: O
Drugs O
that O
induce O
CYP3A4 O
activity O
may O
decrease O
dasatinib B-DRUG
plasma O
concentrations O
. O
In O
patients O
in O
whom O
CYP3A4 O
inducers O
( O
eg O
, O
dexamethasone B-DRUG
, O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
rifampicin B-DRUG
, O
phenobarbital B-DRUG
) O
are O
indicated O
, O
alternative O
agents O
with O
less O
enzyme O
induction O
potential O
should O
be O
used O
. O
If O
SPRYCEL B-BRAND
must O
be O
administered O
with O
a O
CYP3A4 O
inducer O
, O
a O
dose O
increase O
in O
SPRYCEL B-BRAND
should O
be O
considered O
. O
St O
. O
Johns O
wort O
( O
Hypericum O
perforatum O
) O
may O
decrease O
SPRYCEL B-BRAND
plasma O
concentrations O
unpredictably O
. O
Patients O
receiving O
SPRYCEL B-BRAND
should O
not O
take O
St O
. O
Johns O
wort O
. O
Antacids B-GROUP
: O
Nonclinical O
data O
demonstrate O
that O
the O
solubility O
of O
dasatinib B-DRUG
is O
pH O
dependent O
. O
Simultaneous O
administration O
of O
SPRYCEL B-BRAND
with O
antacids B-GROUP
should O
be O
avoided O
. O
If O
antacid B-GROUP
therapy O
is O
needed O
, O
the O
antacid O
dose O
should O
be O
administered O
at O
least O
2 O
hours O
prior O
to O
or O
2 O
hours O
after O
the O
dose O
of O
SPRYCEL B-BRAND
. O
H2 B-GROUP
Blockers I-GROUP
/ O
Proton B-GROUP
Pump I-GROUP
Inhibitors I-GROUP
: O
Long O
- O
term O
suppression O
of O
gastric O
acid O
secretion O
by O
H2 B-GROUP
blockers I-GROUP
or O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
( O
eg O
, O
famotidine B-DRUG
and O
omeprazole B-DRUG
) O
is O
likely O
to O
reduce O
dasatinib B-DRUG
exposure O
. O
The O
concomitant O
use O
of O
H2 B-GROUP
blockers I-GROUP
or O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
with O

SPRYCEL B-BRAND
is O
not O
recommended O
. O
The O
use O
of O
antacids B-GROUP
should O
be O
considered O
in O
place O
of O
H2 B-GROUP
blockers I-GROUP
or O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
in O
patients O
receiving O
SPRYCEL B-BRAND
therapy O
. O
Drugs O
that O
may O
have O
their O
plasma O
concentration O
altered O
by O
dasatinib B-DRUG
CYP3A4 O
Substrates O
: O
Dasatinib B-DRUG
is O
a O
time O
- O
dependent O
inhibitor O
of O
CYP3A4 O
. O
Therefore O
, O
CYP3A4 O
substrates O
known O
to O
have O
a O
narrow O
therapeutic O
index O
such O
as O
alfentanil B-DRUG
, O
astemizole B-DRUG
, O
terfenadine B-DRUG
, O
cisapride B-DRUG
, O
cyclosporine B-DRUG
, O
fentanyl B-DRUG
, O
pimozide B-DRUG
, O
quinidine B-DRUG
, O
sirolimus B-DRUG
, O
tacrolimus B-DRUG
, O
or O
ergot B-GROUP
alkaloids I-GROUP
( O
ergotamine B-DRUG
, O
dihydroergotamine B-DRUG
) O
should O
be O
administered O
with O
caution O
in O
patients O
receiving O
SPRYCEL B-BRAND
. O
Hepatic O
Impairment O
There O
are O
currently O
no O
clinical O
studies O
with O
SPRYCEL B-BRAND
in O
patients O
with O
impaired O
liver O
function O
( O
clinical O
studies O
have O
excluded O
patients O
with O
ALT O
and O
/ O
or O
AST O
2 O
. O
5 O
times O
the O
upper O
limit O
of O
the O
normal O
range O
and O
/ O
or O
total O
bilirubin O
2 O
times O
the O
upper O
limit O
of O
the O
normal O
range O
) O
. O
Metabolism O
of O
dasatinib B-DRUG
is O
mainly O
hepatic O
. O
Caution O
is O
recommended O
in O
patients O
with O
hepatic O
impairment O
. O
Renal O
Impairment O
There O
are O
currently O
no O
clinical O
studies O
with O
SPRYCEL B-BRAND
in O
patients O
with O
impaired O
renal O
function O
( O
clinical O
studies O
have O
excluded O
patients O
with O
serum O
creatinine O
concentration O
1 O
. O
5 O
times O
the O
upper O
limit O
of O
the O
normal O
range O
) O
. O
Dasatinib B-DRUG
and O
its O
metabolites O
are O
minimally O
excreted O
via O
the O
kidney O
. O
Since O
the O
renal O
excretion O
of O
unchanged O
dasatinib B-DRUG
and O
its O
metabolites O
is O
4 O
% O
, O
a O
decrease O
in O
total O
body O
clearance O
is O
not O
expected O
in O
patients O
with O
renal O
insufficiency O
. O

Use O
of O
Cerubidine B-BRAND
in O
a O
patient O
who O
has O
previously O
received O
doxorubicin B-DRUG
increases O
the O
risk O
of O
cardiotoxicity O
. O
Cerubidine B-BRAND
should O
not O
be O
used O
in O
patients O
who O
have O
previously O
received O
the O
recommended O
maximum O
cumulative O
doses O
of O
doxorubicin B-DRUG
or O
Cerubidine B-BRAND
. O
Cyclophosphamide B-DRUG
used O
concurrently O
with O
Cerubidine B-BRAND
may O
also O
result O
in O
increased O
cardiotoxicity O
. O
Dosage O
reduction O
of O
Cerubidine B-BRAND
may O
be O
required O
when O
used O
concurrently O
with O
other O
myelosuppressive O
agents O
. O
Hepatotoxic O
medications O
, O
such O
as O
high O
- O
dose O
methotrexate B-DRUG
, O
may O
impair O
liver O
function O
and O
increase O
the O
risk O
of O
toxicity O
. O

Potentially O
fatal O
drug O
interactions O
may O
occur O
when O
coadministered O
with O
digoxin B-DRUG
, O
as O
this O
may O
enhance O
cardiovascular O
depression O
and O
bradyarrhythmias O
may O
occur O
. O
Anticholinesterases B-GROUP
( O
neostgmine O
, O
physostigmine B-DRUG
) O
, O
lignocaine B-DRUG
, O
quinine B-DRUG
, O
procainamide B-DRUG
can O
enhance O
toxicity O
and O
cause O
cardio O
respiratory O
depression O
. O
In O
addition O
, O
neuromuscular O
blocking O
action O
is O
enhanced O
by O
general O
anesthetics B-GROUP
, O
local O
anesthetics B-GROUP
like O
lidocaine B-DRUG
, O
procaine B-DRUG
, O
beta B-GROUP
- I-GROUP
blockers I-GROUP
, O
metaclopramide B-DRUG
, O
lithium B-DRUG
carbonate I-DRUG
, O
and O
terbutaline B-DRUG
. O

Drug O
interaction O
studies O
with O
decitabine B-DRUG
have O
not O
been O
conducted O
. O
In O
vitro O
studies O
in O
human O
liver O
microsomes O
suggest O
that O
decitabine B-DRUG
is O
unlikely O
to O
inhibit O
or O
induce O
cytochrome O
P450 O
enzymes O
. O
In O
vitro O
metabolism O
studies O
have O
suggested O
that O
decitabine B-DRUG
is O
not O
a O
substrate O
for O
the O
human O
liver O
cytochrome O
P450 O
enzymes O
. O
As O
plasma O
protein O
binding O
of O
decitabine B-DRUG
is O
negligible O
( O
1 O
% O
) O
, O
interactions O
due O
to O
displacement O
of O
more O
highly O
protein O
bound O
drugs O
from O
plasma O
proteins O
are O
not O
expected O
. O

The O
concomitant O
administration O
of O
Exjade B-BRAND
and O
aluminum B-DRUG
- O
containing O
antacid B-GROUP
preparations I-GROUP
has O
not O
been O
formally O
studied O
. O
Although O
deferasirox B-DRUG
has O
a O
lower O
affinity O
for O
aluminum B-DRUG
than O
for O
iron B-DRUG
, O
Exjade B-BRAND
should O
not O
be O
taken O
with O
aluminum B-DRUG
- O
containing O
antacid B-GROUP
preparations I-GROUP
. O
In O
healthy O
volunteers O
, O
Exjade B-BRAND
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
digoxin B-DRUG
. O
The O
effect O
of O
digoxin B-DRUG
on O
Exjade B-BRAND
pharmacokinetics O
has O
not O
been O
studied O
. O
The O
concomitant O
administration O
of O
Exjade B-BRAND
and O
vitamin B-DRUG
C I-DRUG
has O
not O
been O
formally O
studied O
. O
Doses O
of O
vitamin B-DRUG
C I-DRUG
up O
to O
200 O
mg O
were O
allowed O
in O
clinical O
studies O
without O
negative O
consequences O
. O
The O
interaction O
of O
Exjade B-BRAND
with O
hydroxyurea B-DRUG
has O
not O
been O
formally O
studied O
. O
No O
inhibition O
of O
deferasirox B-DRUG
metabolism O
by O
hydroxyurea B-DRUG
is O
expected O
based O
on O
the O
results O
of O
an O
in O
vitro O
study O
. O
Exjade B-BRAND
should O
not O
be O
combined O
with O
other O
iron O
chelator O
therapies O
, O
as O
safety O
of O
such O
combinations O
has O
not O
been O
established O
. O
Drug O
/ O
Food O
Interactions O
The O
bioavailability O
( O
AUC O
) O
of O
deferasirox B-DRUG
was O
variably O
increased O
when O
taken O
with O
a O
meal O
. O
Deferasirox B-DRUG
should O
be O
taken O
on O
an O
empty O
stomach O
30 O
minutes O
before O
eating O
. O
Exjade B-BRAND
tablets O
for O
oral O
suspension O
can O
be O
dispersed O
in O
water O
, O
orange O
juice O
, O
or O
apple O
juice O
. O

Antiacid O
, O
clarithromycin B-DRUG
, O
Didanosine B-DRUG
, O
Fluconazole B-DRUG
, O
Fluoxetine B-DRUG
, O
Indanavir O
, O
Ketoconazole B-DRUG
, O
Phenytoin B-DRUG
, O
Phenobarbitol O
, O
carbamazepine B-DRUG
, O
Rifabutin B-DRUG
, O
Rifampin B-DRUG
, O
Ritanovir O
, O
Saquinavir B-DRUG
. O

Possible O
drug O
interactions O
of O
HUMORSOL B-BRAND
with O
succinylcholine B-DRUG
or O
with O
other O
anticholinesterase B-GROUP
agents I-GROUP
. O

Because O
the O
tetracyclines B-GROUP
have O
been O
shown O
to O
depress O
plasma O
prothrombin O
activity O
, O
patients O
who O
are O
on O
anticoagulant B-GROUP
therapy O
may O
require O
downward O
adjustment O
of O
their O
anticoagulant B-GROUP
dosage O
. O
Since O
bacteriostatic O
drugs O
, O
such O
as O
the O
tetracycline B-GROUP
class I-GROUP
of O
antibiotics B-GROUP
, O
may O
interfere O
with O
the O
bactericidal O
action O
of O
penicillins B-GROUP
, O
it O
is O
not O
advisable O
to O
administer O
these O
drugs O
concomitantly O
. O
Concurrent O
use O
of O
tetracyclines B-GROUP
with O
oral O
contraceptives B-GROUP
may O
render O
oral O
contraceptives B-GROUP
less O
effective O
. O
Breakthrough O
bleeding O
has O
been O
reported O

No O
clinical O
drug O
interaction O
studies O
have O
been O
conducted O
. O
However O
, O
in O
a O
single O
in O
vivo O
rodent O
study O
denileukin B-DRUG
diftitox I-DRUG
had O
no O
effect O
on O
P450 O
levels O
. O

Taking O
a O
rauwolfia B-GROUP
alkaloid I-GROUP
while O
you O
are O
taking O
or O
within O
2 O
weeks O
of O
taking O
MAO B-GROUP
inhibitors I-GROUP
may O
increase O
the O
risk O
of O
central O
nervous O
system O
depression O
or O
may O
cause O
a O
severe O
high O
blood O
pressure O
reaction O
. O

No O
clinically O
significant O
adverse O
interactions O
with O
commonly O
used O
preanesthetic O
drugs O
, O
or O
drugs O
used O
during O
anesthesia O
( O
muscle B-GROUP
relaxants I-GROUP
, O
intravenous O
agents O
, O
and O
local O
anesthetic B-GROUP
agents I-GROUP
) O
were O
reported O
in O
clinical O
trials O
. O
The O
effect O
of O
desflurane B-DRUG
on O
the O
disposition O
of O
other O
drugs O
has O
not O
been O
determined O
. O
Like O
isoflurane B-DRUG
, O
desflurane B-DRUG
does O
not O
predispose O
to O
premature O
ventricular O
arrhythmias O
in O
the O
presence O
of O
exogenously O
infused O
epinephrine B-DRUG
in O
swine O
. O

1 O
. O
Drugs O
Metabolized O
by O
P450 O
2D6 O
: O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
caucasian O
population O
( O
about O
7 O
to O
10 O
% O
of O
caucasians O
are O
so O
called O
poor O
metabolizers O
) O
; O
reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O
Poor O
metabolizers O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-GROUP
antidepressants I-GROUP
( O
TCAs B-GROUP
) O
when O
given O
usual O
doses O
. O
Depending O
on O
the O
traction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8 O
fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA B-GROUP
) O
. O
In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
p O
. O
o O
. O
metabolizers O
. O
An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCA B-GROUP
may O
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O
The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-DRUG
; O
cimetidine B-DRUG
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-GROUP
, O
phenothiazines B-GROUP
, O
and O
the O
Type O
1C O
antiarrhythrnics O
propatenone O
and O
flecainide B-DRUG
) O
. O
While O
all O
the O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
( O
SSRIs B-GROUP
) O
, O
e O
. O
g O
. O
, O
fluoxetine B-DRUG
, O
seriraline O
, O
and O
paroxetine B-DRUG
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O
The O
extent O
to O
which O
SSRI B-GROUP
- O
TCA B-GROUP
interactions O
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-GROUP
involved O
. O
Nevertheless O
, O
caution O
is O
indicated O
in O
the O
co O
- O
administration O
of O
T B-GROUP
. I-GROUP
A I-GROUP
. I-GROUP
with O
any O
of O
the O
SSRIs B-GROUP
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O
Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCA O
treatment O
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-DRUG
, O
given O
the O
long O
half O
- O
life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O
Concomitant O
use O
of O

tricyclic B-GROUP
antidepressants I-GROUP
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-GROUP
antidepressant I-GROUP
or O
the O
other O
drug O
. O
Furthermore O
, O
whenever O
one O
of O
these O
other O
drugs O
is O
withdrawn O
from O
co O
- O
therapy O
, O
an O
increased O
dose O
of O
tricyclic B-GROUP
antidepressant I-GROUP
may O
be O
required O
. O
It O
is O
desirable O
to O
monitor O
TCA B-GROUP
plasma O
levels O
whenever O
a O
TCA B-GROUP
is O
going O
to O
be O
co O
- O
administered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
. O
2 O
. O
Close O
supervision O
and O
careful O
adjustment O
of O
dosage O
are O
required O
when O
this O
drug O
is O
given O
concomitantly O
with O
anticholinergic B-GROUP
or O
sympathomimetic B-GROUP
drugs I-GROUP
. O
3 O
. O
Clinical O
experience O
in O
the O
concurrent O
administration O
of O
ECT O
and O
antidepressant B-GROUP
drugs I-GROUP
is O
limited O
. O
Thus O
, O
if O
such O
treatment O
is O
essential O
, O
the O
possibility O
of O
increased O
risk O
relative O
to O
benefits O
should O
be O
considered O
. O
4 O
. O
If O
desipramine B-DRUG
hydrochloride I-DRUG
is O
to O
be O
combined O
with O
other O
psychotropic B-GROUP
agents I-GROUP
such O
as O
tranquilizers B-GROUP
or O
sedative B-GROUP
/ O
hypnotics B-GROUP
, O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
the O
agents O
employed O
since O
the O
sedative O
effects O
of O
desipramine B-DRUG
and O
benzodiazepines B-GROUP
( O
e O
. O
g O
. O
, O
chlordiazepoxide B-DRUG
or O
diazepam B-DRUG
) O
are O
additive O
. O
Both O
the O
sedative O
and O
anticholinergic O
effects O
of O
the O
major B-GROUP
tranquilizers I-GROUP
are O
also O
additive O
to O
those O
of O
desipramine B-DRUG
. O
5 O
. O
Concurrent O
administration O
of O
cimetidine B-DRUG
and O
tricyclic B-GROUP
antidepressants I-GROUP
can O
produce O
clinically O
significant O
increases O
in O
the O
plasma O
levels O
of O
the O
tricyclic B-GROUP
antidepressants I-GROUP
. O
Conversely O
, O
decreases O
in O
plasma O
levels O
of O
the O
tricyclic B-GROUP
antidepressants I-GROUP
have O
been O
reported O
upon O
discontinuation O
of O
cimetidine B-DRUG
which O
may O
result O
in O
the O
loss O
of O
the O
therapeutic O
efficacy O
of O
the O
tricyclic B-GROUP
antidepressant I-GROUP
6 O
. O
There O
have O
been O
greater O
than O
two O
- O
fold O
increases O
of O
previously O
stable O
plasma O
levels O
of O
tricyclic B-GROUP
antidepressants I-GROUP
when O
fluoxetine B-DRUG
has O
been O
administered O
in O
combination O
with O
these O
agents O
. O

In O
two O
controlled O
crossover O
clinical O
pharmacology O
studies O
in O
healthy O
male O
( O
n O
= O
12 O
in O
each O
study O
) O
a O
nd O
female O
( O
n O
= O
12 O
in O
each O
study O
) O
volunteers O
, O
desloratadine B-DRUG
7 O
. O
5 O
mg O
( O
1 O
. O
5 O
times O
the O
daily O
dose O
) O
once O
daily O
was O
coadministered O
with O
erythromycin B-DRUG
500 O
mg O
every O
8 O
hours O
or O
ketoconazole B-DRUG
200 O
mg O
every O
12 O
hours O
for O
10 O
days O
. O
In O
three O
separate O
controlled O
, O
parallel O
group O
clinical O
pharmacology O
studies O
, O
desloratadine B-DRUG
at O
the O
clinical O
dose O
of O
5 O
mg O
has O
been O
coadministered O
with O
azithromycin B-DRUG
500 O
mg O
followed O
by O
250 O
mg O
once O
daily O
for O
4 O
days O
( O
n O
= O
18 O
) O
or O
with O
fluoxetine B-DRUG
20 O
mg O
once O
daily O
for O
7 O
days O
after O
a O
23 O
day O
pretreatment O
period O
with O
fluoxetine B-DRUG
( O
n O
= O
18 O
) O
or O
with O
cimetidine B-DRUG
600 O
mg O
every O
12 O
hours O
for O
14 O
days O
( O
n O
= O
18 O
) O
under O
steady O
state O
conditions O
to O
normal O
healthy O
male O
and O
female O
volunteers O
. O
Although O
increased O
plasma O
concentrations O
( O
C O
max O
and O
AUC O
0 O
- O
24 O
hrs O
) O
of O
desloratadine B-DRUG
and O
3 B-DRUG_N
- I-DRUG_N
hydroxydesloratadine I-DRUG_N
were O
observed O
, O
there O
were O
no O
clinically O
relevant O
changes O
in O
the O
safety O
profile O
of O
desloratadine B-DRUG
, O
as O
assessed O
by O
electrocardiographic O
parameters O
( O
including O
the O
corrected O
QT O
interval O
) O
, O
clinical O
laboratory O
tests O
, O
vital O
signs O
, O
and O
adverse O
events O
. O
Table O
1 O
Changes O
in O
Desloratadine B-DRUG
and O
3 B-DRUG_N
- I-DRUG_N
Hydroxydesloratadine I-DRUG_N
Pharmacokinetics O
in O
Healthy O
Male O
and O
Female O
Volunteers O
Desloratadine B-DRUG
3 B-DRUG_N
- I-DRUG_N
Hydroxydesloratadine I-DRUG_N
C O
max O
AUC O
0 O
- O
24 O
hrs O
C O
max O
AUC O
0 O
- O
24 O
hrs O
Erythromycin B-DRUG
( O
500 O
mg O
Q8h O
) O
+ O
24 O
% O
+ O
14 O
% O
+ O
43 O
% O
+ O
40 O
% O
Ketoconazole B-DRUG
( O
200 O
mg O
Q12h O
) O
+ O
45 O
% O
+ O
39 O
% O
+ O
43 O
% O
+ O
72 O
% O
Azithromycin B-DRUG
( O
500 O
mg O
day O
1 O
, O
250 O
mg O
QD O
4 O
days O
) O
+ O
15 O
% O
+ O
5 O
% O
+ O
15 O
% O
+ O
4 O
% O
Fluoxetine B-DRUG
( O
20 O
mg O
QD O
) O
+ O
15 O
% O
+ O
0 O
% O
+ O
17 O
% O
+ O
13 O
% O
Cimetidine B-DRUG
( O
600 O
mg O
Q12h O
) O
+ O
12 O
% O
+ O
19 O
% O
- O
11 O
% O
- O
3 O
% O

Although O
the O
pressor O
activity O
of O
Desmopressin B-DRUG
is O
very O
low O
compared O
to O
its O
antidiuretic O
activity O
, O
large O
doses O
of O
Desmopressin B-DRUG
Tablets O
should O
be O
used O
with O
other O
pressor O
agents O
only O
with O
careful O
patient O
monitoring O
. O

Reduced O
efficacy O
and O
increased O
incidence O
of O
breakthrough O
bleeding O
and O
menstrual O
irregularities O
have O
been O
associated O
with O
concomitant O
use O
of O
rifampin B-DRUG
. O
A O
similar O
association O
, O
though O
less O
marked O
, O
has O
been O
suggested O
with O
barbiturates B-GROUP
, O
phenyl O
- O
butazone O
, O
phenytoin B-DRUG
sodium I-DRUG
, O
carbamazepine B-DRUG
and O
possibly O
with O
griseofulvin B-DRUG
, O
ampicillin B-DRUG
, O
and O
tetracyclines B-GROUP
( O
72 O
) O
. O

No O
specific O
information O
available O
. O

Aminoglutethimide B-DRUG
: O
Aminoglutethimide B-DRUG
may O
diminish O
adrenal O
suppression O
by O
corticosteroids B-GROUP
. O
Amphotericin B-DRUG
B I-DRUG
injection O
and O
potassium O
- O
depleting O
agents O
: O
When O
corticosteroids B-GROUP
are O
administered O
concomitantly O
with O
potassium O
- O
depleting O
agents O
( O
e O
. O
g O
. O
, O
amphotericin B-DRUG
B I-DRUG
, O
diuretics B-GROUP
) O
, O
patients O
should O
be O
observed O
closely O
for O
development O
of O
hypokalemia O
. O
In O
addition O
, O
there O
have O
been O
cases O
reported O
in O
which O
concomitant O
use O
of O
amphotericin B-DRUG
B I-DRUG
and O
hydrocortisone B-DRUG
was O
followed O
by O
cardiac O
enlargement O
and O
congestive O
heart O
failure O
. O
Antibiotics B-GROUP
: O
Macrolide B-GROUP
antibiotics I-GROUP
have O
been O
reported O
to O
cause O
a O
significant O
decrease O
in O
corticosteroid B-GROUP
clearance O
. O
Anticholinesterases B-GROUP
: O
Concomitant O
use O
of O
anticholinesterase B-GROUP
agents I-GROUP
and O
corticosteroids B-GROUP
may O
produce O
severe O
weakness O
in O
patients O
with O
myasthenia O
gravis O
. O
If O
possible O
, O
anticholinesterase B-GROUP
agents I-GROUP
should O
be O
withdrawn O
at O
least O
24 O
hours O
before O
initiating O
corticosteroid B-GROUP
therapy O
. O
Anticoagulants B-GROUP
, O
oral O
: O
Co O
- O
administration O
of O
corticosteroids B-GROUP
and O
warfarin B-DRUG
usually O
results O
in O
inhibition O
of O
response O
to O
warfarin B-DRUG
, O
although O
there O
have O
been O
some O
conflicting O
reports O
. O
Therefore O
, O
coagulation O
indices O
should O
be O
monitored O
frequently O
to O
maintain O
the O
desired O
anticoagulant O
effect O
. O
Antidiabetics B-GROUP
: O
Because O
corticosteroids B-GROUP
may O
increase O
blood O
glucose O
concentrations O
, O
dosage O
adjustments O
of O
antidiabetic B-GROUP
agents I-GROUP
may O
be O
required O
. O
Antitubercular O
drugs O
: O
Serum O
concentrations O
of O
isoniazid B-DRUG
may O
be O
decreased O
. O
Cholestyramine B-DRUG
: O
Cholestyramine B-DRUG
may O
increase O
the O
clearance O
of O
corticosteroids B-GROUP
. O
Cyclosporine B-DRUG
: O
Increased O
activity O
of O
both O
cyclosporine B-DRUG
and O
corticosteroids B-GROUP
may O
occur O
when O
the O
two O
are O
used O
concurrently O
. O
Convulsions O
have O
been O
reported O
with O
this O
concurrent O
use O
. O
Dexamethasone O
suppression O
test O
( O
DST O
) O
: O
False O
- O
negative O
results O
in O
the O
dexamethasone O
suppression O
test O
( O
DST O
) O
in O
patients O
being O
treated O
with O
indomethacin B-DRUG
have O
been O
reported O
. O
Thus O
, O
results O
of O
the O
DST O
should O
be O
interpreted O
with O
caution O
in O
these O
patients O
. O
Digitalis B-GROUP
glycosides I-GROUP
: O
Patients O
on O
digitalis B-GROUP
glycosides I-GROUP
may O
be O
at O
increased O
risk O
of O
arrhythmias O
due O
to O
hypokalemia O
. O
Ephedrine B-DRUG
: O
Ephedrine B-DRUG
may O

enhance O
the O
metabolic O
clearance O
of O
corticosteroids B-GROUP
, O
resulting O
in O
decreased O
blood O
levels O
and O
lessened O
physiologic O
activity O
, O
thus O
requiring O
an O
increase O
in O
corticosteroid B-GROUP
dosage O
. O
Estrogens B-GROUP
, O
including O
oral O
contraceptives B-GROUP
: O
Estrogens B-GROUP
may O
decrease O
the O
hepatic O
metabolism O
of O
certain O
corticosteroids B-GROUP
, O
thereby O
increasing O
their O
effect O
. O
Hepatic O
Enzyme O
Inducers O
, O
Inhibitors O
and O
Substrates O
: O
Drugs O
which O
induce O
cytochrome O
P450 O
3A4 O
( O
CYP O
3A4 O
) O
enzyme O
activity O
( O
e O
. O
g O
. O
, O
barbiturates B-GROUP
, O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
rifampin B-DRUG
) O
may O
enhance O
the O
metabolism O
of O
corticosteroids B-GROUP
and O
require O
that O
the O
dosage O
of O
the O
corticosteroid B-GROUP
be O
increased O
. O
Drugs O
which O
inhibit O
CYP O
3A4 O
( O
e O
. O
g O
. O
, O
ketoconazole B-DRUG
, O
macrolide B-GROUP
antibiotics I-GROUP
such O
as O
erythromycin B-DRUG
) O
have O
the O
potential O
to O
result O
in O
increased O
plasma O
concentrations O
of O
corticosteroids B-GROUP
. O
Dexamethasone B-DRUG
is O
a O
moderate O
inducer O
of O
CYP O
3A4 O
. O
Co O
- O
administration O
with O
other O
drugs O
that O
are O
metabolized O
by O
CYP O
3A4 O
( O
e O
. O
g O
. O
, O
indinavir B-DRUG
, O
erythromycin B-DRUG
) O
may O
increase O
their O
clearance O
, O
resulting O
in O
decreased O
plasma O
concentration O
. O
Ketoconazole B-DRUG
: O
Ketoconazole B-DRUG
has O
been O
reported O
to O
decrease O
the O
metabolism O
of O
certain O
corticosteroids B-GROUP
by O
up O
to O
60 O
% O
, O
leading O
to O
increased O
risk O
of O
corticosteroid B-GROUP
side O
effects O
. O
In O
addition O
, O
ketoconazole B-DRUG
alone O
can O
inhibit O
adrenal O
corticosteroid B-DRUG
synthesis O
and O
may O
cause O
adrenal O
insufficiency O
during O
corticosteroid O
withdrawal O
. O
Nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
( O
NSAIDS B-GROUP
) O
: O
Concomitant O
use O
of O
aspirin B-BRAND
( O
or O
other O
nonsteroidal B-GROUP
antiinflammatory I-GROUP
agents I-GROUP
) O
and O
corticosteroids B-GROUP
increases O
the O
risk O
of O
gastrointestinal O
side O
effects O
. O
Aspirin B-BRAND
should O
be O
used O
cautiously O
in O
conjunction O
with O
corticosteroids B-GROUP
in O
hypoprothrombinemia O
. O
The O
clearance O
of O
salicylates B-GROUP
may O
be O
increased O
with O
concurrent O
use O
of O
corticosteroids B-GROUP
. O
Phenytoin B-DRUG
: O
In O
post O
- O
marketing O
experience O
, O
there O
have O
been O
reports O
of O
both O
increases O
and O
decreases O
in O
phenytoin B-DRUG
levels O
with O
dexamethasone B-DRUG
co O
- O
administration O
, O
leading O
to O
alterations O
in O
seizure O
control O
. O
Skin O
tests O
: O

Corticosteroids B-GROUP
may O
suppress O
reactions O
to O
skin O
tests O
. O
Thalidomide B-DRUG
: O
Co O
- O
administration O
with O
thalidomide B-DRUG
should O
be O
employed O
cautiously O
, O
as O
toxic O
epidermal O
necrolysis O
has O
been O
reported O
with O
concomitant O
use O
. O
Vaccines B-GROUP
: O
Patients O
on O
corticosteroid B-GROUP
therapy O
may O
exhibit O
a O
diminished O
response O
to O
toxoids O
and O
live B-GROUP
or I-GROUP
inactivated I-GROUP
vaccines I-GROUP
due O
to O
inhibition O
of O
antibody O
response O
. O
Corticosteroids B-GROUP
may O
also O
potentiate O
the O
replication O
of O
some O
organisms O
contained O
in O
live B-GROUP
attenuated I-GROUP
vaccines I-GROUP
. O
Routine O
administration O
of O
vaccines B-GROUP
or O
toxoids O
should O
be O
deferred O
until O
corticosteroid B-GROUP
therapy O
is O
discontinued O
if O
possible O
. O

Dexbrompheniramine B-DRUG
can O
interact O
with O
alcohol B-DRUG
or O
other O
CNS B-GROUP
depressants I-GROUP
( O
may O
potentiate O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
antihistamines B-GROUP
) O
, O
anticholinergics B-GROUP
or O
other O
medications O
with O
anticholinergic O
activity O
( O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
antihistamines B-GROUP
) O
, O
and O
monoamine B-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
( O
concurrent O
use O
with O
antihistamines B-GROUP
may O
prolong O
and O
intensify O
the O
anticholinergic O
and O
CNS O
depressant O
effects O
of O
antihistamines B-GROUP
) O
. O

In O
patients O
receiving O
nonselective O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
( O
MAOIs B-GROUP
) O
( O
e O
. O
g O
. O
, O
selegiline B-DRUG
hydrochloride I-DRUG
) O
in O
combination O
with O
serotoninergic B-GROUP
agents I-GROUP
( O
e O
. O
g O
. O
, O
fluoxetine B-DRUG
, O
fluvoxamine B-DRUG
, O
paroxetine B-DRUG
, O
sertraline B-DRUG
, O
venlafaxine B-DRUG
) O
, O
there O
have O
been O
reports O
of O
serious O
, O
sometimes O
fatal O
, O
reactions O
. O
Because O
dexfenfluramine B-DRUG
is O
a O
serotonin O
releaser O
and O
reuptake O
inhibitor O
, O
dexfenfluramine B-DRUG
should O
not O
be O
used O
concomitantly O
with O
a O
MAO B-GROUP
inhibitor I-GROUP
. O
At O
least O
14 O
days O
should O
elapse O
between O
discontinuation O
of O
a O
MAO B-GROUP
inhibitor I-GROUP
and O
initiation O
of O
treatment O
with O
dexfenfluramine B-DRUG
. O
At O
least O
3 O
weeks O
should O
elapse O
between O
discontinuation O
of O
dexfenfluramine B-DRUG
and O
initiation O
of O
treatment O
with O
a O
MAO B-GROUP
inhibitor I-GROUP
. O
A O
rare O
, O
but O
serious O
, O
constellation O
of O
symptoms O
, O
termed O
serotonin O
syndrome O
, O
has O
been O
reported O
with O
the O
concomitant O
use O
of O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
( O
SSRIs B-GROUP
) O
and O
agents O
for O
migraine O
therapy O
, O
such O
as O
Imitrex B-BRAND
( O
sumatriptan B-DRUG
succinate I-DRUG
) O
and O
dihydroergotamine B-DRUG
. O
The O
syndrome O
requires O
immediate O
medical O
attention O
and O
may O
include O
one O
or O
more O
of O
the O
following O
symptoms O
: O
excitement O
, O
hypomania O
, O
restlessness O
, O
loss O
of O
consciousness O
, O
confusion O
, O
disorientation O
, O
anxiety O
, O
agitation O
, O
motor O
weakness O
, O
myoclonus O
, O
tremor O
, O
hemiballismus O
, O
hyperreflexia O
, O
ataxia O
, O
dysarthria O
, O
incoordination O
, O
hyperthermia O
, O
shivering O
, O
pupillary O
dilation O
, O
diaphoresis O
, O
emesis O
, O
and O
tachycardia O
. O
Dexfenfluramine B-DRUG
should O
not O
be O
administered O
with O
other O
serotoninergic B-GROUP
agents I-GROUP
. O
The O
appropriate O
interval O
between O
administration O
of O
these O
agents O
and O
dexfenfluramine B-DRUG
has O
not O
been O
established O
. O
The O
use O
of O
dexfenfluramine B-DRUG
with O
other O
CNS O
- O
active O
drugs O
has O
not O
been O
systematically O
evaluated O
; O
consequently O
, O
caution O
is O
advised O
if O
dexfenfluramine B-DRUG
and O
such O
drugs O
are O
prescribed O
concurrently O
. O

General O
In O
vitro O
studies O
in O
human O
liver O
microsomes O
demonstrated O
no O
evidence O
of O
cytochrome O
P450 O
- O
mediated O
drug O
interactions O
that O
are O
likely O
to O
be O
of O
clinical O
relevance O
. O
Anesthetics B-GROUP
/ O
Sedatives B-GROUP
/ O
Hypnotics B-GROUP
/ O
Opioids B-GROUP
: O
Co O
- O
administration O
of O
PRECEDEX B-BRAND
with O
anesthetics B-GROUP
, O
sedatives B-GROUP
, O
hypnotics B-GROUP
, O
and O
opioids B-GROUP
is O
likely O
to O
lead O
to O
an O
enhancement O
of O
effects O
. O
Specific O
studies O
have O
confirmed O
these O
effects O
with O
sevoflurane B-DRUG
, O
isoflurane B-DRUG
, O
propofol B-DRUG
, O
alfentanil B-DRUG
, O
and O
midazolam B-DRUG
. O
No O
pharmacokinetic O
interactions O
between O
dexmedetomidine B-DRUG
and O
isoflurane B-DRUG
, O
propofol B-DRUG
, O
alfentanil B-DRUG
, O
and O
midazolam B-DRUG
have O
been O
demonstrated O
. O
However O
, O
due O
to O
possible O
pharmacodynamic O
interactions O
, O
when O
co O
- O
administered O
with O
PRECEDEX B-BRAND
, O
a O
reduction O
in O
dosage O
of O
PRECEDEX B-BRAND
on O
the O
concomitant O
anesthetic B-GROUP
, O
sedative B-GROUP
, O
hypnotic B-GROUP
or O
opioid B-GROUP
may O
be O
required O
. O
Neuromuscular B-GROUP
Blockers I-GROUP
: O
In O
one O
study O
of O
10 O
healthy O
volunteers O
, O
administration O
of O
PRECEDEX B-BRAND
for O
45 O
minutes O
at O
a O
plasma O
concentration O
of O
1 O
( O
one O
) O
ng O
/ O
mL O
resulted O
in O
no O
clinically O
meaningful O
increases O
in O
the O
magnitude O
or O
neuromuscular O
blockade O
associated O
with O
rocuronium B-DRUG
administration O
. O

ZINECARD B-BRAND
does O
not O
influence O
the O
pharmacokinetics O
of O
doxorubicin B-DRUG
. O
Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
No O
long O
- O
term O
carcinogenicity O
studies O
have O
been O
carried O
out O
with O
dexrazoxane B-DRUG
in O
animals O
. O
Dexrazoxane B-DRUG
was O
not O
mutagenic O
in O
the O
Ames O
test O
but O
was O
found O
to O
be O
clastogenic O
to O
human O
lymphocytes O
in O
vitro O
and O
to O
mouse O
bone O
marrow O
erythrocytes O
in O
vivo O
( O
micronucleus O
test O
) O
. O
The O
possible O
adverse O
effects O
of O
ZINECARD B-BRAND
on O
the O
fertility O
of O
humans O
and O
experimental O
animals O
, O
male O
or O
female O
, O
have O
not O
been O
adequately O
studied O
. O
Testicular O
atrophy O
was O
seen O
with O
dexrazoxane B-DRUG
administration O
at O
doses O
as O
low O
as O
30 O
mg O
/ O
kg O
weekly O
for O
6 O
weeks O
in O
rats O
( O
1 O
/ O
3 O
the O
human O
dose O
on O
a O
mg O
/ O
m O
2 O
basis O
) O
and O
as O
low O
as O
20 O
mg O
/ O
kg O
weekly O
for O
13 O
weeks O
in O
dogs O
( O
approximately O
equal O
to O
the O
human O
dose O
on O
a O
mg O
/ O
m O
2 O
basis O
) O
. O

Acidifying B-GROUP
agents I-GROUP
: O
Gastrointestinal B-GROUP
acidifying I-GROUP
agents I-GROUP
( O
guanethidine B-DRUG
, O
reserpine B-DRUG
, O
glutamic B-DRUG
acid I-DRUG
HCl I-DRUG
, O
ascorbic B-DRUG
acid I-DRUG
, O
fruit O
juices O
, O
etc O
. O
) O
lower O
absorption O
of O
amphetamines B-GROUP
. O
Urinary B-GROUP
acidifying I-GROUP
agents I-GROUP
( O
ammonium B-DRUG
chloride I-DRUG
, O
sodium B-DRUG
acid I-DRUG
phosphate I-DRUG
, O
etc O
. O
) O
increase O
the O
concentration O
of O
the O
ionized O
species O
of O
the O
amphetamine B-DRUG
molecule O
, O
thereby O
increasing O
urinary O
excretion O
. O
Both O
groups O
of O
agents O
lower O
blood O
levels O
and O
efficacy O
of O
amphetamines B-GROUP
. O
Adrenergic B-GROUP
blockers I-GROUP
: O
Adrenergic B-GROUP
blockers I-GROUP
are O
inhibited O
by O
amphetamines B-GROUP
. O
Alkalinizing O
agents O
: O
Gastrointestinal O
alkalinizing O
agents O
( O
sodium B-DRUG
bicarbonate I-DRUG
, O
etc O
. O
) O
increase O
absorption O
of O
amphetamines B-DRUG
. O
Urinary O
alkalinizing O
agents O
( O
acetazolamide B-DRUG
, O
some O
thiazides B-GROUP
) O
increase O
the O
concentration O
of O
the O
non O
- O
ionized O
species O
of O
the O
amphetamine B-DRUG
molecule O
, O
thereby O
decreasing O
urinary O
excretion O
. O
Both O
groups O
of O
agents O
increase O
blood O
levels O
and O
therefore O
potentiate O
the O
actions O
of O
amphetamines B-GROUP
. O
Antidepressants B-GROUP
, O
tricyclic B-GROUP
: O
Amphetamines B-GROUP
may O
enhance O
the O
activity O
of O
tricyclic B-GROUP
or O
sympathomimetic B-GROUP
agents I-GROUP
; O
d B-DRUG
- I-DRUG
amphetamine I-DRUG
with O
desipramine B-DRUG
or O
protriptyline B-DRUG
and O
possibly O
other O
tricyclics B-GROUP
cause O
striking O
and O
sustained O
increases O
in O
the O
concentration O
of O
d B-DRUG
- I-DRUG
amphetamine I-DRUG
in O
the O
brain O
; O
cardiovascular O
effects O
can O
be O
potentiated O
. O
MAO B-GROUP
inhibitors I-GROUP
: O
MAOI B-GROUP
antidepressants I-GROUP
, O
as O
well O
as O
a O
metabolite O
of O
furazolidone B-DRUG
, O
slow O
amphetamine B-GROUP
metabolism O
. O
This O
slowing O
potentiates O
amphetamines B-GROUP
, O
increasing O
their O
effect O
on O
the O
release O
of O
norepinephrine O
and O
other O
monoamines O
from O
adrenergic O
nerve O
endings O
; O
this O
can O
cause O
headaches O
and O
other O
signs O
of O
hypertensive O
crisis O
. O
A O
variety O
of O
neurological O
toxic O
effects O
and O
malignant O
hyperpyrexia O
can O
occur O
, O
sometimes O
with O
fatal O
results O
. O
Antihistamines B-GROUP
: O
Amphetamines B-GROUP
may O
counteract O
the O
sedative O
effect O
of O
antihistamines B-GROUP
. O
Antihypertensives B-GROUP
: O
Amphetamines B-GROUP
may O
antagonize O
the O
hypotensive O
effects O
of O
antihypertensives B-GROUP
. O
Chlorpromazine B-DRUG
: O
Chlorpromazine B-DRUG
blocks O
dopamine O
and O
norepinephrine O
reuptake O
, O
thus O
inhibiting O
the O
central O
stimulant O
effects O
of O

amphetamines B-GROUP
, O
and O
can O
be O
used O
to O
treat O
amphetamine B-GROUP
poisoning O
. O
Ethosuximide B-DRUG
: O
Amphetamines B-GROUP
may O
delay O
intestinal O
absorption O
of O
ethosuximide B-DRUG
. O
Haloperidol B-DRUG
: O
Haloperidol B-DRUG
blocks O
dopamine O
and O
norepinephrine O
reuptake O
, O
thus O
inhibiting O
the O
central O
stimulant O
effects O
of O
amphetamines B-GROUP
. O
Lithium B-DRUG
carbonate I-DRUG
: O
The O
stimulatory O
effects O
of O
amphetamines B-GROUP
may O
be O
inhibited O
by O
lithium B-DRUG
carbonate I-DRUG
. O
Meperidine B-DRUG
: O
Amphetamines B-GROUP
potentiate O
the O
analgesic O
effect O
of O
meperidine B-DRUG
. O
Methenamine B-DRUG
therapy O
: O
Urinary O
excretion O
of O
amphetamines B-GROUP
is O
increased O
, O
and O
efficacy O
is O
reduced O
, O
by O
acidifying B-GROUP
agents I-GROUP
used O
in O
methenamine B-DRUG
therapy O
. O
Norepinephrine B-DRUG
: O
Amphetamines B-GROUP
enhance O
the O
adrenergic O
effect O
of O
norepinephrine B-DRUG
. O
Phenobarbital B-DRUG
: O
Amphetamines B-GROUP
may O
delay O
intestinal O
absorption O
of O
phenobarbital B-DRUG
; O
co O
- O
administration O
of O
phenobarbital B-DRUG
may O
produce O
a O
synergistic O
anticonvulsant O
action O
. O
Phenytoin B-DRUG
: O
Amphetamines B-GROUP
may O
delay O
intestinal O
absorption O
of O
phenytoin B-DRUG
; O
co O
- O
administration O
of O
phenytoin B-DRUG
may O
produce O
a O
synergistic O
anticonvulsant O
action O
. O
Propoxyphene B-DRUG
: O
In O
cases O
of O
propoxyphene B-DRUG
overdosage O
, O
amphetamine B-GROUP
CNS O
stimulation O
is O
potentiated O
and O
fatal O
convulsions O
can O
occur O
. O
Veratrum B-GROUP
alkaloids I-GROUP
: O
Amphetamines B-GROUP
inhibit O
the O
hypotensive O
effect O
of O
veratrum B-GROUP
alkaloids I-GROUP
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
: O
Amphetamines B-GROUP
can O
cause O
a O
significant O
elevation O
in O
plasma O
corticosteroid B-GROUP
levels O
. O
This O
increase O
is O
greatest O
in O
the O
evening O
. O
Amphetamines B-GROUP
may O
interfere O
with O
urinary O
steroid O
determinations O
. O

Additive O
depressant O
effect O
when O
used O
with O
general O
anesthetics B-GROUP
, O
sedatives B-GROUP
, O
antianxiety B-GROUP
drugs I-GROUP
, O
hypnotics B-GROUP
, O
alcohol B-DRUG
, O
and O
other O
opiate B-GROUP
analgesics I-GROUP
. O

May O
interact O
with O
thyroid O
medication O
( O
e O
. O
g O
. O
, O
levothyroxine B-DRUG
) O
, O
iodine B-DRUG
- O
containing O
products O
, O
antacids B-GROUP
, O
H2 B-GROUP
- I-GROUP
antagonists I-GROUP
( O
e O
. O
g O
. O
, O
famotidine B-DRUG
, O
ranitidine B-DRUG
) O
, O
and O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
( O
e O
. O
g O
. O
, O
lansoprazole B-DRUG
, O
omeprazole B-DRUG
) O
. O
This O
product O
can O
affect O
the O
results O
of O
certain O
lab O
tests O
. O

Caution O
is O
advised O
in O
patients O
receiving O
concomitant O
high O
- O
dose O
aspirin B-BRAND
and O
carbonic B-GROUP
anhydrase I-GROUP
inhibitors I-GROUP
, O
as O
anorexia O
, O
tachypnea O
, O
lethargy O
and O
coma O
have O
been O
rarely O
reported O
due O
to O
a O
possible O
drug O
interaction O
. O

Aspirin B-BRAND
: O
Concomitant O
administration O
of O
diclofenac B-DRUG
and O
aspirin B-BRAND
is O
not O
recommended O
because O
diclofenac B-DRUG
is O
displaced O
from O
its O
binding O
sites O
during O
the O
concomitant O
administration O
of O
aspirin B-BRAND
, O
resulting O
in O
lower O
plasma O
concentrations O
, O
peak O
plasma O
levels O
, O
and O
AUC O
values O
. O
Anticoagulants B-GROUP
: O
While O
studies O
have O
not O
shown O
diclofenac B-DRUG
to O
interact O
with O
anticoagulants B-GROUP
of I-GROUP
the I-GROUP
warfarin I-GROUP
type I-GROUP
, O
caution O
should O
be O
exercised O
, O
nonetheless O
, O
since O
interactions O
have O
been O
seen O
with O
other O
NSAIDs B-GROUP
. O
Because O
prostaglandins O
play O
an O
important O
role O
in O
hemostasis O
, O
and O
NSAIDs B-GROUP
affect O
platelet O
function O
as O
well O
, O
concurrent O
therapy O
with O
all O
NSAIDs B-GROUP
, O
including O
diclofenac B-DRUG
, O
and O
warfarin B-DRUG
requires O
close O
monitoring O
of O
patients O
to O
be O
certain O
that O
no O
change O
in O
their O
anticoagulant B-GROUP
dosage O
is O
required O
. O
Digoxin B-DRUG
, O
Methotrexate B-DRUG
, O
Cyclosporine B-DRUG
: O
Diclofenac B-DRUG
, O
like O
other O
NSAIDs B-GROUP
, O
may O
affect O
renal O
prostaglandins O
and O
increase O
the O
toxicity O
of O
certain O
drugs O
. O
Ingestion O
of O
diclofenac B-DRUG
may O
increase O
serum O
concentrations O
of O
digoxin B-DRUG
and O
methotrexate B-DRUG
and O
increase O
cyclosporine B-DRUG
s O
nephrotoxicity O
. O
Patients O
who O
begin O
taking O
diclofenac B-DRUG
or O
who O
increase O
their O
diclofenac B-DRUG
dose O
or O
any O
other O
NSAID B-GROUP
while O
taking O
digoxin B-DRUG
, O
methotrexate B-DRUG
, O
or O
cyclosporine B-DRUG
may O
develop O
toxicity O
characteristics O
for O
these O
drugs O
. O
They O
should O
be O
observed O
closely O
, O
particularly O
if O
renal O
function O
is O
impaired O
. O
In O
the O
case O
of O
digoxin B-DRUG
, O
serum O
levels O
should O
be O
monitored O
. O
Lithium B-DRUG
: O
Diclofenac B-DRUG
decreases O
lithium B-DRUG
renal O
clearance O
and O
increases O
lithium B-DRUG
plasma O
levels O
. O
In O
patients O
taking O
diclofenac B-DRUG
and O
lithium B-DRUG
concomitantly O
, O
lithium B-DRUG
toxicity O
may O
develop O
. O
Oral O
Hypoglycemics B-GROUP
: O
Diclofenac B-DRUG
does O
not O
alter O
glucose O
metabolism O
in O
normal O
subjects O
nor O
does O
it O
alter O
the O
effects O
of O
oral O
hypoglycemic B-GROUP
agents I-GROUP
. O
There O
are O
rare O
reports O
, O
however O
, O
from O
marketing O
experiences O
, O
of O
changes O
in O
effects O
of O
insulin B-DRUG
or O
oral O
hypoglycemic B-GROUP
agents I-GROUP
in O
the O
presence O
of O
diclofenac B-DRUG
that O
necessitated O
changes O
in O
the O
doses O
of O
such O
agents O
. O
Both O
hypo O
- O
and O
hyperglycemic O
effects O
have O
been O
reported O
. O
A O
direct O
causal O
relationship O
has O
not O
been O
established O
, O
but O
physicians O
should O
consider O
the O
possibility O
that O
diclofenac B-DRUG
may O
alter O
a O

diabetic O
patient O
s O
response O
to O
insulin B-DRUG
or O
oral O
hypoglycemic B-GROUP
agents I-GROUP
. O
Diuretics B-GROUP
: O
Diclofenac B-DRUG
and O
other O
NSAIDs B-GROUP
can O
inhibit O
the O
activity O
of O
diuretics B-GROUP
. O
Concomitant O
treatment O
with O
potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
may O
be O
associated O
with O
increased O
serum O
potassium O
levels O
. O
Other O
Drugs O
: O
In O
small O
groups O
of O
patients O
( O
7 O
- O
10 O
/ O
interaction O
study O
) O
, O
the O
concomitant O
administration O
of O
azathioprine B-DRUG
, O
gold B-GROUP
, O
chloroquine B-DRUG
, O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
, O
prednisolone B-DRUG
, O
doxycycline B-DRUG
, O
or O
digitoxin B-DRUG
did O
not O
significantly O
affect O
the O
peak O
levels O
and O
AUC O
values O
of O
diclofenac B-DRUG
. O
Phenobarbital B-DRUG
toxicity O
has O
been O
reported O
to O
have O
occurred O
in O
a O
patient O
on O
chronic O
phenobarbital B-DRUG
treatment O
following O
the O
initiation O
of O
diclofenac B-DRUG
therapy O
. O
Protein O
Binding O
In O
vitro O
, O
diclofenac B-DRUG
interferes O
minimally O
or O
not O
at O
all O
with O
the O
protein O
binding O
of O
salicylic B-DRUG
acid I-DRUG
( O
20 O
% O
decrease O
in O
binding O
) O
, O
tolbutamide B-DRUG
, O
prednisolone B-DRUG
( O
10 O
% O
decrease O
in O
binding O
) O
, O
or O
warfarin B-DRUG
. O
Benzylpenicillin B-DRUG
, O
ampicillin B-DRUG
, O
oxacillin B-DRUG
, O
chlortetracycline B-DRUG
, O
doxycycline B-DRUG
, O
cephalothin B-DRUG
, O
erythromycin B-DRUG
, O
and O
sulfamethoxazole B-DRUG
have O
no O
influence O
in O
vitro O
on O
the O
protein O
binding O
of O
diclofenac B-DRUG
in O
human O
serum O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Effect O
on O
Blood O
Coagulation O
: O
Diclofenac B-DRUG
increases O
platelet O
aggregation O
time O
but O
does O
not O
affect O
bleeding O
time O
, O
plasma O
thrombin O
clotting O
time O
, O
plasma O
fibrinogen O
, O
or O
factors O
V O
and O
VII O
to O
XII O
. O
Statistically O
significant O
changes O
in O
prothrombin O
and O
partial O
thromboplastin O
times O
have O
been O
reported O
in O
normal O
volunteers O
. O
The O
mean O
changes O
were O
observed O
to O
be O
less O
than O
1 O
second O
in O
both O
instances O
, O
however O
, O
and O
are O
unlikely O
to O
be O
clinically O
important O
. O
Diclofenac B-DRUG
is O
a O
prostaglandin O
synthetase O
inhibitor O
, O
however O
, O
and O
all O
drugs O
that O
inhibit O
prostaglandin O
synthesis O
interfere O
with O
platelet O
function O
to O
some O
degree O
; O
therefore O
, O
patients O
who O
may O
be O
adversely O
affected O
by O
such O
an O
action O
should O
be O
carefully O
observed O
. O

Tetracycline B-DRUG
, O
a O
bacteriostatic B-GROUP
antibiotic I-GROUP
, O
may O
antagonize O
the O
bactercidal O
effect O
of O
penicillin B-DRUG
and O
concurrent O
use O
of O
these O
drugs O
should O
be O
avoided O
. O

The O
following O
agents O
may O
increase O
certain O
actions O
or O
side O
effects O
of O
anticholinergic B-GROUP
drugs I-GROUP
. O
amantadine B-DRUG
antiarrhythmic B-GROUP
agents I-GROUP
of O
class O
( O
e O
. O
g O
. O
quinidine B-DRUG
) O
, O
antihistamines B-GROUP
antipsychotic B-GROUP
agents I-GROUP
( O
e O
. O
g O
. O
phenothiazines B-GROUP
) O
, O
benzodiazepines B-GROUP
. O
MAO B-GROUP
inhibitors I-GROUP
, O
narcotic B-GROUP
analgesics I-GROUP
( O
e O
. O
g O
. O
, O
meperidine B-DRUG
) O
, O
nitrates B-GROUP
and O
nitrites B-GROUP
, O
sympathomimetic B-GROUP
agents I-GROUP
, O
tricyclic B-GROUP
antidepressants I-GROUP
, O
and O
other O
drugs O
having O
anticholinergic O
activity O
. O
Anticholinergics B-GROUP
antagonize O
the O
effects O
of O
antiglaucoma B-GROUP
agents I-GROUP
. O
Anticholinergic B-GROUP
drugs I-GROUP
in O
the O
presence O
of O
increased O
intraocular O
pressure O
may O
be O
hazardous O
when O
taken O
concurrently O
with O
agents O
such O
as O
corti O
costeroids O
. O
. O
Anticholinergic B-GROUP
agents I-GROUP
may O
affect O
gastrointestinal O
absorption O
of O
various O
drugs O
, O
such O
as O
slowly O
dissolving O
dosage O
forms O
of O
digoxin B-DRUG
; O
increased O
serum O
digoxin B-DRUG
concentrations O
may O
result O
. O
Anticholinergic B-GROUP
drugs I-GROUP
may O
antagonize O
the O
effects O
of O
the O
drugs O
that O
alter O
gastrointestinal O
motility O
, O
such O
as O
metoclopramide B-DRUG
. O
Because O
antacids B-GROUP
may O
interfere O
with O
the O
absorption O
of O
anticholinergic B-GROUP
agents I-GROUP
, O
simultaneous O
use O
of O
these O
drugs O
should O
be O
avoided O
. O
The O
inhibiting O
effects O
of O
anticholinergic B-GROUP
drugs I-GROUP
on O
gastric O
hydrochloric O
acid O
secretion O
are O
antagonized O
by O
agents O
used O
to O
treat O
achlorhydria O
and O
those O
used O
to O
test O
gastric O
secretion O
. O

Coadministration O
of O
VIDEX B-BRAND
with O
drugs O
that O
are O
known O
to O
cause O
pancreatitis O
may O
increase O
the O
risk O
of O
this O
toxicity O
( O
see O
WARNINGS O
) O
and O
should O
be O
done O
with O
extreme O
caution O
, O
only O
if O
other O
alternatives O
are O
not O
available O
, O
and O
only O
if O
clearly O
indicated O
. O
Neuropathy O
has O
occurred O
more O
frequently O
in O
patients O
with O
a O
history O
of O
neuropathy O
or O
neurotoxic O
drug O
therapy O
, O
including O
stavudine B-DRUG
, O
and O
these O
patients O
may O
be O
at O
increased O
risk O
of O
neuropathy O
during O
VIDEX B-BRAND
therapy O
( O
see O
ADVERSE O
REACTIONS O
) O
. O
Allopurinol B-DRUG
: O
The O
AUC O
of O
didanosine B-DRUG
was O
increased O
about O
4 O
- O
fold O
when O
allopurinol B-DRUG
at O
300 O
mg O
/ O
day O
was O
coadministered O
with O
a O
single O
200 O
- O
mg O
dose O
of O
VIDEX B-BRAND
to O
two O
patients O
with O
renal O
impairment O
( O
CLcr O
= O
15 O
and O
18 O
mL O
/ O
min O
) O
. O
The O
effects O
of O
allopurinol B-DRUG
on O
didanosine B-DRUG
pharmacokinetics O
in O
subjects O
with O
normal O
renal O
function O
are O
not O
known O
. O
Antacids B-GROUP
: O
Concomitant O
administration O
of O
antacids B-GROUP
containing O
magnesium B-DRUG
or O
aluminum B-DRUG
with O
VIDEX B-BRAND
Chewable O
/ O
Dispersible O
Buffered O
Tablets O
or O
Pediatric O
Powder O
for O
Oral O
Solution O
may O
potentiate O
adverse O
events O
associated O
with O
the O
antacid B-GROUP
components O
. O
Drugs O
Whose O
Absorption O
Can O
Be O
Affected O
by O
the O
Level O
of O
Acidity O
in O
the O
Stomach O
: O
Drugs O
such O
as O
ketoconazole B-DRUG
and O
itraconazole B-DRUG
should O
be O
administered O
at O
least O
2 O
hours O
prior O
to O
dosing O
with O
VIDEX B-BRAND
. O
Ganciclovir B-DRUG
: O
Administration O
of O
VIDEX B-BRAND
2 O
hours O
prior O
to O
or O
concurrent O
with O
oral O
ganciclovir B-DRUG
was O
associated O
with O
a O
111 O
( O
114 O
) O
% O
increase O
in O
the O
steady O
- O
state O
AUC O
of O
didanosine B-DRUG
( O
n O
= O
12 O
) O
. O
A O
21 O
( O
17 O
) O
% O
decrease O
in O
the O
steady O
- O
state O
AUC O
of O
ganciclovir B-DRUG
was O
observed O
when O
VIDEX B-BRAND
was O
administered O
2 O
hours O
prior O
to O
ganciclovir B-DRUG
, O
but O
not O
when O
the O
two O
drugs O
were O
administered O
simultaneously O
( O
n O
= O
12 O
) O
. O
Quinolone B-GROUP
Antibiotics I-GROUP
: O
VIDEX B-BRAND
should O
be O
administered O
at O
least O
2 O
hours O
after O
or O
6 O
hours O
before O
dosing O
with O
ciprofloxacin B-DRUG
because O
plasma O
concentrations O
of O
ciprofloxacin B-DRUG
are O
decreased O
when O
administered O
with O
antacids B-GROUP
containing O
magnesium B-DRUG
, O
calcium B-DRUG
, O
or O
aluminum B-DRUG
. O
In O
eight O
HIV O
- O
infected O
patients O
, O
the O

steady O
- O
state O
AUC O
of O
ciprofloxacin B-DRUG
was O
decreased O
an O
average O
of O
26 O
% O
( O
95 O
% O
CI O
= O
14 O
% O
, O
37 O
% O
) O
when O
ciprofloxacin B-DRUG
was O
administered O
2 O
hours O
prior O
to O
a O
marketed O
chewable O
/ O
dispersible O
tablet O
formulation O
of O
VIDEX B-BRAND
. O
The O
AUC O
of O
ciprofloxacin B-DRUG
was O
decreased O
an O
average O
of O
15 O
- O
fold O
in O
12 O
healthy O
subjects O
given O
ciprofloxacin B-DRUG
and O
didanosine B-DRUG
- O
placebo O
tablets O
concurrently O
. O
In O
a O
single O
subject O
given O
one O
dose O
of O
ciprofloxacin B-DRUG
2 O
hours O
after O
a O
dose O
of O
didanosine B-DRUG
- O
placebo O
tablets O
, O
a O
greater O
than O
50 O
% O
reduction O
in O
the O
AUC O
of O
ciprofloxacin B-DRUG
was O
observed O
. O
Plasma O
concentrations O
of O
quinolone B-GROUP
antibiotics I-GROUP
are O
decreased O
when O
administered O
with O
antacids B-GROUP
containing O
magnesium B-DRUG
, O
calcium B-DRUG
, O
or O
aluminum B-DRUG
. O
The O
optimal O
dosing O
interval O
for O
coadministration O
with O
VIDEX B-BRAND
should O
be O
determined O
by O
consulting O
the O
appropriate O
quinolone B-GROUP
package O
insert O
. O
Interactions O
with O
Other O
Antiretroviral B-GROUP
Drugs I-GROUP
: O
Significant O
decreases O
in O
the O
AUC O
of O
delavirdine B-DRUG
( O
20 O
% O
) O
and O
indinavir B-DRUG
( O
84 O
% O
) O
occurred O
following O
simultaneous O
administration O
of O
these O
agents O
with O
VIDEX B-BRAND
. O
To O
avoid O
this O
interaction O
, O
delavirdine B-DRUG
or O
indinavir B-DRUG
should O
be O
given O
1 O
hour O
prior O
to O
dosing O
with O
VIDEX B-BRAND
. O
The O
pharmacokinetics O
of O
nelfinavir B-DRUG
are O
not O
altered O
to O
a O
clinically O
significant O
degree O
when O
it O
is O
administered O
with O
a O
light O
meal O
1 O
hour O
after O
VIDEX B-BRAND
. O

Drug O
/ O
Laboratory O
Test O
Interactions O
Certain O
endocrine O
and O
liver O
function O
tests O
may O
be O
affected O
by O
estrogen B-GROUP
- O
containing O
oral O
contraceptives B-GROUP
. O
The O
following O
similar O
changes O
may O
be O
expected O
with O
larger O
doses O
of O
estrogen B-GROUP
: O
- O
Increased O
sulfobromophthalein O
retention O
. O
- O
Increased O
prothrombin O
and O
factors O
VII O
, O
VIII O
, O
IX O
, O
and O
X O
; O
decreased O
antithrombin B-DRUG
3 I-DRUG
; O
increased O
norepinephrine O
- O
induced O
platelet O
aggregability O
. O
- O
Increased O
thyroid O
- O
binding O
globulin O
( O
TBG O
) O
leading O
to O
in O
- O
creased O
circulating O
total O
thyroid O
hormone O
; O
as O
measured O
by O
PBI O
, O
T4 O
by O
column O
, O
or O
T4 O
by O
radioimmunoassay O
. O
Free O
T3 O
resin O
uptake O
is O
decreased O
, O
reflecting O
the O
elevated O
TBG O
; O
free O
T4 O
concentration O
is O
unaltered O
. O
- O
Impaired O
glucose O
tolerance O
. O
- O
Decreased O
pregnanediol O
excretion O
. O
- O
Reduced O
response O
to O
metyrapone O
test O
. O
- O
Reduced O
serum O
folate O
concentration O
. O
- O
Increased O
serum O
triglyceride O
and O
phospholipid O
concentration O
. O

Antidiabetic B-GROUP
drug I-GROUP
requirements O
( O
i O
. O
e O
. O
, O
insulin B-DRUG
) O
may O
be O
altered O
. O
Concurrent O
use O
with O
general O
anesthetics B-GROUP
may O
result O
in O
arrhythmias O
. O
The O
pressor O
effects O
of O
diethylpropion B-DRUG
and O
those O
of O
other O
drugs O
may O
be O
additive O
when O
the O
drugs O
are O
used O
concomitantly O
; O
conversely O
, O
diethylpropion B-DRUG
may O
interfere O
with O
antihypertensive B-GROUP
drugs I-GROUP
( O
i O
. O
e O
. O
, O
guanethidine B-DRUG
, O
a B-DRUG
- I-DRUG
methyldopa I-DRUG
) O
. O
Concurrent O
use O
of O
phenothiazines B-GROUP
may O
antagonize O
the O
anorectic O
effect O
of O
diethylpropion B-DRUG
. O

May O
interact O
anticoagulants B-GROUP
( O
altered O
hypo O
- O
prothrombinemic O
effect O
) O
, O
barbiturates B-GROUP
, O
rifampin B-DRUG
and O
other O
inducers O
of O
hepatic O
microsomal O
enzyme O
oxidation O
system O
( O
decreased O
effect O
of O
diethylstilbestrol B-DRUG
) O
, O
corticosteroids B-GROUP
( O
increased O
effect O
of O
corticosteroids B-GROUP
) O
. O

Oral O
Anticoagulants B-GROUP
: O
In O
some O
normal O
volunteers O
, O
the O
concomitant O
administration O
of O
diflunisal B-DRUG
and O
warfarin B-DRUG
, O
acenocoumarol B-DRUG
, O
or O
phenprocoumon B-DRUG
resulted O
in O
prolongation O
of O
prothrombin O
time O
. O
This O
may O
occur O
because O
diflunisal B-DRUG
competitively O
displaces O
coumarins B-GROUP
from O
protein O
binding O
sites O
. O
Accordingly O
, O
when O
diflunisal B-DRUG
is O
administered O
with O
oral O
anticoagulants B-GROUP
, O
the O
prothrombin O
time O
should O
be O
closely O
monitored O
during O
and O
for O
several O
days O
after O
concomitant O
drug O
administration O
. O
Adjustment O
of O
dosage O
of O
oral O
anticoagulants B-GROUP
may O
be O
required O
. O
Tolbutamide B-DRUG
: O
In O
diabetic O
patients O
receiving O
diflunisal B-DRUG
and O
tolbutamide B-DRUG
, O
no O
significant O
effects O
were O
seen O
on O
tolbutamide B-DRUG
plasma O
levels O
or O
fasting O
blood O
glucose O
. O
Hydrochlorothiazide B-DRUG
: O
In O
normal O
volunteers O
, O
concomitant O
administration O
of O
diflunisal B-DRUG
and O
hydrochlorothiazide B-DRUG
resulted O
in O
significantly O
increased O
plasma O
levels O
of O
hydrochlorothiazide B-DRUG
. O
Diflunisal B-DRUG
decreased O
the O
hyperuricemic O
effect O
of O
hydrochlorothiazide B-DRUG
. O
Furosemide B-DRUG
: O
In O
normal O
volunteers O
, O
the O
concomitant O
administration O
of O
diflunisal B-DRUG
and O
furosemide B-DRUG
had O
no O
effect O
on O
the O
diuretic O
activity O
of O
furosemide B-DRUG
. O
Diflunisal B-DRUG
decreased O
the O
hyperuricemic O
effect O
of O
furosemide B-DRUG
. O
Antacids B-GROUP
: O
Concomitant O
administration O
of O
antacids B-GROUP
may O
reduce O
plasma O
levels O
of O
diflunisal B-DRUG
. O
This O
effect O
is O
small O
with O
occasional O
doses O
of O
antacids B-GROUP
, O
but O
may O
be O
clinically O
significant O
when O
antacids B-GROUP
are O
used O
on O
a O
continuous O
schedule O
. O
Acetaminophen B-DRUG
: O
In O
normal O
volunteers O
, O
concomitant O
administration O
of O
diflunisal B-DRUG
and O
acetaminophen B-DRUG
resulted O
in O
an O
approximate O
50 O
% O
increase O
in O
plasma O
levels O
of O
acetaminophen B-DRUG
. O
Acetaminophen B-DRUG
had O
no O
effect O
on O
plasma O
levels O
of O
diflunisal B-DRUG
. O
Since O
acetaminophen B-DRUG
in O
high O
doses O
has O
been O
associated O
with O
hepatotoxicity O
, O
concomitant O
administration O
of O
diflunisal B-DRUG
and O
acetaminophen B-DRUG
should O
be O
used O
cautiously O
, O
with O
careful O
monitoring O
of O
patients O
. O
Concomitant O
administration O
of O
diflunisal B-DRUG
and O
acetaminophen B-DRUG
in O
dogs O
, O
but O
not O
in O
rats O
, O
at O
approximately O
2 O
times O
the O
recommended O
maximum O
human O
therapeutic O
dose O
of O

each O
( O
40 O
to O
52 O
mg O
/ O
kg O
/ O
day O
of O
diflunisal B-DRUG
/ O
acetaminophen B-DRUG
) O
resulted O
in O
greater O
gastrointestinal O
toxicity O
than O
when O
either O
drug O
was O
administered O
alone O
. O
The O
clinical O
significance O
of O
these O
findings O
has O
not O
been O
established O
. O
Methotrexate B-DRUG
: O
Caution O
should O
be O
used O
if O
diflunisal B-DRUG
is O
administered O
concomitantly O
with O
methotrexate B-DRUG
. O
Nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
have O
been O
reported O
to O
decrease O
the O
tubular O
secretion O
of O
methotrexate B-DRUG
and O
to O
potentiate O
its O
toxicity O
. O
Cyclosporine B-DRUG
: O
Administration O
of O
nonsteroial B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
concomitantly O
with O
cyclosporine B-DRUG
has O
been O
associated O
with O
an O
increase O
in O
cyclosporine B-DRUG
- O
induced O
toxicity O
, O
possibly O
due O
to O
decreased O
synthesis O
of O
renal O
prostacyclin O
. O
NSAIDs B-GROUP
should O
be O
used O
with O
caution O
in O
patients O
taking O
cyclosporine B-DRUG
, O
and O
renal O
function O
should O
be O
carefully O
monitored O
. O
Nonsteroidal B-GROUP
Anti I-GROUP
- I-GROUP
Inflammatory I-GROUP
Drugs I-GROUP
: O
The O
administration O
of O
diflunisal B-DRUG
to O
normal O
volunteers O
receiving O
indomethacin B-DRUG
decreased O
the O
renal O
clearance O
and O
significantly O
increased O
the O
plasma O
levels O
of O
indomethacin B-DRUG
. O
In O
some O
patients O
the O
combined O
use O
of O
indomethacin B-DRUG
and O
diflunisal B-DRUG
has O
been O
associated O
with O
fatal O
gastrointestinal O
hemorrhage O
. O
Therefore O
, O
indomethacin B-DRUG
and O
diflunisal B-DRUG
should O
not O
be O
used O
concomitantly O
. O
The O
concomitant O
use O
of O
diflunisal B-DRUG
tablets O
and O
other O
NSAIDs B-GROUP
is O
not O
recommended O
due O
to O
the O
increased O
possibility O
of O
gastrointestinal O
toxicity O
, O
with O
little O
or O
no O
increase O
in O
efficacy O
. O
The O
following O
information O
was O
obtained O
from O
studies O
in O
normal O
volunteers O
. O
Aspirin B-BRAND
: O
In O
normal O
volunteers O
, O
a O
small O
decrease O
in O
diflunisal B-DRUG
levels O
was O
observed O
when O
multiple O
doses O
of O
diflunisal B-DRUG
and O
aspirin B-BRAND
were O
administered O
concomitantly O
. O
Sulindac B-DRUG
: O
The O
concomitant O
administration O
of O
diflunisal B-DRUG
and O
sulindac B-DRUG
in O
normal O
volunteers O
resulted O
in O
lowering O
of O
the O
plasma O
levels O
of O
the O
active O
sulindac O
sulfide O
metabolite O
by O
approximately O
one O
- O
third O
. O
Naproxen B-DRUG
: O
The O
concomitant O
administration O
of O
diflunisal B-DRUG
and O
naproxen B-DRUG
in O
normal O
volunteers O
had O
no O
effect O
on O
the O
plasma O
levels O
of O
naproxen B-DRUG
, O
but O
significantly O
decreased O
the O
urinary O
excretion O
of O
naproxen B-DRUG
and O
its O
glucuronide O
metabolite O
. O
Naproxen B-DRUG
had O
no O
effect O

on O
plasma O
levels O
of O
diflunisal B-DRUG
. O
Drug O
laboratory O
Test O
Interactions O
Serum O
Salicylate O
Assays O
: O
Caution O
should O
be O
used O
in O
interpreting O
the O
results O
of O
serum O
salicylate O
assays O
when O
diflunisal B-DRUG
is O
present O
. O
Salicylate B-GROUP
levels O
have O
been O
found O
to O
be O
falsely O
elevated O
with O
some O
assay O
methods O
. O

Potassium B-GROUP
- I-GROUP
depleting I-GROUP
diuretics I-GROUP
are O
a O
major O
contributing O
factor O
to O
digitalis B-GROUP
toxicity O
. O
Calcium B-DRUG
, O
particularly O
if O
administered O
rapidly O
by O
the O
intravenous O
route O
, O
may O
produce O
serious O
arrhythmias O
in O
digitalized O
patients O
. O
Quinidine B-DRUG
, O
verapamil B-DRUG
, O
amiodarone B-DRUG
, O
propafenone B-DRUG
, O
indomethacin B-DRUG
, O
itraconazole B-DRUG
, O
alprazolam B-DRUG
, O
and O
spironolactone B-DRUG
raise O
the O
serum O
digoxin B-DRUG
concentration O
due O
to O
a O
reduction O
in O
clearance O
and O
/ O
or O
in O
volume O
of O
distribution O
of O
the O
drug O
, O
with O
the O
implication O
that O
digitalis B-GROUP
intoxication O
may O
result O
. O
Erythromycin B-DRUG
and O
clarithromycin B-DRUG
( O
and O
possibly O
other O
macrolide B-GROUP
antibiotics I-GROUP
) O
and O
tetracycline B-DRUG
may O
increase O
digoxin B-DRUG
absorption O
in O
patients O
who O
inactivate O
digoxin B-DRUG
by O
bacterial O
metabolism O
in O
the O
lower O
intestine O
, O
so O
that O
digitalis B-GROUP
intoxication O
may O
result O
. O
The O
risk O
of O
this O
interaction O
may O
be O
reduced O
if O
digoxin B-DRUG
is O
given O
as O
capsules O
. O
Propantheline B-DRUG
and O
diphenoxylate B-DRUG
, O
by O
decreasing O
gut O
motility O
, O
may O
increase O
digoxin B-DRUG
absorption O
. O
Antacids B-GROUP
, O
kaolin B-DRUG
- O
pectin O
, O
sulfasalazine B-DRUG
, O
neomycin B-DRUG
, O
cholestyramine B-DRUG
, O
certain O
anticancer O
drugs O
, O
and O
metoclopramide B-DRUG
may O
interfere O
with O
intestinal O
digoxin B-DRUG
absorption O
, O
resulting O
in O
unexpectedly O
low O
serum O
concentrations O
. O
Rifampin B-DRUG
may O
decrease O
serum O
digoxin B-DRUG
concentration O
, O
especially O
in O
patients O
with O
renal O
dysfunction O
, O
by O
increasing O
the O
non O
- O
renal O
clearance O
of O
digoxin B-DRUG
. O
There O
have O
been O
inconsistent O
reports O
regarding O
the O
effects O
of O
other O
drugs O
( O
e O
. O
g O
. O
, O
quinine B-DRUG
, O
penicillamine B-DRUG
) O
on O
serum O
digoxin B-DRUG
concentration O
. O
Thyroid B-GROUP
administration O
to O
a O
digitalized O
, O
hypothyroid O
patient O
may O
increase O
the O
dose O
requirement O
of O
digoxin B-DRUG
. O
Concomitant O
use O
of O
digoxin B-DRUG
and O
sympathomimetics B-GROUP
increases O
the O
risk O
of O
cardiac O
arrhythmias O
. O
Succinylcholine B-DRUG
may O
cause O
a O
sudden O
extrusion O
of O
potassium O
from O
muscle O
cells O
, O
and O
may O
thereby O
cause O
arrhythmias O
in O
digitalized O
patients O
. O
Although O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blockers I-GROUP
or O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
and O
digoxin B-DRUG
may O
be O
useful O
in O
combination O
to O
control O
atrial O
fibrillation O
, O
their O
additive O
effects O
on O
AV O
node O
conduction O
can O
result O
in O
advanced O
or O
complete O
heart O
block O
. O
Due O
to O
the O
considerable O
variability O
of O
these O
interactions O
, O

the O
dosage O
of O
digoxin B-DRUG
should O
be O
individualized O
when O
patients O
receive O
these O
medications O
concurrently O
. O
Furthermore O
, O
caution O
should O
be O
exercised O
when O
combining O
digoxin B-DRUG
with O
any O
drug O
that O
may O
cause O
a O
significant O
deterioration O
in O
renal O
function O
, O
since O
a O
decline O
in O
glomerular O
filtration O
or O
tubular O
secretion O
may O
impair O
the O
excretion O
of O
digoxin B-DRUG
. O

Vasoconstrictors B-GROUP
: O
D B-BRAND
. I-BRAND
H I-BRAND
. I-BRAND
E I-BRAND
. I-BRAND
45 I-BRAND
( O
dihydroergotamine B-DRUG
mesylate I-DRUG
) O
Injection O
, O
USP O
should O
not O
be O
used O
with O
peripheral B-GROUP
vasoconstrictors I-GROUP
because O
the O
combination O
may O
cause O
synergistic O
elevation O
of O
blood O
pressure O
. O
Sumatriptan B-DRUG
: O
Sumatriptan B-DRUG
has O
been O
reported O
to O
cause O
coronary O
artery O
vasospasm O
, O
and O
its O
effect O
could O
be O
additive O
with O
D B-BRAND
. I-BRAND
H I-BRAND
. I-BRAND
E I-BRAND
. I-BRAND
45 I-BRAND
( O
dihydroergotamine B-DRUG
mesylate I-DRUG
) O
Injection O
, O
USP O
. O
Sumatriptan B-DRUG
and O
D B-BRAND
. I-BRAND
H I-BRAND
. I-BRAND
E I-BRAND
. I-BRAND
45 I-BRAND
( O
dihydroergotamine B-DRUG
mesylate I-DRUG
) O
Injection O
, O
USP O
should O
not O
be O
taken O
within O
24 O
hours O
of O
each O
other O
. O
. O
Beta B-GROUP
Blockers I-GROUP
: O
Although O
the O
results O
of O
a O
clinical O
study O
did O
not O
indicate O
a O
safe O
problem O
associated O
with O
the O
administration O
of O
D B-BRAND
. I-BRAND
H I-BRAND
. I-BRAND
E I-BRAND
. I-BRAND
45 I-BRAND
( O
dihydroergotamine B-DRUG
mesylate I-DRUG
) O
Injection O
, O
USP O
to O
subjects O
already O
receiving O
propranolol B-DRUG
, O
there O
have O
been O
reports O
that O
propranolol B-DRUG
may O
potentiate O
the O
vasoconstrictive O
action O
of O
ergotamine B-DRUG
by O
blocking O
the O
vasodilating O
property O
of O
epinephrine O
. O
Nicotine B-DRUG
: O
Nicotine B-DRUG
may O
provoke O
vasoconstriction O
in O
some O
patients O
, O
predisposing O
to O
a O
greater O
ischemic O
response O
to O
ergot B-DRUG
therapy O
. O
Macrolide B-GROUP
Antibiotics I-GROUP
( O
e O
. O
g O
. O
erythromycin B-DRUG
and O
troleandomycin B-DRUG
) O
: O
Agents O
of O
the O
ergot B-GROUP
alkaloid I-GROUP
class I-GROUP
, O
of O
which O
D B-BRAND
. I-BRAND
H I-BRAND
. I-BRAND
E I-BRAND
. I-BRAND
45 I-BRAND
( O
dihydroergotamine B-DRUG
mesylate I-DRUG
) O
Injection O
, O
USP O
is O
a O
member O
, O
have O
been O
shown O
to O
interact O
with O
antibiotics B-GROUP
of O
the O
macrolide B-GROUP
class I-GROUP
, O
resulting O
in O
increased O
plasma O
levels O
of O
unchanged O
alkaloids O
and O
peripheral O
vasoconstriction O
. O
Vasospastic O
reactions O
have O
been O
reported O
with O
therapeutic O
doses O
of O
ergotamine B-DRUG
- O
containing O
drugs O
when O
co O
- O
administered O
with O
these O
antibiotics B-GROUP
. O
SSRIs B-GROUP
: O
Weakness O
hyperreflexia O
, O
and O
incoordination O
have O
been O
reported O
rarely O
when O
5 B-GROUP
- I-GROUP
HT1 I-GROUP
agonists I-GROUP
have O
been O
co O
- O
administered O
with O
SSRIs B-GROUP
( O
e O
. O
g O
. O
fluoxetine B-DRUG
, O
fluvoxamine B-DRUG
, O
paroxetine B-DRUG
, O
sertraline B-DRUG
) O
. O
There O
have O
been O
no O
reported O
cases O
from O
spontaneous O
reports O
of O
drug O
interaction O
between O
SSRIs B-GROUP
and O
D B-BRAND
. I-BRAND
H I-BRAND
. I-BRAND
E I-BRAND
. I-BRAND
45 I-BRAND
( O
dihydroergotamine B-DRUG
mesylate I-DRUG
) O
Injection O
, O
USP O
. O

Oral O
Contraceptives B-GROUP
: O
The O
effect O
of O
oral O
contraceptives B-GROUP
on O
the O
pharmacokinetics O
of O
D B-BRAND
. I-BRAND
H I-BRAND
. I-BRAND
E I-BRAND
. I-BRAND
45 I-BRAND
( O
dihydroergotamine B-DRUG
mesylate I-DRUG
) O
Injection O
, O
USP O
has O
not O
been O
studied O
. O

Administration O
of O
thiazide B-GROUP
diuretics I-GROUP
to O
hypoparathyroid O
patients O
who O
are O
concurrently O
being O
treated O
with O
dihydrotachysterol B-DRUG
may O
cause O
hypercalcemia O
. O

Due O
to O
the O
potential O
for O
additive O
effects O
, O
caution O
and O
careful O
titration O
are O
warranted O
in O
patients O
receiving O
diltiazem B-DRUG
hydrochloride I-DRUG
concomitantly O
with O
other O
agents O
known O
to O
affect O
cardiac O
contractility O
and O
/ O
or O
conduction O
. O
Pharmacologic O
studies O
indicate O
that O
there O
may O
be O
additive O
effects O
in O
prolonging O
AV O
conduction O
when O
using O
beta B-GROUP
- I-GROUP
blockers I-GROUP
or O
digitalis B-GROUP
concomitantly O
with O
Tiazac B-BRAND
. O
As O
with O
all O
drugs O
, O
care O
should O
be O
exercised O
when O
treating O
patients O
with O
multiple O
medications O
. O
Diltiazem B-DRUG
is O
both O
a O
substrate O
and O
an O
inhibitor O
of O
the O
cytochrome O
P O
- O
450 O
3A4 O
enzyme O
system O
. O
Other O
drugs O
that O
are O
specific O
substrates O
, O
inhibitors O
, O
or O
inducers O
of O
the O
enzyme O
system O
may O
have O
a O
significant O
impact O
on O
the O
efficacy O
and O
side O
effect O
profile O
of O
diltiazem B-DRUG
. O
Patients O
taking O
other O
drugs O
that O
are O
substrates O
of O
CYP450 O
3A4 O
, O
especially O
patients O
with O
renal O
and O
/ O
or O
hepatic O
impairment O
, O
may O
require O
dosage O
adjustment O
when O
starting O
or O
stopping O
concomitantly O
administered O
diltiazem B-DRUG
in O
order O
to O
maintain O
optimum O
therapeutic O
blood O
levels O
. O
Beta B-GROUP
Blockers I-GROUP
Controlled O
and O
uncontrolled O
domestic O
studies O
suggest O
that O
concomitant O
use O
of O
diltiazem B-DRUG
hydrochloride I-DRUG
and O
beta B-GROUP
- I-GROUP
blockers I-GROUP
is O
usually O
well O
tolerated O
, O
but O
available O
data O
are O
not O
sufficient O
to O
predict O
the O
effects O
of O
concomitant O
treatment O
in O
patients O
with O
left O
ventricular O
dysfunction O
or O
cardiac O
conduction O
abnormalities O
. O
Administration O
of O
diltiazem B-DRUG
hydrochloride I-DRUG
concomitantly O
with O
propranolol B-DRUG
in O
five O
normal O
volunteers O
resulted O
in O
increased O
propranolol B-DRUG
levels O
in O
all O
subjects O
and O
bioavailability O
of O
propranolol B-DRUG
was O
increased O
approximately O
50 O
% O
. O
In O
vitro O
, O
propranolol B-DRUG
appears O
to O
be O
displaced O
from O
its O
binding O
sites O
by O
diltiazem B-DRUG
. O
If O
combination O
therapy O
is O
initiated O
or O
withdrawn O
in O
conjunction O
with O
propranolol B-DRUG
, O
an O
adjustment O
in O
the O
propranolol B-DRUG
dose O
may O
be O
warranted O
. O
Cimetidine B-DRUG
A O
study O
in O
six O
healthy O
volunteers O
has O
shown O
a O
significant O
increase O
in O
peak O
diltiazem B-DRUG
plasma O
levels O
( O
58 O
% O
) O
and O
AUC O
( O
53 O
% O
) O
after O
a O
1 O
- O
week O
course O
of O
cimetidine B-DRUG
1200 O
mg O
/ O
day O
and O
a O
single O
dose O
of O
diltiazem B-DRUG
60mg O
. O
Ranitidine B-DRUG
produced O
smaller O
, O
nonsignificant O
increases O
. O
The O
effect O
may O
be O
mediated O
by O
cimetidines B-DRUG
known O
inhibition O
of O
hepatic O
cytochrome O
P O
- O
450 O

, O
the O
enzyme O
system O
responsible O
for O
the O
first O
- O
pass O
metabolism O
of O
diltiazem B-DRUG
. O
Patients O
currently O
receiving O
diltiazem B-DRUG
therapy O
should O
be O
carefully O
monitored O
for O
a O
change O
in O
pharmacological O
effect O
when O
initiating O
and O
discontinuing O
therapy O
with O
cimetidine B-DRUG
. O
An O
adjustment O
in O
the O
diltiazem B-DRUG
dose O
may O
be O
warranted O
. O
Digitalis B-GROUP
Administration O
of O
diltiazem B-DRUG
hydrochloride I-DRUG
with O
digoxin B-DRUG
in O
24 O
healthy O
male O
subjects O
increased O
plasma O
digoxin B-DRUG
concentrations O
approximately O
20 O
% O
. O
Another O
investigator O
found O
no O
increase O
in O
digoxin B-DRUG
levels O
in O
12 O
patients O
with O
coronary O
artery O
disease O
. O
Since O
there O
have O
been O
conflicting O
results O
regarding O
the O
effect O
of O
digoxin B-DRUG
levels O
, O
it O
is O
recommended O
that O
digoxin B-DRUG
levels O
be O
monitored O
when O
initiating O
, O
adjusting O
, O
and O
discontinuing O
diltiazem B-DRUG
hydrochloride I-DRUG
therapy O
to O
avoid O
possible O
over O
- O
or O
under O
- O
digitalization O
. O
Anesthetics B-GROUP
The O
depression O
of O
cardiac O
contractility O
, O
conductivity O
, O
and O
automaticity O
as O
well O
as O
the O
vascular O
dilation O
associated O
with O
anesthetics B-GROUP
may O
be O
potentiated O
by O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
. O
When O
used O
concomitantly O
, O
anesthetics B-GROUP
and O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
should O
be O
titrated O
carefully O
. O
Cyclosporine B-DRUG
A O
pharmacokinetic O
interaction O
between O
diltiazem B-DRUG
and O
cyclosporine B-DRUG
has O
been O
observed O
during O
studies O
involving O
renal O
and O
cardiac O
transplant O
patients O
. O
In O
renal O
and O
cardiac O
transplant O
recipients O
, O
a O
reduction O
of O
cyclosporine B-DRUG
dose O
ranging O
from O
15 O
% O
to O
48 O
% O
was O
necessary O
to O
maintain O
cyclosporine B-DRUG
trough O
concentrations O
similar O
to O
those O
seen O
prior O
to O
the O
addition O
of O
diltiazem B-DRUG
. O
If O
these O
agents O
are O
to O
be O
administered O
concurrently O
, O
cyclosporine B-DRUG
concentrations O
should O
be O
monitored O
, O
especially O
when O
diltiazem B-DRUG
therapy O
is O
initiated O
, O
adjusted O
, O
or O
discontinued O
. O
The O
effect O
of O
cyclosporine B-DRUG
on O
diltiazem B-DRUG
plasma O
concentrations O
has O
not O
been O
evaluated O
. O
Carbamazepine B-DRUG
Concomitant O
administration O
of O
diltiazem B-DRUG
with O
carbamazepine B-DRUG
has O
been O
reported O
to O
result O
in O
elevated O
serum O
levels O
of O
carbamazepine B-DRUG
( O
40 O
% O
to O
72 O
% O
increase O
) O
, O
resulting O
in O
toxicity O
in O
some O
cases O
. O
Patients O
receiving O
these O
drugs O
concurrently O
should O
be O
monitored O
for O
a O
potential O
drug O
interaction O
. O
Benzodiazepines B-GROUP
Studies O
showed O
that O
diltiazem B-DRUG
increased O
the O
AUC O
of O
midazolam B-DRUG
and O
triazolam B-DRUG
by O
3 O
- O
4 O
fold O
and O
the O
Cmax O
by O
2 O
- O
fold O
, O
compared O
to O
placebo O
. O

The O
elimination O
half O
life O
of O
midazolam B-DRUG
and O
triazolam B-DRUG
also O
increased O
( O
1 O
. O
5 O
- O
2 O
. O
5 O
fold O
) O
during O
coadministration O
with O
diltiazem B-DRUG
. O
These O
pharmacokinetic O
effects O
seen O
during O
diltiazem B-DRUG
coadministration O
can O
result O
in O
increased O
clinical O
effects O
( O
e O
. O
g O
. O
, O
prolonged O
sodation O
) O
of O
both O
midazolam B-DRUG
and O
triazolam B-DRUG
. O
Lovastatin B-DRUG
In O
a O
ten O
- O
subject O
study O
, O
coadministration O
of O
diltiazem B-DRUG
( O
120 O
mg O
bid O
) O
with O
lovastatin B-DRUG
resulted O
in O
a O
3 O
- O
4 O
times O
increase O
in O
mean O
lovastatin B-DRUG
AUC O
and O
Cmax O
vs O
. O
lovastatin B-DRUG
alone O
; O
no O
change O
in O
pravastatin B-DRUG
AUC O
and O
Cmax O
was O
observed O
during O
diltiazem B-DRUG
coadministration O
. O
Diltiazem B-DRUG
plasma O
levels O
were O
not O
significantly O
affected O
by O
lovastatin B-DRUG
or O
pravastatin B-DRUG
. O
Rifampin B-DRUG
Coadministration O
of O
rifampin B-DRUG
with O
diltiazem B-DRUG
lowered O
the O
diltiazem B-DRUG
plasma O
concentrations O
to O
undetectable O
levels O
. O
Coadministration O
of O
diltiazem B-DRUG
with O
rifampin B-DRUG
or O
any O
known O
CYP3A4 O
inducer O
should O
be O
avoided O
when O
possible O
, O
and O
alternative O
therapy O
considered O
. O

Dimenhydrinate B-DRUG
may O
decrease O
emetic B-GROUP
response O
to O
apomorphine B-DRUG
. O

Oxytocin B-DRUG
or O
other O
oxytocics B-GROUP
( O
concurrent O
use O
with O
dinoprost B-DRUG
may O
result O
in O
uterine O
hypertonus O
, O
possibly O
causing O
uterine O
rupture O
or O
cervical O
laceration O
, O
especially O
in O
the O
absence O
of O
adequate O
cervical O
dilatation O
; O
although O
combinations O
are O
sometimes O
used O
for O
therapeutic O
advantage O
, O
when O
used O
concurrently O
, O
patient O
should O
be O
closely O
monitored O
. O

PROSTIN B-BRAND
E2 I-BRAND
may O
augment O
the O
activity O
of O
other O
oxytocic B-GROUP
drugs I-GROUP
. O
Concomitant O
use O
with O
other O
oxytocic B-GROUP
agents I-GROUP
is O
not O
recommended O
. O

Diphenhydramine B-DRUG
hydrochloride I-DRUG
has O
additive O
effects O
with O
alcohol B-DRUG
and O
other O
CNS B-GROUP
depressants I-GROUP
( O
hypnotics B-GROUP
, O
sedatives B-GROUP
, O
tranquilizers B-GROUP
, O
etc O
) O
. O
MAO B-GROUP
inhibitors I-GROUP
prolong O
and O
intensify O
the O
anticholinergic O
( O
drying O
) O
effects O
of O
antihistamines B-GROUP
. O

CNS O
depression O
producing O
medications O
- O
concurrent O
use O
may O
potentiate O
the O
effects O
of O
either O
these O
medications O
or O
diphenidol B-DRUG
; O
anticholinergics B-GROUP
or O
other O
medications O
with O
anticholinergic O
activity O
- O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
diphenidol B-DRUG
; O
apomorphine B-DRUG
- O
prior O
ingestion O
of O
diphenidol B-DRUG
may O
decrease O
the O
emetic B-GROUP
response O
to O
apomorphine B-DRUG
in O
the O
treatment O
of O
poisoning O
. O

Known O
drug O
interactions O
include O
barbiturates B-GROUP
, O
tranquilizers B-GROUP
, O
and O
alcohol B-DRUG
. O
Diphenoxylate B-DRUG
HCl I-DRUG
and O
atropine B-DRUG
sulfate I-DRUG
may O
interact O
with O
MAO B-GROUP
inhibitors I-GROUP
In O
studies O
with O
male O
rats O
, O
diphenoxylate B-DRUG
hydrochloride I-DRUG
was O
found O
to O
inhibit O
the O
hepatic O
microsomal O
enzyme O
system O
at O
a O
dose O
of O
2 O
mg O
/ O
kg O
/ O
day O
. O
Therefore O
, O
diphenoxylate B-DRUG
has O
the O
potential O
to O
prolong O
the O
biological O
half O
- O
lives O
of O
drugs O
for O
which O
the O
rate O
of O
elimination O
is O
dependent O
on O
the O
microsomal O
drug O
metabolizing O
enzyme O
system O
. O

This O
drug O
may O
interact O
with O
alcohol B-DRUG
or O
other O
CNS B-GROUP
depressants I-GROUP
( O
may O
potentiate O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
antihistamines B-GROUP
) O
, O
anticholinergics B-GROUP
or O
other O
medications O
with O
anticholinergic O
activity O
( O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
antihistamines B-GROUP
) O
, O
and O
monoamine B-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
( O
concurrent O
use O
with O
antihistamines B-DRUG
may O
prolong O
and O
intensify O
the O
anticholinergic O
and O
CNS O
depressant O
effects O
of O
antihistamines B-DRUG
) O
. O

No O
pharmacokinetic O
drug O
- O
drug O
interaction O
studies O
were O
conducted O
with O
PERSANTINE B-BRAND
( O
dipyridamole B-DRUG
USP O
) O
Tablets O
. O
The O
following O
information O
was O
obtained O
from O
the O
literature O
. O
Adenosine B-DRUG
: O
Dipyridamole B-DRUG
has O
been O
reported O
to O
increase O
the O
plasma O
levels O
and O
cardiovascular O
effects O
of O
adenosine B-DRUG
. O
Adjustment O
of O
adenosine B-DRUG
dosage O
may O
be O
necessary O
. O
Cholinesterase B-GROUP
Inhibitors I-GROUP
: O
Dipyridamole B-DRUG
may O
counteract O
the O
anticholinesterase O
effect O
of O
cholinesterase B-GROUP
inhibitors I-GROUP
, O
thereby O
potentially O
aggravating O
myasthenia O
gravis O
. O

Terfenadine B-DRUG
: O
In O
a O
prospective O
study O
involving O
six O
- O
healthy O
- O
male O
volunteers O
, O
dirithromycin B-DRUG
did O
not O
affect O
the O
metabolism O
of O
terfenadine B-DRUG
. O
These O
six O
volunteers O
received O
terfenadine B-DRUG
alone O
( O
60 O
mg O
twice O
daily O
) O
for O
8 O
days O
, O
followed O
by O
terfenadine B-DRUG
in O
combination O
with O
dirithromycin B-DRUG
( O
500 O
mg O
once O
daily O
) O
for O
10 O
days O
. O
( O
Both O
drugs O
were O
thus O
dosed O
to O
steady O
state O
. O
) O
The O
pharmacokinetics O
of O
terfenadine B-DRUG
and O
its O
acid O
metabolite O
and O
the O
electrocardiographic O
QT O
c O
interval O
were O
measured O
during O
both O
periods O
: O
with O
terfenadine B-DRUG
alone O
, O
and O
with O
terfenadine B-DRUG
plus O
dirithromycin B-DRUG
. O
In O
five O
men O
, O
terfenadine B-DRUG
levels O
were O
undetectable O
( O
5 O
ng O
/ O
mL O
) O
throughout O
the O
study O
; O
in O
one O
man O
, O
the O
C O
max O
of O
terfenadine B-DRUG
was O
8 O
. O
1 O
ng O
/ O
mL O
with O
terfenadine B-DRUG
alone O
and O
7 O
. O
2 O
ng O
/ O
mL O
with O
terfenadine B-DRUG
plus O
dirithromycin B-DRUG
. O
The O
mean O
C O
max O
, O
T O
max O
, O
and O
AUC O
of O
the O
acid O
metabolite O
of O
terfenadine B-DRUG
were O
not O
significantly O
changed O
. O
The O
mean O
QT O
c O
interval O
( O
msec O
) O
was O
369 O
with O
terfenadine B-DRUG
alone O
and O
367 O
with O
terfenadine B-DRUG
plus O
dirithromycin B-DRUG
. O
Also O
, O
in O
vitro O
experiments O
demonstrated O
a O
lack O
of O
interaction O
between O
dirithromycin B-DRUG
and O
terfenadine B-DRUG
. O
Thus O
, O
the O
interaction O
observed O
between O
erythromycin B-DRUG
and O
terfenadine B-DRUG
is O
not O
expected O
for O
dirithromycin B-DRUG
. O
Serious O
cardiac O
dysrhythmias O
, O
some O
resulting O
in O
death O
, O
have O
occurred O
in O
patients O
receiving O
terfenadine B-DRUG
concomitantly O
with O
other O
macrolide B-GROUP
antibiotics I-GROUP
. O
In O
addition O
, O
most O
macrolides B-GROUP
are O
contraindicated O
in O
patients O
receiving O
terfenadine B-DRUG
therapy O
who O
have O
pre O
- O
existing O
cardiac O
abnormalities O
( O
arrhythmia O
, O
bradycardia O
, O
QT O
c O
interval O
prolongation O
, O
ischemic O
heart O
disease O
, O
congestive O
heart O
failure O
, O
etc O
. O
) O
or O
electrolyte O
disturbances O
. O
Theophylline B-DRUG
: O
Following O
co O
- O
administration O
of O
two O
250 O
- O
mg O
dirithromycin B-DRUG
tablets O
administered O
once O
daily O
with O
200 O
- O
mg O
theophylline B-DRUG
tablets O
administered O
twice O
daily O
for O
10 O
days O
to O
14 O
healthy O
subjects O
, O
the O
steady O
- O
state O
plasma O
concentration O
of O
theophylline B-DRUG
was O
not O
significantly O
altered O
. O
In O
general O
, O
most O
patients O
treated O
with O
dirithromycin B-DRUG
who O
are O
receiving O

concomitant O
theophylline B-DRUG
therapy O
may O
not O
require O
empiric O
adjustment O
of O
theophylline B-DRUG
dosage O
or O
monitoring O
of O
theophylline B-DRUG
plasma O
concentrations O
. O
However O
, O
theophylline B-DRUG
plasma O
concentrations O
should O
be O
monitored O
, O
with O
dosage O
adjustment O
as O
appropriate O
, O
in O
patients O
whose O
pulmonary O
disease O
requires O
maintaining O
a O
given O
theophylline B-DRUG
plasma O
concentration O
for O
optimal O
pulmonary O
function O
or O
in O
patients O
with O
theophylline B-DRUG
concentrations O
at O
the O
higher O
end O
of O
the O
therapeutic O
range O
. O
Antacids B-GROUP
or O
H B-GROUP
2 I-GROUP
receptor I-GROUP
antagonists I-GROUP
: O
When O
dirithromycin B-DRUG
is O
administered O
immediately O
following O
antacids B-GROUP
or O
H B-GROUP
2 I-GROUP
- I-GROUP
receptor I-GROUP
antagonists I-GROUP
, O
the O
absorption O
of O
dirithromycin B-DRUG
is O
slightly O
enhanced O
. O
The O
following O
drug O
interactions O
have O
been O
reported O
with O
erythromycin B-DRUG
products O
. O
It O
is O
presently O
not O
known O
whether O
these O
same O
drug O
interactions O
occur O
with O
dirithromycin B-DRUG
. O
Until O
further O
data O
are O
available O
regarding O
the O
potential O
interaction O
of O
dirithromycin B-DRUG
with O
these O
compounds O
, O
caution O
should O
be O
used O
during O
coadministration O
. O
Triazolam B-DRUG
: O
Erythromycin B-DRUG
has O
been O
reported O
to O
decrease O
the O
clearance O
of O
triazolam B-DRUG
and O
, O
thus O
, O
may O
increase O
the O
pharmacologic O
effect O
of O
triazolam B-DRUG
. O
Digoxin B-DRUG
: O
Concomitant O
administration O
of O
erythromycin B-DRUG
and O
digoxin B-DRUG
has O
been O
reported O
to O
result O
in O
elevated O
digoxin B-DRUG
serum O
levels O
. O
Anticoagulants B-GROUP
: O
There O
have O
been O
reports O
of O
increased O
anticoagulant O
effects O
when O
erythromycin B-DRUG
and O
oral O
anticoagulants B-GROUP
were O
used O
concomitantly O
. O
Increased O
anticoagulation O
effects O
due O
to O
a O
drug O
interaction O
with O
erythromycin B-DRUG
may O
be O
more O
pronounced O
in O
the O
elderly O
. O
Ergotamine B-DRUG
: O
Concurrent O
use O
of O
erythromycin B-DRUG
and O
ergotamine B-DRUG
or O
dihydroergotamine B-DRUG
has O
been O
associated O
in O
some O
patients O
with O
acute O
ergot O
toxicity O
characterized O
by O
severe O
peripheral O
vasospasm O
and O
dysesthesia O
. O
Other O
drugs O
Drug O
interactions O
have O
been O
reported O
with O
concomitant O
administration O
of O
erythromycin B-DRUG
and O
other O
medications O
, O
including O
cyclosporine B-DRUG
, O
hexobarbital B-DRUG
, O
carbamazepine B-DRUG
, O
alfentanil B-DRUG
, O
disopyramide B-DRUG
, O
phenytoin B-DRUG
, O
bromocriptine B-DRUG
, O
valproate B-DRUG
, O
astemizole B-DRUG
, O
and O
lovastatin B-DRUG
. O

If O
phenytoin B-DRUG
or O
other O
hepatic O
enzyme O
inducers O
are O
taken O
concurrently O
with O
Norpace B-BRAND
or O
Norpace B-BRAND
CR I-BRAND
, O
lower O
plasma O
levels O
of O
disopyramide B-DRUG
may O
occur O
. O
Monitoring O
of O
disopyramide B-DRUG
plasma O
levels O
is O
recommended O
in O
such O
concurrent O
use O
to O
avoid O
ineffective O
therapy O
. O
Other O
antiarrhythmic B-GROUP
drugs I-GROUP
( O
eg O
, O
quinidine B-DRUG
, O
procainamide B-DRUG
, O
lidocaine B-DRUG
, O
propranolol B-DRUG
) O
have O
occasionally O
been O
used O
concurrently O
with O
Norpace B-BRAND
. O
Excessive O
widening O
of O
the O
QRS O
complex O
and O
/ O
or O
prolongation O
of O
the O
Q O
- O
T O
interval O
may O
occur O
in O
these O
situations O
. O
In O
healthy O
subjects O
, O
no O
significant O
drug O
- O
drug O
interaction O
was O
observed O
when O
Norpace B-BRAND
was O
coadministered O
with O
either O
propranolol B-DRUG
or O
diazepam B-DRUG
. O
Concomitant O
administration O
of O
Norpace B-BRAND
and O
quinidine B-DRUG
resulted O
in O
slight O
increases O
in O
plasma O
disopyramide B-DRUG
levels O
and O
slight O
decreases O
in O
plasma O
quinidine B-DRUG
levels O
. O
Norpace B-BRAND
does O
not O
increase O
serum O
digoxin B-DRUG
levels O
. O
Patients O
taking O
disopyramide B-DRUG
phosphate I-DRUG
and O
erythromycin B-DRUG
concomitantly O
may O
develop O
increased O
serum O
concentrations O
of O
disopyramide B-DRUG
resulting O
in O
excessive O
widening O
of O
the O
QRS O
complex O
and O
/ O
or O
prolongation O
of O
the O
Q O
- O
T O
interval O
. O
Patients O
taking O
disopyramide B-DRUG
phosphate I-DRUG
and O
hepatic O
enzyme O
inhibitors O
concomitantly O
should O
be O
closely O
monitored O
. O
Until O
data O
on O
possible O
interactions O
between O
verapamil B-DRUG
and O
disopyramide B-DRUG
phosphate I-DRUG
are O
obtained O
, O
disopyramide B-DRUG
should O
not O
be O
administered O
within O
48 O
hours O
before O
or O
24 O
hours O
after O
verapamil B-DRUG
administration O
. O

Disulfiram B-DRUG
appears O
to O
decrease O
the O
rate O
at O
which O
certain O
drugs O
are O
metabolized O
and O
therefore O
may O
increase O
the O
blood O
levels O
and O
the O
possibility O
of O
clinical O
toxicity O
of O
drugs O
given O
concomitantly O
. O
DISULFIRAM B-DRUG
SHOULD O
BE O
USED O
WITH O
CAUTION O
IN O
THOSE O
PATIENTS O
REVEIVING O
PHENYTOIN B-DRUG
AND O
ITS O
CONGENERS O
. O
SINCE O
THE O
CONCOMITANT O
ADMINISTRATION O
OF O
THESE O
TWO O
DRUGS O
CAN O
LEAD O
TO O
PHENYTOIN B-DRUG
INTOXICATION O
, O
PRIOR O
TO O
ADMINISTERING O
DISULFIRAM B-DRUG
TO O
A O
PATIENT O
ON O
PHENYTOIN B-DRUG
THERAPY O
, O
A O
BASELINE O
PHENYTOIN B-DRUG
SERUM O
LEVEL O
SHOULD O
BE O
OBTAINED O
. O
SUBSEQUENT O
TO O
INITIATION O
OF O
DISULFIRAM B-DRUG
THERAPY O
. O
SERUM O
LEVELS O
OF O
PHENYTOIN B-DRUG
SHOULD O
BE O
DETERMINED O
ON O
DIFFERENT O
DAYS O
FOR O
EVIDENCE O
OF O
AN O
INCREASE O
OR O
FOR O
A O
CONTINUING O
RISE O
IN O
LEVELS O
. O
INCREASED O
PHENYTOIN B-DRUG
LEVELS O
SHOULD O
BE O
TREATED O
WITH O
APPROPRIATE O
DOSAGE O
ADJUSTMENT O
. O
It O
may O
be O
necessary O
to O
adjust O
the O
dosage O
of O
oral O
anticoagulants B-GROUP
upon O
beginning O
or O
stopping O
disulfiram B-DRUG
. O
since O
disulfiram B-DRUG
may O
prolong O
prothrombin O
time O
. O
Patients O
taking O
isoniazid B-DRUG
when O
disulfiram B-DRUG
is O
given O
should O
be O
observed O
for O
the O
appearance O
of O
unsteady O
gait O
or O
marked O
changes O
in O
mental O
status O
; O
the O
disulfiram B-DRUG
should O
be O
discontinued O
if O
such O
signs O
appear O
. O
In O
rats O
, O
simultaneous O
ingestion O
of O
disulfiram B-DRUG
and O
nitrite B-DRUG
in O
the O
diet O
for O
78 O
weeks O
has O
been O
reported O
to O
cause O
tumors O
, O
and O
it O
has O
been O
suggested O
that O
disulfiram B-DRUG
may O
react O
with O
nitrites B-GROUP
in O
the O
rat O
stomach O
to O
form O
a O
nitrosamine O
, O
which O
is O
tumorigenic O
. O
Disulfiram B-DRUG
alone O
in O
the O
rat O
s O
diet O
did O
not O
lead O
to O
such O
tumors O
. O
The O
relevance O
of O
this O
finding O
to O
humans O
is O
not O
known O
at O

this O
time O
. O

Animal O
studies O
indicate O
that O
dobutamine B-DRUG
may O
be O
ineffective O
if O
the O
patient O
has O
recently O
received O
a O
b B-GROUP
- I-GROUP
blocking I-GROUP
drug I-GROUP
. O
In O
such O
a O
case O
, O
the O
peripheral O
vascular O
resistance O
may O
increase O
. O
Preliminary O
studies O
indicate O
that O
the O
concomitant O
use O
of O
dobutamine B-DRUG
and O
nitroprusside B-DRUG
results O
in O
a O
higher O
cardiac O
output O
and O
, O
usually O
, O
a O
lower O
pulmonary O
wedge O
pressure O
than O
when O
either O
drug O
is O
used O
alone O
. O
There O
was O
no O
evidence O
of O
drug O
interactions O
in O
clinical O
studies O
in O
which O
dobutamine B-DRUG
was O
administered O
concurrently O
with O
other O
drugs O
, O
including O
digitalis B-GROUP
preparations I-GROUP
, O
furosemide B-DRUG
, O
spironolactone B-DRUG
, O
lidocaine B-DRUG
, O
glyceryl B-DRUG
trinitrate I-DRUG
, O
isosorbide B-DRUG
dinitrate I-DRUG
, O
morphine B-DRUG
, O
atropine B-DRUG
, O
heparin B-DRUG
, O
protamine B-DRUG
, O
potassium B-DRUG
chloride I-DRUG
, O
folic B-DRUG
acid I-DRUG
, O
and O
acetaminophen B-DRUG
. O

There O
have O
been O
no O
formal O
clinical O
studies O
to O
evaluate O
the O
drug O
interactions O
of O
TAXOTERE B-BRAND
with O
other O
medications O
. O
In O
vitro O
studies O
have O
shown O
that O
the O
metabolism O
of O
docetaxel B-DRUG
may O
be O
modified O
by O
the O
concomitant O
administration O
of O
compounds O
that O
induce O
, O
inhibit O
, O
or O
are O
metabolized O
by O
cytochrome O
P450 O
3A4 O
, O
such O
as O
cyclosporine B-DRUG
, O
terfenadine B-DRUG
, O
ketoconazole B-DRUG
, O
erythromycin B-DRUG
, O
and O
troleandomycin B-DRUG
. O
Caution O
should O
be O
exercised O
with O
these O
drugs O
when O
treating O
patients O
receiving O
TAXOTERE B-BRAND
as O
there O
is O
a O
potential O
for O
a O
significant O
interaction O
. O

Drug O
/ O
Laboratory O
Test O
Interactions O
None O
known O
. O
Drug O
- O
Drug O
Interactions O
Cimetidine B-DRUG
: O
Concomitant O
use O
of O
cimetidine B-DRUG
is O
contraindicated O
. O
Cimetidine B-DRUG
at O
400 O
mg O
BID O
( O
the O
usual O
prescription O
dose O
) O
co O
- O
administered O
with O
TIKOSYN B-BRAND
( O
500 O
mcg O
BID O
) O
for O
7 O
days O
has O
been O
shown O
to O
increase O
dofetilide B-DRUG
plasma O
levels O
by O
58 O
% O
. O
Cimetidine B-DRUG
at O
doses O
of O
100 O
mg O
BID O
( O
OTC O
dose O
) O
resulted O
in O
a O
13 O
% O
increase O
in O
dofetilide B-DRUG
plasma O
levels O
( O
500 O
mcg O
single O
dose O
) O
. O
No O
studies O
have O
been O
conducted O
at O
intermediate O
doses O
of O
cimetidine B-DRUG
. O
If O
a O
patient O
requires O
TIKOSYN B-BRAND
and O
anti B-GROUP
- I-GROUP
ulcer I-GROUP
therapy O
, O
it O
is O
suggested O
that O
omeprazole B-DRUG
, O
ranitidine B-DRUG
, O
or O
antacids B-GROUP
( O
aluminum B-DRUG
and I-DRUG
magnesium I-DRUG
hydroxides I-DRUG
) O
be O
used O
as O
alternatives O
to O
cimetidine B-DRUG
, O
as O
these O
agents O
have O
no O
effect O
on O
the O
pharmacokinetic O
profile O
of O
TIKOSYN B-BRAND
. O
Verapamil B-DRUG
: O
Concomitant O
use O
of O
verapamil B-DRUG
is O
contraindicated O
. O
Co O
- O
administration O
of O
TIKOSYN B-BRAND
with O
verapamil B-DRUG
resulted O
in O
increases O
in O
dofetilide B-DRUG
peak O
plasma O
levels O
of O
42 O
% O
, O
although O
overall O
exposure O
to O
dofetilide B-DRUG
was O
not O
significantly O
increased O
. O
In O
an O
analysis O
of O
the O
supraventricular O
arrhythmia O
and O
DIAMOND O
patient O
populations O
, O
the O
concomitant O
administration O
of O
verapamil B-DRUG
with O
dofetilide B-DRUG
was O
associated O
with O
a O
higher O
occurrence O
of O
torsade O
de O
pointes O
. O
Ketoconazole B-DRUG
: O
Concomitant O
use O
of O
ketoconazole B-DRUG
is O
contraindicated O
. O
Ketoconazole B-DRUG
at O
400 O
mg O
daily O
( O
the O
maximum O
approved O
prescription O
dose O
) O
co O
- O
administered O
with O
TIKOSYN B-BRAND
( O
500 O
mcg O
BID O
) O
for O
7 O
days O
has O
been O
shown O
to O
increase O
dofetilide B-DRUG
Cmax O
by O
53 O
% O
in O
males O
and O
97 O
% O
in O
females O
, O
and O
AUC O
by O
41 O
% O
in O
males O
and O
69 O
% O
in O
females O
. O
Trimethoprim B-DRUG
Alone O
or O
in O
Combination O
with O
Sulfamethoxazole B-DRUG
: O
Concomitant O
use O
of O
trimethoprim B-DRUG
alone O
or O
in O
combination O
with O
sulfamethoxazole B-DRUG
is O
contraindicated O
. O
Hydrochlorothiazide B-DRUG
( O
HCTZ B-DRUG
) O
Alone O
or O
in O
Combination O
with O
Triamterene B-DRUG
: O
Concomitant O
use O

of O
HCTZ B-DRUG
alone O
or O
in O
combination O
with O
triamterene B-DRUG
is O
contraindicated O
. O
HCTZ B-DRUG
50 O
mg O
QD O
or O
HCTZ B-DRUG
/ O
triamterene B-DRUG
50 O
/ O
100 O
mg O
QD O
was O
co O
- O
administered O
with O
TIKOSYN B-BRAND
( O
500 O
mcg O
BID O
) O
for O
5 O
days O
( O
following O
2 O
days O
of O
diuretic B-GROUP
use O
at O
half O
dose O
) O
. O
In O
patients O
receiving O
HCTZ B-DRUG
alone O
, O
dofetilide B-DRUG
AUC O
increased O
by O
27 O
% O
and O
Cmax O
by O
21 O
% O
. O
However O
, O
the O
pharmacodynamic O
effect O
increased O
by O
197 O
% O
( O
QTc O
increase O
over O
time O
) O
and O
by O
95 O
% O
( O
maximum O
QTc O
increase O
) O
. O
However O
, O
the O
pharmacodynamic O
effect O
increased O
by O
190 O
% O
( O
QTc O
increase O
over O
time O
) O
and O
by O
84 O
% O
( O
Maximum O
QTc O
increase O
) O
. O
The O
pharmacodynamic O
effects O
can O
be O
explained O
by O
a O
combination O
of O
the O
increase O
in O
dofetilide B-DRUG
exposure O
and O
the O
reductions O
in O
serum O
potassium O
. O
In O
the O
DIAMOND O
trials O
, O
1252 O
patients O
were O
treated O
with O
TIKOSYN B-BRAND
and O
diuretics B-GROUP
concomitantly O
of O
whom O
493 O
died O
compared O
to O
508 O
deaths O
among O
the O
1248 O
patients O
receiving O
placebo O
and O
diuretics B-GROUP
. O
Of O
the O
229 O
patients O
who O
had O
potassium B-GROUP
depleting I-GROUP
diuretics I-GROUP
added O
to O
their O
concomitant O
medications O
in O
the O
DIAMOND O
trials O
, O
the O
patients O
on O
TIKOSYN B-BRAND
had O
a O
non O
- O
significantly O
reduced O
relative O
risk O
for O
death O
of O
0 O
. O
68 O
( O
95 O
% O
CI O
0 O
. O
376 O
, O
1 O
. O
230 O
) O
. O
Potential O
Drug O
Interactions O
Dofetilide B-DRUG
is O
eliminated O
in O
the O
kidney O
by O
cationic O
secretion O
. O
Inhibitors O
of O
renal O
cationic O
secretion O
are O
contraindicated O
with O
TIKOSYN B-BRAND
. O
In O
addition O
, O
drugs O
that O
are O
actively O
secreted O
via O
this O
route O
( O
e O
. O
g O
. O
, O
triamterene B-DRUG
, O
metformin B-DRUG
and O
amiloride B-DRUG
) O
should O
be O
co O
- O
administered O
with O
care O
as O
they O
might O
increase O
dofetilide B-DRUG
levels O
. O
Dofetilide B-DRUG
is O
metabolized O
to O
a O
small O
extent O
by O
the O
CYP3A4 O
isoenzyme O
of O
the O
cytochrome O
P450 O
system O
. O
Inhibitors O
of O
the O
CYP3A4 O
isoenzyme O
could O
increase O
systemic O
dofetilide B-DRUG
exposure O
. O
Inhibitors O
of O
this O
isoenzyme O
( O
e O
. O
g O
. O
, O
macrolide B-GROUP
antibiotics I-GROUP
, O
azole B-GROUP
antifungal I-GROUP
agents I-GROUP
, O
protease B-GROUP
inhibitors I-GROUP
, O

serotonin B-GROUP
reuptake I-GROUP
inhibitors I-GROUP
, O
amiodarone B-DRUG
, O
cannabinoids B-GROUP
, O
diltiazem B-DRUG
, O
grapefruit O
juice O
, O
nefazadone B-DRUG
, O
norfloxacin B-DRUG
, O
quinine B-DRUG
, O
zafirlukast B-DRUG
) O
should O
be O
cautiously O
coadministered O
with O
TIKOSYN B-BRAND
as O
they O
can O
potentially O
increase O
dofetilide B-DRUG
levels O
. O
Dofetilide B-DRUG
is O
not O
an O
inhibitor O
of O
CYP3A4 O
nor O
of O
other O
cytochrome O
P450 O
isoenzymes O
( O
e O
. O
g O
. O
, O
CYP2C9 O
, O
CYP2D6 O
) O
and O
is O
not O
expected O
to O
increase O
levels O
of O
drugs O
metabolized O
by O
CYP3A4 O
. O
Other O
Drug O
Interaction O
Information O
Digoxin B-DRUG
: O
Studies O
in O
healthy O
volunteers O
have O
shown O
that O
TIKOSYN B-BRAND
does O
not O
affect O
the O
pharmacokinetics O
of O
digoxin B-DRUG
. O
In O
patients O
, O
the O
concomitant O
administration O
of O
digoxin B-DRUG
with O
dofetilide B-DRUG
was O
associated O
with O
a O
higher O
occurrence O
of O
torsade O
de O
pointes O
. O
It O
is O
not O
clear O
whether O
this O
represents O
an O
interaction O
with O
TIKOSYN B-BRAND
or O
the O
presence O
of O
more O
severe O
structural O
heart O
disease O
in O
patients O
on O
digoxin B-DRUG
; O
structural O
heart O
disease O
is O
a O
known O
risk O
factor O
for O
arrhythmia O
. O
No O
increase O
in O
mortality O
was O
observed O
in O
patients O
taking O
digoxin B-DRUG
as O
concomitant O
medication O
. O
Other O
Drugs O
: O
In O
healthy O
volunteers O
, O
amlodipine B-DRUG
, O
phenytoin B-DRUG
, O
glyburide B-DRUG
, O
ranitidine B-DRUG
, O
omeprazole B-DRUG
, O
hormone O
replacement O
therapy O
( O
a O
combination O
of O
conjugated O
estrogens B-GROUP
and O
medroxyprogesterone B-DRUG
) O
, O
antacid B-GROUP
( O
aluminum B-DRUG
and I-DRUG
magnesium I-DRUG
hydroxides I-DRUG
) O
and O
theophylline B-DRUG
did O
not O
affect O
the O
pharmacokinetics O
of O
TIKOSYN B-BRAND
. O
In O
addition O
, O
studies O
in O
healthy O
volunteers O
have O
shown O
that O
TIKOSYN B-BRAND
does O
not O
affect O
the O
pharmacokinetics O
or O
pharmacodynamics O
of O
warfarin B-DRUG
, O
or O
the O
pharmacokinetics O
of O
propranolol B-DRUG
( O
40 O
mg O
twice O
daily O
) O
, O
phenytoin B-DRUG
, O
theophylline B-DRUG
, O
or O
oral O
contraceptives B-GROUP
. O
Population O
pharmacokinetic O
analyses O
were O
conducted O
on O
plasma O
concentration O
data O
from O
1445 O
patients O
in O
clinical O
trials O
to O
examine O
the O
effects O
of O
concomitant O
medications O
on O
clearance O
or O
volume O
of O
distribution O
of O
dofetilide B-DRUG
. O
Concomitant O
medications O
were O
grouped O
as O
ACE B-GROUP
inhibitors I-GROUP
, O
oral O
anticoagulants B-GROUP
, O
calcium B-GROUP

channel I-GROUP
blockers I-GROUP
, O
beta B-GROUP
blockers I-GROUP
, O
cardiac B-GROUP
glycosides I-GROUP
, O
inducers O
of O
CYP3A4 O
, O
substrates O
and O
inhibitors O
of O
CYP3A4 O
, O
substrates O
and O
inhibitors O
of O
P O
- O
glycoprotein O
, O
nitrates B-GROUP
, O
sulphonylureas B-GROUP
, O
loop B-GROUP
diuretics I-GROUP
, O
potassium B-GROUP
sparing I-GROUP
diuretics I-GROUP
, O
thiazide B-GROUP
diuretics I-GROUP
, O
substrates O
and O
inhibitors O
of O
tubular O
organic O
cation O
transport O
, O
and O
QTc O
- O
prolonging O
drugs O
. O
Differences O
in O
clearance O
between O
patients O
on O
these O
medications O
( O
at O
any O
occasion O
in O
the O
study O
) O
and O
those O
off O
medications O
varied O
between O
- O
16 O
% O
and O
+ O
3 O
% O
. O
The O
mean O
clearances O
of O
dofetilide B-DRUG
were O
16 O
% O
and O
15 O
% O
lower O
in O
patients O
on O
thiazide B-GROUP
diuretics I-GROUP
and O
inhibitors O
of O
tubular O
organic O
cation O
transport O
, O
respectively O
. O

The O
potential O
for O
clinically O
significant O
drug O
- O
drug O
interactions O
posed O
by O
dolasetron B-DRUG
and O
hydrodolasetron B-DRUG_N
appears O
to O
be O
low O
for O
drugs O
commonly O
used O
in O
chemotherapy O
or O
surgery O
, O
because O
hydrodolasetron B-DRUG_N
is O
eliminated O
by O
multiple O
routes O
. O
Blood O
levels O
of O
hydrodolasetron B-DRUG_N
increased O
24 O
% O
when O
dolasetron B-DRUG
was O
coadministered O
with O
cimetidine B-DRUG
( O
nonselective O
inhibitor O
of O
cytochrome O
P O
- O
450 O
) O
for O
7 O
days O
, O
and O
decreased O
28 O
% O
with O
coadministration O
of O
rifampin B-DRUG
( O
potent O
inducer O
of O
cytochrome O
P O
- O
450 O
) O
for O
7 O
days O
. O
Dolasetron B-DRUG
has O
been O
safely O
coadministered O
with O
drugs O
used O
in O
chemotherapy O
and O
surgery O
. O
As O
with O
other O
agents O
which O
prolong O
ECG O
intervals O
, O
caution O
should O
be O
exercised O
in O
patients O
taking O
drugs O
which O
prolong O
ECG O
intervals O
, O
particularly O
QTc O
. O
In O
patients O
taking O
furosemide B-DRUG
, O
nifedipine B-DRUG
, O
diltiazem B-DRUG
, O
ACE B-GROUP
inhibitors I-GROUP
, O
verapamil B-DRUG
, O
glyburide B-DRUG
, O
propranolol B-DRUG
, O
and O
various O
chemotherapy O
agents O
, O
no O
effect O
was O
shown O
on O
the O
clearance O
of O
hydrodolasetron B-DRUG_N
. O
Clearance O
of O
hydrodolasetron B-DRUG_N
decreased O
by O
about O
27 O
% O
when O
dolasetron B-DRUG
mesylate I-DRUG
was O
administered O
intravenously O
concomitantly O
with O
atenolol B-DRUG
. O
Dolasetron B-DRUG
does O
not O
influence O
anesthesia O
recovery O
time O
in O
patients O
. O
Dolasetron B-DRUG
mesylate I-DRUG
did O
not O
inhibit O
the O
antitumor O
activity O
of O
four O
chemotherapeutic B-GROUP
agents I-GROUP
( O
cisplatin B-DRUG
, O
5 B-DRUG
- I-DRUG
fluorouracil I-DRUG
, O
doxorubicin B-DRUG
, O
cyclophosphamide B-DRUG
) O
in O
four O
murine O
models O
. O

Drugs O
that O
inhibit O
or O
Induce O
CYP O
2D6 O
and O
CYP O
3A4 O
may O
affect O
the O
concentration O
on O
Aricept B-BRAND
. O

Because O
dopamine B-DRUG
is O
metabolized O
by O
monoamine O
oxidase O
( O
MAO O
) O
, O
inhibition O
of O
this O
enzyme O
prolongs O
and O
potentiates O
the O
effect O
of O
dopamine B-DRUG
. O
Patients O
who O
have O
been O
treated O
with O
MAO B-GROUP
inhibitors I-GROUP
within O
two O
to O
three O
weeks O
prior O
to O
the O
administration O
of O
dopamine B-DRUG
HCl I-DRUG
should O
receive O
initial O
doses O
of O
dopamine B-DRUG
HCl I-DRUG
no O
greater O
than O
one O
- O
tenth O
( O
1 O
/ O
10 O
) O
of O
the O
usual O
dose O
. O
Concurrent O
administration O
of O
low O
- O
dose O
dopamine B-DRUG
HCl I-DRUG
and O
diuretic B-GROUP
agents I-GROUP
may O
produce O
an O
additive O
or O
potentiating O
effect O
on O
urine O
flow O
. O
Tricyclic B-GROUP
antidepressants I-GROUP
may O
potentiate O
the O
cardiovascular O
effects O
of O
adreneric O
agents O
. O
Cardiac O
effects O
of O
dopamine B-DRUG
are O
antagonized O
by O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
, O
such O
as O
propranolol B-DRUG
and O
metoprolol B-DRUG
. O
The O
peripheral O
vasoconstriction O
caused O
by O
high O
doses O
of O
dopamine B-DRUG
HCl I-DRUG
is O
antagonized O
by O
alpha B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
. O
Dopamine B-DRUG
- O
induced O
renal O
and O
mesenteric O
vasodilation O
is O
not O
antagonized O
by O
either O
alpha B-GROUP
- I-GROUP
or I-GROUP
beta I-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
. O
Butyrophenones B-GROUP
( O
such O
as O
haloperidol B-DRUG
) O
and O
phenothiazines B-GROUP
can O
suppress O
the O
dopaminergic B-DRUG
renal O
and O
mesenteric O
vasodilation O
induced O
with O
low O
dose O
dopamine O
infusion O
. O
Cyclopropane B-DRUG
or O
halogenated B-GROUP
hydrocarbon I-GROUP
anesthetics I-GROUP
increase O
cardiac O
autonomic O
irritability O
and O
may O
sensitize O
the O
myocardium O
to O
the O
action O
of O
certain O
intravenously O
administered O
catecholamines B-GROUP
, O
such O
as O
dopamine B-DRUG
. O
This O
interaction O
appears O
to O
be O
related O
both O
to O
pressor O
activity O
and O
to O
beta O
- O
adrenergic O
stimulating O
properties O
of O
these O
catecholamines B-GROUP
and O
may O
produce O
ventricular O
arrhythmias O
and O
hypertension O
. O
Therefore O
, O
EXTREME O
CAUTION O
should O
be O
exercised O
when O
administering O
dopamine B-DRUG
HCl I-DRUG
to O
patients O
receiving O
cyclopropane B-DRUG
or O
halogenated B-GROUP
hydrocarbon I-GROUP
anesthetics I-GROUP
. O
It O
has O
been O
reported O
that O
results O
of O
studies O
in O
animals O
indicate O
that O
dopamine B-DRUG
- O
induced O
ventricular O
arrhythmias O
during O
anesthesia O
can O
be O
reversed O
by O
propranolol B-DRUG
. O
The O
concomitant O
use O
of O
vasopressors B-GROUP
, O
vasoconstricting O
agents O
( O
such O
as O
ergonovine B-DRUG
) O
and O

some O
oxytocic B-GROUP
drugs I-GROUP
may O
result O
in O
severe O
hypertension O
. O
Administration O
of O
phenytoin B-DRUG
to O
patients O
receiving O
dopamine B-DRUG
HCl I-DRUG
has O
been O
reported O
to O
lead O
to O
hypotension O
and O
bradycardia O
. O
It O
is O
suggested O
that O
in O
patients O
receiving O
dopamine B-DRUG
HCl I-DRUG
, O
alternatives O
to O
phenytoin B-DRUG
should O
be O
used O
if O
anticonvulsant B-GROUP
therapy O
is O
needed O
. O

Clinical O
trials O
have O
indicated O
that O
Pulmozyme B-BRAND
can O
be O
effectively O
and O
safely O
used O
in O
conjunction O
with O
standard O
cystic O
fibrosis O
therapies O
including O
oral O
, O
inhaled O
and O
/ O
or O
parenteral O
antibiotics B-GROUP
, O
bronchodilators B-GROUP
, O
enzyme O
supplements O
, O
vitamins B-GROUP
, O
oral O
or O
inhaled O
corticosteroids B-GROUP
, O
and O
analgesics B-GROUP
. O
No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
. O

Although O
acid O
- O
base O
and O
electrolyte O
disturbances O
were O
not O
reported O
in O
the O
clinical O
trials O
with O
dorzolamide B-DRUG
, O
these O
disturbances O
have O
been O
reported O
with O
oral O
carbonic B-GROUP
anhydrase I-GROUP
inhibitors I-GROUP
and O
have O
, O
in O
some O
instances O
, O
resulted O
in O
drug O
interactions O
( O
e O
. O
g O
. O
, O
toxicity O
associated O
with O
high O
- O
dose O
salicylate B-GROUP
therapy O
) O
. O
Therefore O
, O
the O
potential O
for O
such O
drug O
interactions O
should O
be O
considered O
in O
patients O
receiving O
dorzolamide B-DRUG
. O

Prior O
administration O
of O
succinylcholine B-DRUG
has O
no O
clinically O
important O
effect O
on O
the O
neuromuscular O
blocking O
action O
of O
NUROMAX B-BRAND
. O
The O
use O
of O
NUROMAX B-BRAND
before O
succinylcholine B-DRUG
to O
attenuate O
some O
of O
the O
side O
effects O
of O
succinylcholine B-DRUG
has O
not O
been O
studied O
. O
There O
are O
no O
clinical O
data O
on O
concomitant O
use O
of O
NUROMAX B-BRAND
and O
other O
nondepolarizing O
neuromuscular B-GROUP
blocking I-GROUP
agents I-GROUP
. O
Isoflurane B-DRUG
, O
enflurane B-DRUG
, O
and O
halothane B-DRUG
decrease O
the O
ED50 O
of O
NUROMAX B-BRAND
by O
30 O
% O
to O
45 O
% O
. O
These O
agents O
may O
also O
prolong O
the O
clinically O
effective O
duration O
of O
action O
by O
up O
to O
25 O
% O
. O
Other O
drugs O
which O
may O
enhance O
the O
neuromuscular O
blocking O
action O
of O
nondepolarizing O
agents O
such O
as O
NUROMAX B-BRAND
include O
certain O
antibiotics B-GROUP
( O
e O
. O
g O
. O
, O
aminoglycosides B-GROUP
, O
tetracyclines B-GROUP
, O
bacitracin B-GROUP
, O
polymyxins B-GROUP
, O
lincomycin B-DRUG
, O
clindamycin B-DRUG
, O
colistin B-DRUG
, O
and O
sodium B-DRUG
colistimethate I-DRUG
) O
, O
magnesium B-DRUG
salts O
, O
lithium B-DRUG
, O
local O
anesthetics B-GROUP
, O
procainamide B-DRUG
, O
and O
quinidine B-DRUG
. O
As O
with O
some O
other O
nondepolarizing B-GROUP
neuromuscular I-GROUP
blocking I-GROUP
agents I-GROUP
, O
the O
time O
of O
onset O
of O
neuromuscular O
block O
induced O
by O
NUROMAX B-BRAND
is O
lengthened O
and O
the O
duration O
of O
block O
is O
shortened O
in O
patients O
receiving O
phenytoin B-DRUG
or O
carbamazepine B-DRUG
. O

Administration O
of O
doxapram B-DRUG
to O
patients O
who O
are O
receiving O
sympathomimetic B-GROUP
or O
monoamine B-GROUP
oxidase I-GROUP
inhibiting I-GROUP
drugs I-GROUP
may O
result O
in O
an O
additive O
pressor O
effect O
. O
In O
patients O
who O
have O
received O
muscle B-GROUP
relaxants I-GROUP
, O
doxapram B-DRUG
may O
temporarily O
mask O
the O
residual O
effects O
of O
muscle B-GROUP
relaxant I-GROUP
drugs I-GROUP
. O
In O
patients O
who O
have O
received O
general O
anesthesia O
utilizing O
a O
volatile O
agent O
known O
to O
sensitize O
the O
myocardium O
to O
catecholamines O
, O
administration O
of O
doxapram B-DRUG
should O
be O
delayed O
until O
the O
volatile O
agent O
has O
been O
excreted O
in O
order O
to O
lessen O
the O
potential O
for O
arrhythmias O
, O
including O
ventricular O
tachycardia O
and O
ventricular O
fibrillation O
. O

Most O
( O
98 O
% O
) O
of O
plasma O
doxazosin B-DRUG
is O
protein O
bound O
. O
In O
vitro O
data O
in O
human O
plasma O
indicate O
that O
doxazosin B-DRUG
mesylate I-DRUG
has O
no O
effect O
on O
protein O
binding O
of O
digoxin B-DRUG
, O
warfarin B-DRUG
, O
phenytoin B-DRUG
or O
indomethacin B-DRUG
. O
There O
is O
no O
information O
on O
the O
effect O
of O
other O
highly O
plasma O
protein O
bound O
drugs O
on O
doxazosin B-DRUG
binding O
. O
Doxazosin B-DRUG
mesylate I-DRUG
has O
been O
administered O
without O
any O
evidence O
of O
an O
adverse O
drug O
interaction O
to O
patients O
receiving O
thiazide B-GROUP
diuretics I-GROUP
, O
beta B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
, O
and O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
. O
In O
a O
placebo O
- O
controlled O
trial O
in O
normal O
volunteers O
, O
the O
administration O
of O
a O
single O
1 O
mg O
dose O
of O
doxazosin B-DRUG
on O
day O
1 O
of O
a O
four O
- O
day O
regimen O
of O
oral O
cimetidine B-DRUG
( O
400 O
mg O
twice O
daily O
) O
resulted O
in O
a O
10 O
% O
increase O
in O
mean O
AUC O
of O
doxazosin B-DRUG
( O
p O
= O
0 O
. O
006 O
) O
, O
and O
a O
slight O
but O
not O
statistically O
significant O
increase O
in O
mean O
Cmax O
and O
mean O
half O
- O
life O
of O
doxazosin B-DRUG
. O
The O
clinical O
significance O
of O
this O
increase O
in O
doxazosin B-DRUG
AUC O
is O
unknown O
. O
In O
clinical O
trials O
, O
doxazosin B-DRUG
mesylate I-DRUG
tablets O
have O
been O
administered O
to O
patients O
on O
a O
variety O
of O
concomitant O
medications O
; O
while O
no O
formal O
interaction O
studies O
have O
been O
conducted O
, O
no O
interactions O
were O
observed O
. O
Doxazosin B-DRUG
mesylate I-DRUG
tablets O
have O
been O
used O
with O
the O
following O
drugs O
or O
drug O
classes O
: O
1 O
. O
Analgesic B-GROUP
/ O
anti B-GROUP
- I-GROUP
inflammatory I-GROUP
( O
e O
. O
g O
. O
, O
acetaminophen B-DRUG
, O
aspirin B-BRAND
, O
codeine B-DRUG
and O
codeine B-DRUG
combinations O
, O
ibuprofen B-DRUG
, O
indomethacin B-DRUG
) O
. O
2 O
. O
Antibiotics B-GROUP
( O
e O
. O
g O
. O
, O
erythromycin B-DRUG
, O
trimethoprim B-DRUG
and O
sulfamethoxazole B-DRUG
, O
amoxicillin B-DRUG
) O
. O
3 O
. O
Antihistamines B-GROUP
( O
e O
. O
g O
. O
, O
chlorpheniramine B-GROUP
) O
. O
4 O
. O
Cardiovascular O
agents O
( O
e O
. O
g O
. O
, O
atenolol B-DRUG
, O
hydrochlorothiazide B-DRUG
, O
propranolol B-DRUG
) O
. O
5 O
. O
Corticosteroids B-GROUP
. O
6 O
. O
Gastrointestinal O
agents O
( O
e O
. O
g O
. O
, O
antacids B-GROUP
) O
. O
7 O
. O
Hypoglycemics B-GROUP
and O
endocrine O
drugs O
. O
8 O
. O
Sedatives B-GROUP
and O
tranquilizers B-GROUP
( O
e O
. O
g O
. O
, O
diazepam B-DRUG
) O
. O
9 O
. O
Cold O
and O
flu O
remedies O
. O

Drugs O
Metabolized O
by O
P450 O
2D6 O
: O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
Caucasian O
population O
( O
about O
7 O
- O
10 O
% O
of O
Caucasians O
are O
so O
- O
called O
poor O
metabolizers O
) O
; O
reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O
Poor O
metabolizers O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-GROUP
antidepressants I-GROUP
( O
TCAs B-GROUP
) O
when O
given O
usual O
doses O
. O
Depending O
on O
the O
fraction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8 O
- O
fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA O
) O
. O
In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
poor O
metabolizers O
. O
An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCA B-GROUP
may O
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O
The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-DRUG
; O
cimetidine B-DRUG
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-GROUP
, O
phenothiazines B-GROUP
, O
and O
the O
Type B-GROUP
1C I-GROUP
antiarrhythmics I-GROUP
propafenone B-DRUG
and O
flecainide B-DRUG
) O
. O
While O
all O
the O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
( O
SSRIs B-GROUP
) O
, O
e O
. O
g O
. O
, O
citalopram B-DRUG
, O
escitalopram B-DRUG
, O
fluoxetine B-DRUG
, O
sertraline B-DRUG
, O
and O
paroxetine B-DRUG
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O
The O
extent O
to O
which O
SSRI B-GROUP
- O
TCA B-GROUP
interactions O
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-GROUP
involved O
. O
Nevertheless O
, O
caution O
is O
indicated O
in O
the O
co O
- O
administration O
of O
TCAs B-GROUP
with O
any O
of O
the O
SSRIs B-GROUP
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O
Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCA O
treatment O
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-DRUG
, O
given O
the O
long O
half O
- O
life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O
Concomitant O

use O
of O
tricyclic B-GROUP
antidepressants I-GROUP
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-GROUP
antidepressant I-GROUP
or O
the O
other O
drug O
. O
Furthermore O
, O
whenever O
one O
of O
these O
other O
drugs O
is O
withdrawn O
from O
co O
- O
therapy O
, O
an O
increased O
dose O
of O
tricyclic B-GROUP
antidepressant I-GROUP
may O
be O
required O
. O
It O
is O
desirable O
to O
monitor O
TCA B-GROUP
plasma O
levels O
whenever O
a O
TCA B-GROUP
is O
going O
to O
be O
co O
- O
administered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
. O
Doxepin B-DRUG
is O
primarily O
metabolized O
by O
CYP2D6 O
( O
with O
CYP1A2 O
and O
CYP3A4 O
as O
minor O
pathways O
) O
. O
Inhibitors O
or O
substrates O
of O
CYP2D6 O
( O
i O
. O
e O
. O
, O
quinidine B-DRUG
, O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
[ O
SSRIs B-GROUP
] O
) O
may O
increase O
the O
plasma O
concentration O
of O
doxepin B-DRUG
when O
administered O
concomitantly O
. O
The O
extent O
of O
interaction O
depends O
on O
the O
variability O
of O
effect O
on O
CYP2D6 O
. O
The O
clinical O
significance O
of O
this O
interaction O
with O
doxepin B-DRUG
has O
not O
been O
systematically O
evaluated O
. O
MAO B-GROUP
Inhibitors I-GROUP
: O
Serious O
side O
effects O
and O
even O
death O
have O
been O
reported O
following O
the O
concomitant O
use O
of O
certain O
drugs O
with O
MAO B-GROUP
inhibitors I-GROUP
. O
Therefore O
, O
MAO B-GROUP
inhibitors I-GROUP
should O
be O
discontinued O
at O
least O
two O
weeks O
prior O
to O
the O
cautious O
initiation O
of O
therapy O
with O
SINEQUAN B-BRAND
. O
The O
exact O
length O
of O
time O
may O
vary O
and O
is O
dependent O
upon O
the O
particular O
MAO B-GROUP
inhibitor I-GROUP
being O
used O
, O
the O
length O
of O
time O
it O
has O
been O
administered O
, O
and O
the O
dosage O
involved O
. O
Cimetidine B-DRUG
: O
Cimetidine B-DRUG
has O
been O
reported O
to O
produce O
clinically O
significant O
fluctuations O
in O
steady O
- O
state O
serum O
concentrations O
of O
various O
tricyclic B-GROUP
antidepressants I-GROUP
. O
Serious O
anticholinergic O
symptoms O
( O
i O
. O
e O
. O
, O
severe O
dry O
mouth O
, O
urinary O
retention O
and O
blurred O
vision O
) O
have O
been O
associated O
with O
elevations O
in O
the O
serum O
levels O
of O
tricyclic B-GROUP
antidepressant I-GROUP
when O
cimetidine B-DRUG
therapy O
is O
initiated O
. O
Additionally O
, O
higher O
than O
expected O
tricyclic B-GROUP
antidepressant I-GROUP
levels O
have O
been O
observed O
when O
they O
are O
begun O
in O
patients O
already O
taking O
cimetidine B-DRUG
. O
In O
patients O
who O
have O
been O
reported O
to O
be O
well O
controlled O
on O
tricyclic B-GROUP
antidepressants I-GROUP
receiving O
concurrent O
cimetidine B-DRUG
therapy O
, O
discontinuation O
of O
cimetidine B-DRUG
has O
been O
reported O
to O
decrease O
established O
steady O
- O
state O
serum O
tricyclic B-GROUP
antidepressant I-GROUP
levels O
and O
compromise O
their O
therapeutic O
effects O
. O
Alcohol B-DRUG
: O
It O
should O
be O
borne O
in O
mind O
that O

alcohol B-DRUG
ingestion O
may O
increase O
the O
danger O
inherent O
in O
any O
intentional O
or O
unintentional O
SINEQUAN B-BRAND
overdosage O
. O
This O
is O
especially O
important O
in O
patients O
who O
may O
use O
alcohol B-DRUG
excessively O
. O
Tolazamide B-DRUG
: O
A O
case O
of O
severe O
hypoglycemia O
has O
been O
reported O
in O
a O
type O
II O
diabetic O
patient O
maintained O
on O
tolazamide B-DRUG
( O
1 O
gm O
/ O
day O
) O
11 O
days O
after O
the O
addition O
of O
doxepin B-DRUG
( O
75 O
mg O
/ O
day O
) O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
with O
DOXIL B-BRAND
. O
Until O
specific O
compatibility O
data O
are O
available O
, O
it O
is O
not O
recommended O
that O
DOXIL B-BRAND
be O
mixed O
with O
other O
drugs O
. O
DOXIL B-BRAND
may O
interact O
with O
drugs O
known O
to O
interact O
with O
the O
conventional O
formulation O
of O
doxorubicin B-DRUG
HCl I-DRUG
. O

Because O
tetracyclines B-GROUP
have O
been O
shown O
to O
depress O
plasma O
prothrombin O
activity O
, O
patients O
who O
are O
on O
anticoagulant B-GROUP
therapy O
may O
require O
downward O
adjustment O
of O
their O
anticoagulant B-GROUP
dosage O
. O
Since O
bacteriostatic O
drugs O
may O
interfere O
with O
the O
bactericidal O
action O
of O
penicillin B-DRUG
, O
it O
is O
advisable O
to O
avoid O
giving O
tetracyclines B-GROUP
in O
conjunction O
with O
penicillin B-GROUP
. O
Absorption O
of O
tetracyclines B-GROUP
is O
impaired O
by O
antacids B-GROUP
containing O
aluminum B-DRUG
, O
calcium B-DRUG
, O
or O
magnesium B-DRUG
, O
and O
iron B-DRUG
- O
containing O
preparations O
. O
Absorption O
of O
tetracycline B-DRUG
is O
impaired O
by O
bismuth B-DRUG
subsalicylate I-DRUG
. O
Barbiturates B-GROUP
, O
carbamazepine B-DRUG
, O
and O
phenytoin B-DRUG
decrease O
the O
half O
- O
life O
of O
doxycycline B-DRUG
. O
The O
concurrent O
use O
of O
tetracycline B-DRUG
and O
Penthrane B-BRAND
( O
methoxyflurane B-DRUG
) O
has O
been O
reported O
to O
result O
in O
fatal O
renal O
toxicity O
. O
Concurrent O
use O
of O
tetracycline B-DRUG
may O
render O
oral O
contraceptives B-GROUP
less O
effective O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
False O
elevations O
of O
urinary O
catecholamine O
levels O
may O
occur O
due O
to O
interference O
with O
the O
fluorescence O
test O
. O

Potential O
drug O
interactions O
for O
doxylamine B-DRUG
include O
, O
increased O
sedation O
if O
doxylamine B-DRUG
is O
combined O
with O
other O
CNS B-GROUP
depressant I-GROUP
drugs I-GROUP
. O
Antihistamines B-GROUP
may O
partially O
counteract O
the O
anticoagulation O
effects O
of O
heparin B-DRUG
or O
warfarin B-DRUG
. O
Doxylamine B-DRUG
may O
enhance O
the O
effects O
of O
epinephrine B-DRUG
. O

Androgens B-GROUP
may O
increase O
sensitivity O
to O
oral O
anticoagulahts O
. O
Dosage O
of O
the O
anticoagulant B-GROUP
may O
require O
reduction O
in O
order O
to O
maintain O
satisfactory O
therapeutic O
hypoprothrombinemia O
. O
Concurrent O
administration O
of O
oxyphenbutazone B-DRUG
and O
androgens B-GROUP
may O
result O
in O
elevated O
serum O
levels O
of O
oxyphenbutazone B-DRUG
. O
In O
diabetic O
patients O
, O
the O
metabolic O
effects O
of O
androgens B-GROUP
may O
decrease O
blood O
glucose O
and O
therefore O
, O
insulin B-DRUG
requirements O
. O

Other O
CNS B-GROUP
depressant I-GROUP
drugs I-GROUP
( O
e O
. O
g O
. O
barbiturates B-GROUP
, O
tranquilizers B-GROUP
, O
opioids B-GROUP
and O
general O
anesthetics B-GROUP
) O
have O
additive O
or O
potentiating O
effects O
with O
INAPSINE B-BRAND
. O
When O
patients O
have O
received O
such O
drugs O
, O
the O
dose O
of O
INAPSINE B-BRAND
required O
will O
be O
less O
than O
usual O
. O
Following O
the O
administration O
of O
INAPSINE B-BRAND
, O
the O
dose O
of O
other O
CNS B-GROUP
depressant I-GROUP
drugs I-GROUP
should O
be O
reduced O
. O

Drug O
interaction O
studies O
with O
Xigris B-BRAND
have O
not O
been O
performed O
in O
patients O
with O
severe O
sepsis O
. O
However O
, O
since O
there O
is O
an O
increased O
risk O
of O
bleeding O
with O
Xigris B-BRAND
, O
caution O
should O
be O
employed O
when O
Xigris B-BRAND
is O
used O
with O
other O
drugs O
that O
affect O
hemostasis O
. O
Approximately O
2 O
/ O
3 O
of O
the O
patients O
in O
the O
Phase O
3 O
study O
received O
either O
prophylactic O
low O
dose O
heparin B-DRUG
( O
unfractionated B-DRUG
heparin I-DRUG
up O
to O
15 O
, O
000 O
units O
/ O
day O
) O
or O
prophylactic O
doses O
of O
low B-GROUP
molecular I-GROUP
weight I-GROUP
heparins I-GROUP
as O
indicated O
in O
the O
prescribing O
information O
for O
the O
specific O
products O
. O
Concomitant O
use O
of O
prophylactic O
low O
dose O
heparin B-DRUG
did O
not O
appear O
to O
affect O
safety O
, O
however O
, O
its O
effects O
on O
the O
efficacy O
of O
Xigris B-BRAND
have O
not O
been O
evaluated O
in O
an O
adequate O
and O
well O
- O
controlled O
clinical O
trial O
. O
Drug O
/ O
Laboratory O
Test O
Interaction O
Because O
Xigris B-BRAND
may O
affect O
the O
APTT O
assay O
, O
Xigris B-BRAND
present O
in O
plasma O
samples O
may O
interfere O
with O
one O
- O
stage O
coagulation O
assays O
based O
on O
the O
APTT O
( O
such O
as O
factor O
VIII O
, O
IX O
, O
and O
XI O
assays O
) O
. O
This O
interference O
may O
result O
in O
an O
apparent O
factor O
concentration O
that O
is O
lower O
than O
the O
true O
concentration O
. O
Xigris B-BRAND
present O
in O
plasma O
samples O
does O
not O
interfere O
with O
one O
- O
stage O
factor O
assays O
based O
on O
the O
PT O
( O
such O
as O
factor O
II O
, O
V O
, O
VII O
, O
and O
X O
assays O
) O
. O

Potential O
for O
Other O
Drugs O
to O
Affect O
Duloxetine B-DRUG
: O
Both O
CYP1A2 O
and O
CYP2D6 O
are O
responsible O
for O
duloxetine B-DRUG
metabolism O
. O
Inhibitors O
of O
CYP1A2 O
: O
Concomitant O
use O
of O
duloxetine B-DRUG
with O
fluvoxamine B-DRUG
, O
an O
inhibitor O
of O
CYP1A2 O
, O
results O
in O
approximately O
a O
6 O
- O
fold O
increase O
in O
AUC O
and O
about O
a O
2 O
. O
5 O
- O
fold O
increase O
in O
Cmax O
of O
duloxetine B-DRUG
. O
Some O
quinolone B-GROUP
antibiotics I-GROUP
would O
be O
expected O
to O
have O
similar O
effects O
and O
these O
combinations O
should O
be O
avoided O
. O
Inhibitors O
of O
CYP2D6 O
: O
Because O
CYP2D6 O
is O
involved O
in O
duloxetine B-DRUG
metabolism O
, O
concomitant O
use O
of O
duloxetine B-DRUG
with O
potent O
inhibitors O
of O
CYP2D6 O
may O
result O
in O
higher O
concentrations O
of O
duloxetine B-DRUG
. O
Paroxetine B-DRUG
( O
20 O
mg O
QD O
) O
increased O
the O
concentration O
of O
duloxetine B-DRUG
( O
40 O
mg O
QD O
) O
by O
about O
60 O
% O
, O
and O
greater O
degrees O
of O
inhibition O
are O
expected O
with O
higher O
doses O
of O
paroxetine B-DRUG
. O
Similar O
effects O
would O
be O
expected O
with O
other O
potent O
CYP2D6 O
inhibitors O
( O
e O
. O
g O
. O
, O
fluoxetine B-DRUG
, O
quinidine B-DRUG
) O
. O
Potential O
for O
Duloxetine B-DRUG
to O
Affect O
Other O
Drugs O
: O
Drugs O
Metabolized O
by O
CYP1A2 O
: O
In O
vitro O
drug O
interaction O
studies O
demonstrate O
that O
duloxetine B-DRUG
does O
not O
induce O
CYP1A2 O
activity O
, O
and O
it O
is O
unlikely O
to O
have O
a O
clinically O
significant O
effect O
on O
the O
metabolism O
of O
CYP1A2 O
substrates O
. O
Drugs O
Metabolized O
by O
CYP2D6 O
: O
Duloxetine B-DRUG
is O
a O
moderate O
inhibitor O
of O
CYP2D6 O
. O
When O
duloxetine B-DRUG
was O
administered O
( O
at O
a O
dose O
of O
60 O
mg O
BID O
) O
in O
conjunction O
with O
a O
single O
50 O
- O
mg O
dose O
of O
desipramine B-DRUG
, O
a O
CYP2D6 O
substrate O
, O
the O
AUC O
of O
desipramine B-DRUG
increased O
3 O
- O
fold O
. O
Therefore O
, O
co O
- O
administration O
of O
Duloxetine B-DRUG
with O
other O
drugs O
that O
are O
extensively O
metabolized O
by O
this O
isozyme O
and O
which O
have O
a O
narrow O
therapeutic O
index O
, O
including O
certain O
antidepressants B-GROUP
( O
tricyclic B-GROUP
antidepressants I-GROUP
[ O
TCAs B-GROUP
] O
, O
such O
as O
nortriptyline B-DRUG
, O
amitriptyline B-DRUG
, O
and O
imipramine B-DRUG
) O
, O
phenothiazines B-GROUP
and O
Type B-GROUP
1C I-GROUP
antiarrhythmics I-GROUP
( O
e O
. O
g O
. O
, O
propafenone B-DRUG
, O

flecainide B-DRUG
) O
, O
should O
be O
approached O
with O
caution O
. O
Plasma O
TCA B-GROUP
concentrations O
may O
need O
to O
be O
monitored O
and O
the O
dose O
of O
the O
TCA B-GROUP
may O
need O
to O
be O
reduced O
if O
a O
TCA B-GROUP
is O
co O
- O
administered O
with O
Duloxetine B-DRUG
. O
Because O
of O
the O
risk O
of O
serious O
ventricular O
arrhythmias O
and O
sudden O
death O
potentially O
associated O
with O
elevated O
plasma O
levels O
of O
thioridazine B-DRUG
, O
Duloxetine B-DRUG
and O
thioridazine B-DRUG
should O
not O
be O
co O
- O
administered O
. O
Drugs O
Metabolized O
by O
CYP3A O
: O
Results O
of O
in O
vitro O
studies O
demonstrate O
that O
duloxetine B-DRUG
does O
not O
inhibit O
or O
induce O
CYP3A O
activity O
. O
Duloxetine B-DRUG
May O
Have O
a O
Clinically O
Important O
Interaction O
with O
the O
Following O
Other O
Drugs O
: O
Alcohol B-DRUG
: O
When O
Duloxetine B-DRUG
and O
ethanol B-DRUG
were O
administered O
several O
hours O
apart O
so O
that O
peak O
concentrations O
of O
each O
would O
coincide O
, O
Duloxetine B-DRUG
did O
not O
increase O
the O
impairment O
of O
mental O
and O
motor O
skills O
caused O
by O
alcohol B-DRUG
. O
In O
the O
Duloxetine B-DRUG
clinical O
trials O
database O
, O
three O
Duloxetine B-DRUG
- O
treated O
patients O
had O
liver O
injury O
as O
manifested O
by O
ALT O
and O
total O
bilirubin O
elevations O
, O
with O
evidence O
of O
obstruction O
. O
Substantial O
intercurrent O
ethanol B-DRUG
use O
was O
present O
in O
each O
of O
these O
cases O
, O
and O
this O
may O
have O
contributed O
to O
the O
abnormalities O
seen O
. O
CNS O
Acting O
Drugs O
: O
Given O
the O
primary O
CNS O
effects O
of O
Duloxetine B-DRUG
, O
it O
should O
be O
used O
with O
caution O
when O
it O
is O
taken O
in O
combination O
with O
or O
substituted O
for O
other O
centrally O
acting O
drugs O
, O
including O
those O
with O
a O
similar O
mechanism O
of O
action O
. O
Potential O
for O
Interaction O
with O
Drugs O
that O
Affect O
Gastric O
Acidity O
: O
Duloxetine B-DRUG
has O
an O
enteric O
coating O
that O
resists O
dissolution O
until O
reaching O
a O
segment O
of O
the O
gastrointestinal O
tract O
where O
the O
pH O
exceeds O
5 O
. O
5 O
. O
In O
extremely O
acidic O
conditions O
, O
Duloxetine B-DRUG
, O
unprotected O
by O
the O
enteric O
coating O
, O
may O
undergo O
hydrolysis O
to O
form O
naphthol O
. O
Caution O
is O
advised O
in O
using O
Duloxetine B-DRUG
in O
patients O
with O
conditions O
that O
may O
slow O
gastric O
emptying O
( O
e O
. O
g O
. O
, O
some O
diabetics O
) O
. O
Drugs O
that O
raise O
the O
gastrointestinal O
pH O
may O
lead O
to O
an O
earlier O
release O
of O
duloxetine B-DRUG
. O
However O
, O
co O
- O
administration O
of O
Duloxetine B-DRUG
with O
aluminum B-DRUG
- O
and O
magnesium B-DRUG
- O
containing O
antacids B-GROUP
( O
51 O
mEq O
) O
or O
Duloxetine B-DRUG
with O
famotidine B-DRUG
, O
had O
no O
significant O
effect O
on O
the O
rate O
or O
extent O
of O
duloxetine B-DRUG
absorption O
after O
administration O
of O
a O
40 O
- O
mg O
oral O
dose O

. O
It O
is O
unknown O
whether O
the O
concomitant O
administration O
of O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
affects O
duloxetine B-DRUG
absorption O
. O

Synergism O
between O
xanthine B-GROUP
bronchodilators I-GROUP
( O
e O
. O
g O
. O
, O
theophylline B-DRUG
) O
, O
ephedrine B-DRUG
, O
and O
other O
sympathomimetic B-GROUP
bronchodilators I-GROUP
has O
been O
reported O
. O
This O
should O
be O
considered O
whenever O
these O
agents O
are O
prescribed O
concomitantly O
. O
Concurrent O
administration O
of O
dyphylline B-DRUG
and O
probenecid B-DRUG
, O
which O
competes O
for O
tubular O
secretion O
, O
has O
been O
shown O
to O
increase O
the O
plasma O
half O
- O
life O
of O
dyphylline B-DRUG
. O

Phospholine B-DRUG
Iodide I-DRUG
potentiates O
other O
cholinesterase B-GROUP
inhibitors I-GROUP
such O
as O
succinylcholine B-DRUG
or O
organophosphate B-DRUG_N
and I-DRUG_N
carbamate I-DRUG_N
insecticides I-DRUG_N
. O
Patients O
undergoing O
systemic O
anticholinesterase O
treatment O
should O
be O
warned O
of O
the O
possible O
additive O
effects O
of O
Phospholine B-DRUG
Iodide I-DRUG
. O

Drug O
interaction O
studies O
have O
not O
been O
performed O
with O
Soliris B-BRAND
. O

There O
is O
no O
known O
drug O
interference O
with O
standard O
clinical O
laboratory O
tests O
. O
Steroids B-GROUP
enhance O
the O
renal O
toxicity O
of O
edetate B-DRUG
calcium I-DRUG
disodium I-DRUG
in O
animals O
. O
7 O
Edetate B-DRUG
calcium I-DRUG
disodium I-DRUG
interferes O
with O
the O
action O
of O
zinc B-DRUG
insulin I-DRUG
preparations O
by O
chelating O
the O
zinc B-DRUG
. O
7 O

Care O
should O
be O
given O
when O
administering O
this O
drug O
to O
patients O
with O
symptoms O
of O
myasthenic O
weakness O
who O
are O
also O
on O
anticholinesterase B-GROUP
drugs I-GROUP
. O
Since O
symptoms O
of O
anticholinesterase O
overdose O
( O
cholinergic O
crisis O
) O
may O
mimic O
underdosage O
( O
myasthenic O
weakness O
) O
, O
their O
condition O
may O
be O
worsened O
by O
the O
use O
of O
this O
drug O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
with O
RAPTIVA B-BRAND
. O
RAPTIVA B-BRAND
should O
not O
be O
used O
with O
other O
immunosuppressive B-GROUP
drugs I-GROUP
. O
Acellular B-GROUP
, I-GROUP
live I-GROUP
and I-GROUP
live I-GROUP
- I-GROUP
attenuated I-GROUP
vaccines I-GROUP
should O
not O
be O
administered O
during O
RAPTIVA B-BRAND
treatment O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Increases O
in O
lymphocyte O
counts O
related O
to O
the O
pharmacologic O
mechanism O
of O
action O
are O
frequently O
observed O
during O
RAPTIVA B-BRAND
treatment O
. O

Efavirenz B-DRUG
has O
been O
shown O
in O
vivo O
to O
induce O
CYP3A4 O
. O
Other O
compounds O
that O
are O
substrates O
of O
CYP3A4 O
may O
have O
decreased O
plasma O
concentrations O
when O
coadministered O
with O
SUSTIVA B-BRAND
( O
efavirenz B-DRUG
) O
. O
In O
vitro O
studies O
have O
demonstrated O
that O
efavirenz B-DRUG
inhibits O
2C9 O
, O
2C19 O
, O
and O
3A4 O
isozymes O
in O
the O
range O
of O
observed O
efavirenz B-DRUG
plasma O
concentrations O
. O
Coadministration O
of O
efavirenz B-DRUG
with O
drugs O
primarily O
metabolized O
by O
these O
isozymes O
may O
result O
in O
altered O
plasma O
concentrations O
of O
the O
coadministered O
drug O
. O
Therefore O
, O
appropriate O
dose O
adjustments O
may O
be O
necessary O
for O
these O
drugs O
. O
Drugs O
which O
induce O
CYP3A4 O
activity O
( O
eg O
, O
phenobarbital B-DRUG
, O
rifampin B-DRUG
, O
rifabutin B-DRUG
) O
would O
be O
expected O
to O
increase O
the O
clearance O
of O
efavirenz B-DRUG
resulting O
in O
lowered O
plasma O
concentrations O
. O
Drug O
interactions O
with O
SUSTIVA B-BRAND
are O
summarized O
in O
Table O
5 O
. O
Table O
5a O
: O
Drugs O
That O
Should O
Not O
Be O
Coadministered O
With O
SUSTIVA B-BRAND
Drug O
Class O
Drugs O
Within O
Class O
Not O
To O
Be O
Coadministered O
With O
SUSTIVA B-BRAND
Antihistamines B-GROUP
: O
Benzodiazepines B-GROUP
GI O
Motility O
Agents O
Anti B-GROUP
- I-GROUP
Migraine I-GROUP
Antifungal B-GROUP
astemizole B-DRUG
midazolam B-DRUG
, O
triazolam B-DRUG
cisapride B-DRUG
ergot O
derivatives O
voriconazole B-DRUG
Established O
Drug O
Interactions O
Drug O
Name O
Effect O
Clinical O
Comment O
Atazanavir B-DRUG
atazanavir B-DRUG
When O
coadministered O
with O
SUSTIVA B-BRAND
in O
treatment O
- O
naive O
patients O
, O
the O
recommended O
dose O
of O
atazanavir B-DRUG
is O
300 O
mg O
with O
ritonavir B-DRUG
100 O
mg O
and O
SUSTIVA B-BRAND
600 O
mg O
( O
all O
once O
daily O
) O
. O
Dosing O
recommendations O
for O
SUSTIVA B-BRAND
and O
atazanavir B-DRUG
in O
treatment O
- O
experienced O
patients O
have O
not O
been O
established O
. O
Established O
Drug O
Interactions O
( O
continued O
) O
Drug O
Name O
Effect O
Clinical O
Comment O
Clarithromycin B-DRUG
clarithromycin B-DRUG
concentration O
Plasma O
concentrations O
decreased O
by O
SUSTIVA B-BRAND
; O
clinical O
significance O
unknown O
. O
In O
uninfected O
volunteers O
, O
46 O
% O
developed O
rash O
while O
receiving O
SUSTIVA B-BRAND
and O
clarithromycin B-DRUG
. O
No O
dose O
adjustment O
of O
SUSTIVA B-BRAND
is O
recommended O
when O
given O
with O
clarithromycin B-DRUG
. O
Alternatives O
to O
clarithromycin B-DRUG
, O
such O
as O
azithromycin B-DRUG
, O
should O
be O
considered O
. O
Other O
macrolide B-GROUP
antibiotics I-GROUP
, O
such O
as O
erythromycin B-DRUG
, O
have O

not O
been O
studied O
in O
combination O
with O
SUSTIVA B-BRAND
. O
14 O
- O
OH O
metabolite O
concentration O
Indinavir B-DRUG
indinavir B-DRUG
concentration O
The O
optimal O
dose O
of O
indinavir B-DRUG
, O
when O
given O
in O
combination O
with O
SUSTIVA B-BRAND
, O
is O
not O
known O
. O
Increasing O
the O
indinavir B-DRUG
dose O
to O
1000 O
mg O
every O
8 O
hours O
does O
not O
compensate O
for O
the O
increased O
indinavir B-DRUG
metabolism O
due O
to O
SUSTIVA B-BRAND
. O
When O
indinavir B-DRUG
at O
an O
increased O
dose O
( O
1000 O
mg O
every O
8 O
hours O
) O
was O
given O
with O
SUSTIVA B-BRAND
( O
600 O
mg O
once O
daily O
) O
, O
the O
indinavir B-DRUG
AUC O
and O
Cmin O
were O
decreased O
on O
average O
by O
33 O
- O
46 O
% O
and O
39 O
- O
57 O
% O
, O
respectively O
, O
compared O
to O
when O
indinavir B-DRUG
( O
800 O
mg O
every O
8 O
hours O
) O
was O
given O
alone O
. O
Lopinavir B-DRUG
/ O
ritonavir B-DRUG
lopinavir B-DRUG
concentration O
A O
dose O
increase O
of O
lopinavir B-DRUG
/ O
ritonavir B-DRUG
to O
533 O
/ O
133 O
mg O
( O
4 O
capsules O
or O
6 O
. O
5 O
mL O
) O
twice O
daily O
taken O
with O
food O
is O
recommended O
when O
used O
in O
combination O
with O
SUSTIVA B-BRAND
. O
Methadone B-DRUG
methadone B-DRUG
concentration O
Coadministration O
in O
HIV O
- O
infected O
individuals O
with O
a O
history O
of O
injection O
drug O
use O
resulted O
in O
decreased O
plasma O
levels O
of O
methadone B-DRUG
and O
signs O
of O
opiate B-GROUP
withdrawal O
. O
Methadone B-DRUG
dose O
was O
increased O
by O
a O
mean O
of O
22 O
% O
to O
alleviate O
withdrawal O
symptoms O
. O
Patients O
should O
be O
monitored O
for O
signs O
of O
withdrawal O
and O
their O
methadone B-DRUG
dose O
increased O
as O
required O
to O
alleviate O
withdrawal O
symptoms O
. O
Ethinyl B-DRUG
estradiol I-DRUG
ethinyl B-DRUG
estradiol I-DRUG
concentration O
Plasma O
concentrations O
increased O
by O
SUSTIVA B-BRAND
( O
efavirenz B-DRUG
) O
; O
clinical O
significance O
unknown O
. O
Because O
the O
potential O
interaction O
of O
efavirenz B-DRUG
with O
oral O
contraceptives B-GROUP
has O
not O
been O
fully O
characterized O
, O
a O
reliable O
method O
of O
barrier O
contraception O
should O
be O
used O
in O
addition O
to O
oral O
contraceptives B-GROUP
. O
Rifabutin B-DRUG
rifabutin B-DRUG
concentration O
Increase O
daily O
dose O
of O
rifabutin B-DRUG
by O
50 O
% O
. O
Consider O
doubling O
the O
rifabutin B-DRUG
dose O
in O
regimens O
where O
rifabutin B-DRUG
is O
given O
2 O
or O
3 O
times O
a O
week O
. O
Rifampin B-DRUG
efavirenz B-DRUG
concentration O
Clinical O
significance O
of O
reduced O
efavirenz B-DRUG
concentrations O
unknown O
. O
Ritonavir B-DRUG
ritonavir B-DRUG
concentration O
Combination O
was O
associated O
with O
a O
higher O
frequency O
of O
adverse O
clinical O
experiences O
( O
eg O
, O
dizziness O
, O
nausea O
, O
paresthesia O
) O
and O
laboratory O
abnormalities O
( O
elevated O
liver O
enzymes O
) O
. O
Monitoring O
of O
liver O
enzymes O
is O
recommended O
when O
SUSTIVA B-BRAND
is O
used O
in O
combination O
with O
ritonavir B-DRUG
. O

efavirenz B-DRUG
concentration O
Saquinavir B-DRUG
saquinavir B-DRUG
concentration O
Should O
not O
be O
used O
as O
sole O
protease B-GROUP
inhibitor I-GROUP
in O
combination O
with O
SUSTIVA B-BRAND
. O
Sertraline B-DRUG
sertraline B-DRUG
concentration O
Increases O
in O
sertraline B-DRUG
dose O
should O
be O
guided O
by O
clinical O
response O
. O
Other O
Potentially O
Clinically O
Significant O
Drug O
or O
Herbal O
Product O
Interactions O
With O
SUSTIVAb O
Anticoagulants B-GROUP
: O
Warfarin B-DRUG
Plasma O
concentrations O
and O
effects O
potentially O
increased O
or O
decreased O
by O
SUSTIVA B-BRAND
. O
Anticonvulsants B-GROUP
: O
Phenytoin B-DRUG
Phenobarbital B-DRUG
Carbamazepine B-DRUG
Potential O
for O
reduction O
in O
anticonvulsant B-GROUP
and O
/ O
or O
efavirenz B-DRUG
plasma O
levels O
; O
periodic O
monitoring O
of O
anticonvulsant B-GROUP
plasma O
levels O
should O
be O
conducted O
. O
Antifungals B-GROUP
: O
Itraconazole B-DRUG
Ketoconazole B-DRUG
Drug O
interaction O
studies O
with O
SUSTIVA B-BRAND
and O
these O
imidazole B-GROUP
and I-GROUP
triazole I-GROUP
antifungals I-GROUP
have O
not O
been O
conducted O
. O
SUSTIVA B-BRAND
has O
the O
potential O
to O
decrease O
plasma O
concentrations O
of O
itraconazole B-DRUG
and O
ketoconazole B-DRUG
. O
Anti B-GROUP
- I-GROUP
HIV I-GROUP
protease I-GROUP
inhibitors I-GROUP
: O
Saquinavir B-DRUG
/ O
ritonavir B-DRUG
combination O
No O
pharmacokinetic O
data O
are O
available O
. O
Amprenavir B-DRUG
SUSTIVAhas O
the O
potential O
to O
decrease O
serum O
concentrations O
of O
amprenavir B-DRUG
. O
Non B-GROUP
- I-GROUP
nucleoside I-GROUP
reverse I-GROUP
transcriptase I-GROUP
inhibitors I-GROUP
No O
studies O
have O
been O
performed O
with O
other O
NNRTIs B-GROUP
. O
St O
. O
John O
s O
wort O
( O
Hypericum O
perforatum O
) O
Expected O
to O
substantially O
decrease O
plasma O
levels O
of O
efavirenz B-DRUG
; O
has O
not O
been O
studied O
in O
combination O
with O
SUSTIVA B-BRAND
. O
a O
See O
Tables O
1 O
and O
2 O
. O
b O
This O
table O
is O
not O
all O
- O
inclusive O
. O
Other O
Drugs O
: O
Based O
on O
the O
results O
of O
drug O
interaction O
studies O
, O
no O
dosage O
adjustment O
is O
recommended O
when O
SUSTIVA B-BRAND
( O
efavirenz B-DRUG
) O
is O
given O
with O
the O
following O
: O
aluminum B-GROUP
/ I-GROUP
magnesium I-GROUP
hydroxide I-GROUP
antacids I-GROUP
, O
azithromycin B-DRUG
, O
cetirizine B-DRUG
, O
famotidine B-DRUG
, O
fluconazole B-DRUG
, O
lamivudine B-DRUG
, O
lorazepam B-DRUG
, O
nelfinavir B-DRUG
, O
paroxetine B-DRUG
, O
and O
zidovudine B-DRUG
. O
Specific O
drug O
interaction O
studies O
have O
not O
been O
performed O
with O
SUSTIVA B-BRAND
and O
NRTIs B-GROUP
other O
than O
lamivudine B-DRUG
and O
zidovudine B-DRUG
. O
Clinically O
significant O
interactions O
would O
not O
be O
expected O
since O
the O
NRTIs B-GROUP
are O
metabolized O
via O
a O
different O

route O
than O
efavirenz B-DRUG
and O
would O
be O
unlikely O
to O
compete O
for O
the O
same O
metabolic O
enzymes O
and O
elimination O
pathways O
. O

The O
potential O
for O
drug O
interactions O
with O
EMTRIVA B-BRAND
has O
been O
studied O
in O
combination O
with O
indinavir B-DRUG
, O
stavudine B-DRUG
, O
famciclovir B-DRUG
, O
and O
tenofovir B-DRUG
disoproxil I-DRUG
fumarate I-DRUG
. O
There O
were O
no O
clinically O
significant O
drug O
interactions O
for O
any O
of O
these O
drugs O
. O

Hypotension O
: O
Patients O
on O
Diuretic O
Therapy O
: O
Patients O
on O
diuretics B-DRUG
and O
especially O
those O
in O
whom O
diuretic O
therapy O
was O
recently O
instituted O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
therapy O
with O
enalapril B-DRUG
or O
enalaprilat B-DRUG
. O
The O
possibility O
of O
hypotensive O
effects O
with O
enalapril B-DRUG
or O
enalaprilat B-DRUG
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-DRUG
or O
increasing O
the O
salt O
intake O
prior O
to O
initiation O
of O
treatment O
with O
enalapril B-DRUG
or O
enalaprilat B-DRUG
. O
If O
it O
is O
necessary O
to O
continue O
the O
diuretic B-GROUP
, O
provide O
close O
medical O
supervision O
after O
the O
initial O
dose O
for O
at O
least O
two O
hours O
and O
until O
blood O
pressure O
has O
stabilized O
for O
at O
least O
an O
additional O
hour O
. O
. O
Agents O
Causing O
Renin O
Release O
: O
The O
antihypertensive O
effect O
of O
enalapril B-DRUG
and O
enalapril B-DRUG
IV O
is O
augmented O
by O
antihypertensive B-GROUP
agents I-GROUP
that O
cause O
renin O
release O
( O
e O
. O
g O
. O
, O
diuretics B-GROUP
) O
. O
Non B-GROUP
- I-GROUP
steroidal I-GROUP
Anti I-GROUP
- I-GROUP
inflammatory I-GROUP
Agents I-GROUP
: O
In O
some O
patients O
with O
compromised O
renal O
function O
who O
are O
being O
treated O
with O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
, O
the O
co O
- O
administration O
of O
enalapril B-DRUG
may O
result O
in O
a O
further O
deterioration O
of O
renal O
function O
. O
These O
effects O
are O
usually O
reversible O
. O
In O
a O
clinical O
pharmacology O
study O
, O
indomethacin B-DRUG
or O
sulindac B-DRUG
was O
administered O
to O
hypertensive O
patients O
receiving O
VASOTEC B-BRAND
. O
In O
this O
study O
there O
was O
no O
evidence O
of O
a O
blunting O
of O
the O
antihypertensive O
action O
of O
VASOTEC B-BRAND
. O
However O
, O
reports O
suggest O
that O
NSAIDs B-GROUP
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE B-GROUP
inhibitors I-GROUP
. O
This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
NSAIDs B-GROUP
concomitantly O
with O
ACE B-GROUP
inhibitors I-GROUP
. O
Other O
Cardiovascular O
Agents O
: O
Enalapril B-DRUG
and O
enalapril B-DRUG
IV O
have O
been O
used O
concomitantly O
with O
beta B-GROUP
adrenergic I-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
, O
methyldopa B-DRUG
, O
nitrates B-GROUP
, O
calcium B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
, O
hydralazine B-DRUG
, O
prazosin B-DRUG
and O
digoxin B-DRUG
without O
evidence O
of O
clinically O
significant O
adverse O
interactions O
. O
Enalapril B-DRUG
IV O
has O
been O
used O
concomitantly O
with O
digitalis B-GROUP
without O
evidence O
of O
clinically O
significant O
adverse O
reactions O
. O
Agents O
Increasing O
Serum O
Potassium O
: O
Enalapril B-DRUG
and O
enalapril B-DRUG
IV O
attenuate O
potassium O
loss O
caused O
by O
thiazide B-GROUP
- I-GROUP
type I-GROUP
diuretics I-GROUP
. O
Potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
( O
e O
. O

g O
. O
, O
spironolactone B-DRUG
, O
triamterene B-DRUG
, O
or O
amiloride B-DRUG
) O
, O
potassium B-DRUG
supplements O
, O
or O
potassium B-DRUG
- O
containing O
salt O
substitutes O
may O
lead O
to O
significant O
increases O
in O
serum O
potassium O
. O
Therefore O
, O
if O
concomitant O
use O
of O
these O
agents O
is O
indicated O
because O
of O
demonstrated O
hypokalemia O
, O
they O
should O
be O
used O
with O
caution O
and O
with O
frequent O
monitoring O
of O
serum O
potassium O
. O
Potassium O
sparing O
agents O
should O
generally O
not O
be O
used O
in O
patients O
with O
heart O
failure O
receiving O
enalapril B-DRUG
. O
Lithium B-DRUG
: O
Lithium B-DRUG
toxicity O
has O
been O
reported O
in O
patients O
receiving O
lithium B-DRUG
concomitantly O
with O
drugs O
which O
cause O
elimination O
of O
sodium O
, O
including O
ACE B-GROUP
inhibitors I-GROUP
. O
It O
is O
recommended O
that O
serum O
lithium B-DRUG
levels O
be O
monitored O
frequently O
if O
enalapril B-DRUG
is O
administered O
concomitantly O
with O
lithium B-DRUG
. O

The O
action O
of O
nondepolarizing O
relaxants O
is O
augmented O
by O
Enflurane B-DRUG
. O
Less O
than O
the O
usual O
amounts O
of O
these O
medicines O
should O
be O
used O
. O
If O
the O
usual O
amounts O
of O
nondepolarizing O
relaxants O
are O
given O
, O
the O
time O
for O
recovery O
from O
neuromuscular O
blockade O
will O
be O
longer O
in O
the O
presence O
of O
Enflurane B-DRUG
than O
when O
halothane B-DRUG
or O
nitrous B-DRUG
oxide I-DRUG
with O
a O
balanced O
technique O
are O
used O
. O

CYP450 O
Metabolized O
Drugs O
Results O
from O
in O
vitro O
and O
in O
vivo O
studies O
suggest O
that O
enfuvirtide B-DRUG
is O
unlikely O
to O
have O
significant O
drug O
interactions O
with O
concomitantly O
administered O
drugs O
metabolized O
by O
CYP450 O
enzymes O
. O
Antiretroviral B-GROUP
Agents I-GROUP
: O
No O
drug O
interactions O
with O
other O
antiretroviral B-GROUP
medications I-GROUP
have O
been O
identified O
that O
would O
warrant O
alteration O
of O
either O
the O
enfuvirtide B-DRUG
dose O
or O
the O
dose O
of O
the O
other O
antiretroviral B-GROUP
medication I-GROUP
. O

Bismuth B-DRUG
: O
Bismuth B-DRUG
subsalicylate I-DRUG
, O
given O
concomitantly O
with O
enoxacin B-DRUG
or O
60 O
minutes O
following O
enoxacin B-DRUG
administration O
, O
decreased O
enoxacin B-DRUG
bioavailability O
by O
approximately O
25 O
% O
. O
Thus O
, O
concomitant O
administration O
of O
enoxacin B-DRUG
and O
bismuth B-DRUG
subsalicylate I-DRUG
should O
be O
avoided O
. O
Caffeine B-DRUG
: O
Enoxacin B-DRUG
is O
a O
potent O
inhibitor O
of O
the O
cytochrome O
P O
- O
450 O
isozymes O
responsible O
for O
the O
metabolism O
of O
methylxanthines B-GROUP
. O
In O
a O
multiple O
- O
dose O
study O
, O
enoxacin B-DRUG
caused O
a O
dose O
- O
related O
increase O
in O
the O
mean O
elimination O
half O
- O
life O
of O
caffeine B-DRUG
, O
thereby O
decreasing O
the O
clearance O
of O
caffeine B-DRUG
by O
up O
to O
80 O
% O
and O
leading O
to O
a O
five O
- O
fold O
increase O
in O
the O
AUC O
and O
the O
half O
- O
life O
of O
caffeine B-DRUG
. O
Trough O
plasma O
enoxacin B-DRUG
levels O
were O
also O
20 O
% O
higher O
when O
caffeine B-DRUG
and O
enoxacin B-DRUG
were O
administered O
concomitantly O
. O
Caffeine B-DRUG
- O
related O
adverse O
effects O
have O
occurred O
in O
patients O
consuming O
caffeine B-DRUG
while O
on O
therapy O
with O
enoxacin B-DRUG
. O
Cyclosporine B-DRUG
: O
Elevated O
serum O
levels O
of O
cyclosporine B-DRUG
have O
been O
reported O
with O
concomitant O
use O
of O
cyclosporine B-DRUG
with O
other O
members O
of O
the O
quinolone B-GROUP
class I-GROUP
. O
Digoxin B-DRUG
: O
Enoxacin B-DRUG
may O
raise O
serum O
digoxin B-DRUG
levels O
in O
some O
individuals O
. O
If O
signs O
and O
symptoms O
suggestive O
of O
digoxin B-DRUG
toxicity O
occur O
when O
enoxacin B-DRUG
and O
digoxin B-DRUG
are O
given O
concomitantly O
, O
physicians O
are O
advised O
to O
obtain O
serum O
digoxin B-DRUG
levels O
and O
adjust O
digoxin B-DRUG
doses O
appropriately O
. O
Non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
: O
Seizures O
have O
been O
reported O
in O
patients O
taking O
enoxacin B-DRUG
concomitantly O
with O
the O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drug I-GROUP
fenbufen B-DRUG
. O
Animal O
studies O
also O
suggest O
an O
increased O
potential O
for O
seizures O
when O
these O
two O
drugs O
are O
given O
concomitantly O
. O
Fenbufen B-DRUG
is O
not O
approved O
in O
the O
United O
States O
at O
this O
time O
. O
Sucralfate B-DRUG
and O
antacids B-GROUP
: O
Quinolones B-GROUP
form O
chelates O
with O
metal O
cations O
. O
Therefore O
, O
administration O
of O
quinolones B-GROUP
with O
antacids B-GROUP
containing O
calcium B-DRUG
, O
magnesium B-DRUG
, O
or O
aluminum B-DRUG
; O
with O
sucralfate B-DRUG
; O
with O
divalent O
or O
trivalent O
cations O
such O
as O
iron B-DRUG
; O
or O
with O
multivitamins B-GROUP
containing O
zinc B-DRUG
may O
substantially O
interfere O
with O
drug O
absorption O
and O
result O
in O
insufficient O
plasma O
and O
tissue O
quinolone B-GROUP
concentrations O
. O
Antacids B-GROUP

containing O
aluminum B-DRUG
hydroxide I-DRUG
and O
magnesium B-DRUG
hydroxide I-DRUG
reduce O
the O
oral O
absorption O
of O
enoxacin B-DRUG
by O
75 O
% O
. O
The O
oral O
bioavailability O
of O
enoxacin B-DRUG
is O
reduced O
by O
60 O
% O
with O
coadministration O
of O
ranitidine B-DRUG
. O
These O
agents O
should O
not O
be O
taken O
for O
8 O
hours O
before O
or O
for O
2 O
hours O
after O
enoxacin B-DRUG
administration O
. O
Theophylline B-DRUG
: O
Enoxacin B-DRUG
is O
a O
potent O
inhibitor O
of O
the O
cytochrome O
P O
- O
450 O
isozymes O
responsible O
for O
the O
metabolism O
of O
methylxanthines B-GROUP
. O
Enoxacin B-DRUG
interferes O
with O
the O
metabolism O
of O
theophylline B-DRUG
resulting O
in O
a O
42 O
% O
to O
74 O
% O
dose O
- O
related O
decrease O
in O
theophylline B-DRUG
clearance O
and O
a O
subsequent O
260 O
% O
to O
350 O
% O
increase O
in O
serum O
theophylline O
levels O
. O
Theophylline B-DRUG
- O
related O
adverse O
effects O
have O
occurred O
in O
patients O
when O
theophylline B-DRUG
and O
enoxacin B-DRUG
were O
coadministered O
. O
Warfarin B-DRUG
: O
Quinolones B-GROUP
, O
including O
enoxacin B-DRUG
, O
decrease O
the O
clearance O
of O
R B-DRUG
- I-DRUG
warfarin I-DRUG
, O
the O
less O
active O
isomer O
of O
racemic O
warfarin B-DRUG
. O
Enoxacin B-DRUG
does O
not O
affect O
the O
clearance O
of O
the O
active O
S O
- O
isomer O
, O
and O
changes O
in O
clotting O
time O
have O
not O
been O
observed O
when O
enoxacin B-DRUG
and O
warfarin B-DRUG
were O
coadministered O
. O
Nevertheless O
, O
the O
prothrombin O
time O
or O
other O
suitable O
coagulation O
test O
should O
be O
monitored O
when O
warfarin B-DRUG
or O
its O
derivatives O
and O
enoxacin B-DRUG
are O
given O
concomitantly O
. O

Unless O
really O
needed O
, O
agents O
which O
may O
enhance O
the O
risk O
of O
hemorrhage O
should O
be O
discontinued O
prior O
to O
initiation O
of O
Lovenox B-BRAND
Injection O
therapy O
. O
These O
agents O
include O
medications O
such O
as O
: O
anticoagulants B-GROUP
, O
platelet B-GROUP
inhibitors I-GROUP
including O
acetylsalicylic B-DRUG
acid I-DRUG
, O
sali O
- O
cylates O
, O
NSAIDs B-GROUP
( O
including O
ketorolac B-DRUG
tromethamine I-DRUG
) O
, O
dipyridamole B-DRUG
, O
or O
sulfinpyrazone B-DRUG
. O
If O
co O
- O
administration O
is O
essential O
, O
conduct O
close O
clinical O
and O
laboratory O
monitoring O
. O

In O
vitro O
studies O
of O
human O
CYP O
enzymes O
showed O
that O
entacapone B-DRUG
inhibited O
the O
CYP O
enzymes O
1A2 O
, O
2A6 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
2E1 O
and O
3A O
only O
at O
very O
high O
concentrations O
( O
IC50 O
from O
200 O
to O
over O
1000 O
uM O
; O
an O
oral O
200 O
mg O
dose O
achieves O
a O
highest O
level O
of O
approximately O
5 O
uM O
in O
people O
) O
; O
these O
enzymes O
would O
therefore O
not O
be O
expected O
to O
be O
inhibited O
in O
clinical O
use O
. O
Protein O
Binding O
: O
Entacapone B-DRUG
is O
highly O
protein O
bound O
( O
98 O
% O
) O
. O
In O
vitro O
studies O
have O
shown O
no O
binding O
displacement O
between O
entacapone B-DRUG
and O
other O
highly O
bound O
drugs O
, O
such O
as O
warfarin B-DRUG
, O
salicylic B-DRUG
acid I-DRUG
, O
phenylbutazone B-DRUG
, O
and O
diazepam B-DRUG
. O
Drugs O
Metabolized O
by O
Catechol O
- O
O O
- O
methyltransferase O
( O
COMT O
) O
: O
Hormone O
levels O
: O
Levodopa B-DRUG
is O
known O
to O
depress O
prolactin O
secretion O
and O
increase O
growth O
hormone O
levels O
. O
Treatment O
with O
entacapone B-DRUG
coadministered O
with O
levodopa B-DRUG
/ O
dopa B-GROUP
decarboxylase I-GROUP
inhibitor I-GROUP
does O
not O
change O
these O
effects O
. O
No O
interaction O
was O
noted O
with O
the O
MAO B-GROUP
- I-GROUP
B I-GROUP
inhibitor I-GROUP
selegiline B-DRUG
in O
two O
multiple O
- O
dose O
interaction O
studies O
when O
entacapone B-DRUG
was O
coadministered O
with O
a O
levodopa B-DRUG
/ O
dopa B-GROUP
decarboxylase I-GROUP
inhibitor I-GROUP
( O
n O
= O
29 O
) O
. O
More O
than O
600 O
Parkinsons O
disease O
patients O
in O
clinical O
trials O
have O
used O
selegiline B-DRUG
in O
combination O
with O
entacapone B-DRUG
and O
levodopa B-DRUG
/ O
dopa B-GROUP
decarboxylase I-GROUP
inhibitor I-GROUP
. O
As O
most O
entacapone B-DRUG
excretion O
is O
via O
the O
bile O
, O
caution O
should O
be O
exercised O
when O
drugs O
known O
to O
interfere O
with O
biliary O
excretion O
, O
glucuronidation O
, O
and O
intestinal O
beta O
- O
glucuronidase O
are O
given O
concurrently O
with O
entacapone B-DRUG
. O
These O
include O
probenecid B-DRUG
, O
cholestyramine B-DRUG
, O
and O
some O
antibiotics B-GROUP
( O
e O
. O
g O
. O
erythromycin B-DRUG
, O
rifamipicin O
, O
ampicillin B-DRUG
and O
chloramphenicol B-DRUG
) O
. O
No O
interaction O
with O
the O
tricyclic B-GROUP
antidepressant I-GROUP
imipramine B-DRUG
was O
shown O
in O
a O
single O
- O
dose O
study O
with O
entacapone B-DRUG
without O
coadministered O
levodopa B-DRUG
/ O
dopa B-GROUP
- I-GROUP
decarboxylase I-GROUP
inhibitor I-GROUP
. O

Since O
entecavir B-DRUG
is O
primarily O
eliminated O
by O
the O
kidneys O
, O
coadministration O
of O
BARACLUDE B-BRAND
with O
drugs O
that O
reduce O
renal O
function O
or O
compete O
for O
active O
tubular O
secretion O
may O
increase O
serum O
concentrations O
of O
either O
entecavir B-DRUG
or O
the O
coadministered O
drug O
. O
Coadministration O
of O
entecavir B-DRUG
with O
lamivudine B-DRUG
, O
adefovir B-DRUG
dipivoxil I-DRUG
, O
or O
tenofovir B-DRUG
disoproxil I-DRUG
fumarate I-DRUG
did O
not O
result O
in O
significant O
drug O
interactions O
. O
The O
effects O
of O
coadministration O
of O
BARACLUDE B-BRAND
with O
other O
drugs O
that O
are O
renally O
eliminated O
or O
are O
known O
to O
affect O
renal O
function O
have O
not O
been O
evaluated O
, O
and O
patients O
should O
be O
monitored O
closely O
for O
adverse O
events O
when O
BARACLUDE B-BRAND
is O
coadministered O
with O
such O
drugs O
. O

None O
Reported O

Epinephrine B-DRUG
should O
be O
used O
cautiously O
in O
patients O
with O
hyperthyroidism O
, O
hypertension O
and O
cardiac O
arrhythmias O
. O
All O
vasopressors B-GROUP
should O
be O
used O
cautiously O
in O
patients O
taking O
monoamine B-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
. O
Epinephrine B-DRUG
should O
not O
be O
administered O
concomitantly O
with O
other O
sympathomimetic B-GROUP
drugs I-GROUP
( O
such O
as O
isoproterenol B-DRUG
) O
because O
of O
possible O
additive O
effects O
and O
increased O
toxicity O
. O
Combined O
effects O
may O
induce O
serious O
cardiac O
arrhythmias O
. O
They O
may O
be O
administered O
alternately O
when O
the O
preceding O
effect O
of O
other O
such O
drug O
has O
subsided O
. O
Administration O
of O
epinephrine B-DRUG
to O
patients O
receiving O
cyclopropane B-DRUG
or O
halogenated B-GROUP
hydrocarbon I-GROUP
general I-GROUP
anesthetics I-GROUP
such O
as O
halothane B-DRUG
which O
sensitize O
the O
myocardium O
, O
may O
induce O
cardiac O
arrhythmia O
. O
. O
When O
encountered O
, O
such O
arrhythmias O
may O
respond O
to O
administration O
of O
a O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
drug I-GROUP
. O
Epinephrine B-DRUG
also O
should O
be O
used O
cautiously O
with O
other O
drugs O
( O
e O
. O
g O
. O
, O
digitalis B-GROUP
, O
glycosides B-GROUP
) O
that O
sensitize O
the O
myocardium O
to O
the O
actions O
of O
sympathomimetic B-GROUP
drugs I-GROUP
. O
Diuretic B-GROUP
agents I-GROUP
may O
decrease O
vascular O
response O
to O
pressor O
drugs O
such O
as O
epinephrine B-DRUG
. O
Epinephrine B-DRUG
may O
antagonize O
the O
neuron O
blockade O
produced O
by O
guanethidine B-DRUG
resulting O
in O
decreased O
antihypertensive O
effect O
and O
requiring O
increased O
dosage O
of O
the O
latter O
. O

ELLENCE B-BRAND
when O
used O
in O
combination O
with O
other O
cytotoxic O
drugs O
may O
show O
on O
- O
treatment O
additive O
toxicity O
, O
especially O
hematologic O
and O
gastrointestinal O
effects O
. O
Concomitant O
use O
of O
ELLENCE B-BRAND
with O
other O
cardioactive O
compounds O
that O
could O
cause O
heart O
failure O
( O
e O
. O
g O
. O
, O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
) O
, O
requires O
close O
monitoring O
of O
cardiac O
function O
throughout O
treatment O
. O
There O
are O
few O
data O
regarding O
the O
coadministration O
of O
radiation O
therapy O
and O
epirubicin B-DRUG
. O
In O
adjuvant O
trials O
of O
epirubicin B-DRUG
- O
containing O
CEF O
- O
120 O
or O
FEC O
- O
100 O
chemotherapies O
, O
breast O
irradiation O
was O
delayed O
until O
after O
chemotherapy O
was O
completed O
. O
This O
practice O
resulted O
in O
no O
apparent O
increase O
in O
local O
breast O
cancer O
recurrence O
relative O
to O
published O
accounts O
in O
the O
literature O
. O
A O
small O
number O
of O
patients O
received O
epirubicin B-DRUG
- O
based O
chemotherapy O
concomitantly O
with O
radiation O
therapy O
but O
had O
chemotherapy O
interrupted O
in O
order O
to O
avoid O
potential O
overlapping O
toxicities O
. O
It O
is O
likely O
that O
use O
of O
epirubicin B-DRUG
with O
radiotherapy O
may O
sensitize O
tissues O
to O
the O
cytotoxic O
actions O
of O
irradiation O
. O
Administration O
of O
ELLENCE B-BRAND
after O
previous O
radiation O
therapy O
may O
induce O
an O
inflammatory O
recall O
reaction O
at O
the O
site O
of O
the O
irradiation O
. O
Epirubicin B-DRUG
is O
extensively O
metabolized O
by O
the O
liver O
. O
Changes O
in O
hepatic O
function O
induced O
by O
concomitant O
therapies O
may O
affect O
epirubicin B-DRUG
metabolism O
, O
pharmacokinetics O
, O
therapeutic O
efficacy O
, O
and O
/ O
or O
toxicity O
. O
Cimetidine B-DRUG
increased O
the O
AUC O
of O
epirubicin B-DRUG
by O
50 O
% O
. O
Cimetidine B-DRUG
treatment O
should O
be O
stopped O
during O
treatment O
with O
ELLENCE B-BRAND
. O
Drug O
- O
Laboratory O
Test O
Interactions O
There O
are O
no O
known O
interactions O
between O
ELLENCE B-BRAND
and O
laboratory O
tests O
. O

Inhibitors O
of O
CYP3A4 O
- O
Eplerenone B-DRUG
metabolism O
is O
predominantly O
mediated O
via O
CYP3A4 O
. O
A O
pharmacokinetic O
study O
evaluating O
the O
administration O
of O
a O
single O
dose O
of O
INSPRA B-BRAND
100 O
mg O
with O
ketoconazole B-DRUG
200 O
mg O
BID O
, O
a O
potent O
inhibitor O
of O
the O
CYP3A4 O
pathway O
, O
showed O
a O
1 O
. O
7 O
- O
fold O
increase O
in O
Cmax O
of O
eplerenone B-DRUG
and O
a O
5 O
. O
4 O
- O
fold O
increase O
in O
AUC O
of O
eplerenone B-DRUG
. O
INSPRA B-BRAND
should O
not O
be O
used O
with O
drugs O
described O
as O
strong O
inhibitors O
of O
CYP3A4 O
in O
their O
labeling O
. O
Administration O
of O
eplerenone B-DRUG
with O
other O
CYP3A4 O
inhibitors O
( O
e O
. O
g O
. O
, O
erythromycin B-DRUG
500 O
mg O
BID O
, O
verapamil B-DRUG
240 O
mg O
QD O
, O
saquinavir B-DRUG
1200 O
mg O
TID O
, O
fluconazole B-DRUG
200 O
mg O
QD O
) O
resulted O
in O
increases O
in O
Cmax O
of O
eplerenone B-DRUG
ranging O
from O
1 O
. O
4 O
- O
to O
1 O
. O
6 O
- O
fold O
and O
AUC O
from O
2 O
. O
0 O
- O
to O
2 O
. O
9 O
- O
fold O
. O
ACE B-GROUP
Inhibitors I-GROUP
and O
Angiotensin B-GROUP
II I-GROUP
Receptor I-GROUP
Antagonists I-GROUP
( O
Congestive O
Heart O
Failure O
Post O
- O
Myocardial O
Infarction O
) O
- O
In O
EPHESUS O
, O
3020 O
( O
91 O
% O
) O
patients O
receiving O
INSPRA B-BRAND
25 O
to O
50 O
mg O
also O
received O
ACE B-GROUP
inhibitors I-GROUP
or O
angiotensin B-GROUP
II I-GROUP
receptor I-GROUP
antagonists I-GROUP
( O
ACEI B-GROUP
/ O
ARB B-GROUP
) O
. O
Rates O
of O
patients O
with O
maximum O
potassium O
levels O
5 O
. O
5 O
mEq O
/ O
L O
were O
similar O
regardless O
of O
the O
use O
of O
ACEI B-GROUP
/ O
ARB B-GROUP
. O
ACE B-GROUP
Inhibitors I-GROUP
and O
Angiotensin B-GROUP
II I-GROUP
Receptor I-GROUP
Antagonists I-GROUP
( O
Hypertension O
) O
- O
In O
clinical O
studies O
of O
patients O
with O
hypertension O
, O
the O
addition O
of O
INSPRA B-BRAND
50 O
to O
100 O
mg O
to O
ACE B-GROUP
inhibitors I-GROUP
and O
angiotensin B-GROUP
II I-GROUP
receptor I-GROUP
antagonists I-GROUP
increased O
mean O
serum O
potassium O
slightly O
( O
about O
0 O
. O
09 O
- O
0 O
. O
13 O
mEq O
/ O
L O
) O
. O
In O
a O
study O
in O
diabetics O
with O
microalbuminuria O
INSPRA B-BRAND
200 O
mg O
combined O
with O
the O
ACE B-GROUP
inhibitor I-GROUP
enalapril B-DRUG
10 O
mg O
increased O
the O
frequency O
of O
hyperkalemia O
( O
serum O
potassium O
5 O
. O
5 O
mEq O
/ O
L O
) O
from O
17 O
% O
on O
enalapril B-DRUG
alone O
to O
38 O
% O
. O
Lithium B-DRUG
- O
A O
drug O
interaction O
study O
of O
eplerenone B-DRUG
with O
lithium B-DRUG
has O
not O
been O
conducted O
. O
Serum O
lithium B-DRUG
levels O
should O
be O
monitored O
frequently O
if O
INSPRA B-BRAND
is O

administered O
concomitantly O
with O
lithium B-DRUG
. O
Nonsteroidal B-GROUP
Anti I-GROUP
- I-GROUP
Inflammatory I-GROUP
Drugs I-GROUP
( O
NSAIDs B-GROUP
) O
- O
A O
drug O
interaction O
study O
of O
eplerenone B-DRUG
with O
an O
NSAID B-GROUP
has O
not O
been O
conducted O
. O
The O
administration O
of O
other O
potassium B-GROUP
- I-GROUP
sparing I-GROUP
antihypertensives I-GROUP
with O
NSAIDs B-GROUP
has O
been O
shown O
to O
reduce O
the O
antihypertensive O
effect O
in O
some O
patients O
and O
result O
in O
severe O
hyperkalemia O
in O
patients O
with O
impaired O
renal O
function O
. O
Therefore O
, O
when O
INSPRA B-BRAND
and O
NSAIDs B-GROUP
are O
used O
concomitantly O
, O
patients O
should O
be O
observed O
to O
determine O
whether O
the O
desired O
effect O
on O
blood O
pressure O
is O
obtained O
. O

No O
evidence O
of O
interaction O
of O
PROCRIT B-BRAND
with O
other O
drugs O
was O
observed O
in O
the O
course O
of O
clinical O
trials O
. O

Additional O
reductions O
in O
blood O
pressure O
may O
occur O
when O
FLOLAN B-BRAND
is O
administered O
with O
diuretics B-GROUP
, O
antihypertensive B-GROUP
agents I-GROUP
, O
or O
other O
vasodilators B-GROUP
. O
When O
other O
antiplatelet B-GROUP
agents I-GROUP
or O
anticoagulants B-GROUP
are O
used O
concomitantly O
, O
there O
is O
the O
potential O
for O
FLOLAN B-BRAND
to O
increase O
the O
risk O
of O
bleeding O
. O
However O
, O
patients O
receiving O
infusions O
of O
FLOLAN B-BRAND
in O
clinical O
trials O
were O
maintained O
on O
anticoagulants B-GROUP
without O
evidence O
of O
increased O
bleeding O
. O
In O
clinical O
trials O
, O
FLOLAN B-BRAND
was O
used O
with O
digoxin B-DRUG
, O
diuretics B-GROUP
, O
anticoagulants B-GROUP
, O
oral O
vasodilators B-GROUP
, O
and O
supplemental O
oxygen B-DRUG
. O
In O
a O
pharmacokinetic O
substudy O
in O
patients O
with O
congestive O
heart O
failure O
receiving O
furosemide B-DRUG
or O
digoxin B-DRUG
in O
whom O
therapy O
with O
FLOLAN B-BRAND
was O
initiated O
, O
apparent O
oral O
clearance O
values O
for O
furosemide B-DRUG
( O
n O
= O
23 O
) O
and O
digoxin B-DRUG
( O
n O
= O
30 O
) O
were O
decreased O
by O
13 O
% O
and O
15 O
% O
, O
respectively O
, O
on O
the O
second O
day O
of O
therapy O
and O
had O
returned O
to O
baseline O
values O
by O
day O
87 O
. O
The O
change O
in O
furosemide B-DRUG
clearance O
value O
is O
not O
likely O
to O
be O
clinically O
significant O
. O
However O
, O
patients O
on O
digoxin B-DRUG
may O
show O
elevations O
of O
digoxin B-DRUG
concentrations O
after O
initiation O
of O
therapy O
with O
FLOLAN B-BRAND
, O
which O
may O
be O
clinically O
significant O
in O
patients O
prone O
to O
digoxin B-DRUG
toxicity O
. O

Eprosartan B-DRUG
has O
been O
shown O
to O
have O
no O
effect O
on O
the O
pharmacokinetics O
of O
digoxin B-DRUG
and O
the O
pharmacodynamics O
of O
warfarin B-DRUG
and O
glyburide B-DRUG
. O
Thus O
no O
dosing O
adjustments O
are O
necessary O
during O
concomitant O
use O
with O
these O
agents O
. O
Because O
eprosartan B-DRUG
is O
not O
metabolized O
by O
the O
cytochrome O
P450 O
system O
, O
inhibitors O
of O
CYP450 O
enzyme O
would O
not O
be O
expected O
to O
affect O
its O
metabolism O
, O
and O
ketoconazole B-DRUG
and O
fluconazole B-DRUG
, O
potent O
inhibitors O
of O
CYP3A O
and O
2C9 O
, O
respectively O
, O
have O
been O
shown O
to O
have O
no O
effect O
on O
eprosartan B-DRUG
pharmacokinetics O
. O
Ranitidine B-DRUG
also O
has O
no O
effect O
on O
eprosartan B-DRUG
pharmacokinetics O
. O
Eprosartan B-DRUG
( O
up O
to O
400 O
mg O
b O
. O
i O
. O
d O
. O
or O
800 O
mg O
q O
. O
d O
. O
) O
doses O
have O
been O
safely O
used O
concomitantly O
with O
a O
thiazide B-GROUP
diuretic I-GROUP
( O
hydrochlorothiazide B-DRUG
) O
. O
Eprosartan B-DRUG
doses O
of O
up O
to O
300 O
mg O
b O
. O
i O
. O
d O
. O
have O
been O
safely O
used O
concomitantly O
with O
sustained O
- O
release O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
( O
sustained O
- O
release O
nifedipine B-DRUG
) O
with O
no O
clinically O
significant O
adverse O
interactions O
. O

Enoxaparin B-DRUG
dosed O
as O
a O
1 O
. O
0 O
mg O
/ O
kg O
subcutaneous O
injection O
q12h O
for O
four O
doses O
did O
not O
alter O
the O
pharmacokinetics O
of O
eptifibatide B-DRUG
or O
the O
level O
of O
platelet O
aggregation O
in O
healthy O
adults O
. O

Mineral B-DRUG
oil I-DRUG
interferes O
with O
the O
absorption O
of O
fat B-GROUP
- I-GROUP
soluble I-GROUP
vitamins I-GROUP
, O
including O
vitamin B-GROUP
D I-GROUP
preparations I-GROUP
. O
Administration O
of O
thiazide B-GROUP
diuretics I-GROUP
to O
hypoparathyroid O
patients O
who O
are O
concurrently O
being O
treated O
with O
ergocalciferol B-DRUG
may O
cause O
hypercalcemia O
. O

No O
reported O
interactions O
. O

The O
effects O
of O
ERGOMAR B-BRAND
may O
be O
potentiated O
by O
triacetyloleandomycin B-DRUG
which O
inhibits O
the O
metabolism O
of O
ergotamine B-DRUG
. O
The O
pressor O
effects O
of O
ERGOMAR B-BRAND
and O
other O
vasoconstrictor B-GROUP
drugs I-GROUP
can O
combine O
to O
cause O
dangerous O
hypertension O
. O

Co O
- O
treatment O
with O
the O
potent O
CYP3A4 O
inhibitor O
ketoconazole B-DRUG
increases O
erlotinib B-DRUG
AUC O
by O
2 O
/ O
3 O
. O
Caution O
should O
be O
used O
when O
administering O
or O
taking O
TARCEVA B-BRAND
with O
ketoconazole B-DRUG
and O
other O
strong O
CYP3A4 O
inhibitors O
such O
as O
, O
but O
not O
limited O
to O
, O
atazanavir B-DRUG
, O
clarithromycin B-DRUG
, O
indinavir B-DRUG
, O
itraconazole B-DRUG
, O
nefazodone B-DRUG
, O
nelfinavir B-DRUG
, O
ritonavir B-DRUG
, O
saquinavir B-DRUG
, O
telithromycin B-DRUG
, O
troleandomycin B-DRUG
( O
TAO B-DRUG
) O
, O
and O
voriconazole B-DRUG
. O
Pre O
- O
treatment O
with O
the O
CYP3A4 O
inducer O
rifampicin B-DRUG
decreased O
erlotinib B-DRUG
AUC O
by O
about O
2 O
/ O
3 O
. O
Alternate O
treatments O
lacking O
CYP3A4 O
inducing O
activity O
should O
be O
considered O
. O
If O
an O
alternative O
treatment O
is O
unavailable O
, O
a O
TARCEVA B-BRAND
dose O
greater O
than O
150 O
mg O
should O
be O
considered O
for O
NSCLC O
patients O
, O
and O
greater O
than O
100 O
mg O
considered O
for O
pancreatic O
cancer O
patients O
. O
If O
the O
TARCEVA B-BRAND
dose O
is O
adjusted O
upward O
, O
the O
dose O
will O
need O
to O
be O
reduced O
upon O
discontinuation O
of O
rifampicin B-DRUG
or O
other O
inducers O
. O
Other O
CYP3A4 O
inducers O
include O
, O
but O
are O
not O
limited O
to O
, O
rifabutin B-DRUG
, O
rifapentine B-DRUG
, O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
phenobarbital B-DRUG
and O
St O
. O
Johns O
Wort O
. O
Hepatotoxicity O
Asymptomatic O
increases O
in O
liver O
transaminases O
have O
been O
observed O
in O
TARCEVA B-BRAND
treated O
patients O
; O
therefore O
, O
periodic O
liver O
function O
testing O
( O
transaminases O
, O
bilirubin O
, O
and O
alkaline O
phosphatase O
) O
should O
be O
considered O
. O
Dose O
reduction O
or O
interruption O
of O
TARCEVA B-BRAND
should O
be O
considered O
if O
changes O
in O
liver O
function O
are O
severe O
. O
Patients O
with O
Hepatic O
Impairment O
In O
vitro O
and O
in O
vivo O
evidence O
suggest O
that O
erlotinib B-DRUG
is O
cleared O
primarily O
by O
the O
liver O
. O
Therefore O
, O
erlotinib B-DRUG
exposure O
may O
be O
increased O
in O
patients O
with O
hepatic O
dysfunction O
. O
Elevated O
International O
Normalized O
Ratio O
and O
Potential O
Bleeding O
International O
Normalized O
Ratio O
( O
INR O
) O
elevations O
and O
infrequent O
reports O
of O
bleeding O
events O
including O
gastrointestinal O
and O
non O
- O
gastrointestinal O
bleedings O
have O
been O
reported O
in O
clinical O
studies O
, O
some O
associated O
with O
concomitant O
warfarin B-DRUG
administration O
. O
Patients O

taking O
warfarin B-DRUG
or O
other O
coumarin B-GROUP
- I-GROUP
derivative I-GROUP
anticoagulants I-GROUP
should O
be O
monitored O
regularly O
for O
changes O
in O
prothrombin O
time O
or O
INR O
. O

When O
ertapenem B-DRUG
is O
co O
- O
administered O
with O
probenecid B-DRUG
( O
500 O
mg O
p O
. O
o O
. O
every O
6 O
hours O
) O
, O
probenecid B-DRUG
competes O
for O
active O
tubular O
secretion O
and O
reduces O
the O
renal O
clearance O
of O
ertapenem B-DRUG
. O
Based O
on O
total O
ertapenem B-DRUG
concentrations O
, O
probenecid B-DRUG
increased O
the O
AUC O
by O
25 O
% O
and O
reduced O
the O
plasma O
and O
renal O
clearances O
by O
20 O
% O
and O
35 O
% O
, O
respectively O
. O
The O
half O
- O
life O
increased O
from O
4 O
. O
0 O
to O
4 O
. O
8 O
hours O
. O
Because O
of O
the O
small O
effect O
on O
half O
- O
life O
, O
the O
coadministration O
with O
probenecid B-DRUG
to O
extend O
the O
half O
- O
life O
of O
ertapenem B-DRUG
is O
not O
recommended O
. O
In O
vitro O
studies O
indicate O
that O
ertapenem B-DRUG
does O
not O
inhibit O
P O
- O
glycoprotein O
- O
mediated O
transport O
of O
digoxin B-DRUG
or O
vinblastine B-DRUG
and O
that O
ertapenem B-DRUG
is O
not O
a O
substrate O
for O
P O
- O
glycoprotein O
- O
mediated O
transport O
. O
In O
vitro O
studies O
in O
human O
liver O
microsomes O
indicate O
that O
ertapenem B-DRUG
does O
not O
inhibit O
metabolism O
mediated O
by O
any O
of O
the O
following O
six O
cytochrome O
p450 O
( O
CYP O
) O
isoforms O
: O
1A2 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
2E1 O
and O
3A4 O
. O
Drug O
interactions O
caused O
by O
inhibition O
of O
P O
- O
glycoprotein O
- O
mediated O
drug O
clearance O
or O
CYP O
- O
mediated O
drug O
clearance O
with O
the O
listed O
isoforms O
are O
unlikely O
. O
Other O
than O
with O
probenecid B-DRUG
, O
no O
specific O
clinical O
drug O
interaction O
studies O
have O
been O
conducted O
. O

Erythromycin B-DRUG
use O
in O
patients O
who O
are O
receiving O
high O
doses O
of O
theophylline B-DRUG
may O
be O
associated O
with O
an O
increase O
in O
serum O
theophylline B-DRUG
levels O
and O
potential O
theophylline B-DRUG
toxicity O
. O
In O
case O
of O
theophylline B-DRUG
toxicity O
and O
/ O
or O
elevated O
serum O
theophylline B-DRUG
levels O
, O
the O
dose O
of O
theophylline B-DRUG
should O
be O
reduced O
while O
the O
patient O
is O
receiving O
concomitant O
erythromycin B-DRUG
therapy O
. O
Concomitant O
administration O
of O
erythromycin B-DRUG
and O
digoxin B-DRUG
has O
been O
reported O
to O
result O
in O
elevated O
digoxin B-DRUG
serum O
levels O
. O
There O
have O
been O
reports O
of O
increased O
anticoagulant O
effects O
when O
erythromycin B-DRUG
and O
oral O
anticoagulants B-GROUP
were O
used O
concomitantly O
. O
Increased O
anticoagulation O
effects O
due O
to O
interactions O
of O
erythromycin B-DRUG
with O
various O
oral O
anticoagulents O
may O
be O
more O
pronounced O
in O
the O
elderly O
. O
Concurrent O
use O
of O
erythromycin B-DRUG
and O
ergotamine B-DRUG
or O
dihydroergotamine B-DRUG
has O
been O
associated O
in O
some O
patients O
with O
acute O
ergot O
toxicity O
characterized O
by O
severe O
peripheral O
vasospasm O
and O
dysesthesia O
. O
Erythromycin B-DRUG
has O
been O
reported O
to O
decrease O
the O
clearance O
of O
triazolam B-DRUG
and O
midazolam B-DRUG
and O
thus O
may O
increase O
the O
pharmacologic O
effect O
of O
these O
benzodiazepines B-GROUP
. O
The O
use O
of O
erythromycin B-DRUG
in O
patients O
concurrently O
taking O
drugs O
metabolized O
by O
the O
cytochrome O
P450 O
system O
may O
be O
associated O
with O
elevations O
in O
serum O
levels O
of O
these O
other O
drugs O
. O
There O
have O
been O
reports O
of O
interactions O
of O
erythromycin B-DRUG
with O
carbamazepine B-DRUG
, O
cyclosporine B-DRUG
, O
tacrolimus B-DRUG
, O
hexobarbital B-DRUG
, O
phenytoin B-DRUG
, O
alfentanil B-DRUG
, O
cisapride B-DRUG
, O
disopyramide B-DRUG
, O
lovastatin B-DRUG
, O
bromocriptine B-DRUG
, O
valproate B-DRUG
, O
terfenadine B-DRUG
, O
and O
astemizole B-DRUG
. O
Serum O
concentrations O
of O
drugs O
metabolized O
by O
the O
cytochrome O
P450 O
system O
should O
be O
monitored O
closely O
in O
patients O
concurrently O
receiving O
erythromycin B-DRUG
. O
Erythromycin B-DRUG
has O
been O
reported O
to O
significantly O
alter O
the O
metabolism O
of O
nonsedating O
antihistamines B-GROUP
terfenadine B-DRUG
and O
astemizole B-DRUG
when O
taken O
concomitantly O
. O
Rare O
cases O
of O
serious O
cardiovascular O
adverse O
events O
, O
including O
electrocardiographic O
QT O
/ O
QTc O
interval O
prolongation O
, O
cardiac O
arrest O
, O
torsades O
de O
pointes O
, O
and O
other O
ventricular O
arrhythmias O
have O
been O
observed O

. O
In O
addition O
, O
deaths O
have O
been O
reported O
rarely O
with O
concomitant O
administration O
of O
terfenadine B-DRUG
and O
erythromycin B-DRUG
. O
There O
have O
been O
postmarketing O
reports O
of O
drug O
interactions O
when O
erythromycin B-DRUG
is O
coadministered O
with O
cisapride B-DRUG
, O
resulting O
in O
QT O
prolongation O
, O
cardiac O
arrythmias O
, O
ventricular O
tachycardia O
, O
ventricular O
fibrulation O
, O
and O
torsades O
de O
pointes O
, O
most O
like O
due O
to O
inhibition O
of O
hepatic O
metabolism O
of O
cisapride B-DRUG
by O
erythromycin B-DRUG
. O
Fatalities O
have O
been O
reported O
. O
Patients O
receiving O
concomitant O
lovastatin B-DRUG
and O
erythromycin B-DRUG
should O
be O
carefully O
monitored O
; O
cases O
of O
rhabdomyolysis O
have O
been O
reported O
in O
seriously O
ill O
patients O
. O

CNS O
Drugs O
- O
Given O
the O
primary O
CNS O
effects O
of O
escitalopram B-DRUG
, O
caution O
should O
be O
used O
when O
it O
is O
taken O
in O
combination O
with O
other O
centrally O
acting O
drugs O
. O
Alcohol B-DRUG
- O
Although O
LEXAPRO B-BRAND
did O
not O
potentiate O
the O
cognitive O
and O
motor O
effects O
of O
alcohol B-DRUG
in O
a O
clinical O
trial O
, O
as O
with O
other O
psychotropic B-GROUP
medications I-GROUP
, O
the O
use O
of O
alcohol B-DRUG
by O
patients O
taking O
LEXAPRO B-BRAND
is O
not O
recommended O
. O
Monoamine B-GROUP
Oxidase I-GROUP
Inhibitors I-GROUP
( O
MAOIs B-GROUP
) O
Drugs O
That O
Interfere O
With O
Hemostasis O
( O
NSAIDs B-GROUP
, O
Aspirin B-BRAND
, O
Warfarin B-DRUG
, O
etc O
. O
) O
Serotonin O
release O
by O
platelets O
plays O
an O
important O
role O
in O
hemostasis O
. O
Epidemiological O
studies O
of O
the O
case O
- O
control O
and O
cohort O
design O
that O
have O
demonstrated O
an O
association O
between O
use O
of O
psychotropic B-GROUP
drugs I-GROUP
that O
interfere O
with O
serotonin O
reuptake O
and O
the O
occurrence O
of O
upper O
gastrointestinal O
bleeding O
have O
also O
shown O
that O
concurrent O
use O
of O
an O
NSAID B-GROUP
or O
aspirin B-BRAND
potentiated O
the O
risk O
of O
bleeding O
. O
Thus O
, O
patients O
should O
be O
cautioned O
about O
the O
use O
of O
such O
drugs O
concurrently O
with O
LEXAPRO B-BRAND
. O
Cimetidine B-DRUG
- O
In O
subjects O
who O
had O
received O
21 O
days O
of O
40 O
mg O
/ O
day O
racemic O
citalopram B-DRUG
, O
combined O
administration O
of O
400 O
mg O
/ O
day O
cimetidine B-DRUG
for O
8 O
days O
resulted O
in O
an O
increase O
in O
citalopram B-DRUG
AUC O
and O
Cmax O
of O
43 O
% O
and O
39 O
% O
, O
respectively O
. O
The O
clinical O
significance O
of O
these O
findings O
is O
unknown O
. O
Digoxin B-DRUG
- O
In O
subjects O
who O
had O
received O
21 O
days O
of O
40 O
mg O
/ O
day O
racemic O
citalopram B-DRUG
, O
combined O
administration O
of O
citalopram B-DRUG
and O
digoxin B-DRUG
( O
single O
dose O
of O
1 O
mg O
) O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
either O
citalopram B-DRUG
or O
digoxin B-DRUG
. O
Lithium B-DRUG
- O
Coadministration O
of O
racemic O
citalopram B-DRUG
( O
40 O
mg O
/ O
day O
for O
10 O
days O
) O
and O
lithium B-DRUG
( O
30 O
mmol O
/ O
day O
for O
5 O
days O
) O
had O
no O
significant O
effect O
on O
the O
pharmacokinetics O
of O
citalopram B-DRUG
or O
lithium B-DRUG
. O
Nevertheless O
, O
plasma O
lithium B-DRUG
levels O
should O
be O
monitored O
with O
appropriate O
adjustment O
to O
the O
lithium B-DRUG
dose O
in O
accordance O
with O
standard O
clinical O
practice O
. O
Because O
lithium B-DRUG
may O
enhance O
the O
serotonergic O
effects O
of O
escitalopram B-DRUG
, O
caution O
should O
be O
exercised O
when O
LEXAPRO B-BRAND
and O
lithium B-DRUG
are O
coadministered O
. O
Pimozide B-DRUG
and O
Celexa B-BRAND
- O
In O
a O
controlled O
study O
, O
a O
single O
dose O
of O
pimozide B-DRUG
2 O
mg O
co O
- O

administered O
with O
racemic O
citalopram B-DRUG
40 O
mg O
given O
once O
daily O
for O
11 O
days O
was O
associated O
with O
a O
mean O
increase O
in O
QTc O
values O
of O
approximately O
10 O
msec O
compared O
to O
pimozide B-DRUG
given O
alone O
. O
Racemic O
citalopram B-DRUG
did O
not O
alter O
the O
mean O
AUC O
or O
Cmax O
of O
pimozide B-DRUG
. O
The O
mechanism O
of O
this O
pharmacodynamic O
interaction O
is O
not O
known O
. O
Sumatriptan B-DRUG
- O
There O
have O
been O
rare O
postmarketing O
reports O
describing O
patients O
with O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
following O
the O
use O
of O
a O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitor I-GROUP
( O
SSRI B-GROUP
) O
and O
sumatriptan B-DRUG
. O
If O
concomitant O
treatment O
with O
sumatriptan B-DRUG
and O
an O
SSRI B-GROUP
( O
e O
. O
g O
. O
, O
fluoxetine B-DRUG
, O
fluvoxamine B-DRUG
, O
paroxetine B-DRUG
, O
sertraline B-DRUG
, O
citalopram B-DRUG
, O
escitalopram B-DRUG
) O
is O
clinically O
warranted O
, O
appropriate O
observation O
of O
the O
patient O
is O
advised O
. O
Theophylline B-DRUG
- O
Combined O
administration O
of O
racemic O
citalopram B-DRUG
( O
40 O
mg O
/ O
day O
for O
21 O
days O
) O
and O
the O
CYP1A2 O
substrate O
theophylline B-DRUG
( O
single O
dose O
of O
300 O
mg O
) O
did O
not O
affect O
the O
pharmacokinetics O
of O
theophylline B-DRUG
. O
The O
effect O
of O
theophylline B-DRUG
on O
the O
pharmacokinetics O
of O
citalopram B-DRUG
was O
not O
evaluated O
. O
Warfarin B-DRUG
- O
Administration O
of O
40 O
mg O
/ O
day O
racemic O
citalopram B-DRUG
for O
21 O
days O
did O
not O
affect O
the O
pharmacokinetics O
of O
warfarin B-DRUG
, O
a O
CYP3A4 O
substrate O
. O
Prothrombin O
time O
was O
increased O
by O
5 O
% O
, O
the O
clinical O
significance O
of O
which O
is O
unknown O
. O
Carbamazepine B-DRUG
- O
Combined O
administration O
of O
racemic O
citalopram B-DRUG
( O
40 O
mg O
/ O
day O
for O
14 O
days O
) O
and O
carbamazepine B-DRUG
( O
titrated O
to O
400 O
mg O
/ O
day O
for O
35 O
days O
) O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
carbamazepine B-DRUG
, O
a O
CYP3A4 O
substrate O
. O
Although O
trough O
citalopram B-DRUG
plasma O
levels O
were O
unaffected O
, O
given O
the O
enzyme O
- O
inducing O
properties O
of O
carbamazepine B-DRUG
, O
the O
possibility O
that O
carbamazepine B-DRUG
might O
increase O
the O
clearance O
of O
escitalopram B-DRUG
should O
be O
considered O
if O
the O
two O
drugs O
are O
coadministered O
. O
Triazolam B-DRUG
- O
Combined O
administration O
of O
racemic O
citalopram B-DRUG
( O
titrated O
to O
40 O
mg O
/ O
day O
for O
28 O
days O
) O
and O
the O
CYP3A4 O
substrate O
triazolam B-DRUG
( O
single O
dose O
of O

0 O
. O
25 O
mg O
) O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
either O
citalopram B-DRUG
or O
triazolam B-DRUG
. O
Ketoconazole B-DRUG
- O
Combined O
administration O
of O
racemic O
citalopram B-DRUG
( O
40 O
mg O
) O
and O
ketoconazole B-DRUG
( O
200 O
mg O
) O
decreased O
the O
Cmax O
and O
AUC O
of O
ketoconazole B-DRUG
by O
21 O
% O
and O
10 O
% O
, O
respectively O
, O
and O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
citalopram B-DRUG
. O
Ritonavir B-DRUG
- O
Combined O
administration O
of O
a O
single O
dose O
of O
ritonavir B-DRUG
( O
600 O
mg O
) O
, O
both O
a O
CYP3A4 O
substrate O
and O
a O
potent O
inhibitor O
of O
CYP3A4 O
, O
and O
escitalopram B-DRUG
( O
20 O
mg O
) O
did O
not O
affect O
the O
pharmacokinetics O
of O
either O
ritonavir B-DRUG
or O
escitalopram B-DRUG
. O
CYP3A4 O
and O
- O
2C19 O
Inhibitors O
- O
In O
vitro O
studies O
indicated O
that O
CYP3A4 O
and O
- O
2C19 O
are O
the O
primary O
enzymes O
involved O
in O
the O
metabolism O
of O
escitalopram B-DRUG
. O
However O
, O
coadministration O
of O
escitalopram B-DRUG
( O
20 O
mg O
) O
and O
ritonavir B-DRUG
( O
600 O
mg O
) O
, O
a O
potent O
inhibitor O
of O
CYP3A4 O
, O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
escitalopram B-DRUG
. O
Because O
escitalopram B-DRUG
is O
metabolized O
by O
multiple O
enzyme O
systems O
, O
inhibition O
of O
a O
single O
enzyme O
may O
not O
appreciably O
decrease O
escitalopram B-DRUG
clearance O
. O
Drugs O
Metabolized O
by O
Cytochrome O
P4502D6 O
- O
In O
vitro O
studies O
did O
not O
reveal O
an O
inhibitory O
effect O
of O
escitalopram B-DRUG
on O
CYP2D6 O
. O
In O
addition O
, O
steady O
state O
levels O
of O
racemic O
citalopram B-DRUG
were O
not O
significantly O
different O
in O
poor O
metabolizers O
and O
extensive O
CYP2D6 O
metabolizers O
after O
multiple O
- O
dose O
administration O
of O
citalopram B-DRUG
, O
suggesting O
that O
coadministration O
, O
with O
escitalopram B-DRUG
, O
of O
a O
drug O
that O
inhibits O
CYP2D6 O
, O
is O
unlikely O
to O
have O
clinically O
significant O
effects O
on O
escitalopram B-DRUG
metabolism O
. O
However O
, O
there O
are O
limited O
in O
vivo O
data O
suggesting O
a O
modest O
CYP2D6 O
inhibitory O
effect O
for O
escitalopram B-DRUG
, O
i O
. O
e O
. O
, O
coadministration O
of O
escitalopram B-DRUG
( O
20 O
mg O
/ O
day O
for O
21 O
days O
) O
with O
the O
tricyclic B-GROUP
antidepressant I-GROUP
desipramine B-DRUG
( O
single O
dose O
of O
50 O
mg O
) O
, O

a O
substrate O
for O
CYP2D6 O
, O
resulted O
in O
a O
40 O
% O
increase O
in O
Cmax O
and O
a O
100 O
% O
increase O
in O
AUC O
of O
desipramine B-DRUG
. O
The O
clinical O
significance O
of O
this O
finding O
is O
unknown O
. O
Nevertheless O
, O
caution O
is O
indicated O
in O
the O
coadministration O
of O
escitalopram B-DRUG
and O
drugs O
metabolized O
by O
CYP2D6 O
. O
Metoprolol B-DRUG
- O
Administration O
of O
20 O
mg O
/ O
day O
LEXAPRO B-BRAND
for O
21 O
days O
in O
healthy O
volunteers O
resulted O
in O
a O
50 O
% O
increase O
in O
Cmax O
and O
82 O
% O
increase O
in O
AUC O
of O
the O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocker I-GROUP
metoprolol B-DRUG
( O
given O
in O
a O
single O
dose O
of O
100 O
mg O
) O
. O
Increased O
metoprolol B-DRUG
plasma O
levels O
have O
been O
associated O
with O
decreased O
cardioselectivity O
. O
Coadministration O
of O
LEXAPRO B-BRAND
and O
metoprolol B-DRUG
had O
no O
clinically O
significant O
effects O
on O
blood O
pressure O
or O
heart O
rate O
. O
Electroconvulsive O
Therapy O
( O
ECT O
) O
- O
There O
are O
no O
clinical O
studies O
of O
the O
combined O
use O
of O
ECT O
and O
escitalopram B-DRUG
. O
Concomitant O
Administration O
with O
Racemic O
Citalopram B-DRUG
Citalopram B-DRUG
- O
Since O
escitalopram B-DRUG
is O
the O
active O
isomer O
of O
racemic O
citalopram B-DRUG
( O
Celexa B-BRAND
) O
, O
the O
two O
agents O
should O
not O
be O
coadministered O
. O

Catecholamine O
- O
depleting O
drugs O
, O
e O
. O
g O
. O
, O
reserpine B-DRUG
, O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta B-GROUP
blocking I-GROUP
agents I-GROUP
. O
Patients O
treated O
concurrently O
with O
BREVIBLOC B-BRAND
( O
esmolol B-DRUG
HCl I-DRUG
) O
and O
a O
catecholamine O
depletor O
should O
therefore O
be O
closely O
observed O
for O
evidence O
of O
hypotension O
or O
marked O
bradycardia O
, O
which O
may O
result O
in O
vertigo O
, O
syncope O
, O
or O
postural O
hypotension O
. O
A O
study O
of O
interaction O
between O
BREVIBLOC B-BRAND
and O
warfarin B-DRUG
showed O
that O
concomitant O
administration O
of O
BREVIBLOC B-BRAND
and O
warfarin B-DRUG
does O
not O
alter O
warfarin B-DRUG
plasma O
levels O
. O
BREVIBLOC B-BRAND
concentrations O
were O
equivocally O
higher O
when O
given O
with O
warfarin B-DRUG
, O
but O
this O
is O
not O
likely O
to O
be O
clinically O
important O
. O
When O
digoxin B-DRUG
and O
BREVIBLOC B-BRAND
were O
concomitantly O
administered O
intravenously O
to O
normal O
volunteers O
, O
there O
was O
a O
10 O
- O
20 O
% O
increase O
in O
digoxin B-DRUG
blood O
levels O
at O
some O
time O
points O
. O
Digoxin B-DRUG
did O
not O
affect O
BREVIBLOC B-BRAND
pharmacokinetics O
. O
When O
intravenous O
morphine B-DRUG
and O
BREVIBLOC B-BRAND
were O
concomitantly O
administered O
in O
normal O
subjects O
, O
no O
effect O
on O
morphine B-DRUG
blood O
levels O
was O
seen O
, O
but O
BREVIBLOC B-BRAND
steady O
- O
state O
blood O
levels O
were O
increased O
by O
46 O
% O
in O
the O
presence O
of O
morphine B-DRUG
. O
No O
other O
pharmacokinetic O
parameters O
were O
changed O
. O
The O
effect O
of O
BREVIBLOC B-DRUG
on O
the O
duration O
of O
succinylcholine B-DRUG
- O
induced O
neuromuscular O
blockade O
was O
studied O
in O
patients O
undergoing O
surgery O
. O
The O
onset O
of O
neuromuscular O
blockade O
by O
succinylcholine B-DRUG
was O
unaffected O
by O
BREVIBLOC B-BRAND
, O
but O
the O
duration O
of O
neuromuscular O
blockade O
was O
prolonged O
from O
5 O
minutes O
to O
8 O
minutes O
. O
Although O
the O
interactions O
observed O
in O
these O
studies O
do O
not O
appear O
to O
be O
of O
major O
clinical O
importance O
, O
BREVIBLOC B-BRAND
should O
be O
titrated O
with O
caution O
in O
patients O
being O
treated O
concurrently O
with O
digoxin B-DRUG
, O
morphine B-DRUG
, O
succinylcholine B-DRUG
or O
warfarin B-DRUG
. O
While O
taking O
beta B-GROUP
blockers I-GROUP
, O
patients O
with O
a O
history O
of O
severe O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
be O
more O
reactive O
to O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
, O
or O
therapeutic O
. O
Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-DRUG
used O
to O
treat O
allergic O
reaction O
. O
Caution O
should O
be O
exercised O
when O
considering O
the O
use O
of O

BREVIBLOC B-BRAND
and O
verapamil B-DRUG
in O
patients O
with O
depressed O
myocardial O
function O
. O
Fatal O
cardiac O
arrests O
have O
occurred O
in O
patients O
receiving O
both O
drugs O
. O
Additionally O
, O
BREVIBLOC B-BRAND
should O
not O
be O
used O
to O
control O
supraventricular O
tachycardia O
in O
the O
presence O
of O
agents O
which O
are O
vasoconstrictive O
and O
inotropic O
such O
as O
dopamine B-DRUG
, O
epinephrine B-DRUG
, O
and O
norepinephrine B-DRUG
because O
of O
the O
danger O
of O
blocking O
cardiac O
contractility O
when O
systemic O
vascular O
resistance O
is O
high O
. O

Esomeprazole B-DRUG
is O
extensively O
metabolized O
in O
the O
liver O
by O
CYP2C19 O
and O
CYP3A4 O
. O
In O
vitro O
and O
in O
vivo O
studies O
have O
shown O
that O
esomeprazole B-DRUG
is O
not O
likely O
to O
inhibit O
CYPs O
1A2 O
, O
2A6 O
, O
2C9 O
, O
2D6 O
, O
2E1 O
and O
3A4 O
. O
No O
clinically O
relevant O
interactions O
with O
drugs O
metabolized O
by O
these O
CYP O
enzymes O
would O
be O
expected O
. O
Drug O
interaction O
studies O
have O
shown O
that O
esomeprazole B-DRUG
does O
not O
have O
any O
clinically O
significant O
interactions O
with O
phenytoin B-DRUG
, O
warfarin B-DRUG
, O
quinidine B-DRUG
, O
clarithromycin B-DRUG
or O
amoxicillin B-DRUG
. O
Post O
- O
marketing O
reports O
of O
changes O
in O
prothrombin O
measures O
have O
been O
received O
among O
patients O
on O
concomitant O
warfarin B-DRUG
and O
esomeprazole B-DRUG
therapy O
. O
Increases O
in O
INR O
and O
prothrombin O
time O
may O
lead O
to O
abnormal O
bleeding O
and O
even O
death O
. O
Patients O
treated O
with O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
and O
warfarin B-DRUG
concomitantly O
may O
need O
to O
be O
monitored O
for O
increases O
in O
INR O
and O
prothrombin O
time O
. O
Esomeprazole B-DRUG
may O
potentially O
interfere O
with O
CYP2C19 O
, O
the O
major O
esomeprazole B-DRUG
metabolizing O
enzyme O
. O
Coadministration O
of O
esomeprazole B-DRUG
30 O
mg O
and O
diazepam B-DRUG
, O
a O
CYP2C19 O
substrate O
, O
resulted O
in O
a O
45 O
% O
decrease O
in O
clearance O
of O
diazepam B-DRUG
. O
Increased O
plasma O
levels O
of O
diazepam B-DRUG
were O
observed O
12 O
hours O
after O
dosing O
and O
onwards O
. O
However O
, O
at O
that O
time O
, O
the O
plasma O
levels O
of O
diazepam B-DRUG
were O
below O
the O
therapeutic O
interval O
, O
and O
thus O
this O
interaction O
is O
unlikely O
to O
be O
of O
clinical O
relevance O
. O
Esomeprazole B-DRUG
inhibits O
gastric O
acid O
secretion O
. O
Therefore O
, O
esomeprazole B-DRUG
may O
interfere O
with O
the O
absorption O
of O
drugs O
where O
gastric O
pH O
is O
an O
important O
determinant O
of O
bioavailability O
( O
eg O
, O
ketoconazole B-DRUG
, O
iron B-DRUG
salts O
and O
digoxin B-DRUG
) O
. O
Coadministration O
of O
oral O
contraceptives B-GROUP
, O
diazepam B-DRUG
, O
phenytoin B-DRUG
, O
or O
quinidine B-DRUG
did O
not O
seem O
to O
change O
the O
pharmacokinetic O
profile O
of O
esomeprazole B-DRUG
. O
Concomitant O
administration O
of O
clarithromycin B-DRUG
with O
pimozide B-DRUG
is O
contraindicated O
. O

If O
ProSom B-BRAND
is O
given O
concomitantly O
with O
other O
drugs O
acting O
on O
the O
central O
nervous O
system O
, O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
all O
agents O
. O
The O
action O
of O
the O
benzodiazepines B-GROUP
may O
be O
potentiated O
by O
anticonvulsants B-GROUP
, O
antihistamines B-GROUP
, O
alcohol B-DRUG
, O
barbiturates B-GROUP
, O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
, O
narcotics B-GROUP
, O
phenothiazines B-GROUP
, O
psychotropic B-GROUP
medications I-GROUP
, O
or O
other O
drugs O
that O
produce O
CNS O
depression O
. O
Smokers O
have O
an O
increased O
clearance O
of O
benzodiazepines B-GROUP
as O
compared O
to O
nonsmokers O
; O
this O
was O
seen O
in O
studies O
with O
estazolam B-DRUG
. O
While O
no O
in O
vivo O
drug O
- O
drug O
interaction O
studies O
were O
conducted O
between O
estazolam B-DRUG
and O
inducers O
of O
CYP3A O
, O
compounds O
that O
are O
potent O
CYP3A O
inducers O
( O
such O
as O
carbamazepine B-DRUG
, O
phenytoin B-DRUG
, O
rifampin B-DRUG
, O
and O
barbiturates B-GROUP
) O
would O
be O
expected O
to O
decrease O
estazolam B-DRUG
concentrations O
. O
Estazolam B-DRUG
: O
Interaction O
with O
Drugs O
that O
Inhibit O
Metabolism O
via O
Cytochrome O
P450 O
3A O
( O
CYP3A O
) O
: O
The O
metabolism O
of O
estazolam B-DRUG
to O
the O
major O
circulating O
metabolite O
4 B-DRUG_N
- I-DRUG_N
hydroxy I-DRUG_N
- I-DRUG_N
estazolam I-DRUG_N
and O
the O
metabolism O
of O
other O
triazolobenzodiazepines B-GROUP
is O
catalyzed O
by O
CYP3A O
. O
Consequently O
, O
estazolam B-DRUG
should O
be O
avoided O
in O
patients O
receiving O
ketoconazole B-DRUG
and O
itraconazole B-DRUG
, O
which O
are O
very O
potent O
inhibitors O
of O
CYP3A O
. O
With O
drugs O
inhibiting O
CYP3A O
to O
a O
lesser O
, O
but O
still O
significant O
degree O
, O
estazolam B-DRUG
should O
be O
used O
only O
with O
caution O
and O
consideration O
of O
appropriate O
dosage O
reduction O
. O
The O
following O
are O
examples O
of O
drugs O
known O
to O
inhibit O
the O
metabolism O
of O
other O
related O
benzodiazepines B-GROUP
, O
presumably O
through O
inhibition O
of O
CYP3A O
: O
nefazodone B-DRUG
, O
fluvoxamine B-DRUG
, O
cimetidine B-DRUG
, O
diltiazem B-DRUG
, O
isoniazide B-DRUG
, O
and O
some O
macrolide B-GROUP
antibiotics I-GROUP
. O
Drug O
Interaction O
with O
Fluoxetine B-DRUG
: O
A O
multiple O
- O
dose O
study O
was O
conducted O
to O
assess O
the O
effect O
of O
fluoxetine B-DRUG
20 O
mg O
BID O
on O
the O
pharmacokinetics O
of O
estazolam B-DRUG
2 O
mg O
QHS O
after O
seven O
days O
. O
The O
pharmacokinetics O
of O
estazolam B-DRUG
( O
Cmax O
and O
AUC O
) O
were O
not O
affected O
during O
multiple O
- O
dose O
fluoxetine B-DRUG

, O
suggesting O
no O
clinically O
significant O
pharmacokinetic O
interaction O
. O
Estazolam B-DRUG
: O
Interaction O
with O
Other O
Drugs O
that O
are O
Metabolized O
by O
Cytochrome O
P450 O
( O
CYP O
) O
: O
At O
clinically O
relevant O
concentrations O
, O
in O
vitro O
studies O
indicate O
that O
estazolam B-DRUG
( O
0 O
. O
6 O
M O
) O
was O
not O
inhibitory O
towards O
the O
major O
cytochrome O
P450 O
isoforms O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
and O
CYP3A O
. O
Therefore O
, O
based O
on O
these O
in O
vitro O
data O
, O
estazolam B-DRUG
is O
very O
unlikely O
to O
inhibit O
the O
biotransformation O
of O
other O
drugs O
metabolized O
by O
these O
CYP O
isoforms O
. O

D O
. O
Drug O
and O
Laboratory O
Test O
Interactions O
1 O
. O
Accelerated O
prothrombin O
time O
, O
partial O
thromboplastin O
time O
, O
and O
platelet O
aggregation O
time O
; O
increased O
platelet O
count O
; O
increased O
factors O
II O
, O
VII O
antigen O
, O
VIII O
antigen O
, O
VIII O
coagulant O
activity O
, O
IX O
, O
X O
, O
XII O
, O
VII O
- O
X O
complex O
, O
II O
- O
VII O
- O
X O
complex O
, O
and O
beta O
- O
thromboglobulin O
; O
decreased O
levels O
of O
anti O
- O
factor O
Xa O
and O
antithrombin O
III O
, O
decreased O
antithrombin O
III O
activity O
; O
increased O
levels O
of O
fibrinogen O
and O
fibrinogen O
activity O
; O
increased O
plasminogen O
antigen O
and O
activity O
. O
2 O
. O
Increased O
thyroid O
- O
binding O
globulin O
( O
TBG O
) O
leading O
to O
increased O
circulating O
total O
thyroid O
hormone O
levels O
, O
as O
measured O
by O
protein O
- O
bound O
iodine O
( O
PBI O
) O
, O
T4 O
levels O
( O
by O
column O
or O
by O
radioimmunoassay O
) O
or O
T3 O
levels O
by O
radioimmunoassay O
. O
T3 O
resin O
uptake O
is O
decreased O
, O
reflecting O
the O
elevated O
TBG O
. O
Free O
T4 O
and O
T3 O
concentrations O
are O
unaltered O
. O
Patients O
on O
thyroid O
replacement O
therapy O
may O
require O
higher O
doses O
of O
thyroid B-GROUP
hormone I-GROUP
. O
3 O
. O
Other O
binding O
proteins O
may O
be O
elevated O
in O
serum O
, O
i O
. O
e O
. O
, O
corticosteroid O
binding O
globulin O
( O
CBG O
) O
, O
sex O
hormone O
- O
binding O
globulin O
( O
SHBG O
) O
, O
leading O
to O
increased O
total O
circulating O
corticosteroids B-GROUP
and O
sex B-GROUP
steroids I-GROUP
, O
respectively O
. O
Free O
hormone O
concentrations O
may O
be O
decreased O
. O
Other O
plasma O
proteins O
may O
be O
increased O
( O
angiotensinogen O
/ O
renin O
substrate O
, O
alpha O
- O
1 O
- O
antitrypsin O
, O
ceruloplasmin O
) O
. O
4 O
. O
Increased O
plasma O
HDL O
and O
HDL2 O
cholesterol O
subfraction O
concentrations O
, O
reduced O
LDL O
cholesterol O
concentration O
, O
increased O
triglyceride O
levels O
. O
5 O
. O
Impaired O
glucose O
tolerance O
. O
6 O
. O
Reduced O
response O
to O
metyrapone O
test O
. O

Milk O
, O
milk O
products O
, O
and O
calcium B-DRUG
- O
rich O
foods O
or O
drugs O
may O
impair O
the O
absorption O
of O
EMCYT B-BRAND
. O

CNS O
- O
Active O
Drugs O
Ethanol B-DRUG
An O
additive O
effect O
on O
psychomotor O
performance O
was O
seen O
with O
coadministration O
of O
eszopiclone B-DRUG
and O
ethanol B-DRUG
0 O
. O
70 O
g O
/ O
kg O
for O
up O
to O
4 O
hours O
after O
ethanol B-DRUG
administration O
. O
Paroxetine B-DRUG
: O
Coadministration O
of O
single O
doses O
of O
eszopiclone B-DRUG
3 O
mg O
and O
paroxetine B-DRUG
20 O
mg O
daily O
for O
7 O
days O
produced O
no O
pharmacokinetic O
or O
pharmacodynamic O
interaction O
. O
Lorazepam B-DRUG
: O
Coadministration O
of O
single O
doses O
of O
eszopiclone B-DRUG
3 O
mg O
and O
lorazepam B-DRUG
2 O
mg O
did O
not O
have O
clinically O
relevant O
effects O
on O
the O
pharmacodynamics O
or O
pharmacokinetics O
of O
either O
drug O
. O
Olanzapine B-DRUG
: O
Coadministration O
of O
eszopiclone B-DRUG
3 O
mg O
and O
olanzapine B-DRUG
10 O
mg O
produced O
a O
decrease O
in O
DSST O
scores O
. O
The O
interaction O
was O
pharmacodynamic O
; O
there O
was O
no O
alteration O
in O
the O
pharmacokinetics O
of O
either O
drug O
. O
Drugs O
That O
Inhibit O
CYP3A4 O
( O
Ketoconazole B-DRUG
) O
CYP3A4 O
is O
a O
major O
metabolic O
pathway O
for O
elimination O
of O
eszopiclone B-DRUG
. O
The O
AUC O
of O
eszopiclone B-DRUG
was O
increased O
2 O
. O
2 O
- O
fold O
by O
coadministration O
of O
ketoconazole B-DRUG
, O
a O
potent O
inhibitor O
of O
CYP3A4 O
, O
400 O
mg O
daily O
for O
5 O
days O
. O
Cmax O
and O
t1 O
/ O
2 O
were O
increased O
1 O
. O
4 O
- O
fold O
and O
1 O
. O
3 O
- O
fold O
, O
respectively O
. O
Other O
strong O
inhibitors O
of O
CYP3A4 O
( O
e O
. O
g O
. O
, O
itraconazole B-DRUG
, O
clarithromycin B-DRUG
, O
nefazodone B-DRUG
, O
troleandomycin B-DRUG
, O
ritonavir B-DRUG
, O
nelfinavir B-DRUG
) O
would O
be O
expected O
to O
behave O
similarly O
. O
Drugs O
That O
Induce O
CYP3A4 O
( O
Rifampicin B-DRUG
) O
Racemic O
zopiclone B-DRUG
exposure O
was O
decreased O
80 O
% O
by O
concomitant O
useof O
rifampicin B-DRUG
, O
a O
potent O
inducer O
of O
CYP3A4 O
. O
A O
similar O
effect O
would O
be O
expected O
with O
eszopiclone B-DRUG
. O
Drugs O
Highly O
Bound O
To O
Plasma O
Protein O
Eszopiclone B-DRUG
is O
not O
highly O
bound O
to O
plasma O
proteins O
( O
52 O
- O
59 O
% O
bound O
) O
; O
therefore O
, O
the O
disposition O
of O
eszopiclone B-DRUG
is O
not O
expected O
to O
be O
sensitive O
to O
alterations O
in O
protein O
binding O
. O
Administration O
of O
eszopiclone B-DRUG
3 O
mg O
to O
a O
patient O
taking O
another O
drug O
that O
is O
highly O
protein O
- O
bound O
would O
not O
be O
expected O
to O
cause O
an O

alteration O
in O
the O
free O
concentration O
of O
either O
drug O
. O
Drugs O
With O
A O
Narrow O
Therapeutic O
Index O
Digoxin B-DRUG
A O
single O
dose O
of O
eszopiclone B-DRUG
3 O
mg O
did O
not O
affect O
the O
pharmacokinetics O
of O
digoxin B-DRUG
measured O
at O
steady O
state O
following O
dosing O
of O
0 O
. O
5 O
mg O
twice O
daily O
for O
one O
day O
and O
0 O
. O
25 O
mg O
daily O
for O
the O
next O
6 O
days O
. O
Warfarin B-DRUG
: O
Eszopiclone B-DRUG
3 O
mg O
administered O
daily O
for O
5 O
days O
did O
not O
affect O
the O
pharmacokinetics O
of O
( B-DRUG
R I-DRUG
) I-DRUG
- I-DRUG
or I-DRUG
( I-DRUG
S I-DRUG
) I-DRUG
- I-DRUG
warfarin I-DRUG
, O
nor O
were O
there O
any O
changes O
in O
the O
pharmacodynamic O
profile O
( O
prothrombin O
time O
) O
following O
a O
single O
25 O
mg O
oral O
dose O
of O
warfarin B-DRUG
. O

Specific O
drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
ENBREL B-BRAND
. O
However O
, O
it O
was O
observed O
that O
the O
pharmacokinetics O
of O
ENBREL B-BRAND
was O
unaltered O
by O
concomitant O
methotrexate B-DRUG
in O
rheumatoid O
arthritis O
patients O
. O
In O
a O
study O
in O
which O
patients O
with O
active O
RA O
were O
treated O
for O
up O
to O
24 O
weeks O
with O
concurrent O
ENBREL B-BRAND
and O
anakinra B-DRUG
therapy O
, O
a O
7 O
% O
rate O
of O
serious O
infections O
was O
observed O
, O
which O
was O
higher O
than O
that O
observed O
with O
ENBREL B-BRAND
alone O
( O
0 O
% O
) O
. O
Two O
percent O
of O
patients O
treated O
concurrently O
with O
ENBREL B-BRAND
and O
anakinra B-DRUG
developed O
neutropenia O
( O
ANC O
1 O
x O
109 O
/ O
L O
) O
. O
Patients O
in O
a O
clinical O
study O
who O
were O
on O
established O
therapy O
with O
sulfasalazine B-DRUG
, O
to O
which O
ENBREL B-BRAND
was O
added O
, O
were O
noted O
to O
develop O
a O
mild O
decrease O
in O
mean O
neutrophil O
counts O
in O
comparison O
to O
groups O
treated O
with O
either O
ENBREL B-BRAND
CI O
or O
sulfasalazine B-DRUG
alone O
. O
The O
clinical O
significance O
of O
this O
observation O
is O
unknown O
. O

Lithium B-DRUG
generally O
should O
not O
be O
given O
with O
diuretics B-GROUP
because O
they O
reduce O
its O
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium B-DRUG
toxicity O
. O
Read O
circulars O
for O
lithium B-DRUG
preparations O
before O
use O
of O
such O
concomitant O
therapy O
. O
EDECRIN B-BRAND
may O
increase O
the O
ototoxic O
potential O
of O
other O
drugs O
such O
as O
aminoglycoside B-GROUP
and O
some O
cephalosporin B-GROUP
antibiotics I-GROUP
. O
Their O
concurrent O
use O
should O
be O
avoided O
. O
A O
number O
of O
drugs O
, O
including O
ethacrynic B-DRUG
acid I-DRUG
, O
have O
been O
shown O
to O
displace O
warfarin B-DRUG
from O
plasma O
protein O
; O
a O
reduction O
in O
the O
usual O
anticoagulant B-GROUP
dosage O
may O
be O
required O
in O
patients O
receiving O
both O
drugs O
. O
In O
some O
patients O
, O
the O
administration O
of O
a O
non B-GROUP
- I-GROUP
steroidal I-GROUP
antiinflammatory I-GROUP
agent I-GROUP
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop B-GROUP
, I-GROUP
potassium I-GROUP
- I-GROUP
sparing I-GROUP
and I-GROUP
thiazide I-GROUP
diuretics I-GROUP
. O
Therefore O
, O
when O
EDECRIN B-BRAND
and O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-GROUP
is O
obtained O
. O

The O
results O
of O
a O
study O
of O
coadministration O
of O
ethambutol B-DRUG
( O
50 O
mg O
/ O
kg O
) O
with O
an O
aluminum B-DRUG
hydroxide I-DRUG
containing O
antacid B-GROUP
to O
13 O
patients O
with O
tuberculosis O
showed O
a O
reduction O
of O
mean O
serum O
concentrations O
and O
urinary O
excretion O
of O
ethambutol B-DRUG
of O
approximately O
20 O
% O
and O
13 O
% O
, O
respectively O
, O
suggesting O
that O
the O
oral O
absorption O
of O
ethambutol B-DRUG
may O
be O
reduced O
by O
these O
antacid B-GROUP
products I-GROUP
. O
It O
is O
recommended O
to O
avoid O
concurrent O
administration O
of O
ethambutol B-DRUG
with O
aluminum B-DRUG
hydroxide I-DRUG
containing O
antacids B-GROUP
for O
at O
least O
4 O
hours O
following O
ethambutol B-DRUG
administration O
. O

Dicumarol B-DRUG
and O
warfarin B-DRUG
may O
decrease O
hypoprothrombinemic O
effect O
. O
Other O
depressasnts O
such O
as O
alcohol B-DRUG
, O
barbiturates B-GROUP
, O
and O
MAOIs B-GROUP
may O
enhance O
CNS O
depression O
when O
administered O
with O
ethchlorvynol B-DRUG
. O

May O
interact O
with O
addictive O
medications O
, O
especially O
central B-GROUP
nervous I-GROUP
system I-GROUP
( I-GROUP
CNS I-GROUP
) I-GROUP
depressants I-GROUP
with O
habituating O
potential O
( O
prolonged O
concurrent O
use O
may O
increase O
the O
risk O
of O
habituation O
) O
, O
alcohol B-DRUG
or O
CNS O
depression O
producing O
medications O
( O
concurrent O
use O
may O
increase O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
ethinamate B-DRUG
) O
. O

Certain O
endocrine O
and O
liver O
function O
tests O
may O
be O
affected O
by O
estrogen B-GROUP
- O
containing O
oral O
contraceptives B-GROUP
. O
The O
following O
similar O
changes O
may O
be O
expected O
with O
larger O
doses O
of O
estrogen B-GROUP
: O
Increased O
sulfobromophthalein O
retention O
; O
increased O
prothrombin O
and O
factors O
VII O
, O
VIII O
, O
IX O
, O
and O
X O
; O
decreased O
antithrombin O
3 O
; O
increased O
norepinephrine O
- O
induced O
platel O
et O
aggregation O
; O
increased O
thyroid O
binding O
globulin O
( O
TBG O
) O
leading O
to O
increased O
circulating O
total O
thyroid O
hormone O
, O
as O
measured O
by O
PBI O
, O
T4 O
by O
column O
, O
or O
T4 O
by O
radioimmunoassay O
. O
Free O
T3 O
resin O
uptake O
is O
decreased O
, O
reflecting O
the O
elevated O
TBG O
; O
free O
T4 O
concentration O
is O
unaltered O
: O
impaired O
glucose O
tolerance O
; O
decreased O
pregnanediol O
excretion O
; O
reduced O
response O
to O
metyrapone O
test O
; O
reduced O
serum O
folate O
concentration O
; O
increased O
serum O
triglyceride O
and O
phospholipid O
concentration O
. O

Trecator B-BRAND
has O
been O
found O
to O
temporarily O
raise O
serum O
concentrations O
of O
isoniazid B-DRUG
. O
Trecator B-BRAND
may O
potentiate O
the O
adverse O
effects O
of O
other O
antituberculous B-GROUP
drugs I-GROUP
administered O
concomitantly O
. O
In O
particular O
, O
convulsions O
have O
been O
reported O
when O
ethionamide B-DRUG
is O
administered O
with O
cycloserine B-DRUG
and O
special O
care O
should O
be O
taken O
when O
the O
treatment O
regimen O
includes O
both O
of O
these O
drugs O
. O
Excessive O
ethanol B-DRUG
ingestion O
should O
be O
avoided O
because O
a O
psychotic O
reaction O
has O
been O
reported O
. O

Ethopropazine B-DRUG
may O
interact O
with O
alcohol B-DRUG
or O
other O
CNS B-GROUP
depressants I-GROUP
, O
causing O
increased O
sedative O
effects O
. O
It O
may O
also O
interact O
with O
amantadine B-DRUG
or O
other O
anticholinergic B-GROUP
drugs I-GROUP
or O
MAOIs B-GROUP
, O
which O
may O
intensify O
the O
anticholinergic O
action O
. O
Ethopropazine B-DRUG
can O
interact O
with O
chlorpromazine B-DRUG
, O
increasing O
the O
metabolism O
of O
chlorpromazine B-DRUG
. O

Since O
Zarontin B-BRAND
( O
ethosuximide B-DRUG
) O
may O
interact O
with O
concurrently O
administered O
antiepileptic B-GROUP
drugs I-GROUP
, O
periodic O
serum O
level O
determinations O
of O
these O
drugs O
may O
be O
necessary O
( O
eg O
, O
ethosuximide B-DRUG
may O
elevate O
phenytoin B-DRUG
serum O
levels O
and O
valproic B-DRUG
acid I-DRUG
has O
been O
reported O
to O
both O
increase O
and O
decrease O
ethosuximide B-DRUG
levels O
) O
. O

PEGANONE B-BRAND
used O
in O
combination O
with O
other O
drugs O
known O
to O
adversely O
affect O
the O
hematopoietic O
system O
should O
be O
avoided O
if O
possible O
. O
Considerable O
caution O
should O
be O
exercised O
if O
PEGANONE B-BRAND
is O
administered O
concurrently O
with O
Phenurone B-BRAND
( O
phenacemide B-DRUG
) O
since O
paranoid O
symptoms O
have O
been O
reported O
during O
therapy O
with O
this O
combination O
. O
A O
two O
- O
way O
interaction O
between O
the O
hydantoin B-GROUP
antiepileptic I-GROUP
, O
phenytoin B-DRUG
, O
and O
the O
coumarin B-GROUP
anticoagulants I-GROUP
has O
been O
suggested O
. O
Presumably O
, O
phenytoin B-DRUG
acts O
as O
a O
stimulator O
of O
coumarin B-GROUP
metabolism O
and O
has O
been O
reported O
to O
cause O
decreased O
serum O
levels O
of O
the O
coumarin B-GROUP
anticoagulants I-GROUP
and O
increased O
prothrombin O
- O
proconvertin O
concentrations O
. O
Conversely O
, O
the O
coumarin B-GROUP
anticoagulants I-GROUP
have O
been O
reported O
to O
increase O
the O
serum O
levels O
and O
prolong O
the O
serum O
half O
- O
life O
of O
phenytoin B-DRUG
by O
inhibiting O
its O
metabolism O
. O
Although O
there O
is O
no O
documentation O
of O
such O
, O
a O
similar O
interaction O
between O
ethotoin B-DRUG
and O
the O
coumarin B-GROUP
anticoagulants I-GROUP
may O
occur O
. O
Caution O
is O
therefore O
advised O
when O
administering O
PEGANONE B-BRAND
to O
patients O
receiving O
coumarin B-GROUP
anticoagulants I-GROUP
. O

Ethoxzolamide B-DRUG
may O
increase O
the O
action O
of O
tricyclics B-GROUP
, O
amphetamines B-GROUP
, O
procainamide B-DRUG
, O
and O
quinidine B-DRUG
. O
It O
may O
increase O
excretion O
of O
barbiturates B-GROUP
, O
lithium B-DRUG
, O
and O
ASA B-DRUG
and O
may O
also O
increase O
the O
toxicity O
of O
salicylates B-GROUP
. O
Coadministration O
of O
ethoxzolamide B-DRUG
with O
other O
diuretics B-GROUP
, O
amphotericin B-DRUG
B I-DRUG
, O
and O
corticosteroids B-GROUP
may O
cause O
hypokalemia O
. O

Ethinyl B-DRUG
estradiol I-DRUG
: O
Substrate O
of O
CYP3A4 O
( O
major O
) O
, O
3A5 O
- O
7 O
( O
minor O
) O
; O
Inhibits O
CYP1A2 O
( O
weak O
) O
, O
2B6 O
( O
weak O
) O
, O
2C19 O
( O
weak O
) O
, O
3A4 O
( O
weak O
) O
. O
Acetaminophen B-DRUG
: O
May O
increase O
plasma O
concentration O
of O
synthetic B-GROUP
estrogens I-GROUP
, O
possibly O
by O
inhibiting O
conjugation O
. O
Combination O
hormonal B-GROUP
contraceptives I-GROUP
may O
also O
decrease O
the O
plasma O
concentration O
of O
acetaminophen B-DRUG
. O
Acitretin B-DRUG
: O
Interferes O
with O
the O
contraceptive O
effect O
of O
microdosed O
progestin B-GROUP
- O
containing O
minipill O
preparations O
. O
The O
effect O
on O
other O
progestational B-GROUP
contraceptives I-GROUP
( O
eg O
, O
implants O
, O
injectables O
) O
is O
unknown O
. O
Aminoglutethimide B-DRUG
: O
May O
increase O
CYP O
metabolism O
of O
progestins B-GROUP
leading O
to O
possible O
decrease O
in O
contraceptive O
effectiveness O
. O
Use O
of O
a O
nonhormonal B-GROUP
contraceptive I-GROUP
product I-GROUP
is O
recommended O
. O
Antibiotics B-GROUP
( O
ampicillin B-DRUG
, O
tetracycline B-DRUG
) O
: O
Pregnancy O
has O
been O
reported O
following O
concomitant O
use O
, O
however O
, O
pharmacokinetic O
studies O
have O
not O
shown O
consistent O
effects O
with O
these O
antibiotics B-GROUP
on O
plasma O
concentrations O
of O
synthetic B-GROUP
steroids I-GROUP
. O
Use O
of O
a O
nonhormonal B-GROUP
contraceptive I-GROUP
product I-GROUP
is O
recommended O
. O
Anticoagulants B-GROUP
: O
Combination O
hormonal B-GROUP
contraceptives I-GROUP
may O
increase O
or O
decrease O
the O
effects O
of O
coumarin B-GROUP
derivatives I-GROUP
. O
Combination O
hormonal B-GROUP
contraceptives I-GROUP
may O
also O
increase O
risk O
of O
thromboembolic O
disorders O
. O
Anticonvulsants B-GROUP
( O
carbamazepine B-DRUG
, O
felbamate B-DRUG
, O
phenobarbital B-DRUG
, O
phenytoin B-DRUG
, O
topiramate B-DRUG
) O
: O
Increase O
the O
metabolism O
of O
ethinyl B-DRUG
estradiol I-DRUG
and O
/ O
or O
some O
progestins B-GROUP
, O
leading O
to O
possible O
decrease O
in O
contraceptive O
effectiveness O
. O
Use O
of O
a O
nonhormonal B-GROUP
contraceptive I-GROUP
product I-GROUP
is O
recommended O
. O
Ascorbic B-DRUG
acid I-DRUG
: O
Doses O
of O
ascorbic B-DRUG
acid I-DRUG
( O
vitamin B-DRUG
C I-DRUG
) O
1 O
g O
/ O
day O
have O
been O
reported O
to O
increase O
plasma O
concentration O
of O
synthetic B-GROUP
estrogens I-GROUP
by O
~ O
47 O
% O
, O
possibly O
by O
inhibiting O
conjugation O
; O
clinical O
implications O
are O
unclear O
. O
Atorvastatin B-DRUG
: O
Atorvastatin B-DRUG
increases O
the O
AUC O
for O
norethindrone B-DRUG
and O
ethinyl B-DRUG
estradiol I-DRUG
. O
Benzodiazepines B-GROUP
: O
Combination O
hormonal B-GROUP
contraceptives I-GROUP
may O
decrease O
the O
clearance O
of O
some O
benzodiazepines B-GROUP

( O
alprazolam B-DRUG
, O
chlordiazepoxide B-DRUG
, O
diazepam B-DRUG
) O
and O
increase O
the O
clearance O
of O
others O
( O
lorazepam B-DRUG
, O
oxazepam B-DRUG
, O
temazepam B-DRUG
) O
. O
Clofibric B-DRUG_N
acid I-DRUG_N
: O
Combination O
hormonal B-GROUP
contraceptives I-GROUP
may O
increase O
the O
clearance O
of O
clofibric B-DRUG_N
acid I-DRUG_N
. O
Cyclosporine B-DRUG
: O
Combination O
hormonal B-GROUP
contraceptives I-GROUP
may O
inhibit O
the O
metabolism O
of O
cyclosporine B-DRUG
, O
leading O
to O
increased O
plasma O
concentrations O
; O
monitor O
cyclosporine B-DRUG
levels O
. O
CYP3A4 O
inducers O
: O
CYP3A4 O
inducers O
may O
decrease O
the O
levels O
/ O
effects O
of O
ethinyl B-DRUG
estradiol I-DRUG
. O
Example O
inducers O
include O
aminoglutethimide B-DRUG
, O
carbamazepine B-DRUG
, O
nafcillin B-DRUG
, O
nevirapine B-DRUG
, O
phenobarbital B-DRUG
, O
phenytoin B-DRUG
, O
and O
rifamycins B-GROUP
. O
Griseofulvin B-DRUG
: O
Griseofulvin B-DRUG
may O
induce O
the O
metabolism O
of O
combination B-GROUP
hormonal I-GROUP
contraceptives I-GROUP
causing O
menstrual O
changes O
; O
pregnancies O
have O
been O
reported O
. O
Use O
of O
barrier O
form O
of O
contraception O
is O
suggested O
while O
on O
griseofulvin B-DRUG
therapy O
. O
Morphine B-DRUG
: O
Combination O
hormonal B-GROUP
contraceptives I-GROUP
may O
increase O
the O
clearance O
of O
morphine B-DRUG
. O
Non B-GROUP
- I-GROUP
nucleoside I-GROUP
reverse I-GROUP
transcriptase I-GROUP
inhibitors I-GROUP
( O
NNRTIs B-GROUP
) O
: O
Nevirapine B-DRUG
may O
decrease O
plasma O
levels O
of O
combination B-GROUP
hormonal I-GROUP
contraceptives I-GROUP
; O
use O
of O
a O
nonhormonal B-GROUP
contraceptive I-GROUP
product I-GROUP
is O
recommended O
. O
No O
data O
for O
delavirdine B-DRUG
; O
incomplete O
data O
for O
efavirenz B-DRUG
. O
Prednisolone B-DRUG
: O
Ethinyl B-DRUG
estradiol I-DRUG
may O
inhibit O
the O
metabolism O
of O
prednisolone B-DRUG
, O
leading O
to O
increased O
plasma O
concentrations O
. O
Protease B-GROUP
inhibitors I-GROUP
: O
Amprenavir B-DRUG
, O
lopinavir B-DRUG
, O
nelfinavir B-DRUG
, O
and O
ritonavir B-DRUG
have O
been O
shown O
to O
decrease O
plasma O
levels O
of O
combination B-GROUP
hormonal I-GROUP
contraceptives I-GROUP
; O
use O
of O
a O
nonhormonal B-GROUP
contraceptive I-GROUP
product I-GROUP
is O
recommended O
. O
Indinavir B-DRUG
has O
been O
shown O
to O
increase O
plasma O
levels O
of O
combination B-GROUP
hormonal I-GROUP
contraceptives I-GROUP
. O
No O
data O
for O
saquinavir B-DRUG
. O
Rifampin B-DRUG
: O
Rifampin B-DRUG
increases O
the O
metabolism O
of O
ethinyl B-DRUG
estradiol I-DRUG
and O
some O
progestins B-GROUP
( O
norethindrone B-DRUG
) O
resulting O
in O
decreased O
contraceptive O
effectiveness O
and O
increased O
menstrual O
irregularities O
. O
Use O
of O
a O
nonhormonal B-GROUP

contraceptive I-GROUP
product I-GROUP
is O
recommended O
. O
Salicylic B-DRUG
acid I-DRUG
: O
Combination O
hormonal B-GROUP
contraceptives I-GROUP
may O
increase O
the O
clearance O
of O
salicylic B-DRUG
acid I-DRUG
. O
Selegiline B-DRUG
: O
Combination B-GROUP
hormonal I-GROUP
contraceptives I-GROUP
may O
increase O
the O
serum O
concentration O
of O
selegiline B-DRUG
. O
Theophylline B-DRUG
: O
Ethinyl B-DRUG
estradiol I-DRUG
may O
inhibit O
the O
metabolism O
of O
theophylline B-DRUG
, O
leading O
to O
increased O
plasma O
concentrations O
. O
Tricyclic B-GROUP
antidepressants I-GROUP
( O
amitriptyline B-DRUG
, O
imipramine B-DRUG
, O
nortriptyline B-DRUG
) O
: O
Metabolism O
may O
be O
inhibited O
by O
combination B-GROUP
hormonal I-GROUP
contraceptives I-GROUP
, O
increasing O
plasma O
levels O
of O
antidepressant B-GROUP
; O
use O
caution O
. O
ETHANOL B-DRUG
/ O
NUTRITION O
/ O
HERB O
INTERACTIONS O
: O
Food O
: O
CNS O
effects O
of O
caffeine B-DRUG
may O
be O
enhanced O
if O
combination B-GROUP
hormonal I-GROUP
contraceptives I-GROUP
are O
used O
concurrently O
with O
caffeine B-DRUG
. O
Grapefruit O
juice O
increases O
ethinyl B-DRUG
estradiol I-DRUG
concentrations O
and O
would O
be O
expected O
to O
increase O
progesterone B-DRUG
serum O
levels O
as O
well O
; O
clinical O
implications O
are O
unclear O
. O
Herb O
/ O
Nutraceutical O
: O
St O
Johns O
wort O
may O
decrease O
the O
effectiveness O
of O
combination B-GROUP
hormonal I-GROUP
contraceptives I-GROUP
by O
inducing O
hepatic O
enzymes O
. O
Avoid O
dong O
quai O
and O
black O
cohosh O
( O
have O
estrogen O
activity O
) O
. O
Avoid O
saw O
palmetto O
, O
red O
clover O
, O
ginseng O
. O

There O
have O
been O
isolated O
reports O
of O
patients O
experiencing O
increases O
in O
their O
prothrombin O
times O
when O
etidronate B-DRUG
was O
added O
to O
warfarin B-DRUG
therapy O
. O
The O
majority O
of O
these O
reports O
concerned O
variable O
elevations O
in O
prothrombin O
times O
without O
clinically O
significant O
sequelae O
. O
Although O
the O
relevance O
of O
these O
reports O
and O
any O
mechanism O
of O
coagulation O
alterations O
is O
unclear O
, O
patients O
on O
warfarin B-DRUG
should O
have O
their O
prothrombin O
time O
monitored O
. O

ACE B-GROUP
- I-GROUP
inhibitors I-GROUP
Reports O
suggest O
that O
NSAIDs B-GROUP
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE B-GROUP
- I-GROUP
inhibitors I-GROUP
. O
This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
NSAIDs B-GROUP
concomitantly O
with O
ACE B-GROUP
- I-GROUP
inhibitors I-GROUP
. O
Antacids B-GROUP
: O
The O
concomitant O
administration O
of O
antacids B-GROUP
has O
no O
apparent O
effect O
on O
the O
extent O
of O
absorption O
of O
Lodine B-BRAND
. O
However O
, O
antacids B-GROUP
can O
decrease O
the O
peak O
concentration O
reached O
by O
15 O
% O
to O
20 O
% O
but O
have O
no O
detectable O
effect O
on O
the O
time O
- O
to O
- O
peak O
. O
Aspirin B-BRAND
: O
When O
Lodine B-BRAND
is O
administered O
with O
aspirin B-BRAND
, O
its O
protein O
binding O
is O
reduced O
, O
although O
the O
clearance O
of O
free O
etodolac B-DRUG
is O
not O
altered O
. O
The O
clinical O
significance O
of O
this O
interaction O
is O
not O
known O
; O
however O
, O
as O
with O
other O
NSAIDs B-GROUP
, O
concomitant O
administration O
of O
Lodine B-BRAND
and O
aspirin B-BRAND
is O
not O
generally O
recommended O
because O
of O
the O
potential O
of O
increased O
adverse O
effects O
. O
Cyclosporine O
, O
Digoxin O
, O
Methotrexate O
Lodine B-BRAND
, O
like O
other O
NSAIDs B-GROUP
, O
through O
effects O
on O
renal O
prostaglandins O
, O
may O
cause O
changes O
in O
the O
elimination O
of O
these O
drugs O
leading O
to O
elevated O
serum O
levels O
of O
cyclosporine B-DRUG
, O
digoxin B-DRUG
, O
methotrexate B-DRUG
, O
and O
increased O
toxicity O
. O
Nephrotoxicity O
associated O
with O
cyclosporine B-DRUG
may O
also O
be O
enhanced O
. O
Patients O
receiving O
these O
drugs O
who O
are O
given O
Lodine B-BRAND
, O
or O
any O
other O
NSAID B-GROUP
, O
and O
particularly O
those O
patients O
with O
altered O
renal O
function O
, O
should O
be O
observed O
for O
the O
development O
of O
the O
specific O
toxicities O
of O
these O
drugs O
. O
Diuretics B-GROUP
: O
Etodolac O
has O
no O
apparent O
pharmacokinetic O
interaction O
when O
administered O
with O
furosemide B-DRUG
or O
hydrochlorothiazide B-DRUG
. O
Nevertheless O
, O
clinical O
studies O
, O
as O
well O
as O
postmarketing O
observations O
have O
shown O
that O
Lodine B-BRAND
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-DRUG
and O
thiazides B-GROUP
in O
some O
patients O
. O
This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O
During O
concomitant O
therapy O
with O
NSAIDs B-GROUP
, O
the O
patient O
should O
be O
observed O
closely O
for O
signs O
of O
renal O
failure O
, O
as O
well O
as O
to O
assure O
diuretic O
efficacy O
. O
Glyburide B-DRUG
: O
Etodolac B-DRUG
has O
no O
apparent O
pharmacokinetic O
interaction O
when O
administered O
with O
glyburide B-DRUG
. O
Lithium B-DRUG
: O
NSAIDs B-GROUP
have O
produced O
an O
elevation O
of O
plasma O
lithium B-DRUG
levels O
and O
a O
reduction O
in O
renal O
lithium B-DRUG
clearance O
. O
The O
mean O
minimum O
lithium B-DRUG
concentration O
increased O
15 O
% O

and O
the O
renal O
clearance O
was O
decreased O
by O
approximately O
20 O
% O
. O
These O
effects O
have O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
by O
the O
NSAID B-GROUP
. O
Thus O
, O
when O
NSAIDs B-GROUP
and O
lithium B-DRUG
are O
administered O
concurrently O
, O
subjects O
should O
be O
observed O
carefully O
for O
signs O
of O
lithium B-DRUG
toxicity O
. O
Phenylbutazone B-DRUG
: O
Phenylbutazone B-DRUG
causes O
increase O
( O
by O
about O
80 O
% O
) O
in O
the O
free O
fraction O
of O
etodolac B-DRUG
. O
Although O
in O
vivo O
studies O
have O
not O
been O
done O
to O
see O
if O
etodolac B-DRUG
clearance O
is O
changed O
by O
coadministration O
of O
phenylbutazone B-DRUG
, O
it O
is O
not O
recommended O
that O
they O
be O
coadministered O
. O
Phenytoin B-DRUG
: O
Etodolac B-DRUG
has O
no O
apparent O
pharmacokinetic O
interaction O
when O
administered O
with O
phenytoin B-DRUG
. O
Warfarin B-DRUG
: O
The O
effects O
of O
warfarin B-DRUG
and O
NSAIDs B-GROUP
on O
GI O
bleeding O
are O
synergistic O
, O
such O
that O
users O
of O
both O
drugs O
together O
have O
a O
risk O
of O
serious O
GI O
bleeding O
higher O
than O
that O
of O
users O
of O
either O
drug O
alone O
. O
Short O
- O
term O
pharmacokinetic O
studies O
have O
demonstrated O
that O
concomitant O
administration O
of O
warfarin B-DRUG
and O
Lodine B-BRAND
( O
etodolac B-DRUG
capsules O
and O
tablets O
) O
results O
in O
reduced O
protein O
binding O
of O
warfarin B-DRUG
, O
but O
there O
was O
no O
change O
in O
the O
clearance O
of O
free O
warfarin B-DRUG
. O
There O
was O
no O
significant O
difference O
in O
the O
pharmacodynamic O
effect O
of O
warfarin B-DRUG
administered O
alone O
and O
warfarin B-DRUG
administered O
with O
Lodine B-BRAND
as O
measured O
by O
prothrombin O
time O
. O
Thus O
, O
concomitant O
therapy O
with O
warfarin B-DRUG
and O
Lodine B-BRAND
should O
not O
require O
dosage O
adjustment O
of O
either O
drug O
. O
However O
, O
caution O
should O
be O
exercised O
because O
there O
have O
been O
a O
few O
spontaneous O
reports O
of O
prolonged O
prothrombin O
times O
, O
with O
or O
without O
bleeding O
, O
in O
etodolac B-DRUG
- O
treated O
patients O
receiving O
concomitant O
warfarin B-DRUG
therapy O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
The O
urine O
of O
patients O
who O
take O
Lodine B-BRAND
can O
give O
a O
false O
- O
positive O
reaction O
for O
urinary O
bilirubin O
( O
urobilin O
) O
due O
to O
the O
presence O
of O
phenolic O
metabolites O
of O
etodolac B-DRUG
. O
Diagnostic O
dip O
- O
stick O
methodology O
, O
used O
to O
detect O
ketone O
bodies O
in O
urine O
, O
has O
resulted O
in O
false O
- O
positive O
findings O
in O
some O
patients O
treated O
with O
Lodine B-BRAND
. O
Generally O
, O
this O
phenomenon O
has O
not O
been O
associated O
with O
other O
clinically O
significant O
events O
. O
No O
dose O
relationship O
has O
been O
observed O
. O
Lodine B-BRAND
treatment O
is O
associated O
with O
a O
small O
decrease O
in O
serum O
uric O
acid O
levels O
. O
In O
clinical O
trials O
, O
mean O
decreases O
of O
1 O

to O
2 O
mg O
/ O
dL O
were O
observed O
in O
arthritic O
patients O
receiving O
etodolac B-DRUG
( O
600 O
mg O
to O
1000 O
mg O
/ O
day O
) O
after O
4 O
weeks O
of O
therapy O
. O
These O
levels O
then O
remained O
stable O
for O
up O
to O
1 O
year O
of O
therapy O
. O

The O
following O
drug O
interactions O
have O
been O
reported O
with O
etomidate B-DRUG
. O
Drug O
Effect O
Probenecid B-DRUG
Prolonged O
action O
of O
etomidate B-DRUG
Diazoxide B-DRUG
Hypotension O
Zimelidine B-DRUG_N
etomidate B-DRUG
antagonism O
Opioid B-GROUP
analgesics I-GROUP
Decreased O
antinociceptive O
action O
Aminophylline B-DRUG
Etomidate B-DRUG
antagonism O
Midazolam B-DRUG
Synergism O

Etonogestrel B-DRUG
may O
interact O
with O
the O
following O
medications O
: O
acetaminophen B-DRUG
( O
Tylenol B-BRAND
) O
, O
antibiotics B-GROUP
such O
as O
ampicillin B-DRUG
and O
tetracycline B-DRUG
, O
anticonvulsants B-GROUP
( O
Dilantin B-BRAND
, O
Phenobarbital B-DRUG
, O
Tegretol B-BRAND
, O
Trileptal B-BRAND
, O
Topamax B-BRAND
, O
Felbatol B-BRAND
) O
, O
antifungals B-GROUP
( O
Gris B-BRAND
- I-BRAND
PEG I-BRAND
, O
Nizoral B-BRAND
, O
Sporanox B-BRAND
) O
, O
atorvastatin B-DRUG
( O
Lipitor B-BRAND
) O
, O
clofibrate B-DRUG
( O
Atromid B-BRAND
- I-BRAND
S I-BRAND
) O
, O
cyclosporine B-DRUG
( O
Neoral B-BRAND
, O
Sandimmune B-BRAND
) O
, O
HIV O
drugs O
classified O
as O
protease B-GROUP
inhibitors I-GROUP
( O
Agenerase B-BRAND
, O
Crixivan B-BRAND
, O
Fortovase B-BRAND
, O
Invirase B-BRAND
, O
Kaletra B-BRAND
, O
Norvir B-BRAND
, O
Viracept B-BRAND
) O
, O
morphine B-DRUG
( O
Astramorph B-BRAND
, O
Kadian B-BRAND
, O
MS B-BRAND
Contin I-BRAND
) O
, O
phenylbutazone B-DRUG
, O
prednisolone B-DRUG
( O
Prelone B-BRAND
) O
, O
rifadin B-BRAND
( O
rifampin B-DRUG
) O
, O
St O
. O
Johns O
wort O
, O
temazepam B-DRUG
, O
theophylline B-DRUG
( O
Theo B-BRAND
- I-BRAND
Dur I-BRAND
) O
, O
and O
vitamin B-DRUG
C I-DRUG
. O

Caution O
should O
be O
exercised O
when O
administering O
ETOPOPHOS B-BRAND
with O
drugs O
that O
are O
known O
to O
inhibit O
phosphatase O
activities O
( O
e O
. O
g O
. O
, O
levamisole B-DRUG
hydrochloride I-DRUG
) O
. O
High O
- O
dose O
cyclosporin B-DRUG
A I-DRUG
resulting O
in O
concentrations O
above O
2000 O
ng O
/ O
mL O
administered O
with O
oral O
etoposide B-DRUG
has O
led O
to O
an O
80 O
% O
increase O
in O
etoposide B-DRUG
exposure O
with O
a O
38 O
% O
decrease O
in O
total O
body O
clearance O
of O
etoposide B-DRUG
compared O
to O
etoposide B-DRUG
alone O
. O

Exemestane B-DRUG
is O
extensively O
metabolized O
by O
CYP O
3A4 O
, O
but O
coadministration O
of O
ketoconazole B-DRUG
, O
a O
potent O
inhibitor O
of O
CYP O
3A4 O
, O
has O
no O
significant O
effect O
on O
exemestane B-DRUG
pharmacokinetics O
. O
Significant O
pharmacokinetic O
interactions O
mediated O
by O
inhibition O
of O
CYP O
isoenzymes O
therefore O
appear O
unlikely O
. O
Co O
- O
medications O
that O
induce O
CYP O
3A4 O
( O
e O
. O
g O
. O
, O
rifampicin B-DRUG
, O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
phenobarbital B-DRUG
, O
or O
St O
. O
John O
s O
wort O
) O
may O
significantly O
decrease O
exposure O
to O
exemestane B-DRUG
. O
Dose O
modification O
is O
recommended O
for O
patients O
who O
are O
also O
receiving O
a O
potent O
CYP O
3A4 O
inducer O
. O
Drug O
/ O
Laboratory O
Tests O
Interactions O
No O
clinically O
relevant O
changes O
in O
the O
results O
of O
clinical O
laboratory O
tests O
have O
been O
observed O
. O

Concurrent O
use O
with O
probenecid B-DRUG
or O
other O
drugs O
significantly O
eliminated O
by O
active O
renal O
tubular O
secretion O
may O
result O
in O
increased O
plasma O
concentrations O
of O
penciclovir B-DRUG
. O
The O
conversion O
of O
6 B-DRUG_N
- I-DRUG_N
deoxy I-DRUG_N
penciclovir I-DRUG_N
to O
penciclovir B-DRUG
is O
catalyzed O
by O
aldehyde O
oxidase O
. O
Interactions O
with O
other O
drugs O
metabolized O
by O
this O
enzyme O
could O
potentially O
occur O
. O

No O
drug O
interactions O
have O
been O
identified O
. O
Studies O
with O
famotidine B-DRUG
in O
man O
, O
in O
animal O
models O
, O
and O
in O
vitro O
have O
shown O
no O
significant O
interference O
with O
the O
disposition O
of O
compounds O
metabolized O
by O
the O
hepatic O
microsomal O
enzymes O
, O
e O
. O
g O
. O
, O
cytochrome O
P450 O
system O
. O
Compounds O
tested O
in O
man O
include O
warfarin B-DRUG
, O
theophylline B-DRUG
, O
phenytoin B-DRUG
, O
diazepam B-DRUG
, O
aminopyrine B-DRUG
and O
antipyrine B-DRUG
. O
Indocyanine B-DRUG_N
green I-DRUG_N
as O
an O
index O
of O
hepatic O
drug O
extraction O
has O
been O
tested O
and O
no O
significant O
effects O
have O
been O
found O
. O

The O
drug O
interaction O
data O
described O
in O
this O
section O
were O
obtained O
from O
controlled O
clinical O
trials O
and O
studies O
involving O
otherwise O
healthy O
adults O
with O
epilepsy O
. O
Use O
in O
Conjunction O
with O
Other O
Antiepileptic B-GROUP
Drugs I-GROUP
: O
The O
addition O
of O
Felbatol B-BRAND
to O
antiepileptic B-GROUP
drugs I-GROUP
( O
AEDs B-GROUP
) O
affects O
the O
steady O
- O
state O
plasma O
concentrations O
of O
AEDs B-GROUP
. O
The O
net O
effect O
of O
these O
interactions O
is O
summarized O
in O
the O
following O
table O
: O
AED B-GROUP
AED B-GROUP
Felbatol B-BRAND
Coadministered O
Concentration O
Concentration O
Phenytoin B-DRUG
Valproate B-DRUG
* O
* O
Carbamazepine B-DRUG
( O
CBZ B-DRUG
) O
* O
CBZ O
epoxide O
Phenobarbital B-DRUG
* O
Not O
administered O
, O
but O
an O
active O
metabolite O
of O
carbamazepine B-DRUG
. O
* O
* O
No O
significant O
effect O
. O
Specific O
Effects O
of O
Felbatol B-BRAND
on O
Other O
Antiepileptic B-GROUP
Drugs I-GROUP
Phenytoin B-DRUG
: O
Felbatol B-BRAND
causes O
an O
increase O
in O
steady O
- O
state O
phenytoin B-DRUG
plasma O
concentrations O
. O
In O
10 O
otherwise O
healthy O
subjects O
with O
epilepsy O
ingesting O
phenytoin B-DRUG
, O
the O
steadystate O
trough O
( O
Cmin O
) O
phenytoin B-DRUG
plasma O
concentration O
was O
17 O
5 O
micrograms O
/ O
mL O
. O
The O
steady O
- O
state O
Cmin O
increased O
to O
21 O
5 O
micrograms O
/ O
mL O
when O
1200 O
mg O
/ O
day O
of O
felbamate B-DRUG
was O
coadministered O
. O
Increasing O
the O
felbamate B-DRUG
dose O
to O
1800 O
mg O
/ O
day O
in O
six O
of O
these O
subjects O
increased O
the O
steady O
- O
state O
phenytoin B-DRUG
Cmin O
to O
25 O
7 O
micrograms O
/ O
mL O
. O
In O
order O
to O
maintain O
phenytoin B-DRUG
levels O
, O
limit O
adverse O
experiences O
, O
and O
achieve O
the O
felbamate B-DRUG
dose O
of O
3600 O
mg O
/ O
day O
, O
a O
phenytoin B-DRUG
dose O
reduction O
of O
approximately O
40 O
% O
was O
necessary O
for O
eight O
of O
these O
10 O
subjects O
. O
In O
a O
controlled O
clinical O
trial O
, O
a O
20 O
% O
reduction O
of O
the O
phenytoin B-DRUG
dose O
at O
the O
initiation O
of O
Felbatol B-BRAND
therapy O
resulted O
in O
phenytoin B-DRUG
levels O
comparable O
to O
those O
prior O
to O
Felbatol B-BRAND
administration O
. O
Carbamazepine B-DRUG
: O
Felbatol B-BRAND
causes O
a O
decrease O
in O
the O
steady O
- O
state O
carbamazepine B-DRUG
plasma O
concentrations O
and O
an O
increase O
in O
the O
steady O
- O
state O
carbamazepine B-DRUG_N
epoxide I-DRUG_N
plasma O
concentration O
. O
In O
nine O
otherwise O
healthy O
subjects O
with O
epilepsy O
ingesting O
carbamazepine B-DRUG
, O
the O
steady O
- O
state O
trough O
( O
Cmin O
) O
carbamazepine B-DRUG
concentration O
was O
8 O
2 O
micrograms O
/ O
mL O
. O
The O
carbamazepine B-DRUG
steady O
- O
state O
Cmin O
decreased O
31 O
% O
to O

5 O
1 O
micrograms O
/ O
mL O
when O
felbamate B-DRUG
( O
3000 O
mg O
/ O
day O
, O
divided O
into O
three O
doses O
) O
was O
coadministered O
. O
Carbamazepine B-DRUG_N
epoxide I-DRUG_N
steady O
- O
state O
Cmin O
concentrations O
increased O
57 O
% O
from O
1 O
. O
0 O
0 O
. O
3 O
to O
1 O
. O
6 O
0 O
. O
4 O
micrograms O
/ O
mL O
with O
the O
addition O
of O
felbamate B-DRUG
. O
In O
clinical O
trials O
, O
similar O
changes O
in O
carbamazepine B-DRUG
and O
carbamazepine B-DRUG_N
epoxide I-DRUG_N
were O
seen O
. O
Valproate B-DRUG
: O
Felbatol B-BRAND
causes O
an O
increase O
in O
steady O
- O
state O
valproate B-DRUG
concentrations O
. O
In O
four O
subjects O
with O
epilepsy O
ingesting O
valproate B-DRUG
, O
the O
steady O
- O
state O
trough O
( O
Cmin O
) O
valproate B-DRUG
plasma O
concentration O
was O
63 O
16 O
micrograms O
/ O
mL O
. O
The O
steady O
- O
state O
Cmin O
increased O
to O
78 O
14 O
micrograms O
/ O
mL O
when O
1200 O
mg O
/ O
day O
of O
felbamate B-DRUG
was O
coadministered O
. O
Increasing O
the O
felbamate B-DRUG
dose O
to O
2400 O
mg O
/ O
day O
increased O
the O
steadystate O
valproate B-DRUG
Cmin O
to O
96 O
25 O
micrograms O
/ O
mL O
. O
Corresponding O
values O
for O
free O
valproate B-DRUG
Cmin O
concentrations O
were O
7 O
3 O
, O
9 O
4 O
, O
and O
11 O
6 O
micrograms O
/ O
mL O
for O
0 O
, O
1200 O
, O
and O
2400 O
mg O
/ O
day O
Felbatol B-BRAND
, O
respectively O
. O
The O
ratios O
of O
the O
AUCs O
of O
unbound O
valproate B-DRUG
to O
the O
AUCs O
of O
the O
total O
valproate B-DRUG
were O
11 O
. O
1 O
% O
, O
13 O
. O
0 O
% O
, O
and O
11 O
. O
5 O
% O
, O
with O
coadministration O
of O
0 O
, O
1200 O
, O
and O
2400 O
mg O
/ O
day O
of O
Felbatol B-BRAND
, O
respectively O
. O
Phenobarbital B-DRUG
: O
Coadministration O
of O
felbamate B-DRUG
with O
phenobarbital B-DRUG
causes O
an O
increase O
in O
phenobarbital B-DRUG
plasma O
concentrations O
, O
In O
12 O
otherwise O
healthy O
male O
volunteers O
ingesting O
phenobarbital B-DRUG
, O
the O
steady O
- O
state O
trough O
( O
Cmin O
) O
phenobarbital B-DRUG
concentration O
was O
14 O
. O
2 O
micrograms O
/ O
mL O
. O
The O
steady O
- O
state O
Cmin O
concentration O
increased O
to O
17 O
. O
8 O
micrograms O
/ O
mL O
when O
2400 O
mg O
/ O
day O
of O
felbamate B-DRUG
was O
coadministered O
for O
one O
week O
. O
Effects O
of O
Other O
Antiepileptic B-GROUP
Drugs I-GROUP
on O
Felbatol B-BRAND
Phenytoin B-DRUG
: O
Phenytoin B-DRUG
causes O
an O
approximate O
doubling O
of O
the O
clearance O
of O
Felbatol B-BRAND
( O

felbamate B-DRUG
) O
at O
steady O
state O
and O
, O
therefore O
, O
the O
addition O
of O
phenytoin B-DRUG
causes O
an O
approximate O
45 O
% O
decrease O
in O
the O
steady O
- O
state O
trough O
concentrations O
of O
Felbatol B-BRAND
as O
compared O
to O
the O
same O
dose O
of O
Felbatol B-BRAND
given O
as O
monotherapy O
. O
Carbamazepine B-DRUG
: O
Carbamazepine B-DRUG
causes O
an O
approximate O
50 O
% O
increase O
in O
the O
clearance O
of O
Felbatol B-BRAND
at O
steady O
state O
and O
, O
therefore O
, O
the O
addition O
of O
carbamazepine B-DRUG
results O
in O
an O
approximate O
40 O
% O
decrease O
in O
the O
steady O
- O
state O
trough O
concentrations O
of O
Felbatol B-BRAND
as O
compared O
to O
the O
same O
dose O
of O
Felbatol B-BRAND
given O
as O
monotherapy O
. O
Valproate B-DRUG
: O
Available O
data O
suggest O
that O
there O
is O
no O
significant O
effect O
of O
valproate B-DRUG
on O
the O
clearance O
of O
Felbatol B-BRAND
at O
steady O
state O
, O
Therefore O
, O
the O
addition O
of O
valproate B-DRUG
is O
not O
expected O
to O
cause O
a O
clinically O
important O
effect O
on O
Felbatol B-BRAND
( O
felbamate B-DRUG
) O
plasma O
concentrations O
. O
Phenobarbital B-DRUG
: O
It O
appears O
that O
phenobarbital B-DRUG
may O
reduce O
plasma O
felbamate B-DRUG
concentrations O
. O
Steady O
- O
state O
plasma O
felbamate B-DRUG
concentrations O
were O
found O
to O
be O
29 O
% O
lower O
than O
the O
mean O
concentrations O
of O
a O
group O
of O
newly O
diagnosed O
subjects O
with O
epilepsy O
also O
receiving O
2400 O
mg O
of O
felbamate B-DRUG
a O
day O
. O
Effects O
of O
Antacids B-GROUP
on O
Felbatol B-BRAND
The O
rate O
and O
extent O
of O
absorption O
of O
a O
2400 O
mg O
dose O
of O
Felbatol B-BRAND
as O
monotherapy O
given O
as O
tablets O
was O
not O
affected O
when O
coadministered O
with O
antacids B-GROUP
. O
Effects O
of O
Erythromycin B-DRUG
on O
Felbatol B-BRAND
The O
coadministration O
of O
erythromycin B-DRUG
( O
1000 O
mg O
/ O
day O
) O
for O
10 O
days O
did O
not O
alter O
the O
pharmacokinetic O
parameters O
of O
Cmax O
, O
Cmin O
, O
AUC O
, O
CI O
/ O
kg O
or O
tmax O
at O
felbamate B-DRUG
daily O
doses O
of O
3000 O
or O
3600 O
mg O
/ O
day O
in O
10 O
otherwise O
healthy O
subjects O
with O
epilepsy O
. O
Effects O
of O
Felbatol B-BRAND
on O
Low O
- O
Dose O
Combination B-GROUP
Oral I-GROUP
Contraceptives I-GROUP
A O
group O
of O
24 O
nonsmoking O
, O
healthy O
white O
female O
volunteers O
established O
on O
an O
oral O
contraceptive B-GROUP
regimen O
containing O
30 O
mg O
ethinyl B-DRUG
estradiol I-DRUG
and O
75 O
mg O
gestodene B-DRUG
for O
at O
least O
3 O
months O
received O
2400 O
mg O
/ O
day O
of O
felbamate B-DRUG
from O
midcycle O
( O
day O
15 O
) O
to O
midcycle O
( O
day O
14 O
) O
of O
two O
consecutive O
oral O
contraceptive B-GROUP
cycles O
. O
Felbamate B-DRUG
treatment O
resulted O
in O
a O
42 O
% O
decrease O
in O

the O
gestodene B-DRUG
AUC O
0 O
- O
24 O
, O
but O
no O
clinically O
relevant O
effect O
was O
observed O
on O
the O
pharmacokinetic O
parameters O
of O
ethinyl B-DRUG
estradiol I-DRUG
. O
No O
volunteer O
showed O
hormonal O
evidence O
of O
ovulation O
, O
but O
one O
volunteer O
reported O
intermenstrual O
bleeding O
during O
felbamate B-DRUG
treatment O
. O

CYP3A4 B-DRUG
Inhibitors O
Felodipine O
is O
metabolized O
by O
CYP3A4 B-DRUG
. O
Co O
- O
administration O
of O
CYP3A4 O
inhibitors O
( O
eg O
, O
ketoconazole B-DRUG
, O
itraconazole B-DRUG
, O
erythromycin B-DRUG
, O
grapefruit O
juice O
, O
cimetidine B-DRUG
) O
with O
felodipine B-DRUG
may O
lead O
to O
several O
- O
fold O
increases O
in O
the O
plasma O
levels O
of O
felodipine B-DRUG
, O
either O
due O
to O
an O
increase O
in O
bioavailability O
or O
due O
to O
a O
decrease O
in O
metabolism O
. O
These O
increases O
in O
concentration O
may O
lead O
to O
increased O
effects O
, O
( O
lower O
blood O
pressure O
and O
increased O
heart O
rate O
) O
. O
These O
effects O
have O
been O
observed O
with O
co O
- O
administration O
of O
itraconazole B-DRUG
( O
a O
potent O
CYP3A4 B-DRUG
inhibitor O
) O
. O
Caution O
should O
be O
used O
when O
CYP3A4 B-DRUG
inhibitors O
are O
co O
- O
administered O
with O
felodipine B-DRUG
. O
A O
conservative O
approach O
to O
dosing O
felodipine B-DRUG
should O
be O
taken O
. O
The O
following O
specific O
interactions O
have O
been O
reported O
: O
Itraconazole O
Co O
- O
administration O
of O
another O
extended O
release O
formulation O
of O
felodipine B-DRUG
with O
itraconazole B-DRUG
resulted O
in O
approximately O
8 O
- O
fold O
increase O
in O
the O
AUC O
, O
more O
than O
6 O
- O
fold O
increase O
in O
the O
Cmax O
, O
and O
2 O
- O
fold O
prolongation O
in O
the O
half O
- O
life O
of O
felodipine B-DRUG
. O
Erythromycin O
Co O
- O
administration O
of O
felodipine B-DRUG
( O
PLENDIL B-DRUG
) O
with O
erythromycin B-DRUG
resulted O
in O
approximately O
2 O
. O
5 O
- O
fold O
increase O
in O
the O
AUC O
and O
Cmax O
, O
and O
about O
2 O
- O
fold O
prolongation O
in O
the O
half O
- O
life O
of O
felodipine B-DRUG
. O
Grapefruit O
juice O
Co O
- O
administration O
of O
felodipine B-DRUG
with O
grapefruit O
juice O
resulted O
in O
more O
than O
2 O
- O
fold O
increase O
in O
the O
AUC O
and O
Cmax O
, O
but O
no O
prolongation O
in O
the O
half O
- O
life O
of O
felodipine B-DRUG
. O
Cimetidine O
Co O
- O
administration O
of O
felodipine B-DRUG
with O
cimetidine B-DRUG
( O
a O
non O
- O
specific O
CYP O
- O
450 O
inhibitor O
) O
resulted O
in O
an O
increase O
of O
approximately O
50 O
% O
in O
the O
AUC O
and O
the O
Cmax O
, O
of O
felodipine B-DRUG
. O
Beta O
- O
Blocking O
Agents O
A O
pharmacokinetic O
study O
of O
felodipine B-DRUG
in O
conjunction O
with O
metoprolol B-DRUG
demonstrated O
no O
significant O
effects O
on O
the O
pharmacokinetics O
of O
felodipine B-DRUG
. O
The O
AUC O
and O
Cmax O
of O
metoprolol B-DRUG
, O
however O
, O
were O
increased O
approximately O
31 O
and O
38 O
% O
, O
respectively O
. O
In O
controlled O
clinical O
trials O
, O
however O
, O
beta B-DRUG
blockers I-DRUG
including O
metoprolol B-DRUG
were O
concurrently O

administered O
with O
felodipine B-DRUG
and O
were O
well O
tolerated O
. O
Digoxin O
When O
given O
concomitantly O
with O
PLENDIL B-DRUG
the O
pharmacokinetics O
of O
digoxin B-DRUG
in O
patients O
with O
heart O
failure O
were O
not O
significantly O
altered O
. O
Anticonvulsants B-GROUP
: O
In O
a O
pharmacokinetic O
study O
, O
maximum O
plasma O
concentrations O
of O
felodipine B-DRUG
were O
considerably O
lower O
in O
epileptic O
patients O
on O
long O
- O
term O
anticonvulsant B-GROUP
therapy O
( O
eg O
, O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
or O
phenobarbital B-DRUG
) O
than O
in O
healthy O
volunteers O
. O
In O
such O
patients O
, O
the O
mean O
area O
under O
the O
felodipine B-DRUG
plasma O
concentration O
- O
time O
curve O
was O
also O
reduced O
to O
approximately O
6 O
% O
of O
that O
observed O
in O
healthy O
volunteers O
. O
Since O
a O
clinically O
significant O
interaction O
may O
be O
anticipated O
, O
alternative O
antihypertensive B-DRUG
therapy O
should O
be O
considered O
in O
these O
patients O
. O
Tacrolimus O
Felodipine B-DRUG
may O
increase O
the O
blood O
concentration O
of O
tacrolimus B-DRUG
. O
When O
given O
concomitantly O
with O
felodipine B-DRUG
, O
the O
tacrolimus B-DRUG
blood O
concentration O
should O
be O
followed O
and O
the O
tacrolimus O
dose O
may O
need O
to O
be O
adjusted O
. O
Other O
Concomitant O
Therapy O
In O
healthy O
subjects O
there O
were O
no O
clinically O
significant O
interactions O
when O
felodipine B-DRUG
was O
given O
concomitantly O
with O
indomethacin B-DRUG
or O
spironolactone B-DRUG
. O
Interaction O
with O
Food O
See O
CLINICAL O
PHARMACOLOGY O
, O
Pharmacokinetics O
and O
Metabolism O
. O

Fenfluramine B-DRUG
may O
increase O
slightly O
the O
effect O
of O
antihypertensive B-GROUP
drugs I-GROUP
, O
e O
. O
g O
. O
, O
guanethidine B-DRUG
, O
methyldopa B-DRUG
, O
reserpine B-DRUG
. O
Other O
CNS B-GROUP
depressant I-GROUP
drugs I-GROUP
should O
be O
used O
with O
caution O
in O
patients O
taking O
fenfluramine B-DRUG
, O
since O
the O
effects O
may O
be O
additive O
. O

Oral O
Anticoagulants B-GROUP
CAUTION O
SHOULD O
BE O
EXERCISED O
WHEN O
COUMARIN B-GROUP
ANTICOAGULANTS I-GROUP
ARE O
GIVEN O
IN O
CONJUNCTION O
WITH O
TRICOR B-BRAND
. O
THE O
DOSAGE O
OF O
THE O
ANTICOAGULANTS B-GROUP
SHOULD O
BE O
REDUCED O
TO O
MAINTAIN O
THE O
PROTHROMBIN O
TIME O
/ O
INR O
AT O
THE O
DESIRED O
LEVEL O
TO O
PREVENT O
BLEEDING O
COMPLICATIONS O
. O
FREQUENT O
PROTHROMBIN O
TIME O
/ O
INR O
DETERMINATIONS O
ARE O
ADVISABLE O
UNTIL O
IT O
HAS O
BEEN O
DEFINITELY O
DETERMINED O
THAT O
THE O
PROTHROMBIN O
TIME O
/ O
INR O
HAS O
STABILIZED O
. O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
: O
The O
combined O
use O
of O
TRICOR B-BRAND
and O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
should O
be O
avoided O
unless O
the O
benefit O
of O
further O
alterations O
in O
lipid O
levels O
is O
likely O
to O
outweigh O
the O
increased O
risk O
of O
this O
drug O
combination O
. O
Resins B-GROUP
: O
Since O
bile B-GROUP
acid I-GROUP
sequestrants I-GROUP
may O
bind O
other O
drugs O
given O
concurrently O
, O
patients O
should O
take O
TRICOR B-BRAND
at O
least O
1 O
hour O
before O
or O
4 O
- O
6 O
hours O
after O
a O
bile B-GROUP
acid I-GROUP
binding I-GROUP
resin I-GROUP
to O
avoid O
impeding O
its O
absorption O
. O
Cyclosporine B-DRUG
: O
Because O
cyclosporine B-DRUG
can O
produce O
nephrotoxicity O
with O
decreases O
in O
creatinine O
clearance O
and O
rises O
in O
serum O
creatinine O
, O
and O
because O
renal O
excretion O
is O
the O
primary O
elimination O
route O
of O
fibrate B-GROUP
drugs I-GROUP
including O
TRICOR B-BRAND
, O
there O
is O
a O
risk O
that O
an O
interaction O
will O
lead O
to O
deterioration O
. O
The O
benefits O
and O
risks O
of O
using O
TRICOR B-BRAND
with O
immunosuppressants B-GROUP
and O
other O
potentially O
nephrotoxic O
agents O
should O
be O
carefully O
considered O
, O
and O
the O
lowest O
effective O
dose O
employed O
. O
Drug O
- O
drug O
interactions O
In O
vitro O
studies O
using O
human O
liver O
microsomes O
indicate O
that O
fenofibrate B-DRUG
and O
fenofibric B-DRUG_N
acid I-DRUG_N
are O
not O
inhibitors O
of O
cytochrome O
( O
CYP O
) O
P450 O
isoforms O
CYP3A4 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
or O
CYP1A2 O
. O
They O
are O
weak O
inhibitors O
of O
CYP2C19 O
and O

CYP2A6 O
, O
and O
mild O
- O
to O
- O
moderate O
inhibitors O
of O
CYP2C9 O
at O
therapeutic O
concentrations O
. O
Potentiation O
of O
coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
has O
been O
observed O
with O
prolongation O
of O
the O
prothrombin O
time O
/ O
INR O
. O
Bile B-GROUP
acid I-GROUP
sequestrants I-GROUP
have O
been O
shown O
to O
bind O
other O
drugs O
given O
concurrently O
. O
Therefore O
, O
fenofibrate B-DRUG
should O
be O
taken O
at O
least O
1 O
hour O
before O
or O
4 O
- O
6 O
hours O
after O
a O
bile B-GROUP
acid I-GROUP
binding I-GROUP
resin I-GROUP
to O
avoid O
impeding O
its O
absorption O
. O
Concomitant O
administration O
of O
fenofibrate B-DRUG
( O
equivalent O
to O
145mg O
TRICOR B-BRAND
) O
with O
pravastatin B-DRUG
( O
40 O
mg O
) O
once O
daily O
for O
10 O
days O
has O
been O
shown O
to O
increase O
the O
mean O
Cmax O
and O
AUC O
values O
for O
pravastatin B-DRUG
by O
36 O
% O
( O
range O
from O
69 O
% O
decrease O
to O
321 O
% O
increase O
) O
and O
28 O
% O
( O
range O
from O
54 O
% O
decrease O
to O
128 O
% O
increase O
) O
, O
respectively O
, O
and O
for O
3 O
- O
hydroxy O
- O
iso O
- O
pravastatin O
by O
55 O
% O
( O
range O
from O
32 O
% O
decrease O
to O
314 O
% O
increase O
) O
and O
39 O
% O
( O
range O
from O
24 O
% O
decrease O
to O
261 O
% O
increase O
) O
, O
respectively O
in O
23 O
healthy O
adults O
. O
A O
single O
dose O
of O
pravastatin B-DRUG
had O
no O
clinically O
important O
effect O
on O
the O
pharmacokinetics O
of O
fenofibric B-DRUG_N
acid I-DRUG_N
. O
Concomitant O
administration O
of O
fenofibrate B-DRUG
( O
equivalent O
to O
145 O
mg O
TRICOR B-BRAND
) O
with O
atorvastatin B-DRUG
( O
20 O
mg O
) O
once O
daily O
for O
10 O
days O
resulted O
in O
approximately O
17 O
% O
decrease O
( O
range O
from O
67 O
% O
decrease O
to O
44 O
% O
increase O
) O
in O
atorvastatin B-DRUG
AUC O
values O
in O
22 O
healthy O
males O
. O
The O
atorvastatin B-DRUG
Cmax O
values O
were O
not O
significantly O
affected O
by O
fenofibrate B-DRUG
. O
The O
pharmacokinetics O
of O
fenofibric B-DRUG_N
acid I-DRUG_N
were O
not O
significantly O
affected O
by O
atorvastatin B-DRUG
. O

Drug O
Interactions O
with O
Beta B-GROUP
- I-GROUP
Blockers I-GROUP
: O
Concomitant O
use O
of O
fenoldopam B-DRUG
with O
beta B-GROUP
- I-GROUP
blockers I-GROUP
should O
be O
avoided O
. O
If O
the O
drugs O
are O
used O
together O
, O
caution O
should O
be O
exercised O
because O
unexpected O
hypotension O
could O
result O
from O
beta O
- O
blocker O
inhibition O
of O
the O
sympathetic O
reflex O
response O
to O
fenoldopam B-DRUG
. O
Drug O
Interactions O
, O
General O
: O
Although O
there O
have O
been O
no O
formal O
interaction O
studies O
, O
intravenous O
fenoldopam B-DRUG
has O
been O
administered O
safely O
with O
drugs O
such O
as O
digitalis B-GROUP
and O
sublingual O
nitroglycerin B-DRUG
. O
There O
is O
limited O
experience O
with O
concomitant O
antihypertensive B-GROUP
agents I-GROUP
such O
as O
alpha B-GROUP
- I-GROUP
blockers I-GROUP
, O
calcium B-GROUP
channel I-GROUP
- I-GROUP
blockers I-GROUP
, O
ACE B-GROUP
inhibitors I-GROUP
, O
and O
diuretics B-GROUP
( O
both O
thiazide B-GROUP
- O
like O
and O
loop O
) O
. O

The O
coadministration O
of O
aspirin B-BRAND
decreases O
the O
biologic O
half O
- O
life O
of O
fenoprofen B-DRUG
because O
of O
an O
increase O
in O
metabolic O
clearance O
that O
results O
in O
a O
greater O
amount O
of O
hydroxylated B-DRUG_N
fenoprofen I-DRUG_N
in O
the O
urine O
. O
Although O
the O
mechanism O
of O
interaction O
between O
fenoprofen B-DRUG
and O
aspirin B-BRAND
is O
not O
totally O
known O
, O
enzyme O
induction O
and O
displacement O
of O
fenoprofen B-DRUG
from O
plasma O
albumin O
binding O
sites O
are O
possibilities O
. O
Because O
Nalfon B-BRAND
has O
not O
been O
shown O
to O
produce O
any O
additional O
effect O
beyond O
that O
obtained O
with O
aspirin B-BRAND
alone O
and O
because O
aspirin B-BRAND
increases O
the O
rate O
of O
excretion O
of O
Nalfon B-BRAND
, O
the O
concomitant O
use O
of O
Nalfon B-BRAND
and O
salicylates B-GROUP
is O
not O
recommended O
. O
Chronic O
administration O
of O
phenobarbital B-DRUG
, O
a O
known O
enzyme O
inducer O
, O
may O
be O
associated O
with O
a O
decrease O
in O
the O
plasma O
half O
- O
life O
of O
fenoprofen B-DRUG
. O
When O
phenobarbital B-DRUG
is O
added O
to O
or O
withdrawn O
from O
treatment O
, O
dosage O
adjustment O
of O
Nalfon B-BRAND
may O
be O
required O
. O
In O
vitro O
studies O
have O
shown O
that O
fenoprofen B-DRUG
, O
because O
of O
its O
affinity O
for O
albumin O
, O
may O
displace O
from O
their O
binding O
sites O
other O
drugs O
that O
are O
also O
albumin O
bound O
, O
and O
this O
may O
lead O
to O
drug O
interaction O
. O
Theoretically O
, O
fenoprofen B-DRUG
could O
likewise O
be O
displaced O
. O
Patients O
receiving O
hydantoins B-GROUP
, O
sulfonamides B-GROUP
, O
or O
sulfonylureas B-GROUP
should O
be O
observed O
for O
increased O
activity O
of O
these O
drugs O
and O
, O
therefore O
, O
signs O
of O
toxicity O
from O
these O
drugs O
. O
In O
patients O
receiving O
coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
, O
the O
addition O
of O
Nalfon B-BRAND
to O
therapy O
could O
prolong O
the O
prothrombin O
time O
. O
Patients O
receiving O
both O
drugs O
should O
be O
under O
careful O
observation O
. O
Patients O
treated O
with O
Nalfon B-BRAND
may O
be O
resistant O
to O
the O
effects O
of O
loop B-GROUP
diuretics I-GROUP
. O
In O
patients O
receiving O
Nalfon B-BRAND
and O
a O
steroid B-GROUP
concomitantly O
, O
any O
reduction O
in O
steroid B-GROUP
dosage O
should O
be O
gradual O
in O
order O
to O
avoid O
the O
possible O
complications O
of O
sudden O
steroid B-GROUP
withdrawal O
. O

Agents O
Affecting O
Cytochrome O
P450 O
3A4 O
Isoenzyme O
System O
Fentanyl B-DRUG
is O
metabolized O
mainly O
via O
the O
human O
cytochrome O
P450 O
3A4 O
isoenzyme O
system O
( O
CYP3A4 O
) O
, O
therefore O
potential O
interactions O
may O
occur O
when O
DURAGESIC B-BRAND
is O
given O
concurrently O
with O
agents O
that O
affect O
CYP3A4 O
activity O
. O
Coadminstration O
with O
agents O
that O
induce O
3A4 O
activity O
may O
reduce O
the O
efficacy O
of O
DURAGESIC B-BRAND
. O
The O
concomitant O
use O
of O
transdermal O
fentanyl B-DRUG
with O
ritonavir B-DRUG
or O
other O
potent O
3A4 O
inhibitors O
such O
as O
ketoconazole B-DRUG
, O
itraconazole B-DRUG
, O
troleandomycin B-DRUG
, O
clarithromycin B-DRUG
, O
nelfinavir B-DRUG
, O
and O
nefazadone O
may O
result O
in O
an O
increase O
in O
fentanyl B-DRUG
plasma O
concentrations O
. O
The O
concomitant O
use O
of O
other O
CYP3A4 O
inhibitors O
such O
as O
diltiazem B-DRUG
and O
erythromycin B-DRUG
with O
transdermal O
fentanyl B-DRUG
may O
also O
result O
in O
an O
increase O
in O
fentanyl B-DRUG
plasma O
concentrations O
, O
which O
could O
increase O
or O
prolong O
adverse O
drug O
effects O
and O
may O
cause O
serious O
respiratory O
depression O
. O
In O
this O
situation O
, O
special O
patient O
care O
and O
observation O
are O
appropriate O
. O
Central B-GROUP
Nervous I-GROUP
System I-GROUP
Depressants I-GROUP
: O
The O
concomitant O
use O
of O
DURAGESIC B-BRAND
( O
fentanyl B-DRUG
transdermal O
system O
) O
with O
other O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressants I-GROUP
, O
including O
but O
not O
limited O
to O
other O
opioids B-GROUP
, O
sedatives B-GROUP
, O
hypnotics B-GROUP
, O
tranquilizers B-GROUP
( O
e O
. O
g O
. O
, O
benzodiazepines B-GROUP
) O
, O
general O
anesthetics B-GROUP
, O
phenothiazines B-GROUP
, O
skeletal B-GROUP
muscle I-GROUP
relaxants I-GROUP
, O
and O
alcohol B-DRUG
, O
may O
cause O
respiratory O
depression O
, O
hypotension O
, O
and O
profound O
sedation O
, O
or O
potentially O
result O
in O
coma O
or O
death O
. O
When O
such O
combined O
therapy O
is O
contemplated O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
significantly O
reduced O
. O
MAO B-GROUP
Inhibitors I-GROUP
: O
DURAGESIC B-BRAND
is O
not O
recommended O
for O
use O
in O
patients O
who O
have O
received O
MAOI B-GROUP
within O
14 O
days O
because O
severe O
and O
unpredictable O
potentiation O
by O
MAO B-GROUP
inhibitors I-GROUP
has O
been O
reported O
with O
opioid B-GROUP
analgesics I-GROUP
. O

Drug O
Interaction O
with O
Erythromycin B-DRUG
and O
Ketoconazole B-DRUG
Fexofenadine B-DRUG
has O
been O
shown O
to O
exhibit O
minimal O
( O
ca O
. O
5 O
% O
) O
metabolism O
. O
However O
, O
co O
administration O
of O
fexofenadine B-DRUG
hydrochloride I-DRUG
with O
either O
ketoconazole B-DRUG
or O
erythromycin B-DRUG
led O
to O
increased O
plasma O
concentrations O
of O
fexofenadine B-DRUG
. O
Fexofenadine B-DRUG
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
either O
erythromycin B-DRUG
or O
ketoconazole B-DRUG
. O
In O
2 O
separate O
studies O
, O
fexofenadine B-DRUG
hydrochloride I-DRUG
120 O
mg O
twice O
daily O
( O
240 O
mg O
total O
daily O
dose O
) O
was O
co O
- O
administered O
with O
either O
erythromycin B-DRUG
500 O
mg O
every O
8 O
hours O
or O
ketoconazole B-DRUG
400 O
mg O
once O
daily O
under O
steady O
- O
state O
conditions O
to O
healthy O
volunteers O
( O
n O
= O
24 O
, O
each O
study O
) O
. O
No O
differences O
in O
adverse O
events O
or O
QTc O
interval O
were O
observed O
when O
subjects O
were O
administered O
fexofenadine B-DRUG
hydrochloride I-DRUG
alone O
or O
in O
combination O
with O
either O
erythromycin B-DRUG
or O
ketoconazole B-DRUG
. O
The O
findings O
of O
these O
studies O
are O
summarized O
in O
the O
following O
table O
: O
Effects O
on O
steady O
- O
state O
fexofenadine B-DRUG
pharmacokinetics O
after O
7 O
days O
of O
co O
- O
administration O
with O
fexofenadine B-DRUG
hydrochloride I-DRUG
120 O
mg O
every O
12 O
hours O
( O
two O
times O
the O
recommended O
twice O
daily O
dose O
) O
in O
healthy O
volunteers O
( O
n O
= O
24 O
) O
Concomitant O
Drug O
cmaxSS O
( O
Peak O
plasma O
concentration O
) O
AUCss O
( O
0 O
- O
12h O
) O
( O
Extent O
of O
systemic O
exposure O
) O
Erythromycin B-DRUG
( O
500 O
mg O
every O
8 O
hrs O
) O
+ O
82 O
% O
+ O
109 O
% O
Ketoconazole B-DRUG
( O
400 O
mg O
once O
daily O
) O
+ O
135 O
% O
+ O
164 O
% O
The O
changes O
in O
plasma O
levels O
were O
within O
the O
range O
of O
plasma O
levels O
achieved O
in O
adequate O
and O
well O
- O
controlled O
clinical O
trials O
. O
The O
mechanism O
of O
these O
interactions O
has O
been O
evaluated O
in O
in O
vitro O
, O
in O
situ O
, O
and O
in O
vivo O
animal O
models O
. O
These O
studies O
indicate O
that O
ketoconazole B-DRUG
or O
erythromycin B-DRUG
co O
- O
administration O
enhances O
fexofenadine B-DRUG
gastrointestinal O
absorption O
. O
This O
observed O
increase O
in O
the O
bioavailability O
of O
fexofenadine B-DRUG
may O
be O
due O
to O
transport O
- O
related O
effects O
, O
such O
as O
p O
- O
glycoprotein O
. O
in O
vivo O
animal O
studies O
also O
suggest O
that O
in O
addition O
to O
enhancing O
absorption O
, O
ketoconazole B-DRUG
decreases O
fexofenadine B-DRUG
gastrointestinal O
secretion O
, O
while O
erythromycin B-DRUG
may O
also O
decrease O

biliary O
excretion O
. O
Drug O
Interactions O
with O
Antacids B-GROUP
Administration O
of O
120 O
mg O
of O
fexofenadine B-DRUG
hydrochloride I-DRUG
( O
2 O
x O
60 O
mg O
capsule O
) O
within O
15 O
minutes O
of O
an O
aluminum B-DRUG
and O
magnesium B-DRUG
containing O
antacid B-GROUP
( O
Maalox B-BRAND
) O
decreased O
fexofenadine B-DRUG
AUC O
by O
41 O
% O
and O
cmax O
by O
43 O
% O
. O
ALLEGRA B-BRAND
should O
not O
be O
taken O
closely O
in O
time O
with O
aluminum B-DRUG
and O
magnesium B-DRUG
containing O
antacids B-GROUP
. O
Interactions O
with O
Fruit O
Juices O
Fruit O
juices O
such O
as O
grapefruit O
, O
orange O
and O
apple O
may O
reduce O
the O
bioavailability O
and O
exposure O
of O
fexofenadine B-DRUG
. O
This O
is O
based O
on O
the O
results O
from O
3 O
clinical O
studies O
using O
histamine B-DRUG
induced O
skin O
wheals O
and O
flares O
coupled O
with O
population O
pharmacokinetic O
analysis O
. O
The O
size O
of O
wheal O
and O
flare O
were O
significantly O
larger O
when O
fexofenadine B-DRUG
hydrochloride I-DRUG
was O
administered O
with O
either O
grapefruit O
or O
orange O
juices O
compared O
to O
water O
. O
Based O
on O
the O
literature O
reports O
, O
the O
same O
effects O
may O
be O
extrapolated O
to O
other O
fruit O
juices O
such O
as O
apple O
juice O
. O
The O
clinical O
significance O
of O
these O
observations O
is O
unknown O
. O
In O
addition O
, O
based O
on O
the O
population O
pharmacokinetics O
analysis O
of O
the O
combined O
data O
from O
grapefruit O
and O
orange O
juices O
studies O
with O
the O
data O
from O
a O
bioequivalence O
study O
, O
the O
bioavailability O
of O
fexofenadine B-DRUG
was O
reduced O
by O
36 O
% O
. O
Therefore O
, O
to O
maximize O
the O
effects O
of O
fexofenadine B-DRUG
, O
it O
is O
recommended O
that O
ALLEGRA B-BRAND
should O
be O
taken O
with O
water O
. O

Drug O
interactions O
between O
NEUPOGEN B-BRAND
and O
other O
drugs O
have O
not O
been O
fully O
evaluated O
. O
Drugs O
which O
may O
potentiate O
the O
release O
of O
neutrophils O
, O
such O
as O
lithium B-DRUG
, O
should O
be O
used O
with O
caution O
. O

No O
drug O
interactions O
of O
clinical O
importance O
have O
been O
identified O
. O
Finasteride B-DRUG
does O
not O
appear O
to O
affect O
the O
cytochrome O
P450 O
- O
linked O
drug O
- O
metabolizing O
enzyme O
system O
. O
Compounds O
that O
have O
been O
tested O
in O
man O
include O
antipyrine B-DRUG
, O
digoxin B-DRUG
, O
propranolol B-DRUG
, O
theophylline B-DRUG
, O
and O
warfarin B-DRUG
and O
no O
clinically O
meaningful O
interactions O
were O
found O
. O
Other O
concomitant O
therapy O
Although O
specific O
interaction O
studies O
were O
not O
performed O
, O
finasteride B-DRUG
doses O
of O
1 O
mg O
or O
more O
were O
concomitantly O
used O
in O
clinical O
studies O
with O
acetaminophen B-DRUG
, O
acetylsalicylic B-DRUG
acid I-DRUG
, O
a O
- O
blockers O
, O
analgesics B-GROUP
, O
angiotensin B-GROUP
- I-GROUP
converting I-GROUP
enzyme I-GROUP
( I-GROUP
ACE I-GROUP
) I-GROUP
inhibitors I-GROUP
, O
anticonvulsants B-GROUP
, O
benzodiazepines B-GROUP
, O
beta B-GROUP
blockers I-GROUP
, O
calcium B-GROUP
- I-GROUP
channel I-GROUP
blockers I-GROUP
, O
cardiac O
nitrates B-GROUP
, O
diuretics B-GROUP
, O
H2 B-GROUP
antagonists I-GROUP
, O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
, O
prostaglandin B-GROUP
synthetase I-GROUP
inhibitors I-GROUP
( O
also O
referred O
to O
as O
NSAIDs B-GROUP
) O
, O
and O
quinolone B-GROUP
anti I-GROUP
- I-GROUP
infectives I-GROUP
without O
evidence O
of O
clinically O
significant O
adverse O
interactions O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Finasteride B-DRUG
had O
no O
effect O
on O
circulating O
levels O
of O
cortisol O
, O
thyroid O
- O
stimulating O
hormone O
, O
or O
thyroxine O
, O
nor O
did O
it O
affect O
the O
plasma O
lipid O
profile O
( O
e O
. O
g O
. O
, O
total O
cholesterol O
, O
low O
- O
density O
lipoproteins O
, O
high O
- O
density O
lipoproteins O
and O
triglycerides O
) O
or O
bone O
mineral O
density O
. O
In O
studies O
with O
finasteride B-DRUG
, O
no O
clinically O
meaningful O
changes O
in O
luteinizing O
hormone O
( O
LH O
) O
, O
follicle O
- O
stimulating O
hormone O
( O
FSH O
) O
or O
prolactin O
were O
detected O
. O
In O
healthy O
volunteers O
, O
treatment O
with O
finasteride B-DRUG
did O
not O
alter O
the O
response O
of O
LH O
and O
FSH O
to O
gonadotropin O
- O
releasing O
hormone O
indicating O
that O
the O
hypothalamic O
- O
pituitary O
- O
testicular O
axis O
was O
not O
affected O
. O
In O
clinical O
studies O
with O
PROPECIA B-BRAND
( O
finasteride B-DRUG
, O
1 O
mg O
) O
in O
men O
18 O
- O
41 O
years O
of O
age O
, O
the O
mean O
value O
of O
serum O
prostate O
- O
specific O
antigen O
( O
PSA O
) O
decreased O
from O
0 O
. O
7 O
ng O
/ O
mL O
at O
baseline O
to O
0 O
. O
5 O
ng O
/ O
mL O
at O
Month O
12 O
. O
Further O
, O
in O
clinical O
studies O
with O
PROSCAR B-BRAND
( O
finasteride B-DRUG
, O
5 O
mg O
) O
when O
used O
in O
older O
men O
who O
have O
benign O
prostatic O
hyperplasia O
( O

BPH O
) O
, O
PSA O
levels O
are O
decreased O
by O
approximately O
50 O
% O
. O
These O
findings O
should O
be O
taken O
into O
account O
for O
proper O
interpretation O
of O
serum O
PSA O
when O
evaluating O
men O
treated O
with O
finasteride B-DRUG
. O

Drug O
Interactions O
. O
TAMBOCOR B-BRAND
has O
been O
administered O
to O
patients O
receiving O
digitalis B-GROUP
preparations I-GROUP
or O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
without O
adverse O
effects O
. O
During O
administration O
of O
multiple O
oral O
doses O
of O
TAMBOCOR B-BRAND
to O
healthy O
subjects O
stabilized O
on O
a O
maintenance O
dose O
of O
digoxin B-DRUG
, O
a O
13 O
% O
- O
19 O
% O
increase O
in O
plasma O
digoxin B-DRUG
levels O
occurred O
at O
six O
hours O
postdose O
. O
In O
a O
study O
involving O
healthy O
subjects O
receiving O
TAMBOCOR B-BRAND
and O
propranolol B-DRUG
concurrently O
, O
plasma O
flecainide B-DRUG
levels O
were O
increased O
about O
20 O
% O
and O
propranolol B-DRUG
levels O
were O
increased O
about O
30 O
% O
compared O
to O
control O
values O
. O
In O
this O
formal O
interaction O
study O
, O
TAMBOCOR B-BRAND
and O
propranolol B-DRUG
were O
each O
found O
to O
have O
negative O
inotropic O
effects O
; O
when O
the O
drugs O
were O
administered O
together O
, O
the O
effects O
were O
additive O
. O
The O
effects O
of O
concomitant O
administration O
of O
TAMBOCOR B-BRAND
and O
propranolol B-DRUG
on O
the O
PR O
interval O
were O
less O
than O
additive O
. O
In O
TAMBOCOR B-BRAND
clinical O
trials O
, O
patients O
who O
were O
receiving O
beta B-GROUP
blockers I-GROUP
concurrently O
did O
not O
experience O
an O
increased O
incidence O
of O
side O
effects O
. O
Nevertheless O
, O
the O
possibility O
of O
additive O
negative O
inotropic O
effects O
of O
beta B-GROUP
blockers I-GROUP
and O
flecainide B-DRUG
should O
be O
recognized O
. O
Flecainide B-DRUG
is O
not O
extensively O
bound O
to O
plasma O
proteins O
. O
In O
vitro O
studies O
with O
several O
drugs O
which O
may O
be O
administered O
concomitantly O
showed O
that O
the O
extent O
of O
flecainide B-DRUG
binding O
to O
human O
plasma O
proteins O
is O
either O
unchanged O
or O
only O
slightly O
less O
. O
Consequently O
, O
interactions O
with O
other O
drugs O
which O
are O
highly O
protein O
bound O
( O
e O
. O
g O
. O
, O
anticoagulants B-GROUP
) O
would O
not O
be O
expected O
. O
TAMBOCOR B-BRAND
has O
been O
used O
in O
a O
large O
number O
of O
patients O
receiving O
diuretics B-GROUP
without O
apparent O
interaction O
. O
Limited O
data O
in O
patients O
receiving O
known O
enzyme O
inducers O
( O
phenytoin B-DRUG
, O
phenobarbital B-DRUG
, O
carbamazepine B-DRUG
) O
indicate O
only O
a O
30 O
% O
increase O
in O
the O
rate O
of O
flecainide B-DRUG
elimination O
. O
In O
healthy O
subjects O
receiving O
cimetidine B-DRUG
( O
1 O
gm O
daily O
) O
for O
one O
week O
, O
plasma O
flecainide B-DRUG
levels O
increased O
by O
about O
30 O
% O
and O
half O
- O
life O
increased O
by O
about O
10 O
% O
. O
When O
amiodarone B-DRUG
is O
added O
to O
flecainide B-DRUG
therapy O
, O
plasma O
flecainide B-DRUG
levels O
may O
increase O
two O
- O
fold O
or O
more O
in O
some O
patients O
, O
if O
flecainide B-DRUG
dosage O
is O
not O
reduced O
. O
Drugs O
that O
inhibit O
cytochrome O
P450IID6 O
, O
such O
as O
quinidine B-DRUG
, O
might O
increase O
the O
plasma O
concentrations O
of O
flecainide B-DRUG
in O
patients O
that O
are O
on O
chronic O

flecainide B-DRUG
therapy O
; O
especially O
if O
these O
patients O
are O
extensive O
metabolizers O
. O
There O
has O
been O
little O
experience O
with O
the O
coadministration O
of O
TAMBOCOR B-BRAND
and O
either O
disopyramide B-DRUG
or O
verapamil B-DRUG
. O
Because O
both O
of O
these O
drugs O
have O
negative O
inotropic O
properties O
and O
the O
effects O
of O
coadministration O
with O
TAMBOCOR B-BRAND
are O
unknown O
, O
neither O
disopyramide B-DRUG
nor O
verapamil B-DRUG
should O
be O
administered O
concurrently O
with O
TAMBOCOR B-BRAND
unless O
, O
in O
the O
judgment O
of O
the O
physician O
, O
the O
benefits O
of O
this O
combination O
outweigh O
the O
risks O
. O
There O
has O
been O
too O
little O
experience O
with O
the O
coadministration O
of O
TAMBOCOR B-BRAND
with O
nifedipine B-DRUG
or O
diltiazem B-DRUG
to O
recommend O
concomitant O
use O
. O

Combination O
Therapy O
: O
Any O
form O
of O
therapy O
which O
adds O
to O
the O
stress O
of O
the O
patient O
, O
interferes O
with O
nutrition O
or O
depresses O
bone O
marrow O
function O
will O
increase O
the O
toxicity O
of O
Floxuridine B-DRUG
. O

Cytosine B-DRUG
arabinoside I-DRUG
, O
a O
cytostatic B-GROUP
agent I-GROUP
, O
has O
been O
reported O
to O
inactivate O
the O
antifungal O
activity O
of O
flucytosine B-DRUG
by O
competitive O
inhibition O
. O
Drugs O
which O
impair O
glomerular O
filtration O
may O
prolong O
the O
biological O
half O
- O
life O
of O
flucytosine B-DRUG
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
: O
Measurement O
of O
serum O
creatinine O
levels O
should O
be O
determined O
by O
the O
Jaffe O
reaction O
, O
since O
Ancobon B-BRAND
does O
not O
interfere O
with O
the O
determination O
of O
creatinine O
values O
by O
this O
method O
. O
Most O
automated O
equipment O
for O
measurement O
of O
creatinine O
makes O
use O
of O
the O
Jaffe O
reaction O
. O

The O
use O
of O
FLUDARA B-BRAND
FOR O
INJECTION O
in O
combination O
with O
pentostatin B-DRUG
is O
not O
recommended O
due O
to O
the O
risk O
of O
severe O
pulmonary O
toxicity O
. O

When O
administered O
concurrently O
, O
the O
following O
drugs O
may O
interact O
with O
adrenal B-GROUP
corticosteroids I-GROUP
. O
Amphotericin B-DRUG
B I-DRUG
or O
potassium B-GROUP
- I-GROUP
depleting I-GROUP
diuretics I-GROUP
( O
benzothiadiazines B-GROUP
and O
related O
drugs O
, O
ethacrynic B-DRUG
acid I-DRUG
and O
furosemide B-DRUG
) O
enhanced O
hypokalemia O
. O
Check O
serum O
potassium O
levels O
at O
frequent O
intervals O
; O
use O
potassium B-DRUG
supplements O
if O
necessary O
. O
Digitalis B-GROUP
glycosides I-GROUP
enhanced O
possibility O
of O
arrhythmias O
or O
digitalis B-GROUP
toxicity O
associated O
with O
hypokalemia O
. O
Monitor O
serum O
potassium O
levels O
; O
use O
potassium B-DRUG
supplements O
if O
necessary O
. O
Oral O
anticoagulants B-GROUP
decreased O
prothrombin O
time O
response O
. O
Monitor O
prothrombin O
levels O
and O
adjust O
anticoagulant B-GROUP
dosage O
accordingly O
. O
Antidiabetic B-GROUP
drugs I-GROUP
( O
oral O
agents O
and O
insulin B-DRUG
) O
diminished O
antidiabetic O
effect O
. O
Monitor O
for O
symptoms O
of O
hyperglycemia O
; O
adjust O
dosage O
of O
antidiabetic B-GROUP
drug I-GROUP
upward O
if O
necessary O
. O
Aspirin B-BRAND
increased O
ulcerogenic O
effect O
; O
decreased O
pharmacologic O
effect O
of O
aspirin B-BRAND
. O
Rarely O
salicylate B-GROUP
toxicity O
may O
occur O
in O
patients O
who O
discontinue O
steroids B-GROUP
after O
concurrent O
high O
- O
dose O
aspirin B-BRAND
therapy O
. O
Monitor O
salicylate B-GROUP
levels O
or O
the O
therapeutic O
effect O
for O
which O
aspirin B-BRAND
is O
given O
; O
adjust O
salicylate B-GROUP
dosage O
accordingly O
if O
effect O
is O
altered O
. O
Barbiturates B-GROUP
, O
phenytoin B-DRUG
, O
or O
rifampin B-DRUG
increased O
metabolic O
clearance O
of O
fludrocortisone B-DRUG
acetate I-DRUG
because O
of O
the O
induction O
of O
hepatic O
enzymes O
. O
Observe O
the O
patient O
for O
possible O
diminished O
effect O
of O
steroid B-GROUP
and O
increase O
the O
steroid B-GROUP
dosage O
accordingly O
. O
Anabolic B-GROUP
steroids I-GROUP
( O
particularly O
C O
- O
17 O
alkylated O
androgens B-GROUP
such O
as O
oxymetholone B-DRUG
, O
methandrostenolone B-DRUG
, O
norethandrolone B-DRUG
, O
and O
similar O
compounds O
) O
enhanced O
tendency O
toward O
edema O
. O
Use O
caution O
when O
giving O
these O
drugs O
together O
, O
especially O
in O
patients O
with O
hepatic O
or O
cardiac O
disease O
. O
Vaccines B-GROUP
neurological O
complications O
and O
lack O
of O
antibody O
response O
. O
Estrogen B-GROUP
increased O
levels O
of O
corticosteroid O
- O
binding O
globulin O
, O
thereby O
increasing O
the O
bound O
( O
inactive O
) O
fraction O
; O
this O
effect O
is O
at O
least O
balanced O
by O
decreased O
metabolism O
of O
corticosteroids B-GROUP
. O
When O
estrogen B-GROUP
therapy O
is O
initiated O
, O
a O
reduction O
in O
corticosteroid B-GROUP
dosage O
may O
be O
required O
, O
and O
increased O
amounts O
may O
be O
required O
when O
estrogen B-GROUP
is O
terminated O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Corticosteroids B-GROUP
may O
affect O
the O
nitrobluetetrazolium O
test O

for O
bacterial O
infection O
and O
produce O
false O
- O
negative O
results O
. O

Interaction O
with O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressants I-GROUP
other O
than O
benzodiazepines B-GROUP
has O
not O
been O
specifically O
studied O
; O
however O
, O
no O
deleterious O
interactions O
were O
seen O
when O
ROMAZICON B-BRAND
was O
administered O
after O
narcotics B-GROUP
, O
inhalational O
anesthetics B-GROUP
, O
muscle B-GROUP
relaxants I-GROUP
and O
muscle O
relaxant O
antagonists O
administered O
in O
conjunction O
with O
sedation O
or O
anesthesia O
. O
Particular O
caution O
is O
necessary O
when O
using O
ROMAZICON B-BRAND
in O
cases O
of O
mixed O
drug O
overdosage O
since O
the O
toxic O
effects O
( O
such O
as O
convulsions O
and O
cardiac O
dysrhythmias O
) O
of O
other O
drugs O
taken O
in O
overdose O
( O
especially O
cyclic B-GROUP
antidepressants I-GROUP
) O
may O
emerge O
with O
the O
reversal O
of O
the O
benzodiazepine B-GROUP
effect O
by O
flumazenil B-DRUG
. O
The O
use O
of O
ROMAZICON B-BRAND
is O
not O
recommended O
in O
epileptic O
patients O
who O
have O
been O
receiving O
benzodiazepine O
treatment O
for O
a O
prolonged O
period O
. O
Although O
ROMAZICON B-BRAND
exerts O
a O
slight O
intrinsic O
anticonvulsant O
effect O
, O
its O
abrupt O
suppression O
of O
the O
protective O
effect O
of O
a O
benzodiazepine B-GROUP
agonist O
can O
give O
rise O
to O
convulsions O
in O
epileptic O
patients O
. O
ROMAZICON B-BRAND
blocks O
the O
central O
effects O
of O
benzodiazepines B-GROUP
by O
competitive O
interaction O
at O
the O
receptor O
level O
. O
The O
effects O
of O
nonbenzodiazepine O
agonists O
at O
benzodiazepine O
receptors O
, O
such O
as O
zopiclone B-DRUG
, O
triazolopyridazines O
and O
others O
, O
are O
also O
blocked O
by O
ROMAZICON B-BRAND
. O
The O
pharmacokinetics O
of O
benzodiazepines B-GROUP
are O
unaltered O
in O
the O
presence O
of O
flumazenil B-DRUG
and O
vice O
versa O
. O
There O
is O
no O
pharmacokinetic O
interaction O
between O
ethanol B-DRUG
and O
flumazenil B-DRUG
. O
Use O
in O
Ambulatory O
Patients O
The O
effects O
of O
ROMAZICON B-BRAND
may O
wear O
off O
before O
a O
long B-GROUP
- I-GROUP
acting I-GROUP
benzodiazepine I-GROUP
is O
completely O
cleared O
from O
the O
body O
. O
In O
general O
, O
if O
a O
patient O
shows O
no O
signs O
of O
sedation O
within O
2 O
hours O
after O
a O
1 O
- O
mg O
dose O
of O
flumazenil B-DRUG
, O
serious O
resedation O
at O
a O
later O
time O
is O
unlikely O
. O
An O
adequate O
period O
of O
observation O
must O
be O
provided O
for O
any O
patient O
in O
whom O
either O
long B-GROUP
- I-GROUP
acting I-GROUP
benzodiazepines I-GROUP
( O
such O
as O
diazepam B-DRUG
) O
or O
large O
doses O
of O
short B-GROUP
- I-GROUP
acting I-GROUP
benzodiazepines I-GROUP
( O
such O
as O
10 O
mg O
of O
midazolam B-DRUG
) O
have O
been O
used O
. O
Because O
of O
the O
increased O
risk O
of O
adverse O
reactions O
in O
patients O
who O
have O
been O
taking O
benzodiazepines B-GROUP
on O
a O
regular O
basis O
, O
it O
is O
particularly O
important O

that O
physicians O
query O
patients O
or O
their O
guardians O
carefully O
about O
benzodiazepine B-GROUP
, O
alcohol B-DRUG
and O
sedative B-GROUP
use O
as O
part O
of O
the O
history O
prior O
to O
any O
procedure O
in O
which O
the O
use O
of O
ROMAZICON B-BRAND
is O
planned O
. O

No O
information O
available O
. O

Do O
not O
take O
this O
medicine O
with O
thioridizine O
, O
or O
within O
5 O
weeks O
of O
taking O
fluoxetine B-DRUG
. O
Talk O
to O
your O
doctor O
if O
you O
are O
taking O
certain O
antibiotics B-GROUP
such O
as O
erythromycin B-DRUG
, O
clarithromycin B-DRUG
or O
azithromycin B-DRUG
. O
This O
medicine O
should O
not O
be O
taken O
with O
MAO B-GROUP
inhibitors I-GROUP
. O
Caution O
should O
be O
exercised O
when O
taking O
this O
medicine O
certain O
antibiotics B-GROUP
, O
such O
as O
erythromycin B-DRUG
, O
clarithromycin B-DRUG
, O
or O
azithromycin B-DRUG
. O
This O
medicine O
should O
not O
be O
taken O
with O
MAO B-GROUP
inhibitors I-GROUP
. O
If O
you O
think O
you O
are O
taking O
an O
MAO B-GROUP
inhibitor I-GROUP
talk O
to O
your O
doctor O
or O
pharmacist O
. O
Do O
not O
take O
this O
medicine O
with O
St O
. O
Johns O
Wort O
because O
of O
the O
additive O
effects O
of O
sertonin O
. O
This O
medication O
should O
not O
be O
taken O
with O
MAO B-GROUP
inhibitors I-GROUP
. O
Your O
doctor O
or O
pharmacist O
can O
give O
you O
more O
information O
on O
MAO B-GROUP
inhibitors I-GROUP
. O
Wait O
5 O
weeks O
after O
stopping O
escitalopram B-DRUG
before O
starting O
a O
non B-GROUP
- I-GROUP
selective I-GROUP
MAO I-GROUP
inhibitor I-GROUP
. O
Wait O
2 O
weeks O
after O
stopping O
an O
MAO B-GROUP
inhibitor I-GROUP
before O
starting O
escitalopram B-DRUG
. O
If O
you O
are O
taking O
medications O
for O
migraines O
such O
as O
Imitrex B-BRAND
, O
talk O
to O
your O
doctor O
before O
starting O
this O
medicine O
. O
If O
you O
are O
taking O
a O
tricyclic B-GROUP
antidepressant I-GROUP
, O
talk O
to O
your O
doctor O
before O
taking O
this O
medicine O
. O
St O
. O
John O
s O
Wort O
should O
be O
avoided O
while O
taking O
this O
medicine O
due O
to O
the O
additive O
effects O
of O
serotonin O
. O
Tell O
your O
doctor O
if O
you O
are O
taking O
any O
of O
the O
following O
drugs O
: O
blood B-GROUP
thinners I-GROUP
( O
Coumadin B-BRAND
) O
other O
antidepressants B-GROUP
metoprolol B-DRUG
antihistamines B-GROUP
carbamazepine B-DRUG
( O
Tegretol B-BRAND
) O
cimetidine B-DRUG
( O
Tagamet B-BRAND
) O
estrogens B-GROUP
fluoxetine B-DRUG
( O
Prozac B-BRAND
) O
intraconazole O
( O
Sporanox B-BRAND
) O
ketoconazole B-DRUG
( O
Nizoral B-BRAND
) O
levodopa B-DRUG
lithium B-DRUG
muscle B-GROUP
relaxants I-GROUP
birth O
control O
pills O
sleeping O
pills O
thyroid O
medications O

Androgens B-GROUP
may O
increase O
sensitivity O
to O
oral O
anticoagulahts O
. O
Dosage O
of O
the O
anticoagulant B-GROUP
may O
require O
reduction O
in O
order O
to O
maintain O
satisfactory O
therapeutic O
hypoprothrombinemia O
. O
Concurrent O
administration O
of O
oxyphenbutazone B-DRUG
and O
androgens B-GROUP
may O
result O
in O
elevated O
serum O
levels O
of O
oxyphenbutazone B-DRUG
. O
In O
diabetic O
patients O
, O
the O
metabolic O
effects O
of O
androgens B-GROUP
may O
decrease O
blood O
glucose O
and O
therefore O
, O
insulin B-DRUG
requirements O
. O

Drug O
Interactions O
: O
Flupenthixol B-DRUG
may O
interact O
with O
some O
drugs O
, O
like O
Monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
( O
MAOI B-GROUP
) O
: O
MAOI B-GROUP
could O
theoretically O
affect O
flupenthixol B-DRUG
pharmacodynamics O
- O
Arecoline B-DRUG_N
- O
Eproxindine O
- O
Ethanol B-DRUG
: O
Flupenthixol B-DRUG
and O
Ethanol B-DRUG
cause O
additive O
CNS O
depression O
- O
Tricyclic B-GROUP
antidepressants I-GROUP
: O
Flupenthixol B-DRUG
increases O
the O
effect O
of O
Tricyclic B-GROUP
antidepressants I-GROUP

Antacids B-GROUP
: O
Administration O
of O
flurbiprofen B-DRUG
to O
volunteers O
under O
fasting O
conditions O
, O
or O
with O
antacid B-GROUP
suspension O
yielded O
similar O
serum O
flurbiprofen B-DRUG
time O
profiles O
in O
young O
subjects O
( O
n O
= O
12 O
) O
. O
In O
geriatric O
subjects O
( O
n O
= O
7 O
) O
there O
was O
a O
reduction O
in O
the O
rate O
but O
not O
the O
extent O
of O
flurbiprofen B-DRUG
absorption O
. O
Anticoagulants B-GROUP
: O
Flurbiprofen B-DRUG
like O
other O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
, O
has O
been O
shown O
to O
affect O
bleeding O
parameters O
in O
patients O
receiving O
anti B-GROUP
- I-GROUP
coagulants I-GROUP
, O
and O
serious O
clinical O
bleeding O
has O
been O
reported O
. O
The O
physician O
should O
be O
cautious O
when O
administering O
flurbiprofen B-DRUG
to O
patients O
taking O
anticoagulants B-GROUP
. O
Aspirin B-BRAND
: O
Concurrent O
administration O
of O
aspirin B-BRAND
and O
flurbiprofen B-DRUG
resulted O
in O
50 O
% O
lower O
serum O
flurbiprofen B-DRUG
concentrations O
. O
This O
effect O
of O
aspirin B-BRAND
( O
which O
also O
lowers O
serum O
concentrations O
of O
other O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
given O
with O
it O
) O
has O
been O
demonstrated O
in O
patients O
with O
rheumatoid O
arthritis O
( O
n O
= O
15 O
) O
as O
well O
as O
normal O
volunteers O
( O
n O
= O
16 O
) O
. O
Concurrent O
use O
of O
flurbiprofen B-DRUG
and O
aspirin B-BRAND
is O
therefore O
not O
recommended O
. O
Beta B-GROUP
- I-GROUP
adrenergic I-GROUP
Blocking I-GROUP
Agents I-GROUP
: O
The O
effect O
of O
flurbiprofen B-DRUG
on O
blood O
pressure O
response O
to O
propranolol B-DRUG
and O
atenolol B-DRUG
was O
evaluated O
in O
men O
with O
mild O
uncomplicated O
hypertension O
( O
n O
= O
10 O
) O
. O
Flurbiprofen B-DRUG
pretreatment O
attenuated O
the O
hypotensive O
effect O
of O
a O
single O
dose O
of O
propranolol B-DRUG
but O
not O
atenolol B-DRUG
. O
Flurbiprofen B-DRUG
did O
not O
appear O
to O
affect O
the O
beta O
- O
blocker O
- O
mediated O
reduction O
in O
heart O
rate O
. O
Flurbiprofen B-DRUG
did O
not O
affect O
the O
pharmacokinetic O
profile O
of O
either O
drug O
, O
and O
the O
mechanism O
under O
lying O
the O
interference O
with O
propranolols B-DRUG
hypotensive O
effect O
is O
unknown O
. O
Patients O
taking O
both O
flurbiprofen B-DRUG
and O
a O
beta B-GROUP
- I-GROUP
blocker I-GROUP
should O
be O
monitored O
to O
ensure O
that O
a O
satisfactory O
hypotensive O
effect O
is O
achieved O
. O
Cimetidine B-DRUG
, O
Ranitidine B-DRUG
: O
In O
normal O
volunteers O
( O
n O
= O
9 O
) O
, O
pretreatment O
with O
cimetidine B-DRUG
or O
ranitidine B-DRUG
did O
not O
affect O
flurbiprofen B-DRUG
pharmacokinetics O
except O
that O
a O
small O
( O
13 O
% O
) O
but O
statistically O
significant O
increase O
in O
the O
area O
under O
the O
serum O
concentration O
curve O
of O
flurbiprofen B-DRUG
resulted O
with O
cimetidine B-DRUG
. O

Digoxin B-DRUG
: O
Studies O
of O
concomitant O
administration O
of O
flurbiprofen B-DRUG
and O
digoxin B-DRUG
to O
healthy O
men O
( O
n O
= O
14 O
) O
did O
not O
show O
a O
change O
in O
the O
steady O
state O
serum O
levels O
of O
either O
drug O
. O
Diuretics B-GROUP
: O
Studies O
in O
normal O
volunteers O
have O
shown O
that O
flurbiprofen B-DRUG
like O
other O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
, O
can O
interfere O
with O
the O
effects O
of O
furosemide B-DRUG
. O
Although O
results O
have O
varied O
from O
study O
to O
study O
, O
effects O
have O
been O
shown O
on O
furosemide B-DRUG
- O
stimulated O
diuresis O
, O
natriuresis O
, O
and O
kaliuresis O
. O
Other O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
that O
inhibit O
prostaglandin O
synthesis O
have O
been O
shown O
to O
interfere O
with O
thiazide B-GROUP
diuretics I-GROUP
in O
some O
studies O
and O
with O
potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
. O
Patients O
receiving O
flurbiprofen B-DRUG
and O
furosemide B-DRUG
or O
other O
diuretics B-GROUP
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
is O
obtained O
. O
Oral O
Hypoglycemic B-GROUP
Agents I-GROUP
: O
In O
one O
study O
, O
flurbiprofen B-DRUG
was O
given O
to O
adult O
diabetics O
who O
were O
already O
receiving O
glyburide B-DRUG
( O
n O
= O
4 O
) O
, O
metformin B-DRUG
( O
n O
= O
2 O
) O
chlorpropamide B-DRUG
with O
phenformin B-DRUG
( O
n O
= O
3 O
) O
or O
glyburide B-DRUG
with O
phenformin B-DRUG
( O
n O
= O
6 O
) O
. O
Although O
there O
was O
a O
slight O
reduction O
in O
blood O
sugar O
concentrations O
during O
concomitant O
administration O
of O
flurbiprofen B-DRUG
and O
hypoglycemic B-GROUP
agents I-GROUP
, O
there O
were O
no O
signs O
or O
symptoms O
of O
hypoglycemia O
. O

Increases O
in O
prothrombin O
time O
have O
been O
noted O
in O
patients O
receiving O
long O
- O
term O
warfarin B-DRUG
therapy O
after O
flutamide B-DRUG
was O
initiated O
. O
Therefore O
, O
close O
monitoring O
of O
prothrombin O
time O
is O
recommended O
and O
adjustment O
of O
the O
anticoagulant B-GROUP
dose O
may O
be O
necessary O
when O
EULEXIN B-BRAND
Capsules O
are O
administered O
concomitantly O
with O
warfarin B-DRUG
. O

Potential O
for O
Interaction O
with O
Monoamine B-GROUP
Oxidase I-GROUP
Inhibitors I-GROUP
In O
patients O
receiving O
another O
serotonin B-GROUP
reuptake I-GROUP
inhibitor I-GROUP
drug I-GROUP
in O
combination O
with O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
( O
MAOI B-GROUP
) O
, O
there O
have O
been O
reports O
of O
serious O
, O
sometimes O
fatal O
, O
reactions O
including O
hyperthermia O
, O
rigidity O
, O
myoclonus O
, O
autonomic O
instability O
with O
possible O
rapid O
fluctuations O
of O
vital O
signs O
, O
and O
mental O
status O
changes O
that O
include O
extreme O
agitation O
progressing O
to O
delirium O
and O
coma O
. O
These O
reactions O
have O
also O
been O
reported O
in O
patients O
who O
have O
discontinued O
that O
drug O
and O
have O
been O
started O
on O
a O
MAOI B-GROUP
. O
Some O
cases O
presented O
with O
features O
resembling O
neuroleptic O
malignant O
syndrome O
. O
Therefore O
, O
it O
is O
recommended O
that O
Fluvoxamine B-DRUG
Tablets O
not O
be O
used O
in O
combination O
with O
MAOIs B-GROUP
, O
or O
within O
14 O
days O
of O
discontinuing O
treatment O
with O
a O
MAOI B-GROUP
. O
After O
stopping O
Fluvoxamine B-DRUG
Tablets O
, O
at O
least O
2 O
weeks O
should O
be O
allowed O
before O
starting O
a O
MAOI B-GROUP
. O
Potential O
Terfenadine B-DRUG
, O
Astemizole B-DRUG
, O
and O
Cisapride B-DRUG
Interactions O
Terfenadine B-DRUG
, O
astemizole B-DRUG
and O
cisapride B-DRUG
are O
all O
metabolized O
by O
the O
cytochrome O
P450IIIA4 O
isozyme O
, O
and O
it O
has O
been O
demonstrated O
that O
ketoconazole B-DRUG
, O
a O
potent O
inhibitor O
of O
IIIA4 O
, O
blocks O
the O
metabolism O
of O
these O
drugs O
, O
resulting O
in O
increased O
plasma O
concentrations O
of O
parent O
drug O
. O
Increased O
plasma O
concentrations O
of O
terfenadine B-DRUG
, O
astemizole B-DRUG
, O
and O
cisapride B-DRUG
cause O
QT O
prolongation O
and O
have O
been O
associated O
with O
torsades O
de O
pointes O
- O
type O
ventricular O
tachycardia O
, O
sometimes O
fatal O
. O
As O
noted O
below O
, O
a O
sub O
- O
for O
fluvoxamine B-DRUG
in O
combination O
with O
alprazolam B-DRUG
, O
a O
drug O
that O
is O
known O
to O
be O
metabolized O
by O
the O
IIIA4 O
isozyme O
. O
Although O
it O
has O
not O
been O
definitively O
demonstrated O
that O
fluvoxamine B-DRUG
is O
a O
potent O
IIIA4 O
inhibitor O
, O
it O
is O
likely O
to O
be O
, O
given O
the O
substantial O
interaction O
of O
fluvoxamine B-DRUG
with O
alprazolam B-DRUG
. O
Consequently O
, O
it O
is O
recommended O
that O
fluvoxamine B-DRUG
not O
be O
used O
in O
combination O
with O
either O
terbinafine B-DRUG
, O
astemizole B-DRUG
, O
or O
cisapride B-DRUG
. O
Other O
Potentially O
Important O
Drug O
Interactions O
: O
Benzodiazepines B-GROUP
: O
Benzodiazepines B-GROUP
metabolized O
by O
hepatic O
oxidation O
( O
e O
. O
g O
. O
, O
alprazolam B-DRUG
, O
midazolam B-DRUG
, O

triazolam B-DRUG
elc O
. O
) O
should O
be O
used O
with O
caution O
because O
the O
clearance O
of O
these O
drugs O
is O
likely O
to O
be O
reduced O
by O
fluvoxamine B-DRUG
. O
The O
clearance O
of O
benzodiazepines B-GROUP
metabolized O
by O
glucuronidation O
( O
e O
. O
g O
. O
, O
lorazepam B-DRUG
, O
oxazepam B-DRUG
, O
temazepam B-DRUG
) O
is O
unlikely O
to O
be O
affected O
by O
fluvoxamine B-DRUG
. O
Alprazolam B-DRUG
: O
When O
fluvoxamine B-DRUG
maleate I-DRUG
( O
100 O
mg O
qd O
) O
and O
alprazolam B-DRUG
( O
1 O
mg O
q O
. O
d O
. O
were O
co O
- O
administered O
to O
steady O
state O
, O
plasma O
concentration O
and O
other O
pharmacokinetics O
parameters O
( O
AUC O
, O
Cmax O
, O
T1 O
/ O
2 O
, O
) O
of O
alprazolam B-DRUG
were O
approximately O
twice O
those O
observed O
when O
alprazolam B-DRUG
was O
administered O
alone O
; O
oral O
clearance O
was O
reduced O
by O
about O
50 O
% O
. O
The O
elevated O
plasma O
alprazolam B-DRUG
concentrations O
resulted O
in O
decreased O
psychomotor O
performance O
and O
memory O
. O
This O
interaction O
, O
which O
has O
not O
been O
investigated O
using O
higher O
doses O
of O
fluvoxamine B-DRUG
, O
may O
be O
more O
pronounced O
if O
a O
300 O
mg O
daily O
dose O
is O
co O
- O
administered O
, O
particularly O
since O
fluvoxamine B-DRUG
exhibits O
non O
- O
linear O
pharmacokinetics O
over O
the O
dosage O
range O
100 O
- O
300 O
mg O
. O
If O
alprazolam B-DRUG
is O
co O
- O
administered O
with O
Fluvoxamine B-DRUG
Tablets O
, O
the O
initial O
alprazolam B-DRUG
dosage O
should O
be O
at O
least O
halved O
and O
titration O
to O
the O
lowest O
effective O
dose O
is O
recommended O
. O
No O
dosage O
adjustment O
is O
required O
for O
Fluvoxamine B-DRUG
Tablets O
. O
Diazepam B-DRUG
: O
The O
co O
- O
administration O
of O
Fluvoxamine B-DRUG
Tablets O
and O
diazepam B-DRUG
is O
generally O
not O
advisable O
. O
Because O
fluvoxamine B-DRUG
reduces O
the O
clearance O
of O
both O
diazepam B-DRUG
and O
its O
active O
metabolite O
, O
N B-DRUG_N
- I-DRUG_N
desmethyldiazepam I-DRUG_N
, O
there O
is O
a O
strong O
likelihood O
of O
substantial O
accumulation O
of O
both O
species O
during O
chronic O
co O
- O
administration O
. O
Evidence O
supporting O
the O
conclusion O
that O
it O
is O
inadvisable O
to O
co O
- O
administer O
fluvoxamine B-DRUG
and O
diazepam B-DRUG
is O
derived O
from O
a O
study O
in O
which O
healthy O
volunteers O
taking O
150 O
mg O
/ O
day O
of O
fluvoxamine B-DRUG
were O
administered O
a O
single O
oral O
dose O
of O
10 O
mg O
of O
diazepam B-DRUG
. O
In O
these O
subjects O
( O
R O
= O
B O
) O
, O
the O
clearance O
of O
diazepam B-DRUG
was O
reduced O
by O
65 O
% O
and O
that O
of O
N B-DRUG_N
- I-DRUG_N
desmethyldiazepam I-DRUG_N
to O
a O
level O
that O
was O
too O
low O
to O
measure O
over O
the O
course O
of O
the O
2 O
week O
long O
study O
. O
It O
is O
likely O
that O
experience O
significantly O
underestimates O
the O
degree O
of O
accumulation O
that O

might O
occur O
with O
repealed O
diazepam B-DRUG
administration O
. O
Moreover O
, O
as O
noted O
with O
alprazolam B-DRUG
, O
the O
effect O
of O
fluvoxamine B-DRUG
may O
even O
be O
more O
pronounced O
when O
it O
is O
administered O
at O
higher O
doses O
. O
Accordingly O
, O
diazepam B-DRUG
and O
fluvoxamine B-DRUG
should O
not O
ordinarily O
be O
co O
- O
administered O
. O
Theophylline B-DRUG
: O
The O
effect O
of O
steady O
- O
state O
fluvoxamine B-DRUG
l50 O
mg O
bid O
on O
the O
pharmacokinetics O
of O
a O
single O
dose O
of O
Theophylline B-DRUG
( O
375 O
mg O
) O
as O
442 O
mg O
aminophylline B-DRUG
was O
evaluated O
in O
12 O
healthy O
non O
- O
smoking O
, O
male O
volunteers O
. O
The O
clearance O
of O
theophylline B-DRUG
was O
decreased O
approximately O
3 O
- O
fold O
. O
Therefore O
, O
if O
theophylline B-DRUG
is O
co O
- O
administered O
with O
fluvoxamine B-DRUG
maleate I-DRUG
, O
its O
dose O
should O
be O
reduced O
to O
one O
third O
of O
the O
usual O
daily O
maintenance O
dose O
and O
plasma O
concentrations O
of O
theophylline B-DRUG
should O
to O
monitored O
. O
No O
dosage O
adjustment O
is O
required O
for O
Fluvoxamine B-DRUG
Tablets O
. O
Warfarin B-DRUG
: O
When O
fluvoxamine B-DRUG
maleate I-DRUG
( O
50 O
mg O
tid O
) O
was O
administered O
concomitantly O
with O
warfarin B-DRUG
for O
two O
weeks O
, O
warfarin B-DRUG
plasma O
concentrations O
increased O
by O
98 O
% O
and O
prothrombin O
times O
were O
prolonged O
. O
Thus O
patients O
receiving O
oral O
anticoagulants B-GROUP
and O
Fluvoxamine B-DRUG
Tablets O
should O
have O
their O
prothrombin O
time O
monitored O
and O
their O
anticoagulant B-GROUP
dose O
adjusted O
accordingly O
. O
No O
dosage O
adjustment O
is O
required O
for O
Fluvoxamine B-DRUG
Tablets O
. O

Medications O
that O
interfere O
with O
your O
bodys O
ability O
to O
use O
folate O
may O
also O
increase O
the O
need O
for O
this O
vitamin B-GROUP
. O
Medications O
can O
interfere O
with O
folate O
utilization O
, O
including O
: O
anticonvulsant B-GROUP
medications I-GROUP
( O
such O
as O
phenytoin B-DRUG
, O
and O
primidone B-DRUG
) O
metformin B-DRUG
( O
sometimes O
prescribed O
to O
control O
blood O
sugar O
in O
type O
2 O
diabetes O
) O
sulfasalazine B-DRUG
( O
used O
to O
control O
inflammation O
associated O
with O
Crohns O
disease O
and O
ulcerative O
colitis O
) O
triamterene B-DRUG
( O
a O
diuretic B-GROUP
) O
Methotrexate B-DRUG
There O
has O
been O
concern O
about O
the O
interaction O
between O
vitamin B-DRUG
B12 I-DRUG
and O
folic B-DRUG
acid I-DRUG
. O
Folic B-DRUG
acid I-DRUG
supplements O
can O
correct O
the O
anemia O
associated O
with O
vitamin O
B12 O
deficiency O
. O
Unfortunately O
, O
folic B-DRUG
acid I-DRUG
will O
not O
correct O
changes O
in O
the O
nervous O
system O
that O
result O
from O
vitamin O
B12 O
deficiency O
. O
Permanent O
nerve O
damage O
could O
theoretically O
occur O
if O
vitamin O
B12 O
deficiency O
is O
not O
treated O
. O
Therefore O
, O
intake O
of O
supplemental O
folic B-DRUG
acid I-DRUG
should O
not O
exceed O
1000 O
micrograms O
( O
g O
, O
sometimes O
mcg O
) O
per O
day O
to O
prevent O
folic B-DRUG
acid I-DRUG
from O
masking O
symptoms O
of O
vitamin O
B12 O
deficiency O
. O
It O
is O
important O
for O
older O
adults O
to O
be O
aware O
of O
the O
relationship O
between O
folic B-DRUG
acid I-DRUG
and O
vitamin B-DRUG
B12 I-DRUG
because O
they O
are O
at O
greater O
risk O
of O
having O
a O
vitamin O
B12 O
deficiency O
. O
If O
you O
are O
50 O
years O
of O
age O
or O
older O
, O
ask O
your O
physician O
to O
check O
your O
B12 O
status O
before O
you O
take O
a O
supplement O
that O
contains O
folic B-DRUG
acid I-DRUG
. O

No O
drug O
/ O
drug O
interaction O
studies O
have O
been O
performed O
. O

Oral O
doses O
of O
Antizol B-BRAND
( O
10 O
- O
20 O
mg O
/ O
kg O
) O
, O
via O
alcohol O
dehydrogenase O
inhibition O
, O
significantly O
reduced O
the O
rate O
of O
elimination O
of O
ethanol B-DRUG
( O
by O
approximately O
40 O
% O
) O
given O
to O
healthy O
volunteers O
in O
moderate O
doses O
. O
Similarly O
, O
ethanol B-DRUG
decreased O
the O
rate O
of O
elimination O
of O
Antizol B-BRAND
( O
by O
approximately O
50 O
% O
) O
by O
the O
same O
mechanism O
. O
Reciprocal O
interactions O
may O
occur O
with O
concomitant O
use O
of O
Antizol B-BRAND
and O
drugs O
that O
increase O
or O
inhibit O
the O
cytochrome O
P450 O
system O
( O
e O
. O
g O
. O
, O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
cimetidine B-DRUG
, O
ketoconazole B-DRUG
) O
, O
though O
this O
has O
not O
been O
studied O
. O

In O
clinical O
studies O
performed O
with O
Fondaparinux B-DRUG
, O
the O
concomitant O
use O
of O
oral O
anticoagulants B-GROUP
( O
warfarin B-DRUG
) O
, O
platelet B-GROUP
inhibitors I-GROUP
( O
acetylsalicylic B-DRUG
acid I-DRUG
) O
, O
NSAIDs B-GROUP
( O
piroxicam B-DRUG
) O
, O
and O
digoxin B-DRUG
did O
not O
significantly O
affect O
the O
pharmacokinetics O
/ O
pharmacodynamics O
of O
fondaparinux B-DRUG
sodium I-DRUG
. O
In O
addition O
, O
Fondaparinux B-DRUG
neither O
influenced O
the O
pharmacodynamics O
of O
warfarin B-DRUG
, O
acetylsalicylic B-DRUG
acid I-DRUG
, O
piroxicam B-DRUG
, O
and O
digoxin B-DRUG
, O
nor O
the O
pharmacokinetics O
of O
digoxin B-DRUG
at O
steady O
state O
. O
Agents O
that O
may O
enhance O
the O
risk O
of O
hemorrhage O
should O
be O
discontinued O
prior O
to O
initiation O
of O
Fondaparinux B-DRUG
therapy O
. O
If O
co O
- O
administration O
is O
essential O
, O
close O
monitoring O
may O
be O
appropriate O
. O
In O
an O
in O
vitro O
study O
in O
human O
liver O
microsomes O
, O
inhibition O
of O
CYP2A6 O
hydroxylation O
of O
coumarin B-GROUP
by O
fondaparinux B-DRUG
( O
200 O
m O
m O
M O
i O
. O
e O
. O
, O
350 O
mg O
/ O
L O
) O
was O
17 O
- O
28 O
% O
. O
Inhibition O
of O
the O
other O
isozymes O
evaluated O
( O
CYPs O
2A1 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
3A4 O
, O
and O
3E1 O
) O
was O
0 O
- O
16 O
% O
. O
Since O
fondaparinux B-DRUG
does O
not O
markedly O
inhibit O
CYP450s O
( O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
or O
CYP3A4 O
) O
in O
vitro O
, O
fondaparinux B-DRUG
sodium I-DRUG
is O
not O
expected O
to O
significantly O
interact O
with O
other O
drugs O
in O
vivo O
by O
inhibition O
of O
metabolism O
mediated O
by O
these O
isozymes O
. O
Since O
fondaparinux B-DRUG
sodium I-DRUG
does O
not O
bind O
significantly O
to O
plasma O
proteins O
other O
than O
ATIII O
, O
no O
drug O
interactions O
by O
protein O
- O
binding O
displacement O
are O
expected O
. O

Short B-GROUP
- I-GROUP
Acting I-GROUP
beta2 I-GROUP
- I-GROUP
agonists I-GROUP
: O
Aerosol O
bronchodilators B-GROUP
of O
the O
short O
- O
acting O
adrenergic O
stimulant O
type O
may O
be O
used O
for O
relief O
of O
breakthrough O
symptoms O
while O
using O
formoterol B-DRUG
. O
However O
, O
increasing O
use O
of O
such O
preparations O
to O
control O
symptoms O
indicates O
deterioration O
of O
asthma O
control O
and O
the O
need O
to O
reassess O
the O
patient O
s O
therapy O
. O
Concomitant O
administration O
of O
other O
sympathomimetic B-GROUP
agents I-GROUP
may O
potentiate O
the O
undesirable O
effects O
of O
FORADIL B-BRAND
. O
Monoamine B-GROUP
Oxidase I-GROUP
Inhibitors I-GROUP
and O
Tricyclic B-GROUP
Antidepressants I-GROUP
: O
FORADIL B-BRAND
should O
be O
administered O
with O
extreme O
caution O
in O
patients O
being O
treated O
with O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
or O
tricyclic B-GROUP
antidepressants I-GROUP
because O
the O
action O
of O
formoterol B-DRUG
on O
the O
cardiovascular O
system O
may O
be O
potentiated O
by O
these O
agents O
. O
Corticosteroids B-GROUP
, O
Methylxanthines B-GROUP
and O
Diuretics B-GROUP
: O
Concomitant O
treatment O
with O
xanthine B-GROUP
derivatives I-GROUP
, O
steroids B-GROUP
, O
or O
diuretics B-GROUP
may O
potentiate O
a O
possible O
hypokalemic O
effect O
of O
beta2 B-GROUP
- I-GROUP
agonists I-GROUP
. I-GROUP
Hypokalemia O
may O
increase O
susceptibility O
to O
cardiac O
arrhythmias O
in O
patients O
treated O
with O
digitalis B-GROUP
. O
- O
adrenergic O
Blockers O
: O
- O
adrenergic O
blockers O
may O
weaken O
or O
antagonise O
the O
effect O
of O
FORADIL B-BRAND
. O
Therefore O
FORADIL B-BRAND
should O
not O
be O
given O
together O
with O
- O
adrenergic O
blockers O
( O
including O
eye O
drops O
) O
unless O
there O
are O
compelling O
reasons O
for O
their O
use O
. O
Other O
Drugs O
: O
Drugs O
such O
as O
quinidine B-DRUG
, O
disopyramide B-DRUG
, O
procainamide B-DRUG
, O
phenothiazines B-GROUP
, O
antihistamines B-GROUP
, O
and O
tricyclic B-GROUP
antidepressants I-GROUP
may O
be O
associated O
with O
QT O
- O
interval O
prolongation O
and O
an O
increased O
risk O
of O
ventricular O
arrhythmia O
. O
INFORMATION O
TO O
BE O
PROVIDED O
TO O
THE O
PATIENT O
OR O
GUARDIAN O
See O
illustrated O
Information O
For O
The O
Patient O
or O
Guardian O
section O
. O
It O
is O
important O
that O
patients O
understand O
how O
to O
use O
FORADIL B-BRAND
( O
formoterol B-DRUG
fumarate I-DRUG
) O
capsules O
with O
the O
supplied O
AerolizerTM O
inhalation O
device O
and O
how O
it O
should O
be O
used O
in O
relation O
to O
other O
asthma O
or O
COPD O
medications O
they O
are O
taking O
. O
Patients O
/ O
Guardians O
should O
be O
given O
the O
following O
information O
: O
i O
. O
The O
recommended O
dosage O
( O
one O
or O
two O
capsules O
twice O
daily O
, O
morning O
and O

evening O
) O
should O
not O
be O
exceeded O
. O
ii O
. O
FORADIL B-BRAND
is O
not O
meant O
to O
relieve O
acute O
asthma O
or O
COPD O
symptoms O
and O
extra O
doses O
should O
not O
be O
used O
for O
that O
purpose O
. O
Acute O
symptoms O
should O
be O
treated O
with O
a O
short O
- O
acting O
, O
inhaled O
beta2 B-GROUP
- I-GROUP
agonist I-GROUP
such O
as O
salbutamol B-DRUG
( O
the O
physician O
should O
provide O
the O
patient O
with O
such O
medication O
and O
instruct O
the O
patient O
in O
how O
it O
should O
be O
used O
) O
. O
iii O
. O
The O
physician O
should O
be O
notified O
immediately O
if O
any O
of O
the O
following O
situations O
occur O
, O
which O
may O
be O
a O
sign O
of O
seriously O
worsening O
asthma O
: O
Decreased O
effectiveness O
of O
short B-GROUP
- I-GROUP
acting I-GROUP
, I-GROUP
inhaled I-GROUP
beta2 I-GROUP
- I-GROUP
agonists I-GROUP
; O
Need O
for O
more O
inhalations O
than O
usual O
of O
short B-GROUP
- I-GROUP
acting I-GROUP
, I-GROUP
inhaled I-GROUP
beta2 I-GROUP
- I-GROUP
agonists I-GROUP
. O
iv O
. O
FORADIL B-BRAND
should O
not O
be O
used O
as O
a O
substitute O
for O
oral O
or O
inhaled O
corticosteroids B-GROUP
. O
The O
dosage O
of O
these O
medications O
should O
not O
be O
changed O
and O
they O
should O
not O
be O
stopped O
without O
consulting O
the O
physician O
, O
even O
if O
the O
patient O
feels O
better O
after O
initiating O
treatment O
with O
FORADIL B-BRAND
. O
v O
. O
Patients O
should O
be O
cautioned O
regarding O
potential O
adverse O
cardiovascular O
effects O
, O
such O
as O
palpitations O
or O
chest O
pain O
. O
vi O
. O
In O
patients O
receiving O
FORADIL B-BRAND
, O
other O
inhaled O
medications O
should O
be O
used O
only O
as O
directed O
by O
the O
physician O
. O
vii O
. O
Guardians O
of O
children O
who O
have O
been O
prescribed O
FORADIL B-BRAND
should O
be O
alerted O
to O
the O
general O
concern O
regarding O
asthma O
therapy O
compliance O
, O
especially O
neglect O
of O
anti O
- O
inflammatory O
therapy O
and O
overuse O
of O
short B-GROUP
- I-GROUP
acting I-GROUP
beta2 I-GROUP
- I-GROUP
agonists I-GROUP
. O

A O
possible O
drug O
interaction O
of O
FOSCAVIR B-BRAND
and O
intravenous O
pentamidine B-DRUG
has O
been O
described O
. O
Concomitant O
treatment O
of O
four O
patients O
in O
the O
United O
Kingdom O
with O
FOSCAVIR B-BRAND
and O
intravenous O
pentamidine B-DRUG
may O
have O
caused O
hypocalcemia O
; O
one O
patient O
died O
with O
severe O
hypocalcemia O
. O
Toxicity O
associated O
with O
concomitant O
use O
of O
aerosolized O
pentamidine B-DRUG
has O
not O
been O
reported O
. O
Because O
of O
foscarnets B-DRUG
tendency O
to O
cause O
renal O
impairment O
, O
the O
use O
of O
FOSCAVIR B-BRAND
should O
be O
avoided O
in O
combination O
with O
potentially O
nephrotoxic O
drugs O
such O
as O
aminoglycosides B-GROUP
, O
amphotericin B-DRUG
B I-DRUG
and O
intravenous O
pentamidine B-DRUG
unless O
the O
potential O
benefits O
outweigh O
the O
risks O
to O
the O
patient O
. O
Since O
FOSCAVIR B-BRAND
decreases O
serum O
concentrations O
of O
ionized O
calcium O
, O
concurrent O
treatment O
with O
other O
drugs O
known O
to O
influence O
serum O
calcium O
concentrations O
should O
be O
used O
with O
particular O
caution O
. O
Ganciclovir B-DRUG
: O
The O
pharmacokinetics O
of O
foscarnet B-DRUG
and O
ganciclovir B-DRUG
were O
not O
altered O
in O
13 O
patients O
receiving O
either O
concomitant O
therapy O
or O
daily O
alternating O
therapy O
for O
maintenance O
of O
CMV O
disease O
. O

Metoclopramide B-DRUG
: O
When O
coadministered O
with O
MONUROL B-BRAND
, O
metoclopramide B-DRUG
, O
a O
drug O
which O
increases O
gastrointestinal O
motility O
, O
lowers O
the O
serum O
concentration O
and O
urinary O
excretion O
of O
fosfomycin B-DRUG
. O
Other O
drugs O
that O
increase O
gastrointestinal O
motility O
may O
produce O
similar O
effects O
. O
Cimetidine B-DRUG
: O
Cimetidine B-DRUG
does O
not O
affect O
the O
pharmacokinetics O
of O
fosfomycin B-DRUG
when O
coadministered O
with O
MONUROL B-BRAND
. O

Diuretics B-GROUP
: O
Patients O
on O
diuretics B-GROUP
, O
especially O
those O
with O
intravascular O
volume O
depletion O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
therapy O
with O
fosinopril B-DRUG
sodium I-DRUG
. O
The O
possibility O
of O
hypotensive O
effects O
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-GROUP
or O
increasing O
salt O
intake O
prior O
to O
initiation O
of O
treatment O
with O
fosinopril B-DRUG
sodium I-DRUG
. O
If O
this O
is O
not O
possible O
, O
the O
starting O
dose O
should O
be O
reduced O
and O
the O
patient O
should O
be O
observed O
closely O
for O
several O
hours O
following O
an O
initial O
dose O
and O
until O
blood O
pressure O
has O
stabilized O
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
. O
) O
Potassium B-DRUG
Supplements O
and O
Potassium B-GROUP
- I-GROUP
Sparing I-GROUP
Diuretics I-GROUP
: O
Fosinopril B-DRUG
sodium I-DRUG
can O
attenuate O
potassium O
loss O
caused O
by O
thiazide B-GROUP
diuretics I-GROUP
. O
Potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
( O
spironolactone B-DRUG
, O
amiloride B-DRUG
, O
triamterene B-DRUG
, O
and O
others O
) O
or O
potassium B-DRUG
supplements O
can O
increase O
the O
risk O
of O
hyperkalemia O
. O
Therefore O
, O
if O
concomitant O
use O
of O
such O
agents O
is O
indicated O
, O
they O
should O
be O
given O
with O
caution O
, O
and O
the O
patients O
serum O
potassium O
should O
be O
monitored O
frequently O
. O
Lithium B-DRUG
: O
Increased O
serum O
lithium B-DRUG
levels O
and O
symptoms O
of O
lithium B-DRUG
toxicity O
have O
been O
reported O
in O
patients O
receiving O
ACE B-GROUP
inhibitors I-GROUP
during O
therapy O
with O
lithium B-DRUG
. O
These O
drugs O
should O
be O
coadministered O
with O
caution O
, O
and O
frequent O
monitoring O
of O
serum O
lithium B-DRUG
levels O
is O
recommended O
. O
If O
a O
diuretic B-GROUP
is O
also O
used O
, O
the O
risk O
of O
lithium O
toxicity O
may O
be O
increased O
. O
Antacids B-GROUP
: O
In O
a O
clinical O
pharmacology O
study O
, O
coadministration O
of O
an O
antacid B-GROUP
( O
aluminum B-DRUG
hydroxide I-DRUG
, O
magnesium B-DRUG
hydroxide I-DRUG
, O
and O
simethicone B-DRUG
) O
with O
fosinopril B-DRUG
reduced O
serum O
levels O
and O
urinary O
excretion O
of O
fosinoprilat B-DRUG_N
as O
compared O
with O
fosinopril B-DRUG
administered O
alone O
, O
suggesting O
that O
antacids B-GROUP
may O
impair O
absorption O
of O
fosinopril B-DRUG
. O
Therefore O
, O
if O
concomitant O
administration O
of O
these O
agents O
is O
indicated O
, O
dosing O
should O
be O
separated O
by O
2 O
hours O
. O
Other O
: O
Neither O
fosinopril B-DRUG
sodium I-DRUG
nor O
its O
metabolites O
have O
been O
found O
to O
interact O
with O
food O
. O
In O
separate O
single O
or O
multiple O
dose O
pharmacokinetic O
interaction O
studies O
with O
chlorthalidone B-DRUG
, O
nifedipine B-DRUG
, O
propanolol B-DRUG
, O
hydrochlorothiazide B-DRUG
, O
cimetidine B-DRUG
, O
metoclopramide B-DRUG
, O

propantheline B-DRUG
, O
digoxin B-DRUG
, O
and O
warfarin B-DRUG
, O
the O
bioavailability O
of O
fosinoprilat B-DRUG_N
was O
not O
altered O
by O
coadministration O
of O
fosinopril B-DRUG
with O
any O
one O
of O
these O
drugs O
. O
In O
a O
study O
with O
concomitant O
administration O
of O
aspirin B-BRAND
and O
fosinopril B-DRUG
sodium I-DRUG
, O
the O
bioavailability O
of O
unbound O
fosinoprilat B-DRUG_N
was O
not O
altered O
. O
In O
a O
pharmacokinetic O
interaction O
study O
with O
warfarin B-DRUG
, O
bioavailability O
parameters O
, O
the O
degree O
of O
protein O
binding O
, O
and O
the O
anticoagulant O
effect O
( O
measured O
by O
prothrombin O
time O
) O
of O
warfarin B-DRUG
were O
not O
significantly O
changed O
. O
Drug O
/ O
Laboratory O
Test O
Interaction O
Fosinopril B-DRUG
may O
cause O
a O
false O
low O
measurement O
of O
serum O
digoxin B-DRUG
levels O
with O
the O
Digi O
- O
Tab O
RIA O
Kit O
for O
Digoxin B-DRUG
. O
Other O
kits O
, O
such O
as O
the O
Coat O
- O
A O
- O
Count O
RIA O
Kit O
, O
may O
be O
used O
. O

No O
drugs O
are O
known O
to O
interfere O
with O
the O
conversion O
of O
fosphenytoin B-DRUG
to O
phenytoin B-DRUG
. O
Conversion O
could O
be O
affected O
by O
alterations O
in O
the O
level O
of O
phosphatase O
activity O
, O
but O
given O
the O
abundance O
and O
wide O
distribution O
of O
phosphatases O
in O
the O
body O
it O
is O
unlikely O
that O
drugs O
would O
affect O
this O
activity O
enough O
to O
affect O
conversion O
of O
fosphenytoin B-DRUG
to O
phenytoin B-DRUG
. O
Drugs O
highly O
bound O
to O
albumin O
could O
increase O
the O
unbound O
fraction O
of O
fosphenytoin B-DRUG
. O
Although O
, O
it O
is O
unknown O
whether O
this O
could O
result O
in O
clinically O
significant O
effects O
, O
caution O
is O
advised O
when O
administering O
Cerebyx B-BRAND
with O
other O
drugs O
that O
significantly O
bind O
to O
serum O
albumin O
. O
The O
pharmacokinetics O
and O
protein O
binding O
of O
fosphenytoin B-DRUG
, O
phenytoin B-DRUG
, O
and O
diazepam B-DRUG
were O
not O
altered O
when O
diazepam B-DRUG
and O
Cerebyx B-BRAND
were O
concurrently O
administered O
in O
single O
submaximal O
doses O
. O
The O
most O
significant O
drug O
interactions O
following O
administration O
of O
Cerebyx B-BRAND
are O
expected O
to O
occur O
with O
drugs O
that O
interact O
with O
phenytoin B-DRUG
. O
Phenytoin B-DRUG
is O
extensively O
bound O
to O
serum O
plasma O
proteins O
and O
is O
prone O
to O
competitive O
displacement O
. O
Phenytoin B-DRUG
is O
metabolized O
by O
hepatic O
cytochrome O
P450 O
enzymes O
and O
is O
particularly O
susceptible O
to O
inhibitory O
drug O
interactions O
because O
it O
is O
subject O
to O
saturable O
metabolism O
. O
Inhibition O
of O
metabolism O
may O
produce O
significant O
increases O
in O
circulating O
phenytoin B-DRUG
concentrations O
and O
enhance O
the O
risk O
of O
drug O
toxicity O
. O
Phenytoin B-DRUG
is O
a O
potent O
inducer O
of O
hepatic O
drug O
- O
metabolizing O
enzymes O
. O
The O
most O
commonly O
occurring O
drug O
interactions O
are O
listed O
below O
: O
- O
Drugs O
that O
may O
increase O
plasma O
phenytoin B-DRUG
concentrations O
include O
: O
acute O
alcohol B-DRUG
intake O
, O
amiodarone B-DRUG
, O
chboramphenicol O
, O
chlordiazepoxide B-DRUG
, O
cimetidine B-DRUG
, O
diazepam B-DRUG
, O
dicumarol B-DRUG
, O
disulfiram B-DRUG
, O
estrogens B-GROUP
, O
ethosuximide B-DRUG
, O
fluoxetine B-DRUG
, O
H2 B-GROUP
- I-GROUP
antagonists I-GROUP
, O
halothane B-DRUG
, O
isoniazid B-DRUG
, O
methylphenidate B-DRUG
, O
phenothiazines B-GROUP
, O
phenylbutazone B-DRUG
, O
salicylates B-GROUP
, O
succinimides B-GROUP
, O
sulfonamides B-GROUP
, O
tolbutamide B-DRUG
, O
trazodone B-DRUG
. O
- O
Drugs O
that O
may O
decrease O
plasma O
phenytoin B-DRUG
concentrations O
include O
: O
carbamazepine B-DRUG
, O
chronic O
alcohol B-DRUG
abuse O
, O
reserpine B-DRUG
. O
- O
Drugs O
that O
may O
either O
increase O
or O
decrease O
plasma O
phenytoin B-DRUG
concentrations O

include O
: O
phenobarbital B-DRUG
, O
vaiproic O
acid O
, O
and O
sodium B-DRUG
valproate I-DRUG
. O
Similarly O
, O
the O
effects O
of O
phenytoin B-DRUG
on O
phenobarbital B-DRUG
, O
valproic B-DRUG
acid I-DRUG
and O
sodium O
plasma O
valproate B-DRUG
concentrations O
are O
unpredictable O
. O
- O
Although O
not O
a O
true O
drug O
interaction O
, O
tricyclic B-GROUP
antidepressants I-GROUP
may O
precipitate O
seizures O
in O
susceptible O
patients O
and O
Cerebyx B-BRAND
dosage O
may O
need O
to O
be O
adjusted O
. O
- O
Drugs O
whose O
efficacy O
is O
impaired O
by O
phenytoin B-DRUG
include O
: O
anticoagulants B-GROUP
, O
corticosteroids B-GROUP
, O
coumarin B-GROUP
, O
digitoxin B-DRUG
, O
doxycycline B-DRUG
, O
estrogens B-GROUP
, O
furosemide B-DRUG
, O
oral O
contraceptives B-GROUP
, O
rifampin B-DRUG
, O
quinidine B-DRUG
, O
theophylline B-DRUG
, O
vitamin B-GROUP
D I-GROUP
. O
Monitoring O
of O
plasma O
phenytoin B-DRUG
concentrations O
may O
be O
helpful O
when O
possible O
drug O
interactions O
are O
suspected O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Phenytoin B-DRUG
may O
decrease O
serum O
concentrations O
of O
14 O
. O
It O
may O
also O
produce O
artifactually O
low O
results O
in O
dexamethasone O
or O
metyrapone O
tests O
. O
Phenytoin B-DRUG
may O
also O
cause O
increased O
serum O
concentrations O
of O
glucose O
, O
alkaline O
phosphatase O
, O
and O
gamma O
glutamyl O
transpeptidase O
( O
GGT O
) O
. O
Care O
should O
be O
taken O
when O
using O
immunoanalytical O
methods O
to O
measure O
plasma O
phenytoin B-DRUG
concentrations O
following O
Cerebyx B-BRAND
administration O
. O

Ergot O
- O
containing O
drugs O
have O
been O
reported O
to O
cause O
prolonged O
vasospastic O
reactions O
. O
Due O
to O
a O
theoretical O
risk O
of O
a O
pharmacodynamic O
interaction O
, O
use O
of O
ergotamine B-DRUG
- O
containing O
or O
ergot B-GROUP
- I-GROUP
type I-GROUP
medications I-GROUP
( O
like O
dihydroergotamine B-DRUG
or O
methysergide B-DRUG
) O
and O
FROVA B-BRAND
within O
24 O
hours O
of O
each O
other O
should O
be O
avoided O
( O
see O
a O
href O
= O
frova O
_ O
od O
. O
htm O
# O
CI O
CONTRAINDICATIONS O
) O
. O
Concomitant O
use O
of O
other O
5 O
- O
HT1B O
/ O
1D O
agonists O
within O
24 O
hours O
of O
FROVA B-BRAND
treatment O
is O
not O
recommended O
. O
Selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
( O
SSRIs B-GROUP
) O
( O
e O
. O
g O
. O
, O
fluoxetine B-DRUG
, O
fluvoxamine B-DRUG
, O
paroxetine B-DRUG
, O
sertraline B-DRUG
) O
have O
been O
reported O
, O
rarely O
, O
to O
cause O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
when O
coadministered O
with O
5 B-GROUP
- I-GROUP
HT1 I-GROUP
agonists I-GROUP
. O
If O
concomitant O
treatment O
with O
frovatriptan B-DRUG
and O
an O
SSRI B-GROUP
is O
clinically O
warranted O
, O
appropriate O
observation O
of O
the O
patient O
is O
advised O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
FROVA B-BRAND
is O
not O
known O
to O
interfere O
with O
commonly O
employed O
clinical O
laboratory O
tests O
. O

Fulvestrant B-DRUG
is O
metabolized O
by O
CYP O
3A4 O
in O
vitro O
. O
Clinical O
studies O
of O
the O
effect O
of O
strong O
CYP O
3A4 O
inhibitors O
on O
the O
pharmacokinetics O
of O
fulvestrant B-DRUG
have O
not O
been O
performed O
. O
Carcinogenesis O
, O
Mutagenesis O
and O
Impairment O
of O
Fertility O
A O
two O
- O
year O
carcinogenesis O
study O
was O
conducted O
in O
female O
and O
male O
rats O
, O
at O
intramuscular O
doses O
of O
15 O
mg O
/ O
kg O
/ O
30 O
days O
, O
10 O
mg O
/ O
rat O
/ O
30 O
days O
and O
10 O
mg O
/ O
rat O
/ O
15 O
days O
. O
These O
doses O
correspond O
to O
approximately O
1 O
- O
, O
3 O
- O
, O
and O
5 O
- O
fold O
( O
in O
females O
) O
and O
1 O
. O
3 O
- O
, O
1 O
. O
3 O
- O
, O
and O
1 O
. O
6 O
- O
fold O
( O
in O
males O
) O
the O
systemic O
exposure O
[ O
AUC0 O
- O
30 O
days O
] O
] O
achieved O
in O
women O
receiving O
the O
recommended O
dose O
of O
250 O
mg O
/ O
month O
. O
An O
increased O
incidence O
of O
benign O
ovarian O
granulosa O
cell O
tumors O
and O
testicular O
Leydig O
cell O
tumors O
was O
evident O
, O
in O
females O
dosed O
at O
10 O
mg O
/ O
rat O
/ O
15 O
days O
and O
males O
dosed O
at O
15 O
mg O
/ O
rat O
/ O
30 O
days O
, O
respectively O
. O
Induction O
of O
such O
tumors O
is O
consistent O
with O
the O
pharmacology O
- O
related O
endocrine O
feedback O
alterations O
in O
gonadotropin O
levels O
caused O
by O
an O
antiestrogen B-GROUP
. O
Fulvestrant B-DRUG
was O
not O
mutagenic O
or O
clastogenic O
in O
multiple O
in O
vitro O
tests O
with O
and O
without O
the O
addition O
of O
a O
mammalian O
liver O
metabolic O
activation O
factor O
( O
bacterial O
mutation O
assay O
in O
strains O
of O
Salmonella O
typhimurium O
and O
Escherichia O
coli O
, O
in O
vitro O
cytogenetics O
study O
in O
human O
lymphocytes O
, O
mammalian O
cell O
mutation O
assay O
in O
mouse O
lymphoma O
cells O
and O
in O
vivo O
micronucleus O
test O
in O
rat O
. O
In O
female O
rats O
, O
fulvestrant B-DRUG
administered O
at O
doses O
0 O
. O
01 O
mg O
/ O
kg O
/ O
day O
( O
approximately O
one O
- O
hundredth O
of O
the O
human O
recommended O
dose O
based O
on O
body O
surface O
area O
[ O
BSA O
] O
, O
for O
2 O
weeks O
prior O
to O
and O
for O
1 O
week O
following O
mating O
, O
caused O
a O
reduction O
in O
fertility O
and O
embryonic O
survival O
. O
No O
adverse O
effects O
on O
female O
fertility O
and O
embryonic O
survival O
were O
evident O
in O
female O
animals O
dosed O
at O
0 O
. O
001 O
mg O
/ O
kg O
/ O
day O
( O
approximately O
one O
- O
thousandth O
of O
the O
human O
dose O
based O
on O
BSA O
) O
. O
Restoration O
of O
female O
fertility O
to O
values O
similar O
to O
controls O
was O
evident O
following O
a O
29 O
- O
day O
withdrawal O
period O
after O
dosing O
at O
2 O
mg O
/ O
kg O
/ O
day O
( O
twice O
the O
human O
dose O
based O

on O
BSA O
) O
. O
The O
effects O
of O
fulvestrant B-DRUG
on O
the O
fertility O
of O
female O
rats O
appear O
to O
be O
consistent O
with O
its O
anti O
- O
estrogenic O
activity O
. O
The O
potential O
effects O
of O
fulvestrant B-DRUG
on O
the O
fertility O
of O
male O
animals O
were O
not O
studied O
but O
in O
a O
6 O
- O
month O
toxicology O
study O
, O
male O
rats O
treated O
with O
intramuscular O
doses O
of O
15 O
mg O
/ O
kg O
/ O
30 O
days O
, O
10 O
mg O
/ O
rat O
/ O
30 O
days O
, O
or O
10 O
mg O
/ O
rat O
/ O
15 O
days O
fulvestrant B-DRUG
showed O
a O
loss O
of O
spermatozoa O
from O
the O
seminiferous O
tubules O
, O
seminiferous O
tubular O
atrophy O
, O
and O
degenerative O
changes O
in O
the O
epididymides O
. O
Changes O
in O
the O
testes O
and O
epididymides O
had O
not O
recovered O
20 O
weeks O
after O
cessation O
of O
dosing O
. O
These O
fulvestrant B-DRUG
doses O
correspond O
to O
approximately O
2 O
- O
, O
3 O
- O
, O
and O
3 O
- O
fold O
the O
systemic O
exposure O
[ O
AUC0 O
- O
30 O
days O
] O
achieved O
in O
women O
. O
Pregnancy O
Pregnancy O
Category O
D O
: O
. O
In O
studies O
in O
female O
rats O
at O
doses O
0 O
. O
01 O
mg O
/ O
kg O
/ O
day O
( O
IM O
; O
approximately O
one O
- O
hundredth O
of O
the O
human O
recommended O
dose O
based O
on O
body O
surface O
area O
[ O
BSA O
] O
) O
, O
fulvestrant B-DRUG
caused O
a O
reversible O
reduction O
in O
female O
fertility O
, O
as O
well O
as O
effects O
on O
embryo O
/ O
fetal O
development O
consistent O
with O
its O
anti O
- O
estrogenic O
activity O
. O
Fulvestrant B-DRUG
caused O
an O
increased O
incidence O
of O
fetal O
abnormalities O
in O
rats O
( O
tarsal O
flexure O
of O
the O
hind O
paw O
at O
2 O
mg O
/ O
kg O
/ O
day O
IM O
; O
twice O
the O
human O
dose O
on O
BSA O
) O
and O
non O
- O
ossification O
of O
the O
odontoid O
and O
ventral O
tubercle O
of O
the O
first O
cervical O
vertebra O
at O
doses O
0 O
. O
1 O
mg O
/ O
kg O
/ O
day O
IM O
( O
approximately O
one O
- O
tenth O
of O
the O
human O
dose O
on O
BSA O
) O
when O
administered O
during O
the O
period O
of O
organogenesis O
. O
Rabbits O
failed O
to O
maintain O
pregnancy O
when O
dosed O
with O
1 O
mg O
/ O
kg O
/ O
day O
fulvestrant B-DRUG
IM O
( O
twice O
the O
human O
dose O
on O
BSA O
) O
during O
the O
period O
of O
organogenesis O
. O
Further O
, O
in O
rabbits O
dosed O
at O
0 O
. O
25 O
mg O
/ O
kg O
/ O
day O
( O
about O
one O
- O
half O
the O
human O
dose O
on O
BSA O
) O
, O
increases O
in O
placental O
weight O
and O
post O
- O
implantation O
loss O
were O
observed O
but O
, O
there O
were O
no O
observed O
effects O
on O
fetal O
development O
. O
Fulvestrant B-DRUG
was O
associated O
with O
an O
increased O
incidence O
of O
fetal O
variations O
in O
rabbits O
( O
backwards O
displacement O
of O
the O
pelvic O
girdle O
, O

and O
27 O
pre O
- O
sacral O
vertebrae O
at O
0 O
. O
25 O
mg O
/ O
kg O
/ O
day O
IM O
; O
one O
- O
half O
the O
human O
dose O
on O
BSA O
) O
when O
administered O
during O
the O
period O
of O
organogenesis O
. O
Because O
pregnancy O
could O
not O
be O
maintained O
in O
the O
rabbit O
following O
doses O
of O
fulvestrant B-DRUG
of O
1 O
mg O
/ O
kg O
/ O
day O
and O
above O
, O
this O
study O
was O
inadequate O
to O
fully O
define O
the O
possible O
adverse O
effects O
on O
fetal O
development O
at O
clinically O
relevant O
exposures O
. O
Nursing O
Mothers O
Fulvestrant B-DRUG
is O
found O
in O
rat O
milk O
at O
levels O
significantly O
higher O
( O
approximately O
12 O
- O
fold O
) O
than O
plasma O
after O
administration O
of O
2 O
mg O
/ O
kg O
. O
Drug O
exposure O
in O
rodent O
pups O
from O
fulvestrant B-DRUG
- O
treated O
lactating O
dams O
was O
estimated O
as O
10 O
% O
of O
the O
administered O
dose O
. O
It O
is O
not O
known O
if O
fulvestrant B-DRUG
is O
excreted O
in O
human O
milk O
. O
Because O
many O
drugs O
are O
excreted O
in O
human O
milk O
, O
and O
because O
of O
the O
potential O
for O
serious O
adverse O
reactions O
from O
FASLODEX B-BRAND
in O
nursing O
infants O
, O
a O
decision O
should O
be O
made O
whether O
to O
discontinue O
nursing O
or O
to O
discontinue O
the O
drug O
taking O
into O
account O
the O
importance O
of O
the O
drug O
to O
the O
mother O
. O
Pediatric O
Use O
The O
safety O
and O
efficacy O
of O
FASLODEX B-BRAND
in O
pediatric O
patients O
have O
not O
been O
established O
. O
Geriatric O
Use O
When O
tumor O
response O
was O
considered O
by O
age O
, O
objective O
responses O
were O
seen O
in O
24 O
% O
and O
22 O
% O
of O
patients O
under O
65 O
years O
of O
age O
and O
in O
16 O
% O
and O
11 O
% O
of O
patients O
65 O
years O
of O
age O
and O
older O
, O
who O
were O
treated O
with O
FASLODEX B-BRAND
in O
the O
European O
and O
North O
American O
trials O
, O
respectively O
. O

Furosemide B-DRUG
may O
increase O
the O
ototoxic O
potential O
of O
aminoglycoside B-GROUP
antibiotics I-GROUP
, O
especially O
in O
the O
presence O
of O
impaired O
renal O
function O
. O
Except O
in O
life O
- O
threatening O
situations O
, O
avoid O
this O
combination O
. O
Furosemide B-DRUG
should O
not O
be O
used O
concomitantly O
with O
ethacrynic B-DRUG
acid I-DRUG
because O
of O
the O
possibility O
of O
ototoxicity O
. O
Patients O
receiving O
high O
doses O
of O
salicylates B-GROUP
concomitantly O
with O
furosemide B-DRUG
, O
as O
in O
rheumatic O
disease O
, O
may O
experience O
salicylate B-GROUP
toxicity O
at O
lower O
doses O
because O
of O
competitive O
renal O
excretory O
sites O
. O
Furosemide B-DRUG
has O
a O
tendency O
to O
antagonize O
the O
skeletal O
muscle O
relaxing O
effect O
of O
tubocurarine B-DRUG
and O
may O
potentiate O
the O
action O
of O
succinylcholine B-DRUG
. O
Lithium B-DRUG
generally O
should O
not O
be O
given O
with O
diuretics B-GROUP
because O
they O
reduce O
lithiums B-DRUG
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium B-DRUG
toxicity O
. O
Furosemide B-DRUG
may O
add O
to O
or O
potentiate O
the O
therapeutic O
effect O
of O
other O
antihypertensive B-GROUP
drugs I-GROUP
. O
Potentiation O
occurs O
with O
ganglionic B-GROUP
or I-GROUP
peripheral I-GROUP
adrenergic I-GROUP
blocking I-GROUP
drugs I-GROUP
. O
Furosemide B-DRUG
may O
decrease O
arterial O
responsiveness O
to O
norepinephrine B-DRUG
. O
However O
, O
norepinephrine B-DRUG
may O
still O
be O
used O
effectively O
. O
Tablets O
Simultaneous O
administration O
of O
sucralfate B-DRUG
and O
furosemide B-DRUG
tablets O
may O
reduce O
the O
natriuretic O
and O
antihypertensive O
effects O
of O
furosemide B-DRUG
. O
Patients O
receiving O
both O
drugs O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
diuretic O
and O
/ O
or O
antihypertensive O
effect O
of O
furosemide B-DRUG
is O
achieved O
. O
The O
intake O
of O
furosemide B-DRUG
and O
sucralfate B-DRUG
should O
be O
separated O
by O
at O
least O
two O
hours O
. O
Tablets O
, O
Injection O
, O
and O
Oral O
Solution O
One O
study O
in O
six O
subjects O
demonstrated O
that O
the O
combination O
of O
furosemide B-DRUG
and O
acetylsalicylic B-DRUG
acid I-DRUG
temporarily O
reduced O
creatinine O
clearance O
in O
patients O
with O
chronic O
renal O
insufficiency O
. O
There O
are O
case O
reports O
of O
patients O
who O
developed O
increased O
BUN O
, O
serum O
creatinine O
and O
serum O
potassium O
levels O
, O
and O
weight O
gain O
when O
furosemide B-DRUG
was O
used O
in O
conjunction O
with O
NSAIDs B-GROUP
. O
Literature O
reports O
indicate O
that O
coadministration O
of O
indomethacin B-DRUG
may O
reduce O
the O
natriuretic O
and O
antihypertensive O
effects O
of O
furosemide B-DRUG
in O
some O
patients O
by O
inhibiting O
prostaglandin O
synthesis O
. O
Indomethacin B-DRUG
may O
also O
affect O
plasma O
renin O
levels O
, O
aldosterone O
excretion O
, O

and O
renin O
profile O
evaluation O
. O
Patients O
receiving O
both O
indomethacin B-DRUG
and O
furosemide B-DRUG
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
diuretic O
and O
/ O
or O
antihypertensive O
effect O
of O
furosemide B-DRUG
is O
achieved O
. O

In O
vitro O
studies O
were O
conducted O
to O
investigate O
the O
potential O
of O
gabapentin B-DRUG
to O
inhibit O
the O
major O
cytochrome O
P450 O
enzymes O
( O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
and O
CYP3A4 O
) O
that O
mediate O
drug O
and O
xenobiotic O
metabolism O
using O
isoform O
selective O
marker O
substrates O
and O
human O
liver O
microsomal O
preparations O
. O
Only O
at O
the O
highest O
concentration O
tested O
( O
171 O
g O
/ O
mL O
; O
1 O
mM O
) O
was O
a O
slight O
degree O
of O
inhibition O
( O
14 O
% O
- O
30 O
% O
) O
of O
isoform O
CYP2A6 O
observed O
. O
No O
inhibition O
of O
any O
of O
the O
other O
isoforms O
tested O
was O
observed O
at O
gabapentin B-DRUG
concentrations O
up O
to O
171 O
mg O
/ O
mL O
( O
approximately O
15 O
times O
the O
Cmax O
at O
3600 O
mg O
/ O
day O
) O
. O
Gabapentin B-DRUG
is O
not O
appreciably O
metabolized O
nor O
does O
it O
interfere O
with O
the O
metabolism O
of O
commonly O
coadministered O
antiepileptic B-GROUP
drugs I-GROUP
. O
The O
drug O
interaction O
data O
described O
in O
this O
section O
were O
obtained O
from O
studies O
involving O
healthy O
adults O
and O
adult O
patients O
with O
epilepsy O
. O
Phenytoin B-DRUG
: O
In O
a O
single O
( O
400 O
mg O
) O
and O
multiple O
dose O
( O
400 O
mg O
TID O
) O
study O
of O
Neurontin B-BRAND
in O
epileptic O
patients O
( O
N O
= O
8 O
) O
maintained O
on O
phenytoin B-DRUG
monotherapy O
for O
at O
least O
2 O
months O
, O
gabapentin B-DRUG
had O
no O
effect O
on O
the O
steady O
- O
state O
trough O
plasma O
concentrations O
of O
phenytoin B-DRUG
and O
phenytoin B-DRUG
had O
no O
effect O
on O
gabapentin B-DRUG
pharmacokinetics O
. O
Carbamazepine B-DRUG
: O
Steady O
- O
state O
trough O
plasma O
carbamazepine B-DRUG
and O
carbamazepine B-DRUG_N
10 I-DRUG_N
, I-DRUG_N
11 I-DRUG_N
epoxide I-DRUG_N
concentrations O
were O
not O
affected O
by O
concomitant O
gabapentin B-DRUG
( O
400 O
mg O
TID O
; O
N O
= O
12 O
) O
administration O
. O
Likewise O
, O
gabapentin B-DRUG
pharmacokinetics O
were O
unaltered O
by O
carbamazepine B-DRUG
administration O
. O
Valproic B-DRUG
Acid I-DRUG
: O
The O
mean O
steady O
- O
state O
trough O
serum O
valproic B-DRUG
acid I-DRUG
concentrations O
prior O
to O
and O
during O
concomitant O
gabapentin B-DRUG
administration O
( O
400 O
mg O
TID O
; O
N O
= O
17 O
) O
were O
not O
different O
and O
neither O
were O
gabapentin B-DRUG
pharmacokinetic O
parameters O
affected O
by O
valproic B-DRUG
acid I-DRUG
. O
Phenobarbital B-DRUG
: O
Estimates O
of O
steady O
- O
state O
pharmacokinetic O
parameters O
for O
phenobarbital B-DRUG

or O
gabapentin B-DRUG
( O
300 O
mg O
TID O
; O
N O
= O
12 O
) O
are O
identical O
whether O
the O
drugs O
are O
administered O
alone O
or O
together O
. O
Naproxen B-DRUG
: O
Coadministration O
( O
N O
= O
18 O
) O
of O
naproxen B-DRUG
sodium I-DRUG
capsules O
( O
250 O
mg O
) O
with O
Neurontin B-BRAND
( O
125 O
mg O
) O
appears O
to O
increase O
the O
amount O
of O
gabapentin B-DRUG
absorbed O
by O
12 O
% O
to O
15 O
% O
. O
Gabapentin B-DRUG
had O
no O
effect O
on O
naproxen B-DRUG
pharmacokinetic O
parameters O
. O
These O
doses O
are O
lower O
than O
the O
therapeutic O
doses O
for O
both O
drugs O
. O
The O
magnitude O
of O
interaction O
within O
the O
recommended O
dose O
ranges O
of O
either O
drug O
is O
not O
known O
. O
Hydrocodone B-DRUG
: O
Coadministration O
of O
Neurontin B-BRAND
( O
125 O
to O
500 O
mg O
; O
N O
= O
48 O
) O
decreases O
hydrocodone B-DRUG
( O
10 O
mg O
; O
N O
= O
50 O
) O
Cmax O
and O
AUC O
values O
in O
a O
dose O
- O
dependent O
manner O
relative O
to O
administration O
of O
hydrocodone B-DRUG
alone O
; O
Cmax O
and O
AUC O
values O
are O
3 O
% O
to O
4 O
% O
lower O
, O
respectively O
, O
after O
administration O
of O
125 O
mg O
Neurontin B-BRAND
and O
21 O
% O
to O
22 O
% O
lower O
, O
respectively O
, O
after O
administration O
of O
500 O
mg O
Neurontin B-BRAND
. O
The O
mechanism O
for O
this O
interaction O
is O
unknown O
. O
Hydrocodone B-DRUG
increases O
gabapentin B-DRUG
AUC O
values O
by O
14 O
% O
. O
The O
magnitude O
of O
interaction O
at O
other O
doses O
is O
not O
known O
. O
Morphine B-DRUG
: O
A O
literature O
article O
reported O
that O
when O
a O
60 O
- O
mg O
controlled O
- O
release O
morphine B-DRUG
capsule O
was O
administered O
2 O
hours O
prior O
to O
a O
600 O
- O
mg O
Neurontin B-BRAND
capsule O
( O
N O
= O
12 O
) O
, O
mean O
gabapentin B-DRUG
AUC O
increased O
by O
44 O
% O
compared O
to O
gabapentin B-DRUG
administered O
without O
morphine B-DRUG
. O
Morphine B-DRUG
pharmacokinetic O
parameter O
values O
were O
not O
affected O
by O
administration O
of O
Neurontin B-BRAND
2 O
hours O
after O
morphine B-DRUG
. O
The O
magnitude O
of O
interaction O
at O
other O
doses O
is O
not O
known O
. O
Cimetidine B-DRUG
: O
In O
the O
presence O
of O
cimetidine B-DRUG
at O
300 O
mg O
QID O
( O
N O
= O
12 O
) O
the O
mean O
apparent O
oral O
clearance O
of O
gabapentin B-DRUG
fell O
by O
14 O
% O
and O
creatinine O
clearance O
fell O
by O
10 O
% O
. O
Thus O
cimetidine B-DRUG
appeared O
to O
alter O
the O
renal O
excretion O
of O
both O
gabapentin B-DRUG
and O
creatinine O
, O
an O
endogenous O
marker O
of O
renal O
function O
. O
This O
small O
decrease O
in O
excretion O
of O
gabapentin B-DRUG
by O
cimetidine B-DRUG
is O
not O
expected O
to O
be O
of O
clinical O
importance O
. O
The O
effect O
of O
gabapentin B-DRUG
on O
cimetidine B-DRUG
was O
not O
evaluated O
. O
Oral O
Contraceptive B-GROUP
: O
Based O
on O
AUC O
and O

half O
- O
life O
, O
multiple O
- O
dose O
pharmacokinetic O
profiles O
of O
norethindrone B-DRUG
and O
ethinyl B-DRUG
estradiol I-DRUG
following O
administration O
of O
tablets O
containing O
2 O
. O
5 O
mg O
of O
norethindrone B-DRUG
acetate I-DRUG
and O
50 O
mcg O
of O
ethinyl B-DRUG
estradiol I-DRUG
were O
similar O
with O
and O
without O
coadministration O
of O
gabapentin B-DRUG
( O
400 O
mg O
TID O
; O
N O
= O
13 O
) O
. O
The O
Cmax O
of O
norethindrone B-DRUG
was O
13 O
% O
higher O
when O
it O
was O
coadministered O
with O
gabapentin B-DRUG
; O
this O
interaction O
is O
not O
expected O
to O
be O
of O
clinical O
importance O
. O
Antacid B-GROUP
( O
Maalox B-BRAND
) O
: O
Maalox B-BRAND
reduced O
the O
bioavailability O
of O
gabapentin B-DRUG
( O
N O
= O
16 O
) O
by O
about O
20 O
% O
. O
This O
decrease O
in O
bioavailability O
was O
about O
5 O
% O
when O
gabapentin B-DRUG
was O
administered O
2 O
hours O
after O
Maalox B-BRAND
. O
It O
is O
recommended O
that O
gabapentin B-DRUG
be O
taken O
at O
least O
2 O
hours O
following O
Maalox B-BRAND
administration O
. O
Effect O
of O
Probenecid B-DRUG
: O
Probenecid B-DRUG
is O
a O
blocker O
of O
renal O
tubular O
secretion O
. O
Gabapentin B-DRUG
pharmacokinetic O
parameters O
without O
and O
with O
probenecid B-DRUG
were O
comparable O
. O
This O
indicates O
that O
gabapentin B-DRUG
does O
not O
undergo O
renal O
tubular O
secretion O
by O
the O
pathway O
that O
is O
blocked O
by O
probenecid B-DRUG
. O
Drug O
/ O
Laboratory O
Tests O
Interactions O
Because O
false O
positive O
readings O
were O
reported O
with O
the O
Ames O
N O
- O
Multistix O
SG O
dipstick O
test O
for O
urinary O
protein O
when O
gabapentin B-DRUG
was O
added O
to O
other O
antiepileptic B-GROUP
drugs I-GROUP
, O
the O
more O
specific O
sulfosalicylic O
acid O
precipitation O
procedure O
is O
recommended O
to O
determine O
the O
presence O
of O
urine O
protein O
. O

LABORATORY O
TEST O
FINDINGS O
Asymptomatic O
, O
transitory O
changes O
in O
serum O
iron O
have O
been O
observed O
. O
The O
clinical O
significance O
is O
unknown O
. O
Omniscan B-BRAND
interferes O
with O
serum O
calcium O
measurements O
with O
some O
colorimetric O
( O
complexometric O
) O
methods O
commonly O
used O
in O
hospitals O
, O
resulting O
in O
serum O
calcium O
concentrations O
lower O
than O
the O
true O
values O
. O
Thus O
, O
it O
is O
recommended O
not O
to O
use O
such O
methods O
for O
12 O
- O
24 O
hours O
after O
administration O
of O
Omniscan B-BRAND
. O
If O
such O
measurements O
are O
necessary O
, O
the O
use O
of O
other O
methods O
is O
recommended O
. O
All O
patients O
in O
whom O
this O
effect O
was O
observed O
remained O
asymptomatic O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
. O

No O
drug O
interactions O
have O
been O
observed O
with O
the O
Vitrasert B-BRAND
Implant O
. O
There O
is O
limited O
experience O
with O
use O
of O
retinal O
tamponades O
in O
conjunction O
with O
the O
Vitrasert B-BRAND
Implant O
. O

Substances O
that O
are O
inducers O
of O
CYP3A4 O
activity O
increase O
the O
metabolism O
of O
gefitinib B-DRUG
and O
decrease O
its O
plasma O
concentrations O
. O
In O
patients O
receiving O
a O
potent O
CYP3A4 O
inducer O
such O
as O
rifampicin B-DRUG
or O
phenytoin B-DRUG
, O
a O
dose O
increase O
to O
500 O
mg O
daily O
should O
be O
considered O
in O
the O
absence O
of O
severe O
adverse O
drug O
reaction O
, O
and O
clinical O
response O
and O
adverse O
events O
should O
be O
carefully O
monitored O
( O
see O
CLINICAL O
PHARMACOLOGY O
- O
Pharmacokinetics O
- O
Drug O
- O
Drug O
Interactions O
and O
DOSAGE O
AND O
ADMINISTRATION O
- O
Dosage O
Adjustment O
sections O
) O
. O
International O
Normalized O
Ratio O
( O
INR O
) O
elevations O
and O
/ O
or O
bleeding O
events O
have O
been O
reported O
in O
some O
patients O
taking O
warfarin B-DRUG
while O
on O
IRESSA B-BRAND
therapy O
. O
Patients O
taking O
warfarin B-DRUG
should O
be O
monitored O
regularly O
for O
changes O
in O
prothrombin O
time O
or O
INR O
. O
Substances O
that O
are O
potent O
inhibitors O
of O
CYP3A4 O
activity O
( O
eg O
, O
ketoconazole B-DRUG
and O
itraconazole B-DRUG
) O
decrease O
gefitinib B-DRUG
metabolism O
and O
increase O
gefitinib B-DRUG
plasma O
concentrations O
. O
This O
increase O
may O
be O
clinically O
relevant O
as O
adverse O
experiences O
are O
related O
to O
dose O
and O
exposure O
; O
therefore O
, O
caution O
should O
be O
used O
when O
administering O
CYP3A4 O
inhibitors O
with O
IRESSA B-BRAND
. O
Drugs O
that O
cause O
significant O
sustained O
elevation O
in O
gastric O
pH O
( O
histamine B-GROUP
H2 I-GROUP
- I-GROUP
receptor I-GROUP
antagonists I-GROUP
such O
as O
ranitidine B-DRUG
or O
cimetidine B-DRUG
) O
may O
reduce O
plasma O
concentrations O
of O
IRESSA B-BRAND
and O
therefore O
potentially O
may O
reduce O
efficacy O
. O
Phase O
II O
clinical O
trial O
data O
, O
where O
IRESSA B-BRAND
and O
vinorelbine B-DRUG
have O
been O
used O
concomitantly O
, O
indicate O
that O
IRESSA B-BRAND
may O
exacerbate O
the O
neutropenic O
effect O
of O
vinorelbine B-DRUG
. O

No O
specific O
drug O
interaction O
studies O
have O
been O
conducted O
. O
For O
information O
on O
the O
pharmacokinetics O
of O
Gemzar B-BRAND
and O
cisplatin B-DRUG
in O
combination O
, O
see O
Drug O
Interactions O
under O
CLINICAL O
PHARMACOLOGY O
section O
. O

) O
Clinical O
Laboratory O
increased O
creatine O
positive O
antinuclear O
phosphokinase O
antibody O
increased O
bilirubin O
increased O
liver O
transaminases O
( O
AST O
( O
SGOT O
) O
, O
ALT O
( O
SGPT O
) O
increased O
alkaline O
phophatase O
Hematopoietic O
anemia O
thrombocytopenia O
leukopenia O
bone O
marrow O
hypoplasia O
eosinophilia O
Immunologic O
angioedema O
anaphylaxis O
laryngeal O
edema O
Lupus O
- O
like O
syndrome O
urticaria O
vasculitis O
Integumentary O
exfoliative O
dermatitis O
alopecia O
rash O
dermatitis O
pruritus O

Administration O
of O
repeat O
doses O
of O
FACTIVE B-BRAND
had O
no O
effect O
on O
the O
repeat O
dose O
pharmacokinetics O
of O
theophylline B-DRUG
, O
digoxin B-DRUG
or O
an O
ethinylestradiol B-DRUG
/ O
levonorgestrol O
oral O
contraceptive B-GROUP
product I-GROUP
in O
healthy O
subjects O
. O
Concomitant O
administration O
of O
FACTIVE B-BRAND
and O
calcium B-DRUG
carbonate I-DRUG
, O
cimetidine B-DRUG
, O
omeprazole B-DRUG
, O
or O
an O
estrogen B-GROUP
/ O
progesterone B-DRUG
oral O
contraceptive B-GROUP
produced O
minor O
changes O
in O
the O
pharmacokinetics O
of O
gemifloxacin B-DRUG
, O
which O
were O
considered O
to O
be O
without O
clinical O
significance O
. O
Concomitant O
administration O
of O
FACTIVE B-BRAND
with O
probenecid B-DRUG
resulted O
in O
a O
45 O
% O
increase O
in O
systemic O
exposure O
to O
gemifloxacin B-DRUG
. O
FACTIVE B-BRAND
had O
no O
significant O
effect O
on O
the O
anticoagulant O
effect O
of O
warfarin B-DRUG
in O
healthy O
subjects O
on O
stable O
warfarin B-DRUG
therapy O
. O
However O
, O
because O
some O
quinolones B-GROUP
have O
been O
reported O
to O
enhance O
the O
anticoagulant O
effects O
of O
warfarin B-DRUG
or O
its O
derivatives O
in O
patients O
, O
the O
prothrombin O
time O
or O
other O
suitable O
coagulation O
test O
should O
be O
closely O
monitored O
if O
a O
quinolone B-GROUP
antimicrobial I-GROUP
is O
administered O
concomitantly O
with O
warfarin B-DRUG
or O
its O
derivatives O
. O
Quinolones B-GROUP
form O
chelates O
with O
alkaline O
earth O
and O
transition O
metals O
. O
The O
absorption O
of O
oral O
gemifloxacin B-DRUG
is O
significantly O
reduced O
by O
the O
concomitant O
administration O
of O
an O
antacid B-GROUP
containing O
aluminum B-DRUG
and O
magnesium B-DRUG
. O
Magnesium B-DRUG
- O
and O
/ O
or O
aluminum B-DRUG
- O
containing O
antacids B-GROUP
, O
products O
containing O
ferrous B-DRUG
sulfate I-DRUG
( O
iron B-DRUG
) O
, O
multivitamin B-GROUP
preparations I-GROUP
containing O
zinc B-DRUG
or O
other O
metal O
cations O
, O
or O
Videx B-BRAND
( O
didanosine B-DRUG
) O
chewable O
/ O
buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
should O
not O
be O
taken O
within O
3 O
hours O
before O
or O
2 O
hours O
after O
FACTIVE B-BRAND
. O
Sucralfate B-DRUG
should O
not O
be O
taken O
within O
2 O
hours O
of O
FACTIVE B-BRAND
. O

There O
have O
been O
no O
formal O
drug O
- O
interaction O
studies O
performed O
with O
Mylotarg B-BRAND
. O
The O
potential O
for O
drug O
- O
drug O
interaction O
with O
drugs O
affected O
by O
cytochrome O
P450 O
enzymes O
may O
not O
be O
ruled O
out O
. O
Laboratory O
Test O
Interactions O
Mylotarg B-BRAND
is O
not O
known O
to O
interfere O
with O
any O
routine O
diagnostic O
tests O
. O

Interactions O
between O
COPAXONE B-BRAND
and O
other O
drugs O
have O
not O
been O
fully O
evaluated O
. O
Results O
from O
existing O
clinical O
trials O
suggest O
no O
significant O
interactions O
between O
COPAXONE B-BRAND
and O
other O
therapies O
commonly O
used O
in O
MS O
patients O
, O
including O
the O
concurrent O
use O
of O
corticosteroids B-GROUP
for O
up O
to O
28 O
days O
. O
COPAXONE B-BRAND
has O
not O
been O
formally O
evaluated O
in O
combination O
with O
Interferon B-DRUG
beta I-DRUG
. O
However O
, O
10 O
patients O
who O
switched O
from O
therapy O
with O
Interferon B-DRUG
beta I-DRUG
to O
COPAXONE B-BRAND
did O
not O
report O
any O
serious O
and O
unexpected O
adverse O
reactions O
thought O
to O
be O
related O
to O
treatment O
. O

The O
hypoglycemic O
action O
of O
sulfonylureas B-GROUP
may O
be O
potentiated O
by O
certain O
drugs O
including O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
and O
other O
drugs O
that O
are O
highly O
protein O
bound O
, O
salicylates B-GROUP
, O
sulfonamides B-GROUP
, O
chloramphenicol B-DRUG
, O
probenecid B-DRUG
, O
coumarins B-GROUP
, O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
, O
and O
beta B-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
. O
When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
MICRONASE B-BRAND
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O
When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
MICRONASE B-BRAND
, O
the O
patient O
should O
be O
observed O
closely O
for O
loss O
of O
control O
. O
Certain O
drugs O
tend O
to O
produce O
hyperglycemia O
and O
may O
lead O
to O
loss O
of O
control O
. O
These O
drugs O
include O
the O
thiazides B-GROUP
and O
other O
diuretics B-GROUP
, O
corticosteroids B-GROUP
, O
phe O
- O
nothiazines O
, O
thyroid B-GROUP
products I-GROUP
, O
estrogens B-GROUP
, O
oral O
contraceptives B-GROUP
, O
phenytoin B-DRUG
, O
nicotinic B-DRUG
acid I-DRUG
, O
sympathomimet O
- O
ics O
, O
calcium B-GROUP
channel I-GROUP
blocking I-GROUP
drugs I-GROUP
, O
and O
isoniazid B-DRUG
. O
When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
MICRONASE B-BRAND
, O
the O
patient O
should O
be O
closely O
observed O
for O
loss O
of O
control O
. O
When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
MICRONASE B-BRAND
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O
A O
possible O
interaction O
between O
glyburide B-DRUG
and O
ciprofloxacin B-DRUG
, O
a O
fluoroquinolone B-GROUP
antibiotic I-GROUP
, O
has O
been O
reported O
, O
resulting O
in O
a O
potentiation O
of O
the O
hypoglycemic O
action O
of O
glyburide B-DRUG
. O
The O
mechanism O
for O
this O
interaction O
is O
not O
known O
. O
A O
potential O
interaction O
between O
oral O
miconazole B-DRUG
and O
oral O
hypoglycemic B-GROUP
agents I-GROUP
leading O
to O
severe O
hypoglycemia O
has O
been O
reported O
. O
Whether O
this O
interaction O
also O
occurs O
with O
the O
intravenous O
, O
topical O
or O
vaginal O
preparations O
of O
miconazole B-DRUG
is O
not O
known O
. O
Metformin B-DRUG
: O
In O
a O
single O
- O
dose O
interaction O
study O
in O
NIDDM O
subjects O
, O
decreases O
in O
glyburide B-DRUG
AUC O
and O
Cmax O
were O
observed O
, O
but O
were O
highly O
variable O
. O
The O
single O
- O
dose O
nature O
of O
this O
study O
and O
the O
lack O
of O
correlation O
between O
glyburide B-DRUG
blood O
levels O
and O
pharmaco O
- O
dynamic O
effects O
, O
makes O
the O
clinical O
significance O
of O
this O
interaction O
uncertain O
. O
Coadministration O
of O
gly O
- O
buride O
and O
metformin B-DRUG
did O
not O
result O
in O
any O
changes O
in O
either O
metformin B-DRUG

pharmacokinetics O
or O
pharmaco O
- O
dynamics O
. O

Many O
other O
medicines O
may O
increase O
or O
decrease O
the O
effects O
of O
glimepiride B-DRUG
or O
affect O
your O
condition O
. O
Before O
taking O
glimepiride B-DRUG
, O
tell O
your O
doctor O
if O
you O
are O
taking O
any O
of O
the O
following O
medicines O
: O
- O
aspirin B-BRAND
or O
another O
salicylate B-GROUP
such O
as O
magnesium B-DRUG
/ I-DRUG
choline I-DRUG
salicylate I-DRUG
( O
Trilisate B-BRAND
) O
, O
salsalate B-DRUG
( O
Disalcid B-BRAND
, O
others O
) O
, O
choline B-DRUG
salicylate I-DRUG
( O
Arthropan B-DRUG
) O
, O
magnesium B-DRUG
salicylate I-DRUG
( O
Magan B-BRAND
) O
, O
or O
bismuth B-DRUG
subsalicylate I-DRUG
( O
Pepto B-BRAND
- I-BRAND
Bismol I-BRAND
) O
; O
- O
a O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drug I-GROUP
( O
NSAID B-GROUP
) O
such O
as O
ibuprofen B-DRUG
( O
Motrin B-BRAND
, O
Advil B-BRAND
, O
Nuprin B-BRAND
, O
others O
) O
, O
ketoprofen B-DRUG
( O
Orudis B-BRAND
, O
Orudis B-BRAND
KT I-BRAND
, O
Oruvail B-BRAND
) O
, O
diclofenac B-DRUG
( O
Voltaren B-BRAND
, O
Cataflam B-BRAND
) O
, O
etodolac B-DRUG
( O
Lodine B-BRAND
) O
, O
indomethacin B-DRUG
( O
Indocin B-BRAND
) O
, O
nabumetone B-DRUG
( O
Relafen B-BRAND
) O
, O
oxaprozin B-DRUG
( O
Daypro B-BRAND
) O
, O
and O
naproxen B-DRUG
( O
Anaprox B-BRAND
, O
Naprosyn B-BRAND
, O
Aleve B-BRAND
) O
; O
- O
a O
sulfa O
- O
based O
drug O
such O
as O
sulfamethoxazole B-DRUG
- O
trimethoprim B-DRUG
( O
Bactrim B-BRAND
, O
Septra B-BRAND
) O
, O
sulfisoxazole B-DRUG
( O
Gantrisin B-BRAND
) O
, O
or O
sulfasalazine B-DRUG
( O
Azulfidine B-BRAND
) O
; O
- O
a O
monoamine B-GROUP
oxidase I-GROUP
inhibitor I-GROUP
( O
MAOI B-GROUP
) O
such O
as O
isocarboxazid B-DRUG
( O
Marplan B-BRAND
) O
, O
tranylcypromine B-DRUG
( O
Parnate B-BRAND
) O
, O
or O
phenelzine B-DRUG
( O
Nardil B-BRAND
) O
; O
- O
a O
beta B-GROUP
- I-GROUP
blocker I-GROUP
such O
as O
propranolol B-DRUG
( O
Inderal B-BRAND
) O
, O
atenolol B-DRUG
( O
Tenormin B-BRAND
) O
, O
acebutolol B-DRUG
( O
Sectral B-BRAND
) O
, O
metoprolol B-DRUG
( O
Lopressor B-BRAND
) O
, O
and O
others O
; O
- O
a O
diuretic B-GROUP
( O
water O
pill O
) O
such O
as O
hydrochlorothiazide B-DRUG
( O
HCTZ B-DRUG
, O
Hydrodiuril B-BRAND
) O
, O
chlorothiazide B-DRUG
( O
Diuril B-BRAND
) O
, O
and O
others O
; O
- O
a O
steroid B-GROUP
medicine I-GROUP
such O
as O
prednisone B-DRUG
( O
Deltasone B-BRAND
, O
Orasone B-BRAND
, O
others O
) O
, O
methylprednisolone B-DRUG
( O
Medrol B-BRAND
, O
others O
) O
, O
prednisolone B-DRUG
( O

Prelone B-BRAND
, O
Pediapred B-BRAND
, O
others O
) O
, O
and O
others O
; O
- O
a O
phenothiazine B-GROUP
such O
as O
chlorpromazine B-DRUG
( O
Thorazine B-BRAND
) O
, O
fluphenazine B-DRUG
( O
Prolixin B-BRAND
, O
Permitil B-BRAND
) O
, O
prochlorperazine B-DRUG
( O
Compazine B-BRAND
) O
, O
promethazine B-DRUG
( O
Phenergan B-BRAND
) O
, O
and O
others O
; O
- O
phenytoin B-DRUG
( O
Dilantin B-BRAND
) O
; O
- O
isoniazid B-DRUG
( O
Nydrazid B-BRAND
) O
; O
- O
rifampin B-DRUG
( O
Rifadin B-BRAND
, O
Rifamate B-BRAND
) O
; O
or O
- O
over O
- O
the O
- O
counter O
cough O
, O
cold O
, O
allergy O
, O
or O
weight O
loss O
medications O
. O
You O
may O
require O
a O
dosage O
adjustment O
or O
special O
monitoring O
if O
you O
are O
taking O
any O
of O
the O
medicines O
listed O
above O
. O
Drugs O
other O
than O
those O
listed O
here O
may O
also O
interact O
with O
glimepiride B-DRUG
or O
affect O
your O
condition O
. O
Talk O
to O
your O
doctor O
and O
pharmacist O
before O
taking O
any O
prescription O
or O
over O
- O
the O
- O
counter O
medicines O
, O
including O
herbal O
products O
. O

Immediate O
and O
Extended O
Release O
Tablets O
The O
hypoglycemic O
action O
of O
sulfonylureas B-GROUP
may O
be O
potentiated O
by O
certain O
drugs O
including O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
, O
some O
azoles B-GROUP
and O
other O
drugs O
that O
are O
highly O
protein O
bound O
, O
salicylates B-GROUP
, O
sulfonamides B-GROUP
, O
chloramphenicol B-DRUG
, O
probenecid B-DRUG
, O
coumarins B-GROUP
, O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
, O
and O
beta B-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
. O
When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
glipizide B-DRUG
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O
When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
glipizide B-DRUG
, O
the O
patient O
should O
be O
observed O
closely O
for O
loss O
of O
control O
. O
In O
vitro O
binding O
studies O
with O
human O
serum O
proteins O
indicate O
that O
glipizide B-DRUG
binds O
differently O
than O
tolbutamide B-DRUG
and O
does O
not O
interact O
with O
salicylate B-GROUP
or O
dicumarol B-DRUG
. O
However O
, O
caution O
must O
be O
exercised O
in O
extrapolating O
these O
findings O
to O
the O
clinical O
situation O
and O
in O
the O
use O
of O
glipizide B-DRUG
with O
these O
drugs O
. O
Certain O
drugs O
tend O
to O
produce O
hyperglycemia O
and O
may O
lead O
to O
loss O
of O
control O
. O
These O
drugs O
include O
the O
thiazides B-GROUP
and O
other O
diuretics B-GROUP
, O
corticosteroids B-GROUP
, O
phenothiazines B-GROUP
, O
thyroid B-GROUP
products I-GROUP
, O
estrogens B-GROUP
, O
oral O
contraceptives B-GROUP
, O
phenytoin B-DRUG
, O
nicotinic B-DRUG
acid I-DRUG
, O
sympathomimetics B-GROUP
, O
calcium B-GROUP
channel I-GROUP
blocking I-GROUP
drugs I-GROUP
, O
and O
isoniazid B-DRUG
. O
When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
glipizide B-DRUG
, O
the O
patient O
should O
be O
closely O
observed O
for O
loss O
of O
control O
. O
When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
glipizide B-DRUG
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O
A O
potential O
interaction O
between O
oral O
miconazole B-DRUG
and O
oral O
hypoglycemic B-GROUP
agents I-GROUP
leading O
to O
severe O
hypoglycemia O
has O
been O
reported O
. O
Whether O
this O
interaction O
also O
occurs O
with O
the O
intravenous O
, O
topical O
, O
or O
vaginal O
preparations O
of O
miconazole B-DRUG
is O
not O
known O
. O
The O
effect O
of O
concomitant O
administration O
of O
fluconazole B-DRUG
and O
glipizide B-DRUG
has O
been O
demonstrated O
in O
a O
placebo O
- O
controlled O
crossover O
study O
in O
normal O
volunteers O
. O
All O
subjects O
received O
glipizide B-DRUG
alone O
and O
following O
treatment O
with O
100 O
mg O
of O
fluconazole B-DRUG
as O
a O
single O
daily O
oral O
dose O
for O
seven O
days O
. O
The O
mean O
percentage O
increase O
in O
the O
glipizide B-DRUG
AUC O
after O
fluconazole B-DRUG
administration O
was O
56 O
. O
9 O
% O
( O
range O

: O
35 O
to O
81 O
) O
. O

The O
concurrent O
use O
of O
Robinul B-BRAND
Injection O
with O
other O
anticholinergics B-GROUP
or O
medications O
with O
anticholinergic O
activity O
, O
such O
as O
phenothiazines B-GROUP
, O
antiparkinson B-GROUP
drugs I-GROUP
, O
or O
tricyclic B-GROUP
antidepressants I-GROUP
, O
may O
intensify O
the O
antimuscarinic O
effects O
and O
may O
result O
in O
an O
increase O
in O
anticholinergic O
side O
effects O
. O
Concomitant O
administration O
of O
Robinul B-BRAND
Injection O
and O
potassium B-DRUG
chloride I-DRUG
in O
a O
wax O
matrix O
may O
increase O
the O
severity O
of O
potassium O
chloride O
- O
induced O
gastrointestinal O
lesions O
as O
a O
result O
of O
a O
slower O
gastrointestinal O
transit O
time O
. O

The O
Factrel B-BRAND
test O
should O
be O
conducted O
in O
the O
absence O
of O
other O
drugs O
which O
directly O
affect O
the O
pituitary O
secretion O
of O
the O
gonadotropins O
. O
These O
would O
include O
a O
variety O
of O
preparations O
which O
contain O
androgens B-GROUP
, O
estrogens B-GROUP
, O
progestins B-GROUP
, O
or O
glucocorticoids B-GROUP
. O
The O
gonadotropin O
levels O
may O
be O
transiently O
elevated O
by O
spironolactone B-DRUG
, O
minimally O
elevated O
by O
levodopa B-DRUG
, O
and O
suppressed O
by O
oral O
contraceptives B-GROUP
and O
digoxin B-DRUG
. O
The O
response O
to O
Factrel B-BRAND
may O
be O
blunted O
by O
phenothiazines B-GROUP
and O
dopamine B-GROUP
antagonists I-GROUP
which O
cause O
a O
rise O
in O
prolactin O
. O

No O
formal O
drug O
- O
drug O
interaction O
studies O
have O
been O
performed O
. O
No O
confirmed O
interactions O
have O
been O
reported O
between O
ZOLADEX B-BRAND
and O
other O
drugs O

Antacids B-GROUP
, O
Sucralfate B-DRUG
, O
Metal O
Cations O
, O
Multivitamins B-GROUP
Quinolones B-GROUP
form O
chelates O
with O
alkaline O
earth O
and O
transition O
metal O
cations O
. O
Administration O
of O
quinolones B-GROUP
with O
antacids B-GROUP
containing O
aluminum B-DRUG
, O
magnesium B-DRUG
, O
or O
calcium B-DRUG
, O
with O
sucralfate B-DRUG
, O
with O
metal O
cations O
such O
as O
iron B-DRUG
, O
or O
with O
multivitamins B-GROUP
containing O
iron B-DRUG
or O
zinc B-DRUG
, O
or O
with O
formulations O
containing O
divalent O
and O
trivalent O
cations O
such O
as O
VIDEX B-BRAND
( O
didanosine B-DRUG
) O
chewable O
/ O
buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
, O
may O
substantially O
interfere O
with O
the O
absorption O
of O
quinolones B-GROUP
, O
resulting O
in O
systemic O
concentrations O
considerably O
lower O
than O
desired O
. O
These O
agents O
should O
not O
be O
taken O
within O
4 O
hours O
before O
or O
4 O
hours O
after O
grepafloxacin B-DRUG
administration O
. O
Caffeine B-DRUG
Theobromine B-DRUG
Grepafloxacin B-DRUG
, O
like O
other O
quinolones B-GROUP
, O
may O
inhibit O
the O
metabolism O
of O
caffeine B-DRUG
and O
theobromine B-DRUG
. O
These O
stimulants O
are O
commonly O
found O
in O
coffee O
and O
tea O
, O
respectively O
. O
In O
some O
patients O
, O
this O
may O
lead O
to O
reduced O
clearance O
, O
prolongation O
of O
plasma O
half O
- O
life O
, O
and O
enhanced O
effects O
of O
caffeine B-DRUG
and O
theobromine B-DRUG
. O
Theophylline B-DRUG
: O
Grepafloxacin B-DRUG
is O
a O
competitive O
inhibitor O
of O
the O
metabolism O
of O
theophylline B-DRUG
. O
Serum O
theophylline B-DRUG
concentrations O
increase O
when O
grepafloxacin B-DRUG
is O
initiated O
in O
a O
patient O
maintained O
on O
theophylline B-DRUG
. O
When O
initiating O
a O
multi O
- O
day O
course O
of O
grepafloxacin B-DRUG
in O
a O
patient O
maintained O
on O
theophylline B-DRUG
, O
the O
theophylline B-DRUG
maintenance O
dose O
should O
be O
halved O
for O
the O
period O
of O
concurrent O
use O
of O
grepafloxacin B-DRUG
and O
monitoring O
of O
serum O
theophylline B-DRUG
concentrations O
should O
be O
initiated O
as O
a O
guide O
to O
further O
dosage O
adjustments O
. O
Warfarin B-DRUG
: O
In O
subjects O
receiving O
warfarin B-DRUG
, O
no O
significant O
change O
in O
clotting O
time O
was O
observed O
when O
grepafloxacin B-DRUG
was O
coadministered O
. O
However O
, O
because O
some O
quinolones B-GROUP
have O
been O
reported O
to O
enhance O
the O
effects O
of O
warfarin B-DRUG
or O
its O
derivatives O
, O
prothrombin O
time O
or O
other O
suitable O
anticoagulation O
test O
should O
be O
monitored O
closely O
if O
a O
quinolone B-GROUP
antimicrobial I-GROUP
is O
administered O
with O
warfarin B-DRUG
or O
its O
derivatives O
. O
Drugs O
Metabolized O
by O
Cytochrome O
P450 O
Enzymes O
The O
drug O
interaction O
study O
evaluating O
the O
effect O
of O
grepafloxacin B-DRUG
on O
theophylline B-DRUG
indicates O

that O
grepafloxacin B-DRUG
inhibits O
theophylline B-DRUG
metabolism O
, O
which O
is O
mediated O
by O
CYP1A2 O
. O
While O
no O
clinical O
studies O
have O
been O
conducted O
to O
evaluate O
the O
effect O
of O
grepafloxacin B-DRUG
on O
the O
metabolism O
of O
C O
. O
P O
. O
A O
. O
substrates O
, O
in O
vitro O
data O
suggest O
similar O
effects O
of O
grepafloxacin B-DRUG
in O
CYP3A4 O
mediated O
metabolism O
and O
theophylline B-DRUG
metabolism O
. O
In O
addition O
, O
other O
quinolones B-GROUP
have O
been O
reported O
to O
decrease O
the O
CYP3A4 O
- O
mediated O
metabolism O
of O
cyclosporine B-DRUG
. O
Other O
drugs O
metabolized O
by O
C O
. O
P O
. O
A O
. O
include O
terfenadine B-DRUG
, O
astemizole B-DRUG
, O
cisapride B-DRUG
, O
midazolam B-DRUG
, O
and O
triazolam B-DRUG
. O
The O
clinical O
relevance O
of O
the O
potential O
effect O
of O
grepafloxacin B-DRUG
on O
the O
metabolism O
of O
C O
. O
P O
. O
A O
. O
substrates O
is O
not O
known O
. O
Patients O
receiving O
concurrent O
administration O
of O
substrates O
of O
C O
. O
P O
. O
A O
. O
were O
not O
excluded O
from O
clinical O
trials O
of O
grepafloxacin B-DRUG
. O
Nonsteroidal B-GROUP
Anti I-GROUP
- I-GROUP
inflammatory I-GROUP
Drugs I-GROUP
( O
NSAIDs B-GROUP
) O
: O
The O
concomitant O
administration O
of O
a O
nonsteroidal B-GROUP
anti I-GROUP
inflammatory I-GROUP
drug I-GROUP
with O
a O
quinolone B-GROUP
may O
increase O
the O
risks O
of O
CNS O
stimulation O
and O
convulsions O
. O
Antidiabetic B-GROUP
Agents I-GROUP
: O
Disturbances O
of O
blood O
glucose O
, O
including O
hyperglycemia O
and O
hypoglycemia O
, O
have O
been O
reported O
in O
patients O
treated O
concomitantly O
with O
quinolones B-GROUP
and O
an O
antidiabetic B-GROUP
agent I-GROUP
. O
Therefore O
, O
careful O
monitoring O
of O
blood O
glucose O
is O
recommended O
when O
these O
agents O
are O
coadministered O
. O

Patients O
on O
warfarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulant I-GROUP
therapy O
may O
require O
dosage O
adjustment O
of O
the O
anticoagulant O
during O
and O
after O
griseofulvin B-DRUG
therapy O
. O
Concomitant O
use O
of O
barbiturates B-GROUP
usually O
depresses O
griseofulvin B-DRUG
activity O
and O
may O
necessitate O
raising O
the O
dosage O
. O
The O
concomitant O
administration O
of O
griseofulvin B-DRUG
has O
been O
reported O
to O
reduce O
the O
efficacy O
of O
oral O
contraceptives B-GROUP
and O
to O
increase O
the O
incidence O
of O
breakthrough O
bleeding O
. O

The O
use O
of O
codeine B-DRUG
may O
result O
in O
additive O
CNS O
depressant O
effects O
when O
coadministered O
with O
alcohol B-DRUG
, O
antihistamines B-GROUP
, O
psychotropics B-GROUP
or O
other O
drugs O
that O
produce O
CNS O
depression O
. O
Serious O
toxicity O
may O
result O
if O
dextromethorphan B-DRUG
is O
coadministered O
with O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
( O
MAOIs B-GROUP
) O
. O
The O
use O
of O
dextromethorphan B-DRUG
hydrobromide I-DRUG
may O
result O
in O
additive O
CNS O
depressant O
effects O
when O
coadministered O
with O
alcohol B-DRUG
, O
antihistamines B-GROUP
, O
psychotropics B-GROUP
or O
other O
drugs O
that O
produce O
CNS O
depression O
. O

http O
: O
/ O
/ O
www O
. O
rxlist O
. O
com O
/ O
cgi O
/ O
generic3 O
/ O
guanethidine O
_ O
od O
. O
htm O

The O
potential O
for O
increased O
sedation O
when O
guanfacine B-DRUG
is O
given O
with O
other O
CNS B-GROUP
- I-GROUP
depressant I-GROUP
drug I-GROUP
should O
be O
appreciated O
. O
The O
administration O
of O
guanfacine B-DRUG
concomitantly O
with O
known O
microsomal O
enzyme O
inducer O
( O
phenobarbital B-DRUG
or O
phenytoin B-DRUG
) O
to O
two O
patients O
with O
renal O
impairment O
reportedly O
resulted O
in O
significant O
reductions O
in O
elimination O
half O
- O
life O
and O
plasma O
concentration O
. O
In O
such O
cases O
, O
therefore O
, O
more O
frequent O
dosing O
may O
be O
required O
to O
achieve O
or O
maintain O
the O
desired O
hypotensive O
response O
. O
Further O
, O
if O
guanfacine B-DRUG
is O
to O
be O
discontinued O
in O
such O
patients O
, O
careful O
tapering O
of O
the O
dosage O
may O
be O
necessary O
in O
order O
to O
avoid O
rebound O
phenomena O
. O
TCAs B-GROUP
decrease O
the O
hypotensive O
effect O
of O
guanfacine B-DRUG
. O
Noncardioselective B-GROUP
beta I-GROUP
- I-GROUP
blockers I-GROUP
( O
nadolol B-DRUG
, O
porpranolol O
, O
timolol B-DRUG
) O
may O
exacerbate O
rebound O
hypertension O
when O
guanfacine B-DRUG
is O
withdrawn O
. O
The O
beta B-GROUP
- I-GROUP
blocker I-GROUP
should O
be O
withdrawn O
first O
. O
The O
gradual O
withdrawal O
of O
guafacine B-DRUG
or O
a O
cardioselective B-GROUP
beta I-GROUP
- I-GROUP
blocker I-GROUP
could O
be O
substituted O
. O
Anticoagulants B-GROUP
: O
Ten O
patients O
who O
were O
stabilized O
on O
oral O
anticoagulants B-GROUP
were O
given O
guanfacine B-DRUG
, O
1 O
- O
2 O
mg O
/ O
day O
, O
for O
4 O
weeks O
. O
No O
changes O
were O
observed O
in O
the O
degree O
of O
anticoagulation O
. O
In O
several O
well O
- O
controlled O
studies O
, O
guanfacine B-DRUG
was O
administered O
together O
with O
diuretics B-GROUP
with O
no O
drug O
interactions O
reported O
. O
In O
the O
long O
- O
term O
safety O
studies O
, O
guanfacine B-DRUG
was O
given O
concomitantly O
with O
many O
drugs O
without O
evidence O
of O
any O
interactions O
. O
The O
principal O
drugs O
given O
( O
number O
of O
patients O
in O
parentheses O
) O
were O
: O
cardiac B-GROUP
glycosides I-GROUP
( O
115 O
) O
, O
sedatives B-GROUP
and O
hypnotics B-GROUP
( O
103 O
) O
, O
coronary B-GROUP
vasodilators I-GROUP
( O
52 O
) O
, O
oral O
hypoglycemics B-GROUP
( O
45 O
) O
, O
cough O
and O
cold O
preparations O
( O
45 O
) O
, O
NSAIDs B-GROUP
( O
38 O
) O
, O
antihyperlipidemics B-GROUP
( O
29 O
) O
, O
antigout B-GROUP
drugs I-GROUP
( O
24 O
) O
, O
oral O
contraceptives B-GROUP
( O
18 O
) O
, O
bronchodilators B-GROUP
( O
13 O
) O
, O
insulin B-DRUG
( O
10 O
) O
, O
and O
beta B-GROUP
blockers I-GROUP
( O
10 O
) O
. O
Laboratory O
Test O
In O
clinical O
trials O
, O
no O
clinically O
relevant O
laboratory O
test O
abnormalities O
were O
identified O
as O
causally O
related O
to O
drug O
during O
short O
- O
term O
treatment O
with O
guanfacine B-DRUG
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
No O
laboratory O
test O
abnormalities O
related O
to O
the O

use O
of O
guanfacine B-DRUG
have O
been O
identified O
. O

An O
encephalopathic O
syndrome O
( O
characterized O
by O
weakness O
, O
lethargy O
, O
fever O
, O
tremulousness O
and O
confusion O
, O
extrapyramidal O
symptoms O
, O
leukocytosis O
, O
elevated O
serum O
enzymes O
, O
BUN O
, O
and O
FBS O
) O
followed O
by O
irreversible O
brain O
damage O
has O
occurred O
in O
a O
few O
patients O
treated O
with O
lithium B-DRUG
plus O
HALDOL B-BRAND
. O
A O
causal O
relationship O
between O
these O
events O
and O
the O
concomitant O
administration O
of O
lithium B-DRUG
and O
HALDOL B-BRAND
has O
not O
been O
established O
; O
however O
, O
patients O
receiving O
such O
combined O
therapy O
should O
be O
monitored O
closely O
for O
early O
evidence O
of O
neurological O
toxicity O
and O
treatment O
discontinued O
promptly O
if O
such O
signs O
appear O
. O
As O
with O
other O
antipsychotic B-GROUP
agents I-GROUP
, O
it O
should O
be O
noted O
that O
HALDOL B-BRAND
may O
be O
capable O
of O
potentiating O
CNS B-GROUP
depressants I-GROUP
such O
as O
anesthetics B-GROUP
, O
opiates B-GROUP
, O
and O
alcohol B-DRUG
. O
In O
a O
study O
of O
12 O
schizophrenic O
patients O
coadministered O
oral O
haloperidol B-DRUG
and O
rifampin B-DRUG
, O
plasma O
haloperidol B-DRUG
levels O
were O
decreased O
by O
a O
mean O
of O
70 O
% O
and O
mean O
scores O
on O
the O
Brief O
Psychiatric O
Rating O
Scale O
were O
increased O
from O
baseline O
. O
In O
5 O
other O
schizophrenic O
patients O
treated O
with O
oral O
haloperidol B-DRUG
and O
rifampin B-DRUG
, O
discontinuation O
of O
rifampin B-DRUG
produced O
a O
mean O
3 O
. O
3 O
- O
fold O
increase O
in O
haloperidol B-DRUG
concentrations O
. O
Thus O
, O
careful O
monitoring O
of O
clinical O
status O
is O
warranted O
when O
rifampin B-DRUG
is O
administered O
or O
discontinued O
in O
haloperidol B-DRUG
- O
treated O
patients O
. O

FLUOTHANE B-BRAND
augments O
the O
action O
of O
non B-GROUP
- I-GROUP
depolarising I-GROUP
muscle I-GROUP
relaxants I-GROUP
and O
the O
muscle O
relaxant O
effects O
of O
aminoglycosides B-GROUP
. O
FLUOTHANE B-BRAND
may O
augment O
the O
hypotension O
caused O
by O
the O
ganglionic O
- O
blocking O
effect O
of O
tubocurarine B-DRUG
. O
Caution O
should O
be O
exercised O
during O
the O
administration O
of O
adrenaline B-DRUG
to O
patients O
anaesthetised O
with O
FLUOTHANE B-BRAND
as O
arrhythmias O
may O
be O
precipitated O
. O
For O
this O
reason O
the O
dose O
of O
adrenaline B-DRUG
should O
be O
restricted O
and O
an O
antiarrhythmic B-GROUP
agent I-GROUP
administered O
as O
appropriate O
. O
Caution O
should O
also O
be O
applied O
for O
other O
sympathomimetics B-GROUP
, O
and O
for O
aminophylline B-DRUG
and O
theophylline B-DRUG
and O
tricyclic B-GROUP
antidepressants I-GROUP
, O
which O
may O
also O
precipitate O
arrhythmias O
. O

Drug O
Interactions O
: O
a O
. O
Drugs O
Enhancing O
Heparin B-DRUG
Effect O
: O
Oral O
anticoagulants B-GROUP
: O
Heparin B-DRUG
sodium I-DRUG
may O
prolong O
the O
one O
- O
stage O
prothrombin O
time O
. O
Therefore O
, O
when O
heparin B-DRUG
sodium I-DRUG
is O
given O
with O
dicumarol B-DRUG
or O
warfarin B-DRUG
sodium I-DRUG
, O
a O
period O
of O
at O
least O
5 O
hours O
after O
the O
last O
intravenous O
dose O
or O
24 O
hours O
after O
the O
last O
subcutaneous O
dose O
should O
elapse O
before O
blood O
is O
drawn O
if O
a O
valid O
prothrombin O
time O
is O
to O
be O
obtained O
. O
Platelet B-GROUP
inhibitors I-GROUP
: O
Drugs O
such O
as O
acetylsalicylic B-DRUG
acid I-DRUG
, O
dextran B-DRUG
, O
phenylbutazone B-DRUG
, O
ibuprofen B-DRUG
, O
indomethacin B-DRUG
, O
dipyridamole B-DRUG
, O
hydroxychloroquine B-DRUG
and O
others O
that O
interfere O
with O
platelet O
- O
aggregation O
reactions O
( O
the O
main O
hemostatic O
defense O
of O
heparinized O
patients O
) O
may O
induce O
bleeding O
and O
should O
be O
used O
with O
caution O
in O
patients O
receiving O
heparin B-DRUG
sodium I-DRUG
. O
The O
anticoagulant O
effect O
of O
heparin B-DRUG
is O
enhanced O
by O
concurrent O
treatment O
with O
antithrombin B-DRUG
III I-DRUG
( O
human O
) O
in O
patients O
with O
hereditary O
antithrombin O
III O
deficiency O
. O
Thus O
in O
order O
to O
avoid O
bleeding O
, O
reduced O
dosage O
of O
heparin B-DRUG
is O
recommended O
during O
treatment O
with O
antithrombin B-DRUG
III I-DRUG
( O
human O
) O
. O
b O
. O
Drugs O
Decreasing O
Heparin B-DRUG
Effect O
: O
Digitalis B-GROUP
, O
tetracyclines B-GROUP
, O
nicotine B-DRUG
, O
or O
antihistamines B-GROUP
may O
partially O
counteract O
the O
anticoagulant O
action O
of O
heparin B-DRUG
sodium I-DRUG
. O
Heparin B-DRUG
Sodium I-DRUG
Injection O
should O
not O
be O
mixed O
with O
doxorubicin B-DRUG
, O
droperidol B-DRUG
, O
ciprofloxacin B-DRUG
, O
or O
mitoxantrone B-DRUG
, O
since O
it O
has O
been O
reported O
that O
these O
drugs O
are O
incompatible O
with O
heparin B-DRUG
and O
a O
precipitate O
may O
form O
. O
Drug O
/ O
Laboratory O
Tests O
Interactions O
Hyperaminotransferasemia O
: O
Significant O
elevations O
of O
aminotransferase O
( O
SGOT O
[ O
S O
- O
AST O
] O
and O
SGPT O
[ O
S O
- O
ALT O
] O
) O
levels O
have O
occurred O
in O
a O
high O
percentage O
of O
patients O
( O
and O
healthy O
subjects O
) O
who O
have O
received O
heparin B-DRUG
sodium I-DRUG
. O
Since O
aminotransferase O
determinations O
are O
important O
in O
the O
differential O
diagnosis O
of O
myocardial O
infarction O
, O
liver O
disease O
and O
pulmonary O
emboli O
, O
rises O
that O
might O
be O
caused O
by O
drugs O
( O
heparin B-DRUG
sodium I-DRUG
) O
should O
be O
interpreted O
with O
caution O
. O

Opioids B-GROUP
are O
strong O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressants I-GROUP
, O
but O
regular O
users O
develop O
physiological O
tolerance O
allowing O
gradually O
increased O
dosages O
. O
In O
combination O
with O
other O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressants I-GROUP
, O
heroin B-DRUG_N
may O
still O
kill O
even O
experienced O
users O
, O
particularly O
if O
their O
tolerance O
to O
the O
drug O
has O
reduced O
or O
the O
strength O
of O
their O
usual O
dose O
has O
increased O
. O
Toxicology O
studies O
of O
heroin B-DRUG_N
- O
related O
deaths O
reveal O
frequent O
involvement O
of O
other O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressants I-GROUP
, O
including O
alcohol B-DRUG
, O
benzodiazepines B-GROUP
such O
as O
diazepam B-DRUG
( O
Valium B-BRAND
) O
, O
and O
, O
to O
a O
rising O
degree O
, O
methadone B-DRUG
. O
Ironically O
, O
benzodiazepines B-GROUP
are O
often O
used O
in O
the O
treatment O
of O
heroin B-DRUG
addiction O
while O
they O
cause O
much O
more O
severe O
withdrawal O
symptoms O
. O
Cocaine B-DRUG
sometimes O
proves O
to O
be O
fatal O
when O
used O
in O
combination O
with O
heroin B-DRUG_N
. O

No O
information O
available O
. O

Barbiturates B-GROUP
may O
decrease O
the O
effectiveness O
of O
oral O
contraceptives B-GROUP
, O
certain O
antibiotics B-GROUP
, O
quinidine B-DRUG
, O
theophylline B-DRUG
, O
corticosteroids B-GROUP
, O
anticoagulants B-GROUP
, O
and O
beta B-GROUP
blockers I-GROUP
. O

MAO B-GROUP
inhibitors I-GROUP
should O
be O
used O
with O
caution O
in O
patients O
receiving O
hydralazine B-DRUG
. O
When O
other O
potent O
parental O
antihypertensive B-GROUP
drugs I-GROUP
, O
such O
as O
diazoxide B-DRUG
, O
are O
used O
in O
combination O
with O
hydralazine B-DRUG
, O
patients O
should O
be O
continuously O
observed O
for O
several O
hours O
for O
any O
excessive O
fall O
in O
blood O
pressure O
. O
Profound O
hypotensive O
episodes O
may O
occur O
when O
diazoxide B-DRUG
infection O
and O
hydralazine B-DRUG
are O
used O
concomitantly O
. O
Beta B-GROUP
- I-GROUP
blockers I-GROUP
( O
metoprolol B-DRUG
, O
propranolol B-DRUG
) O
serum O
concentrations O
and O
pharmacologic O
effects O
may O
be O
increased O
. O
Monitor O
cardiovascular O
status O
. O
Propranolol B-DRUG
increases O
hydralazines B-DRUG
serum O
concentrations O
. O
Acebutolol B-DRUG
, O
atenolol B-DRUG
, O
and O
nadolol B-DRUG
( O
low O
hepatic O
clearance O
or O
no O
first O
- O
pass O
metabolism O
) O
are O
unlikely O
to O
be O
affected O
. O
NSAIDs B-GROUP
may O
decrease O
the O
hemodynamic O
effects O
of O
hydralazine B-DRUG
; O
avoid O
use O
if O
possible O
or O
closely O
monitor O
cardiovascular O
status O
at O
the O
end O
of O
drug O
interactions O

When O
given O
concurrently O
the O
following O
drugs O
may O
interact O
with O
thiazide B-GROUP
diuretics I-GROUP
. O
Alcohol B-DRUG
, O
barbiturates B-GROUP
, O
or O
narcotics B-GROUP
: O
potentiation O
of O
orthostatic O
hypotension O
may O
occur O
. O
Antidiabetic B-GROUP
drugs I-GROUP
: O
( O
oral O
agents O
and O
insulin B-DRUG
) O
- O
dosage O
adjustment O
of O
the O
antidiabetic B-GROUP
drug I-GROUP
may O
be O
required O
. O
Other O
antihypertensive B-GROUP
drugs I-GROUP
: O
additive O
effect O
or O
potentiation O
. O
Cholestyramine B-DRUG
and O
colestipol B-DRUG
resins B-GROUP
: O
Absorption O
of O
hydrochlorothiazide B-DRUG
is O
impaired O
in O
the O
presence O
of O
anionic B-GROUP
exchange I-GROUP
resins I-GROUP
. O
Single O
doses O
of O
either O
cholestyramine B-DRUG
or O
colestipol B-DRUG
resins B-GROUP
bind O
the O
hydrochlorothiazide B-DRUG
and O
reduce O
its O
absorption O
from O
the O
gastrointestinal O
tract O
by O
up O
to O
85 O
and O
43 O
percent O
, O
respectively O
. O
Corticosteroids B-GROUP
, O
ACTH B-DRUG
: O
intensified O
electrolyte O
depletion O
, O
particularly O
hypokalemia O
. O
Pressor O
amines O
( O
e O
. O
g O
. O
, O
norepinephrine B-DRUG
) O
: O
possible O
decreased O
response O
to O
pressor O
amines O
but O
not O
sufficient O
to O
preclude O
their O
use O
. O
Skeletal B-GROUP
muscle I-GROUP
relaxants I-GROUP
, O
nondepolarizing O
( O
e O
. O
g O
. O
, O
tubocurarine B-DRUG
) O
: O
possible O
increased O
responsiveness O
to O
the O
muscle B-GROUP
relaxant I-GROUP
. O
Lithium B-DRUG
: O
generally O
should O
not O
be O
given O
with O
diuretics B-GROUP
. O
Diuretic B-GROUP
agents I-GROUP
reduce O
the O
renal O
clearance O
of O
lithium B-DRUG
and O
add O
a O
high O
risk O
of O
lithium B-DRUG
toxicity O
. O
Refer O
to O
the O
package O
insert O
for O
lithium B-DRUG
preparations O
before O
use O
of O
such O
preparations O
with O
Hydrochlorothiazide B-DRUG
. O
Non B-GROUP
- I-GROUP
steroidal I-GROUP
Anti I-GROUP
- I-GROUP
inflammatory I-GROUP
Drugs I-GROUP
: O
In O
some O
patients O
, O
the O
administration O
of O
a O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agent I-GROUP
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop B-GROUP
, I-GROUP
potassium I-GROUP
- I-GROUP
sparing I-GROUP
and I-GROUP
thiazide I-GROUP
diuretics I-GROUP
. O
Therefore O
, O
when O
Hydrochlorothiazide B-DRUG
and O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-GROUP
is O
obtained O
. O

Patients O
receiving O
other O
narcotic B-GROUP
analgesics I-GROUP
, O
antipsychotics B-GROUP
, O
antianxiety B-GROUP
agents I-GROUP
, O
or O
other O
CNS B-GROUP
depressants I-GROUP
( O
including O
alcohol B-DRUG
) O
concomitantly O
with O
hydrocodone B-DRUG
and O
acetaminophen B-DRUG
tablets O
may O
exhibit O
an O
additive O
CNS O
depression O
. O
When O
combined O
therapy O
is O
contemplated O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O
The O
use O
of O
MAO B-GROUP
inhibitors I-GROUP
or O
tricyclic B-GROUP
antidepressants I-GROUP
with O
hydrocodone B-DRUG
preparations O
may O
increase O
the O
effect O
of O
either O
the O
antidepressant B-GROUP
or O
hydrocodone B-DRUG
. O
The O
concurrent O
use O
of O
anticholinergics B-GROUP
with O
hydrocodone B-DRUG
may O
produce O
paralytic O
ileus O
. O

No O
information O
available O
. O

Anticoagulants B-GROUP
, O
oral O
( O
Effects O
may O
be O
decreased O
when O
used O
concurrently O
with O
thiazide B-GROUP
diuretics I-GROUP
; O
dosage O
adjustments O
may O
be O
necessary O
. O
) O
Antigout B-GROUP
medications I-GROUP
( O
Thiazide B-GROUP
diuretics I-GROUP
may O
raise O
the O
level O
of O
blood O
uric O
acid O
; O
dosage O
adjustment O
of O
antigout B-GROUP
medications I-GROUP
may O
be O
necessary O
to O
control O
hyperuricemia O
and O
gout O
. O
) O
Antihypertensive B-GROUP
medications I-GROUP
, O
other O
, O
especially O
diazoxide B-DRUG
, O
or O
preanesthetic B-GROUP
and O
anesthetic O
agents O
used O
in O
surgery O
or O
skeletal B-GROUP
- I-GROUP
muscle I-GROUP
relaxants I-GROUP
, O
nondepolarizing O
, O
used O
in O
surgery O
( O
Effects O
may O
be O
potentiated O
when O
used O
concurrently O
with O
thiazide B-GROUP
diuretics I-GROUP
; O
dosage O
adjustments O
may O
be O
necessary O
. O
) O
Amphotericin B-DRUG
B I-DRUG
or O
Corticosteroids B-GROUP
or O
Corticotropin B-DRUG
( O
ACTH B-DRUG
) O
( O
Concurrent O
use O
with O
thiazide B-GROUP
diuretics I-GROUP
may O
intensify O
electrolyte O
imbalance O
, O
particularly O
hypokalemia O
. O
) O
Cardiac B-GROUP
glycosides I-GROUP
( O
Concurrent O
use O
with O
thiazide B-GROUP
diuretics I-GROUP
may O
enhance O
the O
possibility O
of O
digitalis B-GROUP
toxicity O
associated O
with O
hypokalemia O
. O
) O
Colestipol B-DRUG
( O
May O
inhibit O
gastrointestinal O
absorption O
of O
the O
thiazide B-GROUP
diuretics I-GROUP
; O
administration O
1 O
hour O
before O
or O
4 O
hours O
after O
colestipol B-DRUG
is O
recommended O
. O
) O
Hypoglycemics B-GROUP
( O
Thiazide B-GROUP
diuretics I-GROUP
may O
raise O
blood O
glucose O
levels O
; O
for O
adult O
- O
onset O
diabetics O
, O
dosage O
adjustment O
of O
hypoglycemic B-GROUP
medications I-GROUP
may O
be O
necessary O
during O
and O
after O
thiazide B-GROUP
diuretic I-GROUP
therapy O
; O
insulin B-DRUG
requirements O
may O
be O
increased O
, O
decreased O
, O
or O
unchanged O
. O
) O
Lithium B-DRUG
salts O
( O
Concurrent O
use O
with O
thiazide B-GROUP
diuretics I-GROUP
is O
not O
recommended O
, O
as O
they O
may O
provoke O
lithium B-DRUG
toxicity O
because O
of O
reduced O
renal O
clearance O
. O
) O
Methenamine B-DRUG
( O
Effectiveness O
may O
be O
decreased O
when O
used O
concurrently O
with O
thiazide B-GROUP
diuretics I-GROUP
because O
of O
alkalinization O
of O
the O
urine O
. O
) O
Nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
( O
In O
some O
patients O
, O
the O
steroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agent I-GROUP
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop B-GROUP
, I-GROUP
potassium I-GROUP
sparing I-GROUP
, I-GROUP
and I-GROUP
thiazide I-GROUP
diuretics I-GROUP
. O
Therefore O
, O
when O
hydroflumethiazide B-DRUG
and O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-GROUP
is O
obtained O
. O

) O
Norepinephrine B-DRUG
( O
Thiazides B-GROUP
may O
decrease O
arterial O
responsiveness O
to O
norepinephrine B-DRUG
. O
This O
diminution O
is O
not O
sufficient O
to O
preclude O
effectiveness O
of O
the O
pressor O
agent O
for O
therapeutic O
use O
. O
) O
Tubocurarine B-DRUG
( O
Thiazide B-GROUP
drugs I-GROUP
may O
increase O
the O
responsiveness O
to O
tubocurarine B-DRUG
. O
) O
DIAGNOSTIC O
INTERFERENCE O
With O
expected O
physiologic O
effects O
: O
Blood O
and O
urine O
glucose O
levels O
( O
usually O
only O
in O
patients O
with O
a O
predisposition O
for O
glucose O
intolerance O
) O
and O
Serum O
bilirubin O
levels O
( O
by O
displacement O
from O
albumin O
binding O
) O
and O
Serum O
calcium O
levels O
( O
thiazide B-GROUP
diuretics I-GROUP
should O
be O
discontinued O
before O
parathyroid O
- O
function O
tests O
are O
carried O
out O
) O
and O
Serum O
uric O
acid O
levels O
( O
may O
be O
increased O
) O
Serum O
magnesium O
, O
potassium O
, O
and O
sodium O
levels O
( O
may O
be O
decreased O
; O
serum O
magnesium O
levels O
may O
increase O
in O
uremic O
patients O
) O
Serum O
protein O
- O
bound O
iodine O
( O
PBI O
) O
levels O
( O
may O
be O
decreased O
) O
Thiazides B-GROUP
should O
be O
discontinued O
before O
carrying O
out O
tests O
for O
parathyroid O
function O
. O

Patients O
receiving O
other O
narcotic B-GROUP
analgesics I-GROUP
, O
general O
anesthetics B-GROUP
, O
phenothiazines B-GROUP
, O
tranquilizers B-GROUP
, O
sedative B-GROUP
- I-GROUP
hypnotics I-GROUP
, O
tricyclic B-GROUP
antidepressants I-GROUP
or O
other O
CNS B-GROUP
depressants I-GROUP
( O
including O
alcohol B-DRUG
) O
concomitantly O
with O
DILAUDID B-BRAND
may O
exhibit O
an O
additive O
CNS O
depression O
. O
When O
such O
combined O
therapy O
is O
contemplated O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
with O
Cyanokit B-BRAND
. O

Prospective O
studies O
on O
the O
potential O
for O
hydroxyurea B-DRUG
to O
interact O
with O
other O
drugs O
have O
not O
been O
performed O
. O
Concurrent O
use O
of O
hydroxyurea B-DRUG
and O
other O
myelosuppressive O
agents O
or O
radiation O
therapy O
may O
increase O
the O
likelihood O
of O
bone O
marrow O
depression O
or O
other O
adverse O
events O
. O
Since O
hydroxyurea B-DRUG
may O
raise O
the O
serum O
uric O
acid O
level O
, O
dosage O
adjustment O
of O
uricosuric B-GROUP
medication I-GROUP
may O
be O
necessary O
. O

THE O
POTENTIATING O
ACTION O
OF O
HYDROXYZINE B-DRUG
MUST O
BE O
CONSIDERED O
WHEN O
THE O
DRUG O
IS O
USED O
IN O
CONJUNCTION O
WITH O
CENTRAL B-GROUP
NERVOUS I-GROUP
SYSTEM I-GROUP
DEPRESSANTS I-GROUP
SUCH O
AS O
NARCOTICS B-GROUP
, O
NON B-GROUP
- I-GROUP
NARCOTIC I-GROUP
ANALGESICS I-GROUP
AND O
BARBITURATES B-GROUP
. O
Therefore O
when O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressants I-GROUP
are O
administered O
concomitantly O
with O
hydroxyzine B-DRUG
their O
dosage O
should O
be O
reduced O
. O
Since O
drowsiness O
may O
occur O
with O
use O
of O
this O
drug O
, O
patients O
should O
be O
warned O
of O
this O
possibility O
and O
cautioned O
against O
driving O
a O
car O
or O
operating O
dangerous O
machinery O
while O
taking O
Atarax B-BRAND
. O
Patients O
should O
be O
advised O
against O
the O
simultaneous O
use O
of O
other O
CNS B-GROUP
depressant I-GROUP
drugs I-GROUP
, O
and O
cautioned O
that O
the O
effect O
of O
alcohol B-DRUG
may O
be O
increased O
. O

Additive O
adverse O
effects O
resulting O
from O
cholinergic O
blockade O
may O
occur O
when O
LEVSIN B-BRAND
is O
administered O
concomitantly O
with O
other O
antimuscarinics B-GROUP
, O
amantadine B-DRUG
, O
haloperidol B-DRUG
, O
phenothiazines B-GROUP
, O
monoamine B-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
, O
tricyclic B-GROUP
antidepressants I-GROUP
or O
some O
antihistamines B-GROUP
. O
Antacids B-GROUP
may O
interfere O
with O
the O
absorption O
of O
LEVSIN B-BRAND
. O
Administer O
LEVSIN B-BRAND
before O
meals O
; O
antacids B-GROUP
after O
meals O
. O

Calcium B-DRUG
Supplements O
/ O
Antacids B-GROUP
Products O
containing O
calcium B-DRUG
and O
other O
multivalent O
cations O
( O
such O
as O
aluminum B-DRUG
, O
magnesium B-DRUG
, O
iron B-DRUG
) O
are O
likely O
to O
interfere O
with O
absorption O
of O
Ibandronate B-DRUG
. O
Ibandronate B-DRUG
should O
be O
taken O
at O
least O
60 O
minutes O
before O
any O
oral O
medications O
containing O
multivalent O
cations O
( O
including O
antacids B-GROUP
, O
supplements O
or O
vitamins B-GROUP
) O
. O
H2 B-GROUP
Blockers I-GROUP
and O
Proton B-GROUP
Pump I-GROUP
Inhibitors I-GROUP
( O
PPIs B-GROUP
) O
Of O
over O
3500 O
patients O
enrolled O
in O
the O
Ibandronate B-DRUG
osteoporosis O
Treatment O
and O
Prevention O
Studies O
, O
15 O
% O
used O
anti O
- O
peptic O
agents O
( O
primarily O
H2 B-GROUP
blockers I-GROUP
and O
PPIs B-GROUP
) O
. O
Among O
these O
patients O
, O
the O
incidence O
of O
upper O
gastrointestinal O
adverse O
experiences O
in O
the O
patients O
treated O
with O
Ibandronate B-DRUG
was O
similar O
to O
that O
in O
placebo O
- O
treated O
patients O
. O
Similarly O
, O
of O
over O
1600 O
patients O
enrolled O
in O
a O
study O
comparing O
once O
- O
monthly O
with O
daily O
dosing O
regimens O
of O
ibandronate B-DRUG
, O
14 O
% O
of O
patients O
used O
anti O
- O
peptic O
agents O
. O
Among O
these O
patients O
, O
the O
incidence O
of O
upper O
gastrointestinal O
adverse O
experiences O
in O
the O
patients O
treated O
with O
Ibandronate B-DRUG
150 O
mg O
once O
monthly O
was O
similar O
to O
that O
in O
patients O
treated O
with O
Ibandronate B-DRUG
2 O
. O
5 O
mg O
once O
daily O
. O
Aspirin B-BRAND
/ O
Nonsteroidal B-GROUP
Antiinflammatory I-GROUP
Drugs I-GROUP
( O
NSAIDs B-GROUP
) O
In O
the O
large O
, O
placebo O
- O
controlled O
osteoporosis O
Treatment O
Study O
, O
aspirin B-BRAND
and O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
were O
taken O
by O
62 O
% O
of O
the O
2946 O
patients O
. O
Among O
aspirin B-BRAND
or O
NSAID B-GROUP
users O
, O
the O
incidence O
of O
upper O
gastrointestinal O
adverse O
events O
in O
patients O
treated O
with O
ibandronate B-DRUG
2 O
. O
5 O
mg O
daily O
( O
28 O
. O
9 O
% O
) O
was O
similar O
to O
that O
in O
placebo O
- O
treated O
patients O
( O
30 O
. O
7 O
% O
) O
. O
Similarly O
, O
in O
the O
1 O
- O
year O
monthly O
comparison O
study O
, O
aspirin B-BRAND
and O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
were O
taken O
by O
39 O
% O
of O
the O
1602 O
patients O
. O
The O
incidence O
of O
upper O
gastrointestinal O
events O
in O
patients O
concomitantly O
taking O
aspirin B-BRAND
or O
NSAIDs B-GROUP
was O
similar O
in O
patients O
taking O
ibandronate B-DRUG
2 O
. O
5 O
mg O
daily O
( O
21 O
. O
7 O
% O
) O
and O
150 O
mg O
once O
monthly O
( O
22 O
. O
0 O
% O
) O
. O
However O
, O
since O
aspirin B-BRAND
, O
NSAIDs B-GROUP
, O
and O
bisphosphonates B-GROUP
are O
all O
associated O
with O
gastrointestinal O
irritation O
, O
caution O
should O
be O
exercised O
in O
the O
concomitant O
use O
of O
aspirin B-BRAND
or O
NSAIDs B-GROUP
with O

Ibandronate B-DRUG
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Bisphosphonates B-GROUP
are O
known O
to O
interfere O
with O
the O
use O
of O
bone O
- O
imaging O
agents O
. O
Specific O
studies O
with O
ibandronate B-DRUG
have O
not O
been O
performed O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
with O
ZEVALIN B-BRAND
. O
Due O
to O
the O
frequent O
occurrence O
of O
severe O
and O
prolonged O
thrombocytopenia O
, O
the O
potential O
benefits O
of O
medications O
which O
interfere O
with O
platelet O
function O
and O
/ O
or O
anticoagulation O
should O
be O
weighed O
against O
the O
potential O
increased O
risks O
of O
bleeding O
and O
hemorrhage O
. O
Patients O
receiving O
medications O
that O
interfere O
with O
platelet O
function O
or O
coagulation O
should O
have O
more O
frequent O
laboratory O
monitoring O
for O
thrombocytopenia O
. O
In O
addition O
, O
the O
transfusion O
practices O
for O
such O
patients O
may O
need O
to O
be O
modified O
given O
the O
increased O
risk O
of O
bleeding O
. O
Patients O
in O
clinical O
studies O
were O
prohibited O
from O
receiving O
growth O
factor O
treatment O
for O
2 O
weeks O
prior O
to O
the O
ZEVALIN B-BRAND
therapeutic O
regimen O
as O
well O
as O
for O
2 O
weeks O
following O
completion O
of O
the O
regimen O
. O

Coumarin B-GROUP
- I-GROUP
Type I-GROUP
Anticoagulants I-GROUP
: O
Several O
short O
- O
term O
controlled O
studies O
failed O
to O
wshow O
that O
ibuprofen B-DRUG
significantly O
affected O
prothrombin O
times O
or O
a O
variety O
of O
other O
clotting O
factors O
when O
administered O
to O
individuals O
on O
coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
. O
However O
, O
because O
bleeding O
has O
been O
reported O
when O
ibuprofen B-DRUG
and O
other O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
have O
been O
administered O
to O
patients O
on O
coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
, O
the O
physician O
should O
be O
cautious O
when O
administering O
ibuprofen B-DRUG
to O
patients O
on O
anticoagulants B-GROUP
. O
Aspirin B-BRAND
: O
Animal O
studies O
wshow O
that O
aspirin B-BRAND
given O
with O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
, O
including O
ibuprofen B-DRUG
, O
yields O
a O
net O
decrease O
in O
anti O
- O
inflammatory O
activity O
with O
lowered O
blood O
levels O
of O
the O
non O
- O
aspirin O
drug O
. O
Single O
dose O
bioavailability O
studies O
in O
normal O
volunteers O
have O
failed O
to O
wshow O
an O
effect O
of O
aspirin B-BRAND
on O
ibuprofen B-DRUG
blood O
levels O
. O
Correlative O
clinical O
studies O
have O
not O
been O
performed O
. O
Methotrexate B-DRUG
: O
Ibuprofen B-DRUG
, O
as O
well O
as O
other O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
, O
probably O
reduces O
the O
tubular O
secretion O
of O
methotrexate B-DRUG
based O
on O
in O
vitro O
studies O
in O
rabbit O
kidney O
slices O
. O
This O
may O
indicate O
that O
ibuprofen B-DRUG
could O
enhance O
the O
toxicity O
of O
methotrexate B-DRUG
. O
Caution O
should O
be O
used O
if O
ibuprofen B-DRUG
is O
administered O
concomitantly O
with O
methotrexate B-DRUG
. O
H O
- O
2 O
Antagonists O
: O
In O
studies O
with O
human O
volunteers O
, O
co O
- O
administration O
of O
cimetidine B-DRUG
or O
ranitidine B-DRUG
with O
ibuprofen B-DRUG
had O
no O
substantive O
effect O
on O
ibuprofen B-DRUG
serum O
concentrations O
. O
Furosemide B-DRUG
: O
Clinical O
studies O
, O
as O
well O
as O
random O
observations O
, O
have O
shown O
that O
ibuprofen B-DRUG
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-DRUG
and O
thiazides B-GROUP
in O
some O
patients O
. O
This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O
During O
concomitant O
therapy O
with O
ibuprofen B-DRUG
, O
the O
patient O
should O
be O
observed O
closely O
for O
signs O
of O
renal O
failure O
, O
as O
well O
as O
to O
assure O
diuretic B-GROUP
efficacy O
. O
Lithium B-DRUG
: O
Ibuprofen B-DRUG
produced O
an O
elevation O
of O
plasma O
lithium B-DRUG
levels O
and O
a O
reduction O
in O
renal O
lithium B-DRUG
clearance O
in O
a O
study O
of O
eleven O
normal O
volunteers O
. O
The O
mean O
minimum O
lithium B-DRUG
concentration O
increased O
15 O
% O
and O
the O
renal O
clearance O
of O
lithium B-DRUG
was O
decreased O
by O
19 O
% O
during O

this O
period O
of O
concomitant O
drug O
administration O
. O
This O
effect O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
by O
ibuprofen B-DRUG
. O
Thus O
, O
when O
ibuprofen B-DRUG
and O
lithium B-DRUG
are O
administered O
concurrently O
, O
subjects O
should O
be O
observed O
carefully O
for O
signs O
of O
lithium B-DRUG
toxicity O
. O
( O
Read O
circulars O
for O
lithium B-DRUG
preparation O
before O
use O
of O
such O
concurrent O
therapy O
) O
. O

No O
specific O
pharmacokinetic O
or O
other O
formal O
drug O
interaction O
studies O
were O
conducted O
. O
Digoxin B-DRUG
: O
Supraventricular O
arrhythmias O
may O
mask O
the O
cardiotoxicity O
associated O
with O
excessive O
digoxin B-DRUG
levels O
. O
Therefore O
, O
it O
is O
advisable O
to O
be O
particularly O
cautious O
in O
patients O
whose O
plasma O
digoxin B-DRUG
levels O
are O
above O
or O
suspected O
to O
be O
above O
the O
usual O
therapeutic O
range O
. O
Coadministration O
of O
digoxin B-DRUG
did O
not O
have O
effects O
on O
either O
the O
safety O
or O
efficacy O
of O
ibutilide B-DRUG
in O
the O
clinical O
trials O
. O
Calcium B-GROUP
channel I-GROUP
blocking I-GROUP
agents I-GROUP
: O
Coadministration O
of O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
did O
not O
have O
any O
effect O
on O
either O
the O
safety O
or O
efficacy O
of O
ibutilide B-DRUG
in O
the O
clinical O
trials O
. O
Beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
: O
Coadministration O
of O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
did O
not O
have O
any O
effect O
on O
either O
the O
safety O
or O
efficacy O
of O
ibutilide B-DRUG
in O
the O
clinical O
trials O
. O

General O
No O
clinical O
drug O
interaction O
studies O
were O
performed O
. O
No O
evaluation O
of O
EXTRANEALs B-BRAND
effects O
on O
the O
cytochrome O
P450 O
system O
was O
conducted O
. O
As O
with O
other O
dialysis B-GROUP
solutions I-GROUP
, O
blood O
concentrations O
of O
dialyzable O
drugs O
may O
be O
reduced O
by O
dialysis O
. O
Dosage O
adjustment O
of O
concomitant O
medications O
may O
be O
necessary O
. O
In O
patients O
using O
cardiac B-GROUP
glycosides I-GROUP
( O
digoxin B-DRUG
and O
others O
) O
, O
plasma O
levels O
of O
calcium O
, O
potassium O
and O
magnesium O
must O
be O
carefully O
monitored O
. O
Insulin B-DRUG
: O
A O
clinical O
study O
in O
6 O
insulin O
- O
dependent O
diabetic O
patients O
demonstrated O
no O
effect O
of O
EXTRANEAL B-BRAND
on O
insulin B-DRUG
absorption O
from O
the O
peritoneal O
cavity O
or O
on O
insulins B-DRUG
ability O
to O
control O
blood O
glucose O
when O
insulin B-DRUG
was O
administered O
intraperitoneally O
with O
EXTRANEAL B-BRAND
. O
However O
, O
appropriate O
monitoring O
of O
blood O
glucose O
should O
be O
performed O
when O
initiating O
EXTRANEAL B-BRAND
in O
diabetic O
patients O
and O
insulin B-DRUG
dosage O
should O
be O
adjusted O
if O
needed O
. O
Heparin B-DRUG
: O
No O
human O
drug O
interaction O
studies O
with O
heparin B-DRUG
were O
conducted O
. O
In O
vitro O
studies O
demonstrated O
no O
evidence O
of O
incompatibility O
of O
heparin B-DRUG
with O
EXTRANEAL B-BRAND
. O
Antibiotics B-GROUP
: O
No O
human O
drug O
interaction O
studies O
with O
antibiotics B-GROUP
were O
conducted O
. O
In O
vitro O
studies O
evaluating O
the O
minimum O
inhibitory O
concentration O
( O
MIC O
) O
of O
vancomycin B-DRUG
, O
cefazolin B-DRUG
, O
ampicillin B-DRUG
, O
ampicillin B-DRUG
/ O
flucoxacillin O
, O
ceftazidime B-DRUG
, O
gentamicin B-DRUG
, O
and O
amphotericin B-DRUG
demonstrated O
no O
evidence O
of O
incompatibility O
of O
these O
antibiotics B-GROUP
with O
EXTRANEAL B-BRAND
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Blood O
Glucose O
Blood O
glucose O
measurement O
must O
be O
done O
with O
a O
glucose O
- O
specific O
method O
to O
prevent O
maltose O
interference O
with O
test O
results O
. O
Since O
falsely O
elevated O
glucose O
levels O
have O
been O
observed O
with O
blood O
glucose O
monitoring O
devices O
and O
test O
strips O
that O
use O
glucose O
dehydrogenase O
pyrroloquinolinequinone O
( O
GDH O
PQQ O
) O
- O
based O
methods O
, O
GDH O
PQQ O
- O
based O
methods O
should O
not O
be O
used O
to O
measure O
glucose O
levels O
in O
patients O
administered O
EXTRANEAL B-BRAND
. O
. O
Serum O
Amylase O
An O
apparent O
decrease O
in O
serum O
amylase O
activity O
has O
been O
observed O
in O
patients O
administered O
EXTRANEAL B-BRAND
. O
Preliminary O
investigations O
indicate O
that O
icodextrin B-DRUG
and O
its O
metabolites O
interfere O
with O
enzymatic O
- O
based O
amylase O
assays O
, O
resulting O
in O
inaccurately O
low O
values O
. O
This O
should O
be O
taken O
into O
account O
when O
evaluating O
serum O
amylase O
levels O
for O
diagnosis O

or O
monitoring O
of O
pancreatitis O
in O
patients O
using O
EXTRANEAL B-BRAND
. O

Interactions O
may O
occur O
between O
EPA B-DRUG
supplements O
and O
aspirin B-BRAND
and O
other O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
and O
herbs O
such O
as O
garlic O
( O
Allium O
sativum O
) O
and O
ginkgo B-DRUG
( O
Ginkgo B-DRUG
biloba I-DRUG
) O
. O
Such O
interactions O
might O
be O
manifested O
by O
increased O
susceptibility O
to O
bruising O
, O
nosebleeds O
, O
hemoptysis O
, O
hematemesis O
, O
hematuria O
and O
blood O
in O
the O
stool O
. O
Most O
who O
take O
EPA B-DRUG
supplements O
and O
the O
above O
drugs O
or O
herbs O
do O
not O
suffer O
from O
these O
problems O
and O
if O
they O
occur O
, O
they O
are O
rare O
. O
If O
they O
do O
occur O
, O
the O
EPA B-DRUG
dose O
should O
be O
lowered O
or O
discontinued O
. O
Conflicting O
results O
have O
been O
reported O
regarding O
the O
effects O
of O
EPA B-DRUG
supplements O
on O
glycemic O
control O
in O
non O
- O
diabetics O
with O
glucose O
intolerance O
, O
and O
those O
with O
type O
2 O
diabetes O
. O
Some O
early O
studies O
indicated O
that O
EPA B-DRUG
supplements O
might O
have O
detrimental O
effects O
in O
those O
groups O
. O
Recent O
, O
better O
designed O
studies O
have O
not O
reported O
these O
adverse O
effects O
. O
There O
is O
no O
evidence O
that O
EPA B-DRUG
supplements O
have O
detrimental O
effects O
on O
glucose O
tolerance O
, O
insulin O
secretion O
or O
insulin O
resistance O
in O
non O
- O
diabetic O
subjects O
. O
Diabetics O
should O
discuss O
the O
use O
of O
these O
supplements O
with O
their O
physicians O
and O
note O
if O
the O
supplements O
affect O
their O
glycemic O
control O
. O
Diabetics O
who O
take O
EPA B-DRUG
supplements O
should O
be O
monitored O
by O
their O
physicians O
. O

Other O
medicines O
- O
Although O
certain O
medicines O
should O
not O
be O
used O
together O
at O
all O
, O
in O
other O
cases O
two O
different O
medicines O
may O
be O
used O
together O
even O
if O
an O
interaction O
might O
occur O
. O
In O
these O
cases O
, O
your O
doctor O
may O
want O
to O
change O
the O
dose O
, O
or O
other O
precautions O
may O
be O
necessary O
. O
When O
you O
are O
using O
idoxuridine B-DRUG
, O
it O
is O
especially O
important O
that O
your O
health O
care O
professional O
know O
if O
you O
are O
using O
the O
following O
: O
Eye O
product O
containing O
boric B-DRUG
acid I-DRUG
. O
Boric B-DRUG
acid I-DRUG
may O
interact O
with O
the O
idoxuridine B-DRUG
preparation O
causing O
a O
gritty O
substance O
to O
form O
or O
may O
interact O
with O
the O
preservative O
in O
the O
idoxuridine B-DRUG
preparation O
causing O
a O
toxic O
effect O
in O
the O
eye O
. O

The O
physician O
should O
be O
alert O
for O
possible O
combined O
drug O
actions O
, O
desirable O
or O
undesirable O
, O
involving O
ifosfamide B-DRUG
even O
though O
ifosfamide B-DRUG
has O
been O
used O
successfully O
concurrently O
with O
other O
drugs O
, O
including O
other O
cytotoxic O
drugs O
. O

In O
studies O
in O
normal O
volunteers O
, O
there O
was O
no O
pharmacodynamic O
interaction O
between O
intravenous O
iloprost B-DRUG
and O
either O
nifedipine B-DRUG
, O
diltiazem B-DRUG
, O
or O
captopril B-DRUG
. O
However O
, O
iloprost B-DRUG
has O
the O
potential O
to O
increase O
the O
hypotensive O
effect O
of O
vasodilators B-GROUP
and O
antihypertensive B-GROUP
agents I-GROUP
. O
Since O
iloprost B-DRUG
inhibits O
platelet O
function O
, O
there O
is O
a O
potential O
for O
increased O
risk O
of O
bleeding O
, O
particularly O
in O
patients O
maintained O
on O
anticoagulants B-GROUP
. O
During O
clinical O
trials O
, O
iloprost B-DRUG
was O
used O
concurrently O
with O
anticoagulants B-GROUP
, O
diuretics B-GROUP
, O
cardiac B-GROUP
glycosides I-GROUP
, O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
, O
analgesics B-GROUP
, O
antipyretics B-GROUP
, O
nonsteroidal B-GROUP
antiinflammatories I-GROUP
, O
corticosteroids B-GROUP
, O
and O
other O
medications O
. O
Intravenous O
infusion O
of O
iloprost B-DRUG
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
digoxin B-DRUG
. O
Acetylsalicylic B-DRUG
acid I-DRUG
did O
not O
alter O
the O
clearance O
( O
pharmacokinetics O
) O
of O
iloprost B-DRUG
. O
Although O
clinical O
studies O
have O
not O
been O
conducted O
, O
in O
vitro O
studies O
of O
iloprost B-DRUG
indicate O
that O
no O
relevant O
inhibition O
of O
cytochrome O
P450 O
drug O
metabolism O
would O
be O
expected O
. O

Drugs O
that O
may O
alter O
imatinib B-DRUG
plasma O
concentrations O
Drugs O
that O
may O
increase O
imatinib B-DRUG
plasma O
concentrations O
: O
Caution O
is O
recommended O
when O
administering O
Gleevec B-BRAND
with O
inhibitors O
of O
the O
CYP3A4 O
family O
( O
e O
. O
g O
. O
, O
ketoconazole B-DRUG
, O
itraconazole B-DRUG
, O
erythromycin B-DRUG
, O
clarithromycin B-DRUG
) O
. O
Substances O
that O
inhibit O
the O
cytochrome O
P450 O
isoenzyme O
( O
CYP3A4 O
) O
activity O
may O
decrease O
metabolism O
and O
increase O
imatinib B-DRUG
concentrations O
. O
There O
is O
a O
significant O
increase O
in O
exposure O
to O
imatinib B-DRUG
when O
Gleevec B-BRAND
is O
coadministered O
with O
ketoconazole B-DRUG
( O
CYP3A4 O
inhibitor O
) O
. O
Drugs O
that O
may O
decrease O
imatinib B-DRUG
plasma O
concentrations O
: O
Substances O
that O
are O
inducers O
of O
CYP3A4 O
activity O
may O
increase O
metabolism O
and O
decrease O
imatinib B-DRUG
plasma O
concentrations O
. O
Co O
- O
medications O
that O
induce O
CYP3A4 O
( O
e O
. O
g O
. O
, O
dexamethasone B-DRUG
, O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
rifampin B-DRUG
, O
phenobarbital B-DRUG
or O
St O
. O
Johns O
Wort O
) O
may O
significantly O
reduce O
exposure O
to O
Gleevec B-BRAND
. O
Pretreatment O
of O
healthy O
volunteers O
with O
multiple O
doses O
of O
rifampin B-DRUG
followed O
by O
a O
single O
dose O
of O
Gleevec B-BRAND
, O
increased O
Gleevec B-BRAND
oral O
- O
dose O
clearance O
by O
3 O
. O
8 O
- O
fold O
, O
which O
significantly O
( O
p O
0 O
. O
05 O
) O
decreased O
mean O
cmax O
and O
AUC O
( O
0 O
- O
8 O
) O
. O
In O
patients O
where O
rifampin B-DRUG
or O
other O
CYP3A4 O
inducers O
are O
indicated O
, O
alternative O
therapeutic O
agents O
with O
less O
enzyme O
induction O
potential O
should O
be O
considered O
. O
Drugs O
that O
may O
have O
their O
plasma O
concentration O
altered O
by O
Gleevec B-BRAND
Gleevec B-BRAND
increases O
the O
mean O
cmax O
and O
AUC O
of O
simvastatin B-DRUG
( O
CYP3A4 O
substrate O
) O
2 O
- O
and O
3 O
. O
5 O
- O
fold O
, O
respectively O
, O
suggesting O
an O
inhibition O
of O
the O
CYP3A4 O
by O
Gleevec B-BRAND
. O
Particular O
caution O
is O
recommended O
when O
administering O
Gleevec B-BRAND
with O
CYP3A4 O
substrates O
that O
have O
a O
narrow O
therapeutic O
window O
( O
e O
. O
g O
. O
, O
cyclosporine B-DRUG
or O
pimozide B-DRUG
) O
. O
Gleevec B-BRAND
will O
increase O
plasmaconcentration O
of O
other O
CYP3A4 O
metabolized O
drugs O
( O
e O
. O
g O
. O
, O
triazolo O
- O
benzodiazepines B-GROUP
, O
dihydropyridine B-GROUP
calcium I-GROUP
channel I-GROUP
blockers I-GROUP
, O
certain O
HMG B-GROUP
- I-GROUP
CoA I-GROUP

reductase I-GROUP
inhibitors I-GROUP
, O
etc O
. O
) O
. O
Because O
warfarin B-DRUG
is O
metabolized O
by O
CYP2C9 O
and O
CYP3A4 O
, O
patients O
who O
require O
anticoagulation O
should O
receive O
low O
- O
molecular O
weight O
or O
standard O
heparin B-DRUG
. O
in O
vitro O
, O
Gleevec B-BRAND
inhibits O
the O
cytochrome O
P450 O
isoenzyme O
CYP2D6 O
activity O
at O
similar O
concentrations O
that O
affect O
CYP3A4 O
activity O
. O
Systemic O
exposure O
to O
substrates O
of O
CYP2D6 O
is O
expected O
to O
be O
increased O
when O
coadministered O
with O
Gleevec O
. O
No O
specific O
studies O
have O
been O
performed O
and O
caution O
is O
recommended O
. O
in O
vitro O
, O
Gleevec B-BRAND
inhibits O
acetaminophen O
O O
- O
glucuronidation O
( O
Ki O
value O
of O
58 O
. O
5 O
M O
) O
at O
therapeutic O
levels O
. O
Systemic O
exposure O
to O
acetaminophen B-DRUG
is O
expected O
to O
be O
increased O
when O
coadministered O
with O
Gleevec B-BRAND
. O
No O
specific O
studies O
in O
humans O
have O
been O
performed O
and O
caution O
is O
recommended O
. O

In O
occasional O
susceptible O
patients O
or O
in O
those O
receiving O
anticholinergic B-GROUP
drugs I-GROUP
( O
including O
antiparkinsonism O
agents O
) O
in O
addition O
, O
the O
atropine O
- O
like O
effects O
may O
become O
more O
pronounced O
( O
e O
. O
g O
. O
, O
paralytic O
ileus O
) O
. O
Close O
supervision O
and O
careful O
adjustment O
of O
dosage O
is O
required O
when O
this O
drug O
is O
administered O
concomitantly O
with O
anticholinergic B-GROUP
drugs I-GROUP
. O
Avoid O
the O
use O
of O
preparations O
such O
as O
decongestants B-GROUP
and O
local O
anesthetics B-GROUP
which O
contain O
any O
sympathomimetic B-GROUP
amine I-GROUP
( O
e O
. O
g O
. O
, O
epinephrine B-DRUG
, O
norepinephrine B-DRUG
) O
, O
since O
it O
has O
been O
reported O
that O
tricyclic B-GROUP
antidepressants I-GROUP
can O
potentiate O
the O
effects O
of O
catecholamines O
. O
Caution O
should O
be O
exercised O
when O
imipramine B-DRUG
hydrochloride I-DRUG
is O
used O
with O
agents O
that O
lower O
blood O
pressure O
. O
Imipramine B-DRUG
hydrochloride I-DRUG
may O
potentiate O
the O
effects O
of O
CNS B-GROUP
depressant I-GROUP
drugs I-GROUP
. O
The O
plasma O
concentration O
of O
imipramine B-DRUG
may O
increase O
when O
the O
drug O
is O
given O
concomitantly O
with O
hepatic O
enzyme O
inhibitors O
( O
e O
. O
g O
. O
, O
cimetidine B-DRUG
, O
fluoxetine B-DRUG
) O
and O
decrease O
by O
concomitant O
administration O
of O
hepatic O
enzyme O
inducers O
( O
e O
. O
g O
. O
, O
barbiturates B-GROUP
, O
phenytoin B-DRUG
) O
, O
and O
adjustment O
of O
the O
dosage O
of O
imipramine B-DRUG
may O
therefore O
be O
necessary O
. O
Drugs O
Metabolized O
by O
P450 O
2D6 O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
caucasian O
population O
( O
about O
7 O
to O
10 O
% O
of O
caucasians O
are O
so O
called O
poor O
metabolizers O
) O
; O
reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O
Poor O
metabolizers O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-GROUP
antidepressants I-GROUP
( O
TCAs B-GROUP
) O
when O
given O
usual O
doses O
. O
Depending O
on O
the O
fraction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8 O
- O
fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA B-GROUP
) O
. O
In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
p O
. O
o O
. O
metabolizers O
. O
An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCA B-GROUP
may O
become O
abruptly O
toxic O
when O
given O

one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O
The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-DRUG
; O
cimetidine B-DRUG
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-GROUP
, O
phenothiazines B-GROUP
, O
and O
the O
Type B-GROUP
1C I-GROUP
antiarrhythmics I-GROUP
propafenone B-DRUG
and O
flecainide B-DRUG
) O
. O
While O
all O
the O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
( O
SSRIs B-GROUP
) O
, O
e O
. O
g O
. O
, O
fluoxetine B-DRUG
, O
sertraline B-DRUG
, O
and O
paroxetine B-DRUG
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O
The O
extent O
to O
which O
SSRI B-GROUP
- O
TCA B-GROUP
interactions O
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
, O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-GROUP
involved O
. O
Nevertheless O
, O
caution O
is O
indicated O
in O
the O
co O
- O
administration O
of O
TCA5 O
with O
any O
of O
the O
SSRIs B-GROUP
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O
Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCA O
treatment O
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-DRUG
, O
given O
the O
long O
half O
- O
life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O
Concomitant O
use O
of O
tricyclic B-GROUP
antidepressants I-GROUP
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-GROUP
antidepressant I-GROUP
or O
the O
other O
drug O
. O
Furthermore O
, O
whenever O
one O
of O
these O
other O
drugs O
is O
withdrawn O
from O
cotherapy O
, O
an O
increased O
dose O
of O
tricyclic B-GROUP
antidepressant I-GROUP
may O
be O
required O
. O
It O
is O
desirable O
to O
monitor O
TCA B-GROUP
plasma O
levels O
whenever O
a O
TCA B-GROUP
is O
going O
to O
be O
co O
- O
administered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
. O

No O
information O
available O
. O

Indinavir B-DRUG
is O
an O
inhibitor O
of O
the O
cytochrome O
P450 O
isoform O
CYP3A4 O
. O
Coadministration O
of O
CRIXIVAN B-BRAND
and O
drugs O
primarily O
metabolized O
by O
CYP3A4 O
may O
result O
in O
increased O
plasma O
concentrations O
of O
the O
other O
drug O
, O
which O
could O
increase O
or O
prolong O
its O
therapeutic O
and O
adverse O
effects O
. O
Indinavir B-DRUG
is O
metabolized O
by O
CYP3A4 O
. O
Drugs O
that O
induce O
CYP3A4 O
activity O
would O
be O
expected O
to O
increase O
the O
clearance O
of O
indinavir B-DRUG
, O
resulting O
in O
lowered O
plasma O
concentrations O
of O
indinavir B-DRUG
. O
Coadministration O
of O
CRIXIVAN B-BRAND
and O
other O
drugs O
that O
inhibit O
CYP3A4 O
may O
decrease O
the O
clearance O
of O
indinavir B-DRUG
and O
may O
result O
in O
increased O
plasma O
concentrations O
of O
indinavir B-DRUG
. O
Table O
8 O
Drugs O
That O
Should O
Not O
Be O
Coadministered O
with O
CRIXIVAN B-BRAND
Drug O
Class O
: O
Drug O
Name O
Clinical O
Comment O
Antiarrhythmics B-GROUP
: O
amiodarone B-DRUG
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and O
/ O
or O
life O
- O
threatening O
reactions O
such O
as O
cardiac O
arrhythmias O
. O
Ergot O
derivatives O
: O
dihydroergotamine B-DRUG
, O
ergonovine B-DRUG
, O
ergotamine B-DRUG
, O
methylergonovine B-DRUG
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and O
/ O
or O
life O
- O
threatening O
reactions O
such O
as O
acute O
ergot O
toxicity O
characterized O
by O
peripheral O
vasospasm O
and O
ischemia O
of O
the O
extremities O
and O
other O
tissues O
. O
Sedative B-GROUP
/ O
hypnotics B-GROUP
: O
midazolam B-DRUG
, O
triazolam B-DRUG
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and O
/ O
or O
life O
- O
threatening O
reactions O
such O
as O
prolonged O
or O
increased O
sedation O
or O
respiratory O
depression O
. O
GI O
motility O
agents O
: O
cisapride B-DRUG
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and O
/ O
or O
life O
- O
threatening O
reactions O
such O
as O
cardiac O
arrhythmias O
. O
Neuroleptic B-GROUP
: O
pimozide B-DRUG
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and O
/ O
or O
life O
- O
threatening O
reactions O
such O
as O
cardiac O
arrhythmias O
. O
Herbal O
products O
: O
St O
. O
John O
s O
wort O
( O
Hypericum O
perforatum O
) O
May O
lead O
to O
loss O
of O
virologic O
response O
and O
possible O
resistance O
to O
CRIXIVAN B-BRAND
or O
to O
the O
class O
of O
protease B-GROUP
inhibitors I-GROUP
. O
Antimycobacterial B-GROUP
: O
rifampin B-DRUG
May O
lead O
to O
loss O
of O
virologic O
response O
and O
possible O
resistance O
to O
CRIXIVAN B-BRAND

or O
to O
the O
class O
of O
protease B-GROUP
inhibitors I-GROUP
or O
other O
coadministered O
antiretroviral B-GROUP
agents I-GROUP
. O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
Reductase I-GROUP
inhibitors I-GROUP
: O
lovastatin B-DRUG
, O
simvastatin B-DRUG
Potential O
for O
serious O
reactions O
such O
as O
risk O
of O
myopathy O
including O
rhabdomyolysis O
. O
Protease B-GROUP
inhibitor I-GROUP
: O
atazanavir B-DRUG
Both O
CRIXIVAN B-BRAND
and O
atazanavir B-DRUG
are O
associated O
with O
indirect O
( O
unconjugated O
) O
hyperbilirubinemia O
. O
Combinations O
of O
these O
drugs O
have O
not O
been O
studied O
and O
coadministration O
of O
CRIXIVAN B-BRAND
and O
atazanavir B-DRUG
is O
not O
recommended O
. O
Table O
9 O
Established O
and O
Other O
Potentially O
Significant O
Drug O
Interactions O
: O
Alteration O
in O
Dose O
or O
Regimen O
May O
Be O
Recommended O
Based O
on O
Drug O
Interaction O
Studies O
or O
Predicted O
Interaction O
Drug O
Name O
Effect O
Clinical O
Comment O
HIV B-GROUP
Antiviral I-GROUP
Agents I-GROUP
Delavirdine B-DRUG
indinavir B-DRUG
concentration O
Dose O
reduction O
of O
CRIXIVAN B-BRAND
to O
600 O
mg O
every O
8 O
hours O
should O
be O
considered O
when O
taking O
delavirdine B-DRUG
400 O
mg O
three O
times O
a O
day O
. O
Didanosine B-DRUG
Indinavir B-DRUG
and O
didanosine B-DRUG
formulations O
containing O
buffer O
should O
be O
administered O
at O
least O
one O
hour O
apart O
on O
an O
empty O
stomach O
. O
Efavirenz B-DRUG
indinavir B-DRUG
concentration O
The O
optimal O
dose O
of O
indinavir B-DRUG
, O
when O
given O
in O
combination O
with O
efavirenz B-DRUG
, O
is O
not O
known O
. O
Increasing O
the O
indinavir B-DRUG
dose O
to O
1000 O
mg O
every O
8 O
hours O
does O
not O
compensate O
for O
the O
increased O
indinavir B-DRUG
metabolism O
due O
to O
efavirenz B-DRUG
. O
Nelfinavir B-DRUG
indinavir B-DRUG
concentration O
The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O
Nevirapine B-DRUG
indinavir B-DRUG
concentration O
Indinavir B-DRUG
concentrations O
may O
be O
decreased O
in O
the O
presence O
of O
nevirapine B-DRUG
. O
The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O
Ritonavir B-DRUG
indinavir B-DRUG
concentration O
ritonavir B-DRUG
concentration O
The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O
Preliminary O
clinical O
data O
suggest O
that O
the O
incidence O
of O
nephrolithiasis O
is O
higher O
in O
patients O
receiving O
indinavir B-DRUG
in O
combination O
with O
ritonavir B-DRUG
than O
those O
receiving O
CRIXIVAN B-BRAND
800 O
mg O
q8h O
. O
Saquinavir B-DRUG
saquinavir B-DRUG
concentration O
The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O
Other O
Agents O
Antiarrhythmics B-GROUP
: O
bepridil B-DRUG
, O

lidocaine B-DRUG
( O
systemic O
) O
and O
quinidine B-DRUG
antiarrhythmic B-GROUP
agents I-GROUP
concentration O
Caution O
is O
warranted O
and O
therapeutic O
concentration O
monitoring O
is O
recommended O
for O
antiarrhythmics B-GROUP
when O
coadministered O
with O
CRIXIVAN B-BRAND
. O
Anticonvulsants B-GROUP
: O
carbamazepine B-DRUG
, O
phenobarbital B-DRUG
, O
phenytoin B-DRUG
indinavir B-DRUG
concentration O
Use O
with O
caution O
. O
CRIXIVAN B-BRAND
may O
not O
be O
effective O
due O
to O
decreased O
indinavir B-DRUG
concentrations O
in O
patients O
taking O
these O
agents O
concomitantly O
. O
Calcium B-GROUP
Channel I-GROUP
Blockers I-GROUP
, O
Dihydropyridine B-GROUP
: O
e O
. O
g O
. O
, O
felodipine B-DRUG
, O
nifedipine B-DRUG
, O
nicardipine B-DRUG
dihydropyridine B-GROUP
calcium I-GROUP
channel I-GROUP
blockers I-GROUP
concentration O
Caution O
is O
warranted O
and O
clinical O
monitoring O
of O
patients O
is O
recommended O
. O
Clarithromycin B-DRUG
clarithromycin B-DRUG
concentration O
indinavir B-DRUG
concentration O
The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
Reductase I-GROUP
Inhibitor I-GROUP
: O
atorvastatin B-DRUG
atorvastatin B-DRUG
concentration O
Use O
lowest O
possible O
dose O
of O
atorvastatin B-DRUG
with O
careful O
monitoring O
, O
or O
consider O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
that O
are O
not O
primarily O
metabolized O
by O
CYP3A4 O
, O
such O
as O
pravastatin B-DRUG
, O
fluvastatin B-DRUG
, O
or O
rosuvastatin B-DRUG
in O
combination O
with O
CRIXIVAN B-BRAND
. O
Immunosuppressants B-GROUP
: O
cyclosporine B-DRUG
, O
tacrolimus B-DRUG
, O
sirolimus B-DRUG
immunosuppressant B-GROUP
agents I-GROUP
concentration O
Plasma O
concentrations O
may O
be O
increased O
by O
CRIXIVAN B-BRAND
. O
Itraconazole B-DRUG
indinavir B-DRUG
concentration O
Dose O
reduction O
of O
CRIXIVAN B-BRAND
to O
600 O
mg O
every O
8 O
hours O
is O
recommended O
when O
administering O
itraconazole B-DRUG
concurrently O
. O
Ketoconazole B-DRUG
indinavir B-DRUG
concentration O
Dose O
reduction O
of O
CRIXIVAN B-BRAND
to O
600 O
mg O
every O
8 O
hours O
should O
be O
considered O
. O
Rifabutin B-DRUG
indinavir B-DRUG
concentration O
rifabutin B-DRUG
concentration O
Dose O
reduction O
of O
rifabutin B-DRUG
to O
half O
the O
standard O
dose O
and O
a O
dose O
increase O
of O
CRIXIVAN B-BRAND
to O
1000 O
mg O
( O
three O
333 O
- O
mg O
capsules O
) O
every O
8 O
hours O
are O
recommended O
when O
rifabutin B-DRUG
and O
CRIXIVAN B-BRAND
are O
coadministered O
. O
Sildenafil B-DRUG
sildenafil B-DRUG
concentration O
Sildenafil B-DRUG
dose O
should O
not O
exceed O
a O
maximum O
of O
25 O
mg O
in O
a O
48 O
- O
hour O
period O
in O
patients O

receiving O
concomitant O
indinavir B-DRUG
therapy O
. O
Tadalafil B-DRUG
tadalafil B-DRUG
concentration O
Tadalafil B-DRUG
dose O
should O
not O
exceed O
a O
maximum O
of O
10 O
mg O
in O
a O
72 O
- O
hour O
period O
in O
patients O
receiving O
concomitant O
indinavir B-DRUG
therapy O
. O
Vardenafil B-DRUG
vardenafil B-DRUG
concentration O
Vardenafil B-DRUG
dose O
should O
not O
exceed O
a O
maximum O
of O
2 O
. O
5 O
mg O
in O
a O
24 O
- O
hour O
period O
in O
patients O
receiving O
concomitant O
indinavir B-DRUG
therapy O
. O
Note O
: O
= O
increase O
; O
= O
decrease O

In O
normal O
volunteers O
receiving O
indomethacin B-DRUG
, O
the O
administration O
of O
diflunisal B-DRUG
decreased O
the O
renal O
clearance O
and O
significantly O
increased O
the O
plasma O
levels O
of O
indomethacin B-DRUG
. O
In O
some O
patients O
, O
combined O
use O
of O
INDOCIN B-BRAND
and O
diflunisal B-DRUG
has O
been O
associated O
with O
fatal O
gastrointestinal O
hemorrhage O
. O
Therefore O
, O
diflunisal B-DRUG
and O
INDOCIN B-BRAND
should O
not O
be O
used O
concomitantly O
. O
In O
a O
study O
in O
normal O
volunteers O
, O
it O
was O
found O
that O
chronic O
concurrent O
administration O
of O
3 O
. O
6 O
g O
of O
aspirin B-BRAND
per O
day O
decreases O
indomethacin B-DRUG
blood O
levels O
approximately O
20 O
% O
. O
The O
concomitant O
use O
of O
INDOCIN B-BRAND
with O
other O
NSAIDs B-GROUP
is O
not O
recommended O
due O
to O
the O
increased O
possibility O
of O
gastrointestinal O
toxicity O
, O
with O
little O
or O
no O
increase O
in O
efficacy O
. O
Clinical O
studies O
have O
shown O
that O
INDOCIN B-BRAND
does O
not O
influence O
the O
hypoprothrombinemia O
produced O
by O
anticoagulants B-GROUP
. O
However O
, O
when O
any O
additional O
drug O
, O
including O
INDOCIN B-BRAND
, O
is O
added O
to O
the O
treatment O
of O
patients O
on O
anticoagulant B-GROUP
therapy O
, O
the O
patients O
should O
be O
observed O
for O
alterations O
of O
the O
prothrombin O
time O
. O
In O
post O
- O
marketing O
experience O
, O
bleeding O
has O
been O
reported O
in O
patients O
on O
concomitant O
treatment O
with O
anticoagulants B-GROUP
and O
INDOCIN B-BRAND
. O
Caution O
should O
be O
exercised O
when O
INDOCIN B-BRAND
and O
anticoagulants B-GROUP
are O
administered O
concomitantly O
. O
When O
INDOCIN B-BRAND
is O
given O
to O
patients O
receiving O
probenecid B-DRUG
, O
the O
plasma O
levels O
of O
indomethacin B-DRUG
are O
likely O
to O
be O
increased O
. O
Therefore O
, O
a O
lower O
total O
daily O
dosage O
of O
INDOCIN B-BRAND
may O
produce O
a O
satisfactory O
therapeutic O
effect O
. O
When O
increases O
in O
the O
dose O
of O
INDOCIN B-BRAND
are O
made O
, O
they O
should O
be O
made O
carefully O
and O
in O
small O
increments O
. O
Caution O
should O
be O
used O
if O
INDOCIN B-BRAND
is O
administered O
simultaneously O
with O
methotrexate B-DRUG
. O
INDOCIN B-BRAND
has O
been O
reported O
to O
decrease O
the O
tubular O
secretion O
of O
methotrexate B-DRUG
and O
to O
potentiate O
its O
toxicity O
. O
Administration O
of O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
concomitantly O
with O
cyclosporine B-DRUG
has O
been O
associated O
with O
an O
increase O
in O
cyclosporine B-DRUG
- O
induced O
toxicity O
, O
possibly O
due O
to O
decreased O
synthesis O
of O
renal O
prostacyclin O
. O
NSAIDs B-GROUP
should O
be O
used O
with O
caution O
in O
patients O
taking O
cyclosporine B-DRUG
, O
and O
renal O
function O
should O
be O
carefully O
monitored O
. O
Capsules O
INDOCIN B-BRAND
50 O
mg O
t O
. O
i O
. O
d O
. O
produced O
a O
clinically O
relevant O
elevation O

of O
plasma O
lithium B-DRUG
and O
reduction O
in O
renal O
lithium B-DRUG
clearance O
in O
psychiatric O
patients O
and O
normal O
subjects O
with O
steady O
state O
plasma O
lithium B-DRUG
concentrations O
. O
This O
effect O
has O
been O
attributed O
to O
inhibition O
of O
prostaglandin O
synthesis O
. O
As O
a O
consequence O
, O
when O
INDOCIN B-BRAND
and O
lithium B-DRUG
are O
given O
concomitantly O
, O
the O
patient O
should O
be O
carefully O
observed O
for O
signs O
of O
lithium B-DRUG
toxicity O
. O
( O
Read O
circulars O
for O
lithium B-DRUG
preparations O
before O
use O
of O
such O
concomitant O
therapy O
. O
) O
In O
addition O
, O
the O
frequency O
of O
monitoring O
serum O
lithium B-DRUG
concentration O
should O
be O
increased O
at O
the O
outset O
of O
such O
combination O
drug O
treatment O
. O
INDOCIN B-BRAND
given O
concomitantly O
with O
digoxin B-DRUG
has O
been O
reported O
to O
increase O
the O
serum O
concentration O
and O
prolong O
the O
half O
- O
life O
of O
digoxin B-DRUG
. O
Therefore O
, O
when O
INDOCIN B-BRAND
and O
digoxin B-DRUG
are O
used O
concomitantly O
, O
serum O
digoxin B-DRUG
levels O
should O
be O
closely O
monitored O
. O
In O
some O
patients O
, O
the O
administration O
of O
INDOCIN B-BRAND
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop B-GROUP
, I-GROUP
potassium I-GROUP
- I-GROUP
sparing I-GROUP
, I-GROUP
and I-GROUP
thiazide I-GROUP
diuretics I-GROUP
. O
Therefore O
, O
when O
INDOCIN B-BRAND
and O
INDOCIN B-BRAND
. O
( O
Indomethacin B-DRUG
) O
diuretics B-GROUP
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-GROUP
is O
obtained O
. O
INDOCIN B-BRAND
reduces O
basal O
plasma O
renin O
activity O
( O
PRA O
) O
, O
as O
well O
as O
those O
elevations O
of O
PRA O
induced O
by O
furosemide B-DRUG
administration O
, O
or O
salt O
or O
volume O
depletion O
. O
These O
facts O
should O
be O
considered O
when O
evaluating O
plasma O
renin O
activity O
in O
hypertensive O
patients O
. O
It O
has O
been O
reported O
that O
the O
addition O
of O
triamterene B-DRUG
to O
a O
maintenance O
schedule O
of O
INDOCIN B-BRAND
resulted O
in O
reversible O
acute O
renal O
failure O
in O
two O
of O
four O
healthy O
volunteers O
. O
INDOCIN B-BRAND
and O
triamterene B-DRUG
should O
not O
be O
administered O
together O
. O
INDOCIN B-BRAND
and O
potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
each O
may O
be O
associated O
with O
increased O
serum O
potassium O
levels O
. O
The O
potential O
effects O
of O
INDOCIN B-BRAND
and O
potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
on O
potassium O
kinetics O
and O
renal O
function O
should O
be O
considered O
when O
these O
agents O
are O
administered O
concurrently O
. O
Most O
of O
the O
above O
effects O
concerning O
diuretics B-GROUP
have O
been O
attributed O
, O
at O
least O
in O
part O
, O
to O
mechanisms O
involving O
inhibition O
of O
prostaglandin O
synthesis O
by O
INDOCIN B-BRAND
. O
Blunting O
of O
the O
antihypertensive O
effect O
of O
beta B-GROUP
- I-GROUP
adrenoceptor I-GROUP
blocking I-GROUP
agents I-GROUP
by O
non B-GROUP
- I-GROUP
steroidal I-GROUP
antiinflammatory I-GROUP
drugs I-GROUP
including O

INDOCIN B-BRAND
has O
been O
reported O
. O
Therefore O
, O
when O
using O
these O
blocking O
agents O
to O
treat O
hypertension O
, O
patients O
should O
be O
observed O
carefully O
in O
order O
to O
confirm O
that O
the O
desired O
therapeutic O
effect O
has O
been O
obtained O
. O
INDOCIN B-BRAND
can O
reduce O
the O
antihypertensive O
effects O
of O
captopril B-DRUG
and O
losartan B-DRUG
. O
False O
- O
negative O
results O
in O
the O
dexamethasone O
suppression O
test O
( O
DST O
) O
in O
patients O
being O
treated O
with O
INDOCIN B-BRAND
have O
been O
reported O
. O
Thus O
, O
results O
of O
the O
DST O
should O
be O
interpreted O
with O
caution O
in O
these O
patients O
. O

Concurrent O
administration O
of O
etanercept B-DRUG
( O
another O
TNF O
- O
blocking O
agent O
) O
and O
anakinra B-DRUG
( O
an O
interleukin B-GROUP
- I-GROUP
1 I-GROUP
antagonist I-GROUP
) O
has O
been O
associated O
with O
an O
increased O
risk O
of O
serious O
infections O
, O
and O
increased O
risk O
of O
neutropenia O
and O
no O
additional O
benefit O
compared O
to O
these O
medicinal O
products O
alone O
. O
Other O
TNFa B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
( O
including O
REMICADE B-BRAND
) O
used O
in O
combination O
with O
anakinra B-DRUG
may O
also O
result O
in O
similar O
toxicities O
. O
Specific O
drug O
interaction O
studies O
, O
including O
interactions O
with O
MTX B-DRUG
, O
have O
not O
been O
conducted O
. O
The O
majority O
of O
patients O
in O
rheumatoid O
arthritis O
or O
Crohn O
s O
disease O
clinical O
studies O
received O
one O
or O
more O
concomitant O
medications O
. O
In O
rheumatoid O
arthritis O
, O
concomitant O
medications O
besides O
MTX B-DRUG
were O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
, O
folic B-DRUG
acid I-DRUG
, O
corticosteroids B-GROUP
and O
/ O
or O
narcotics B-GROUP
. O
Concomitant O
Crohn O
s O
disease O
medications O
were O
antibiotics B-GROUP
, O
antivirals B-GROUP
, O
corticosteroids B-GROUP
, O
6 B-DRUG
- I-DRUG
MP I-DRUG
/ O
AZA B-DRUG
and O
aminosalicylates O
. O
In O
psoriatic O
arthritis O
clinical O
trials O
, O
concomitant O
medications O
included O
MTX B-DRUG
in O
approximately O
half O
of O
the O
patients O
as O
well O
as O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
, O
folic B-DRUG
acid I-DRUG
and O
corticosteroids B-GROUP
. O
Patients O
with O
Crohn O
s O
disease O
who O
received O
immunosuppressants B-GROUP
tended O
to O
experience O
fewer O
infusion O
reactions O
compared O
to O
patients O
on O
no O
immunosuppressants B-GROUP
. O
Serum O
infliximab B-DRUG
concentrations O
appeared O
to O
be O
unaffected O
by O
baseline O
use O
of O
medications O
for O
the O
treatment O
of O
Crohn O
s O
disease O
including O
corticosteroids B-GROUP
, O
antibiotics B-GROUP
( O
metronidazole B-DRUG
or O
ciprofloxacin B-DRUG
) O
and O
aminosalicylates O
. O

A O
number O
of O
substances O
affect O
glucose O
metabolism O
and O
may O
require O
insulin B-DRUG
dose O
adjustment O
and O
particularly O
close O
monitoring O
. O
The O
following O
are O
examples O
of O
substances O
that O
may O
increase O
the O
blood O
- O
glucose O
- O
lowering O
effect O
and O
susceptibility O
to O
hypoglycemia O
: O
oral O
antidiabetes O
products O
, O
ACE B-GROUP
inhibitors I-GROUP
, O
disopyramide B-DRUG
, O
fibrates B-GROUP
, O
fluoxetine B-DRUG
, O
MAO B-GROUP
inhibitors I-GROUP
, O
propoxyphene B-DRUG
, O
salicylates B-GROUP
, O
somatostatin B-GROUP
analog I-GROUP
( O
e O
. O
g O
. O
, O
octreotide B-DRUG
) O
, O
sulfonamide B-GROUP
antibiotics I-GROUP
. O
The O
following O
are O
examples O
of O
substances O
that O
may O
reduce O
the O
blood O
- O
glucose O
- O
lowering O
effect O
of O
insulin B-DRUG
: O
corticosteroids B-GROUP
, O
danazol B-DRUG
, O
diuretics B-GROUP
, O
sympathomimetic B-GROUP
agents I-GROUP
( O
e O
. O
g O
. O
, O
epinephrine B-DRUG
, O
albuterol B-DRUG
, O
terbutaline B-DRUG
) O
, O
isoniazid B-DRUG
, O
phenothiazine B-GROUP
derivatives I-GROUP
, O
somatropin B-DRUG
, O
thyroid B-GROUP
hormones I-GROUP
, O
estrogens B-GROUP
, O
progestogens B-GROUP
( O
e O
. O
g O
. O
, O
in O
oral O
contraceptives B-GROUP
) O
. O
Beta B-GROUP
- I-GROUP
blockers I-GROUP
, O
clonidine B-DRUG
, O
lithium B-DRUG
salts O
, O
and O
alcohol B-DRUG
may O
either O
potentiate O
or O
weaken O
the O
blood O
- O
glucose O
- O
lowering O
effect O
of O
insulin B-DRUG
. O
Pentamidine B-DRUG
may O
cause O
hypoglycemia O
, O
which O
may O
sometimes O
be O
followed O
by O
hyperglycemia O
. O
In O
addition O
, O
under O
the O
influence O
of O
sympatholytic O
medicinal O
products O
such O
as O
beta B-GROUP
- I-GROUP
blockers I-GROUP
, O
clonidine B-DRUG
, O
guanethidine B-DRUG
, O
and O
reserpine B-DRUG
, O
the O
signs O
of O
hypoglycemia O
may O
be O
reduced O
or O
absent O
. O

A O
number O
of O
substances O
affect O
glucose O
metabolism O
and O
may O
require O
insulin B-DRUG
dose O
adjustment O
and O
particularly O
close O
monitoring O
. O
The O
following O
are O
examples O
of O
substances O
that O
may O
increase O
the O
blood O
- O
glucose O
- O
lowering O
effect O
and O
susceptibility O
to O
hypoglycemia O
: O
oral O
antidiabetic B-GROUP
products I-GROUP
, O
ACE B-GROUP
inhibitors I-GROUP
, O
disopyramide B-DRUG
, O
fibrates B-GROUP
, O
fluoxetine B-DRUG
, O
monoamine B-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
, O
propoxyphene B-DRUG
, O
salicylates B-GROUP
, O
somatostatin B-GROUP
analog I-GROUP
( O
e O
. O
g O
. O
, O
octreotide B-DRUG
) O
, O
sulfonamide B-GROUP
antibiotics I-GROUP
. O
The O
following O
are O
examples O
of O
substances O
that O
may O
reduce O
the O
blood O
- O
glucose O
- O
lowering O
effect O
: O
corticosteroids B-GROUP
, O
niacin B-DRUG
, O
danazol B-DRUG
, O
diuretics B-GROUP
, O
sympathomimetic B-GROUP
agents I-GROUP
( O
e O
. O
g O
. O
, O
epinephrine B-DRUG
, O
salbutamol B-DRUG
, O
terbutaline B-DRUG
) O
, O
isoniazid B-DRUG
, O
phenothiazine B-GROUP
derivatives I-GROUP
, O
somatropin B-DRUG
, O
thyroid B-GROUP
hormones I-GROUP
, O
estrogens B-GROUP
, O
progestogens B-GROUP
( O
e O
. O
g O
. O
, O
in O
oral O
contraceptives B-GROUP
) O
. O
Beta B-GROUP
- I-GROUP
blockers I-GROUP
, O
clonidine B-DRUG
, O
lithium B-DRUG
salts O
, O
and O
alcohol B-DRUG
may O
either O
potentiate O
or O
weaken O
the O
blood O
- O
glucose O
- O
lowering O
effect O
of O
insulin B-DRUG
. O
Pentamidine B-DRUG
may O
cause O
hypoglycemia O
, O
which O
may O
sometimes O
be O
followed O
by O
hyperglycemia O
. O
In O
addition O
, O
under O
the O
influence O
of O
sympatholytic O
medicinal O
products O
such O
as O
beta B-GROUP
- I-GROUP
blockers I-GROUP
, O
clonidine B-DRUG
, O
guanethidine B-DRUG
, O
and O
reserpine B-DRUG
, O
the O
signs O
of O
hypoglycemia O
may O
be O
reduced O
or O
absent O
. O
Mixing O
of O
Insulins B-GROUP
A O
clinical O
study O
in O
healthy O
male O
volunteers O
( O
n O
= O
24 O
) O
demonstrated O
that O
mixing O
NovoLog B-BRAND
with O
NPH B-DRUG
human I-DRUG
insulin I-DRUG
immediately O
before O
injection O
produced O
some O
attenuation O
in O
the O
peak O
concentration O
of O
NovoLog B-BRAND
, O
but O
that O
the O
time O
to O
peak O
and O
the O
total O
bioavailability O
of O
NovoLog B-BRAND
were O
not O
significantly O
affected O
. O
If O
NovoLog B-BRAND
is O
mixed O
with O
NPH B-DRUG
human I-DRUG
insulin I-DRUG
, O
NovoLog B-BRAND
should O
be O
drawn O
into O
the O
syringe O
first O
. O
The O
injection O
should O
be O
made O
immediately O
after O
mixing O
. O
Because O
there O
are O
no O
data O
on O
the O
compatibility O
of O
NovoLog B-BRAND
and O
crystalline O
zinc B-DRUG
insulin I-DRUG
preparations O
, O
NovoLog B-BRAND
should O
not O
be O
mixed O
with O
these O
preparations O
. O
The O
effects O
of O
mixing O
NovoLog B-BRAND
with O
insulins B-GROUP
of O
animal O
source O
or O
insulin B-DRUG
preparations O
produced O
by O
other O
manufacturers O
have O
not O
been O
studied O

. O
Mixtures O
should O
not O
be O
administered O
intravenously O
. O
When O
used O
in O
external O
subcutaneous O
infusion O
pumps O
for O
insulin B-DRUG
, O
NovoLog B-BRAND
should O
not O
be O
mixed O
with O
any O
other O
insulins B-GROUP
or O
diluent O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
with O
Rebif B-BRAND
. O
Due O
to O
its O
potential O
to O
cause O
neutropenia O
and O
lymphopenia O
, O
proper O
monitoring O
of O
patients O
is O
required O
if O
Rebif B-BRAND
is O
given O
in O
combination O
with O
myelosuppressive O
agents O
. O
Also O
, O
the O
potential O
for O
hepatic O
injury O
should O
be O
considered O
when O
Rebif B-BRAND
is O
used O
in O
combination O
with O
other O
products O
associated O
with O
hepatic O
injury O
, O
or O
when O
new O
agents O
are O
added O
to O
the O
regimen O
of O
patients O
already O
on O
Rebif B-BRAND
. O

Interactions O
between O
Betaseron B-BRAND
and O
other O
drugs O
have O
not O
been O
fully O
evaluated O
. O
Although O
studies O
designed O
to O
examine O
drug O
interactions O
have O
not O
been O
done O
, O
it O
was O
noted O
that O
corticosteroid B-GROUP
or O
ACTH B-DRUG
treatment O
of O
relapses O
for O
periods O
of O
up O
to O
28 O
days O
has O
been O
administered O
to O
patients O
( O
N O
= O
180 O
) O
receiving O
Betaseron B-BRAND
. O
Betaseron B-BRAND
administration O
to O
three O
cancer O
patients O
over O
a O
dose O
range O
of O
0 O
. O
025 O
mg O
to O
2 O
. O
2 O
mg O
led O
to O
a O
dose O
- O
dependent O
inhibition O
of O
antipyrine B-DRUG
elimination O
. O
14 O
The O
effect O
of O
alternate O
- O
day O
administration O
of O
0 O
. O
25 O
mg O
of O
Betaseron B-BRAND
on O
drug O
metabolism O
in O
MS O
patients O
is O
unknown O
. O

ATROVENT B-BRAND
Inhalation O
Aerosol O
has O
been O
used O
concomitantly O
with O
other O
drugs O
, O
including O
sympathomimetic B-GROUP
bronchodilators I-GROUP
, O
methylxanthines B-GROUP
, O
and O
steroids B-GROUP
, O
commonly O
used O
in O
the O
treatment O
of O
chronic O
obstructive O
pulmonary O
disease O
. O
With O
the O
exception O
of O
albuterol B-DRUG
, O
there O
are O
no O
formal O
studies O
fully O
evaluating O
the O
interaction O
effects O
of O
ATROVENT B-BRAND
Inhalation O
Aerosol O
and O
these O
drugs O
with O
respect O
to O
effectiveness O
. O
Anticholinergic B-GROUP
agents I-GROUP
: O
Although O
ipratropium B-DRUG
bromide I-DRUG
is O
minimally O
absorbed O
into O
the O
systemic O
circulation O
, O
there O
is O
some O
potential O
for O
an O
additive O
interaction O
with O
concomitantly O
used O
anticholinergic B-GROUP
medications I-GROUP
. O
Caution O
is O
therefore O
advised O
in O
the O
coadministration O
of O
ATROVENT B-BRAND
Inhalation O
Aerosol O
with O
other O
anticholinergic B-GROUP
- O
containing O
drugs O
. O

No O
significant O
drug O
- O
drug O
pharmacokinetic O
( O
or O
pharmacodynamic O
) O
interactions O
have O
been O
found O
in O
interaction O
studies O
with O
hydrochlorothiazide B-DRUG
, O
digoxin B-DRUG
, O
warfarin B-DRUG
, O
and O
nifedipine B-DRUG
. O
In O
vitro O
studies O
show O
significant O
inhibition O
of O
the O
formation O
of O
oxidized O
irbesartan O
metabolites O
with O
the O
known O
cytochrome O
CYP O
2C9 O
substrates O
/ O
inhibitors O
sulphenazole B-DRUG
, O
tolbutamide B-DRUG
and O
nifedipine B-DRUG
. O
However O
, O
in O
clinical O
studies O
the O
consequences O
of O
concomitant O
irbesartan B-DRUG
on O
the O
pharmacodynamics O
of O
warfarin B-DRUG
were O
negligible O
. O
Based O
on O
in O
vitro O
data O
, O
no O
interaction O
would O
be O
expected O
with O
drugs O
whose O
metabolism O
is O
dependent O
upon O
cytochrome O
P450 O
isozymes O
1A1 O
, O
1A2 O
, O
2A6 O
, O
2B6 O
, O
2D6 O
, O
2E1 O
, O
or O
3A4 O
. O
In O
separate O
studies O
of O
patients O
receiving O
maintenance O
doses O
of O
warfarin B-DRUG
, O
hydrochlorothiazide B-DRUG
, O
or O
digoxin B-DRUG
, O
irbesartan B-DRUG
administration O
for O
7 O
days O
had O
no O
effect O
on O
the O
pharmacodynamics O
of O
warfarin B-DRUG
( O
prothrombin O
time O
) O
or O
pharmacokinetics O
of O
digoxin B-DRUG
. O
The O
pharmacokinetics O
of O
irbesartan B-DRUG
were O
not O
affected O
by O
coadministration O
of O
nifedipine B-DRUG
or O
hydrochlorothiazide B-DRUG
. O

The O
adverse O
effects O
of O
CAMPTOSAR B-BRAND
, O
such O
as O
myelosuppression O
and O
diarrhea O
, O
would O
be O
expected O
to O
be O
exacerbated O
by O
other O
antineoplastic B-GROUP
agents I-GROUP
having O
similar O
adverse O
effects O
. O
Patients O
who O
have O
previously O
received O
pelvic O
/ O
abdominal O
irradiation O
are O
at O
increased O
risk O
of O
severe O
myelosuppression O
following O
the O
administration O
of O
CAMPTOSAR B-BRAND
. O
The O
concurrent O
administration O
of O
CAMPTOSAR B-BRAND
with O
irradiation O
has O
not O
been O
adequately O
studied O
and O
is O
not O
recommended O
. O
Lymphocytopenia O
has O
been O
reported O
in O
patients O
receiving O
CAMPTOSAR B-BRAND
, O
and O
it O
is O
possible O
that O
the O
administration O
of O
dexamethasone B-DRUG
as O
antiemetic O
prophylaxis O
may O
have O
enhanced O
the O
likelihood O
of O
this O
effect O
. O
However O
, O
serious O
opportunistic O
infections O
have O
not O
been O
observed O
, O
and O
no O
complications O
have O
specifically O
been O
attributed O
to O
lymphocytopenia O
. O
Hyperglycemia O
has O
also O
been O
reported O
in O
patients O
receiving O
CAMPTOSAR B-BRAND
. O
Usually O
, O
this O
has O
been O
observed O
in O
patients O
with O
a O
history O
of O
diabetes O
mellitus O
or O
evidence O
of O
glucose O
intolerance O
prior O
to O
administration O
of O
CAMPTOSAR B-BRAND
. O
It O
is O
probable O
that O
dexamethasone B-DRUG
, O
given O
as O
antiemetic O
prophylaxis O
, O
contributed O
to O
hyperglycemia O
in O
some O
patients O
. O
The O
incidence O
of O
akathisia O
in O
clinical O
trials O
of O
the O
weekly O
dosage O
schedule O
was O
greater O
( O
8 O
. O
5 O
% O
, O
4 O
/ O
47 O
patients O
) O
when O
prochlorperazine B-DRUG
was O
administered O
on O
the O
same O
day O
as O
CAMPTOSAR B-BRAND
than O
when O
these O
drugs O
were O
given O
on O
separate O
days O
( O
1 O
. O
3 O
% O
, O
1 O
/ O
80 O
patients O
) O
. O
The O
8 O
. O
5 O
% O
incidence O
of O
akathisia O
, O
however O
, O
is O
within O
the O
range O
reported O
for O
use O
of O
prochlorperazine B-DRUG
when O
given O
as O
a O
premedication O
for O
other O
chemotherapies O
. O
It O
would O
be O
expected O
that O
laxative B-GROUP
use O
during O
therapy O
with O
CAMPTOSAR B-BRAND
would O
worsen O
the O
incidence O
or O
severity O
of O
diarrhea O
, O
but O
this O
has O
not O
been O
studied O
. O
In O
view O
of O
the O
potential O
risk O
of O
dehydration O
secondary O
to O
vomiting O
and O
/ O
or O
diarrhea O
induced O
by O
CAMPTOSAR B-BRAND
, O
the O
physician O
may O
wish O
to O
withhold O
diuretics B-GROUP
during O
dosing O
with O
CAMPTOSAR B-BRAND
and O
, O
certainly O
, O
during O
periods O
of O
active O
vomiting O
or O
diarrhea O
. O
Drug O
- O
Laboratory O
Test O
Interactions O
There O
are O
no O
known O
interactions O
between O
CAMPTOSAR B-BRAND
and O
laboratory O
tests O
. O

Isocarboxazid B-DRUG
should O
be O
administered O
with O
caution O
to O
patients O
receiving O
Antabuse B-BRAND
( O
disulfiram B-DRUG
, O
Wyeth O
- O
Ayerst O
Laboratories O
) O
. O
In O
a O
single O
study O
, O
rats O
given O
high O
intraperitoneal O
doses O
of O
an O
MAO B-GROUP
inhibitor I-GROUP
plus O
disulfiram B-DRUG
experienced O
severe O
toxicity O
, O
including O
convulsions O
and O
death O
. O
Concomitant O
use O
of O
Isocarboxazid B-DRUG
and O
other O
psychotropic B-GROUP
agents I-GROUP
is O
generally O
not O
recommended O
because O
of O
possible O
potentiating O
effects O
. O
This O
is O
especially O
true O
in O
patients O
who O
may O
subject O
themselves O
to O
an O
overdosage O
of O
drugs O
. O
If O
combination O
therapy O
is O
needed O
, O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
all O
agents O
to O
be O
used O
. O
The O
monoamine O
oxidase O
inhibitory O
effects O
of O
Isocarboxazid B-DRUG
may O
persist O
for O
a O
substantial O
period O
after O
discontinuation O
of O
the O
drug O
, O
and O
this O
should O
be O
borne O
in O
mind O
when O
another O
drug O
is O
prescribed O
following O
Isocarboxazid B-DRUG
. O
To O
avoid O
potentiation O
, O
the O
physician O
wishing O
to O
terminate O
treatment O
with O
Isocarboxazid B-DRUG
and O
begin O
therapy O
with O
another O
agent O
should O
allow O
for O
an O
interval O
of O
10 O
days O
. O

May O
interact O
with O
the O
following O
: O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
( O
these O
medicines O
may O
make O
your O
condition O
worse O
and O
prevent O
the O
adrenergic B-GROUP
bronchodilators I-GROUP
from O
working O
properly O
) O
and O
disopyramide B-DRUG
, O
quinidine B-DRUG
, O
phenothiazines B-GROUP
, O
and O
procainamide B-DRUG
( O
these O
medicines O
may O
increase O
the O
risk O
of O
heart O
problems O
) O
. O

Isoflurane B-DRUG
potentiates O
the O
muscle O
relaxant O
effect O
of O
all O
muscle B-GROUP
relaxants I-GROUP
, O
most O
notably O
nondepolarizing B-GROUP
muscle I-GROUP
relaxants I-GROUP
, O
and O
MAC O
( O
minimum O
alveolar O
concentration O
) O
is O
reduced O
by O
concomitant O
administration O
of O
N O
2O O
. O
See O
CLINICAL O
PHARMACOLOGY O
. O

Food O
: O
Isoniazid B-DRUG
should O
not O
be O
administered O
with O
food O
. O
Studies O
have O
shown O
that O
the O
bioavailability O
of O
isoniazid B-DRUG
is O
reduced O
significantly O
when O
administered O
with O
food O
. O
Acetaminophen B-DRUG
: O
A O
report O
of O
severe O
acetaminophen B-DRUG
toxicity O
was O
reported O
in O
a O
patient O
receiving O
Isoniazid B-DRUG
. O
It O
is O
believed O
that O
the O
toxicity O
may O
have O
resulted O
from O
a O
previously O
unrecognized O
interaction O
between O
isoniazid B-DRUG
and O
acetaminophen B-DRUG
and O
a O
molecular O
basis O
for O
this O
interaction O
has O
been O
proposed O
. O
However O
, O
current O
evidence O
suggests O
that O
isoniazid B-DRUG
does O
induce O
P O
- O
450IIE1 O
, O
a O
mixed O
- O
function O
oxidase O
enzyme O
that O
appears O
to O
generate O
the O
toxic O
metabolites O
, O
in O
the O
liver O
. O
Furthermore O
it O
has O
been O
proposed O
that O
isoniazid B-DRUG
resulted O
In O
induction O
of O
P O
- O
450IIE1 O
in O
the O
patients O
liver O
which O
, O
in O
turn O
, O
resulted O
in O
a O
greater O
proportion O
of O
the O
ingested O
acetaminophen B-DRUG
being O
converted O
to O
the O
toxic O
metabolites O
. O
Studies O
have O
demonstrated O
that O
pretreatment O
with O
isoniazid B-DRUG
potentiates O
a O
cetaminophen O
hepatoxicity O
in O
rats O
. O
Carbamazepine B-DRUG
: O
Isoniazid B-DRUG
is O
known O
to O
slow O
the O
metabolism O
of O
carbamazepine B-DRUG
and O
increase O
its O
serum O
levels O
Carbamazepine B-DRUG
levels O
should O
be O
determined O
prior O
to O
concurrent O
administration O
with O
isoniazid B-DRUG
, O
signs O
and O
symptoms O
of O
carbamazepine B-DRUG
toxicity O
should O
be O
monitored O
closely O
, O
and O
appropriate O
dosage O
adjustment O
of O
the O
anticonvulsant B-GROUP
should O
be O
made O
. O
Ketoconazole B-DRUG
: O
Potential O
interaction O
of O
Ketoconazole B-DRUG
and O
Isoniazid B-DRUG
may O
exist O
. O
Phenytoin B-DRUG
: O
Isoniazid B-DRUG
may O
increase O
serum O
levels O
of O
phenytoin B-DRUG
. O
To O
avoid O
phenytoin B-DRUG
intoxication O
, O
appropriate O
adjustment O
of O
the O
anticonvulsant B-GROUP
should O
be O
made O
. O
Therophylline O
: O
A O
recent O
study O
has O
shown O
that O
concomitan O
administration O
of O
isoniazid B-DRUG
and O
theophylline B-DRUG
may O
cause O
elevated O
plasma O
levels O
of O
theophylline B-DRUG
, O
and O
in O
some O
instances O
a O
slight O
decrease O
in O
the O
elimination O
of O
isoniazid B-DRUG
. O
Since O
the O
therapeutic O
range O
of O
theophylline B-DRUG
is O
narrow O
theophylline B-DRUG
serum O
levels O
should O
be O
monitored O
closely O
, O
and O
appropriate O
dosage O
adjustments O
of O
theophylline B-DRUG
should O
be O
made O
. O
Valproate B-DRUG
: O
A O
recent O
case O
study O
has O
shown O
a O
possible O
increase O
in O
the O
plasma O
level O
of O
valproate B-DRUG
when O
co O
administered O
with O
isoniazid B-DRUG
. O
Plasma O
valproate B-DRUG
concentration O
should O
be O
monitored O
when O

isoniazid B-DRUG
and O
valproate B-DRUG
are O
co O
administered O
, O
and O
appropriate O
dosage O
adjustments O
of O
valproate B-DRUG
should O
be O
made O
. O

Isoproterenol B-DRUG
hydrochloride I-DRUG
injection O
and O
epinephrine B-DRUG
should O
not O
be O
administered O
simultaneously O
because O
both O
drugs O
are O
direct O
cardiac O
stimulants O
and O
their O
combined O
effects O
may O
induce O
serious O
arrhythmias O
. O
The O
drugs O
may O
, O
however O
, O
be O
administered O
alternately O
provided O
a O
proper O
interval O
has O
elapsed O
between O
doses O
. O
ISUPREL B-BRAND
should O
be O
used O
with O
caution O
, O
if O
at O
all O
, O
when O
potent O
inhalational O
anesthetics B-GROUP
such O
as O
halothane B-DRUG
are O
employed O
because O
of O
potential O
to O
sensitize O
the O
myocardium O
to O
effects O
of O
sympathomimetic B-GROUP
amines I-GROUP
. O

The O
vasodilating O
effects O
of O
isosorbide B-DRUG
dinitrate I-DRUG
may O
be O
additive O
with O
those O
of O
other O
vasodilators B-GROUP
. O
Alcohol B-DRUG
, O
in O
particular O
, O
has O
been O
found O
to O
exhibit O
additive O
effects O
of O
this O
variety O
. O

The O
vasodilating O
effects O
of O
isosorbide B-DRUG
mononitrate I-DRUG
may O
be O
additive O
with O
those O
of O
other O
vasodilators B-GROUP
. O
Alcohol B-DRUG
, O
in O
particular O
, O
has O
been O
found O
to O
exhibit O
additive O
effects O
of O
this O
variety O
. O
Marked O
symptomatic O
orthostatic O
hypotension O
has O
been O
reported O
when O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
and O
organic B-GROUP
nitrates I-GROUP
were O
used O
in O
combination O
. O
Dose O
adjustments O
of O
either O
class O
of O
agents O
may O
be O
necessary O
. O

Vitamin B-GROUP
A I-GROUP
: O
Because O
of O
the O
relationship O
of O
Accutane B-BRAND
to O
vitamin B-GROUP
A I-GROUP
, O
patients O
should O
be O
advised O
against O
taking O
vitamin B-GROUP
supplements I-GROUP
containing O
vitamin B-GROUP
A I-GROUP
to O
avoid O
additive O
toxic O
effects O
. O
Tetracyclines B-GROUP
: O
Concomitant O
treatment O
with O
Accutane B-BRAND
and O
tetracyclines B-GROUP
should O
be O
avoided O
because O
Accutane B-BRAND
use O
has O
been O
associated O
with O
a O
number O
of O
cases O
of O
pseudotumor O
cerebri O
( O
benign O
intracranial O
hypertension O
) O
, O
some O
of O
which O
involved O
concomitant O
use O
of O
tetracyclines B-GROUP
. O
Micro O
- O
dosed O
Progesterone B-DRUG
Preparations O
: O
Micro O
- O
dosed O
progesterone B-DRUG
preparations O
( O
minipills O
that O
do O
not O
contain O
an O
estrogen B-GROUP
) O
may O
be O
an O
inadequate O
method O
of O
contraception O
during O
Accutane B-BRAND
therapy O
. O
Although O
other O
hormonal B-GROUP
contraceptives I-GROUP
are O
highly O
effective O
, O
there O
have O
been O
reports O
of O
pregnancy O
from O
women O
who O
have O
used O
combined B-GROUP
oral I-GROUP
contraceptives I-GROUP
, O
as O
well O
as O
topical O
/ O
injectable O
/ O
implantable O
/ O
insertable O
hormonal O
birth O
control O
products O
. O
These O
reports O
are O
more O
frequent O
for O
women O
who O
use O
only O
a O
single O
method O
of O
contraception O
. O
It O
is O
not O
known O
if O
hormonal B-GROUP
contraceptives I-GROUP
differ O
in O
their O
effectiveness O
when O
used O
with O
Accutane B-BRAND
. O
Therefore O
, O
it O
is O
critically O
important O
for O
women O
of O
childbearing O
potential O
to O
select O
and O
commit O
to O
use O
2 O
forms O
of O
effective O
contraception O
simultaneously O
, O
at O
least O
1 O
of O
which O
must O
be O
a O
primary O
form O
, O
unless O
absolute O
abstinence O
is O
the O
chosen O
method O
, O
or O
the O
patient O
has O
undergone O
a O
hysterectomy O
. O
Phenytoin B-DRUG
: O
Accutane B-BRAND
has O
not O
been O
shown O
to O
alter O
the O
pharmacokinetics O
of O
phenytoin B-DRUG
in O
a O
study O
in O
seven O
healthy O
volunteers O
. O
These O
results O
are O
consistent O
with O
the O
in O
vitro O
finding O
that O
neither O
isotretinoin B-DRUG
nor O
its O
metabolites O
induce O
or O
inhibit O
the O
activity O
of O
the O
CYP O
2C9 O
human O
hepatic O
P450 O
enzyme O
. O
Phenytoin B-DRUG
is O
known O
to O
cause O
osteomalacia O
. O
No O
formal O
clinical O
studies O
have O
been O
conducted O
to O
assess O
if O
there O
is O
an O
interactive O
effect O
on O
bone O
loss O
between O
phenytoin B-DRUG
and O
Accutane B-BRAND
. O
Therefore O
, O
caution O
should O
be O
exercised O
when O
using O
these O
drugs O
together O
. O
Systemic B-GROUP
Corticosteroids I-GROUP
: O
Systemic B-GROUP
corticosteroids I-GROUP
are O
known O
to O
cause O
osteoporosis O
. O
No O
formal O
clinical O
studies O
have O
been O
conducted O
to O
assess O
if O
there O
is O
an O
interactive O
effect O
on O
bone O
loss O
between O
systemic B-GROUP
corticosteroids I-GROUP
and O

Accutane B-BRAND
. O
Therefore O
, O
caution O
should O
be O
exercised O
when O
using O
these O
drugs O
together O
. O
Prescribers O
are O
advised O
to O
consult O
the O
package O
insert O
of O
medication O
administered O
concomitantly O
with O
hormonal B-GROUP
contraceptives I-GROUP
, O
since O
some O
medications O
may O
decrease O
the O
effectiveness O
of O
these O
birth O
control O
products O
. O
Accutane B-BRAND
use O
is O
associated O
with O
depression O
in O
some O
patients O
. O
Pregnancies O
have O
been O
reported O
by O
users O
of O
combined B-GROUP
hormonal I-GROUP
contraceptives I-GROUP
who O
also O
used O
some O
form O
of O
St O
. O
Johns O
Wort O
. O
Laboratory O
Tests O
Pregnancy O
Test O
Female O
patients O
of O
childbearing O
potential O
must O
have O
negative O
results O
from O
2 O
urine O
or O
serum O
pregnancy O
tests O
with O
a O
sensitivity O
of O
at O
least O
25 O
mIU O
/ O
mL O
before O
receiving O
the O
initial O
Accutane B-BRAND
prescription O
. O
The O
first O
test O
is O
obtained O
by O
the O
prescriber O
when O
the O
decision O
is O
made O
to O
pursue O
qualification O
of O
the O
patient O
for O
Accutane B-BRAND
( O
a O
screening O
test O
) O
. O
The O
second O
pregnancy O
test O
( O
a O
confirmation O
test O
) O
should O
be O
done O
during O
the O
first O
5 O
days O
of O
the O
menstrual O
period O
immediately O
preceding O
the O
beginning O
of O
Accutane B-BRAND
therapy O
. O
For O
patients O
with O
amenorrhea O
, O
the O
second O
test O
should O
be O
done O
at O
least O
11 O
days O
after O
the O
last O
act O
of O
unprotected O
sexual O
intercourse O
( O
without O
using O
2 O
effective O
forms O
of O
contraception O
) O
. O
Each O
month O
of O
therapy O
, O
the O
patient O
must O
have O
a O
negative O
result O
from O
a O
urine O
or O
serum O
pregnancy O
test O
. O
A O
pregnancy O
test O
must O
be O
repeated O
each O
month O
prior O
to O
the O
female O
patient O
receiving O
each O
prescription O
. O
Lipids O
: O
Pretreatment O
and O
follow O
- O
up O
blood O
lipids O
should O
be O
obtained O
under O
fasting O
conditions O
. O
After O
consumption O
of O
alcohol B-DRUG
, O
at O
least O
36 O
hours O
should O
elapse O
before O
these O
determinations O
are O
made O
. O
It O
is O
recommended O
that O
these O
tests O
be O
performed O
at O
weekly O
or O
biweekly O
intervals O
until O
the O
lipid O
response O
to O
Accutane B-BRAND
is O
established O
. O
The O
incidence O
of O
hypertriglyceridemia O
is O
1 O
patient O
in O
4 O
on O
Accutane B-BRAND
therapy O
. O
Liver O
Function O
Tests O
: O
Since O
elevations O
of O
liver O
enzymes O
have O
been O
observed O
during O
clinical O
trials O
, O
and O
hepatitis O
has O
been O
reported O
, O
pretreatment O
and O
follow O
- O
up O
liver O
function O
tests O
should O
be O
performed O
at O
weekly O
or O
biweekly O
intervals O
until O
the O
response O
to O
Accutane B-BRAND
has O
been O
established O
. O
Glucose O
: O
Some O
patients O
receiving O
Accutane B-BRAND
have O
experienced O
problems O
in O
the O
control O
of O
their O
blood O
sugar O
. O
In O
addition O
, O
new O
cases O
of O
diabetes O
have O
been O
diagnosed O
during O
Accutane B-BRAND
therapy O
, O
although O
no O
causal O
relationship O
has O
been O
established O
. O
CPK O
: O
Some O
patients O
undergoing O
vigorous O
physical O
activity O
while O
on O
Accutane B-BRAND
therapy O
have O

experienced O
elevated O
CPK O
levels O
; O
however O
, O
the O
clinical O
significance O
is O
unknown O
. O
There O
have O
been O
rare O
postmarketing O
reports O
of O
rhabdomyolysis O
, O
some O
associated O
with O
strenuous O
physical O
activity O
. O
In O
a O
clinical O
trial O
of O
217 O
pediatric O
patients O
( O
12 O
to O
17 O
years O
) O
with O
severe O
recalcitrant O
nodular O
acne O
, O
transient O
elevations O
in O
CPK O
were O
observed O
in O
12 O
% O
of O
patients O
, O
including O
those O
undergoing O
strenuous O
physical O
activity O
in O
association O
with O
reported O
musculoskeletal O
adverse O
events O
such O
as O
back O
pain O
, O
arthralgia O
, O
limb O
injury O
, O
or O
muscle O
sprain O
. O
In O
these O
patients O
, O
approximately O
half O
of O
the O
CPK O
elevations O
returned O
to O
normal O
within O
2 O
weeks O
and O
half O
returned O
to O
normal O
within O
4 O
weeks O
. O
No O
cases O
of O
rhabdomyolysis O
were O
reported O
in O
this O
trial O
. O

Nitroglycerin B-DRUG
: O
DynaCirc B-BRAND
( O
isradipine B-DRUG
) O
has O
been O
safely O
coadministered O
with O
nitroglycerin B-DRUG
. O
Hydrochlorothiazide B-DRUG
: O
A O
study O
in O
normal O
healthy O
volunteers O
has O
shown O
that O
concomitant O
administration O
of O
DynaCirc B-BRAND
( O
isradipine B-DRUG
) O
and O
hydrochlorothiazide B-DRUG
does O
not O
result O
in O
altered O
pharmacoktnetics O
of O
either O
drug O
. O
In O
a O
study O
in O
hypertensive O
patients O
, O
addition O
of O
isradipine B-DRUG
to O
existing O
hydrochlorothiazide B-DRUG
therapy O
did O
not O
result O
in O
any O
unexpected O
adverse O
effects O
, O
and O
isradipine B-DRUG
had O
an O
additional O
antihypertensive O
effect O
. O
Propranolol B-DRUG
: O
In O
a O
single O
dose O
study O
in O
normal O
volunteers O
, O
coadministration O
of O
propranolol B-DRUG
had O
a O
small O
effect O
on O
the O
rate O
but O
no O
effect O
on O
the O
extent O
of O
isradipine B-DRUG
bioavailability O
. O
Significant O
increases O
In O
AUC O
( O
27 O
% O
) O
and O
Cmax O
( O
58 O
% O
) O
and O
decreases O
in O
tmax O
( O
23 O
% O
) O
of O
propranolol B-DRUG
were O
noted O
in O
this O
study O
. O
However O
, O
concomitant O
administration O
of O
5 O
mg O
b O
. O
i O
. O
d O
. O
isradipine B-DRUG
and O
40 O
mg O
b O
. O
i O
. O
d O
. O
propranolol B-DRUG
to O
healthy O
volunteers O
under O
steady O
- O
state O
conditions O
had O
no O
relevant O
effect O
on O
either O
drug O
s O
bioavailability O
, O
AUC O
and O
Cmax O
, O
differences O
were O
20 O
% O
between O
isradipine B-DRUG
given O
singly O
and O
in O
combination O
with O
propranolol B-DRUG
, O
and O
between O
propranolol B-DRUG
given O
singly O
and O
in O
combination O
with O
isradipine B-DRUG
. O
Cimetidine B-DRUG
: O
In O
a O
study O
in O
healthy O
volunteers O
, O
a O
one O
- O
week O
course O
of O
cimetidine B-DRUG
at O
400 O
mg O
b O
. O
i O
. O
d O
. O
with O
a O
single O
5 O
mg O
dose O
of O
isradipine B-DRUG
on O
the O
sixth O
day O
showed O
an O
increase O
in O
isradipine B-DRUG
mean O
peak O
plasma O
concentrations O
( O
36 O
% O
) O
and O
significant O
increase O
in O
area O
under O
the O
curve O
( O
50 O
% O
) O
. O
If O
isradipine B-DRUG
therapy O
is O
initiated O
in O
a O
patient O
currently O
receiving O
cimetidine B-DRUG
careful O
monitoring O
for O
adverse O
reactions O
is O
advised O
and O
downward O
dose O
adjustment O
may O
be O
required O
. O
Rifampicin B-DRUG
: O
In O
a O
study O
in O
healthy O
volunteers O
, O
a O
six O
- O
day O
course O
of O
rifampicin B-DRUG
at O
600 O
mg O
/ O
day O
followed O
by O
a O
single O
5 O
mg O
dose O
of O
isradipine B-DRUG
resulted O
in O
a O
reduction O
in O
isradipine B-DRUG
levels O
to O
below O
detectable O
limits O
. O
If O
rifampicin B-DRUG
therapy O
is O
required O
, O
isradipine B-DRUG
concentrations O
and O
therapeutic O
effects O
are O
likely O
to O

be O
markedly O
reduced O
or O
abolished O
as O
a O
consequence O
of O
increased O
metabolism O
and O
higher O
clearance O
of O
isradipine B-DRUG
. O
Warfarin B-DRUG
: O
In O
a O
study O
in O
healthy O
volunteers O
, O
no O
clinically O
relevant O
pharmacokinetic O
or O
pharmacodynamic O
interaction O
between O
isradipine B-DRUG
and O
racemic O
warfarin B-DRUG
was O
seen O
when O
two O
single O
oral O
doses O
of O
warfarin B-DRUG
( O
0 O
. O
7 O
mg O
/ O
kg O
body O
weight O
) O
were O
administered O
during O
11 O
days O
of O
multipledose O
treatment O
with O
5 O
mg O
b O
. O
i O
. O
d O
. O
isradipine B-DRUG
. O
Neither O
racemic O
warfarin B-DRUG
nor O
isradipine B-DRUG
binding O
to O
plasma O
proteins O
in O
vitro O
was O
altered O
by O
the O
addition O
of O
the O
other O
drug O
. O
Digoxin B-DRUG
: O
The O
concomitant O
administration O
of O
DynaCirc B-BRAND
( O
isradipine B-DRUG
) O
and O
digoxin B-DRUG
in O
a O
single O
- O
dose O
pharmacokinetic O
study O
did O
not O
affect O
renal O
, O
nonrenal O
and O
total O
body O
clearance O
of O
digoxin B-DRUG
. O
Fentanyl B-DRUG
Anesthesia O
: O
Severe O
hypotension O
has O
been O
reported O
during O
fentanyl B-DRUG
anesthesia O
with O
concomitant O
use O
of O
a O
beta B-GROUP
blocker I-GROUP
and O
a O
calcium B-GROUP
channel I-GROUP
blocker I-GROUP
. O
Even O
though O
such O
interactions O
have O
not O
been O
seen O
in O
clinical O
studies O
with O
DynaCirc B-BRAND
( O
isradipine B-DRUG
) O
, O
an O
increased O
volume O
of O
circulating O
fluids O
might O
be O
required O
if O
such O
an O
interaction O
were O
to O
occur O
. O

Both O
itraconazole B-DRUG
and O
its O
major O
metabolite O
, O
hydroxyitraconazole B-DRUG_N
, O
are O
inhibitors O
of O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
. O
Coadministration O
of O
Itraconazole B-DRUG
and O
drugs O
primarily O
metabolized O
by O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
may O
result O
in O
increased O
plasma O
concentrations O
of O
the O
drugs O
that O
could O
increase O
or O
prolong O
both O
therapeutic O
and O
adverse O
effects O
. O
Therefore O
, O
unless O
otherwise O
specified O
, O
appropriate O
dosage O
adjustments O
may O
be O
necessary O
. O
Coadministration O
of O
terfenadine B-DRUG
with O
Itraconazole B-DRUG
has O
led O
to O
elevated O
plasma O
concentrations O
of O
terfenadine B-DRUG
, O
resulting O
in O
rare O
instances O
of O
life O
- O
threatening O
cardiac O
dysrhythmias O
and O
one O
death O
. O
Another O
oral O
azole B-GROUP
antifungal I-GROUP
, O
ketoconazole B-DRUG
, O
inhibits O
the O
metabolism O
of O
astemizole B-DRUG
, O
resulting O
in O
elevated O
plasma O
concentrations O
of O
astemizole B-DRUG
and O
its O
active O
metabolite O
desmethylastermizole B-DRUG_N
which O
may O
prolong O
QT O
intervals O
. O
In O
vitro O
data O
suggest O
that O
itraconazole B-DRUG
, O
when O
compared O
to O
ketoconazole B-DRUG
, O
has O
a O
less O
pronounced O
effect O
on O
the O
biotransformation O
system O
responsible O
for O
the O
metabolism O
of O
astemizole B-DRUG
. O
Based O
on O
the O
chemical O
resemblance O
of O
itraconazole B-DRUG
and O
ketoconazole B-DRUG
, O
coadministration O
of O
astemizole B-DRUG
with O
itraconazole B-DRUG
is O
contraindicated O
. O
Human O
pharmacokinetics O
data O
indicate O
that O
oral O
ketoconazole B-DRUG
potently O
inhibits O
the O
metabolism O
of O
cisapride B-DRUG
resulting O
in O
an O
eight O
- O
fold O
increase O
in O
the O
mean O
AUC O
of O
cisapride B-DRUG
. O
Data O
suggest O
that O
coadministration O
of O
oral O
ketoconazole B-DRUG
and O
cisapride B-DRUG
can O
result O
in O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O
In O
vitro O
data O
suggest O
that O
itraconazole B-DRUG
also O
markedly O
inhibits O
the O
biotransformation O
system O
mainly O
responsible O
for O
the O
metabolism O
of O
cisapride B-DRUG
; O
therefore O
concomitant O
administration O
of O
Itraconazole B-DRUG
with O
cisapride B-DRUG
is O
contraindicated O
. O
Coadministration O
of O
Itraconazole B-DRUG
with O
oral O
midazolam B-DRUG
or O
triazolam B-DRUG
has O
resulted O
in O
elevated O
plasma O
concentrations O
of O
the O
latter O
two O
drugs O
. O
This O
may O
potentiate O
and O
prolong O
hypnotic O
and O
sedative O
effects O
. O
These O
agents O
should O
not O
be O
used O
in O
patients O
treated O
with O
Itraconazole B-DRUG
. O
If O

midazolam B-DRUG
is O
administered O
parenterally O
, O
special O
precaution O
is O
required O
since O
the O
sedative O
effect O
may O
be O
prolonged O
. O
Coadministration O
of O
Itraconazole B-DRUG
and O
cyclosporine B-DRUG
, O
tacrolimus B-DRUG
or O
digoxin B-DRUG
has O
led O
to O
increased O
plasma O
concentrations O
of O
the O
latter O
three O
drugs O
. O
Cyclosporine B-DRUG
, O
tacrolimus B-DRUG
and O
digoxin B-DRUG
concentrations O
should O
be O
monitored O
at O
the O
initiation O
of O
Itraconazole B-DRUG
therapy O
and O
frequently O
thereafter O
, O
and O
the O
dose O
of O
these O
three O
drug O
products O
adjusted O
appropriately O
. O
Rhabdomyolysis O
has O
been O
observed O
in O
patients O
receiving O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitors I-GROUP
administered O
alone O
( O
at O
recommended O
dosages O
) O
or O
concomitantly O
with O
immunosuppressive B-GROUP
drugs I-GROUP
including O
cyclosporine B-DRUG
. O
When O
Itraconazole B-DRUG
was O
coadministered O
with O
phenytoin B-DRUG
, O
rifampin B-DRUG
, O
or O
H2antagonists O
, O
reduced O
plasma O
concentrations O
of O
itraconazole B-DRUG
were O
reported O
. O
The O
physician O
is O
advised O
to O
monitor O
the O
plasma O
concentrations O
of O
itraconazole B-DRUG
when O
any O
of O
these O
drugs O
is O
taken O
concurrently O
, O
and O
to O
increase O
the O
dose O
of O
Itraconazole B-DRUG
if O
necessary O
. O
Although O
no O
studies O
have O
been O
conducted O
, O
concomitant O
administration O
of O
Itraconazole B-DRUG
and O
phenytoin B-DRUG
may O
alter O
the O
metabolism O
of O
phenytoin B-DRUG
; O
therefore O
, O
plasma O
concentrations O
of O
phenytoin B-DRUG
should O
also O
be O
monitored O
when O
it O
is O
given O
concurrently O
with O
Itraconazole B-DRUG
. O
It O
has O
been O
reported O
that O
Itraconazole B-DRUG
enhances O
the O
anticoagulant O
effect O
of O
coumarin B-GROUP
- O
like O
drugs O
. O
Therefore O
, O
prothrombin O
time O
should O
be O
carefully O
monitored O
in O
patients O
receiving O
Itraconazole B-DRUG
and O
coumarin B-GROUP
- O
like O
drugs O
simultaneously O
. O
Plasma O
concentrations O
of O
azole B-GROUP
antifungal I-GROUP
agents I-GROUP
are O
reduced O
when O
given O
concurrently O
with O
isoniazid B-DRUG
. O
Itraconazole B-DRUG
plasma O
concentrations O
should O
be O
monitored O
when O
Itraconazole B-DRUG
and O
isoniazid B-DRUG
are O
coadministered O
. O
Severe O
hypoglycemia O
has O
been O
reported O
in O
patients O
concomitantly O
receiving O
azole B-GROUP
antifungal I-GROUP
agents I-GROUP
and O
oral O
hypoglycemic B-GROUP
agents I-GROUP
. O
Blood O
glucose O
concentrations O
should O
be O
carefully O
monitored O
when O
Itraconazole B-DRUG
and O
oral O
hypoglycemic B-GROUP
agents I-GROUP
are O
coadministered O
. O
Tinnitus O
and O
decreased O
hearing O
have O
been O
reported O
in O
patients O
concomitantly O
receiving O
Itraconazole B-DRUG
and O
quinidine B-DRUG
. O
Edema O
has O
been O
reported O
in O
patients O
concomitantly O
receiving O

Itraconazole B-DRUG
and O
dihydropyridine B-GROUP
calcium I-GROUP
channel I-GROUP
blockers I-GROUP
. O
Appropriate O
dosage O
adjustments O
may O
be O
necessary O
. O
The O
results O
from O
a O
study O
in O
which O
eight O
HIV O
- O
infected O
individuals O
were O
treated O
with O
zidovudine B-DRUG
, O
8 O
+ O
/ O
- O
0 O
. O
4 O
mg O
/ O
kg O
/ O
day O
, O
showed O
that O
the O
pharmacokinetics O
of O
zidovudine B-DRUG
were O
not O
affected O
during O
concomitant O
administration O
of O
Itraconazole B-DRUG
, O
100 O
mg O
b O
. O
i O
. O
d O
. O

In O
vitro O
mixing O
of O
an O
aminoglycoside B-GROUP
with O
beta O
- O
lactamtype O
antibiotics B-GROUP
( O
penicillins B-GROUP
or O
cephalosporins B-GROUP
) O
may O
result O
in O
a O
significant O
mutual O
inactivation O
. O
Even O
when O
an O
aminoglycoside B-GROUP
and O
a O
penicillin B-GROUP
- O
type O
drug O
are O
administered O
separately O
by O
different O
routes O
, O
a O
reduction O
in O
aminoglycoside B-GROUP
serum O
half O
- O
life O
or O
serum O
levels O
has O
been O
reported O
in O
patients O
with O
impaired O
renal O
function O
and O
in O
some O
patients O
with O
normal O
renal O
function O
. O
Usually O
, O
such O
inactivation O
of O
the O
aminoglycoside B-GROUP
is O
clinically O
significant O
only O
in O
patients O
with O
severely O
impaired O
renal O
function O
. O
. O
See O

Prolonged O
recovery O
time O
may O
occur O
if O
barbiturates B-GROUP
and O
/ O
or O
narcotics B-GROUP
are O
used O
concurrently O
with O
ketamine B-DRUG
. O
Ketamine B-DRUG
is O
clinically O
compatible O
with O
the O
commonly O
used O
general O
and O
local O
anesthetic B-GROUP
agents I-GROUP
when O
an O
adequate O
respiratory O
exchange O
is O
maintained O
. O

Ketoconazole B-DRUG
is O
a O
potent O
inhibitor O
of O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
. O
Coadministration O
of O
NIZORAL B-BRAND
Tablets O
and O
drugs O
primarily O
metabolized O
by O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
may O
result O
in O
increased O
plasma O
concentrations O
of O
the O
drugs O
that O
could O
increase O
or O
prolong O
both O
therapeutic O
and O
adverse O
effects O
. O
Therefore O
, O
unless O
otherwise O
specified O
, O
appropriate O
dosage O
adjustments O
may O
be O
necessary O
. O
The O
following O
drug O
interactions O
have O
been O
identified O
involving O
NIZORAL B-BRAND
Tablets O
and O
other O
drugs O
metabolized O
by O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
: O
Ketoconazole B-DRUG
tablets O
inhibit O
the O
metabolism O
of O
terfenadine B-DRUG
, O
resulting O
in O
an O
increased O
plasma O
concentration O
of O
terfenadine B-DRUG
and O
a O
delay O
in O
the O
elimination O
of O
its O
acid O
metabolite O
. O
The O
increased O
plasma O
concentration O
of O
terfenadine B-DRUG
or O
its O
metabolite O
may O
result O
in O
prolonged O
QT O
intervals O
. O
Pharmacokinetic O
data O
indicate O
that O
oral O
ketoconazole B-DRUG
inhibits O
the O
metabolism O
of O
astemizole B-DRUG
, O
resulting O
in O
elevated O
plasma O
levels O
of O
astemizole B-DRUG
and O
its O
active O
metabolite O
desmethylastemizole B-DRUG_N
which O
may O
prolong O
QT O
intervals O
. O
Coadministration O
of O
astemizole B-DRUG
with O
ketoconazole B-DRUG
tablets O
is O
therefore O
contraindicated O
. O
Human O
pharmacokinetics O
data O
indicate O
that O
oral O
ketoconazole B-DRUG
potently O
inhibits O
the O
metabolism O
of O
cisapride B-DRUG
resulting O
in O
a O
mean O
eight O
- O
fold O
increase O
in O
AUC O
of O
cisapride B-DRUG
. O
Data O
suggest O
that O
coadministration O
of O
oral O
ketoconazole B-DRUG
and O
cisapride B-DRUG
can O
result O
in O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O
Therefore O
concomitant O
administration O
of O
ketoconazole B-DRUG
tablets O
with O
cisapride B-DRUG
is O
contraindicated O
. O
Ketoconazole B-DRUG
tablets O
may O
alter O
the O
metabolism O
of O
cyclosporine B-DRUG
, O
tacrolimus B-DRUG
, O
and O
methylprednisolone B-DRUG
, O
resulting O
in O
elevated O
plasma O
concentrations O
of O
the O
latter O
drugs O
. O
Dosage O
adjustment O
may O
be O
required O
if O
cyclosporine B-DRUG
, O
tacrolimus B-DRUG
, O
or O
methylprednisolone B-DRUG
are O
given O
concomitantly O
with O
NIZORAL B-BRAND
Tablets O
. O
Coadministration O
of O
NIZORAL B-BRAND
Tablets O
with O
midazolam B-DRUG
or O
triazolam B-DRUG
has O
resulted O
in O
elevated O
plasma O
concentrations O
of O
the O
latter O
two O
drugs O
. O
This O
may O
potentiate O
and O
prolong O
hypnotic O
and O

sedative O
effects O
, O
especially O
with O
repeated O
dosing O
or O
chronic O
administration O
of O
these O
agents O
. O
These O
agents O
should O
not O
be O
used O
in O
patients O
treated O
with O
NIZORAL B-BRAND
Tablets O
. O
If O
midazolam B-DRUG
is O
administered O
parenterally O
, O
special O
precaution O
is O
required O
since O
the O
sedative O
effect O
may O
be O
prolonged O
. O
Rare O
cases O
of O
elevated O
plasma O
concentrations O
of O
digoxin B-DRUG
have O
been O
reported O
. O
It O
is O
not O
clear O
whether O
this O
was O
due O
to O
the O
combination O
of O
therapy O
. O
It O
is O
, O
therefore O
, O
advisable O
to O
monitor O
digoxin B-DRUG
concentrations O
in O
patients O
receiving O
ketoconazole B-DRUG
. O
When O
taken O
orally O
, O
imidazole B-GROUP
compounds I-GROUP
like O
ketoconazole B-DRUG
may O
enhance O
the O
anticoagulant O
effect O
of O
coumarin B-GROUP
- O
like O
drugs O
. O
In O
simultaneous O
treatment O
with O
imidazole B-GROUP
drugs I-GROUP
and O
coumarin B-GROUP
drugs I-GROUP
, O
the O
anticoagulant O
effect O
should O
be O
carefully O
titrated O
and O
monitored O
. O
Because O
severe O
hypoglycemia O
has O
been O
reported O
in O
patients O
concomitantly O
receiving O
oral O
miconazole B-DRUG
( O
an O
imidazole B-GROUP
) O
and O
oral O
hypoglycemic B-GROUP
agents I-GROUP
, O
such O
a O
potential O
interaction O
involving O
the O
latter O
agents O
when O
used O
concomitantly O
with O
ketoconazole B-DRUG
tablets O
( O
an O
imidazole B-GROUP
) O
can O
not O
be O
ruled O
out O
. O
Concomitant O
administration O
of O
ketoconazole B-DRUG
tablets O
with O
phenytoin B-DRUG
may O
alter O
the O
metabolism O
of O
one O
or O
both O
of O
the O
drugs O
. O
It O
is O
suggested O
to O
monitor O
both O
ketoconazole B-DRUG
and O
phenytoin B-DRUG
. O
Concomitant O
administration O
of O
rifampin B-DRUG
with O
ketoconazole B-DRUG
tablets O
reduces O
the O
blood O
levels O
of O
the O
latter O
. O
INH B-DRUG
( O
Isoniazid B-DRUG
) O
is O
also O
reported O
to O
affect O
ketoconazole B-DRUG
concentrations O
adversely O
. O
These O
drugs O
should O
not O
be O
given O
concomitantly O
. O
After O
the O
coadministration O
of O
200 O
mg O
oral O
ketoconazole B-DRUG
twice O
daily O
and O
one O
20 O
mg O
dose O
of O
loratadine B-DRUG
to O
11 O
subjects O
, O
the O
AUC O
and O
Cmax O
of O
loratadine B-DRUG
averaged O
302 O
% O
( O
142 O
S O
. O
D O
. O
) O
and O
251 O
% O
( O
68 O
S O
. O
D O
. O
) O
, O
respectively O
, O
of O
those O
obtained O
after O
co O
- O
treatment O
with O
placebo O
. O
The O
AUC O
and O
Cmax O
of O
descarboethoxyloratadine B-DRUG_N
, O
an O
active O
metabolite O
, O
averaged O
155 O
% O
( O
27 O
S O
. O
D O
. O
) O
and O
141 O
% O
( O
35 O
S O
. O
D O
. O
) O
, O
respectively O
. O
However O
, O
no O
related O
changes O
were O
noted O
in O
the O
QT0 O
on O
ECG O
taken O
at O
2 O
, O
6 O
, O
and O
24 O
hours O
after O
the O
coadministration O
. O
Also O
, O

there O
were O
no O
clinically O
significant O
differences O
in O
adverse O
events O
when O
loratadine B-DRUG
was O
administered O
with O
or O
without O
ketoconazole B-DRUG
. O
Rare O
cases O
of O
a O
disulfiram O
- O
like O
reaction O
to O
alcohol B-DRUG
have O
been O
reported O
. O
These O
experiences O
have O
been O
characterized O
by O
flushing O
, O
rash O
, O
peripheral O
edema O
, O
nausea O
, O
and O
headache O
. O
Symptoms O
resolved O
within O
a O
few O
hours O
. O

The O
following O
drug O
interactions O
were O
studied O
with O
ketoprofen B-DRUG
doses O
of O
200 O
mg O
/ O
day O
. O
The O
possibility O
of O
increased O
interaction O
should O
be O
kept O
in O
mind O
when O
Orudis B-BRAND
doses O
greater O
than O
50 O
mg O
as O
a O
single O
dose O
or O
200 O
mg O
of O
ketoprofen B-DRUG
per O
day O
are O
used O
concomitantly O
with O
highly O
bound O
drugs O
. O
1 O
. O
Antacids B-GROUP
: O
Concomitant O
administration O
of O
magnesium B-DRUG
hydroxide I-DRUG
and O
aluminum B-DRUG
hydroxide I-DRUG
does O
not O
interfere O
with O
the O
rate O
or O
extent O
of O
the O
absorption O
of O
ketoprofen B-DRUG
administered O
as O
Orudis B-BRAND
. O
2 O
. O
Aspirin B-BRAND
: O
Ketoprofen B-DRUG
does O
not O
alter O
aspirin B-BRAND
absorption O
; O
however O
, O
in O
a O
study O
of O
12 O
normal O
subjects O
, O
concurrent O
administration O
of O
aspirin B-BRAND
decreased O
ketoprofen B-DRUG
protein O
binding O
and O
increased O
ketoprofen B-DRUG
plasma O
clearance O
from O
0 O
. O
07 O
L O
/ O
kg O
/ O
h O
without O
aspirin B-BRAND
to O
0 O
. O
11 O
L O
/ O
kg O
/ O
h O
with O
aspirin B-BRAND
. O
The O
clinical O
significance O
of O
these O
changes O
has O
not O
been O
adequately O
studied O
. O
Therefore O
, O
concurrent O
use O
of O
aspirin B-BRAND
and O
ketoprofen B-DRUG
is O
not O
recommended O
. O
3 O
. O
Diuretic B-GROUP
: O
Hydrochlorothiazide B-DRUG
, O
given O
concomitantly O
with O
ketoprofen B-DRUG
, O
produces O
a O
reduction O
in O
urinary O
potassium O
and O
chloride O
excretion O
compared O
to O
hydrochlorothiazide B-DRUG
alone O
. O
Patients O
taking O
diuretics B-GROUP
are O
at O
a O
greater O
risk O
of O
developing O
renal O
failure O
secondary O
to O
a O
decrease O
in O
renal O
blood O
flow O
caused O
by O
prostaglandin O
inhibition O
. O
4 O
. O
Digoxin B-DRUG
: O
In O
a O
study O
in O
12 O
patients O
with O
congestive O
heart O
failure O
where O
ketoprofen B-DRUG
and O
digoxin B-DRUG
were O
concomitantly O
administered O
, O
ketoprofen B-DRUG
did O
not O
alter O
the O
serum O
levels O
of O
digoxin B-DRUG
. O
5 O
. O
Warfarin B-DRUG
: O
In O
a O
short O
- O
term O
controlled O
study O
in O
14 O
normal O
volunteers O
, O
ketoprofen B-DRUG
did O
not O
significantly O
interfere O
with O
the O
effect O
of O
warfarin B-DRUG
on O
prothrombin O
time O
. O
Bleeding O
from O
a O
number O
of O
sites O
may O
be O
a O
complication O
of O
warfarin B-DRUG
treatment O
and O
GI O
bleeding O
a O
complication O
of O
ketoprofen B-DRUG
treatment O
. O
Because O
prostaglandina O
play O
an O
important O
role O
in O
hemostasis O
and O
ketoprofen B-DRUG
has O
an O
effect O
on O
platelet O
function O
as O
well O
, O
concurent O
therapy O
with O
ketoprofen B-DRUG
and O
warfarin B-DRUG
requires O
close O
monitoring O
of O
patients O
on O
both O
drugs O
. O
6 O
. O
Probenecid B-DRUG
: O
Probenecid B-DRUG
increases O
both O
free O
and O
bound O
ketoprofen B-DRUG
by O
reducing O
the O
plasma O

clearance O
of O
ketoprofen B-DRUG
to O
about O
one O
- O
third O
, O
as O
well O
as O
decreasing O
its O
protein O
binding O
. O
Therefore O
, O
the O
combination O
of O
ketoprofen B-DRUG
and O
probenecid B-DRUG
is O
not O
recommended O
. O
7 O
. O
Methotrexate B-DRUG
: O
Ketoprofen B-DRUG
, O
like O
other O
NSAIDs B-GROUP
, O
may O
cause O
changes O
in O
the O
elimination O
of O
methotrexate B-DRUG
leading O
to O
elevated O
serum O
levels O
of O
the O
drug O
and O
increased O
toxicity O
. O
8 O
. O
Lithium B-DRUG
: O
Nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
have O
been O
reported O
to O
increase O
steadystate O
plasma O
lithium B-DRUG
levels O
. O
It O
is O
recommended O
that O
plasma O
lithium B-DRUG
levels O
be O
monitored O
when O
ketoprofen B-DRUG
is O
coadministered O
with O
lithium B-DRUG
. O
DRUG O
/ O
LABORATORY O
TEST O
INTERACTIONS O
: O
EFFECT O
ON O
BLOOD O
COAGULATION O
Ketoprofen B-DRUG
decreases O
platelet O
adhesion O
and O
aggregation O
. O
Therefore O
, O
it O
can O
prolong O
bleeding O
time O
by O
approximately O
3 O
to O
4 O
minutes O
from O
baseline O
values O
. O
There O
is O
no O
significant O
change O
in O
platelet O
count O
, O
prothrombin O
time O
, O
partial O
thromboplastin O
time O
, O
or O
thrombin O
time O
. O

Ketorolac B-DRUG
is O
highly O
bound O
to O
human O
plasma O
protein O
( O
mean O
99 O
. O
2 O
% O
) O
. O
Warfarin B-DRUG
, O
Digoxin B-DRUG
, O
Salicylate B-GROUP
, O
and O
Heparin B-DRUG
The O
in O
vitro O
binding O
of O
warfarin B-DRUG
to O
plasma O
proteins O
is O
only O
slightly O
reduced O
by O
ketorolac B-DRUG
tromethamine I-DRUG
( O
99 O
. O
5 O
% O
control O
vs O
99 O
. O
3 O
% O
) O
when O
ketorolac B-DRUG
plasma O
concentrations O
reach O
5 O
to10 O
m O
g O
/ O
mL O
. O
Ketorolac B-DRUG
does O
not O
alter O
digoxin B-DRUG
protein O
binding O
. O
In O
vitro O
studies O
indicate O
that O
, O
at O
therapeutic O
concentrations O
of O
salicylate B-GROUP
( O
300 O
m O
g O
/ O
mL O
) O
, O
the O
binding O
of O
ketorolac B-DRUG
was O
reduced O
from O
approximately O
99 O
. O
2 O
% O
to O
97 O
. O
5 O
% O
, O
representing O
a O
potential O
twofold O
increase O
in O
unbound O
ketorolac B-DRUG
plasma O
levels O
. O
Therapeutic O
concentrations O
of O
digoxin B-DRUG
, O
warfarin B-DRUG
, O
ibuprofen B-DRUG
, O
naproxen B-DRUG
, O
piroxicam B-DRUG
, O
acetaminophen B-DRUG
, O
phenytoin B-DRUG
andtolbutamide O
did O
not O
alter O
ketorolac B-DRUG
tromethamine I-DRUG
protein O
binding O
. O
In O
a O
study O
involving O
12 O
adult O
volunteers O
, O
TORADOLORAL O
was O
coadministered O
with O
a O
single O
dose O
of O
25 O
mg O
warfarin B-DRUG
, O
causing O
no O
significant O
changes O
in O
pharmacokinetics O
or O
pharmacodynamics O
of O
warfarin B-DRUG
. O
In O
another O
study O
, O
TORADOLIV O
/ O
IM O
was O
given O
with O
two O
doses O
of O
5000 O
U O
of O
heparin B-DRUG
to O
11 O
healthy O
volunteers O
, O
resulting O
in O
a O
mean O
template O
bleeding O
time O
of O
6 O
. O
4 O
minutes O
( O
3 O
. O
2 O
to O
11 O
. O
4 O
min O
) O
compared O
to O
a O
mean O
of O
6 O
. O
0 O
minutes O
( O
3 O
. O
4 O
to O
7 O
. O
5 O
min O
) O
for O
heparin B-DRUG
alone O
and O
5 O
. O
1 O
minutes O
( O
3 O
. O
5 O
to O
8 O
. O
5 O
min O
) O
for O
placebo O
. O
Although O
these O
results O
do O
not O
indicate O
a O
significant O
interaction O
between O
TORADOL B-BRAND
and O
warfarin B-DRUG
or O
heparin B-DRUG
, O
the O
administration O
of O
TORADOL B-BRAND
to O
patients O
taking O
anticoagulants B-GROUP
should O
be O
done O
extremely O
cautiously O
, O
and O
patients O
should O
be O
closely O
monitored O
. O
Furosemide B-DRUG
: O
TORADOL B-BRAND
IV O
/ O
IM O
reduced O
the O
diuretic B-GROUP
response O
to O
furosemide B-DRUG
in O
normovolemic O
healthy O
subjects O
by O
approximately O
20 O
% O
( O
mean O
sodium O
and O
urinary O
output O
decreased O
17 O
% O
) O
. O
Probenecid B-DRUG
: O
Concomitant O
administration O
of O
TORADOL B-BRAND
ORAL O
and O
probenecid B-DRUG
resulted O
in O
decreased O
clearance O
of O
ketorolac B-DRUG
and O
significant O
increases O
in O
ketorolac B-DRUG

plasma O
levels O
( O
total O
AUC O
increased O
approximately O
threefold O
from O
5 O
. O
4 O
to O
17 O
. O
8 O
m O
g O
/ O
h O
/ O
mL O
) O
and O
terminal O
half O
- O
life O
increased O
approximately O
twofold O
from O
6 O
. O
6 O
to O
15 O
. O
1 O
hours O
. O
Therefore O
, O
concomitant O
use O
of O
TORADOL B-BRAND
and O
probenecid B-DRUG
is O
contraindicated O
. O
Lithium B-DRUG
: O
Inhibition O
of O
renal O
lithium B-DRUG
clearance O
, O
leading O
to O
an O
increase O
in O
plasma O
lithium B-DRUG
concentration O
, O
has O
been O
reported O
with O
some O
prostaglandin O
synthesis O
- O
inhibiting O
drugs O
. O
The O
effect O
of O
TORADOL B-BRAND
on O
plasma O
lithium B-DRUG
has O
not O
been O
studied O
, O
but O
cases O
of O
increased O
lithium B-DRUG
plasma O
levels O
during O
TORADOL B-BRAND
therapy O
have O
been O
reported O
. O
Methotrexate B-DRUG
: O
Concomitant O
administration O
of O
methotrexate B-DRUG
and O
some O
NSAIDs B-GROUP
has O
been O
reported O
to O
reduce O
the O
clearance O
of O
methotrexate B-DRUG
, O
enhancing O
the O
toxicity O
of O
methotrexate B-DRUG
. O
The O
effect O
of O
TORADOL B-BRAND
on O
methotrexate B-DRUG
clearance O
has O
not O
been O
studied O
. O
Nondepolarizing B-GROUP
Muscle I-GROUP
Relaxants I-GROUP
: O
In O
postmarketing O
experience O
there O
have O
been O
reports O
of O
a O
possible O
interaction O
between O
TORADOLIV O
/ O
IM O
and O
nondepolarizing B-GROUP
muscle I-GROUP
relaxants I-GROUP
that O
resulted O
in O
apnea O
. O
The O
concurrent O
use O
of O
TORADOL B-BRAND
with O
muscle B-GROUP
relaxants I-GROUP
has O
not O
been O
formally O
studied O
. O
ACE B-GROUP
Inhibitors I-GROUP
: O
Concomitant O
use O
of O
ACE B-GROUP
inhibitors I-GROUP
may O
increase O
the O
risk O
of O
renal O
impairment O
, O
particularly O
in O
volume O
- O
depleted O
patients O
. O
Antiepileptic B-GROUP
Drugs I-GROUP
: O
Sporadic O
cases O
of O
seizures O
have O
been O
reported O
during O
concomitant O
use O
of O
TORADOL B-BRAND
and O
antiepileptic B-GROUP
drugs I-GROUP
( O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
) O
. O
Psychoactive B-GROUP
Drugs I-GROUP
: O
Hallucinations O
have O
been O
reported O
when O
TORADOL B-BRAND
was O
used O
in O
patients O
taking O
psychoactive B-GROUP
drugs I-GROUP
( O
fluoxetine B-DRUG
, O
thiothixene B-DRUG
, O
alprazolam B-DRUG
) O
. O
Morphine B-DRUG
: O
TORADOLIV O
/ O
IM O
has O
been O
administered O
concurrently O
with O
morphine B-DRUG
in O
several O
clinical O
trials O
of O
postoperative O
pain O
without O
evidence O
of O
adverse O
interactions O
. O
Do O
not O
mix O
TORADOL B-BRAND
and O
morphine B-DRUG
in O
the O
same O
syringe O
. O
There O
is O
no O
evidence O
in O
animal O
or O
human O
studies O
that O
TORADOL B-BRAND
induces O
or O
inhibits O
hepatic O
enzymes O
capable O
of O
metabolizing O
itself O
or O
other O
drugs O
. O

Cyclosporine B-DRUG
- O
L B-DRUG
- I-DRUG
arginine I-DRUG
may O
counteract O
the O
antinaturetic O
effect O
of O
cyclosporin B-DRUG
. O
Ibuprofen B-DRUG
- O
L B-DRUG
- I-DRUG
arginine I-DRUG
may O
increase O
the O
absorption O
of O
ibuprofen B-DRUG
if O
taken O
concomitantly O
. O
Organic O
nitrates B-GROUP
- O
L B-DRUG
- I-DRUG
arginine I-DRUG
supplements O
theoretically O
may O
potentiate O
the O
effects O
of O
organic O
nitrates B-DRUG
if O
taken O
concomitantly O
. O
Sildenafil B-DRUG
citrate I-DRUG
- O
Theoretically O
, O
L B-DRUG
- I-DRUG
arginine I-DRUG
supplements O
taken O
concomitantly O
with O
sildenafil B-DRUG
citrate I-DRUG
, O
may O
potentiate O
the O
effects O
of O
the O
drug O
. O

No O
drug O
, O
nutritional O
supplement O
, O
food O
or O
herb O
interactions O
are O
known O
. O

Interacts O
with O
valproic B-DRUG
acid I-DRUG

No O
well O
- O
known O
drug O
interactions O
with O
glutamic B-DRUG
acid I-DRUG

Human B-DRUG
growth I-DRUG
hormone I-DRUG
- O
Concomitant O
use O
of O
L B-DRUG
- I-DRUG
glutamine I-DRUG
and O
human B-DRUG
growth I-DRUG
hormone I-DRUG
may O
enhance O
nutrient O
absorption O
in O
those O
with O
severe O
short O
bowel O
syndrome O
. O
L B-DRUG
- I-DRUG
glutamine I-DRUG
has O
orphan O
drug O
status O
for O
this O
indication O
. O
Indomethacin B-DRUG
- O
Concomitant O
use O
of O
L B-DRUG
- I-DRUG
glutamine I-DRUG
and O
indomethacin B-DRUG
may O
ameliorate O
increased O
intestinal O
permeability O
caused O
by O
indomethacin B-DRUG
. O
The O
reported O
dose O
used O
for O
L B-DRUG
- I-DRUG
glutamine I-DRUG
was O
21 O
grams O
daily O
taken O
in O
divided O
doses O
three O
times O
a O
day O
. O
Further O
, O
misoprostol B-DRUG
is O
reported O
to O
have O
a O
synergistic O
effect O
with O
this O
combination O
in O
ameliorating O
intestinal O
permeability O
. O
Methotrexate B-DRUG
- O
There O
is O
one O
report O
that O
methotrexate B-DRUG
may O
decrease O
the O
possible O
effectiveness O
of O
supplemental O
L B-DRUG
- I-DRUG
glutamine I-DRUG
for O
chemotherapy O
- O
induced O
mucositis O
. O
In O
another O
report O
, O
nine O
patients O
with O
breast O
cancer O
were O
reported O
to O
have O
decreased O
symptoms O
of O
methotrexate B-DRUG
- O
related O
toxicity O
when O
given O
supplemental O
L B-DRUG
- I-DRUG
glutamine I-DRUG
at O
a O
dose O
of O
0 O
. O
5 O
gram O
/ O
kilogram O
/ O
day O
. O
Paclitaxel B-DRUG
- O
In O
one O
report O
, O
L B-DRUG
- I-DRUG
glutamine I-DRUG
at O
a O
dose O
of O
10 O
grams O
three O
times O
daily O
, O
given O
24 O
hours O
after O
receiving O
paclitaxel B-DRUG
, O
appeared O
to O
prevent O
the O
development O
of O
myalgia O
and O
arthralgia O
, O
adverse O
reactions O
of O
paclitaxel B-DRUG
. O

Medroxyprogesterone B-DRUG
Acetate I-DRUG
- O
L B-DRUG
- I-DRUG
histidine I-DRUG
was O
observed O
to O
enhance O
( O
in O
tissue O
culture O
) O
the O
effect O
of O
medroxyprogesterone B-DRUG
acetate I-DRUG
in O
reducing O
the O
number O
of O
human O
breast O
cancer O
cells O
that O
were O
in O
the O
S O
phase O
. O
H1 B-GROUP
and I-GROUP
H2 I-GROUP
Blockers I-GROUP
- O
Although O
not O
reported O
, O
L B-DRUG
- I-DRUG
histidine I-DRUG
, O
via O
its O
metabolism O
to O
histamine O
, O
might O
decrease O
the O
efficacy O
of O
H1 B-GROUP
and I-GROUP
H2 I-GROUP
blockers I-GROUP
. O

Concomitant O
use O
of O
calcium B-DRUG
supplements O
and O
L B-DRUG
- I-DRUG
lysine I-DRUG
may O
increase O
calcium B-DRUG
absorption O

Acetaminophen B-DRUG
and O
methotrexate B-DRUG
- O
L B-DRUG
- I-DRUG
methionine I-DRUG
may O
decrease O
hepatic O
toxicity O
in O
those O
with O
acetaminophen B-DRUG
overdosage O
or O
in O
those O
taking O
methotrexate B-DRUG
. O
Theoretically O
, O
it O
may O
decrease O
hepatic O
toxicity O
in O
the O
case O
of O
other O
potential O
hepatotoxic O
drugs O
, O
as O
well O
. O
Gentamicin B-DRUG
- O
Methionine B-DRUG
may O
protect O
against O
the O
ototoxic O
effects O
of O
gentamicin B-DRUG
. O

Non B-GROUP
- I-GROUP
selective I-GROUP
monoamine I-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
- O
including O
phenelzine B-DRUG
sulfate I-DRUG
, O
tranylcypromine B-DRUG
sulfate I-DRUG
and O
pargyline B-DRUG
HC1 O
. O
Concomitant O
use O
of O
L B-DRUG
- I-DRUG
phenylalanine I-DRUG
and O
non B-GROUP
- I-GROUP
selective I-GROUP
MAO I-GROUP
inhibitors I-GROUP
may O
cause O
hypertension O
. O
Selegiline B-DRUG
- O
L B-DRUG
- I-DRUG
phenylalanine I-DRUG
and O
the O
selective B-GROUP
MAO I-GROUP
inhibitor I-GROUP
selegiline B-DRUG
may O
have O
synergistic O
antidepressant O
activity O
if O
used O
concomitantly O
. O
Neuroleptic B-GROUP
Drugs I-GROUP
- O
L B-DRUG
- I-DRUG
phenylalanine I-DRUG
may O
potentiate O
the O
tardive O
dyskinesia O
side O
reactions O
of O
neuroleptic B-GROUP
drugs I-GROUP
if O
used O
concomitantly O
with O
them O
. O

Monoamine B-GROUP
oxidase I-GROUP
( I-GROUP
MAO I-GROUP
) I-GROUP
inhibitors I-GROUP
such O
as O
isocarboxazid B-DRUG
( O
e O
. O
g O
. O
, O
Marplan B-BRAND
) O
, O
phenelzine B-DRUG
( O
e O
. O
g O
. O
, O
Nardil B-BRAND
) O
, O
procarbazine B-DRUG
( O
e O
. O
g O
. O
, O
Matulane B-BRAND
) O
, O
selegiline B-DRUG
( O
e O
. O
g O
. O
, O
Eldepryl B-BRAND
) O
, O
and O
tranylcypromine B-DRUG
( O
e O
. O
g O
. O
, O
Parnate B-BRAND
) O
: O
Using O
these O
medicines O
with O
L B-DRUG
- I-DRUG
tryptophan I-DRUG
may O
increase O
the O
chance O
of O
side O
effects O
. O

Non B-GROUP
- I-GROUP
selective I-GROUP
MAO I-GROUP
inhibitors I-GROUP
including O
tranylcypromine B-DRUG
sulfate I-DRUG
, O
phenelzine B-DRUG
sulfate I-DRUG
, O
and O
pargyline B-DRUG
HC1 O
: O
Concomitant O
use O
of O
L B-DRUG
- I-DRUG
tyrosine I-DRUG
and O
non O
- O
selective O
MAO B-GROUP
inhibitors I-GROUP
may O
cause O
hypertension O
. O

In O
one O
survey O
, O
2 O
. O
3 O
% O
of O
patients O
taking O
labetalol B-DRUG
HCl I-DRUG
in O
combination O
with O
tricyclic B-GROUP
antidepressants I-GROUP
experienced O
tremor O
, O
as O
compared O
to O
0 O
. O
7 O
% O
reported O
to O
occur O
with O
labetalol B-DRUG
HCl I-DRUG
alone O
. O
The O
contribution O
of O
each O
of O
the O
treatments O
to O
this O
adverse O
reaction O
is O
unknown O
but O
the O
possibility O
of O
a O
drug O
interaction O
cannot O
be O
excluded O
. O
Drugs O
possessing O
beta O
- O
blocking O
properties O
can O
blunt O
the O
bronchodilator O
effect O
of O
beta B-GROUP
- I-GROUP
receptor I-GROUP
agonist I-GROUP
drugs I-GROUP
in O
patients O
with O
bronchospasm O
; O
therefore O
, O
doses O
greater O
than O
the O
normal O
antiasthmatic O
dose O
of O
beta B-GROUP
- I-GROUP
agonist I-GROUP
bronchodilator I-GROUP
drugs I-GROUP
may O
be O
required O
. O
Cimetidine B-DRUG
has O
been O
shown O
to O
increase O
the O
bioavailability O
of O
labetalol B-DRUG
HCl I-DRUG
. O
Since O
this O
could O
be O
explained O
either O
by O
enhanced O
absorption O
or O
by O
an O
alteration O
of O
hepatic O
metabolism O
of O
labetalol B-DRUG
HCl I-DRUG
, O
special O
care O
should O
be O
used O
in O
establishing O
the O
dose O
required O
for O
blood O
pressure O
control O
in O
such O
patients O
. O
Synergism O
has O
been O
shown O
between O
halothane B-DRUG
anesthesia O
and O
intravenously O
administered O
labetalol B-DRUG
HCl I-DRUG
. O
During O
controlled O
hypotensive O
anesthesia O
using O
labetalol B-DRUG
HCl I-DRUG
in O
association O
with O
halothane B-DRUG
, O
high O
concentrations O
( O
3 O
% O
or O
above O
) O
of O
halothane B-DRUG
should O
not O
be O
used O
because O
the O
degree O
of O
hypotension O
will O
be O
increased O
and O
because O
of O
the O
possibility O
of O
a O
large O
reduction O
in O
cardiac O
output O
and O
an O
increase O
in O
central O
venous O
pressure O
. O
The O
anesthesiologist O
should O
be O
informed O
when O
a O
patient O
is O
receiving O
labetalol B-DRUG
HCl I-DRUG
. O
Labetalol B-DRUG
HCl I-DRUG
blunts O
the O
reflex O
tachycardia O
produced O
by O
nitroglycerin B-DRUG
without O
preventing O
its O
hypotensive O
effect O
. O
If O
labetalol B-DRUG
HCl I-DRUG
is O
used O
with O
nitroglycerin B-DRUG
in O
patients O
with O
angina O
pectoris O
, O
additional O
antihypertensive O
effects O
may O
occur O
. O
Care O
should O
be O
taken O
if O
labetalol B-DRUG
is O
used O
concomitantly O
with O
calcium B-GROUP
antagonists I-GROUP
of O
the O
verapamil B-DRUG
type O
. O
Risk O
of O
Anaphylactic O
Reaction O
While O
taking O
beta B-GROUP
- I-GROUP
blockers I-GROUP
, O
patients O
with O
a O
history O
of O
severe O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
be O
more O
reactive O
to O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
, O
or O
therapeutic O
. O
Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-DRUG
used O
to O
treat O
allergic O
reaction O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
The O
presence O
of O
labetalol O
metabolites O
in O
the O
urine O
may O
result O
in O
falsely O
elevated O
levels O
of O
urinary O

catecholamines O
, O
metanephrine O
, O
normetanephrine O
and O
vanillylmandelic O
acid O
when O
measured O
by O
fluorimetric O
or O
photometric O
methods O
. O
In O
screening O
patients O
suspected O
of O
having O
a O
pheochromocytoma O
and O
being O
treated O
with O
labetalol B-DRUG
HCl I-DRUG
, O
a O
specific O
method O
, O
such O
as O
a O
high O
performance O
liquid O
chromatographic O
assay O
with O
solid O
phase O
extraction O
( O
e O
. O
g O
. O
, O
J O
Chromatogr O
385 O
: O
241 O
, O
1987 O
) O
should O
be O
employed O
in O
determining O
levels O
of O
catecholamines O
. O
Labetalol B-DRUG
HCl I-DRUG
has O
also O
been O
reported O
to O
produce O
a O
false O
positive O
test O
for O
amphetamine B-DRUG
when O
screening O
urine O
for O
the O
presence O
of O
drugs O
using O
the O
commercially O
available O
assay O
methods O
Toxi O
- O
Lab O
A O
( O
thin O
- O
layer O
chromatographic O
assay O
) O
and O
Emit O
- O
d O
. O
a O
. O
u O
. O
( O
radioenzymatic O
assay O
) O
. O
When O
patients O
being O
treated O
with O
labetalol B-DRUG
have O
a O
positive O
urine O
test O
for O
amphetamine B-DRUG
using O
these O
techniques O
confirmation O
should O
be O
made O
by O
using O
more O
specific O
methods O
such O
as O
a O
gas O
chromatographic O
- O
mass O
spectrometer O
technique O
. O

Results O
of O
preliminary O
studies O
in O
humans O
and O
rats O
suggest O
that O
nonabsorbable O
antacids B-GROUP
given O
concurrently O
with O
lactulose B-DRUG
may O
inhibit O
the O
desired O
lactulose B-DRUG
- O
induced O
drop O
in O
colonic O
pH O
. O
Therefore O
, O
a O
possible O
lack O
of O
desired O
effect O
of O
treatment O
should O
be O
taken O
into O
consideration O
before O
such O
drugs O
are O
given O
concomitantly O
with O
lactulose B-DRUG
. O

Lamivudine B-DRUG
is O
predominantly O
eliminated O
in O
the O
urine O
by O
active O
organic O
cationic O
secretion O
. O
The O
possibility O
of O
interactions O
with O
other O
drugs O
administered O
concurrently O
should O
be O
considered O
, O
particularly O
when O
their O
main O
route O
of O
elimination O
is O
active O
renal O
secretion O
via O
the O
organic O
cationic O
transport O
system O
( O
e O
. O
g O
. O
, O
trimethoprim B-DRUG
) O
. O
No O
change O
in O
dose O
of O
either O
drug O
is O
recommended O
. O
There O
is O
no O
information O
regarding O
the O
effect O
on O
lamivudine B-DRUG
pharmacokinetics O
of O
higher O
doses O
of O
TMP B-DRUG
/ O
SMX B-DRUG
such O
as O
those O
used O
to O
treat O
Pneumocystis O
carinii O
pneumonia O
. O
No O
data O
are O
available O
regarding O
interactions O
with O
other O
drugs O
that O
have O
renal O
clearance O
mechanisms O
similar O
to O
that O
of O
lamivudine B-DRUG
. O
Lamivudine B-DRUG
and O
zalcitabine B-DRUG
may O
inhibit O
the O
intracellular O
phosphorylation O
of O
one O
another O
. O
Therefore O
, O
use O
of O
lamivudine B-DRUG
in O
combination O
with O
zalcitabine B-DRUG
is O
not O
recommended O
. O

Lansoprazole B-DRUG
is O
metabolized O
through O
the O
cytochrome O
P450 O
system O
, O
specifically O
through O
the O
CYP3A O
and O
CYP2C19 O
isozymes O
. O
Studies O
have O
shown O
that O
lansoprazole B-DRUG
does O
not O
have O
clinically O
significant O
interactions O
with O
other O
drugs O
metabolized O
by O
the O
cytochrome O
P450 O
system O
, O
such O
as O
warfarin B-DRUG
, O
antipyrine B-DRUG
, O
indomethacin B-DRUG
, O
ibuprofen B-DRUG
, O
phenytoin B-DRUG
, O
propranolol B-DRUG
, O
prednisone B-DRUG
, O
diazepam B-DRUG
, O
clarithromycin B-DRUG
, O
or O
terfenadine B-DRUG
in O
healthy O
subjects O
. O
These O
compounds O
are O
metabolized O
through O
various O
cytochrome O
P450 O
isozymes O
including O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
and O
CYP3A O
. O
When O
lansoprazole B-DRUG
was O
administered O
concomitantly O
with O
theophylline B-DRUG
( O
CYP1A2 O
, O
CYP3A O
) O
, O
a O
minor O
increase O
( O
10 O
% O
) O
in O
the O
clearance O
of O
theophylline B-DRUG
was O
seen O
. O
Because O
the O
small O
magnitude O
and O
the O
direction O
of O
the O
effect O
on O
theophylline B-DRUG
clearance O
, O
this O
interaction O
is O
unlikely O
to O
be O
clinical O
concern O
. O
Nonetheless O
, O
individual O
patients O
may O
require O
additional O
titration O
of O
their O
theophylline B-DRUG
dosage O
when O
lansoprazole B-DRUG
is O
started O
or O
stopped O
to O
ensure O
clinically O
effective O
blood O
levels O
. O
Lansoprazole B-DRUG
has O
also O
been O
shown O
to O
have O
no O
clinically O
significant O
interaction O
with O
amoxicillin B-DRUG
. O
In O
a O
single O
- O
dose O
crossover O
study O
examining O
lansoprazole B-DRUG
30 O
mg O
and O
omeprazole B-DRUG
20 O
mg O
each O
administered O
alone O
and O
concomitantly O
with O
sucralfate B-DRUG
1 O
gram O
, O
absorption O
of O
the O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
was O
delayed O
and O
their O
bioavailability O
was O
reduced O
by O
17 O
% O
and O
16 O
% O
, O
respectively O
, O
when O
administered O
concomitantly O
with O
sucralfate B-DRUG
. O
Therefore O
, O
proton B-GROUP
pump I-GROUP
inhibitors I-GROUP
should O
be O
taken O
at O
least O
30 O
minutes O
prior O
to O
sucralfate B-DRUG
. O
In O
clinical O
trials O
, O
antacids B-GROUP
were O
administered O
concomitantly O
with O
lansoprazole B-DRUG
delayed O
- O
release O
capsules O
; O
this O
did O
not O
interfere O
with O
its O
effect O
. O
Lansoprazole B-DRUG
causes O
a O
profound O
and O
long O
lasting O
inhibition O
of O
gastric O
acid O
secretion O
; O
therefore O
, O
it O
is O
theoretically O
possible O
that O
lansoprazole B-DRUG
may O
interfere O
with O
the O
absorption O
of O
drugs O
where O
gastric O
pH O
is O
an O
important O
determinant O
of O
bioavailability O
( O
e O
. O
g O
. O

ketoconazole B-DRUG
, O
ampicillin B-DRUG
esters O
, O
iron B-DRUG
salts O
, O
digoxin B-DRUG
) O
. O

Effects O
of O
Lapatinib B-DRUG
on O
Drug O
Metabolizing O
Enzymes O
and O
Drug O
Transport O
Systems O
Lapatinib B-DRUG
inhibits O
CYP3A4 O
and O
CYP2C8 O
in O
vitro O
at O
clinically O
relevant O
concentrations O
. O
Caution O
should O
be O
exercised O
and O
dose O
reduction O
of O
the O
concomitant O
substrate O
drug O
should O
be O
considered O
when O
dosing O
lapatinib B-DRUG
concurrently O
with O
medications O
with O
narrow O
therapeutic O
windows O
that O
are O
substrates O
of O
CYP3A4 O
or O
CYP2C8 O
. O
Lapatinib B-DRUG
did O
not O
significantly O
inhibit O
the O
following O
enzymes O
in O
human O
liver O
microsomes O
: O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
and O
CYP2D6 O
or O
UGT O
enzymes O
in O
vitro O
, O
however O
, O
the O
clinical O
significance O
is O
unknown O
. O
Lapatinib B-DRUG
inhibits O
human O
P O
- O
glycoprotein O
. O
If O
TYKERB B-BRAND
is O
administered O
with O
drugs O
that O
are O
substrates O
of O
Pgp O
, O
increased O
concentrations O
of O
the O
substrate O
drug O
are O
likely O
, O
and O
caution O
should O
be O
exercised O
. O
Drugs O
that O
Inhibit O
or O
Induce O
Cytochrome O
P450 O
3A4 O
Enzymes O
Lapatinib B-DRUG
undergoes O
extensive O
metabolism O
by O
CYP3A4 O
, O
and O
concomitant O
administration O
of O
strong O
inhibitors O
or O
inducers O
of O
CYP3A4 O
alter O
lapatinib B-DRUG
concentrations O
significantly O
. O
Dose O
adjustment O
of O
lapatinib B-DRUG
should O
be O
considered O
for O
patients O
who O
must O
receive O
concomitant O
strong O
inhibitors O
or O
concomitant O
strong O
inducers O
of O
CYP3A4 O
enzymes O
. O
Ketoconazole B-DRUG
: O
In O
healthy O
subjects O
receiving O
ketoconazole B-DRUG
, O
a O
CYP3A4 O
inhibitor O
, O
at O
200 O
mg O
twice O
daily O
for O
7 O
days O
, O
systemic O
exposure O
( O
AUC O
) O
to O
lapatinib B-DRUG
was O
increased O
to O
approximately O
3 O
. O
6 O
- O
fold O
of O
control O
and O
half O
- O
life O
increased O
to O
1 O
. O
7 O
- O
fold O
of O
control O
. O
Carbamazepine B-DRUG
: O
In O
healthy O
subjects O
receiving O
the O
CYP3A4 O
inducer O
, O
carbamazepine B-DRUG
, O
at O
100 O
mg O
twice O
daily O
for O
3 O
days O
and O
200 O
mg O
twice O
daily O
for O
17 O
days O
, O
systemic O
exposure O
( O
AUC O
) O
to O
lapatinib B-DRUG
was O
decreased O
approximately O
72 O
% O
. O
Drugs O
that O
Inhibit O
Drug O
Transport O
Systems O
Lapatinib B-DRUG
is O
a O
substrate O
of O
the O
efflux O
transporter O
P O
- O
glycoprotein O
( O
Pgp O
, O
ABCB1 O
) O
. O
If O
TYKERB B-BRAND
is O
administered O
with O
drugs O
that O
inhibit O
Pgp O
, O
increased O
concentrations O
of O
lapatinib B-DRUG
are O
likely O
, O
and O
caution O
should O
be O
exercised O
. O
Other O

Chemotherapy O
Agents O
In O
a O
separate O
study O
, O
concomitant O
administration O
of O
lapatinib B-DRUG
with O
capecitabine B-DRUG
did O
not O
meaningfully O
alter O
the O
pharmacokinetics O
of O
either O
agent O
( O
or O
the O
metabolites O
of O
capecitabine B-DRUG
) O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
. O

In O
vitro O
studies O
have O
shown O
that O
precipitation O
occurs O
when O
eye O
drops O
containing O
thimerosal B-DRUG_N
are O
mixed O
with O
latanoprost B-DRUG
. O
If O
such O
drugs O
are O
used O
they O
should O
be O
administered O
with O
an O
interval O
of O
at O
least O
5 O
minutes O
between O
applications O
. O

Cholestyramine B-DRUG
and O
Charcoal B-DRUG
Administration O
of O
cholestyramine B-DRUG
or O
activated B-DRUG
charcoal I-DRUG
in O
patients O
( O
n O
= O
13 O
) O
and O
volunteers O
( O
n O
= O
96 O
) O
resulted O
in O
a O
rapid O
and O
significant O
decrease O
in O
plasma O
M1 O
( O
the O
active O
metabolite O
of O
leflunomide B-DRUG
) O
concentration O
. O
Hepatotoxic O
Drugs O
Increased O
side O
effects O
may O
occur O
when O
leflunomide B-DRUG
is O
given O
concomitantly O
with O
hepatotoxic O
substances O
. O
This O
is O
also O
to O
be O
considered O
when O
leflunomide B-DRUG
treatment O
is O
followed O
by O
such O
drugs O
without O
a O
drug O
elimination O
procedure O
. O
In O
a O
small O
( O
n O
= O
30 O
) O
combination O
study O
of O
ARAVA B-BRAND
with O
methotrexate B-DRUG
, O
a O
2 O
- O
to O
3 O
- O
fold O
elevation O
in O
liver O
enzymes O
was O
seen O
in O
5 O
of O
30 O
patients O
. O
All O
elevations O
resolved O
, O
2 O
with O
continuation O
of O
both O
drugs O
and O
3 O
after O
discontinuation O
of O
leflunomide B-DRUG
. O
A O
3 O
- O
fold O
increase O
was O
seen O
in O
another O
5 O
patients O
. O
All O
of O
these O
also O
resolved O
, O
2 O
with O
continuation O
of O
both O
drugs O
and O
3 O
after O
discontinuation O
of O
leflunomide B-DRUG
. O
Three O
patients O
met O
ACR O
criteria O
for O
liver O
biopsy O
( O
1 O
: O
Roegnik O
Grade O
I O
, O
2 O
: O
Roegnik O
Grade O
IIIa O
) O
. O
No O
pharmacokinetic O
interaction O
was O
identified O
. O
NSAIDs B-GROUP
: O
In O
in O
vitro O
studies O
, O
M1 O
was O
shown O
to O
cause O
increases O
ranging O
from O
13 O
- O
50 O
% O
in O
the O
free O
fraction O
of O
diclofenac B-DRUG
and O
ibuprofen B-DRUG
at O
concentrations O
in O
the O
clinical O
range O
. O
The O
clinical O
significance O
of O
this O
finding O
is O
unknown O
; O
however O
, O
there O
was O
extensive O
concomitant O
use O
of O
NSAIDs B-GROUP
in O
clinical O
studies O
and O
no O
differential O
effect O
was O
observed O
. O
Tolbutamide B-DRUG
: O
In O
in O
vitro O
studies O
, O
M1 O
was O
shown O
to O
cause O
increases O
ranging O
from O
13 O
- O
50 O
% O
in O
the O
free O
fraction O
of O
tolbutamide B-DRUG
at O
concentrations O
in O
the O
clinical O
range O
. O
The O
clinical O
significance O
of O
this O
finding O
is O
unknown O
. O
Rifampin B-DRUG
: O
Following O
concomitant O
administration O
of O
a O
single O
dose O
of O
ARAVA B-BRAND
to O
subjects O
receiving O
multiple O
doses O
of O
rifampin B-DRUG
, O
M1 O
peak O
levels O
were O
increased O
( O
~ O
40 O
% O
) O
over O
those O
seen O
when O
ARAVA B-BRAND
was O
given O
alone O
. O
Because O
of O
the O
potential O
for O
ARAVA B-BRAND
levels O
to O
continue O
to O
increase O
with O
multiple O
dosing O
, O
caution O
should O
be O
used O
if O
patients O
are O
to O
be O
receiving O
both O
ARAVA B-BRAND
and O
rifampin B-DRUG
. O
Warfarin B-DRUG
: O
Increased O
INR O
( O
International O
Normalized O
Ratio O
) O
when O
ARAVA B-BRAND
and O
warfarin B-DRUG
were O
co O
- O
administered O
has O
been O

rarely O
reported O
. O

Results O
from O
human O
in O
vitro O
metabolism O
studies O
and O
nonclinical O
studies O
show O
that O
REVLIMID B-BRAND
( O
lenalidomide B-DRUG
) O
is O
neither O
metabolized O
by O
nor O
inhibits O
or O
induces O
the O
cytochrome O
P450 O
pathway O
suggesting O
that O
lenalidomide B-DRUG
is O
not O
likely O
to O
cause O
or O
be O
subject O
to O
P450 O
- O
based O
metabolic O
drug O
interactions O
in O
man O
. O
Co O
- O
administration O
of O
multiple O
doses O
of O
10 O
mg O
of O
lenalidomide B-DRUG
had O
no O
effect O
on O
the O
single O
dose O
pharmacokinetics O
of O
R B-DRUG
- I-DRUG
and I-DRUG
S I-DRUG
- I-DRUG
warfarin I-DRUG
. O
Co O
- O
administration O
of O
single O
25 O
- O
mg O
dose O
warfarin B-DRUG
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
total O
lenalidomide B-DRUG
. O
Expected O
changes O
in O
laboratory O
assessments O
of O
PT O
and O
INR O
were O
observed O
after O
warfarin B-DRUG
administration O
, O
but O
these O
changes O
were O
not O
affected O
by O
concomitant O
lenalidomide B-DRUG
administration O
. O

Concomitant O
treatment O
with O
thrombolytics B-GROUP
( O
eg O
, O
rt O
- O
PA O
or O
streptokinase B-DRUG
) O
may O
: O
- O
increase O
the O
risk O
of O
bleeding O
complications O
- O
considerably O
enhance O
the O
effect O
of O
REFLUDAN B-BRAND
on O
aPTT O
prolongation O
Concomitant O
treatment O
with O
coumarin B-GROUP
derivatives I-GROUP
( O
vitamin B-GROUP
K I-GROUP
antagonists I-GROUP
) O
and O
drugs O
that O
affect O
platelet O
function O
may O
also O
increase O
the O
risk O
of O
bleeding O
. O

Clinical O
interaction O
studies O
with O
cimetidine B-DRUG
and O
warfarin B-DRUG
indicated O
that O
the O
coadministration O
of O
Femara B-BRAND
with O
these O
drugs O
does O
not O
result O
in O
clinically O
- O
significant O
drug O
interactions O
. O
( O
See O
CLINICAL O
PHARMACOLOGY O
) O
Coadministration O
of O
Femara B-BRAND
and O
tamoxifen B-DRUG
20 O
mg O
daily O
resulted O
in O
a O
reduction O
of O
letrozole B-DRUG
plasma O
levels O
by O
38 O
% O
on O
average O
. O
There O
is O
no O
clinical O
experience O
to O
date O
on O
the O
use O
of O
Femara B-BRAND
in O
combination O
with O
other O
anticancer O
agents O
. O
Drug O
/ O
Laboratory O
Test O
- O
Interactions O
None O
observed O
. O

Folic B-DRUG
acid I-DRUG
in O
large O
amounts O
may O
counteract O
the O
antiepileptic O
effect O
of O
phenobarbital B-DRUG
, O
phenytoin B-DRUG
and O
primidone B-DRUG
, O
and O
increase O
the O
frequency O
of O
seizures O
in O
susceptible O
pediatric O
patients O
. O
Preliminary O
animal O
and O
human O
studies O
have O
shown O
that O
small O
quantities O
of O
systemically O
administered O
leucovorin B-DRUG
enter O
the O
CSF O
primarily O
as O
5 O
- O
methyltetrahydro O
- O
folate O
and O
, O
in O
humans O
, O
remain O
1 O
to O
3 O
orders O
of O
magnitude O
lower O
than O
the O
usual O
methotrexate B-DRUG
concentrations O
following O
intrathecal O
administration O
. O
However O
, O
high O
doses O
of O
leucovorin B-DRUG
may O
reduce O
the O
efficacy O
of O
intrathecally O
administered O
methotrexate B-DRUG
. O
Leucovorin B-DRUG
may O
enhance O
the O
toxicity O
of O
5 B-DRUG
- I-DRUG
fluorouracil I-DRUG
. O

ERGAMISOL B-BRAND
( O
levamisole B-DRUG
hydrochloride I-DRUG
) O
has O
been O
reported O
to O
produce O
ANTABUSE O
- O
like O
side O
effects O
when O
given O
concomitantly O
with O
alcohol B-DRUG
. O
The O
physician O
is O
advised O
to O
monitor O
plasma O
levels O
of O
phenytoin B-DRUG
and O
to O
decrease O
the O
dose O
if O
necessary O
. O
Because O
of O
reports O
of O
prolongation O
of O
the O
prothrombin O
time O
beyond O
the O
therapeutic O
range O
in O
patients O
taking O
concurrent O
levamisole B-DRUG
and O
warfarin B-DRUG
sodium I-DRUG
, O
it O
is O
suggested O
that O
the O
prothrombin O
time O
be O
monitored O
carefully O
, O
and O
the O
dose O
of O
warfarin B-DRUG
sodium I-DRUG
or O
other O
coumarin B-GROUP
- O
like O
drugs O
should O
be O
adjusted O
accordingly O
, O
in O
patients O
taking O
both O
drugs O
. O

in O
vitro O
data O
on O
metabolic O
interactions O
indicate O
that O
Keppra B-BRAND
is O
unlikely O
to O
produce O
, O
or O
be O
subject O
to O
, O
pharmacokinetic O
interactions O
. O
Levetiracetam B-DRUG
and O
its O
major O
metabolite O
, O
at O
concentrations O
well O
above O
cmax O
levels O
achieved O
within O
the O
therapeutic O
dose O
range O
, O
are O
neither O
inhibitors O
of O
nor O
high O
affinity O
substrates O
for O
human O
liver O
cytochrome O
P450 O
isoforms O
, O
epoxide O
hydrolase O
or O
UDP O
- O
glucuronidation O
enzymes O
. O
In O
addition O
, O
levetiracetam B-DRUG
does O
not O
affect O
the O
in O
vitro O
glucuronidation O
of O
valproic B-DRUG
acid I-DRUG
. O
Levetiracetam B-DRUG
circulates O
largely O
unbound O
( O
10 O
% O
bound O
) O
to O
plasma O
proteins O
; O
clinically O
significant O
interactions O
with O
other O
drugs O
through O
competition O
for O
protein O
binding O
sites O
are O
therefore O
unlikely O
. O
Potential O
pharmacokinetic O
interactions O
were O
assessed O
in O
clinical O
pharmacokinetic O
studies O
( O
phenytoin B-DRUG
, O
valproate B-DRUG
, O
oral O
contraceptive B-GROUP
, O
digoxin B-DRUG
, O
warfarin B-DRUG
, O
probenecid B-DRUG
) O
and O
through O
pharmacokinetic O
screening O
in O
the O
placebo O
- O
controlled O
clinical O
studies O
in O
epilepsy O
patients O
. O
Drug O
- O
Drug O
Interactions O
Between O
Keppra B-BRAND
And O
Other O
Antiepileptic B-GROUP
Drugs I-GROUP
( O
AEDs B-GROUP
) O
Phenytoin B-DRUG
Keppra B-BRAND
( O
3000 O
mg O
daily O
) O
had O
no O
effect O
on O
the O
pharmacokinetic O
disposition O
of O
phenytoin B-DRUG
in O
patients O
with O
refractory O
epilepsy O
. O
Pharmacokinetics O
of O
levetiracetam B-DRUG
were O
also O
not O
affected O
by O
phenytoin B-DRUG
. O
Valproate B-DRUG
Keppra B-BRAND
( O
1500 O
mg O
twice O
daily O
) O
did O
not O
alter O
the O
pharmacokinetics O
of O
valproate B-DRUG
in O
healthy O
volunteers O
. O
Valproate B-DRUG
500 O
mg O
twice O
daily O
did O
not O
modify O
the O
rate O
or O
extent O
of O
levetiracetam B-DRUG
absorption O
or O
its O
plasma O
clearance O
or O
urinary O
excretion O
. O
There O
also O
was O
no O
effect O
on O
exposure O
to O
and O
the O
excretion O
of O
the O
primary O
metabolite O
, O
ucb O
L057 O
. O
Potential O
drug O
interactions O
between O
Keppra B-BRAND
and O
other O
AEDs B-GROUP
( O
carbamazepine B-DRUG
, O
gabapentin B-DRUG
, O
lamotrigine B-DRUG
, O
phenobarbital B-DRUG
, O
phenytoin B-DRUG
, O
primidone B-DRUG
and O
valproate B-DRUG
) O
were O
also O
assessed O
by O
evaluating O
the O
serum O
concentrations O
of O
levetiracetam B-DRUG
and O
these O
AEDs B-GROUP
during O
placebo O
- O
controlled O
clinical O
studies O
. O
These O
data O
indicate O
that O
levetiracetam B-DRUG
does O

not O
influence O
the O
plasma O
concentration O
of O
other O
AEDs B-GROUP
and O
that O
these O
AEDs B-GROUP
do O
not O
influence O
the O
pharmacokinetics O
of O
levetiracetam B-DRUG
. O
Effect O
of O
AEDs B-GROUP
in O
Pediatric O
Patients O
There O
was O
about O
a O
22 O
% O
increase O
of O
apparent O
total O
body O
clearance O
of O
levetiracetam B-DRUG
when O
it O
was O
co O
- O
administered O
with O
enzyme O
- O
inducing O
AEDs B-GROUP
. O
Dose O
adjustment O
is O
not O
recommended O
. O
Levetiracetam B-DRUG
had O
no O
effect O
on O
plasma O
concentrations O
of O
carbamazepine B-DRUG
, O
valproate B-DRUG
, O
topiramate B-DRUG
, O
or O
lamotrigine B-DRUG
. O
Other O
Drug O
Interactions O
Oral O
Contraceptives B-GROUP
Keppra B-BRAND
( O
500 O
mg O
twice O
daily O
) O
did O
not O
influence O
the O
pharmacokinetics O
of O
an O
oral O
contraceptive B-GROUP
containing O
0 O
. O
03 O
mg O
ethinyl B-DRUG
estradiol I-DRUG
and O
0 O
. O
15 O
mg O
levonorgestrel B-DRUG
, O
or O
of O
the O
luteinizing O
hormone O
and O
progesterone O
levels O
, O
indicating O
that O
impairment O
of O
contraceptive O
efficacy O
is O
unlikely O
. O
Coadministration O
of O
this O
oral O
contraceptive B-GROUP
did O
not O
influence O
the O
pharmacokinetics O
of O
levetiracetam B-DRUG
. O
Digoxin B-DRUG
Keppra B-BRAND
( O
1000 O
mg O
twice O
daily O
) O
did O
not O
influence O
the O
pharmacokinetics O
and O
pharmacodynamics O
( O
ECG O
) O
of O
digoxin B-DRUG
given O
as O
a O
0 O
. O
25 O
mg O
dose O
every O
day O
. O
Coadministration O
of O
digoxin B-DRUG
did O
not O
influence O
the O
pharmacokinetics O
of O
levetiracetam B-DRUG
. O
Warfarin B-DRUG
Keppra B-BRAND
( O
1000 O
mg O
twice O
daily O
) O
did O
not O
influence O
the O
pharmacokinetics O
of O
R B-DRUG
and I-DRUG
S I-DRUG
warfarin I-DRUG
. O
Prothrombin O
time O
was O
not O
affected O
by O
levetiracetam B-DRUG
. O
Coadministration O
of O
warfarin B-DRUG
did O
not O
affect O
the O
pharmacokinetics O
of O
levetiracetam B-DRUG
. O
Probenecid B-DRUG
: O
Probenecid B-DRUG
, O
a O
renal O
tubular O
secretion O
blocking O
agent O
, O
administered O
at O
a O
dose O
of O
500 O
mg O
four O
times O
a O
day O
, O
did O
not O
change O
the O
pharmacokinetics O
of O
levetiracetam B-DRUG
1000 O
mg O
twice O
daily O
. O
Cssmax O
of O
the O
metabolite O
, O
ucb O
L057 O
, O
was O
approximately O
doubled O
in O
the O
presence O
of O
probenecid B-DRUG
while O
the O
fraction O
of O
drug O
excreted O
unchanged O
in O
the O
urine O
remained O
the O
same O
. O
Renal O
clearance O
of O
ucb O
L057 O
in O
the O
presence O
of O
probenecid B-DRUG
decreased O
60 O
% O
, O
probably O
related O
to O
competitive O
inhibition O
of O
tubular O
secretion O
of O
ucb O

L057 O
. O
The O
effect O
of O
Keppra B-BRAND
on O
probenecid B-DRUG
was O
not O
studied O
. O

Although O
BETAGAN B-BRAND
used O
alone O
has O
little O
or O
no O
effect O
on O
pupil O
size O
, O
mydriasis O
resulting O
from O
concomitant O
therapy O
with O
BETAGAN B-BRAND
and O
epinephrine B-DRUG
may O
occur O
. O
Close O
observation O
of O
the O
patient O
is O
recommended O
when O
a O
beta B-GROUP
- I-GROUP
blocker I-GROUP
is O
administered O
to O
patients O
receiving O
catecholamine O
- O
depleting O
drugs O
such O
as O
reserpine B-DRUG
, O
because O
of O
possible O
additive O
effects O
and O
the O
production O
of O
hypotension O
and O
/ O
or O
marked O
bradycardia O
, O
which O
may O
produce O
vertigo O
, O
syncope O
or O
postural O
hypotension O
. O
Patients O
receiving O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
along O
with O
either O
oral O
or O
intravenous O
calcium B-GROUP
antagonists I-GROUP
should O
be O
monitored O
for O
possible O
atrioventricular O
conduction O
disturbances O
, O
left O
ventricular O
failure O
and O
hypotension O
. O
In O
patients O
with O
impaired O
cardiac O
function O
, O
simultaneous O
use O
should O
be O
avoided O
altogether O
. O
The O
concomitant O
use O
of O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
with O
digitalis B-GROUP
and O
calcium B-GROUP
antagonists I-GROUP
may O
have O
additive O
effects O
on O
prolonging O
atrioventricular O
conduction O
time O
. O
Phenothiazine B-GROUP
- I-GROUP
related I-GROUP
compounds I-GROUP
and O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
may O
have O
additive O
hypotensite O
effects O
due O
to O
the O
inhibition O
of O
each O
other O
s O
metabolism O
. O

Chirocaine B-BRAND
should O
be O
used O
with O
caution O
in O
patients O
receiving O
other O
local O
anesthetics B-GROUP
or O
agents O
structurally O
related O
to O
amide O
- O
type O
local O
anesthetics O
since O
the O
toxic O
effects O
of O
these O
drugs O
could O
be O
additive O
. O
In O
vitro O
studies O
indicate O
CYP3A4 O
isoform O
and O
CYP1A2 O
isoform O
mediate O
the O
metabolism O
of O
levobupivacaine B-DRUG
to O
desbutyl B-DRUG_N
levobupivacaine I-DRUG_N
and O
3 B-DRUG_N
- I-DRUG_N
hydroxy I-DRUG_N
levobupivacaine I-DRUG_N
, O
respectively O
. O
Thus O
agents O
likely O
to O
be O
concomitantly O
administered O
with O
Chirocaine B-BRAND
that O
are O
metabolized O
by O
this O
isoenzyme O
family O
may O
potentially O
interact O
with O
Chirocaine B-BRAND
. O
Although O
no O
clinical O
studies O
have O
been O
conducted O
, O
it O
is O
likely O
that O
the O
metabolism O
of O
levobupivacaine B-DRUG
may O
be O
affected O
by O
the O
known O
CYP3A4 O
inducers O
( O
such O
as O
phenytoin B-DRUG
, O
phenobarbital B-DRUG
, O
rifampin B-DRUG
) O
, O
CYP3A4 O
inhibitors O
( O
azole O
antimycotics O
e O
. O
g O
. O
, O
ketoconazole B-DRUG
; O
certain O
protease B-GROUP
inhibitors I-GROUP
e O
. O
g O
. O
, O
ritanovir O
; O
macrolide B-GROUP
antibiotics I-GROUP
e O
. O
g O
. O
, O
erythromycin B-DRUG
; O
and O
calcium B-GROUP
channel I-GROUP
antagonists I-GROUP
e O
. O
g O
. O
, O
verapamil B-DRUG
) O
, O
CYP1A2 O
inducers O
( O
omeprazole B-DRUG
) O
and O
CYP1A2 O
inhibitors O
( O
furafylline B-DRUG
and O
clarithromycin B-DRUG
) O
. O
Dosage O
adjustment O
may O
be O
warranted O
when O
levobupivacaine B-DRUG
is O
concurrently O
administered O
with O
CYP3A4 O
inhibitors O
and O
CYP1A2 O
inhibitors O
as O
systemic O
levobupivacaine B-DRUG
levels O
may O
rise O
resulting O
in O
toxicity O
. O

Specific O
drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
Levofloxacin B-DRUG
. O
However O
, O
the O
systemic O
administration O
of O
some O
quinolones B-GROUP
has O
been O
shown O
to O
elevate O
plasma O
concentrations O
of O
theophylline B-DRUG
, O
interfere O
with O
the O
metabolism O
of O
caffeine B-DRUG
, O
and O
enhance O
the O
effects O
of O
the O
oral O
anticoagulant B-GROUP
warfarin B-DRUG
and O
its O
derivatives O
, O
and O
has O
been O
associated O
with O
transient O
elevations O
in O
serum O
creatinine O
in O
patients O
receiving O
systemic O
cyclosporine B-DRUG
concomitantly O
. O

Interactions O
with O
Other O
CNS O
Agents O
: O
Concurrent O
use O
of O
Levo B-BRAND
- I-BRAND
Dromoran I-BRAND
with O
all O
central B-GROUP
nervous I-GROUP
system I-GROUP
depressants I-GROUP
( O
eg O
, O
alcohol B-DRUG
, O
sedatives B-GROUP
, O
hypnotics B-GROUP
, O
other O
opioids B-GROUP
, O
general O
anesthetics B-GROUP
, O
barbiturates B-GROUP
, O
tricyclic B-GROUP
antidepressants I-GROUP
, O
phenothiazines B-GROUP
, O
tranquilizers B-GROUP
, O
skeletal B-GROUP
muscle I-GROUP
relaxants I-GROUP
and O
antihistamines B-GROUP
) O
may O
result O
in O
additive O
central O
nervous O
system O
depressant O
effects O
. O
Respiratory O
depression O
, O
hypotension O
, O
and O
profound O
sedation O
or O
coma O
may O
occur O
. O
When O
such O
combined O
therapy O
is O
contemplated O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O
Although O
no O
interaction O
between O
MAO B-GROUP
inhibitors I-GROUP
and O
Levo B-BRAND
- I-BRAND
Dromoran I-BRAND
has O
been O
observed O
, O
it O
is O
not O
recommended O
for O
use O
with O
MAO B-GROUP
inhibitors I-GROUP
. O
Most O
cases O
of O
serious O
or O
fatal O
adverse O
events O
involving O
Levo B-BRAND
- I-BRAND
Dromoran I-BRAND
reported O
to O
the O
manufacturer O
or O
the O
FDA O
have O
involved O
either O
the O
administration O
of O
large O
initial O
doses O
or O
too O
frequent O
doses O
of O
the O
drug O
to O
nonopioid O
tolerant O
patients O
, O
or O
the O
simultaneous O
administration O
of O
levorphanol B-DRUG
with O
other O
drugs O
affecting O
respiration O
. O
The O
initial O
dose O
of O
levorphanol B-DRUG
should O
be O
reduced O
by O
approximately O
50 O
% O
or O
more O
when O
it O
is O
given O
to O
patients O
along O
with O
another O
drug O
affecting O
respiration O
. O
Interactions O
with O
Mixed B-GROUP
Agonist I-GROUP
/ I-GROUP
Antagonist I-GROUP
Opioid I-GROUP
Analgesics I-GROUP
: O
Agonist B-GROUP
/ I-GROUP
antagonist I-GROUP
analgesics I-GROUP
( O
eg O
, O
pentazocine B-DRUG
, O
nalbuphine B-DRUG
, O
butorphanol B-DRUG
, O
dezocine B-DRUG
and O
buprenorphine B-DRUG
) O
should O
NOT O
be O
administered O
to O
a O
patient O
who O
has O
received O
or O
is O
receiving O
a O
course O
of O
therapy O
with O
a O
pure B-GROUP
agonist I-GROUP
opioid I-GROUP
analgesic I-GROUP
such O
as O
Levo B-BRAND
- I-BRAND
Dromoran I-BRAND
. O
In O
opioid B-GROUP
- O
dependent O
patients O
, O
mixed B-GROUP
agonist I-GROUP
/ I-GROUP
antagonist I-GROUP
analgesics I-GROUP
may O
precipitate O
withdrawal O
symptoms O
. O

No O
Important O
Interactions O
To O
Date O
Levosimendan B-DRUG
does O
not O
have O
clinically O
important O
pharmacokinetic O
interactions O
with O
captopril B-DRUG
, O
beta B-GROUP
- I-GROUP
blockers I-GROUP
, O
felodipine B-DRUG
, O
digoxin B-DRUG
, O
warfarin B-DRUG
, O
isosorbide B-DRUG
mononitrate I-DRUG
, O
carvedilol B-DRUG
, O
ethanol B-DRUG
or O
itraconazole B-DRUG
. O

The O
magnitude O
and O
relative O
importance O
of O
the O
effects O
noted O
below O
are O
likely O
to O
be O
patient O
specific O
and O
may O
vary O
by O
such O
factors O
as O
age O
, O
gender O
, O
race O
, O
intercurrent O
illnesses O
, O
dose O
of O
either O
agent O
, O
additional O
concomitant O
medications O
, O
and O
timing O
of O
drug O
administration O
. O
Any O
agent O
that O
alters O
thyroid O
hormone O
synthesis O
, O
secretion O
, O
distribution O
, O
effect O
on O
target O
tissues O
, O
metabolism O
, O
or O
elimination O
may O
alter O
the O
optimal O
therapeutic O
dose O
of O
levothyroxine B-DRUG
sodium O
. O
Levothyroxine B-DRUG
Sodium I-DRUG
Absorption O
: O
The O
following O
agents O
may O
bind O
and O
decrease O
absorption O
of O
levothyroxine B-DRUG
sodium I-DRUG
from O
the O
gastrointestinal O
tract O
: O
aluminum B-DRUG
hydoxide I-DRUG
, O
cholestyramine B-DRUG
resin O
, O
colestipol B-DRUG
hydrochloride I-DRUG
, O
ferrous B-DRUG
sulfate I-DRUG
, O
sodium B-DRUG
polystyrene I-DRUG
sulfonate I-DRUG
, O
soybean O
flour O
( O
e O
. O
g O
. O
, O
infant O
formula O
) O
, O
sucralfate B-DRUG
. O
Binding O
to O
Serum O
Proteins O
: O
The O
following O
agents O
may O
either O
inhibit O
levothyroxine B-DRUG
sodium I-DRUG
binding O
to O
serum O
proteins O
or O
alter O
the O
concentrations O
of O
serum O
binding O
proteins O
: O
androgens B-GROUP
and O
related O
anabolic B-GROUP
hormones I-GROUP
, O
asparaginase B-DRUG
, O
clofibrate B-DRUG
, O
estrogens B-GROUP
and O
estrogen B-GROUP
- I-GROUP
containing I-GROUP
compounds I-GROUP
, O
5 B-DRUG
- I-DRUG
fluorouracil I-DRUG
, O
furosemide B-DRUG
, O
glucocorticoids B-GROUP
, O
meclofenamic B-DRUG
acid I-DRUG
, O
mefenamic B-DRUG
acid I-DRUG
, O
methadone B-DRUG
, O
perphenazine B-DRUG
, O
phenylbutazone B-DRUG
, O
phenytoin B-DRUG
, O
salicylates B-GROUP
, O
tamoxifen B-DRUG
. O
Thyroid O
Physiology O
: O
The O
following O
agents O
may O
alter O
thyroid O
hormone O
or O
TSH O
levels O
, O
generally O
by O
effects O
on O
thyroid O
hormone O
synthesis O
, O
secretion O
, O
distribution O
, O
metabolism O
, O
hormone O
action O
, O
or O
elimination O
, O
or O
altered O
TSH O
secretion O
: O
aminoglutethimide B-DRUG
, O
p B-DRUG
- I-DRUG
aminosalicylic I-DRUG
acid I-DRUG
, O
amiodarone B-DRUG
, O
androgens B-GROUP
and O
related O
anabolic O
hormones O
, O
complex O
anions O
( O
thiocyanate B-DRUG
, O
perchlorate B-DRUG
, O
pertechnetate B-DRUG
) O
, O
antithyroid B-GROUP
drugs I-GROUP
, O
b B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
, O
carbamazepine B-DRUG
, O
chloral B-DRUG
hydrate I-DRUG
, O
diazepam B-DRUG
, O
dopamine B-DRUG
and O
dopamine B-GROUP
agonists I-GROUP
, O
ethionamide B-DRUG
, O
glucocorticoids B-GROUP
, O
heparin B-DRUG
, O
hepatic O
enzyme O
inducers O
, O
insulin B-DRUG
, O
iodinated O
cholestographic O
agents O
, O
iodine B-GROUP
- I-GROUP
containing I-GROUP
compounds I-GROUP
, O

levodopa B-DRUG
, O
lovastatin B-DRUG
, O
lithium B-DRUG
, O
6 B-DRUG
- I-DRUG
mercaptopurine I-DRUG
, O
metoclopramide B-DRUG
, O
mitotane B-DRUG
, O
nitroprusside B-DRUG
, O
phenobarbital B-DRUG
, O
phenytoin B-DRUG
, O
resorcinol B-DRUG
, O
rifampin B-DRUG
, O
somatostatin B-GROUP
analogs I-GROUP
, O
sulfonamides B-GROUP
, O
sulfonylureas B-GROUP
, O
thiazide B-GROUP
diuretics I-GROUP
. O
Adrenocorticoids O
: O
Metabolic O
clearance O
of O
adrenocorticoids O
is O
decreased O
in O
hypothyroid O
patients O
and O
increased O
in O
hyperthyroid O
patients O
, O
and O
may O
therefore O
change O
with O
changing O
thyroid O
status O
. O
Amiodarone B-DRUG
: O
Amiodarone B-DRUG
therapy O
alone O
can O
cause O
hypothyroidism O
or O
hyperthyroidism O
. O
Anticoagulants B-GROUP
( O
Oral O
) O
: O
The O
hypoprothrombinemic O
effect O
of O
anticoagulants B-GROUP
may O
be O
potentiated O
, O
apparently O
by O
increased O
catabloism O
of O
vitamin O
K O
- O
dependent O
clotting O
factors O
. O
Antidiabetic B-GROUP
Agents I-GROUP
( O
Insulin B-DRUG
, O
Sulfonylureas B-GROUP
) O
: O
Requirements O
for O
insulin B-DRUG
or O
oral O
antidiabetic B-GROUP
agents I-GROUP
may O
be O
reduced O
in O
hypothyroid O
patients O
with O
diabetes O
mellitus O
and O
may O
subsequently O
increase O
with O
the O
initiation O
of O
thyroid O
hormone O
replacement O
therapy O
. O
b B-GROUP
- I-GROUP
Adrenergic I-GROUP
Blocking I-GROUP
Agents I-GROUP
: O
Actions O
of O
some O
of O
beta B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
may O
be O
impaired O
when O
hypothyroid O
patients O
become O
euthyroid O
. O
Cytokines B-GROUP
( O
interferon B-GROUP
, O
interleukin B-GROUP
) O
: O
Cytokines B-GROUP
have O
been O
reported O
to O
induce O
both O
hyperthyroidism O
and O
hypothyroidism O
. O
Digitalis B-GROUP
Glycosides I-GROUP
: O
Therapeutic O
effects O
of O
digitalis B-GROUP
glycosides I-GROUP
may O
be O
reduced O
. O
Serum O
digitalis B-GROUP
levels O
may O
be O
decreased O
in O
hyperthyroidism O
or O
when O
a O
hypothyroid O
patient O
becomes O
euthyroid O
. O
Ketamine B-DRUG
: O
Marked O
hypertension O
and O
tachycardia O
have O
been O
reported O
in O
association O
with O
concomitant O
administration O
of O
levothyroxine B-DRUG
sodium I-DRUG
and O
ketamine B-DRUG
. O
Maprotiline B-DRUG
: O
Risk O
of O
cardiac O
arrhythmias O
may O
increase O
. O
Sodium B-DRUG
Iodide I-DRUG
( O
123I O
and O
131I O
) O
, O
Sodium B-DRUG
Pertechnetate I-DRUG
Tc99m I-DRUG
: O
Uptake O
of O
radiolabeled O
ions O
may O
be O
decreased O
. O
Somatrem B-DRUG
/ O
Somatropin B-DRUG
: O
Excessive O
concurrent O
use O
of O
thyroid B-GROUP
hormone I-GROUP
may O
accelerate O
epiphyseal O
closure O
. O
Untreated O

hypothyroidism O
may O
interfere O
with O
the O
growth O
response O
to O
somatrem B-DRUG
or O
somatropin B-DRUG
. O
Theophylline B-DRUG
: O
Theophylline B-DRUG
clearance O
may O
decrease O
in O
hypothyroid O
patients O
and O
return O
toward O
normal O
when O
a O
euthyroid O
state O
is O
achieved O
. O
Tricyclic B-GROUP
Antidepressants I-GROUP
: O
Concurrent O
use O
may O
increase O
the O
therapeutic O
and O
toxic O
effects O
of O
both O
drugs O
, O
possibly O
due O
to O
increased O
catecholamine O
sensitivity O
. O
Onset O
of O
action O
of O
tricyclics B-GROUP
may O
be O
accelerated O
. O
Sympathomimetic B-GROUP
Agents I-GROUP
: O
Possible O
increased O
risk O
of O
coronary O
insufficiency O
in O
patients O
with O
coronary O
artery O
disease O
. O

The O
administration O
of O
local O
anesthetic B-GROUP
solutions I-GROUP
containing O
epinephrine B-DRUG
or O
norepinephrine B-DRUG
to O
patients O
receiving O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
or O
tricyclic B-GROUP
antidepressants I-GROUP
may O
produce O
severe O
, O
prolonged O
hypertension O
. O
Phenothiazines B-GROUP
and O
butyrophenones B-GROUP
may O
reduce O
or O
reverse O
the O
pressor O
effect O
of O
epinephrine B-DRUG
. O
Concurrent O
use O
of O
these O
agents O
should O
generally O
be O
avoided O
. O
In O
situations O
when O
concurrent O
therapy O
is O
necessary O
, O
careful O
patient O
monitoring O
is O
essential O
. O
Concurrent O
administration O
of O
vasopressor B-GROUP
drugs I-GROUP
( O
for O
the O
treatment O
of O
hypotension O
related O
to O
obstetric O
blocks O
) O
and O
ergot B-GROUP
- I-GROUP
type I-GROUP
oxytocic I-GROUP
drugs I-GROUP
may O
cause O
severe O
, O
persistent O
hypertension O
or O
cerebrovascular O
accidents O
. O

Lincomycin B-DRUG
has O
been O
shown O
to O
have O
neuromuscular O
blocking O
properties O
that O
may O
enhance O
the O
action O
of O
other O
neuromuscular B-GROUP
blocking I-GROUP
agents I-GROUP
. O
Therefore O
, O
it O
should O
be O
used O
in O
caution O
in O
patients O
receiving O
such O
agents O
. O
Antagonism O
between O
lincomycin B-DRUG
and O
erythromycin B-DRUG
in O
vitro O
has O
been O
demonstrated O
. O
Because O
of O
possible O
clinical O
significance O
, O
the O
two O
drugs O
should O
not O
be O
administered O
concurrently O
. O

Oils O
may O
enhance O
absorption O
. O
Therefore O
, O
simultaneous O
use O
of O
creams O
, O
ointments O
or O
oils O
should O
be O
avoided O
. O

Monoamine O
Oxidase O
Inhibition O
: O
Linezolid B-DRUG
is O
a O
reversible O
, O
nonselective O
inhibitor O
of O
monoamine O
oxidase O
. O
Therefore O
, O
linezolid B-DRUG
has O
the O
potential O
for O
interaction O
with O
adrenergic B-GROUP
and O
serotonergic B-GROUP
agents I-GROUP
. O
Adrenergic B-GROUP
Agents I-GROUP
: O
Some O
individuals O
receiving O
ZYVOX B-BRAND
may O
experience O
a O
reversible O
enhancement O
of O
the O
pressor O
response O
to O
indirect O
- O
acting O
sympathomimetic B-GROUP
agents I-GROUP
, O
vasopressor B-GROUP
or O
dopaminergic B-GROUP
agents I-GROUP
. O
Commonly O
used O
drugs O
such O
as O
phenylpropanolamine B-DRUG
and O
pseudoephedrine B-DRUG
have O
been O
specifically O
studied O
. O
Initial O
doses O
of O
adrenergic B-GROUP
agents I-GROUP
, O
such O
as O
dopamine B-DRUG
or O
epinephrine B-DRUG
, O
should O
be O
reduced O
and O
titrated O
to O
achieve O
the O
desired O
response O
. O
Serotonergic B-GROUP
Agents I-GROUP
: O
Co O
- O
administration O
of O
linezolid B-DRUG
and O
serotonergic B-GROUP
agents I-GROUP
was O
not O
associated O
with O
serotonin O
syndrome O
in O
Phase O
1 O
, O
2 O
or O
3 O
studies O
. O
Spontaneous O
reports O
of O
serotonin O
syndrome O
associated O
with O
co O
- O
administration O
of O
ZYVOX B-BRAND
and O
serotonergic B-GROUP
agents I-GROUP
, O
including O
antidepressants B-GROUP
such O
as O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
( O
SSRIs B-GROUP
) O
, O
have O
been O
reported O
. O
Patients O
who O
are O
treated O
with O
ZYVOX B-BRAND
and O
concomitant O
serotonergic B-GROUP
agents I-GROUP
should O
be O
closely O
observed O
for O
signs O
and O
symptoms O
of O
serotonin O
syndrome O
( O
e O
. O
g O
. O
, O
cognitive O
dysfunction O
, O
hyperpyrexia O
, O
hyperreflexia O
, O
incoordination O
) O
. O
If O
any O
signs O
or O
symptoms O
occur O
physicians O
should O
consider O
discontinuation O
of O
either O
one O
or O
both O
agents O
( O
ZYVOX B-BRAND
or O
concomitant O
serotonergic B-GROUP
agents I-GROUP
) O
. O
Drug O
- O
Laboratory O
Test O
Interactions O
There O
are O
no O
reported O
drug O
- O
laboratory O
test O
interactions O
. O

Oral O
Anticoagulants B-GROUP
: O
Thyroid B-GROUP
hormones I-GROUP
appear O
to O
increase O
catabolism O
of O
vitamin O
K O
- O
dependent O
clotting O
factors O
. O
If O
oral O
anticoagulants B-GROUP
are O
also O
being O
given O
, O
compensatory O
increases O
in O
clotting O
factor O
synthesis O
are O
impaired O
. O
Patients O
stabilized O
on O
oral O
anticoagulants B-GROUP
who O
are O
found O
to O
require O
thyroid B-GROUP
replacement O
therapy O
should O
be O
watched O
very O
closely O
when O
thyroid O
is O
started O
. O
If O
a O
patient O
is O
truly O
hypothyroid O
, O
it O
is O
likely O
that O
a O
reduction O
in O
anticoagulant B-GROUP
dosage O
will O
be O
required O
. O
No O
special O
precautions O
appear O
to O
be O
necessary O
when O
oral O
anticoagulant O
therapy O
is O
begun O
in O
a O
patient O
already O
stabilized O
on O
maintenance O
thyroid O
replacement O
therapy O
. O
Insulin B-DRUG
or O
Oral O
Hypoglycemics B-GROUP
: O
Initiating O
thyroid O
replacement O
therapy O
may O
cause O
increases O
in O
insulin B-DRUG
or O
oral O
hypoglycemic B-GROUP
requirements O
. O
The O
effects O
seen O
are O
poorly O
understood O
and O
depend O
upon O
a O
variety O
of O
factors O
such O
as O
dose O
and O
type O
of O
thyroid B-GROUP
preparations I-GROUP
and O
endocrine O
status O
of O
the O
patient O
. O
Patients O
receiving O
insulin B-DRUG
or O
oral O
hypoglycemics B-GROUP
should O
be O
closely O
watched O
during O
initiation O
of O
thyroid O
replacement O
therapy O
. O
Cholestyramine B-DRUG
: O
Cholestyramine B-DRUG
binds O
both O
T4 B-DRUG
and O
T3 B-DRUG
in O
the O
intestine O
, O
thus O
impairing O
absorption O
of O
these O
thyroid B-GROUP
hormones I-GROUP
. O
In O
vitro O
studies O
indicate O
that O
the O
binding O
is O
not O
easily O
removed O
. O
Therefore O
, O
4 O
to O
5 O
hours O
should O
elapse O
between O
administration O
of O
cholestyramine B-DRUG
and O
thyroid B-GROUP
hormones I-GROUP
. O
Estrogen B-GROUP
, O
Oral O
Contraceptives B-GROUP
: O
Estrogens B-GROUP
tend O
to O
increase O
serum O
thyroxine O
- O
binding O
globulin O
( O
TBg O
) O
. O
In O
a O
patient O
with O
a O
nonfunctioning O
thyroid O
gland O
who O
is O
receiving O
thyroid O
replacement O
therapy O
, O
free O
levothyroxine B-DRUG
may O
be O
decreased O
when O
estrogens B-GROUP
are O
started O
thus O
increasing O
thyroid B-GROUP
requirements O
. O
However O
, O
if O
the O
patients O
thyroid O
gland O
has O
sufficient O
function O
, O
the O
decreased O
free O
thyroxine B-DRUG
will O
result O
in O
a O
compensatory O
increase O
in O
thyroxine O
output O
by O
the O
thyroid O
. O
Therefore O
, O
patients O
without O
a O
functioning O
thyroid B-GROUP
gland O
who O
are O
on O
thyroid O
replacement O
therapy O
may O
need O
to O
increase O
their O
thyroid O
dose O
if O
estrogens B-GROUP
or O
estrogen B-GROUP
- O
containing O
oral O
contraceptives B-GROUP
are O
given O
. O
Tricyclic B-GROUP
Antidepressants I-GROUP
: O
Use O
of O
thyroid B-GROUP
products I-GROUP
with O
imipramine B-DRUG
and O
other O
tricyclic B-GROUP
antidepressants I-GROUP
may O
increase O
receptor O
sensitivity O
and O
enhance O
antidepressant O
activity O
transient O
cardiac O
arrhythmias O

have O
been O
observed O
. O
Thyroid B-GROUP
hormone I-GROUP
activity O
may O
also O
be O
enhanced O
. O
Digitalis B-GROUP
: O
Thyroid B-GROUP
preparations I-GROUP
may O
potentiate O
the O
toxic O
effects O
of O
digitalis B-GROUP
. O
Thyroid O
hormonal O
replacement O
increases O
metabolic O
rate O
, O
which O
requires O
an O
increase O
in O
digitalis B-GROUP
dosage O
. O
Ketamine B-DRUG
: O
When O
administered O
to O
patients O
on O
a O
thyroid B-GROUP
preparation I-GROUP
, O
this O
parenteral O
anesthetic B-GROUP
may O
cause O
hypertension O
and O
tachycardia O
. O
Use O
with O
caution O
and O
be O
prepared O
to O
treat O
hypertension O
, O
if O
necessary O
. O
Vasopressors B-GROUP
: O
Thyroxine B-DRUG
increases O
the O
adrenergic O
effect O
of O
catecholamines O
such O
as O
epinephrine B-DRUG
and O
norepinephrine B-DRUG
. O
Therefore O
, O
injection O
of O
these O
agents O
into O
patients O
receiving O
thyroid B-GROUP
preparations I-GROUP
increases O
the O
risk O
of O
precipitating O
coronary O
insufficiency O
especially O
in O
patients O
with O
coronary O
artery O
disease O
. O
Careful O
observation O
is O
required O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
The O
following O
drugs O
or O
moieties O
are O
known O
to O
interfere O
with O
laboratory O
tests O
performed O
in O
patients O
on O
thyroid B-GROUP
hormone I-GROUP
therapy O
: O
androgens B-GROUP
, O
corticosteroids B-GROUP
, O
estrogens B-GROUP
, O
oral O
contraceptives B-GROUP
containing O
estrogens B-GROUP
, O
iodine B-GROUP
- O
containing O
preparations O
and O
the O
numerous O
preparations O
containing O
salicylates B-GROUP
. O
- O
Changes O
in O
TBg O
concentration O
should O
be O
taken O
into O
consideration O
in O
the O
interpretation O
of O
T4 O
and O
T3 O
values O
. O
In O
such O
cases O
, O
the O
unbound O
( O
free O
) O
hormone O
should O
be O
measured O
. O
Pregnancy O
estrogens B-GROUP
and O
estrogen B-GROUP
- O
containing O
oral O
contraceptives B-GROUP
increase O
TBg O
concentrations O
. O
TBg O
may O
also O
be O
increased O
during O
infectious O
hepatitis O
. O
Decreases O
in O
TBg O
concentrations O
are O
observed O
in O
nephrosis O
, O
acromegaly O
and O
after O
androgen B-GROUP
or O
corticosteroid B-GROUP
therapy O
. O
Familial O
hyper O
- O
or O
hypo O
- O
thyroxine O
- O
binding O
- O
globulinemias O
have O
been O
described O
. O
The O
incidence O
of O
TBg O
deficiency O
approximates O
1 O
in O
9000 O
. O
The O
binding O
of O
thyroxine O
by O
thyroxine O
- O
binding O
prealbumin O
( O
TBPA O
) O
is O
inhibited O
by O
salicylates B-GROUP
. O
- O
Medicinal O
or O
dietary O
iodine B-GROUP
interferes O
with O
all O
in O
vivo O
tests O
of O
radio O
- O
iodine O
uptake O
producing O
low O
uptakes O
which O
may O
not O
be O
reflective O
of O
a O
true O
decrease O
in O
hormone O
synthesis O
. O
- O
The O
persistence O
of O
clinical O
and O
laboratory O
evidence O
of O
hypothyroidism O
in O
spite O
of O
adequate O
dosage O
replacement O
indicates O
either O
poor O
patient O
compliance O
, O
poor O
absorption O
, O
excessive O
fecal O
loss O
, O
or O

inactivity O
of O
the O
preparation O
. O
Intracellular O
resistance O
to O
thyroid B-GROUP
hormone I-GROUP
is O
quite O
rare O
. O

Urinary O
acidifying O
agents O
These O
agents O
( O
ammonium B-DRUG
chloride I-DRUG
, O
sodium B-DRUG
acid I-DRUG
phosphate I-DRUG
, O
etc O
. O
) O
increase O
the O
concentration O
of O
the O
ionized O
species O
of O
the O
amphetamine B-DRUG
molecule O
, O
thereby O
increasing O
urinary O
excretion O
. O
Both O
groups O
of O
agents O
lower O
blood O
levels O
and O
efficacy O
of O
amphetamines B-GROUP
. O
Adrenergic B-GROUP
blockers I-GROUP
Adrenergic B-GROUP
blockers I-GROUP
are O
inhibited O
by O
amphetamines B-GROUP
. O
Antidepressants B-GROUP
, O
tricyclic B-GROUP
Amphetamines B-GROUP
may O
enhance O
the O
activity O
of O
tricyclic B-DRUG
antidepressants I-DRUG
or O
sympathomimetic B-GROUP
agents I-GROUP
; O
d B-DRUG
- I-DRUG
amphetamine I-DRUG
with O
desipramine B-DRUG
or O
protriptyline B-DRUG
and O
possibly O
other O
tricyclics B-GROUP
cause O
striking O
and O
sustained O
increases O
in O
the O
concentration O
of O
d B-DRUG
- I-DRUG
amphetamine I-DRUG
in O
the O
brain O
; O
cardiovascular O
effects O
can O
be O
potentiated O
. O
MAO B-GROUP
inhibitors I-GROUP
MAOI B-GROUP
antidepressants I-GROUP
, O
as O
well O
as O
a O
metabolite O
of O
furazolidone B-DRUG
, O
slow O
amphetamine B-DRUG
metabolism O
. O
This O
slowing O
potentiates O
amphetamines B-GROUP
, O
increasing O
their O
effect O
on O
the O
release O
of O
norepinephrine O
and O
other O
monoamines O
from O
adrenergic O
nerve O
endings O
; O
this O
can O
cause O
headaches O
and O
other O
signs O
of O
hypertensive O
crisis O
. O
A O
variety O
of O
toxic O
neurological O
effects O
and O
malignant O
hyperpyrexia O
can O
occur O
, O
sometimes O
with O
fatal O
results O
. O
Antihistamines B-GROUP
: O
Amphetamines B-GROUP
may O
counteract O
the O
sedative O
effect O
of O
antihistamines B-GROUP
. O
Antihypertensives B-GROUP
: O
Amphetamines B-GROUP
may O
antagonize O
the O
hypotensive O
effects O
of O
antihypertensives B-DRUG
. O
Chlorpromazine B-DRUG
: O
Chlorpromazine B-DRUG
blocks O
dopamine O
and O
norepinephrine O
receptors O
, O
thus O
inhibiting O
the O
central O
stimulant O
effects O
of O
amphetamines B-GROUP
and O
can O
be O
used O
to O
treat O
amphetamine B-GROUP
poisoning O
. O
Ethosuximide B-DRUG
: O
Amphetamines B-GROUP
may O
delay O
intestinal O
absorption O
of O
ethosuximide B-DRUG
. O
Haloperidol B-DRUG
: O
Haloperidol B-DRUG
blocks O
dopamine O
receptors O
, O
thus O
inhibiting O
the O
central O
stimulant O
effects O
of O
amphetamines B-GROUP
. O
Lithium B-DRUG
carbonate I-DRUG
: O
The O
anorectic O
and O
stimulatory O
effects O
of O
amphetamines B-GROUP
may O
be O
inhibited O
by O
lithium B-DRUG
carbonate I-DRUG
. O
Meperidine B-DRUG
: O
Amphetamines B-GROUP
potentiate O
the O
analgesic O
effect O
of O
meperidine B-DRUG
. O
Methenamine B-DRUG
therapy O
Urinary O
excretion O
of O
amphetamines B-GROUP
is O
increased O
, O
and O
efficacy O
is O
reduced O
by O
acidifying O
agents O
used O
in O

methenamine B-DRUG
therapy O
. O
Norepinephrine B-DRUG
: O
Amphetamines B-GROUP
enhance O
the O
adrenergic O
effect O
of O
norepinephrine B-DRUG
. O
Phenobarbital B-DRUG
: O
Amphetamines B-GROUP
may O
delay O
intestinal O
absorption O
of O
phenobarbital B-DRUG
; O
co O
- O
administration O
of O
phenobarbital B-DRUG
may O
produce O
a O
synergistic O
anticonvulsant O
action O
. O
Phenytoin B-DRUG
: O
Amphetamines B-GROUP
may O
delay O
intestinal O
absorption O
of O
phenytoin B-DRUG
; O
co O
- O
administration O
of O
phenytoin B-DRUG
may O
produce O
a O
synergistic O
anticonvulsant O
action O
. O
Propoxyphene B-DRUG
: O
In O
cases O
of O
propoxyphene B-DRUG
overdosage O
, O
amphetamine B-DRUG
CNS O
stimulation O
is O
potentiated O
and O
fatal O
convulsions O
can O
occur O
. O
Veratrum B-GROUP
alkaloids I-GROUP
: O
Amphetamines B-GROUP
inhibit O
the O
hypotensive O
effect O
of O
veratrum B-GROUP
alkaloids I-GROUP
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
: O
Amphetamines B-GROUP
can O
cause O
a O
significant O
elevation O
in O
plasma O
corticosteroid O
levels O
. O
This O
increase O
is O
greatest O
in O
the O
evening O
. O
Amphetamines B-GROUP
may O
interfere O
with O
urinary O
steroid O
determinations O
. O

Hypotension O
- O
Patients O
on O
Diuretic O
Therapy O
: O
Patients O
on O
diuretics B-GROUP
, O
and O
especially O
those O
in O
whom O
diuretic O
therapy O
was O
recently O
instituted O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
therapy O
with O
PRINIVIL B-BRAND
. O
The O
possibility O
of O
hypotensive O
effects O
with O
PRINIVIL B-BRAND
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-GROUP
or O
increasing O
the O
salt O
intake O
prior O
to O
initiation O
of O
treatment O
with O
PRINIVIL B-BRAND
. O
If O
it O
is O
necessary O
to O
continue O
the O
diuretic B-GROUP
, O
initiate O
therapy O
with O
PRINIVIL B-BRAND
at O
a O
dose O
of O
5 O
mg O
daily O
, O
and O
provide O
close O
medical O
supervision O
after O
the O
initial O
dose O
until O
blood O
pressure O
has O
stabilized O
. O
When O
a O
diuretic B-GROUP
is O
added O
to O
the O
therapy O
of O
a O
patient O
receiving O
PRINIVIL B-BRAND
, O
an O
additional O
antihypertensive O
effect O
is O
usually O
observed O
. O
Studies O
with O
ACE B-GROUP
inhibitors I-GROUP
in O
combination O
with O
diuretics B-GROUP
indicate O
that O
the O
dose O
of O
the O
ACE B-GROUP
inhibitor I-GROUP
can O
be O
reduced O
when O
it O
is O
given O
with O
a O
diuretic B-GROUP
. O
Non B-GROUP
- I-GROUP
steroidal I-GROUP
Anti I-GROUP
- I-GROUP
inflammatory I-GROUP
Agents I-GROUP
: O
In O
some O
patients O
with O
compromised O
renal O
function O
who O
are O
being O
treated O
with O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drugs I-GROUP
, O
the O
co O
- O
administration O
of O
lisinopril B-DRUG
may O
result O
in O
a O
further O
deterioration O
of O
renal O
function O
. O
These O
effects O
are O
usually O
reversible O
. O
Reports O
suggest O
that O
NSAIDs B-GROUP
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE B-GROUP
inhibitors I-GROUP
, O
including O
lisinopril B-DRUG
. O
This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
NSAIDs B-GROUP
concomitantly O
with O
ACE B-GROUP
inhibitors I-GROUP
. O
In O
a O
study O
in O
36 O
patients O
with O
mild O
to O
moderate O
hypertension O
where O
the O
antihypertensive O
effects O
of O
PRINIVIL B-BRAND
alone O
were O
compared O
to O
PRINIVIL B-BRAND
given O
concomitantly O
with O
indomethacin B-DRUG
, O
the O
use O
of O
indomethacin B-DRUG
was O
associated O
with O
a O
reduced O
antihypertensive O
effect O
, O
although O
the O
difference O
between O
the O
two O
regimens O
was O
not O
significant O
. O
Other O
Agents O
: O
PRINIVIL B-BRAND
has O
been O
used O
concomitantly O
with O
nitrates B-GROUP
and O
/ O
or O
digoxin B-DRUG
without O
evidence O
of O
clinically O
significant O
adverse O
interactions O
. O
This O
included O
post O
myocardial O
infarction O
patients O
who O
were O
receiving O
intravenous O
or O
transdermal O
nitroglycerin B-DRUG
. O
No O
clinically O
important O
pharmacokinetic O
interactions O
occurred O
when O
PRINIVIL B-BRAND
was O
used O
concomitantly O
with O
propranolol B-DRUG
or O
hydrochlorothiazide B-DRUG
. O
The O
presence O
of O
food O

in O
the O
stomach O
does O
not O
alter O
the O
bioavailability O
of O
PRINIVIL B-BRAND
. O
Agents O
Increasing O
Serum O
Potassium O
: O
PRINIVIL B-BRAND
attenuates O
potassium O
loss O
caused O
by O
thiazide B-GROUP
- I-GROUP
type I-GROUP
diuretics I-GROUP
. O
Use O
of O
PRINIVIL B-BRAND
with O
potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
( O
e O
. O
g O
. O
, O
spironolactone B-DRUG
, O
triamterene B-DRUG
, O
or O
amiloride B-DRUG
) O
, O
potassium B-DRUG
supplements O
, O
or O
potassium O
- O
containing O
salt O
substitutes O
may O
lead O
to O
significant O
increases O
in O
serum O
potassium O
. O
Therefore O
, O
if O
concomitant O
use O
of O
these O
agents O
is O
indicated O
because O
of O
demonstrated O
hypokalemia O
, O
they O
should O
be O
used O
with O
caution O
and O
with O
frequent O
monitoring O
of O
serum O
potassium O
. O
Potassium O
sparing O
agents O
should O
generally O
not O
be O
used O
in O
patients O
with O
heart O
failure O
who O
are O
receiving O
PRINIVIL B-BRAND
. O
Lithium B-DRUG
: O
Lithium B-DRUG
toxicity O
has O
been O
reported O
in O
patients O
receiving O
lithium B-DRUG
concomitantly O
with O
drugs O
which O
cause O
elimination O
of O
sodium O
, O
including O
ACE B-GROUP
inhibitors I-GROUP
. O
Lithium B-DRUG
toxicity O
was O
usually O
reversible O
upon O
discontinuation O
of O
lithium B-DRUG
and O
the O
ACE B-GROUP
inhibitor I-GROUP
. O
It O
is O
recommended O
that O
serum O
lithium B-DRUG
levels O
be O
monitored O
frequently O
if O
PRINIVIL B-BRAND
is O
administered O
concomitantly O
with O
lithium B-DRUG
. O

- O
Lofexidine B-DRUG
may O
enhance O
the O
CNS O
depressive O
effects O
of O
alcohol B-DRUG
, O
barbiturates B-GROUP
and O
other O
sedatives B-GROUP
. O
- O
Lofexidine B-DRUG
may O
enhance O
the O
effects O
of O
anti B-GROUP
- I-GROUP
hypertensive I-GROUP
drug I-GROUP
therapy O
. O
- O
Concomitant O
use O
of O
tricyclic B-GROUP
antidepressants I-GROUP
may O
reduce O
the O
efficacy O
of O
lofexidine B-DRUG
. O

Theophylline B-DRUG
: O
In O
three O
pharmacokinetic O
studies O
including O
46 O
normal O
, O
healthy O
subjects O
, O
theophylline B-DRUG
clearance O
and O
concentration O
were O
not O
significantly O
altered O
by O
the O
addition O
of O
lomefloxacin B-DRUG
. O
In O
clinical O
studies O
where O
patients O
were O
on O
chronic O
theophylline B-DRUG
therapy O
, O
lomefloxacin B-DRUG
had O
no O
measurable O
effect O
on O
the O
mean O
distribution O
of O
theophylline B-DRUG
concentrations O
or O
the O
mean O
estimates O
of O
theophylline B-DRUG
clearance O
. O
Though O
individual O
theophylline B-DRUG
levels O
fluctuated O
, O
there O
were O
no O
clinically O
significant O
symptoms O
of O
drug O
inter O
- O
action O
. O
Antacids B-GROUP
and O
sucralfate B-DRUG
: O
Sucralfate B-DRUG
and O
antacids B-GROUP
containing O
magnesium B-DRUG
or O
aluminum B-DRUG
, O
as O
well O
as O
formulations O
containing O
divalent O
and O
trivalent O
cations O
such O
as O
Videx B-BRAND
( O
didanosine B-DRUG
) O
, O
chewable O
/ O
buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
can O
form O
chelation O
complexes O
with O
lomefloxacin B-DRUG
and O
interfere O
with O
its O
bioavailability O
. O
Sucralfate B-DRUG
administered O
2 O
hours O
before O
lomefloxacin B-DRUG
resulted O
in O
a O
slower O
absorption O
( O
mean O
C O
max O
decreased O
by O
30 O
% O
and O
mean O
T O
max O
increased O
by O
1 O
hour O
) O
and O
a O
lesser O
extent O
of O
absorption O
( O
mean O
AUC O
decreased O
by O
approximately O
25 O
% O
) O
. O
Magnesium B-DRUG
- O
and O
aluminum B-DRUG
- O
containing O
antacids B-GROUP
, O
administered O
concomitantly O
with O
lomefloxacin B-DRUG
, O
significantly O
decreased O
the O
bioavailability O
( O
48 O
% O
) O
of O
lomefloxacin B-DRUG
. O
Separating O
the O
doses O
of O
antacid B-GROUP
and O
lomefloxacin B-DRUG
minimizes O
this O
decrease O
in O
bioavailability O
; O
therefore O
, O
administration O
of O
these O
agents O
should O
precede O
lomefloxacin B-DRUG
dosing O
by O
4 O
hours O
or O
follow O
lomefloxacin B-DRUG
dosing O
by O
at O
least O
2 O
hours O
. O
Caffeine B-DRUG
: O
Two O
hundred O
mg O
of O
caffeine B-DRUG
( O
equivalent O
to O
1 O
to O
3 O
cups O
of O
American O
coffee O
) O
was O
administered O
to O
16 O
normal O
, O
healthy O
volunteers O
who O
had O
achieved O
steady O
- O
state O
blood O
concentrations O
of O
lomefloxacin B-DRUG
after O
being O
dosed O
at O
400 O
mg O
qd O
. O
This O
did O
not O
result O
in O
any O
statistically O
or O
clinically O
relevant O
changes O
in O
the O
pharmacokinetic O
parameters O
of O
either O
caffeine B-DRUG
or O
its O
major O
metabolite O
, O
paraxanthine B-DRUG_N
. O
No O
data O
are O
available O
on O
potential O
interactions O
in O
individuals O
who O
consume O
greater O
than O
200 O
mg O
of O
caffeine B-DRUG
per O
day O
or O
in O
those O
, O
such O
as O
the O
geriatric O
population O
, O
who O
are O
generally O
believed O
to O
be O
more O
susceptible O
to O
the O
development O
of O
drug O
- O
induced O
CNS O
- O

related O
adverse O
effects O
. O
Other O
quinolones B-GROUP
have O
demonstrated O
moderate O
to O
marked O
interference O
with O
the O
metabolism O
of O
caffeine B-DRUG
, O
resulting O
in O
a O
reduced O
clearance O
, O
a O
prolongation O
of O
plasma O
half O
- O
life O
, O
and O
an O
increase O
in O
symptoms O
that O
accompany O
high O
levels O
of O
caffeine B-DRUG
. O
Cimetidine B-DRUG
: O
Cimetidine B-DRUG
has O
been O
demonstrated O
to O
interfere O
with O
the O
elimination O
of O
other O
quinolones B-GROUP
. O
This O
interference O
has O
resulted O
in O
significant O
increases O
in O
half O
- O
life O
and O
AUC O
. O
The O
interaction O
between O
lomefloxacin B-DRUG
and O
cimetidine B-DRUG
has O
not O
been O
studied O
. O
Cyclosporine B-DRUG
: O
Elevated O
serum O
levels O
of O
cyclosporine B-DRUG
have O
been O
reported O
with O
concomitant O
use O
of O
cyclosporine B-DRUG
with O
other O
members O
of O
the O
quinolone B-GROUP
class I-GROUP
. O
Interaction O
between O
lomefloxacin B-DRUG
and O
cyclosporine B-DRUG
has O
not O
been O
studied O
. O
Omeprazole B-DRUG
: O
No O
clinically O
significant O
changes O
in O
lomefloxacin B-DRUG
pharmacokinetics O
( O
AUC O
, O
C O
max O
, O
or O
T O
max O
) O
were O
observed O
when O
a O
single O
dose O
of O
lomefloxacin B-DRUG
400 O
mg O
was O
given O
after O
multiple O
doses O
of O
omeprazole B-DRUG
( O
20 O
mg O
qd O
) O
in O
13 O
healthy O
volunteers O
. O
Changes O
in O
omeprazole B-DRUG
pharmacokinetics O
were O
not O
studied O
. O
Phenytoin B-DRUG
: O
No O
significant O
differences O
were O
observed O
in O
mean O
phenytoin B-DRUG
AUC O
, O
C O
max O
, O
C O
min O
or O
T O
max O
( O
although O
C O
max O
increased O
by O
11 O
% O
) O
when O
extended O
phenytoin B-DRUG
sodium I-DRUG
capsules O
( O
100 O
mg O
tid O
) O
were O
coadministered O
with O
lomefloxacin B-DRUG
( O
400 O
mg O
qd O
) O
for O
five O
days O
in O
15 O
healthy O
males O
. O
Lomefloxacin B-DRUG
is O
unlikely O
to O
have O
a O
significant O
effect O
on O
phenytoin B-DRUG
metabolism O
. O
Probenecid B-DRUG
: O
Probenecid B-DRUG
slows O
the O
renal O
elimination O
of O
lome O
- O
floxacin O
. O
An O
increase O
of O
63 O
% O
in O
the O
mean O
AUC O
and O
increases O
of O
50 O
% O
and O
4 O
% O
, O
respectively O
, O
in O
the O
mean O
T O
max O
and O
mean O
C O
max O
were O
noted O
in O
1 O
study O
of O
6 O
individuals O
. O
Terfenadine B-DRUG
: O
No O
clinically O
significant O
changes O
occurred O
in O
heart O
rate O
or O
corrected O
QT O
intervals O
, O
or O
in O
terfenadine B-DRUG
metabolite O
or O
lomefloxacin B-DRUG
pharmacokinetics O
, O
during O
concurrent O
administration O
of O
lomefloxacin B-DRUG
and O
terfenadine B-DRUG
at O
steady O
- O
state O
in O
28 O
healthy O
males O
. O
Warfarin B-DRUG
: O

Quinolones B-GROUP
may O
enhance O
the O
effects O
of O
the O
oral O
anticoagulant B-GROUP
, O
warfarin B-DRUG
, O
or O
its O
derivatives O
. O
When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
or O
other O
suitable O
coagulation O
tests O
should O
be O
monitored O
closely O
. O
However O
, O
no O
clinically O
or O
statistically O
significant O
differences O
in O
prothrombin O
time O
ratio O
or O
warfarin B-DRUG
enantiomer O
pharmacokinetics O
were O
observed O
in O
a O
small O
study O
of O
7 O
healthy O
males O
who O
received O
both O
warfarin B-DRUG
and O
lomefloxacin B-DRUG
under O
steady O
- O
state O
conditions O
. O

There O
was O
no O
evidence O
in O
clinical O
trials O
of O
drug O
interactions O
with O
concurrent O
medications O
. O

Probenecid B-DRUG
: O
As O
with O
other O
b B-GROUP
- I-GROUP
lactam I-GROUP
antibiotics I-GROUP
, O
renal O
excretion O
of O
loracarbef B-DRUG
is O
inhibited O
by O
probenecid B-DRUG
and O
resulted O
in O
an O
approximate O
80 O
% O
increase O
in O
the O
AUC O
for O
loracarbef B-DRUG
. O

Loratadine B-DRUG
( O
10 O
mg O
once O
daily O
) O
has O
been O
coadministered O
with O
therapeutic O
doses O
of O
erythromycin B-DRUG
, O
cimetidine B-DRUG
, O
and O
ketoconazole B-DRUG
in O
controlled O
clinical O
pharmacology O
studies O
in O
adult O
volunteers O
. O
Although O
increased O
plasma O
concentrations O
( O
AUC O
0 O
- O
24 O
hrs O
) O
of O
loratadine B-DRUG
and O
/ O
or O
descarboethoxyloratadine B-DRUG
were O
observed O
following O
coadministration O
of O
loratadine B-DRUG
with O
each O
of O
these O
drugs O
in O
normal O
volunteers O
( O
n O
= O
24 O
in O
each O
study O
) O
, O
there O
were O
no O
clinically O
relevant O
changes O
in O
the O
safety O
profile O
of O
loratadine B-DRUG
, O
as O
assessed O
by O
electrocardiographic O
parameters O
, O
clinical O
laboratory O
tests O
, O
vital O
signs O
, O
and O
adverse O
events O
. O
There O
were O
no O
significant O
effects O
on O
QTc O
intervals O
, O
and O
no O
reports O
of O
sedation O
or O
syncope O
. O
No O
effects O
on O
plasma O
concentrations O
of O
cimetidine B-DRUG
or O
ketoconazole B-DRUG
were O
observed O
. O
Plasma O
concentrations O
( O
AUC O
0 O
- O
24 O
hrs O
) O
of O
erythromycin B-DRUG
decreased O
15 O
% O
with O
coadministration O
of O
loratadine B-DRUG
relative O
to O
that O
observed O
with O
erythromycin B-DRUG
alone O
. O
The O
clinical O
relevance O
of O
this O
difference O
is O
unknown O
. O
These O
above O
findings O
are O
summarized O
in O
TABLE O
1 O
. O
TABLE O
1 O
Effects O
on O
Plasma O
Concentrations O
( O
AUC O
0 O
- O
24 O
hrs O
) O
of O
Loratadine B-DRUG
and O
Descarboethoxyloratadine B-DRUG
After O
10 O
Days O
of O
Coadministration O
( O
Loratadine B-DRUG
10 O
mg O
) O
in O
Normal O
Volunteers O
Loratadine B-DRUG
Descarboethoxyloratadine B-DRUG
Erythromycin B-DRUG
( O
500 O
mg O
q8h O
) O
+ O
40 O
% O
+ O
46 O
% O
Cimetidine B-DRUG
( O
300 O
mg O
qid O
) O
+ O
103 O
% O
+ O
6 O
% O
Ketoconazole B-DRUG
( O
200 O
mg O
q12h O
) O
+ O
307 O
% O
+ O
73 O
% O
There O
does O
not O
appear O
to O
be O
an O
increase O
in O
adverse O
events O
in O
subjects O
who O
received O
oral O
contraceptives B-GROUP
and O
loratadine B-DRUG
. O

Tablets O
: O
The O
benzodiazepines B-GROUP
, O
including O
lorazepam B-DRUG
, O
produce O
CNS O
- O
depressant O
effects O
when O
administered O
with O
such O
medications O
as O
barbiturates B-GROUP
or O
alcohol B-DRUG
. O
Injection O
: O
Lorazepam B-DRUG
injection O
, O
like O
other O
injectable O
benzodiazepines B-GROUP
, O
produces O
depression O
of O
the O
central O
nervous O
system O
when O
administered O
with O
ethyl B-DRUG
alcohol I-DRUG
, O
phenothiazines B-GROUP
, O
barbiturates B-GROUP
, O
MAO B-GROUP
inhibitors I-GROUP
, O
and O
other O
antidepressants B-GROUP
. O
When O
scopolamine B-DRUG
is O
used O
concomitantly O
with O
injectable O
lorazepam B-DRUG
, O
an O
increased O
incidence O
of O
sedation O
, O
hallucinations O
, O
and O
irrational O
behavior O
has O
been O
observed O
. O

No O
significant O
drug O
- O
drug O
pharmacokinetic O
interactions O
have O
been O
found O
in O
interaction O
studies O
with O
hydrochlorothiazide B-DRUG
, O
digoxin B-DRUG
, O
warfarin B-DRUG
, O
cimetidine B-DRUG
and O
phenobarbital B-DRUG
. O
Rifampin B-DRUG
, O
an O
inducer O
of O
drug O
metabolism O
, O
decreased O
the O
concentrations O
of O
losartan B-DRUG
and O
its O
active O
metabolite O
. O
In O
humans O
, O
two O
inhibitors O
of O
P450 O
3A4 O
have O
been O
studied O
. O
Ketoconazole B-DRUG
did O
not O
affect O
the O
conversion O
of O
losartan B-DRUG
to O
the O
active O
metabolite O
after O
intravenous O
administration O
of O
losartan B-DRUG
, O
and O
erythromycin B-DRUG
had O
no O
clinically O
significant O
effect O
after O
oral O
administration O
. O
Fluconazole B-DRUG
, O
an O
inhibitor O
of O
P450 O
2C9 O
, O
decreased O
active O
metabolite O
concentration O
and O
increased O
losartan B-DRUG
concentration O
. O
The O
pharmacodynamic O
consequences O
of O
concomitant O
use O
of O
losartan B-DRUG
and O
inhibitors O
of O
P450 O
2C9 O
have O
not O
been O
examined O
. O
Subjects O
who O
do O
not O
metabolize O
losartan B-DRUG
to O
active O
metabolite O
have O
been O
shown O
to O
have O
a O
specific O
, O
rare O
defect O
in O
cytochrome O
P450 O
2C9 O
. O
These O
data O
suggest O
that O
the O
conversion O
of O
losartan B-DRUG
to O
its O
active O
metabolite O
is O
mediated O
primarily O
by O
P450 O
2C9 O
and O
not O
P450 O
3A4 O
. O
As O
with O
other O
drugs O
that O
block O
angiotensin O
II O
or O
its O
effects O
, O
concomitant O
use O
of O
potassium B-GROUP
- I-GROUP
sparing I-GROUP
diuretics I-GROUP
( O
e O
. O
g O
. O
, O
spironolactone B-DRUG
, O
triamterene B-DRUG
, O
amiloride B-DRUG
) O
, O
potassium B-DRUG
supplements O
, O
or O
salt O
substitutes O
containing O
potassium O
may O
lead O
to O
increases O
in O
serum O
potassium O
. O
As O
with O
other O
antihypertensive B-GROUP
agents I-GROUP
, O
the O
antihypertensive O
effect O
of O
losartan B-DRUG
may O
be O
blunted O
by O
the O
non B-GROUP
- I-GROUP
steroidal I-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
drug I-GROUP
indomethacin B-DRUG
. O

CYP3A4 O
Interactions O
Lovastatin B-DRUG
is O
metabolized O
by O
CYP3A4 O
but O
has O
no O
CYP3A4 O
inhibitory O
activity O
; O
therefore O
it O
is O
not O
expected O
to O
affect O
the O
plasma O
concentrations O
of O
other O
drugs O
metabolized O
by O
CYP3A4 O
. O
Potent O
inhibitors O
of O
CYP3A4 O
( O
below O
) O
increase O
the O
risk O
of O
myopathy O
by O
reducing O
the O
elimination O
of O
lovastatin B-DRUG
. O
Pharmacokinetics O
. O
Itraconazole B-DRUG
Ketoconazole B-DRUG
Erythromycin B-DRUG
Clarithromycin B-DRUG
Telithromycin B-DRUG
HIV B-GROUP
protease I-GROUP
inhibitors I-GROUP
Nefazodone B-DRUG
Cyclosporine B-DRUG
Large O
quantities O
of O
grapefruit O
juice O
( O
1 O
quart O
daily O
) O
Interactions O
with O
lipid O
- O
lowering O
drugs O
that O
can O
cause O
myopathy O
when O
given O
alone O
. O
The O
risk O
of O
myopathy O
is O
also O
increased O
by O
the O
following O
lipid O
- O
lowering O
drugs O
that O
are O
not O
potent O
CYP3A4 O
inhibitors O
, O
but O
which O
can O
cause O
myopathy O
when O
given O
alone O
. O
See O
WARNINGS O
, O
Myopathy O
/ O
Rhabdomyolysis O
. O
Gemfibrozil B-DRUG
Other O
fibrates B-GROUP
Niacin B-DRUG
( O
nicotinic B-DRUG
acid I-DRUG
) O
( O
= O
1 O
g O
/ O
day O
) O
Other O
drug O
interactions O
Danazol B-DRUG
: O
The O
risk O
of O
myopathy O
/ O
rhabdomyolysis O
is O
increased O
by O
concomitant O
administration O
of O
danazol B-DRUG
particularly O
with O
higher O
doses O
of O
lovastatin B-DRUG
( O
see O
WARNINGS O
, O
Myopathy O
/ O
Rhabdomyolysis O
) O
. O
Amiodarone B-DRUG
or O
Verapamil B-DRUG
: O
The O
risk O
of O
myopathy O
/ O
rhabdomyolysis O
is O
increased O
when O
either O
amiodarone B-DRUG
or O
verapamil B-DRUG
is O
used O
concomitantly O
with O
a O
closely O
related O
member O
of O
the O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitor I-GROUP
class I-GROUP
( O
see O
WARNINGS O
, O
Myopathy O
/ O
Rhabdomyolysis O
) O
. O
Coumarin B-GROUP
Anticoagulants I-GROUP
: O
In O
a O
small O
clinical O
trial O
in O
which O
lovastatin B-DRUG
was O
administered O
to O
warfarin B-DRUG
treated O
patients O
, O
no O
effect O
on O
prothrombin O
time O
was O
detected O
. O
However O
, O
another O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
reductase I-GROUP
inhibitor I-GROUP
has O
been O
found O
to O
produce O
a O
less O
than O
two O
- O
second O
increase O
in O
prothrombin O
time O
in O
healthy O
volunteers O
receiving O
low O
doses O
of O
warfarin B-DRUG
. O
Also O
, O
bleeding O
and O
/ O
or O
increased O
prothrombin O
time O
have O
been O
reported O
in O
a O
few O
patients O
taking O
coumarin B-GROUP
anticoagulants I-GROUP
concomitantly O
with O
lovastatin B-DRUG
. O
It O
is O
recommended O
that O

in O
patients O
taking O
anticoagulants B-GROUP
, O
prothrombin O
time O
be O
determined O
before O
starting O
lovastatin B-DRUG
and O
frequently O
enough O
during O
early O
therapy O
to O
insure O
that O
no O
significant O
alteration O
of O
prothrombin O
time O
occurs O
. O
Once O
a O
stable O
prothrombin O
time O
has O
been O
documented O
, O
prothrombin O
times O
can O
be O
monitored O
at O
the O
intervals O
usually O
recommended O
for O
patients O
on O
coumarin B-GROUP
anticoagulants I-GROUP
. O
If O
the O
dose O
of O
lovastatin B-DRUG
is O
changed O
, O
the O
same O
procedure O
should O
be O
repeated O
. O
Lovastatin B-DRUG
therapy O
has O
not O
been O
associated O
with O
bleeding O
or O
with O
changes O
in O
prothrombin O
time O
in O
patients O
not O
taking O
anticoagulants B-GROUP
. O
Propranolol B-DRUG
: O
In O
normal O
volunteers O
, O
there O
was O
no O
clinically O
significant O
pharmacokinetic O
or O
pharmacodynamic O
interaction O
with O
concomitant O
administration O
of O
single O
doses O
of O
lovastatin B-DRUG
and O
propranolol B-DRUG
. O
Digoxin B-DRUG
: O
In O
patients O
with O
hypercholesterolemia O
, O
concomitant O
administration O
of O
lovastatin B-DRUG
and O
digoxin B-DRUG
resulted O
in O
no O
effect O
on O
digoxin B-DRUG
plasma O
concentrations O
. O
Oral O
Hypoglycemic B-GROUP
Agents I-GROUP
: O
In O
pharmacokinetic O
studies O
of O
MEVACOR B-BRAND
in O
hypercholesterolemic O
noninsulin O
dependent O
diabetic O
patients O
, O
there O
was O
no O
drug O
interaction O
with O
glipizide B-DRUG
or O
with O
chlorpropamide B-DRUG

There O
have O
been O
rare O
reports O
of O
significant O
respiratory O
depression O
, O
stupor O
and O
/ O
or O
hypotension O
with O
the O
concomitant O
use O
of O
loxapine B-DRUG
and O
lorazepam B-DRUG
. O
The O
risk O
of O
using O
loxapine B-DRUG
in O
combination O
with O
CNS O
- O
active O
drugs O
has O
not O
been O
systematically O
evaluated O
. O
Therefore O
, O
caution O
is O
advised O
if O
the O
concomitant O
administration O
of O
loxapine B-DRUG
and O
CNS O
- O
active O
drugs O
is O
required O
. O

The O
absorption O
of O
lymecycline B-DRUG
may O
be O
affected O
by O
the O
simultaneous O
administration O
of O
indigestion O
remedies O
, O
iron B-DRUG
or O
zinc B-DRUG
supplements O
. O
Oral O
contraceptives B-GROUP
may O
be O
less O
effective O
while O
you O
are O
taking O
lymecycline B-DRUG
. O

Warfarin B-DRUG
: O
Meclofenamate B-DRUG
sodium I-DRUG
enhances O
the O
effect O
of O
warfarin B-DRUG
. O
Therefore O
, O
when O
meclofenamate B-DRUG
sodium I-DRUG
is O
given O
to O
a O
patient O
receiving O
warfarin B-DRUG
, O
the O
dosage O
of O
warfarin B-DRUG
should O
be O
reduced O
to O
prevent O
excessive O
prolongation O
of O
the O
prothrombin O
time O
. O
Aspirin B-BRAND
: O
Concurrent O
administration O
of O
aspirin B-BRAND
may O
lower O
meclofenamate B-DRUG
sodium I-DRUG
plasma O
levels O
, O
possibly O
by O
competing O
for O
protein O
- O
binding O
sites O
. O
The O
urinary O
excretion O
of O
meclofenamate B-DRUG
sodium I-DRUG
is O
unaffected O
by O
aspirin B-BRAND
, O
indicating O
no O
change O
in O
meclofenamate B-DRUG
sodium I-DRUG
absorption O
. O
Meclofenamate B-DRUG
sodium I-DRUG
does O
not O
affect O
serum O
salicylate B-GROUP
levels O
. O
Greater O
fecal O
blood O
loss O
results O
from O
concomitant O
administration O
of O
both O
drugs O
than O
from O
either O
drug O
alone O
. O
Propoxyphene B-DRUG
: O
The O
concurrent O
administration O
of O
propoxyphene B-DRUG
hydrochloride I-DRUG
does O
not O
affect O
the O
bioavailability O
of O
meclofenamate B-DRUG
sodium I-DRUG
. O
Antacids B-GROUP
: O
Concomitant O
administration O
of O
aluminum B-DRUG
and I-DRUG
magnesium I-DRUG
hydroxides I-DRUG
does O
not O
interfere O
with O
absorption O
of O
meclofenamate B-DRUG
sodium I-DRUG
. O

Aspirin B-BRAND
: O
As O
with O
other O
NSAIDs B-GROUP
, O
concomitant O
administration O
of O
Ponstel B-BRAND
and O
aspirin B-BRAND
is O
not O
generally O
recommended O
because O
of O
the O
potential O
of O
increased O
adverse O
effects O
. O
Methotrexate B-DRUG
: O
NSAIDs B-GROUP
have O
been O
reported O
to O
competitively O
inhibit O
methotrexate B-DRUG
accumulation O
in O
rabbit O
kidney O
slices O
. O
This O
may O
indicate O
that O
they O
could O
enhance O
the O
toxicity O
of O
methotrexate B-DRUG
. O
Caution O
should O
be O
used O
when O
NSAIDs B-GROUP
are O
administered O
concomitantly O
with O
methotrexate B-DRUG
. O
ACE B-GROUP
inhibitors I-GROUP
: O
Reports O
suggest O
that O
NSAIDs B-GROUP
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE B-GROUP
inhibitors I-GROUP
. O
This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
NSAIDs B-GROUP
concomitantly O
with O
ACE B-GROUP
inhibitors I-GROUP
. O
Furosemide B-DRUG
: O
Clinical O
studies O
, O
as O
well O
as O
post O
- O
marketing O
observations O
, O
have O
shown O
that O
NSAIDs B-GROUP
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-DRUG
and O
thiazides B-GROUP
in O
some O
patients O
. O
This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O
During O
concomitant O
therapy O
of O
Ponstel B-BRAND
with O
furosemide B-DRUG
, O
the O
patient O
should O
be O
observed O
closely O
for O
signs O
of O
renal O
failure O
, O
as O
well O
as O
to O
assure O
diuretic O
efficacy O
. O
Lithium B-DRUG
: O
NSAIDs B-GROUP
have O
produced O
an O
elevation O
of O
plasma O
lithium B-DRUG
levels O
and O
a O
reduction O
in O
renal O
lithium B-DRUG
clearance O
. O
The O
mean O
minimum O
lithium B-DRUG
concentration O
increased O
15 O
% O
and O
the O
renal O
clearance O
was O
decreased O
by O
approximately O
20 O
% O
. O
These O
effects O
have O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
by O
the O
NSAID B-GROUP
. O
Thus O
, O
when O
NSAIDs B-GROUP
and O
lithium B-DRUG
are O
administered O
concurrently O
, O
subjects O
should O
be O
observed O
carefully O
for O
signs O
of O
lithium B-DRUG
toxicity O
. O
Warfarin B-DRUG
: O
The O
effects O
of O
warfarin B-DRUG
and O
NSAIDs B-GROUP
on O
GI O
bleeding O
are O
synergistic O
, O
such O
that O
users O
of O
both O
drugs O
together O
have O
a O
risk O
of O
serious O
GI O
bleeding O
higher O
than O
users O
of O
either O
drug O
alone O
. O
Antacids B-GROUP
: O
In O
a O
single O
dose O
study O
( O
n O
= O
6 O
) O
, O
ingestion O
of O
an O
antacid B-GROUP
containing O
1 O
. O
7 O
- O
gram O
of O
magnesium B-DRUG
hydroxide I-DRUG
with O
500 O
- O
mg O
of O
mefenamic B-DRUG
acid I-DRUG
increased O
the O
Cmax O
and O
AUC O
of O
mefenamic B-DRUG
acid I-DRUG
by O
125 O
% O
and O
36 O
% O
, O
respectively O
. O
A O
number O
of O
compounds O
are O
inhibitors O
of O
CYP2C9 O
including O
fluconazole B-DRUG
, O
lovastatin B-DRUG
and O
trimethoprim B-DRUG
. O
Drug O
interaction O
studies O
of O
mefenamic B-DRUG
acid I-DRUG
and O
these O
compounds O
have O
not O
been O

conducted O
. O
The O
possibility O
of O
altered O
safety O
and O
efficacy O
should O
be O
considered O
when O
Ponstel B-BRAND
is O
used O
concomitantly O
with O
these O
drugs O
. O

Drug O
- O
drug O
interactions O
with O
Mefloquine B-DRUG
have O
not O
been O
explored O
in O
detail O
. O
There O
is O
one O
report O
of O
cardiopulmonary O
arrest O
, O
with O
full O
recovery O
, O
in O
a O
patient O
who O
was O
taking O
a O
beta B-GROUP
blocker I-GROUP
( O
propranolol B-DRUG
) O
. O
The O
effects O
of O
Mefloquineuine O
on O
the O
compromised O
cardiovascular O
system O
have O
not O
been O
evaluated O
. O
The O
benefits O
of O
Mefloquine B-DRUG
therapy O
should O
be O
weighed O
against O
the O
possibility O
of O
adverse O
effects O
in O
patients O
with O
cardiac O
disease O
. O
Because O
of O
the O
danger O
of O
a O
potentially O
fatal O
prolongation O
of O
the O
QTc O
interval O
, O
halofantrine B-DRUG
must O
not O
be O
given O
simultaneously O
with O
or O
subsequent O
to O
Mefloquine B-DRUG
. O
Concomitant O
administration O
of O
Mefloquine B-DRUG
and O
other O
related O
compounds O
( O
eg O
, O
quinine B-DRUG
, O
quinidine B-DRUG
and O
chloroquine B-DRUG
) O
may O
produce O
electrocardiographic O
abnormalities O
and O
increase O
the O
risk O
of O
convulsions O
. O
If O
these O
drugs O
are O
to O
be O
used O
in O
the O
initial O
treatment O
of O
severe O
malaria O
, O
Mefloquine B-DRUG
administration O
should O
be O
delayed O
at O
least O
12 O
hours O
after O
the O
last O
dose O
. O
There O
is O
evidence O
that O
the O
use O
of O
halofantrine B-DRUG
after O
Mefloquineuine O
causes O
a O
significant O
lengthening O
of O
the O
QTc O
interval O
. O
Clinically O
significant O
QTc O
prolongation O
has O
not O
been O
found O
with O
Mefloquineuine O
alone O
. O
This O
appears O
to O
be O
the O
only O
clinically O
relevant O
interaction O
of O
this O
kind O
with O
Mefloquine B-DRUG
, O
although O
theoretically O
, O
coadministration O
of O
other O
drugs O
known O
to O
alter O
cardiac O
conduction O
( O
eg O
, O
anti B-DRUG
- I-DRUG
arrhythmic I-DRUG
or O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
blocking I-GROUP
agents I-GROUP
, O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
, O
antihistamines B-GROUP
or O
H1 B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
, O
tricyclic B-GROUP
antidepressants I-GROUP
and O
phenothiazines B-GROUP
) O
might O
also O
contribute O
to O
a O
prolongation O
of O
the O
QTc O
interval O
. O
There O
are O
no O
data O
that O
conclusively O
establish O
whether O
the O
concomitant O
administration O
of O
Mefloquineuine O
and O
the O
above O
listed O
agents O
has O
an O
effect O
on O
cardiac O
function O
. O
In O
patients O
taking O
an O
anticonvulsant B-GROUP
( O
eg O
, O
valproic B-DRUG
acid I-DRUG
, O
carbamazepine B-DRUG
, O
phenobarbital B-DRUG
or O
phenytoin B-DRUG
) O
, O
the O
concomitant O
use O
of O
Mefloquine B-DRUG
may O
reduce O
seizure O
control O
by O
lowering O
the O
plasma O
levels O
of O
the O
anticonvulsant B-GROUP
. O
Therefore O
, O
patients O
concurrently O
taking O
antiseizure O
medication O
and O
Mefloquine B-DRUG
should O
have O
the O
blood O
level O
of O
their O
antiseizure O
medication O
monitored O
and O
the O
dosage O
adjusted O

appropriately O
. O
When O
Mefloquine B-DRUG
is O
taken O
concurrently O
with O
oral O
live B-GROUP
typhoid I-GROUP
vaccines I-GROUP
, O
attenuation O
of O
immunization O
cannot O
be O
excluded O
. O
Vaccinations O
with O
attenuated O
live O
bacteria O
should O
therefore O
be O
completed O
at O
least O
3 O
days O
before O
the O
first O
dose O
of O
Mefloquine B-DRUG
. O
No O
other O
drug O
interactions O
are O
known O
. O
Nevertheless O
, O
the O
effects O
of O
Mefloquine B-DRUG
on O
travelers O
receiving O
comedication O
, O
particularly O
diabetics O
or O
patients O
using O
anticoagulants B-GROUP
, O
should O
be O
checked O
before O
departure O
. O
In O
clinical O
trials O
, O
the O
concomitant O
administration O
of O
sulfadoxine B-DRUG
and O
pyrimethamine B-DRUG
did O
not O
alter O
the O
adverse O
reaction O
profile O
. O

Broad B-GROUP
- I-GROUP
Spectrum I-GROUP
Antibiotics I-GROUP
- O
Broad B-GROUP
- I-GROUP
spectrum I-GROUP
antibiotics I-GROUP
may O
sterilize O
the O
bowel O
and O
decrease O
the O
vitamin B-GROUP
K I-GROUP
contribution O
to O
the O
body O
by O
the O
intestinal O
microflora O
. O
Cephalosporins B-GROUP
- O
Cephalosporins B-GROUP
containing O
side O
chains O
of O
N O
- O
methylthiotetrazole O
( O
cefmenoxime B-DRUG
, O
cefoperazone B-DRUG
, O
cefotetan B-DRUG
, O
cefamandole B-DRUG
, O
latamoxef B-DRUG
) O
or O
methylthiadiazole O
( O
cefazolin B-DRUG
) O
can O
cause O
vitamin O
K O
deficiency O
and O
hypoprothrombinemia O
. O
These O
cephalosporins B-GROUP
are O
inhibitors O
of O
hepatic O
vitamin O
K O
epoxide O
reductase O
. O
Cholestyramine B-DRUG
- O
Concomitant O
intake O
of O
cholestyramine B-DRUG
and O
vitamin B-GROUP
K I-GROUP
may O
reduce O
the O
absorption O
of O
vitamin B-GROUP
K I-GROUP
. O
Colestipol B-DRUG
- O
Concomitant O
intake O
of O
colestipol B-DRUG
and O
vitamin B-GROUP
K I-GROUP
may O
reduce O
the O
absorption O
of O
vitamin B-GROUP
K I-GROUP
. O
Mineral B-DRUG_N
Oil I-DRUG_N
- O
Concomitant O
intake O
of O
mineral B-DRUG_N
oil I-DRUG_N
and O
vitamin B-GROUP
K I-GROUP
may O
reduce O
the O
absorption O
of O
vitamin B-GROUP
K I-GROUP
. O
Orlistat B-DRUG
- O
Orlistat B-DRUG
may O
decrease O
the O
absorption O
of O
vitamin B-GROUP
K I-GROUP
. O
Salicylates B-GROUP
- O
Salicylates B-GROUP
in O
large O
doses O
may O
inhibit O
vitamin O
K O
epoxide O
reductase O
resulting O
in O
vitamin O
K O
deficiency O
. O
Warfarin B-DRUG
- O
Vitamin B-GROUP
K I-GROUP
can O
antagonize O
the O
effect O
of O
warfarin B-DRUG

Nabilone B-DRUG
should O
be O
administered O
with O
caution O
to O
patients O
who O
are O
taking O
other O
psychoactive B-GROUP
drugs I-GROUP
or O
CNS B-GROUP
depressants I-GROUP
, O
including O
alcohol B-DRUG
, O
barbiturates B-GROUP
and O
narcotic B-GROUP
analgesics I-GROUP
, O
or O
to O
those O
with O
a O
history O
of O
psychiatric O
disorder O
( O
including O
manic O
- O
depressive O
illness O
and O
schizophrenia O
) O
. O
Nabilone B-DRUG
has O
been O
shown O
to O
have O
an O
additive O
CNS O
depressant O
effect O
when O
given O
with O
either O
diazepam B-DRUG
, O
secobarbitone B-BRAND
sodium I-BRAND
, O
alcohol B-DRUG
or O
codeine B-DRUG
. O

In O
vitro O
studies O
have O
shown O
that O
, O
because O
of O
its O
affinity O
for O
protein O
, O
6MNA B-DRUG_N
may O
displace O
other O
protein O
- O
bound O
drugs O
from O
their O
binding O
site O
. O
Caution O
should O
be O
exercised O
when O
administering O
nabumetone B-DRUG
with O
warfarin B-DRUG
since O
interactions O
have O
been O
seen O
with O
other O
NSAIDs B-GROUP
. O
Concomitant O
administration O
of O
an O
aluminum B-DRUG
- O
containing O
antacid B-GROUP
had O
no O
significant O
effect O
in O
the O
bioavailability O
of O
6MNA B-DRUG_N
. O
When O
administered O
with O
food O
or O
milk O
, O
there O
is O
more O
rapid O
absorption O
; O
however O
, O
the O
total O
amount O
of O
6MNA B-DRUG_N
in O
the O
plasma O
is O
unchanged O
. O

When O
administered O
concurrently O
, O
the O
following O
drugs O
may O
interact O
with O
beta B-GROUP
- I-GROUP
adrenergic I-GROUP
receptor I-GROUP
blocking I-GROUP
agents I-GROUP
: O
Anesthetics B-GROUP
, O
general O
: O
exaggeration O
of O
the O
hypotension O
induced O
by O
general O
anesthetics B-GROUP
. O
Antidiabetic B-GROUP
drugs I-GROUP
( O
oral O
agents O
and O
insulin B-DRUG
) O
: O
hypoglycemia O
or O
hyperglycemia O
; O
adjust O
dosage O
of O
antidiabetic B-GROUP
drug I-GROUP
accordingly O
. O
Catecholamine O
- O
depleting O
drugs O
( O
e O
. O
g O
. O
, O
reserpine B-DRUG
) O
: O
additive O
effect O
; O
monitor O
closely O
for O
evidence O
of O
hypotension O
and O
/ O
or O
excessive O
bradycardia O
( O
e O
. O
g O
. O
, O
vertigo O
, O
syncope O
, O
postural O
hypotension O
) O
. O
Response O
to O
Treatment O
for O
Anaphylactic O
Reaction O
: O
While O
taking O
beta B-GROUP
- I-GROUP
blockers I-GROUP
, O
patients O
with O
a O
history O
of O
severe O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
be O
more O
reactive O
to O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
, O
or O
therapeutic O
. O
Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-DRUG
used O
to O
treat O
allergic O
reaction O
. O

No O
pharmacokinetic O
- O
based O
drug O
- O
drug O
interaction O
studies O
have O
been O
conducted O
with O
SYNAREL B-BRAND
. O
However O
, O
because O
nafarelin B-DRUG
acetate I-DRUG
is O
a O
peptide O
that O
is O
primarily O
degraded O
by O
peptidase O
and O
not O
by O
cytochrome O
P O
- O
450 O
enzymes O
, O
and O
the O
drug O
is O
only O
about O
80 O
% O
bound O
to O
plasma O
proteins O
at O
4 O
C O
, O
drug O
interactions O
would O
not O
be O
expected O
to O
occur O
. O

Tetracycline B-DRUG
, O
a O
bacteriostatic B-GROUP
antibiotic I-GROUP
, O
may O
antagonize O
the O
bactericidal O
effect O
of O
penicillin B-DRUG
and O
concurrent O
use O
of O
these O
drugs O
should O
be O
avoided O
. O

No O
specific O
information O
available O
. O

Elevated O
plasma O
levels O
of O
theophylline B-DRUG
have O
been O
reported O
with O
concomitant O
quinolone B-GROUP
use O
. O
There O
have O
been O
reports O
of O
theophylline B-DRUG
- O
related O
side O
effects O
in O
patients O
on O
concomitant O
therapy O
with O
quinolones B-GROUP
and O
theophylline B-DRUG
. O
Therefore O
, O
monitoring O
of O
theophylline B-DRUG
plasma O
levels O
should O
be O
considered O
and O
dosage O
of O
theophylline B-DRUG
adjusted O
, O
as O
required O
. O
Quinolones B-GROUP
have O
been O
shown O
to O
interfere O
with O
the O
metabolism O
of O
caffeine B-DRUG
. O
This O
may O
lead O
to O
reduced O
clearance O
of O
caffeine B-DRUG
and O
the O
prolongation O
of O
its O
plasma O
half O
- O
life O
. O
Quinolones B-GROUP
, O
including O
nalidixic B-DRUG
acid I-DRUG
, O
may O
enhance O
the O
effects O
of O
the O
oral O
anticoagulant B-GROUP
warfarin B-DRUG
or O
its O
derivatives O
. O
When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
time O
or O
other O
suitable O
coagulation O
test O
should O
be O
closely O
monitored O
. O
Nitrofurantoin B-DRUG
interferes O
with O
the O
therapeutic O
action O
of O
nalidixic B-DRUG
acid I-DRUG
. O
Antacids B-GROUP
containing O
magnesium B-DRUG
, O
aluminum B-DRUG
, O
or O
calcium B-DRUG
; O
sucralfate B-DRUG
or O
divalent O
or O
trivalent O
cations O
such O
as O
iron B-DRUG
; O
multivitamins B-GROUP
containing O
zinc B-DRUG
; O
and O
Videx B-BRAND
, O
( O
Didanosine B-DRUG
) O
, O
chewable O
/ O
buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
may O
substantially O
interfere O
with O
the O
absorption O
of O
quinolones B-GROUP
, O
resulting O
in O
systemic O
levels O
considerably O
lower O
than O
desired O
. O
These O
agents O
should O
not O
be O
taken O
within O
the O
two O
hour O
period O
before O
or O
within O
the O
two O
- O
hour O
period O
after O
nalidixic B-DRUG
acid I-DRUG
administration O
. O
Elevated O
serum O
levels O
of O
cyclosporine B-DRUG
have O
been O
reported O
with O
the O
concomitant O
use O
of O
some O
quinolones B-GROUP
and O
cyclosporine B-DRUG
. O
Therefore O
, O
cyclosporine B-DRUG
serum O
levels O
should O
be O
monitored O
and O
appropriate O
cyclosporine B-DRUG
dosage O
adjustments O
made O
when O
these O
drugs O
are O
used O
concomitantly O
. O

Studies O
to O
evaluate O
possible O
interactions O
between O
REVIA B-BRAND
and O
drugs O
other O
than O
opiates B-GROUP
have O
not O
been O
performed O
. O
Consequently O
, O
caution O
is O
advised O
if O
the O
concomitant O
administration O
of O
REVIA B-BRAND
and O
other O
drugs O
is O
required O
. O
The O
safety O
and O
efficacy O
of O
concomitant O
use O
of O
REVIA B-BRAND
and O
disulfiram B-DRUG
is O
unknown O
, O
and O
the O
concomitant O
use O
of O
two O
potentially O
hepatotoxic O
medications O
is O
not O
ordinarily O
recommended O
unless O
the O
probable O
benefits O
outweigh O
the O
known O
risks O
. O
Lethargy O
and O
somnolence O
have O
been O
reported O
following O
doses O
of O
REVIA B-BRAND
and O
thioridazine B-DRUG
. O
Patients O
taking O
REVIA B-BRAND
may O
not O
benefit O
from O
opioid B-GROUP
containing O
medicines O
, O
such O
as O
cough O
and O
cold O
preparations O
, O
antidiarrheal O
preparations O
, O
and O
opioid B-GROUP
analgesics I-GROUP
. O
In O
an O
emergency O
situation O
when O
opioid O
analgesia O
must O
be O
administered O
to O
a O
patient O
receiving O
REVIA B-BRAND
, O
the O
amount O
of O
opioid B-GROUP
required O
may O
be O
greater O
than O
usual O
, O
and O
the O
resulting O
respiratory O
depression O
may O
be O
deeper O
and O
more O
prolonged O
. O

The O
use O
of O
NSAIDs B-GROUP
in O
patients O
who O
are O
receiving O
ACE B-GROUP
inhibitors I-GROUP
may O
potentiate O
renal O
disease O
states O
. O
In O
vitro O
studies O
have O
shown O
that O
naproxen B-DRUG
anion O
, O
because O
of O
its O
affinity O
for O
protein O
, O
may O
displace O
from O
their O
binding O
sites O
other O
drugs O
which O
are O
also O
albumin O
- O
bound O
. O
Theoretically O
, O
the O
naproxen B-DRUG
anion O
itself O
could O
likewise O
be O
displaced O
. O
Short O
- O
term O
controlled O
studies O
failed O
to O
show O
that O
taking O
the O
drug O
significantly O
affects O
prothrombin O
times O
when O
administered O
to O
individuals O
on O
coumarin B-GROUP
- I-GROUP
type I-GROUP
anticoagulants I-GROUP
. O
Caution O
is O
advised O
nonetheless O
, O
since O
interactions O
have O
been O
seen O
with O
other O
nonsteroidal O
agents O
of O
this O
class O
. O
Similarly O
, O
patients O
receiving O
the O
drug O
and O
a O
hydantoin B-GROUP
, O
sulfonamide B-GROUP
or O
sulfonylurea B-GROUP
should O
be O
observed O
for O
signs O
of O
toxicity O
to O
these O
drugs O
. O
Concomitant O
administration O
of O
naproxen B-DRUG
and O
aspirin B-BRAND
is O
not O
recommended O
because O
naproxen B-DRUG
is O
displaced O
from O
its O
binding O
sites O
during O
the O
concomitant O
administration O
of O
aspirin B-BRAND
, O
resulting O
in O
lower O
plasma O
concentrations O
and O
peak O
plasma O
levels O
. O
The O
natriuretic O
effect O
of O
furosemide B-DRUG
has O
been O
reported O
to O
be O
inhibited O
by O
some O
drugs O
of O
this O
class O
. O
Inhibition O
of O
renal O
lithium B-DRUG
clearance O
leading O
to O
increases O
in O
plasma O
lithium B-DRUG
concentrations O
has O
also O
been O
reported O
. O
Naproxen B-DRUG
and O
other O
NSAIDs B-GROUP
can O
reduce O
the O
antihypertensive O
effect O
of O
propranolol B-DRUG
and O
other O
beta B-GROUP
- I-GROUP
blockers I-GROUP
. O
Probenecid B-DRUG
given O
concurrently O
increases O
naproxen B-DRUG
anion O
plasma O
levels O
and O
extends O
its O
plasma O
half O
- O
life O
significantly O
. O
Caution O
should O
be O
used O
if O
naproxen B-DRUG
is O
administered O
concomitantly O
with O
methotrexate B-DRUG
. O
Naproxen B-DRUG
, O
naproxen B-DRUG
sodium I-DRUG
and O
other O
NSAIDs B-GROUP
have O
been O
reported O
to O
reduce O
the O
tubular O
secretion O
of O
methotrexate B-DRUG
in O
an O
animal O
model O
, O
possibly O
increasing O
the O
toxicity O
of O
methotrexate B-DRUG
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
Naproxen B-DRUG
may O
decrease O
platelet O
aggregation O
and O
prolong O
bleeding O
time O
. O
This O
effect O
should O
be O
kept O
in O
mind O
when O
bleeding O
times O
are O
determined O
. O
The O
administration O
of O
naproxen B-DRUG
may O
result O
in O
increased O
urinary O
values O
for O
17 O
- O
ketogenic O
steroids O
because O
of O
an O
interaction O
between O
the O
drug O
and O
/ O
or O
its O
metabolites O
with O
m O
- O
dinitrobenzene O
used O
in O
this O
assay O
. O
Although O
17 O
- O
hydroxy O
- O
corticosteroid O
measurements O
( O
Porter O
- O
Silber O
test O
) O
do O
not O
appear O
to O
be O
artifactually O
altered O
, O
it O
is O
suggested O
that O
therapy O

with O
naproxen B-DRUG
be O
temporarily O
discontinued O
72 O
hours O
before O
adrenal O
function O
tests O
are O
performed O
if O
the O
Porter O
- O
Silber O
test O
is O
to O
be O
used O
. O
Naproxen B-DRUG
may O
interfere O
with O
some O
urinary O
assays O
of O
5 O
- O
hydroxy O
indoleacetic O
acid O
( O
5HIAA O
) O
. O

Ergot B-GROUP
- O
containing O
drugs O
have O
been O
reported O
to O
cause O
prolonged O
vasospastic O
reactions O
. O
Because O
there O
is O
a O
theoretical O
basis O
that O
these O
effects O
may O
be O
additive O
, O
use O
of O
ergotamine B-DRUG
- O
containing O
or O
ergot B-GROUP
- I-GROUP
type I-GROUP
medications I-GROUP
( O
like O
dihydroergotamine B-DRUG
or O
methysergide B-DRUG
) O
and O
naratriptan B-DRUG
within O
24 O
hours O
is O
contraindicated O
. O
The O
administration O
of O
naratriptan B-DRUG
with O
other O
5 B-GROUP
- I-GROUP
HT1 I-GROUP
agonists I-GROUP
has O
not O
been O
evaluated O
in O
migraine O
patients O
. O
Because O
their O
vasospastic O
effects O
may O
be O
additive O
, O
coadministration O
of O
naratriptan B-DRUG
and O
other O
5 B-GROUP
- I-GROUP
HT1 I-GROUP
agonists I-GROUP
within O
24 O
hours O
of O
each O
other O
is O
not O
recommended O
. O
Selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
( O
SSRIs B-GROUP
) O
( O
e O
. O
g O
. O
, O
fluoxetine B-DRUG
, O
fluvoxamine B-DRUG
, O
paroxetine B-DRUG
, O
sertraline B-DRUG
) O
have O
been O
reported O
, O
rarely O
, O
to O
cause O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
when O
coadministered O
with O
5 O
- O
HTv O
agonists O
. O
If O
concomitant O
treatment O
with O
naratriptan B-DRUG
and O
an O
SSRI B-GROUP
is O
clinically O
warranted O
, O
appropriate O
observation O
of O
the O
patient O
is O
advised O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
AMERGE B-BRAND
Tablets O
are O
not O
known O
to O
interfere O
with O
commonly O
employed O
clinical O
laboratory O
tests O
. O

After O
multiple O
dosing O
, O
interferon B-DRUG
beta I-DRUG
- I-DRUG
1a I-DRUG
( O
AVONEX B-BRAND
30 O
mcg O
IM O
once O
weekly O
) O
reduced O
TYSABRI B-BRAND
clearance O
by O
approximately O
30 O
% O
. O
The O
similarity O
of O
the O
TYSABRI B-BRAND
- O
associated O
adverse O
event O
profile O
between O
Study O
1 O
( O
without O
co O
- O
administered O
AVONEX B-BRAND
) O
and O
Study O
2 O
( O
with O
co O
- O
administered O
AVONEX B-BRAND
) O
indicates O
that O
this O
alteration O
in O
clearance O
does O
not O
necessitate O
reduction O
of O
the O
TYSABRI B-BRAND
dose O
to O
maintain O
safety O
, O
General O
) O
. O
Results O
of O
studies O
in O
multiple O
sclerosis O
patients O
taking O
TYSABRI B-BRAND
and O
concomitant O
interferon B-DRUG
beta I-DRUG
- I-DRUG
1a I-DRUG
( O
AVONEX B-BRAND
30 O
mcg O
IM O
once O
weekly O
) O
or O
glatiramer B-DRUG
acetate I-DRUG
were O
inconclusive O
with O
regard O
to O
the O
need O
for O
dose O
adjustment O
of O
the O
beta B-DRUG
- I-DRUG
interferon I-DRUG
or O
glatiramer B-DRUG
acetate I-DRUG
. O

In O
vitro O
drug O
metabolism O
studies O
indicate O
that O
Starlix B-BRAND
is O
predominantly O
metabolized O
by O
the O
cytochrome O
P450 O
isozyme O
CYP2C9 O
( O
70 O
% O
) O
and O
to O
a O
lesser O
extent O
CYP3A4 O
( O
30 O
% O
) O
. O
Starlix B-BRAND
is O
a O
potential O
inhibitor O
of O
the O
CYP2C9 O
isoenzyme O
in O
vivo O
as O
indicated O
by O
its O
ability O
to O
inhibit O
the O
in O
vitro O
metabolism O
of O
tolbutamide B-DRUG
. O
Inhibition O
of O
CYP3A4 O
metabolic O
reactions O
was O
not O
detected O
in O
in O
vitro O
experiments O
. O
Glyburide B-DRUG
: O
In O
a O
randomized O
, O
multiple O
- O
dose O
crossover O
study O
, O
patients O
with O
Type O
2 O
diabetes O
were O
administered O
120 O
mg O
Starlix B-BRAND
three O
times O
a O
day O
before O
meals O
for O
1 O
day O
in O
combination O
with O
glyburide B-DRUG
10 O
mg O
daily O
. O
There O
were O
no O
clinically O
relevant O
alterations O
in O
the O
pharmacokinetics O
of O
either O
agent O
. O
Metformin B-DRUG
: O
When O
Starlix B-BRAND
120 O
mg O
three O
times O
daily O
before O
meals O
was O
administered O
in O
combination O
with O
metformin B-DRUG
500 O
mg O
three O
times O
daily O
to O
patients O
with O
Type O
2 O
diabetes O
, O
there O
were O
no O
clinically O
relevant O
changes O
in O
the O
pharmacokinetics O
of O
either O
agent O
. O
Digoxin B-DRUG
: O
When O
Starlix B-BRAND
120 O
mg O
before O
meals O
was O
administered O
in O
combination O
with O
a O
single O
1 O
- O
mg O
dose O
of O
digoxin B-DRUG
to O
healthy O
volunteers O
, O
there O
were O
no O
clinically O
relevant O
changes O
in O
the O
pharmacokinetics O
of O
either O
agent O
. O
Warfarin B-DRUG
: O
When O
healthy O
subjects O
were O
administered O
Starlix B-BRAND
120 O
mg O
three O
times O
daily O
before O
meals O
for O
four O
days O
in O
combination O
with O
a O
single O
dose O
of O
warfarin B-DRUG
30 O
mg O
on O
day O
2 O
, O
there O
were O
no O
alterations O
in O
the O
pharmacokinetics O
of O
either O
agent O
. O
Prothrombin O
time O
was O
not O
affected O
. O
Diclofenac B-DRUG
: O
Administration O
of O
morning O
and O
lunch O
doses O
of O
Starlix B-BRAND
120 O
mg O
in O
combination O
with O
a O
single O
75 O
- O
mg O
dose O
of O
diclofenac B-DRUG
in O
healthy O
volunteers O
resulted O
in O
no O
significant O
changes O
to O
the O
pharmacokinetics O
of O
either O
agent O
. O
Nateglinide B-DRUG
is O
highly O
bound O
to O
plasma O
proteins O
( O
98 O
% O
) O
, O
mainly O
albumin O
. O
In O
vitro O
displacement O
studies O
with O
highly O
protein O
- O
bound O
drugs O
such O
as O
furosemide B-DRUG
, O
propranolol B-DRUG
, O
captopril B-DRUG
, O
nicardipine B-DRUG
, O
pravastatin B-DRUG
, O
glyburide B-DRUG
, O
warfarin B-DRUG
, O
phenytoin B-DRUG
, O
acetylsalicylic B-DRUG
acid I-DRUG
, O
tolbutamide B-DRUG
, O
and O
metformin B-DRUG
showed O
no O
influence O
on O
the O
extent O
of O
nateglinide B-DRUG
protein O
binding O
. O
Similarly O
, O
nateglinide B-DRUG
had O
no O

influence O
on O
the O
serum O
protein O
binding O
of O
propranolol B-DRUG
, O
glyburide B-DRUG
, O
nicardipine B-DRUG
, O
warfarin B-DRUG
, O
phenytoin B-DRUG
, O
acetylsalicylic B-DRUG
acid I-DRUG
, O
and O
tolbutamide B-DRUG
in O
vitro O
. O
However O
, O
prudent O
evaluation O
of O
individual O
cases O
is O
warranted O
in O
the O
clinical O
setting O
. O
Certain O
drugs O
, O
including O
nonsteroidal B-GROUP
anti I-GROUP
- I-GROUP
inflammatory I-GROUP
agents I-GROUP
( O
NSAIDs B-GROUP
) O
, O
salicylates B-GROUP
, O
monoamine B-GROUP
oxidase I-GROUP
inhibitors I-GROUP
, O
and O
non B-GROUP
- I-GROUP
selective I-GROUP
beta I-GROUP
- I-GROUP
adrenergic I-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
may O
potentiate O
the O
hypoglycemic O
action O
of O
Starlix B-BRAND
and O
other O
oral O
antidiabetic B-GROUP
drugs I-GROUP
. O
Certain O
drugs O
including O
thiazides B-GROUP
, O
corticosteroids B-GROUP
, O
thyroid B-GROUP
products I-GROUP
, O
and O
sympathomimetics B-GROUP
may O
reduce O
the O
hypoglycemic O
action O
of O
Starlix B-BRAND
and O
other O
oral O
antidiabetic B-GROUP
drugs I-GROUP
. O
When O
these O
drugs O
are O
administered O
to O
or O
withdrawn O
from O
patients O
receiving O
Starlix B-BRAND
, O
the O
patient O
should O
be O
observed O
closely O
for O
changes O
in O
glycemic O
control O
. O

In O
clinical O
studies O
, O
Tilade B-BRAND
has O
been O
co O
- O
administered O
with O
other O
anti O
- O
asthma O
medications O
, O
including O
inhaled O
and O
oral O
bronchodilators B-GROUP
, O
and O
inhaled O
corticosteroids B-GROUP
, O
with O
no O
evidence O
of O
increased O
frequency O
of O
adverse O
events O
or O
laboratory O
abnormalities O
. O
No O
formal O
drug O
- O
drug O
interaction O
studies O
, O
however O
, O
have O
been O
conducted O
. O

Nelfinavir B-DRUG
is O
an O
inhibitor O
of O
CYP3A O
( O
cytochrome O
P450 O
3A O
) O
. O
Coadministration O
of O
VIRACEPT B-BRAND
and O
drugs O
primarily O
metabolized O
by O
CYP3A O
( O
e O
. O
g O
. O
, O
dihydropyridine B-GROUP
calcium I-GROUP
channel I-GROUP
blockers I-GROUP
) O
may O
result O
in O
increased O
plasma O
concentrations O
of O
the O
other O
drug O
that O
could O
increase O
or O
prolong O
both O
its O
therapeutic O
and O
adverse O
effects O
. O
Nelfinavir B-DRUG
is O
metabolized O
in O
proof O
by O
C O
. O
P O
. O
A O
. O
Coadministration O
of O
VIRACEPT B-BRAND
and O
drugs O
that O
induce O
CYP3A O
may O
decrease O
nelfinavir B-DRUG
plasma O
concentrations O
and O
reduce O
its O
therapeutic O
effect O
. O
Coadministration O
of O
VIRACEPT B-BRAND
and O
drugs O
that O
inhibit O
CYP3A O
may O
increase O
nelfinavir B-DRUG
plasma O
concentrations O
. O
Based O
on O
known O
metabolic O
profiles O
, O
clinically O
significant O
drug O
interactions O
are O
not O
expected O
between O
VIRACEPT B-BRAND
and O
dapsone B-DRUG
, O
trimethoprim B-DRUG
/ O
sulfamethoxazole B-DRUG
, O
clarithromycin B-DRUG
, O
erythromycin B-DRUG
, O
itraconazole B-DRUG
or O
fluconazole B-DRUG
. O
Drugs O
That O
Should O
Not O
Be O
Coadministered O
With O
VIRACEPT B-BRAND
Antiarrhythmics B-GROUP
: O
amiodarone B-DRUG
, O
quinidine B-DRUG
Antihistamines B-GROUP
: O
astemizole B-DRUG
, O
terfenadine B-DRUG
Antimigraine O
: O
ergot B-GROUP
derivatives I-GROUP
Antimycobacterial B-GROUP
agents I-GROUP
: O
rifampin B-DRUG
Benzodiazepines B-GROUP
midazolam B-DRUG
, O
triazolam B-DRUG
GI O
motility O
agents O
: O
cisapride B-DRUG
Drugs O
Which O
Require O
a O
Dose O
Reduction O
When O
Coadminstered O
With O
VIRACEPT B-BRAND
Antimycobacterial B-GROUP
agents I-GROUP
: O
rifabutin B-DRUG
* O
This O
table O
is O
not O
all O
inclusive O
* O
* O
VIRACEPT B-BRAND
may O
not O
be O
effective O
due O
to O
decreased O
nelfinavir B-DRUG
plasma O
concentrations O
in O
patients O
taking O
these O
agents O
concomitantly O
Antihistamines B-GROUP
Terfenadine B-DRUG
: O
Administration O
of O
terfenadine B-DRUG
with O
VIRACEPT B-BRAND
resulted O
in O
the O
appearance O
of O
unchanged O
terfenadine B-DRUG
in O
plasma O
; O
therefore O
, O
VIRACEPT B-BRAND
should O
not O
be O
administered O
concurrently O
with O
terfenadine B-DRUG
because O
of O
the O
potential O
for O
serious O
and O
/ O
or O
life O
- O
threatening O
cardiac O
arrhythmias O
. O
Because O
a O
similar O
interaction O
is O
likely O
, O
VIRACEPT B-BRAND
should O
also O
not O
be O
administered O
concurrently O
with O
astemizole B-DRUG
. O
Anti B-GROUP
- I-GROUP
HIV I-GROUP
Protease I-GROUP
Inhibitors I-GROUP
Indinavir B-DRUG
: O
Coadministration O
of O
indinavir B-DRUG
with O

VIRACEPT B-BRAND
resulted O
in O
an O
83 O
% O
increase O
in O
nelfinavir B-DRUG
plasma O
AUC O
and O
a O
51 O
% O
increase O
in O
indinavir B-DRUG
plasma O
A O
. O
C O
. O
Currently O
, O
there O
are O
no O
safety O
and O
efficacy O
data O
available O
from O
the O
use O
of O
this O
combination O
. O
Ritonavir B-DRUG
: O
Coadministration O
of O
ritonavir B-DRUG
with O
VIRACEPT B-BRAND
resulted O
in O
a O
152 O
% O
increase O
in O
nelfinavir B-DRUG
plasma O
AUC O
and O
very O
little O
change O
in O
ritonavir B-DRUG
plasma O
A O
. O
C O
. O
Currently O
, O
there O
are O
no O
safety O
and O
efficacy O
data O
available O
from O
the O
use O
of O
this O
combination O
. O
Saquinavir B-DRUG
: O
Coadministration O
of O
saquinavir B-DRUG
( O
using O
an O
experimental O
soft O
- O
gelatin O
capsule O
formulation O
of O
saquinavir B-DRUG
1200mg O
) O
with O
VIRACEPT B-BRAND
resulted O
in O
an O
18 O
% O
increase O
in O
nelfinavir B-DRUG
plasma O
AUC O
and O
a O
4 O
- O
fold O
increase O
in O
saquinavir B-DRUG
plasma O
A O
. O
C O
. O
If O
used O
in O
combination O
with O
saquinavir B-DRUG
hard O
gelatin O
capsules O
at O
the O
recommended O
dose O
of O
600 O
mg O
tid O
, O
no O
dose O
adjustments O
are O
needed O
. O
Currently O
, O
there O
are O
no O
safety O
and O
efficacy O
data O
available O
from O
the O
use O
of O
this O
combination O
. O
Antifungal B-GROUP
Agents I-GROUP
Ketoconazole B-DRUG
: O
Coadministration O
of O
ketoconazole B-DRUG
with O
VIRACEPT B-BRAND
resulted O
in O
a O
35 O
% O
increase O
in O
nelfinavir B-DRUG
plasma O
A O
. O
C O
. O
This O
change O
was O
not O
considered O
clinically O
significant O
and O
no O
dose O
adjustment O
is O
needed O
when O
ketoconazole B-DRUG
and O
VIRACEPT B-BRAND
are O
coadministered O
. O
Anti B-GROUP
- I-GROUP
HIV I-GROUP
Reverse I-GROUP
Transcriptase I-GROUP
Inhibitors I-GROUP
Didanosine B-DRUG
: O
It O
is O
recommended O
that O
didanosine B-DRUG
be O
administered O
on O
an O
empty O
stomach O
; O
therefore O
, O
nelfinavir B-DRUG
should O
be O
administered O
( O
with O
food O
) O
one O
hour O
after O
or O
more O
than O
two O
hours O
before O
didanosine B-DRUG
. O
A O
dose O
adjustment O
is O
not O
needed O
when O
zidovudine B-DRUG
is O
administered O
with O
VIRACEPT B-BRAND
. O
Little O
or O
no O
change O
in O
the O
pharmacokinetics O
of O
either O
drug O
was O
observed O
when O
VIRACEPT B-BRAND
was O
coadministered O
with O
lamivudine B-DRUG
or O
stavudine B-DRUG
. O
Antimycobacterial B-GROUP
Agents I-GROUP
Rifabutin B-DRUG
: O
Coadministration O
of O
rifabutin B-DRUG
and O
VIRACEPT B-BRAND
resulted O
in O
a O
32 O
% O
decrease O
in O
nelfinavir B-DRUG
plasma O
AUC O
and O
a O
207 O
% O
increase O
in O
rifabutin B-DRUG
plasma O
A O
. O
C O
. O
It O
is O
recommended O
that O
the O
dose O
of O
rifabutin B-DRUG
be O
reduced O
to O
one O
- O
half O
the O
usual O
dose O
when O

administered O
with O
VIRACEPT B-BRAND
. O
Rifampin B-DRUG
: O
Coadministration O
of O
rifampin B-DRUG
and O
VIRACEPT B-BRAND
resulted O
in O
an O
82 O
% O
decrease O
in O
nelfinavir B-DRUG
plasma O
A O
. O
C O
. O
VIRACEPT B-BRAND
and O
rifampin B-DRUG
should O
not O
be O
coadministered O
. O
Oral O
Contraceptives B-GROUP
Ethinyl B-DRUG
Estradiol I-DRUG
and O
Norethindrone B-DRUG
: O
Coadministration O
of O
VIRACEPT B-BRAND
with O
OVCON B-BRAND
- I-BRAND
35 I-BRAND
resulted O
in O
a O
47 O
% O
decrease O
in O
ethinyl B-DRUG
estradiol I-DRUG
and O
an O
18 O
% O
decrease O
in O
norethindrone B-DRUG
plasma O
concentrations O
. O
Alternate O
or O
additional O
contraceptive O
measures O
should O
be O
used O
during O
therapy O
with O
VIRACEPT B-BRAND

Caution O
should O
be O
taken O
in O
concurrent O
or O
serial O
use O
of O
other O
neurotoxic O
and O
/ O
or O
nephrotoxic O
drugs O
because O
of O
possible O
enhancement O
of O
the O
nephrotoxicity O
and O
/ O
or O
ototoxicity O
of O
neomycin B-DRUG
. O
Caution O
should O
also O
be O
taken O
in O
concurrent O
or O
serial O
use O
of O
other O
aminoglycosides B-GROUP
and O
polymyxins B-GROUP
because O
they O
may O
enhance O
neomycin O
s O
nephrotoxicity O
and O
/ O
or O
ototoxicity O
and O
potentiate O
neomycin B-DRUG
sulfate I-DRUG
neuromuscular O
blocking O
effects O
. O
Oral O
neomycin B-DRUG
inhibits O
the O
gastrointestinal O
absorption O
of O
penicillin B-DRUG
V I-DRUG
, O
oral O
vitamin B-DRUG
B I-DRUG
- I-DRUG
12 I-DRUG
, O
methotrexate B-DRUG
and O
5 B-DRUG
- I-DRUG
fluorouracil I-DRUG
. O
The O
gastrointestinal O
absorption O
of O
digoxin B-DRUG
also O
appears O
to O
be O
inhibited O
. O
Therefore O
, O
digoxin B-DRUG
serum O
levels O
should O
be O
monitored O
. O
Oral O
neomycin B-DRUG
sulfate I-DRUG
may O
enhance O
the O
effect O
of O
coumarin B-GROUP
in O
anticoagulants B-GROUP
by O
decreasing O
vitamin O
K O
availability O
. O

Certain O
antibiotics B-GROUP
, O
especially O
neomycin B-DRUG
, O
streptomycin B-DRUG
and O
kanamycin B-DRUG
, O
have O
a O
mild O
but O
definite O
nondepolarizing O
blocking O
action O
which O
may O
accentuate O
neuromuscular O
block O
. O
These O
antibiotics B-GROUP
should O
be O
used O
in O
the O
myasthenic O
patient O
only O
where O
definitely O
indicated O
, O
and O
then O
careful O
adjustment O
should O
be O
made O
of O
adjunctive O
anticholinesterase B-GROUP
dosage O
. O
Local O
and O
some O
general O
anesthetics B-GROUP
, O
antiarrhythmic B-GROUP
agents I-GROUP
and O
other O
drugs O
that O
interfere O
with O
neuromuscular O
transmission O
should O
be O
used O
cautiously O
, O
if O
at O
all O
, O
in O
patients O
with O
myasthenia O
gravis O
; O
the O
dose O
of O
Prostigmin B-BRAND
may O
have O
to O
be O
increased O
accordingly O
. O

No O
trials O
specifically O
examining O
potential O
drug O
interactions O
with O
Natrecor B-BRAND
were O
conducted O
, O
although O
many O
concomitant O
drugs O
were O
used O
in O
clinical O
trials O
. O
No O
drug O
interactions O
were O
detected O
except O
for O
an O
increase O
in O
symptomatic O
hypotension O
in O
patients O
receiving O
oral O
ACE B-GROUP
inhibitors I-GROUP
. O
The O
co O
- O
administration O
of O
Natrecor B-BRAND
with O
IV O
vasodilators B-GROUP
such O
as O
nitroglycerin B-DRUG
, O
nitroprusside B-DRUG
, O
milrinone B-DRUG
, O
or O
IV O
ACE B-GROUP
inhibitors I-GROUP
has O
not O
been O
evaluated O
( O
these O
drugs O
were O
not O
co O
- O
administered O
with O
Natrecor B-BRAND
in O
clinical O
trials O
) O
. O

Netilmicin B-DRUG
should O
not O
be O
administered O
concomitantly O
with O
potent O
loop B-GROUP
diuretics I-GROUP
such O
as O
furosemide B-DRUG
and O
ethacrynic B-DRUG
acid I-DRUG
as O
the O
potential O
for O
ototoxicity O
is O
enhanced O
by O
the O
combination O
. O

Nevirapine B-DRUG
is O
principally O
metabolized O
by O
the O
liver O
via O
the O
cytochrome O
P450 O
isoenzymes O
, O
3A4 O
and O
2B6 O
. O
Nevirapine B-DRUG
is O
known O
to O
be O
an O
inducer O
of O
these O
enzymes O
. O
As O
a O
result O
, O
drugs O
that O
are O
metabolized O
by O
these O
enzyme O
systems O
may O
have O
lower O
than O
expected O
plasma O
levels O
when O
coadministered O
with O
nevirapine B-DRUG
. O
The O
specific O
pharmacokinetic O
changes O
that O
occur O
with O
co O
- O
administration O
of O
nevirapine B-DRUG
and O
other O
drugs O
are O
listed O
in O
CLINICAL O
PHARMACOLOGY O
, O
Table O
1 O
. O
Clinical O
comments O
about O
possible O
dosage O
modifications O
based O
on O
these O
pharmacokinetic O
changes O
are O
listed O
in O
Table O
3 O
. O
The O
data O
inTables O
1 O
and O
3 O
are O
based O
on O
the O
results O
of O
drug O
interaction O
studies O
conducted O
in O
HIV O
- O
1 O
seropositive O
subjects O
unless O
otherwise O
indicated O
. O
In O
addition O
to O
established O
drug O
interactions O
, O
there O
may O
be O
potential O
pharmacokinetic O
interactions O
between O
nevirapine B-DRUG
and O
other O
drug O
classes O
that O
are O
metabolized O
by O
the O
cytochrome O
P450 O
system O
. O
These O
potential O
drug O
interactions O
are O
listed O
in O
Table O
4 O
. O
Although O
specific O
drug O
interaction O
studies O
in O
HIV O
- O
1 O
seropositive O
subjects O
have O
not O
been O
conducted O
for O
the O
classes O
of O
drugs O
listed O
in O
Table O
4 O
, O
additional O
clinical O
monitoring O
may O
be O
warranted O
when O
co O
- O
administering O
these O
drugs O
. O
The O
in O
vitro O
interaction O
between O
nevirapine B-DRUG
and O
the O
antithrombotic B-GROUP
agent I-GROUP
warfarin B-DRUG
is O
complex O
. O
As O
a O
result O
, O
when O
giving O
these O
drugs O
concomitantly O
, O
plasma O
warfarin B-DRUG
levels O
may O
change O
with O
the O
potential O
for O
increases O
in O
coagulation O
time O
. O
When O
warfarin B-DRUG
is O
co O
- O
administered O
with O
nevirapine B-DRUG
, O
anticoagulation O
levels O
should O
be O
monitored O
frequently O
. O
Table O
3 O
Established O
Drug O
Interactions O
: O
Alteration O
in O
Dose O
or O
Regimen O
May O
Be O
Recommended O
Based O
on O
Drug O
Interaction O
Studies O
Drug O
Name O
Effect O
on O
Concentration O
of O
Nevirapine B-DRUG
or O
Concomitant O
Drug O
Clinical O
Comment O
Clarithromycin B-DRUG
Clarithromycin B-DRUG
14OH O
- O
clarithromycin O
Clarithromycin B-DRUG
exposure O
was O
significantly O
decreased O
by O
nevirapine B-DRUG
; O
however O
, O
14 O
- O
OH O
metabolite O
concentrations O
were O
increased O
. O
Because O
clarithromycin B-DRUG
active O
metabolite O
has O
reduced O
activity O
against O
Mycobacteriumavium O
- O
intracellulare O
complex O
, O
overallactivity O
against O
this O
pathogen O
may O
bealtered O
. O
Alternatives O
to O
clarithromycin B-DRUG
, O
such O
as O

azithromycin B-DRUG
, O
should O
be O
considered O
. O
Efavirenz B-DRUG
Efavirenz B-DRUG
Appropriate O
doses O
for O
this O
combination O
are O
not O
established O
. O
Ethinyl B-DRUG
estradiol I-DRUG
and O
Norethindrone B-DRUG
Ethinyl B-DRUG
estradiol I-DRUG
Norethindrone B-DRUG
Oral O
contraceptives B-GROUP
and O
other O
hormonalmethods O
of O
birth O
control O
should O
not O
be O
usedas O
the O
sole O
method O
of O
contraception O
inwomen O
taking O
nevirapine B-DRUG
, O
since O
nevirapinemay O
lower O
the O
plasma O
levels O
of O
thesemedications O
. O
An O
alternative O
or O
additional O
method O
of O
contraception O
is O
recommended O
. O
Fluconazole B-DRUG
Nevirapine B-DRUG
Because O
of O
the O
risk O
of O
increased O
exposure O
tonevirapine B-DRUG
, O
caution O
should O
be O
used O
inconcomitant O
administration O
, O
and O
patients O
should O
be O
monitored O
closely O
for O
nevirapine O
- O
associated O
adverse O
events O
. O
Indinavir B-DRUG
Indinavir B-DRUG
Appropriate O
doses O
for O
this O
combination O
arenot O
established O
, O
but O
an O
increase O
in O
thedosage O
of O
indinavir B-DRUG
may O
be O
required O
. O
Ketoconazole B-DRUG
Ketoconazole B-DRUG
Nevirapine B-DRUG
and O
ketoconazole B-DRUG
should O
not O
beadministered O
concomitantly O
becausedecreases O
in O
ketoconazole B-DRUG
plasmaconcentrations O
may O
reduce O
the O
efficacy O
of O
the O
drug O
. O
Lopinavir B-DRUG
/ O
Ritonavir B-DRUG
Lopinavir B-DRUG
A O
dose O
increase O
of O
lopinavir B-DRUG
/ O
ritonavir B-DRUG
to O
533 O
/ O
133 O
mg O
twice O
daily O
with O
food O
isrecommended O
in O
combination O
with O
nevirapine B-DRUG
. O
Methadone B-DRUG
Methadonea O
Methadone B-DRUG
levels O
may O
be O
decreased O
; O
increased O
dosages O
may O
be O
required O
to O
prevent O
symptoms O
of O
opiate B-GROUP
withdrawal O
. O
Methadone B-DRUG
maintained O
patients O
beginning O
nevirapine B-DRUG
therapy O
should O
be O
monitored O
forevidence O
of O
withdrawal O
and O
methadone B-DRUG
dose O
should O
be O
adjusted O
accordingly O
. O
Nelfinavir B-DRUG
Nelfinavir B-DRUG
M8 O
The O
appropriate O
dose O
for O
nelfinavir B-DRUG
incombination O
with O
nevirapine B-DRUG
, O
with O
respectto O
safety O
and O
efficacy O
, O
has O
not O
been O
established O
. O
Rifabutin B-DRUG
Rifabutin B-DRUG
Rifabutin B-DRUG
and O
its O
metabolite O
concentrationswere O
moderately O
increased O
. O
Due O
to O
highintersubject O
variability O
, O
however O
, O
somepatients O
may O
experience O
large O
increases O
inrifabutin B-DRUG
exposure O
and O
may O
be O
at O
higher O
riskfor O
rifabutin O
toxicity O
. O
Therefore O
, O
caution O
should O
be O
used O
in O
concomitant O
administration O
. O
Rifampin B-DRUG
Nevirapine B-DRUG
Nevirapine B-DRUG
and O
rifampin B-DRUG
should O
not O
beadministered O
concomitantly O
becausedecreases O
in O

nevirapine B-DRUG
plasmaconcentrations O
may O
reduce O
the O
efficacy O
ofthe O
drug O
. O
Physicians O
needing O
to O
treatpatients O
co O
- O
infected O
with O
tuberculosis O
andusing O
a O
nevirapine B-DRUG
containing O
regimen O
mayuse O
rifabutin B-DRUG
instead O
. O
Saquinavir B-DRUG
Saquinavir B-DRUG
Appropriate O
doses O
for O
this O
combination O
arenot O
established O
, O
but O
an O
increase O
in O
thedosage O
of O
saquinavir B-DRUG
may O
be O
required O
. O
aBased O
on O
reports O
of O
narcotic O
withdrawal O
syndrome O
in O
patients O
treated O
with O
nevirapine B-DRUG
and O
methadone B-DRUG
concurrently O
, O
and O
evidence O
of O
decreased O
plasma O
concentrations O
of O
methadone B-DRUG
. O
Table O
4 O
Potential O
Drug O
Interactions O
: O
Use O
With O
Caution O
, O
Dose O
Adjustment O
of O
Co O
- O
administered O
Drug O
May O
Be O
Needed O
due O
to O
Possible O
Decrease O
in O
Clinical O
Effect O
Examples O
of O
Drugs O
in O
Which O
Plasma O
Concentrations O
May O
Be O
Decreased O
By O
Co O
- O
administration O
With O
Nevirapine B-DRUG
Drug O
Class O
Examples O
of O
Drugs O
Antiarrhythmics B-GROUP
Amiodarone B-DRUG
, O
disopyramide B-DRUG
, O
lidocaine B-DRUG
Anticonvulsants B-GROUP
Carbamazepine B-DRUG
, O
clonazepam B-DRUG
, O
ethosuximide B-DRUG
Antifungals B-GROUP
Itraconazole B-DRUG
Calcium B-GROUP
channel I-GROUP
blockers I-GROUP
Diltiazem B-DRUG
, O
nifedipine B-DRUG
, O
verapamil B-DRUG
Cancer O
chemotherapy O
Cyclophosphamide B-DRUG
Ergot B-GROUP
alkaloids I-GROUP
Ergotamine B-DRUG
Immunosuppressants B-GROUP
Cyclosporin B-DRUG
, O
tacrolimus B-DRUG
, O
sirolimus B-DRUG
Motility O
agents O
Cisapride B-DRUG
Opiate B-GROUP
agonists I-GROUP
Fentanyl B-DRUG
Examples O
of O
Drugs O
in O
Which O
Plasma O
Concentrations O
May O
Be O
Increased O
By O
Co O
- O
administration O
With O
Nevirapine B-DRUG
Antithrombotics B-GROUP
Warfarin B-DRUG
Potential O
effect O
on O
anticoagulation O
. O
Monitoring O
of O
anticoagulation O
levels O
is O
recommended O
. O
Fat O
redistribution O
: O
Redistribution O
/ O
accumulation O
of O
body O
fat O
including O
central O
obesity O
, O
dorsocervical O
fat O
enlargement O
( O
buffalo O
hump O
) O
, O
peripheral O
wasting O
, O
facial O
wasting O
, O
breast O
enlargement O
, O
and O
cushingoid O
appearance O
have O
been O
observed O
in O
patients O
receiving O
antiretroviral B-GROUP
therapy O
. O
The O
mechanism O
and O
long O
- O
term O
consequences O
of O
these O
events O
are O
currently O
unknown O
. O
A O
causal O
relationship O
has O
not O
been O
established O
. O

Interactions O
for O
Vitamin B-DRUG
B3 I-DRUG
( O
Niacin B-DRUG
) O
: O
Antihypertensive B-GROUP
Therapy O
: O
Nicotinic B-DRUG
acid I-DRUG
may O
potentiate O
the O
effects O
of O
ganglionic B-GROUP
blocking I-GROUP
agents I-GROUP
and O
vasoactive O
drugs O
resulting O
in O
postural O
hypotension O
. O
Aspirin B-BRAND
: O
Concomitant O
aspirin B-BRAND
may O
decrease O
the O
metabolic O
clearance O
of O
nicotinic B-DRUG
acid I-DRUG
. O
The O
clinical O
relevance O
of O
this O
finding O
is O
unclear O
. O
Other O
: O
Concomitant O
alcohol B-DRUG
or O
hot O
drinks O
may O
increase O
the O
side O
effects O
of O
flushing O
and O
pruritus O
and O
should O
be O
avoided O
at O
the O
time O
of O
drug O
ingestion O
. O

Beta B-GROUP
- I-GROUP
Blockers I-GROUP
: O
In O
controlled O
clinical O
studies O
, O
adrenergic B-GROUP
beta I-GROUP
- I-GROUP
receptor I-GROUP
blockers I-GROUP
have O
been O
frequently O
administered O
concomitantly O
with O
nicardipine B-DRUG
HCl I-DRUG
. O
The O
combination O
is O
well O
tolerated O
. O
Cimetidine B-DRUG
: O
Cimetidine B-DRUG
increases O
nicardipine B-DRUG
HCl I-DRUG
plasma O
levels O
. O
Patients O
receiving O
the O
two O
drugs O
concomitantly O
should O
be O
carefully O
monitored O
. O
Digoxin B-DRUG
: O
Some O
calcium B-GROUP
blockers I-GROUP
may O
increase O
the O
concentration O
of O
digitalis B-GROUP
preparations I-GROUP
in O
the O
blood O
. O
Nicardipine B-DRUG
HCl I-DRUG
usually O
does O
not O
alter O
the O
plasma O
levels O
of O
digoxin B-DRUG
, O
however O
, O
serum O
digoxin B-DRUG
levels O
should O
be O
evaluated O
after O
concomitant O
therapy O
with O
nicardipine B-DRUG
HCl I-DRUG
is O
initiated O
. O
Maalox B-BRAND
* O
Coadministration O
of O
Maalox B-BRAND
TC I-BRAND
had O
no O
effect O
on O
nicardipine B-DRUG
HCl I-DRUG
absorption O
. O
Even O
though O
such O
interactions O
were O
not O
seen O
during O
clinical O
studies O
with O
nicardipine B-DRUG
HCl I-DRUG
, O
an O
increased O
volume O
of O
circulating O
fluids O
might O
be O
required O
if O
such O
an O
interaction O
were O
to O
occur O
. O
Cyclosporine B-DRUG
: O
Concomitant O
administration O
of O
nicardipine B-DRUG
and O
cyclosporine B-DRUG
levels O
. O
Plasma O
concentrations O
of O
cyclosporine B-DRUG
should O
therefore O
be O
closely O
monitored O
, O
and O
its O
dosage O
reduced O
accordingly O
, O
in O
patients O
treated O
with O
nicardipine B-DRUG
. O
When O
therapeutic O
concentrations O
of O
furosemide B-DRUG
, O
propranolol B-DRUG
, O
dipyridamole B-DRUG
, O
warfarin B-DRUG
, O
quinidine B-DRUG
, O
or O
naproxen B-DRUG
were O
added O
to O
human O
plasma O
( O
in O
vitro O
) O
, O
the O
plasma O
protein O
binding O
of O
nicardipine B-DRUG
HCl I-DRUG
was O
not O
altered O
. O

Physiological O
changes O
resulting O
from O
smoking O
cessation O
, O
with O
or O
without O
nicotine B-DRUG
replacement O
, O
may O
alter O
the O
pharmacokinetics O
of O
certain O
concomitant O
medications O
, O
such O
as O
tricyclic B-GROUP
antidepressants I-GROUP
and O
theophylline B-DRUG
. O
Doses O
of O
these O
and O
perhaps O
other O
medications O
may O
need O
to O
be O
adjusted O
in O
patients O
who O
successfully O
quit O
smoking O
. O

Beta B-GROUP
- I-GROUP
adrenergic I-GROUP
Blocking I-GROUP
Agents I-GROUP
: O
Experience O
in O
over O
1400 O
patients O
in O
a O
non O
- O
comparative O
clinical O
trial O
has O
shown O
that O
concomitant O
administration O
of O
nifedipine B-DRUG
and O
beta B-GROUP
- I-GROUP
blocking I-GROUP
agents I-GROUP
is O
usually O
well O
tolerated O
, O
but O
there O
have O
been O
occasional O
literature O
reports O
suggesting O
that O
the O
combination O
may O
increase O
the O
likelihood O
of O
congestive O
heart O
failure O
, O
severe O
hypotension O
or O
exacerbation O
of O
angina O
. O
Long O
Acting O
Nitrates B-GROUP
: O
Nifedipine B-DRUG
may O
be O
safely O
co O
- O
administered O
with O
nitrates B-GROUP
, O
but O
there O
have O
been O
no O
controlled O
studies O
to O
evaluate O
the O
antianginal O
effectiveness O
of O
this O
combination O
. O
Digitalis B-GROUP
: O
Immediate O
Release O
Capsules O
: O
Since O
there O
have O
been O
isolated O
reports O
of O
patients O
with O
elevated O
digoxin B-DRUG
levels O
, O
and O
there O
is O
a O
possible O
interaction O
between O
digoxin B-DRUG
and O
nifedipine B-DRUG
, O
it O
is O
recommended O
that O
digoxin B-DRUG
levels O
be O
monitored O
when O
initiating O
, O
adjusting O
, O
and O
discontinuing O
nifedipine B-DRUG
to O
avoid O
possible O
over O
- O
or O
under O
- O
digitalization O
. O
Extended O
Release O
Tablets O
: O
Administration O
of O
nifedipine B-DRUG
with O
digoxin B-DRUG
increased O
digoxin B-DRUG
levels O
in O
9 O
of O
12 O
normal O
volunteers O
. O
The O
average O
increase O
was O
45 O
% O
. O
Another O
investigator O
found O
no O
increase O
in O
digoxin B-DRUG
levels O
in O
13 O
patients O
with O
coronary O
artery O
disease O
. O
In O
an O
uncontrolled O
study O
of O
over O
200 O
patients O
with O
congestive O
heart O
failure O
during O
which O
digoxin B-DRUG
blood O
levels O
were O
not O
measured O
, O
digitalis O
toxicity O
was O
not O
observed O
. O
Since O
there O
have O
been O
isolated O
reports O
of O
patients O
with O
elevated O
digoxin B-DRUG
levels O
, O
it O
is O
recommended O
that O
digoxin B-DRUG
levels O
be O
monitored O
when O
initiating O
, O
adjusting O
, O
and O
discontinuing O
nifedipine B-DRUG
to O
avoid O
possible O
over O
- O
or O
under O
- O
digitalization O
. O
Quinidine B-DRUG
: O
Immediate O
Release O
Capsules O
: O
There O
have O
been O
rare O
reports O
of O
an O
interaction O
between O
quinidine B-DRUG
and O
nifedipine B-DRUG
( O
with O
a O
decreased O
plasma O
level O
of O
quinidine B-DRUG
) O
. O
Coumarin B-GROUP
Anticoagulants I-GROUP
: O
There O
have O
been O
rare O
reports O
of O
increased O
prothrombin O
time O
in O
patients O
taking O
coumarin B-GROUP
anticoagulants I-GROUP
to O
whom O
nifedipine B-DRUG
was O
administered O
. O
However O
, O
the O
relationship O
to O
nifedipine B-DRUG
therapy O
is O
uncertain O
. O
Cimetidine B-DRUG
: O
A O
study O
in O
6 O
healthy O
volunteers O
has O
shown O
a O
significant O
increase O
in O
peak O
nifedipine B-DRUG
plasma O
levels O
( O
80 O
% O
) O
and O
area O
- O
under O
- O
the O
- O
curve O
( O
74 O
% O
) O
after O
a O
1 O
week O
course O
of O
cimetidine B-DRUG
at O
1000 O
mg O
per O
day O
and O
nifedipine B-DRUG
at O
40 O
mg O
per O
day O
. O
Ranitidine B-DRUG
produced O
smaller O

, O
non O
- O
significant O
increases O
. O
The O
effect O
may O
be O
mediated O
by O
the O
known O
inhibition O
of O
cimetidine B-DRUG
on O
hepatic O
cytochrome O
P O
- O
450 O
, O
the O
enzyme O
system O
probably O
responsible O
for O
the O
first O
- O
pass O
metabolism O
of O
nifedipine B-DRUG
. O
If O
nifedipine B-DRUG
therapy O
is O
initiated O
in O
a O
patient O
currently O
receiving O
cimetidine B-DRUG
, O
cautious O
titration O
is O
advised O
. O

In O
vitro O
, O
nilutamide B-DRUG
has O
been O
shown O
to O
inhibit O
the O
activity O
of O
liver O
cytochrome O
P O
- O
450 O
isoenzymes O
and O
therefore O
, O
may O
reduce O
the O
metabolism O
of O
compounds O
requiring O
these O
systems O
. O
Consequently O
, O
drugs O
with O
a O
low O
therapeutic O
margin O
, O
such O
as O
vitamin B-GROUP
K I-GROUP
antagonists I-GROUP
, O
phenytoin B-DRUG
, O
and O
theophylline B-DRUG
, O
could O
have O
a O
delayed O
elimination O
and O
increases O
in O
their O
serum O
half O
- O
life O
leading O
to O
a O
toxic O
level O
. O
The O
dosage O
of O
these O
drugs O
or O
others O
with O
a O
similar O
metabolism O
may O
need O
to O
be O
modified O
if O
they O
are O
administered O
concomitantly O
with O
nilutamide B-DRUG
. O
For O
example O
, O
when O
vitamin B-GROUP
K I-GROUP
antagonists I-GROUP
are O
administered O
concomitantly O
with O
nilutamide B-DRUG
, O
prothrombin O
time O
should O
be O
carefully O
monitored O
and O
if O
necessary O
, O
the O
dosage O
of O
vitamin B-GROUP
K I-GROUP
antagonists I-GROUP
should O
be O
reduced O
. O

It O
is O
possible O
that O
the O
cardiovascular O
action O
of O
other O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
could O
be O
enhanced O
by O
the O
addition O
of O
Nimotop B-BRAND
. O
In O
Europe O
, O
Nimotop B-BRAND
was O
observed O
to O
occasionally O
intensify O
the O
effect O
of O
antihypertensive B-GROUP
compounds I-GROUP
taken O
concomitantly O
by O
patients O
suffering O
from O
hypertension O
; O
this O
phenomenon O
was O
not O
observed O
in O
North O
American O
clinical O
trials O
. O
A O
study O
in O
eight O
healthy O
volunteers O
has O
shown O
a O
50 O
% O
increase O
in O
mean O
peak O
nimodipine B-DRUG
plasma O
concentrations O
and O
a O
90 O
% O
increase O
in O
mean O
area O
under O
the O
curve O
, O
after O
a O
one O
week O
course O
of O
cimetidine B-DRUG
at O
1 O
, O
000 O
mg O
/ O
day O
and O
nimodipine B-DRUG
at O
90 O
mg O
/ O
day O
. O
This O
effect O
may O
be O
mediated O
by O
the O
known O
inhibition O
of O
hepatic O
cytochrome O
P O
- O
450 O
by O
cimetidine B-DRUG
, O
which O
could O
decrease O
first O
pass O
metabolism O
of O
nimodipine B-DRUG
. O

A O
30 O
to O
45 O
% O
increase O
in O
AUC O
and O
Cmax O
of O
nisoldipine B-DRUG
was O
observed O
with O
concomitant O
administration O
of O
cimetidine B-DRUG
400 I-DRUG
mg I-DRUG
twice O
daily O
. O
Ranitidine B-DRUG
150 O
mg O
twice O
daily O
did O
not O
interact O
significantly O
with O
nisoldipine B-DRUG
( O
AUC O
was O
decreased O
by O
15 O
- O
20 O
% O
) O
. O
No O
pharmacodynamic O
effects O
of O
either O
histamine B-GROUP
H2 I-GROUP
receptor I-GROUP
antagonist I-GROUP
were O
observed O
. O
Coadministration O
of O
phenytoin B-DRUG
with O
40 O
mg O
SULAR B-BRAND
tablets O
in O
epileptic O
patients O
lowered O
the O
nisoldipine B-DRUG
plasma O
concentrations O
to O
undetectable O
levels O
. O
Coadministration O
of O
SULAR B-BRAND
with O
phenytoin B-DRUG
or O
any O
known O
CYP3A4 O
inducer O
should O
be O
avoided O
and O
alternative O
antihypertensive B-GROUP
therapy O
should O
be O
considered O
. O
Pharmacokinetic O
interactions O
between O
nisoldipine B-DRUG
and O
beta B-GROUP
- I-GROUP
blockers I-GROUP
( O
atenolol B-DRUG
, O
propranolol B-DRUG
) O
were O
variable O
and O
not O
significant O
. O
Propranolol B-DRUG
attenuated O
the O
heart O
rate O
increase O
following O
administration O
of O
immediate O
release O
nisoldipine B-DRUG
. O
The O
blood O
pressure O
effect O
of O
SULAR B-BRAND
tended O
to O
be O
greater O
in O
patients O
on O
atenolol B-DRUG
than O
in O
patients O
on O
no O
other O
antihypertensive B-GROUP
therapy O
. O
Quinidine B-DRUG
at O
648 O
mg O
bid O
decreased O
the O
bioavailability O
( O
AUC O
) O
of O
nisoldipine B-DRUG
by O
26 O
% O
, O
but O
not O
the O
peak O
concentration O
. O
The O
immediate O
release O
, O
but O
not O
the O
coat O
- O
core O
formulation O
of O
nisoldipine B-DRUG
increased O
plasma O
quinidine B-DRUG
concentrations O
by O
about O
20 O
% O
. O
This O
interaction O
was O
not O
accompanied O
by O
ECG O
changes O
and O
its O
clinical O
significance O
is O
not O
known O
. O
No O
significant O
interactions O
were O
found O
between O
nisoldipine B-DRUG
and O
warfarin B-DRUG
or O
digoxin B-DRUG
. O

Tizoxanide B-DRUG
is O
highly O
bound O
to O
plasma O
protein O
( O
99 O
. O
9 O
% O
) O
. O
Therefore O
, O
caution O
should O
be O
used O
when O
administering O
nitazoxanide B-DRUG
concurrently O
with O
other O
highly O
plasma O
protein O
- O
bound O
drugs O
with O
narrow O
therapeutic O
indices O
, O
as O
competition O
for O
binding O
sites O
may O
occur O
( O
e O
. O
g O
. O
, O
warfarin B-DRUG
) O
. O
In O
vitro O
metabolism O
studies O
have O
demonstrated O
that O
tizoxanide B-DRUG
has O
no O
significant O
inhibitory O
effect O
on O
cytochrome O
P450 O
enzymes O
. O
Although O
no O
drug O
- O
drug O
interaction O
studies O
have O
been O
conducted O
in O
vivo O
, O
it O
is O
expected O
that O
no O
significant O
interaction O
would O
occur O
when O
nitazoxanide B-DRUG
is O
co O
- O
administered O
with O
drugs O
that O
either O
are O
metabolized O
by O
or O
inhibit O
cytochrome O
P450 O
enzymes O
. O

No O
formal O
drug O
- O
interaction O
studies O
have O
been O
performed O
, O
and O
a O
clinically O
significant O
interaction O
with O
other O
medications O
used O
in O
the O
treatment O
of O
hypoxic O
respiratory O
failure O
cannot O
be O
excluded O
based O
on O
the O
available O
data O
. O
INOmax B-BRAND
has O
been O
administered O
with O
tolazoline B-DRUG
, O
dopamine B-DRUG
, O
dobutamine B-DRUG
, O
steroids B-GROUP
, O
surfactant B-DRUG
, O
and O
high O
- O
frequency O
ventilation O
. O
Although O
there O
are O
no O
study O
data O
to O
evaluate O
the O
possibility O
, O
nitric B-GROUP
oxide I-GROUP
donor I-GROUP
compounds I-GROUP
, O
including O
sodium B-DRUG
nitroprusside I-DRUG
and O
nitroglycerin B-DRUG
, O
may O
have O
an O
additive O
effect O
with O
INOmax B-BRAND
on O
the O
risk O
of O
developing O
methemoglobinemia O
. O
An O
association O
between O
prilocaine B-DRUG
and O
an O
increased O
risk O
of O
methaemoglobinaemia O
, O
particularly O
in O
infants O
, O
has O
specifically O
been O
described O
in O
a O
literature O
case O
report O
. O
This O
risk O
is O
present O
whether O
the O
drugs O
are O
administered O
as O
oral O
, O
parenteral O
, O
or O
topical O
formulations O
. O

Antacids B-GROUP
containing O
magnesium B-DRUG
trisilicate I-DRUG
, O
when O
administered O
concomitantly O
with O
nitrofurantoin B-DRUG
, O
reduce O
both O
the O
rate O
and O
extent O
of O
absorption O
. O
The O
mechanism O
for O
this O
interaction O
probably O
is O
adsorption O
of O
nitrofurantoin B-DRUG
onto O
the O
surface O
of O
magnesium B-DRUG
trisilicate I-DRUG
. O
Uricosuric B-GROUP
drugs I-GROUP
, O
such O
as O
probenecid B-DRUG
and O
sulfinpyrazone B-DRUG
, O
can O
inhibit O
renal O
tubular O
secretion O
of O
nitrofurantoin B-DRUG
. O
The O
resulting O
increase O
in O
nitrofurantoin B-DRUG
serum O
levels O
may O
increase O
toxicity O
, O
and O
the O
decreased O
urinary O
levels O
could O
lessen O
its O
efficacy O
as O
a O
urinary O
tract O
antibacterial B-GROUP
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
As O
a O
result O
of O
the O
presence O
of O
nitrofurantoin B-DRUG
, O
a O
false O
- O
positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
. O
This O
has O
been O
observed O
with O
Benedict O
s O
and O
Fehling O
s O
solutions O
but O
not O
with O
the O
glucose O
enzymatic O
test O
. O

The O
vasodilating O
effects O
of O
nitroglycerin B-DRUG
may O
be O
additive O
with O
those O
of O
other O
vasodilators B-GROUP
. O
Alcohol B-DRUG
, O
in O
particular O
, O
has O
been O
found O
to O
exhibit O
additive O
effects O
of O
this O
variety O
. O
Marked O
symptomatic O
orthostatic O
hypotension O
has O
been O
reported O
when O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
and O
organic O
nitrates B-GROUP
were O
used O
in O
combination O
. O
Dose O
adjustments O
of O
either O
class O
of O
agents O
may O
be O
necessary O
. O

The O
hypotensive O
effect O
of O
sodium B-DRUG
nitroprusside I-DRUG
is O
augmented O
by O
that O
of O
most O
other O
hypotensive B-GROUP
drugs I-GROUP
, O
including O
ganglionic B-GROUP
blocking I-GROUP
agents I-GROUP
, O
negative O
inotropic O
agents O
, O
and O
inhaled O
anesthetics B-GROUP
. O

No O
interactions O
have O
been O
observed O
between O
nizatidine B-DRUG
and O
theophylline B-DRUG
, O
chlordiazepoxide B-DRUG
, O
lorazepam B-DRUG
, O
lidocaine B-DRUG
, O
phenytoin B-DRUG
, O
and O
warfarin B-DRUG
. O
Nizatidine B-DRUG
does O
not O
inhibit O
the O
cytochrome O
P O
- O
450 O
- O
linked O
drug O
- O
metabolizing O
enzyme O
system O
; O
therefore O
, O
drug O
interactions O
mediated O
by O
inhibition O
of O
hepatic O
metabolism O
are O
not O
expected O
to O
occur O
. O
In O
patients O
given O
very O
high O
doses O
( O
3900 O
mg O
) O
of O
aspirin B-BRAND
daily O
, O
increases O
in O
serum O
salicylate B-GROUP
levels O
were O
seen O
when O
nizatidine B-DRUG
, O
150 O
mg O
b O
. O
i O
. O
d O
. O
, O
was O
administered O
concurrently O
. O

The O
effectiveness O
of O
progestin B-GROUP
- O
only O
pills O
is O
reduced O
by O
hepatic O
enzyme O
- O
inducing O
drugs O
such O
as O
the O
anticonvulsants B-GROUP
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
and O
barbiturates B-GROUP
, O
and O
the O
antituberculosis B-GROUP
drug I-GROUP
rifampin B-DRUG
. O
No O
significant O
interaction O
has O
been O
found O
with O
broad O
- O
spectrum O
antibiotics B-GROUP
. O

Elevated O
plasma O
levels O
of O
theophylline B-DRUG
have O
been O
reported O
with O
concomitant O
quinolone B-GROUP
use O
. O
There O
have O
been O
reports O
of O
theophylline B-DRUG
- O
related O
side O
effects O
in O
patients O
on O
concomitant O
therapy O
with O
norfloxacin B-DRUG
and O
theophylline B-DRUG
. O
Therefore O
, O
monitoring O
of O
theophylline B-DRUG
plasma O
levels O
should O
be O
considered O
and O
dosage O
of O
theophylline B-DRUG
adjusted O
as O
required O
. O
Elevated O
serum O
levels O
of O
cyclosporine B-DRUG
have O
been O
reported O
with O
concomitant O
use O
of O
cyclosporine B-DRUG
with O
norfloxacin B-DRUG
. O
Therefore O
, O
cyclosporine B-DRUG
serum O
levels O
should O
be O
monitored O
and O
appropriate O
cyclosporine B-DRUG
dosage O
adjustments O
made O
when O
these O
drugs O
are O
used O
concomitantly O
. O
Quinolones B-GROUP
, O
including O
norfloxacin B-DRUG
, O
may O
enhance O
the O
effects O
of O
oral O
anticoagulants B-GROUP
, O
including O
warfarin B-DRUG
or O
its O
derivatives O
or O
similar O
agents O
. O
When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
time O
or O
other O
suitable O
coagulation O
tests O
should O
be O
closely O
monitored O
. O
The O
concomitant O
administration O
of O
quinolones B-GROUP
including O
norfloxacin B-DRUG
with O
glyburide B-DRUG
( O
a O
sulfonylurea B-GROUP
agent I-GROUP
) O
has O
, O
on O
rare O
occasions O
, O
resulted O
in O
severe O
hypoglycemia O
. O
Therefore O
, O
monitoring O
of O
blood O
glucose O
is O
recommended O
when O
these O
agents O
are O
co O
- O
administered O
. O
Diminished O
urinary O
excretion O
of O
norfloxacin B-DRUG
has O
been O
reported O
during O
the O
concomitant O
administration O
of O
probenecid B-DRUG
and O
norfloxacin B-DRUG
. O
The O
concomitant O
use O
of O
nitrofurantoin B-DRUG
is O
not O
recommended O
since O
nitrofurantoin B-DRUG
may O
antagonize O
the O
antibacterial O
effect O
of O
Norfloxacin B-DRUG
in O
the O
urinary O
tract O
. O
Multivitamins B-GROUP
, O
or O
other O
products O
containing O
iron B-DRUG
or O
zinc B-DRUG
, O
antacids B-GROUP
or O
sucralfate B-DRUG
should O
not O
be O
administered O
concomitantly O
with O
, O
or O
within O
2 O
hours O
of O
, O
the O
administration O
of O
norfloxacin B-DRUG
, O
because O
they O
may O
interfere O
with O
absorption O
resulting O
in O
lower O
serum O
and O
urine O
levels O
of O
norfloxacin B-DRUG
. O
Videx B-BRAND
( O
Didanosine B-DRUG
) O
chewable O
/ O
buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
should O
not O
be O
administered O
concomitantly O
with O
, O
or O
within O
2 O
hours O
of O
, O
the O
administration O
of O
norfloxacin B-DRUG
, O
because O
these O
products O
may O
interfere O
with O
absorption O
resulting O
in O
lower O
serum O
and O
urine O
levels O
of O
norfloxacin B-DRUG
. O
Some O
quinolones B-GROUP
have O
also O
been O
shown O
to O
interfere O
with O
the O
metabolism O
of O

caffeine B-DRUG
. O
This O
may O
lead O
to O
reduced O
clearance O
of O
caffeine B-DRUG
and O
a O
prolongation O
of O
its O
plasma O
half O
- O
life O
. O

Reduced O
efficacy O
and O
increased O
incidence O
of O
breakthrough O
bleeding O
and O
menstrual O
irregularities O
have O
been O
associated O
with O
concomitant O
use O
of O
rifampin B-DRUG
. O
A O
similar O
association O
, O
though O
less O
marked O
, O
has O
been O
suggested O
with O
barbiturates B-GROUP
, O
phenylbutazone B-DRUG
, O
phenytoin B-DRUG
sodium I-DRUG
, O
carbamazepine B-DRUG
, O
griseofulvin B-DRUG
, O
topiramate B-DRUG
, O
and O
possibly O
with O
ampicillin B-DRUG
and O
tetracyclines B-GROUP
72 O
. O
A O
possible O
interaction O
has O
been O
suggested O
with O
hormonal B-GROUP
contraceptives I-GROUP
and O
the O
herbal O
supplement O
St O
. O
Johns O
Wort O
based O
on O
some O
reports O
of O
oral O
contraceptive B-GROUP
users O
experiencing O
breakthrough O
bleeding O
shortly O
after O
starting O
St O
. O
Johns O
Wort O
. O
Pregnancies O
have O
been O
reported O
by O
users O
of O
combined B-GROUP
hormonal I-GROUP
contraceptives I-GROUP
who O
also O
used O
some O
form O
of O
St O
. O
Johns O
Wort O
. O
Healthcare O
prescribers O
are O
advised O
to O
consult O
the O
package O
inserts O
of O
medication O
administered O
concomitantly O
with O
oral O
contraceptives B-GROUP
. O

Steady O
- O
state O
serum O
concentrations O
of O
tricyclic B-GROUP
antidepressants I-GROUP
are O
reported O
to O
fluctuate O
significantly O
when O
cimetidine B-DRUG
is O
either O
added O
or O
deleted O
from O
the O
drug O
regimen O
. O
Serious O
anticholinergic O
symptoms O
( O
severe O
dry O
mouth O
, O
urinary O
retention O
, O
blurred O
vision O
) O
have O
been O
associated O
with O
elevations O
in O
the O
serum O
levels O
of O
tricyclic B-GROUP
antidepressants I-GROUP
when O
cimetidine B-DRUG
is O
added O
to O
the O
drug O
regimen O
. O
In O
addition O
, O
higher O
- O
than O
expected O
steady O
- O
state O
serum O
concentrations O
of O
tricyclic B-GROUP
antidepressants I-GROUP
have O
been O
observed O
when O
therapy O
is O
initiated O
in O
patients O
already O
taking O
cimetidine B-DRUG
. O
In O
well O
- O
controlled O
patients O
undergoing O
concurrent O
therapy O
with O
cimetidine B-DRUG
, O
a O
decrease O
in O
the O
steady O
- O
state O
serum O
concentrations O
of O
tricyclic B-GROUP
antidepressants I-GROUP
may O
occur O
when O
cime O
- O
tidine O
therapy O
is O
discontinued O
. O
The O
therapeutic O
efficacy O
of O
tricyclic B-GROUP
antidepressants I-GROUP
may O
be O
compromised O
in O
these O
patients O
when O
cimetidine B-DRUG
is O
discontinued O
. O
Several O
of O
the O
tricyclic B-GROUP
antidepressants I-GROUP
have O
been O
cited O
in O
these O
reports O
. O
There O
have O
been O
greater O
than O
2 O
- O
fold O
increases O
in O
previously O
stable O
plasma O
levels O
of O
other O
antidepressants B-GROUP
, O
including O
nortriptyline B-DRUG
, O
when O
fluoxetine B-DRUG
hydrochloride I-DRUG
has O
been O
administered O
in O
combination O
with O
these O
agents O
. O
Fluoxetine B-DRUG
and O
its O
active O
metabolite O
, O
norfluoxe O
- O
tine O
, O
have O
long O
half O
- O
lives O
( O
4 O
to O
16 O
days O
for O
norfluoxetine B-DRUG_N
) O
, O
that O
may O
affect O
strategies O
during O
conversion O
from O
one O
drug O
to O
the O
other O
. O
Administration O
of O
reserpine B-DRUG
during O
therapy O
with O
a O
tricyclic B-GROUP
antidepressant I-GROUP
has O
been O
shown O
to O
produce O
a O
stimulating O
effect O
in O
some O
depressed O
patients O
. O
Close O
supervision O
and O
careful O
adjustment O
of O
the O
dosage O
are O
required O
when O
nortriptyline B-DRUG
hydrochloride I-DRUG
is O
used O
with O
other O
anticholinergic B-GROUP
drugs I-GROUP
or O
sympathomimetic B-GROUP
drugs I-GROUP
. O
The O
patient O
should O
be O
informed O
that O
the O
response O
to O
alcohol B-DRUG
may O
be O
exaggerated O
. O
Drugs O
Metabolized O
by O
P450IID6 O
A O
subset O
( O
3 O
% O
to O
10 O
% O
) O
of O
the O
population O
has O
reduced O
activity O
of O
certain O
drug O
metabolizing O
enzymes O
such O
as O
the O
cytochrome O
P450 O
isoenzyme O
P450IID6 O
. O
Such O
individuals O
are O
referred O
to O
as O
poor O
metabolizers O
of O
drugs O
such O
as O
debrisoquin B-DRUG
, O
dextromethorphan B-DRUG
, O
and O
the O
tricyclic B-GROUP
antidepressants I-GROUP
. O
These O
individuals O
may O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-GROUP
antidepressants I-GROUP
when O
given O
usual O
doses O
. O
In O

addition O
, O
certain O
drugs O
that O
are O
metabolized O
by O
this O
isoenzyme O
, O
including O
many O
antidepressants B-GROUP
( O
tricyclic B-GROUP
antidepressants I-GROUP
, O
selective B-GROUP
serotonin I-GROUP
reuptake I-GROUP
inhibitors I-GROUP
, O
and O
others O
) O
, O
may O
inhibit O
the O
activity O
of O
this O
isoenzyme O
, O
and O
thus O
may O
make O
normal O
metab O
- O
olizers O
resemble O
poor O
metabolizers O
with O
regard O
to O
concomitant O
therapy O
with O
other O
drugs O
metabolized O
by O
this O
enzyme O
system O
, O
leading O
to O
drug O
interactions O
. O
Concomitant O
use O
of O
tricyclic B-GROUP
antidepressants I-GROUP
with O
other O
drugs O
metabolized O
by O
cytochrome O
P450IID6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-GROUP
antidepressant I-GROUP
or O
the O
other O
drug O
. O
Therefore O
, O
co O
- O
administration O
of O
tricyclic B-GROUP
antidepressants I-GROUP
with O
other O
drugs O
that O
are O
metabolized O
by O
this O
isoenzyme O
, O
including O
other O
antidepressants B-GROUP
, O
phenothiazines B-GROUP
, O
carbamazepine B-DRUG
, O
and O
Type B-GROUP
1C I-GROUP
antiarrhythmics I-GROUP
( O
eg O
, O
propafenone B-DRUG
, O
flecainide B-DRUG
, O
and O
encainide B-DRUG
) O
, O
or O
that O
inhibit O
this O
enzyme O
( O
eg O
, O
quinidine B-DRUG
) O
, O
should O
be O
approached O
with O
caution O
. O

Oxcarbazepine B-DRUG
can O
inhibit O
CYP2C19 O
and O
induce O
CYP3A4 O
/ O
5 O
with O
potentially O
important O
effects O
on O
plasma O
concentrations O
of O
other O
drugs O
. O
In O
addition O
, O
several O
AED B-GROUP
s O
that O
are O
cytochrome O
P450 O
inducers O
can O
decrease O
plasma O
concentrations O
of O
oxcarbazepine B-DRUG
and O
MHD B-DRUG_N
. O
Oxcarbazepine B-DRUG
was O
evaluated O
in O
human O
liver O
microsomes O
to O
determine O
its O
capacity O
to O
inhibit O
the O
major O
cytochrome O
P450 O
enzymes O
responsible O
for O
the O
metabolism O
of O
other O
drugs O
. O
Results O
demonstrate O
that O
oxcarbazepine B-DRUG
and O
its O
pharmacologically O
active O
10 O
- O
monohydroxy O
metabolite O
( O
MHD B-DRUG_N
) O
have O
little O
or O
no O
capacity O
to O
function O
as O
inhibitors O
for O
most O
of O
the O
human O
cytochrome O
P450 O
enzymes O
evaluated O
( O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C9 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
CYP4A9 O
and O
CYP4A11 O
) O
with O
the O
exception O
of O
CYP2C19 O
and O
CYP3A4 O
/ O
5 O
. O
Although O
inhibition O
of O
CYP O
3A4 O
/ O
5 O
by O
OXC B-DRUG
and O
MHD B-DRUG_N
did O
occur O
at O
high O
concentrations O
, O
it O
is O
not O
likely O
to O
be O
of O
clinical O
significance O
. O
The O
inhibition O
of O
CYP O
- O
2C19 O
by O
OXC B-DRUG
and O
MHD B-DRUG_N
, O
however O
, O
is O
clinically O
relevant O
. O
In O
vitro O
, O
the O
UDP O
- O
glucuronyl O
transferase O
level O
was O
increased O
, O
indicating O
induction O
of O
this O
enzyme O
. O
Increases O
of O
22 O
% O
with O
MHD B-DRUG_N
and O
47 O
% O
with O
oxcarbazepine B-DRUG
were O
observed O
. O
As O
MHD B-DRUG_N
, O
the O
predominant O
plasma O
substrate O
, O
is O
only O
a O
weak O
inducer O
of O
UDP O
- O
glucuronyl O
transferase O
, O
it O
is O
unlikely O
to O
have O
an O
effect O
on O
drugs O
that O
are O
mainly O
eliminated O
by O
conjugation O
through O
UDP O
- O
glucuronyl O
transferase O
( O
e O
. O
g O
. O
, O
valproic B-DRUG
acid I-DRUG
, O
lamotrigine B-DRUG
) O
. O
In O
addition O
, O
oxcarbazepine B-DRUG
and O
MHD B-DRUG_N
induce O
a O
subgroup O
of O
the O
cytochrome O
P450 O
3A O
family O
( O
CYP3A4 O
and O
CYP3A5 O
) O
responsible O
for O
the O
metabolism O
of O
dihydropyridine B-GROUP
calcium I-GROUP
antagonists I-GROUP
and O
oral O
contraceptives B-GROUP
, O
resulting O
in O
a O
lower O
plasma O
concentration O
of O
these O
drugs O
. O
As O
binding O
of O
MHD B-DRUG_N
to O
plasma O
proteins O
is O
low O
( O
40 O
% O
) O
, O
clinically O
significant O
interactions O
with O
other O
drugs O
through O
competition O
for O
protein O
binding O
sites O
are O
unlikely O
. O
Antiepileptic B-GROUP
drugs I-GROUP
: O

Potential O
interactions O
between O
Trileptal B-BRAND
and O
other O
AEDs B-GROUP
were O
assessed O
in O
clinical O
studies O
. O
The O
effect O
of O
these O
interactions O
on O
mean O
AUCs O
and O
Cmin O
are O
summarized O
in O
Table O
2 O
: O
Table O
2 O
: O
Summary O
of O
AED O
interactions O
with O
Trileptal B-BRAND
AED B-GROUP
Co O
- O
administered O
Dose O
of O
AED B-GROUP
( O
mg O
/ O
day O
) O
Trileptal B-BRAND
dose O
( O
mg O
/ O
day O
) O
Influence O
of O
Trileptal B-BRAND
on O
AED B-GROUP
Concentration O
( O
Mean O
change O
, O
90 O
% O
Confidence O
Interval O
) O
Influence O
of O
AED B-GROUP
On O
MHD B-DRUG_N
Concentration O
( O
Mean O
change O
, O
90 O
% O
Confidence O
Interval O
) O
Carbamazepine B-DRUG
400 O
- O
2000 O
900 O
nc1 O
40 O
% O
decrease O
[ O
CI O
: O
17 O
% O
decrease O
, O
57 O
% O
decrease O
] O
Phenobarbital B-DRUG
100 O
- O
150 O
600 O
- O
1800 O
14 O
% O
increase O
[ O
CI O
: O
2 O
% O
increase O
, O
24 O
% O
increase O
] O
25 O
% O
decrease O
[ O
CI O
: O
12 O
% O
decrease O
, O
51 O
% O
decrease O
] O
Phenytoin B-DRUG
250 O
- O
500 O
600 O
- O
1800 O
nc1 O
, O
2 O
30 O
% O
decrease O
[ O
CI O
: O
3 O
% O
decrease O
, O
48 O
% O
decrease O
] O
1200 O
- O
2400 O
up O
to O
40 O
% O
increase3 O
[ O
CI O
: O
12 O
% O
increase O
, O
60 O
% O
increase O
] O
Valproic B-DRUG
acid I-DRUG
400 O
- O
2800 O
600 O
- O
1800 O
nc1 O
18 O
% O
decrease O
[ O
CI O
: O
13 O
% O
decrease O
, O
40 O
% O
decrease O
] O
1 O
- O
nc O
denotes O
a O
mean O
change O
of O
less O
than O
10 O
% O
2 O
- O
Pediatrics O
3 O
- O
Mean O
increase O
in O
adults O
at O
high O
Trileptal B-BRAND
doses O
In O
vivo O
, O
the O
plasma O
levels O
of O
phenytoin B-DRUG
increased O
by O
up O
to O
40 O
% O
, O
when O
Trileptal B-BRAND
was O
given O
at O
doses O
above O
1200 O
mg O
/ O
day O
. O
Therefore O
, O
when O
using O
doses O
of O
Trileptal B-BRAND
greater O
than O
1200 O
mg O
/ O
day O
during O
adjunctive O
therapy O
, O
a O
decrease O
in O
the O
dose O
of O
phenytoin B-DRUG
may O
be O
required O
. O
The O
increase O
of O
phenobarbital B-DRUG
level O
, O
however O
, O
is O
small O
( O
15 O
% O
) O
when O
given O
with O
Trileptal B-BRAND
. O
Strong O
inducers O
of O
cytochrome O
P450 O
enzymes O
( O
i O
. O
e O
. O
carbamazepine B-DRUG
, O
phenytoin B-DRUG
and O
phenobarbital B-DRUG
) O
have O
been O
shown O
to O
decrease O
the O
plasma O
levels O
of O
MHD B-DRUG_N
( O
29 O
- O
40 O
% O
) O
. O
No O
autoinduction O
has O
been O
observed O
with O
Trileptal B-BRAND
. O
Hormonal O
contraceptives B-GROUP
Co O
- O
administration O
of O
Trileptal B-BRAND
with O
an O
oral O
contraceptive B-GROUP
has O
been O
shown O
to O
influence O
the O
plasma O
concentrations O
of O
the O
two O

hormonal O
components O
, O
ethinylestradiol B-DRUG
( O
EE O
) O
and O
levonorgestrel B-DRUG
( O
LNG O
) O
. O
The O
mean O
AUC O
values O
of O
EE O
were O
decreased O
by O
48 O
% O
[ O
90 O
% O
CI O
: O
22 O
- O
65 O
] O
in O
one O
study O
and O
52 O
% O
[ O
90 O
% O
CI O
: O
38 O
- O
52 O
] O
in O
another O
study O
[ O
1 O
, O
2 O
] O
. O
The O
mean O
AUC O
values O
of O
LNG O
were O
decreased O
by O
32 O
% O
[ O
90 O
% O
CI O
: O
20 O
- O
45 O
] O
in O
one O
study O
and O
52 O
% O
[ O
90 O
% O
CI O
: O
42 O
- O
52 O
] O
in O
another O
study O
. O
Therefore O
, O
concurrent O
use O
of O
Trileptal B-BRAND
with O
hormonal B-GROUP
contraceptives I-GROUP
may O
render O
these O
contraceptives B-GROUP
less O
effective O
. O
Studies O
with O
other O
oral O
or O
implant O
contraceptives B-GROUP
have O
not O
been O
conducted O
. O
Calcium B-GROUP
Antagonists I-GROUP
: O
After O
repeated O
co O
- O
administration O
of O
Trileptal B-BRAND
, O
the O
AUC O
of O
felodipine B-DRUG
was O
lowered O
by O
28 O
% O
[ O
90 O
% O
CI O
: O
20 O
- O
33 O
] O
. O
Verapamil B-DRUG
produced O
a O
decrease O
of O
20 O
% O
[ O
90 O
% O
CI O
: O
18 O
- O
27 O
] O
of O
the O
plasma O
levels O
of O
MHD B-DRUG_N
. O
Other O
drug O
interactions O
Cimetidine B-DRUG
, O
erythromycin B-DRUG
and O
dextropropoxyphene B-DRUG
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
MHD B-DRUG_N
. O
Results O
with O
warfarin B-DRUG
wshow O
no O
evidence O
of O
interaction O
with O
either O
single O
or O
repeated O
doses O
of O
Trileptal B-BRAND
. O

In O
a O
Phase O
I O
trial O
using O
escalating O
doses O
of O
TAXOL B-BRAND
( O
110 O
- O
200 O
mg O
/ O
m2 O
) O
and O
cisplatin B-DRUG
( O
50 O
or O
75 O
mg O
/ O
m2 O
) O
given O
as O
sequential O
infusions O
, O
myelosuppression O
was O
more O
profound O
when O
TAXOL B-BRAND
was O
given O
after O
cisplatin B-DRUG
than O
with O
the O
alternate O
sequence O
( O
ie O
, O
TAXOL B-BRAND
before O
cisplatin B-DRUG
) O
. O
Pharmacokinetic O
data O
from O
these O
patients O
demonstrated O
a O
decrease O
in O
paclitaxel B-DRUG
clearance O
of O
approximately O
33 O
% O
when O
TAXOL B-BRAND
was O
administered O
following O
cisplatin B-DRUG
. O
The O
metabolism O
of O
TAXOL B-BRAND
is O
catalyzed O
by O
cytochrome O
P450 O
isoen O
- O
zymes O
CYP2C8 O
and O
CYP3A4 O
. O
In O
the O
absence O
of O
formal O
clinical O
drug O
interaction O
studies O
, O
caution O
should O
be O
exercised O
when O
administering O
TAXOL B-BRAND
concomitantly O
with O
known O
substrates O
or O
inhibitors O
of O
the O
cytochrome O
P450 O
isoenzymes O
CYP2C8 O
and O
CYP3A4 O
. O
Potential O
interactions O
between O
TAXOL B-BRAND
, O
a O
substrate O
of O
CYP3A4 O
, O
and O
protease B-GROUP
inhibitors I-GROUP
( O
ritonavir B-DRUG
, O
saquinavir B-DRUG
, O
indinavir B-DRUG
, O
and O
nelfinavir B-DRUG
) O
, O
which O
are O
substrates O
and O
/ O
or O
inhibitors O
of O
CYP3A4 O
, O
have O
not O
been O
evaluated O
in O
clinical O
trials O
. O
Reports O
in O
the O
literature O
suggest O
that O
plasma O
levels O
of O
doxorubicin B-DRUG
( O
and O
its O
active O
metabolite O
doxorubicinol B-DRUG_N
) O
may O
be O
increased O
when O
paclitaxel B-DRUG
and O
doxorubicin B-DRUG
are O
used O
in O
combination O
. O
Hematology O
: O
TAXOL B-BRAND
therapy O
should O
not O
be O
administered O
to O
patients O
with O
baseline O
neutrophil O
counts O
of O
less O
than O
1 O
, O
500 O
cells O
/ O
mm3 O
. O
In O
order O
to O
monitor O
the O
occurrence O
of O
myelotoxicity O
, O
it O
is O
recommended O
that O
frequent O
peripheral O
blood O
cell O
counts O
be O
performed O
on O
all O
patients O
receiving O
TAXOL B-BRAND
. O
Patients O
should O
not O
be O
re O
- O
treated O
with O
subsequent O
cycles O
of O
TAXOL B-BRAND
until O
neutrophils O
recover O
to O
a O
level O
1500 O
cells O
/ O
mm3 O
and O
platelets O
recover O
to O
a O
level O
100 O
, O
000 O
cells O
/ O
mm3 O
. O
In O
the O
case O
of O
severe O
neutropenia O
( O
500 O
cells O
/ O
mm3 O
for O
seven O
days O
or O
more O
) O
during O
a O
course O
of O
TAXOL B-BRAND
therapy O
, O
a O
20 O
% O
reduction O
in O
dose O
for O
subsequent O
courses O
of O
therapy O
is O
recommended O
. O
For O
patients O
with O
advanced O
HIV O
disease O
and O
poor O
- O
risk O
AIDS O
- O
related O

Kaposi O
s O
sarcoma O
, O
TAXOL B-BRAND
, O
at O
the O
recommended O
dose O
for O
this O
disease O
, O
can O
be O
initiated O
and O
repeated O
if O
the O
neutrophil O
count O
is O
at O
least O
1000 O
cells O
/ O
mm3 O
. O
Hypersensitivity O
Reactions O
: O
Patients O
with O
a O
history O
of O
severe O
hypersensitivity O
reactions O
to O
products O
containing O
Cremophor O
EL O
( O
eg O
, O
cyclosporin B-DRUG
for O
injection O
concentrate O
and O
teniposide B-DRUG
for O
injection O
concentrate O
) O
should O
not O
be O
treated O
with O
TAXOL B-BRAND
. O
In O
order O
to O
avoid O
the O
occurrence O
of O
severe O
hypersensitivity O
reactions O
, O
all O
patients O
treated O
with O
TAXOL B-BRAND
should O
be O
premedicated O
with O
corticosteroids B-GROUP
( O
such O
as O
dexamethasone B-DRUG
) O
, O
diphen O
- O
hydramine O
and O
H2 B-GROUP
antagonists I-GROUP
( O
such O
as O
cimetidine B-DRUG
or O
ranitidine B-DRUG
) O
. O
Minor O
symptoms O
such O
as O
flushing O
, O
skin O
reactions O
, O
dyspnea O
, O
hypotension O
, O
or O
tachycardia O
do O
not O
require O
interruption O
of O
therapy O
. O
However O
, O
severe O
reactions O
, O
such O
as O
hypotension O
requiring O
treatment O
, O
dyspnea O
requiring O
bronchodilators B-GROUP
, O
angioedema O
, O
or O
generalized O
urticaria O
require O
immediate O
discontinuation O
of O
TAXOL B-BRAND
and O
aggressive O
symptomatic O
therapy O
. O
Patients O
who O
have O
developed O
severe O
hypersensitivity O
reactions O
should O
not O
be O
rechallenged O
with O
TAXOL B-BRAND
. O
Cardiovascular O
: O
Hypotension O
, O
bradycardia O
, O
and O
hypertension O
have O
been O
observed O
during O
administration O
of O
TAXOL B-BRAND
, O
but O
generally O
do O
not O
require O
treatment O
. O
Occasionally O
TAXOL B-BRAND
infusions O
must O
be O
interrupted O
or O
discontinued O
because O
of O
initial O
or O
recurrent O
hypertension O
. O
Frequent O
vital O
sign O
monitoring O
, O
particularly O
during O
the O
first O
hour O
of O
TAXOL B-BRAND
infusion O
, O
is O
recommended O
. O
Continuous O
cardiac O
monitoring O
is O
not O
required O
except O
for O
patients O
with O
serious O
conduction O
abnormalities O
. O
Nervous O
System O
: O
Although O
the O
occurrence O
of O
peripheral O
neuropathy O
is O
frequent O
, O
the O
development O
of O
severe O
symptomatology O
is O
unusual O
and O
requires O
a O
dose O
reduction O
of O
20 O
% O
for O
all O
subsequentcourses O
of O
TAXOL B-BRAND
. O
TAXOL B-BRAND
contains O
dehydrated O
alcohol O
USP O
, O
396 O
mg O
/ O
mL O
; O
consideration O
should O
be O
given O
to O
possible O
CNS O
and O
other O
effects O
of O
alcohol B-DRUG
. O
Hepatic O
: O
There O
is O
limited O
evidence O
that O
the O
myelotoxicity O
of O
TAXOL B-BRAND
may O
be O
exacerbated O
in O
patients O
with O
serum O
total O

bilirubin O
2 O
times O
ULN O
. O
Extreme O
caution O
should O
be O
exercised O
when O
administering O
TAXOL B-BRAND
to O
such O
patients O
, O
with O
dose O
reduction O
as O
recommended O
in O
DOSAGE O
AND O
ADMINISTRATION O
, O
Table O
17 O
. O
InjectionSite O
Reaction O
: O
Injection O
site O
reactions O
, O
including O
reactions O
secondary O
to O
extravasation O
, O
were O
usually O
mild O
and O
consisted O
of O
erythema O
, O
tenderness O
, O
skin O
discoloration O
, O
or O
swelling O
at O
the O
injection O
site O
. O
These O
reactions O
have O
been O
observed O
more O
frequently O
with O
the O
24 O
- O
hour O
infusion O
than O
with O
the O
3 O
- O
hour O
infusion O
. O
Recurrence O
of O
skin O
reactions O
at O
a O
site O
of O
previous O
extravasation O
following O
administration O
of O
TAXOL B-BRAND
at O
a O
different O
site O
, O
ie O
, O
recall O
, O
has O
been O
reported O
rarely O
. O
Rare O
reports O
of O
more O
severe O
events O
such O
as O
phlebitis O
, O
cellulitis O
, O
induration O
, O
skin O
exfoliation O
, O
necrosis O
, O
and O
fibrosis O
have O
been O
received O
as O
part O
of O
the O
continuing O
surveillance O
of O
TAXOL B-BRAND
safety O
. O
In O
some O
cases O
the O
onset O
of O
the O
injection O
site O
reaction O
either O
occurred O
during O
a O
prolonged O
infusion O
or O
was O
delayed O
by O
a O
week O
to O
ten O
days O
. O
A O
specific O
treatment O
for O
extravasation O
reactions O
is O
unknown O
at O
this O
time O
. O
Given O
the O
possibility O
of O
extravasation O
, O
it O
is O
advisable O
to O
closely O
monitor O
the O
infusion O
site O
for O
possible O
infiltration O
during O
drug O
administration O
. O

Treatment O
with O
PEGASYS B-BRAND
once O
weekly O
for O
4 O
weeks O
in O
healthy O
subjects O
was O
associated O
with O
an O
inhibition O
of O
P450 O
1A2 O
and O
a O
25 O
% O
increase O
in O
theophylline B-DRUG
AUC O
. O
Theophylline B-DRUG
serum O
levels O
should O
be O
monitored O
and O
appropriate O
dose O
adjustments O
considered O
for O
patients O
given O
both O
theophylline B-DRUG
and O
PEGASYS B-BRAND
. O
There O
was O
no O
effect O
on O
the O
pharmacokinetics O
of O
representative O
drugs O
metabolized O
by O
CYP O
2C9 O
, O
CYP O
2C19 O
, O
CYP O
2D6 O
or O
CYP O
3A4 O
. O
In O
patients O
with O
chronic O
hepatitis O
C O
treated O
with O
PEGASYS B-BRAND
in O
combination O
with O
COPEGUS B-BRAND
, O
PEGASYS B-BRAND
treatment O
did O
not O
affect O
ribavirin B-DRUG
distribution O
or O
clearance O
. O
Nucleoside O
Analogues O
Didanosine B-DRUG
Co O
- O
administration O
of O
COPEGUS B-BRAND
and O
didanosine B-DRUG
is O
not O
recommended O
. O
Reports O
of O
fatal O
hepatic O
failure O
, O
as O
well O
as O
peripheral O
neuropathy O
, O
pancreatitis O
, O
and O
symptomatic O
hyperlactatemia O
/ O
lactic O
acidosis O
have O
been O
reported O
in O
clinical O
trials O
. O
Stavudine B-DRUG
and O
Zidovudine B-DRUG
Ribavirin B-DRUG
can O
antagonize O
the O
in O
vitro O
antiviral O
activity O
of O
stavudine B-DRUG
and O
zidovudine B-DRUG
against O
HIV O
. O
Therefore O
, O
concomitant O
use O
of O
ribavirin B-DRUG
with O
either O
of O
these O
drugs O
should O
be O
avoided O
. O
Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
Carcinogenesis O
PEGASYS B-BRAND
has O
not O
been O
tested O
for O
its O
carcinogenic O
potential O
. O
Mutagenesis O
PEGASYS B-BRAND
did O
not O
cause O
DNA O
damage O
when O
tested O
in O
the O
Ames O
bacterial O
mutagenicity O
assay O
and O
in O
the O
in O
vitro O
chromosomal O
aberration O
assay O
in O
human O
lymphocytes O
, O
either O
in O
the O
presence O
or O
absence O
of O
metabolic O
activation O
. O
Use O
With O
Ribavirin B-DRUG
Ribavirin B-DRUG
is O
genotoxic O
and O
mutagenic O
. O
The O
carcinogenic O
potential O
of O
ribavirin B-DRUG
has O
not O
been O
fully O
determined O
. O
In O
a O
p53 O
( O
+ O
/ O
- O
) O
mouse O
carcinogenicity O
study O
at O
doses O
up O
to O
the O
maximum O
tolerated O
dose O
of O
100 O
mg O
/ O
kg O
/ O
day O
ribavirin B-DRUG
was O
not O
oncogenic O
. O
However O
, O
on O
a O
body O
surface O
area O
basis O
, O
this O
dose O
was O
0 O
. O
5 O
times O
maximum O
recommended O
human O
24 O
- O
hour O
dose O
of O
ribavirin B-DRUG
. O
A O
study O
in O
rats O
to O
assess O
the O
carcinogenic O
potential O
of O
ribavirin B-DRUG
is O
ongoing O
. O
Mutagenesis O
Impairment O
of O

Fertility O
PEGASYS B-BRAND
may O
impair O
fertility O
in O
women O
. O
Prolonged O
menstrual O
cycles O
and O
/ O
or O
amenorrhea O
were O
observed O
in O
female O
cynomolgus O
monkeys O
given O
sc O
injections O
of O
600 O
m O
g O
/ O
kg O
/ O
dose O
( O
7200 O
m O
g O
/ O
m2 O
/ O
dose O
) O
of O
PEGASYS B-BRAND
every O
other O
day O
for O
one O
month O
, O
at O
approximately O
180 O
times O
the O
recommended O
weekly O
human O
dose O
for O
a O
60 O
kg O
person O
( O
based O
on O
body O
surface O
area O
) O
. O
Menstrual O
cycle O
irregularities O
were O
accompanied O
by O
both O
a O
decrease O
and O
delay O
in O
the O
peak O
17b O
- O
estradiol O
and O
progesterone O
levels O
following O
administration O
of O
PEGASYS B-BRAND
to O
female O
monkeys O
. O
A O
return O
to O
normal O
menstrual O
rhythm O
followed O
cessation O
of O
treatment O
. O
Every O
other O
day O
dosing O
with O
100m O
g O
/ O
kg O
( O
1200m O
g O
/ O
m2 O
) O
PEGASYS B-BRAND
( O
equivalent O
to O
approximately O
30 O
times O
the O
recommended O
human O
dose O
) O
had O
no O
effects O
on O
cycle O
duration O
or O
reproductive O
hormone O
status O
. O
The O
effects O
of O
PEGASYS B-BRAND
on O
male O
fertility O
have O
not O
been O
studied O
. O
However O
, O
no O
adverse O
effects O
on O
fertility O
were O
observed O
in O
male O
Rhesus O
monkeys O
treated O
with O
non O
- O
pegylated B-DRUG
interferon I-DRUG
alfa I-DRUG
- I-DRUG
2a I-DRUG
for O
5 O
months O
at O
doses O
up O
to O
25 O
x O
106 O
IU O
/ O
kg O
/ O
day O
. O
Pregnancy O
Pregnancy O
: O
Category O
C O
PEGASYS B-BRAND
has O
not O
been O
studied O
for O
its O
teratogenic O
effect O
. O
Non B-DRUG
- I-DRUG
pegylated I-DRUG
interferon I-DRUG
alfa I-DRUG
- I-DRUG
2a I-DRUG
treatment O
of O
pregnant O
Rhesus O
monkeys O
at O
approximately O
20 O
to O
500 O
times O
the O
human O
weekly O
dose O
resulted O
in O
a O
statistically O
significant O
increase O
in O
abortions O
. O
No O
teratogenic O
effects O
were O
seen O
in O
the O
offspring O
delivered O
at O
term O
. O
PEGASYS B-BRAND
should O
be O
assumed O
to O
have O
abortifacient O
potential O
. O
There O
are O
no O
adequate O
and O
well O
- O
controlled O
studies O
of O
PEGASYS B-BRAND
in O
pregnant O
women O
. O
PEGASYS B-BRAND
is O
to O
be O
used O
during O
pregnancy O
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk O
to O
the O
fetus O
. O
PEGASYS B-BRAND
is O
recommended O
for O
use O
in O
women O
of O
childbearing O
potential O
only O
when O
they O
are O
using O
effective O
contraception O
during O
therapy O
. O
Pregnancy O
: O
Category O
X O
: O
Use O
With O
Ribavirin B-DRUG
( O
see O
CONTRAINDICATIONS O
) O
Significant O
teratogenic O
and O
/ O
or O
embryocidal O
effects O
have O
been O
demonstrated O
in O
all O
animal O
species O
exposed O
to O
ribavirin B-DRUG
. O
COPEGUS B-BRAND
therapy O
is O
contraindicated O
in O
women O
who O
are O
pregnant O
and O
in O
the O

male O
partners O
of O
women O
who O
are O
pregnant O
. O
If O
pregnancy O
occurs O
in O
a O
patient O
or O
partner O
of O
a O
patient O
during O
treatment O
or O
during O
the O
6 O
months O
after O
treatment O
cessation O
, O
such O
cases O
should O
be O
reported O
to O
the O
COPEGUS B-BRAND
Pregnancy O
Registry O
at O
1 O
- O
800 O
- O
526 O
- O
6367 O
. O
Nursing O
Mothers O
It O
is O
not O
known O
whether O
peginterferon B-DRUG
or O
ribavirin B-DRUG
or O
its O
components O
are O
excreted O
in O
human O
milk O
. O
The O
effect O
of O
orally O
ingested O
peginterferon B-DRUG
or O
ribavirin B-DRUG
from O
breast O
milk O
on O
the O
nursing O
infant O
has O
not O
been O
evaluated O
. O
Because O
of O
the O
potential O
for O
adverse O
reactions O
from O
the O
drugs O
in O
nursing O
infants O
, O
a O
decision O
must O
be O
made O
whether O
to O
discontinue O
nursing O
or O
discontinue O
PEGASYS B-BRAND
and O
COPEGUS B-BRAND
treatment O
. O
Pediatric O
Use O
The O
safety O
and O
effectiveness O
of O
PEGASYS B-BRAND
, O
alone O
or O
in O
combination O
with O
COPEGUS B-BRAND
in O
patients O
below O
the O
age O
of O
18 O
years O
have O
not O
been O
established O
. O
PEGASYS B-BRAND
contains O
benzyl B-DRUG_N
alcohol I-DRUG_N
. O
Benzyl B-DRUG_N
alcohol I-DRUG_N
has O
been O
reported O
to O
be O
associated O
with O
an O
increased O
incidence O
of O
neurological O
and O
other O
complications O
in O
neonates O
and O
infants O
, O
which O
are O
sometimes O
fatal O
. O
Geriatric O
Use O
Younger O
patients O
have O
higher O
virologic O
response O
rates O
than O
older O
patients O
. O
Clinical O
studies O
of O
PEGASYS B-BRAND
alone O
or O
in O
combination O
with O
COPEGUS B-BRAND
did O
not O
include O
sufficient O
numbers O
of O
subjects O
aged O
65 O
or O
over O
to O
determine O
whether O
they O
respond O
differently O
from O
younger O
subjects O
. O
Adverse O
reactions O
related O
to O
alpha B-DRUG
interferons I-DRUG
, O
such O
as O
CNS O
, O
cardiac O
, O
and O
systemic O
( O
eg O
, O
flu O
- O
like O
) O
effects O
may O
be O
more O
severe O
in O
the O
elderly O
and O
caution O
should O
be O
exercised O
in O
the O
use O
of O
PEGASYS B-BRAND
in O
this O
population O
. O
PEGASYS B-BRAND
and O
COPEGUS B-BRAND
are O
excreted O
by O
the O
kidney O
, O
and O
the O
risk O
of O
toxic O
reactions O
to O
this O
therapy O
may O
be O
greater O
in O
patients O
with O
impaired O
renal O
function O
. O
Because O
elderly O
patients O
are O
more O
likely O
to O
have O
decreased O
renal O
function O
, O
care O
should O
be O
taken O
in O
dose O
selection O
and O
it O
may O
be O
useful O
to O
monitor O
renal O
function O
. O
PEGASYS B-BRAND
should O
be O
used O
with O
caution O
in O
patients O
with O
creatinine O
clearance O
50 O
mL O
/ O
min O
and O
COPEGUS B-BRAND
should O
not O
be O
administered O
to O
patients O
with O
creatinine O
clearance O
50 O
mL O
/ O
min O
. O

Aminoglycosides B-GROUP
: O
The O
mixing O
of O
piperacillin B-DRUG
with O
an O
aminoglycoside B-GROUP
in O
vitro O
can O
result O
in O
substantial O
inactivation O
of O
the O
aminoglycoside B-GROUP
. O
Vecuronium B-DRUG
: O
When O
used O
in O
the O
perioperative O
period O
, O
piperacillin B-DRUG
has O
been O
implicated O
in O
the O
prolongation O
of O
the O
neuromuscular O
blockade O
of O
vecuronium B-DRUG
. O
Caution O
is O
indicated O
when O
piperacillin B-DRUG
is O
used O
perioperatively O
. O
In O
one O
controlled O
clinical O
study O
, O
the O
ureidopenicillins O
, O
including O
piperacillin B-DRUG
, O
were O
reported O
to O
prolong O
the O
action O
of O
vecuronium B-DRUG
. O
Due O
to O
their O
similar O
mechanism O
of O
action O
, O
it O
is O
expected O
that O
the O
neuromuscular O
blockade O
produced O
by O
any O
of O
the O
non B-GROUP
- I-GROUP
depolarizing I-GROUP
muscle I-GROUP
relaxants I-GROUP
could O
be O
prolonged O
in O
the O
presence O
of O
piperacillin B-DRUG
. O
Probenecid B-DRUG
: O
The O
oral O
combination O
of O
probenecid B-DRUG
before O
intramuscular O
injection O
of O
PIPRACIL B-BRAND
produces O
an O
increase O
in O
piperacillin B-DRUG
peak O
serum O
level O
of O
about O
30 O
% O
. O
Anticoagulants B-GROUP
: O
Coagulation O
parameters O
should O
be O
tested O
more O
frequently O
and O
monitored O
regularly O
during O
simultaneous O
administration O
of O
high O
doses O
of O
heparin B-DRUG
, O
oral O
anticoagulants B-GROUP
, O
or O
other O
drugs O
that O
may O
affect O
the O
blood O
coagulation O
system O
or O
the O
thrombocyte O
function O
. O
Methotrexate B-DRUG
: O
Piperacillin B-DRUG
sodium I-DRUG
may O
reduce O
the O
excretion O
of O
methotrexate B-DRUG
. O
Therefore O
, O
serum O
levels O
of O
methotrexate B-DRUG
should O
be O
monitored O
in O
patients O
to O
avoid O
drug O
toxicity O
. O
Drug O
/ O
Laboratory O
Test O
Interactions O
As O
with O
other O
penicillins B-DRUG
, O
the O
administration O
of O
PIPRACIL B-BRAND
may O
result O
in O
a O
false O
- O
positive O
reaction O
for O
glucose O
in O
the O
urine O
using O
a O
copper O
- O
reduction O
method O
. O
It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
be O
used O
. O
There O
have O
been O
reports O
of O
positive O
test O
results O
using O
the O
Bio O
- O
Rad O
Laboratories O
Platelia O
Aspergillus O
EIA O
test O
in O
patients O
receiving O
piperacillin B-DRUG
/ O
tazobactam B-DRUG
injection O
who O
were O
subsequently O
found O
to O
be O
free O
of O
Aspergillus O
infection O
. O
Cross O
- O
reactions O
with O
non O
- O
Aspergillus O
polysaccharides O
and O
polyfuranoses O
with O
the O
Bio O
- O
Rad O
Laboratories O
Platelia O
Aspergillus O
EIA O
test O
have O
been O
reported O
. O
Therefore O
, O
positive O
test O
results O
in O
patients O
receiving O
piperacillin B-DRUG
should O
be O
interpreted O
cautiously O
and O
confirmed O
by O
other O
diagnostic O
methods O
. O

Phenothiazines B-GROUP
- O
Taking O
piperazine B-DRUG
and O
a O
phenothiazine B-GROUP
together O
may O
increase O
the O
risk O
of O
convulsions O
( O
seizures O
) O
. O
Pyrantel B-DRUG
( O
e O
. O
g O
. O
, O
Antiminth B-DRUG
) O
- O
Taking O
piperazine B-DRUG
and O
pyrantel B-DRUG
together O
may O
decrease O
the O
effects O
of O
piperazine B-DRUG
. O

ACE B-GROUP
inhibitors I-GROUP
: O
Reports O
suggest O
that O
NSAIDs B-GROUP
may O
diminish O
the O
antihypertensive O
effect O
of O
Angiotensin B-GROUP
Converting I-GROUP
Enzyme I-GROUP
( I-GROUP
ACE I-GROUP
) I-GROUP
inhibitors I-GROUP
. O
In O
patients O
with O
mild O
to O
moderate O
hypertension O
, O
administration O
of O
25 O
mg O
daily O
of O
VIOXX B-BRAND
with O
the O
ACE B-GROUP
inhibitor I-GROUP
benazepril B-DRUG
, O
10 O
to O
40 O
mg O
for O
4 O
weeks O
, O
was O
associated O
with O
an O
average O
increase O
in O
mean O
arterial O
pressure O
of O
about O
3 O
mm O
Hg O
compared O
to O
ACE B-GROUP
inhibitor I-GROUP
alone O
. O
This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
VIOXX B-BRAND
concomitantly O
with O
ACE B-GROUP
inhibitors I-GROUP
. O
Aspirin B-BRAND
: O
Concomitant O
administration O
of O
low O
- O
dose O
aspirin B-BRAND
with O
VIOXX B-BRAND
may O
result O
in O
an O
increased O
rate O
of O
GI O
ulceration O
or O
other O
complications O
, O
compared O
to O
use O
of O
VIOXX B-BRAND
alone O
. O
In O
a O
12 O
- O
week O
endoscopy O
study O
conducted O
in O
OA O
patients O
there O
was O
no O
difference O
in O
the O
cumulative O
incidence O
of O
endoscopic O
gastroduodenal O
ulcers O
in O
patients O
taking O
low O
- O
dose O
( O
81 O
mg O
) O
enteric O
coated O
aspirin B-BRAND
plus O
VIOXX B-BRAND
25 O
mg O
daily O
, O
as O
compared O
to O
those O
taking O
ibuprofen B-DRUG
2400 O
mg O
daily O
alone O
. O
Patients O
taking O
low O
- O
dose O
aspirin B-BRAND
plus O
ibuprofen B-DRUG
were O
not O
studied O
. O
At O
steady O
state O
, O
VIOXX B-BRAND
50 O
mg O
once O
daily O
had O
no O
effect O
on O
the O
anti O
- O
platelet O
activity O
of O
low O
- O
dose O
( O
81 O
mg O
once O
daily O
) O
aspirin B-BRAND
, O
as O
assessed O
by O
ex O
vivo O
platelet O
aggregation O
and O
serum O
TXB2 O
generation O
in O
clotting O
blood O
. O
Because O
of O
its O
lack O
of O
platelet O
effects O
, O
VIOXX B-BRAND
is O
not O
a O
substitute O
for O
aspirin B-BRAND
for O
cardiovascular O
prophylaxis O
. O
Therefore O
, O
in O
patients O
taking O
VIOXX B-BRAND
, O
antiplatelet O
therapies O
should O
not O
be O
discontinued O
and O
should O
be O
considered O
in O
patients O
with O
an O
indication O
for O
cardiovascular O
prophylaxis O
. O
Prospective O
, O
long O
- O
term O
studies O
on O
concomitant O
administration O
of O
VIOXX B-BRAND
and O
aspirin B-BRAND
have O
not O
been O
conducted O
. O
Cimetidine B-DRUG
: O
Co O
- O
administration O
with O
high O
doses O
of O
cimetidine B-DRUG
[ O
800 O
mg O
twice O
daily O
] O
increased O
the O
Cmax O
of O
rofecoxib B-DRUG
by O
21 O
% O
, O
the O
AUC0 O
- O
120hr O
by O
23 O
% O
and O
the O
t1 O
/ O
2 O
by O
15 O
% O
. O
These O
small O
changes O
are O
not O
clinically O
significant O
and O
no O
dose O
adjustment O
is O
necessary O
. O
Digoxin B-DRUG
: O
Rofecoxib B-DRUG
75 O
mg O
once O
daily O
for O
11 O
days O
does O
not O
alter O
the O
plasma O
concentration O
profile O
or O
renal O
elimination O
of O

digoxin B-DRUG
after O
a O
single O
0 O
. O
5 O
mg O
oral O
dose O
. O
Furosemide B-DRUG
: O
Clinical O
studies O
, O
as O
well O
as O
post O
- O
marketing O
observations O
, O
have O
shown O
that O
NSAIDs B-GROUP
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-DRUG
and O
thiazides B-GROUP
in O
some O
patients O
. O
This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O
Ketoconazole B-DRUG
: O
Ketoconazole B-DRUG
400 O
mg O
daily O
did O
not O
have O
any O
clinically O
important O
effect O
on O
the O
pharmacokinetics O
of O
rofecoxib B-DRUG
. O
Lithium B-DRUG
: O
NSAIDs B-GROUP
have O
produced O
an O
elevation O
of O
plasma O
lithium B-DRUG
levels O
and O
a O
reduction O
in O
renal O
lithium B-DRUG
clearance O
. O
In O
post O
- O
marketing O
experience O
there O
have O
been O
reports O
of O
increases O
in O
plasma O
lithium B-DRUG
levels O
. O
Thus O
, O
when O
VIOXX B-BRAND
and O
lithium B-DRUG
are O
administered O
concurrently O
, O
subjects O
should O
be O
observed O
carefully O
for O
signs O
of O
lithium B-DRUG
toxicity O
. O
Methotrexate B-DRUG
VIOXX B-BRAND
12 O
. O
5 O
, O
25 O
, O
and O
50 O
mg O
, O
each O
dose O
administered O
once O
daily O
for O
7 O
days O
, O
had O
no O
effect O
on O
the O
plasma O
concentration O
of O
methotrexate B-DRUG
as O
measured O
by O
AUC0 O
- O
24hr O
in O
patients O
receiving O
single O
weekly O
methotrexate B-DRUG
doses O
of O
7 O
. O
5 O
to O
20 O
mg O
for O
rheumatoid O
arthritis O
. O
At O
higher O
than O
recommended O
doses O
, O
VIOXX B-BRAND
75 O
mg O
administered O
once O
daily O
for O
10 O
days O
increased O
plasma O
concentrations O
by O
23 O
% O
as O
measured O
by O
AUC0 O
- O
24hr O
in O
patients O
receiving O
methotrexate B-DRUG
7 O
. O
5 O
to O
15 O
mg O
/ O
week O
for O
rheumatoid O
arthritis O
. O
At O
24 O
hours O
postdose O
, O
a O
similar O
proportion O
of O
patients O
treated O
with O
methotrexate B-DRUG
alone O
( O
94 O
% O
) O
and O
subsequently O
treated O
with O
methotrexate B-DRUG
co O
- O
administered O
with O
75 O
mg O
of O
rofecoxib B-DRUG
( O
88 O
% O
) O
had O
methotrexate B-DRUG
plasma O
concentrations O
below O
the O
measurable O
limit O
( O
5 O
ng O
/ O
mL O
) O
. O
Standard O
monitoring O
of O
methotrexate B-DRUG
- O
related O
toxicity O
should O
be O
continued O
if O
VIOXX B-BRAND
and O
methotrexate B-DRUG
are O
administered O
concomitantly O
. O
Oral O
Contraceptives B-GROUP
Rofecoxib B-DRUG
did O
not O
have O
any O
clinically O
important O
effect O
on O
the O
pharmacokinetics O
of O
ethinyl B-DRUG
estradiol I-DRUG
and O
norethindrone B-DRUG
. O
Prednisone B-DRUG
/ O
prednisolone B-DRUG
: O
Rofecoxib B-DRUG
did O
not O
have O
any O
clinically O
important O
effect O
on O
the O
pharmacokinetics O
of O
prednisolone B-DRUG
or O
prednisone B-DRUG
. O
Rifampin B-DRUG
: O
Co O
- O
administration O
of O

VIOXX B-BRAND
with O
rifampin B-DRUG
600 O
mg O
daily O
, O
a O
potent O
inducer O
of O
hepatic O
metabolism O
, O
produced O
an O
approximate O
50 O
% O
decrease O
in O
rofecoxib B-DRUG
plasma O
concentrations O
. O
Therefore O
, O
a O
starting O
daily O
dose O
of O
25 O
mg O
of O
VIOXX B-BRAND
should O
be O
considered O
for O
the O
treatment O
of O
osteoarthritis O
when O
VIOXX B-BRAND
is O
co O
- O
administered O
with O
potent O
inducers O
of O
hepatic O
metabolism O
. O
Theophylline B-DRUG
VIOXX B-BRAND
12 O
. O
5 O
, O
25 O
, O
and O
50 O
mg O
administered O
once O
daily O
for O
7 O
days O
increased O
plasma O
theophylline B-DRUG
concentrations O
( O
AUC O
( O
0 O
- O
) O
) O
by O
38 O
to O
60 O
% O
in O
healthy O
subjects O
administered O
a O
single O
300 O
- O
mg O
dose O
of O
theophylline B-DRUG
. O
Adequate O
monitoring O
of O
theophylline B-DRUG
plasma O
concentrations O
should O
be O
considered O
when O
therapy O
with O
VIOXX B-BRAND
is O
initiated O
or O
changed O
in O
patients O
receiving O
theophylline B-DRUG
. O
These O
data O
suggest O
that O
rofecoxib B-DRUG
may O
produce O
a O
modest O
inhibition O
of O
cytochrome O
P450 O
( O
CYP O
) O
1A2 O
. O
Therefore O
, O
there O
is O
a O
potential O
for O
an O
interaction O
with O
other O
drugs O
that O
are O
metabolized O
by O
CYP O
1A2 O
( O
e O
. O
g O
. O
, O
amitriptyline B-DRUG
, O
tacrine B-DRUG
, O
and O
zileuton B-DRUG
) O
. O
Warfarin B-DRUG
: O
Anticoagulant O
activity O
should O
be O
monitored O
, O
particularly O
in O
the O
first O
few O
days O
after O
initiating O
or O
changing O
VIOXX B-BRAND
therapy O
in O
patients O
receiving O
warfarin B-DRUG
or O
similar O
agents O
, O
since O
these O
patients O
are O
at O
an O
increased O
risk O
of O
bleeding O
complications O
. O
In O
single O
and O
multiple O
dose O
studies O
in O
healthy O
subjects O
receiving O
both O
warfarin B-DRUG
and O
rofecoxib B-DRUG
, O
prothrombin O
time O
( O
measured O
as O
INR O
) O
was O
increased O
by O
approximately O
8 O
% O
to O
11 O
% O
. O
In O
post O
- O
marketing O
experience O
, O
bleeding O
events O
have O
been O
reported O
, O
predominantly O
in O
the O
elderly O
, O
in O
association O
with O
increases O
in O
prothrombin O
time O
in O
patients O
receiving O
VIOXX B-BRAND
concurrently O
with O
warfarin B-DRUG
. O

DRUG O
INTERACTIONS O
Several O
drug O
interaction O
studies O
have O
been O
completed O
with O
both O
INVIRASE B-BRAND
and O
FORTOVASE B-BRAND
. O
Observations O
from O
drug O
interaction O
studies O
with O
FORTOVASE B-BRAND
may O
not O
be O
predictive O
for O
INVIRASE B-BRAND
. O
Because O
ritonavir B-DRUG
is O
coadministered O
, O
prescribers O
should O
also O
refer O
to O
the O
prescribing O
information O
for O
ritonavir B-DRUG
regarding O
drug O
interactions O
associated O
with O
this O
agent O
. O
The O
metabolism O
of O
saquinavir B-DRUG
is O
mediated O
by O
cytochrome O
P450 O
, O
with O
the O
specific O
isoenzyme O
CYP3A4 O
responsible O
for O
90 O
% O
of O
the O
hepatic O
metabolism O
. O
Additionally O
, O
saquinavir B-DRUG
is O
a O
substrate O
for O
P O
- O
Glycoprotein O
( O
Pgp O
) O
. O
Therefore O
, O
drugs O
that O
affect O
CYP3A4 O
and O
/ O
or O
Pgp O
, O
may O
modify O
the O
pharmacokinetics O
of O
saquinavir B-DRUG
. O
Similarly O
, O
saquinavir B-DRUG
might O
also O
modify O
the O
pharmacokinetics O
of O
other O
drugs O
that O
are O
substrates O
for O
CYP3A4 O
or O
Pgp O
. O
Drugs O
that O
are O
contraindicated O
specifically O
due O
to O
the O
expected O
magnitude O
of O
interaction O
and O
potential O
for O
serious O
adverse O
events O
are O
listed O
CONTRAINDICATIONS O
. O
Additional O
drugs O
that O
are O
not O
recommended O
for O
coadministration O
with O
INVIRASE B-BRAND
and O
ritonavir B-DRUG
are O
included O
below O
. O
These O
recommendations O
are O
based O
on O
either O
drug O
interaction O
studies O
or O
predicted O
interactions O
due O
to O
the O
expected O
magnitude O
of O
interaction O
and O
potential O
for O
serious O
events O
or O
loss O
of O
efficacy O
. O
With O
some O
agents O
, O
the O
metabolism O
may O
be O
induced O
, O
resulting O
in O
decreased O
concentrations O
. O
Drugs O
That O
Should O
Not O
Be O
Coadministered O
With O
INVIRASE B-BRAND
/ O
Ritonavir B-DRUG
Drug O
Class O
: O
Drug O
Name O
Clinical O
Comment O
Antiarrhythmics B-GROUP
: O
Amiodarone B-DRUG
, O
bepridil B-DRUG
, O
flecainide B-DRUG
, O
propafenone B-DRUG
, O
quinidine B-DRUG
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and O
/ O
or O
life O
- O
threatening O
reactions O
. O
Antihistamines B-DRUG
: O
astemizole B-DRUG
* O
, O
terfenadine B-DRUG
* O
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and O
/ O
or O
life O
- O
threatening O
cardiac O
arrhythmias O
. O
Ergot B-GROUP
Derivatives I-GROUP
: O
Dihydroergotamine B-DRUG
, O
ergonovine B-DRUG
, O
ergotamine B-DRUG
, O
methylergonovine B-DRUG
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and O
life O
- O
threatening O
reactions O
such O
as O
acute O
ergot B-GROUP
toxicity O
characterized O
by O
peripheral O
vasospasm O

and O
ischemia O
of O
the O
extremities O
and O
other O
tissues O
. O
Antimycobacterial B-GROUP
Agents I-GROUP
: O
rifampin B-DRUG
CONTRAINDICATED O
since O
the O
coadministration O
of O
this O
product O
with O
saquinavir B-DRUG
in O
an O
antiretroviral B-GROUP
regimen O
reduces O
the O
plasma O
concentrations O
of O
saquinavir B-DRUG
. O
Garlic O
Capsules O
Garlic O
capsules O
should O
not O
be O
used O
while O
taking O
saquinavir B-DRUG
( O
FORTOVASE B-BRAND
) O
as O
the O
sole O
protease B-GROUP
inhibitor I-GROUP
due O
to O
the O
risk O
of O
decreased O
saquinavir B-DRUG
plasma O
concentrations O
. O
No O
data O
are O
available O
for O
the O
coadministration O
of O
INVIRASE B-BRAND
/ O
ritonavir B-DRUG
or O
FORTOVASE B-BRAND
/ O
ritonavir B-DRUG
and O
garlic O
capsules O
. O
GI O
Motility O
Agent O
: O
cisapride B-DRUG
* O
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and O
/ O
or O
life O
- O
threatening O
reactions O
such O
as O
cardiac O
arrhythmias O
. O
Herbal O
Products O
: O
St O
. O
John O
s O
wort O
( O
hypericum O
perforatum O
) O
WARNING O
coadministration O
may O
lead O
to O
loss O
of O
virologic O
response O
and O
possible O
resistance O
to O
INVIRASE B-BRAND
or O
to O
the O
class O
of O
protease O
inhibitors O
. O
HMG B-GROUP
- I-GROUP
CoA I-GROUP
Reductase I-GROUP
Inhibitors I-GROUP
: O
lovastatin B-DRUG
, O
simvastatin B-DRUG
WARNING O
potential O
for O
serious O
reactions O
such O
as O
risk O
of O
myopathy O
including O
rhabdomyolysis O
. O
Sedatives B-GROUP
/ O
Hypnotics B-GROUP
: O
triazolam B-DRUG
, O
midazolam B-DRUG
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and O
/ O
or O
life O
- O
threatening O
reactions O
such O
as O
prolonged O
or O
increased O
sedation O
or O
respiratory O
depression O
. O
* O
No O
longer O
marketed O
in O
the O
US O
. O
Drugs O
That O
Are O
Mainly O
Metabolized O
by O
CYP3A4 O
Although O
specific O
studies O
have O
not O
been O
performed O
, O
coadministration O
with O
drugs O
that O
are O
mainly O
metabolized O
by O
CYP3A4 O
( O
eg O
, O
calcium B-GROUP
channel I-GROUP
blockers I-GROUP
, O
dapsone B-DRUG
, O
disopyramide B-DRUG
, O
quinine B-DRUG
, O
amiodarone B-DRUG
, O
quinidine B-DRUG
, O
warfarin B-DRUG
, O
tacrolimus B-DRUG
, O
cyclosporine B-DRUG
, O
ergot B-GROUP
derivatives I-GROUP
, O
pimozide B-DRUG
, O
carbamazepine B-DRUG
, O
fentanyl B-DRUG
, O
alfentanyl B-DRUG
, O
alprazolam B-DRUG
, O
and O
triazolam B-DRUG
) O
may O
have O
elevated O
plasma O
concentrations O
when O
coadministered O
with O
saquinavir B-DRUG
; O
therefore O
, O
these O
combinations O
should O
be O
used O
with O
caution O
. O
Since O

INVIRASE B-BRAND
is O
coadministered O
with O
ritonavir B-DRUG
, O
the O
ritonavir B-DRUG
label O
should O
be O
reviewed O
for O
additional O
drugs O
that O
should O
not O
be O
coadministered O
. O
Inducers O
of O
CYP3A4 O
Coadministration O
with O
compounds O
that O
are O
potent O
inducers O
of O
CYP3A4 O
( O
eg O
, O
phenobarbital B-DRUG
, O
phenytoin B-DRUG
, O
dexamethasone B-DRUG
, O
carbamazepine B-DRUG
) O
may O
result O
in O
decreased O
plasma O
levels O
of O
saquinavir B-DRUG
. O

Sulfacetamide B-DRUG
preparations O
are O
incompatible O
with O
silver B-DRUG
preparations O
. O

Interations O
Sulfapyridine B-DRUG
may O
interact O
with O
any O
of O
the O
following O
: O
- O
Acetaminophen B-DRUG
( O
e O
. O
g O
. O
, O
Tylenol B-BRAND
) O
( O
with O
long O
- O
term O
, O
high O
- O
dose O
use O
) O
or O
- O
Amiodarone B-DRUG
( O
e O
. O
g O
. O
, O
Cordarone B-BRAND
) O
or O
- O
Anabolic B-GROUP
steroids I-GROUP
( O
nandrolone B-DRUG
[ O
e O
. O
g O
. O
, O
Anabolin B-BRAND
] O
, O
oxandrolone B-DRUG
[ O
e O
. O
g O
. O
, O
Anavar B-BRAND
] O
, O
oxymetholone B-DRUG
[ O
e O
. O
g O
. O
, O
Anadrol B-BRAND
] O
, O
stanozolol B-DRUG
[ O
e O
. O
g O
. O
, O
Winstrol B-BRAND
] O
) O
or O
- O
Androgens B-GROUP
( O
male O
hormones O
) O
or O
- O
Antithyroid B-GROUP
agents I-GROUP
( O
medicine O
for O
overactive O
thyroid O
) O
or O
- O
Carbamazepine B-DRUG
( O
e O
. O
g O
. O
, O
Tegretol B-BRAND
) O
or O
- O
Carmustine B-DRUG
( O
e O
. O
g O
. O
, O
BiCNU B-BRAND
) O
or O
- O
Chloroquine B-DRUG
( O
e O
. O
g O
. O
, O
Aralen B-BRAND
) O
or O
- O
Dantrolene B-DRUG
( O
e O
. O
g O
. O
, O
Dantrium B-BRAND
) O
or O
- O
Daunorubicin B-DRUG
( O
e O
. O
g O
. O
, O
Cerubidine B-BRAND
) O
or O
- O
Disulfiram B-DRUG
( O
e O
. O
g O
. O
, O
Antabuse B-BRAND
) O
or O
- O
Divalproex B-DRUG
( O
e O
. O
g O
. O
, O
Depakote B-BRAND
) O
or O
- O
Estrogens B-GROUP
( O
female O
hormones O
) O
or O
- O
Etretinate B-DRUG
( O
e O
. O
g O
. O
, O
Tegison B-BRAND
) O
or O
- O
Gold B-DRUG
salts O
( O
medicine O
for O
arthritis O
) O
or O
- O
Hydroxychloroquine B-DRUG
( O
e O
. O
g O
. O
, O
Plaquenil B-BRAND
) O
or O
- O
Mercaptopurine B-DRUG
( O
e O
. O
g O
. O
, O
Purinethol B-BRAND
) O
or O
- O
Naltrexone B-DRUG
( O
e O
. O
g O
. O
, O
Trexan B-BRAND
) O
( O
with O
long O
- O
term O
, O
high O
- O
dose O
use O
) O
or O
- O
Oral O
contraceptives B-GROUP
( O
birth O
control O
pills O
) O
containing O
estrogen B-GROUP
or O
- O
Other O
anti B-GROUP
- I-GROUP
infectives I-GROUP
by O
mouth O
or O
by O
injection O
( O
medicine O
for O
infection O
) O
or O
- O
Phenothiazines B-GROUP
( O
acetophenazine B-DRUG
[ O
e O
. O
g O
. O
, O
Tindal B-BRAND
] O
, O
chlorpromazine B-DRUG
[ O
e O
. O
g O
. O
, O
Thorazine B-BRAND
] O
, O
fluphenazine B-DRUG
[ O
e O
. O
g O
. O
, O
Prolixin B-BRAND
] O
, O
mesoridazine B-BRAND
[ O
e O
. O
g O
. O
, O
Serentil B-BRAND
] O
, O
perphenazine B-DRUG
[ O
e O
. O
g O
. O
, O
Trilafon B-BRAND
] O
, O
prochlorperazine B-DRUG
[ O
e O
. O
g O
. O
, O
Compazine B-BRAND
] O

, O
promazine B-DRUG
[ O
e O
. O
g O
. O
, O
Sparine B-BRAND
] O
, O
promethazine B-DRUG
[ O
e O
. O
g O
. O
, O
Phenergan B-BRAND
] O
, O
thioridazine B-DRUG
[ O
e O
. O
g O
. O
, O
Mellaril B-BRAND
] O
, O
trifluoperazine B-DRUG
[ O
e O
. O
g O
. O
, O
Stelazine B-BRAND
] O
, O
triflupromazine B-DRUG
[ O
e O
. O
g O
. O
, O
Vesprin B-BRAND
] O
, O
trimeprazine B-DRUG
[ O
e O
. O
g O
. O
, O
Temaril B-BRAND
] O
) O
or O
- O
Plicamycin B-DRUG
( O
e O
. O
g O
. O
, O
Mithracin B-BRAND
) O
or O
- O
Valproic B-DRUG
acid I-DRUG
( O
e O
. O
g O
. O
, O
Depakene B-BRAND
) O
Use O
of O
sulfapyridine B-DRUG
with O
these O
medicines O
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
liver O
- O
Acetohydroxamic B-DRUG
acid I-DRUG
( O
e O
. O
g O
. O
, O
Lithostat B-BRAND
) O
or O
- O
Dapsone B-DRUG
or O
- O
Furazolidone B-DRUG
( O
e O
. O
g O
. O
, O
Furoxone B-BRAND
) O
or O
- O
Nitrofurantoin B-DRUG
( O
e O
. O
g O
. O
, O
Furadantin B-BRAND
) O
or O
- O
Primaquine B-DRUG
or O
- O
Procainamide B-DRUG
( O
e O
. O
g O
. O
, O
Pronestyl B-BRAND
) O
or O
- O
Quinidine B-DRUG
( O
e O
. O
g O
. O
, O
Quinidex B-BRAND
) O
or O
- O
Quinine B-DRUG
( O
e O
. O
g O
. O
, O
Quinamm B-BRAND
) O
or O
- O
Sulfoxone B-DRUG
( O
e O
. O
g O
. O
, O
Diasone B-BRAND
) O
or O
- O
Vitamin B-GROUP
K I-GROUP
( O
e O
. O
g O
. O
, O
AquaMEPHYTON B-BRAND
, O
Synkayvite B-BRAND
) O
Use O
of O
sulfapyridine B-DRUG
with O
these O
medicines O
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
blood O
- O
Anticoagulants B-GROUP
( O
blood B-GROUP
thinners I-GROUP
) O
or O
- O
Ethotoin B-DRUG
( O
e O
. O
g O
. O
, O
Peganone B-BRAND
) O
or O
- O
Mephenytoin B-DRUG
( O
e O
. O
g O
. O
, O
Mesantoin B-BRAND
) O
Use O
of O
sulfapyridine B-DRUG
with O
these O
medicines O
may O
increase O
the O
chance O
of O
side O
effects O
of O
these O
medicines O
- O
Antidiabetics B-GROUP
, O
oral O
( O
diabetes O
medicine O
you O
take O
by O
mouth O
) O
Use O
of O
oral O
antidiabetics B-GROUP
with O
sulfapyridine B-DRUG
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
blood O
and O
/ O
or O
the O
side O
effects O
or O
oral O
antidiabetics B-GROUP
- O
Methotrexate B-DRUG
( O
e O
. O
g O
. O
, O
Mexate B-BRAND
) O
Use O
of O
methotrexate B-DRUG
with O
sulfapyridine B-DRUG
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
liver O
and O
/ O
or O
the O
side O
effects O
of O
methotrexate B-DRUG
- O
Methyldopa B-DRUG
( O
e O
. O
g O

. O
, O
Aldomet B-BRAND
) O
Use O
of O
methyldopa B-DRUG
with O
sulfapyridine B-DRUG
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
liver O
and O
/ O
or O
the O
blood O
- O
Phenytoin B-DRUG
( O
e O
. O
g O
. O
, O
Dilantin B-BRAND
) O
Use O
of O
phenytoin B-DRUG
with O
sulfapyridine B-DRUG
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
liver O
and O
/ O
or O
the O
side O
effects O
of O
phenytoin B-DRUG

In O
evaluating O
the O
potential O
for O
interactions O
among O
co O
- O
administered O
antiepilepsy O
drugs O
( O
AEDs B-GROUP
) O
, O
whether O
or O
not O
an O
AED B-GROUP
induces O
or O
does O
not O
induce O
metabolic O
enzymes O
is O
an O
important O
consideration O
. O
Phenytoin B-DRUG
, O
phenobarbital B-DRUG
and O
carbamazepine B-DRUG
are O
ge O
nerally O
classified O
as O
enzyme O
inducers O
; O
valproate B-DRUG
and O
gabapentin B-DRUG
are O
not O
. O
GABITRIL B-BRAND
is O
considered O
to O
be O
a O
non O
- O
enzyme O
inducing O
AED B-GROUP
. O
The O
drug O
interaction O
data O
described O
in O
this O
section O
were O
obtained O
from O
studies O
involving O
either O
healthy O
subjects O
or O
patients O
with O
epilepsy O
. O
Effects O
of O
GABITRIL B-BRAND
on O
other O
Antiepilepsy O
Drugs O
( O
AEDs B-GROUP
) O
: O
Phenytoin B-DRUG
: O
Tiagabine B-DRUG
had O
no O
effect O
on O
the O
steady O
- O
state O
plasma O
concentrations O
of O
phenytoin B-DRUG
in O
patients O
with O
epilepsy O
. O
Carbamazepine B-DRUG
: O
Tiagabine B-DRUG
had O
no O
effect O
on O
the O
steady O
- O
state O
plasma O
concentrations O
of O
carbamazepine B-DRUG
or O
its O
epoxide O
metabolite O
in O
patients O
with O
epilepsy O
. O
Valproate B-DRUG
: O
Tiagabine B-DRUG
causes O
a O
slight O
decrease O
( O
about O
10 O
% O
) O
in O
steady O
- O
state O
valproate B-DRUG
concentrations O
. O
Phenobarbital B-DRUG
or O
Primidone B-DRUG
: O
No O
formal O
pharmacokinetic O
studies O
have O
been O
performed O
examining O
the O
addition O
of O
tiagabine B-DRUG
to O
regimens O
containing O
phenobarbital B-DRUG
or O
primidone B-DRUG
. O
The O
addition O
of O
tiagabine B-DRUG
in O
a O
limited O
number O
of O
patients O
in O
three O
well O
- O
controlled O
studies O
caused O
no O
systematic O
changes O
in O
phenobarbital B-DRUG
or O
primidone B-DRUG
concentrations O
when O
compared O
to O
placebo O
. O
Effects O
of O
other O
Antiepilepsy O
Drugs O
( O
AEDs B-GROUP
) O
on O
GABITRIL B-BRAND
: O
Carbamazepine B-DRUG
: O
Population O
pharmacokinetic O
analyses O
indicate O
that O
tiagabine B-DRUG
clearance O
is O
60 O
% O
greater O
in O
patients O
taking O
carbamazepine B-DRUG
with O
or O
without O
other O
enzyme O
- O
inducing O
AEDs B-GROUP
. O
Phenytoin B-DRUG
: O
Population O
pharmacokinetic O
analyses O
indicate O
that O
tiagabine B-DRUG
clearance O
is O
60 O
% O
greater O
in O
patients O
taking O
phenytoin B-DRUG
with O
or O
without O
other O
enzyme O
- O
inducing O
AEDs B-GROUP
. O
Phenobarbital B-DRUG
( O
Primidone B-DRUG
) O
: O
Population O
pharmacokinetic O
analyses O
indicate O
that O
tiagabine B-DRUG
clearance O
is O
60 O
% O
greater O
in O
patients O
taking O
phenobarbital B-DRUG
( O
primidone B-DRUG
) O
with O
or O
without O
other O
enzyme O
- O
inducing O
AEDs B-GROUP
. O
Valproate B-DRUG
: O
The O
addition O
of O

tiagabine B-DRUG
to O
patients O
taking O
valproate B-DRUG
chronically O
had O
no O
effect O
on O
tiagabine B-DRUG
pharmacokinetics O
, O
but O
valproate B-DRUG
significantly O
decreased O
tiagabine B-DRUG
binding O
in O
vitro O
from O
96 O
. O
3 O
to O
94 O
. O
8 O
% O
, O
which O
resulted O
in O
an O
increase O
of O
approximately O
40 O
% O
in O
the O
free O
tiagabine O
concentration O
. O
The O
clinical O
relevance O
of O
this O
in O
vitro O
finding O
is O
unknown O
. O
Interaction O
of O
GABITRIL B-BRAND
with O
Other O
Drugs O
: O
Cimetidine B-DRUG
: O
Co O
- O
administration O
of O
cimetidine B-DRUG
( O
800 O
mg O
/ O
day O
) O
to O
patients O
taking O
tiagabine B-DRUG
chronically O
had O
no O
effect O
on O
tiagabine B-DRUG
pharmacokinetics O
. O
Theophylline B-DRUG
: O
A O
single O
10 O
mg O
dose O
of O
tiagabine B-DRUG
did O
not O
affect O
the O
pharmacokinetics O
of O
theophylline B-DRUG
at O
steady O
state O
. O
Warfarin B-DRUG
: O
No O
significant O
differences O
were O
observed O
in O
the O
steady O
- O
state O
pharmacokinetics O
of O
R B-DRUG
- I-DRUG
warfarin I-DRUG
or O
S B-DRUG
- I-DRUG
warfarin I-DRUG
with O
the O
addition O
of O
tiagabine B-DRUG
given O
as O
a O
single O
dose O
. O
Prothrombin O
times O
were O
not O
affected O
by O
tiagabine B-DRUG
. O
Digoxin B-DRUG
: O
Concomitant O
administration O
of O
tiagabine B-DRUG
did O
not O
affect O
the O
steady O
- O
state O
pharmacokinetics O
of O
digoxin B-DRUG
or O
the O
mean O
daily O
trough O
serum O
level O
of O
digoxin B-DRUG
. O
Ethanol B-DRUG
or O
Triazolam B-DRUG
: O
No O
significant O
differences O
were O
observed O
in O
the O
pharmacokinetics O
of O
triazolam B-DRUG
( O
0 O
. O
125 O
mg O
) O
and O
tiagabine B-DRUG
( O
10 O
mg O
) O
when O
given O
together O
as O
a O
single O
dose O
. O
The O
pharmacokinetics O
of O
ethanol B-DRUG
were O
not O
affected O
by O
multiple O
- O
dose O
administration O
of O
tiagabine B-DRUG
. O
Tiagabine B-DRUG
has O
shown O
no O
clinically O
important O
potentiation O
of O
the O
pharmacodynamic O
effects O
of O
triazo O
lam O
or O
alcohol B-DRUG
. O
Because O
of O
the O
possible O
additive O
effects O
of O
drugs O
that O
may O
depress O
the O
nervous O
system O
, O
ethanol B-DRUG
or O
triazolam B-DRUG
should O
be O
used O
cautiously O
in O
combination O
with O
tiagabine B-DRUG
. O
Oral O
Contraceptives B-GROUP
: O
Multiple O
dose O
administration O
of O
tiagabine B-DRUG
( O
8 O
mg O
/ O
day O
monotherapy O
) O
did O
not O
alter O
the O
pharmacokinetics O
of O
oral O
contraceptives B-GROUP
in O
healthy O
women O
of O
childbearing O
age O
. O
Antipyrine B-DRUG
: O
Antipyrine B-DRUG
pharmacokinetics O
were O
not O
significantly O
different O
before O
and O
after O
tiagabine B-DRUG
multiple O
- O
dose O
regimens O
. O
This O
indicates O
that O
tiagabine B-DRUG
does O
not O
cause O
induction O
or O
inhibition O
of O
the O

hepatic O
microsomal O
enzyme O
systems O
responsible O
for O
the O
metabolism O
of O
antipyrine B-DRUG
. O
Interaction O
of O
GABITRIL B-BRAND
with O
Highly O
Protein O
Bound O
Drugs O
: O
In O
vitro O
data O
showed O
that O
tiagabine B-DRUG
is O
96 O
% O
bound O
to O
human O
plasma O
protein O
and O
therefore O
has O
the O
potential O
to O
interact O
with O
other O
highly O
protein O
bound O
compounds O
. O
Such O
an O
interaction O
can O
potentially O
lead O
to O
higher O
free O
fractions O
of O
either O
tiagabine B-DRUG
or O
the O
competing O
drug O
. O

The O
drug O
interaction O
studies O
with O
valdecoxib B-DRUG
were O
performed O
both O
with O
valdecoxib B-DRUG
and O
a O
rapidly O
hydrolyzed O
intravenous O
prodrug O
form O
. O
The O
results O
from O
trials O
using O
the O
intravenous O
prodrug O
are O
reported O
in O
this O
section O
as O
they O
relate O
to O
the O
role O
of O
valdecoxib B-DRUG
in O
drug O
interactions O
. O
General O
: O
In O
humans O
, O
valdecoxib B-DRUG
metabolism O
is O
predominantly O
mediated O
via O
CYP O
3A4 O
and O
2C9 O
with O
glucuronidation O
being O
a O
further O
( O
20 O
% O
) O
route O
of O
metabolism O
. O
In O
vitro O
studies O
indicate O
that O
valdecoxib B-DRUG
is O
a O
moderate O
inhibitor O
of O
CYP O
2C19 O
( O
IC50 O
= O
6 O
g O
/ O
mL O
or O
19 O
M O
) O
and O
2C9 O
( O
IC50 O
= O
13 O
g O
/ O
mL O
or O
41 O
M O
) O
, O
and O
a O
weak O
inhibitor O
of O
CYP O
2D6 O
( O
IC50 O
= O
31 O
g O
/ O
mL O
or O
100 O
M O
) O
and O
3A4 O
( O
IC50 O
= O
44 O
g O
/ O
mL O
or O
141 O
M O
) O
. O
. O
Aspirin B-BRAND
: O
Concomitant O
administration O
of O
aspirin B-BRAND
with O
valdecoxib B-DRUG
may O
result O
in O
an O
increased O
risk O
of O
GI O
ulceration O
and O
complications O
compared O
to O
valdecoxib B-DRUG
alone O
. O
Because O
of O
its O
lack O
of O
anti O
- O
platelet O
effect O
valdecoxib B-DRUG
is O
not O
a O
substitute O
for O
aspirin B-BRAND
for O
cardiovascular O
prophylaxis O
. O
In O
a O
parallel O
group O
drug O
interaction O
study O
comparing O
the O
intravenous O
prodrug O
form O
of O
valdecoxib B-DRUG
at O
40 O
mg O
BID O
( O
n O
= O
10 O
) O
vs O
placebo O
( O
n O
= O
9 O
) O
, O
valdecoxib B-DRUG
had O
no O
effect O
on O
in O
vitro O
aspirin B-BRAND
- O
mediated O
inhibition O
of O
arachidonate O
- O
or O
collagen O
- O
stimulated O
platelet O
aggregation O
. O
Methotrexate B-DRUG
: O
Valdecoxib B-DRUG
10 I-DRUG
mg I-DRUG
BID O
did O
not O
show O
a O
significant O
effect O
on O
the O
plasma O
exposure O
or O
renal O
clearance O
of O
methotrexate B-DRUG
. O
ACE B-GROUP
- I-GROUP
inhibitors I-GROUP
: O
Reports O
suggest O
that O
NSAIDs B-GROUP
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE B-GROUP
- I-GROUP
inhibitors I-GROUP
. O
This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
BEXTRA B-BRAND
concomitantly O
with O
ACE B-GROUP
- I-GROUP
inhibitors I-GROUP
. O
Furosemide B-DRUG
: O
Clinical O
studies O
, O
as O
well O
as O
post O
- O
marketing O
observations O
, O
have O
shown O
that O
NSAIDs B-GROUP
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-DRUG
and O
thiazides B-GROUP
in O
some O
patients O
. O
This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O

prostaglandin O
synthesis O
. O
Anticonvulsants B-GROUP
( O
Phenytoin B-DRUG
) O
: O
Steady O
state O
plasma O
exposure O
( O
AUC O
) O
of O
valdecoxib B-DRUG
( O
40 O
mg O
BID O
for O
12 O
days O
) O
was O
decreased O
by O
27 O
% O
when O
co O
- O
administered O
with O
multiple O
doses O
( O
300 O
mg O
QD O
for O
12 O
days O
) O
of O
phenytoin B-DRUG
( O
a O
CYP O
3A4 O
inducer O
) O
. O
Patients O
already O
stabilized O
on O
valdecoxib B-DRUG
should O
be O
closely O
monitored O
for O
loss O
of O
symptom O
control O
with O
phenytoin B-DRUG
coadministration O
. O
Valdecoxib B-DRUG
did O
not O
have O
a O
statistically O
significant O
effect O
on O
the O
pharmacokinetics O
of O
phenytoin B-DRUG
( O
a O
CYP O
2C9 O
and O
CYP O
2C19 O
substrate O
) O
. O
Drug O
interaction O
studies O
with O
other O
anticonvulsants B-GROUP
have O
not O
been O
conducted O
. O
Routine O
monitoring O
should O
be O
performed O
when O
therapy O
with O
BEXTRA B-BRAND
is O
either O
initiated O
or O
discontinued O
in O
patients O
on O
anticonvulsant O
therapy O
. O
Dextromethorphan B-DRUG
: O
Dextromethorphan B-DRUG
is O
primarily O
metabolized O
by O
CYP O
2D6 O
and O
to O
a O
lesser O
extent O
by O
3A4 O
. O
Coadministration O
with O
valdecoxib B-DRUG
( O
40 O
mg O
BID O
for O
7 O
days O
) O
resulted O
in O
a O
significant O
increase O
in O
dextromethorphan B-DRUG
plasma O
levels O
suggesting O
that O
, O
at O
these O
doses O
, O
valdecoxib B-DRUG
is O
a O
weak O
inhibitor O
of O
2D6 O
. O
Even O
so O
dextromethorphan B-DRUG
plasma O
concentrations O
in O
the O
presence O
of O
high O
doses O
of O
valdecoxib B-DRUG
were O
almost O
5 O
- O
fold O
lower O
than O
those O
seen O
in O
CYP O
2D6 O
poor O
metabolizers O
suggesting O
that O
dose O
adjustment O
is O
not O
necessary O
. O
Lithium B-DRUG
: O
Valdecoxib B-DRUG
40 O
mg O
BID O
for O
7 O
days O
produced O
significant O
decreases O
in O
lithium B-DRUG
serum O
clearance O
( O
25 O
% O
) O
and O
renal O
clearance O
( O
30 O
% O
) O
with O
a O
34 O
% O
higher O
serum O
exposure O
compared O
to O
lithium B-DRUG
alone O
. O
Lithium B-DRUG
serum O
concentrations O
should O
be O
monitored O
closely O
when O
initiating O
or O
changing O
therapy O
with O
BEXTRA B-BRAND
in O
patients O
receiving O
lithium B-DRUG
. O
Lithium B-DRUG
carbonate I-DRUG
( O
450 O
mg O
BID O
for O
7 O
days O
) O
had O
no O
effect O
on O
valdecoxib B-DRUG
pharmacokinetics O
. O
Warfarin B-DRUG
: O
The O
effect O
of O
valdecoxib B-DRUG
on O
the O
anticoagulant O
effect O
of O
warfarin B-DRUG
( O
1 O
- O
8 O
mg O
/ O
day O
) O
was O
studied O
in O
healthy O
subjects O
by O
coadministration O
of O
BEXTRA B-BRAND
40 O
mg O
BID O
for O
7 O
days O
. O
Valdecoxib B-DRUG
caused O

a O
statistically O
significant O
increase O
in O
plasma O
exposures O
of O
R B-DRUG
- I-DRUG
warfarin I-DRUG
and O
S B-DRUG
- I-DRUG
warfarin I-DRUG
( O
12 O
% O
and O
15 O
% O
, O
respectively O
) O
, O
and O
in O
the O
pharmacodynamic O
effects O
( O
prothrombin O
time O
, O
measured O
as O
INR O
) O
of O
warfarin B-DRUG
. O
While O
mean O
INR O
values O
were O
only O
slightly O
increased O
with O
coadministration O
of O
valdecoxib B-DRUG
, O
the O
day O
- O
to O
- O
day O
variability O
in O
individual O
INR O
values O
was O
increased O
. O
Anticoagulant B-BRAND
therapy O
should O
be O
monitored O
, O
particularly O
during O
the O
first O
few O
weeks O
, O
after O
initiating O
therapy O
with O
BEXTRA B-BRAND
in O
patients O
receiving O
warfarin B-DRUG
or O
similar O
agents O
. O
Fluconazole B-DRUG
and O
Ketoconazole B-DRUG
: O
Ketoconazole B-DRUG
and O
fluconazole B-DRUG
are O
predominantly O
CYP O
3A4 O
and O
2C9 O
inhibitors O
, O
respectively O
. O
Concomitant O
single O
dose O
administration O
of O
valdecoxib B-DRUG
20 O
mg O
with O
multiple O
doses O
of O
ketoconazole B-DRUG
and O
fluconazole B-DRUG
produced O
a O
significant O
increase O
in O
exposure O
of O
valdecoxib B-DRUG
. O
Plasma O
exposure O
( O
AUC O
) O
to O
valdecoxib B-DRUG
was O
increased O
62 O
% O
when O
coadministered O
with O
fluconazole B-DRUG
and O
38 O
% O
when O
coadministered O
with O
ketoconazole B-DRUG
. O
Glyburide B-DRUG
: O
Glyburide B-DRUG
is O
a O
CYP O
2C9 O
substrate O
. O
Coadministration O
of O
valdecoxib B-DRUG
( O
10 O
mg O
BID O
for O
7 O
days O
) O
with O
glyburide B-DRUG
( O
5 O
mg O
QD O
or O
10 O
mg O
BID O
) O
did O
not O
affect O
the O
pharmacokinetics O
( O
exposure O
) O
of O
glyburide B-DRUG
. O
Coadministration O
of O
valdecoxib B-DRUG
( O
40 O
mg O
BID O
( O
day O
1 O
) O
and O
40 O
mg O
QD O
( O
days O
2 O
- O
7 O
) O
) O
with O
glyburide B-DRUG
( O
5 O
mg O
QD O
) O
did O
not O
affect O
either O
the O
pharmacokinetics O
( O
exposure O
) O
or O
the O
pharmacodynamics O
( O
blood O
glucose O
and O
insulin O
levels O
) O
of O
glyburide B-DRUG
. O
Coadministration O
of O
valdecoxib B-DRUG
( O
40 O
mg O
BID O
( O
day O
1 O
) O
and O
40 O
mg O
QD O
( O
days O
2 O
- O
7 O
) O
) O
with O
glyburide B-DRUG
( O
10 O
mg O
glyburide B-DRUG
BID O
) O
resulted O
in O
21 O
% O
increase O
in O
glyburide B-DRUG
AUC0 O
- O
12 O
and O
a O
16 O
% O
increase O
in O
glyburide B-DRUG
Cmax O
leading O
to O
a O
16 O
% O
decrease O
in O
glucose O
AUC0 O
- O
24 O
. O
Insulin O
parameters O
were O
not O
affected O
. O
Because O
changes O
in O
glucose O
concentrations O
with O

valdecoxib B-DRUG
coadministration O
were O
within O
the O
normal O
variability O
and O
individual O
glucose O
concentrations O
were O
above O
or O
near O
70 O
mg O
/ O
dL O
, O
dose O
adjustment O
for O
glyburide B-DRUG
( O
5 O
mg O
QD O
and O
10 O
mg O
BID O
) O
with O
valdecoxib B-DRUG
coadministration O
( O
up O
to O
40 O
mg O
QD O
) O
is O
not O
indicated O
. O
Coadministration O
of O
glyburide B-DRUG
with O
doses O
higher O
than O
40 O
mg O
valdecoxib B-DRUG
( O
e O
. O
g O
. O
, O
40 O
mg O
BID O
) O
have O
not O
been O
studied O
. O
Omeprazole B-DRUG
: O
Omeprazole B-DRUG
is O
a O
CYP O
3A4 O
substrate O
and O
CYP O
2C19 O
substrate O
and O
inhibitor O
. O
Valdecoxib B-DRUG
steady O
state O
plasma O
concentrations O
( O
40 O
mg O
BID O
) O
were O
not O
affected O
significantly O
with O
multiple O
doses O
of O
omeprazole B-DRUG
( O
40 O
mg O
QD O
) O
. O
Coadministration O
with O
valdecoxib B-DRUG
increased O
exposure O
of O
omeprazole B-DRUG
( O
AUC O
) O
by O
46 O
% O
. O
Drugs O
whose O
absorption O
is O
sensitive O
to O
pH O
may O
be O
negatively O
impacted O
by O
concomitant O
administration O
of O
omeprazole B-DRUG
and O
valdecoxib B-DRUG
. O
However O
, O
because O
higher O
doses O
( O
up O
to O
360 O
mg O
QD O
) O
of O
omeprazole B-DRUG
are O
tolerated O
in O
Zollinger O
- O
Ellison O
( O
ZE O
) O
patients O
, O
no O
dose O
adjustment O
for O
omeprazole B-DRUG
is O
recommended O
at O
current O
doses O
. O
Coadministration O
of O
valdecoxib B-DRUG
with O
doses O
higher O
than O
40 O
mg O
QD O
omeprazole B-DRUG
has O
not O
been O
studied O
. O
Oral O
Contraceptives B-GROUP
: O
Valdecoxib B-DRUG
( O
40 O
mg O
BID O
) O
did O
not O
induce O
the O
metabolism O
of O
the O
combination O
oral O
contraceptive B-GROUP
norethindrone B-DRUG
/ O
ethinyl B-DRUG
estradiol I-DRUG
( O
1 O
mg O
/ O
35 O
mcg O
combination O
, O
Ortho B-BRAND
- I-BRAND
Novum I-BRAND
1 O
/ O
35 O
) O
. O
Coadministration O
of O
valdecoxib B-DRUG
and O
Ortho B-BRAND
- I-BRAND
Novum I-BRAND
1 O
/ O
35 O
increased O
the O
exposure O
of O
norethindrone B-DRUG
and O
ethinyl B-DRUG
estradiol I-DRUG
by O
20 O
% O
and O
34 O
% O
, O
respectively O
. O
Although O
there O
is O
little O
risk O
for O
loss O
of O
contraceptive O
efficacy O
, O
the O
clinical O
significance O
of O
these O
increased O
exposures O
in O
terms O
of O
safety O
is O
not O
known O
. O
These O
increased O
exposures O
of O
norethindrone B-DRUG
and O
ethinyl B-DRUG
estradiol I-DRUG
should O
be O
taken O
into O
consideration O
when O
selecting O
an O
oral O
contraceptive B-GROUP
for O
women O
taking O
valdecoxib B-DRUG
. O
Diazepam B-DRUG
: O
Diazepam B-DRUG
( O
Valium B-BRAND
) O
is O
a O
CYP O
3A4 O
and O
CYP O
2C19 O
substrate O
. O
Plasma O
exposure O
of O

diazepam B-DRUG
( O
10 O
mg O
BID O
) O
was O
increased O
by O
28 O
% O
following O
administration O
of O
valdecoxib B-DRUG
( O
40 O
mg O
BID O
) O
for O
12 O
days O
, O
while O
plasma O
exposure O
of O
valdecoxib B-DRUG
( O
40 O
mg O
BID O
) O
was O
not O
substantially O
increased O
following O
administration O
of O
diazepam B-DRUG
( O
10 O
mg O
BID O
) O
for O
12 O
days O
. O
Although O
the O
magnitude O
of O
changes O
in O
diazepam B-DRUG
plasma O
exposure O
when O
coadministered O
with O
valdecoxib B-DRUG
were O
not O
sufficient O
to O
warrant O
dosage O
adjustments O
, O
patients O
may O
experience O
enhanced O
sedative O
side O
effects O
caused O
by O
increased O
exposure O
of O
diazepam B-DRUG
under O
this O
circumstance O
. O
Patients O
should O
be O
cautioned O
against O
engaging O
in O
hazardous O
activities O
requiring O
complete O
mental O
alertness O
such O
as O
operating O
machinery O
or O
driving O
a O
motor O
vehicle O
. O

Effect O
of O
other O
drugs O
on O
Vardenafil B-DRUG
In O
vitro O
studies O
: O
Studies O
in O
human O
liver O
microsomes O
showed O
that O
vardenafil B-DRUG
is O
metabolized O
primarily O
by O
cytochrome O
P450 O
( O
CYP O
) O
isoforms O
3A4 O
/ O
5 O
, O
and O
to O
a O
lesser O
degree O
by O
CYP2C9 O
. O
Therefore O
, O
inhibitors O
of O
these O
enzymes O
are O
expected O
to O
reduce O
vardenafil B-DRUG
clearance O
. O
In O
vivo O
studies O
: O
Cytochrome O
P450 O
Inhibitors O
Cimetidine B-DRUG
( O
400 O
mg O
b O
. O
i O
. O
d O
. O
) O
had O
no O
effect O
on O
vardenafil B-DRUG
bioavailability O
( O
AUC O
) O
and O
maximum O
concentration O
( O
Cmax O
) O
of O
vardenafil B-DRUG
when O
co O
- O
administered O
with O
20 O
mg O
Vardenafil B-DRUG
in O
healthy O
volunteers O
. O
Erythromycin B-DRUG
( O
500 O
mg O
t O
. O
i O
. O
d O
) O
produced O
a O
4 O
- O
fold O
increase O
in O
vardenafil B-DRUG
AUC O
and O
a O
3 O
- O
fold O
increase O
in O
Cmax O
when O
co O
- O
administered O
with O
Vardenafil B-DRUG
5 O
mg O
in O
healthy O
volunteers O
. O
It O
is O
recommended O
not O
to O
exceed O
a O
single O
5 O
mg O
dose O
of O
Vardenafil B-DRUG
in O
a O
24 O
- O
hour O
period O
when O
used O
in O
combination O
with O
erythromycin B-DRUG
. O
Ketoconazole B-DRUG
( O
200 O
mg O
once O
daily O
) O
produced O
a O
10 O
- O
fold O
increase O
in O
vardenafil B-DRUG
AUC O
and O
a O
4 O
- O
fold O
increase O
in O
Cmax O
when O
co O
- O
administered O
with O
Vardenafil B-DRUG
( O
5 O
mg O
) O
in O
healthy O
volunteers O
. O
A O
5 O
- O
mg O
Vardenafil B-DRUG
dose O
should O
not O
be O
exceeded O
when O
used O
in O
combination O
with O
200 O
mg O
once O
daily O
ketoconazole B-DRUG
. O
Since O
higher O
doses O
of O
ketoconazole B-DRUG
( O
400 O
mg O
daily O
) O
may O
result O
in O
higher O
increases O
in O
Cmax O
and O
AUC O
, O
a O
single O
2 O
. O
5 O
mg O
dose O
of O
Vardenafil B-DRUG
should O
not O
be O
exceeded O
in O
a O
24 O
- O
hour O
period O
when O
used O
in O
combination O
with O
ketoconazole B-DRUG
400 O
mg O
daily O
. O
HIV B-GROUP
Protease I-GROUP
Inhibitors I-GROUP
: O
Indinavir B-DRUG
( O
800 O
mg O
t O
. O
i O
. O
d O
. O
) O
co O
- O
administered O
with O
Vardenafil B-DRUG
10 O
mg O
resulted O
in O
a O
16 O
- O
fold O
increase O
in O
vardenafil B-DRUG
AUC O
, O
a O
7 O
- O
fold O
increase O
in O
vardenafil B-DRUG
Cmax O
and O
a O
2 O
- O
fold O
increase O
in O
vardenafil B-DRUG
half O
- O
life O
. O
It O
is O
recommended O
not O
to O
exceed O
a O
single O
2 O
. O
5 O
mg O
Vardenafil B-DRUG
dose O
in O
a O
24 O
- O
hour O
period O
when O
used O
in O
combination O
with O
indinavir B-DRUG
. O
Ritonavir B-DRUG
( O
600 O
mg O
b O
. O
i O
. O
d O
. O
) O
co O
- O

administered O
with O
Vardenafil B-DRUG
5 O
mg O
resulted O
in O
a O
49 O
- O
fold O
increase O
in O
vardenafil B-DRUG
AUC O
and O
a O
13 O
- O
fold O
increase O
in O
vardenafil B-DRUG
Cmax O
. O
The O
interaction O
is O
a O
consequence O
of O
blocking O
hepatic O
metabolism O
of O
vardenafil B-DRUG
by O
ritonavir B-DRUG
, O
a O
highly O
potent O
CYP3A4 O
inhibitor O
, O
which O
also O
inhibits O
CYP2C9 O
. O
Ritonavir B-DRUG
significantly O
prolonged O
the O
half O
- O
life O
of O
vardenafil B-DRUG
to O
26 O
hours O
. O
Consequently O
, O
it O
is O
recommended O
not O
to O
exceed O
a O
single O
2 O
. O
5 O
mg O
Vardenafil B-DRUG
dose O
in O
a O
72 O
- O
hour O
period O
when O
used O
in O
combination O
with O
ritonavir B-DRUG
. O
Other O
Drug O
Interactions O
: O
No O
pharmacokinetic O
interactions O
were O
observed O
between O
vardenafil B-DRUG
and O
the O
following O
drugs O
: O
glyburide B-DRUG
, O
warfarin B-DRUG
, O
digoxin B-DRUG
, O
Maalox B-BRAND
, O
and O
ranitidine B-DRUG
. O
In O
the O
warfarin B-DRUG
study O
, O
vardenafil B-DRUG
had O
no O
effect O
on O
the O
prothrombin O
time O
or O
other O
pharmacodynamic O
parameters O
. O
Effects O
of O
Vardenafil B-DRUG
on O
other O
drugs O
In O
vitro O
studies O
: O
Vardenafil B-DRUG
and O
its O
metabolites O
had O
no O
effect O
on O
CYP1A2 O
, O
2A6 O
, O
and O
2E1 O
( O
Ki O
100uM O
) O
. O
Weak O
inhibitory O
effects O
toward O
other O
isoforms O
( O
CYP2C8 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
3A4 O
) O
were O
found O
, O
but O
Ki O
values O
were O
in O
excess O
of O
plasma O
concentrations O
achieved O
following O
dosing O
. O
The O
most O
potent O
inhibitory O
activity O
was O
observed O
for O
vardenafil O
metabolite O
M1 O
, O
which O
had O
a O
Ki O
of O
1 O
. O
4 O
uM O
toward O
CYP3A4 O
, O
which O
is O
about O
20 O
times O
higher O
than O
the O
M1 O
Cmax O
values O
after O
an O
80 O
mg O
Vardenafil B-DRUG
dose O
. O
In O
vivo O
studies O
: O
Nitrates B-GROUP
: O
The O
blood O
pressure O
lowering O
effects O
of O
sublingual O
nitrates B-GROUP
( O
0 O
. O
4 O
mg O
) O
taken O
1 O
and O
4 O
hours O
after O
vardenafil B-DRUG
and O
increases O
in O
heart O
rate O
when O
taken O
at O
1 O
, O
4 O
and O
8 O
hours O
were O
potentiated O
by O
a O
20 O
mg O
dose O
of O
Vardenafil B-DRUG
in O
healthy O
middle O
- O
aged O
subjects O
. O
These O
effects O
were O
not O
observed O
when O
Vardenafil B-DRUG
20 O
mg O
was O
taken O
24 O
hours O
before O
the O
NTG B-DRUG
. O
Potentiation O
of O
the O
hypotensive O
effects O
of O
nitrates B-GROUP
for O
patients O
with O
ischemic O
heart O
disease O
has O
not O
been O
evaluated O
, O
and O
concomitant O
use O
of O
Vardenafil B-DRUG
and O
nitrates B-GROUP

is O
contraindicated O
. O
Nifedipine B-DRUG
: O
Vardenafil B-DRUG
20 O
mg O
, O
when O
co O
- O
administered O
with O
slow O
- O
release O
nifedipine B-DRUG
30 O
mg O
or O
60 O
mg O
once O
daily O
, O
did O
not O
affect O
the O
relative O
bioavailability O
( O
AUC O
) O
or O
maximum O
concentration O
( O
Cmax O
) O
of O
nifedipine B-DRUG
, O
a O
drug O
that O
is O
metabolized O
via O
CYP3A4 O
. O
Nifedipine B-DRUG
did O
not O
alter O
the O
plasma O
levels O
of O
Vardenafil B-DRUG
when O
taken O
in O
combination O
. O
In O
these O
patients O
whose O
hypertension O
was O
controlled O
with O
nifedipine B-DRUG
, O
Vardenafil B-DRUG
20 O
mg O
produced O
mean O
additional O
supine O
systolic O
/ O
diastolic O
blood O
pressure O
reductions O
of O
6 O
/ O
5 O
mm O
Hg O
compared O
to O
placebo O
. O
Alpha B-GROUP
- I-GROUP
blockers I-GROUP
: O
When O
Vardenafil B-DRUG
10 O
or O
20 O
mg O
was O
given O
to O
healthy O
volunteers O
either O
simultaneously O
or O
6 O
hours O
after O
a O
10 O
mg O
dose O
of O
terazosin B-DRUG
, O
significant O
hypotension O
developed O
in O
a O
substantial O
number O
of O
subjects O
. O
With O
simultaneous O
dosing O
of O
Vardenafil B-DRUG
10 O
mg O
and O
terazosin B-DRUG
10 O
mg O
, O
6 O
of O
8 O
subjects O
experienced O
a O
standing O
systolic O
blood O
pressure O
of O
less O
than O
85 O
mm O
Hg O
. O
With O
simultaneous O
dosing O
of O
Vardenafil B-DRUG
20 O
mg O
and O
terazosin B-DRUG
10 O
mg O
, O
2 O
of O
9 O
subjects O
experienced O
a O
standing O
systolic O
blood O
pressure O
of O
less O
than O
85 O
mm O
Hg O
. O
When O
Vardenafil B-DRUG
dosing O
was O
separated O
from O
terazosin B-DRUG
10 O
mg O
by O
6 O
hours O
, O
7 O
of O
28 O
subjects O
who O
received O
20 O
mg O
of O
Vardenafil B-DRUG
experienced O
a O
decrease O
in O
standing O
systolic O
blood O
pressure O
below O
85 O
mm O
Hg O
. O
In O
a O
similar O
study O
with O
tamsulosin B-DRUG
in O
healthy O
volunteers O
, O
1 O
of O
24 O
subjects O
dosed O
with O
Vardenafil B-DRUG
20 O
mg O
and O
tamsulosin B-DRUG
0 O
. O
4 O
mg O
separated O
by O
6 O
hours O
experienced O
a O
standing O
systolic O
blood O
pressure O
below O
85 O
mm O
Hg O
. O
Two O
of O
16 O
subjects O
dosed O
simultaneously O
with O
Vardenafil B-DRUG
10 O
mg O
and O
tamsulosin B-DRUG
0 O
. O
4 O
mg O
experienced O
a O
standing O
systolic O
blood O
pressure O
below O
85 O
mm O
Hg O
. O
The O
administration O
of O
lower O
doses O
of O
Vardenafil B-DRUG
with O
alpha B-GROUP
- I-GROUP
blockers I-GROUP
has O
not O
been O
completely O
evaluated O
to O
determine O
if O
they O
can O
be O
safely O
administered O
together O
. O
Based O
on O
these O
data O
, O
Vardenafil B-DRUG
should O
not O
be O
used O
in O
patients O
on O
alpha B-GROUP
- I-GROUP
blocker I-GROUP
therapy O
. O
Ritonavir B-DRUG
and O
indinavir B-DRUG
: O
Upon O
concomitant O
administration O
of O
5 O
mg O
of O
Vardenafil B-DRUG
with O

600 O
mg O
BID O
ritonavir B-DRUG
, O
the O
Cmax O
and O
AUC O
of O
ritonavir B-DRUG
were O
reduced O
by O
approximately O
20 O
% O
. O
Upon O
administration O
of O
10 O
mg O
of O
Vardenafil B-DRUG
with O
800 O
mg O
TID O
indinavir B-DRUG
, O
the O
Cmax O
and O
AUC O
of O
indinavir B-DRUG
were O
reduced O
by O
40 O
% O
and O
30 O
% O
, O
respectively O
. O
Alcohol B-DRUG
: O
Alcohol B-DRUG
( O
0 O
. O
5 O
g O
/ O
kg O
body O
weight O
: O
approximately O
40 O
mL O
of O
absolute O
alcohol O
in O
a O
70 O
kg O
person O
) O
and O
vardenafil B-DRUG
plasma O
levels O
were O
not O
altered O
when O
dosed O
simultaneously O
. O
Vardenafil B-DRUG
( O
20 O
mg O
) O
did O
not O
potentiate O
the O
hypotensive O
effects O
of O
alcohol B-DRUG
during O
the O
4 O
- O
hour O
observation O
period O
in O
healthy O
volunteers O
when O
administered O
with O
alcohol B-DRUG
( O
0 O
. O
5 O
g O
/ O
kg O
body O
weight O
) O
. O
Aspirin B-BRAND
: O
Vardenafil B-DRUG
( O
10 O
mg O
and O
20 O
mg O
) O
did O
not O
potentiate O
the O
increase O
in O
bleeding O
time O
caused O
by O
aspirin B-BRAND
( O
two O
81 O
mg O
tablets O
) O
. O
Other O
interactions O
: O
Vardenafil B-DRUG
had O
no O
effect O
on O
the O
pharmacodynamics O
of O
glyburide B-DRUG
( O
glucose O
and O
insulin O
concentrations O
) O
and O
warfarin B-DRUG
( O
prothrombin O
time O
or O
other O
pharmacodynamic O
parameters O
) O
. O

Zidovudine B-DRUG
: O
There O
is O
no O
significant O
pharmacokinetic O
interaction O
between O
ZDV B-DRUG
and O
zalcitabine B-DRUG
which O
has O
been O
confirmed O
clinically O
. O
Zalcitabine B-DRUG
also O
has O
no O
significant O
effect O
on O
the O
intracellular O
phosphorylation O
of O
ZDV B-DRUG
, O
as O
shown O
in O
vitro O
in O
peripheral O
blood O
mononuclear O
cells O
or O
in O
two O
other O
cell O
lines O
( O
U937 O
and O
Molt O
- O
4 O
) O
. O
In O
the O
same O
study O
it O
was O
shown O
that O
didanosine B-DRUG
and O
stavudine B-DRUG
had O
no O
significant O
effect O
on O
the O
intracellular O
phosphorylation O
of O
zalcitabine B-DRUG
in O
peripheral O
blood O
mononuclear O
cells O
. O
Lamivudine B-DRUG
: O
In O
vitro O
studies O
in O
peripheral O
blood O
mononuclear O
cells O
, O
U937 O
and O
Molt O
- O
4 O
cells O
revealed O
that O
lamivudine B-DRUG
significantly O
inhibited O
zalcitabine B-DRUG
phosphorylation O
in O
a O
dose O
dependent O
manner O
. O
Effects O
were O
already O
seen O
with O
doses O
corresponding O
to O
relevant O
plasma O
levels O
in O
humans O
, O
and O
the O
intracellular O
phosphorylation O
of O
zalcitabine B-DRUG
to O
its O
three O
metabolites O
( O
including O
the O
active O
zalcitabine O
triphosphate O
metabolite O
) O
was O
significantly O
inhibited O
. O
Zalcitabine B-DRUG
inhibited O
lamivudine B-DRUG
phosphorylation O
at O
high O
concentration O
ratios O
( O
10 O
and O
100 O
) O
; O
however O
, O
it O
is O
considered O
to O
be O
unlikely O
that O
this O
decrease O
of O
phosphorylated O
lamivudine B-DRUG
concentration O
is O
of O
clinical O
significance O
, O
as O
lamivudine B-DRUG
is O
a O
more O
efficient O
substrate O
for O
deoxycytidine O
kinase O
than O
zalcitabine B-DRUG
. O
These O
in O
vitro O
studies O
suggest O
that O
concomitant O
administration O
of O
zalcitabine B-DRUG
and O
lamivudine B-DRUG
in O
humans O
may O
result O
in O
sub O
- O
therapeutic O
concentrations O
of O
active O
phosphorylated O
zalcitabine B-DRUG
, O
which O
may O
lead O
to O
a O
decreased O
antiretroviral B-GROUP
effect O
of O
zalcitabine B-DRUG
. O
It O
is O
unknown O
how O
the O
effect O
seen O
in O
these O
in O
vitro O
studies O
translates O
into O
clinical O
consequences O
. O
Concomitant O
use O
of O
zalcitabine B-DRUG
and O
lamivudine B-DRUG
is O
not O
recommended O
. O
Saquinavir B-DRUG
: O
The O
combination O
of O
HIVID B-DRUG
, O
saquinavir B-DRUG
, O
and O
ZDV B-DRUG
has O
been O
studied O
( O
as O
triple O
combination O
) O
in O
adults O
. O
Pharmacokinetic O
data O
suggest O
that O
absorption O
, O
metabolism O
, O
and O
elimination O
of O
each O
of O
these O
drugs O
are O
unchanged O
when O
they O
are O
used O
together O
. O
Drugs O
Associated O
With O
Peripheral O
Neuropathy O
: O
The O
concomitant O
use O
of O

HIVID B-DRUG
with O
drugs O
that O
have O
the O
potential O
to O
cause O
peripheral O
neuropathy O
should O
be O
avoided O
where O
possible O
. O
Drugs O
that O
have O
been O
associated O
with O
peripheral O
neuropathy O
include O
antiretroviral B-DRUG
nucleoside I-DRUG
analogues I-DRUG
, O
chloramphenicol B-DRUG
, O
cisplatin B-DRUG
, O
dapsone B-DRUG
, O
disulfiram B-DRUG
, O
ethionamide B-DRUG
, O
glutethimide B-DRUG
, O
gold B-DRUG
, O
hydralazine B-DRUG
, O
iodoquinol B-DRUG
, O
isoniazid B-DRUG
, O
metronidazole B-DRUG
, O
nitrofurantoin B-DRUG
, O
phenytoin B-DRUG
, O
ribavirin B-DRUG
, O
and O
vincristine B-DRUG
. O
Concomitant O
use O
of O
HIVID B-DRUG
with O
didanosine B-DRUG
is O
not O
recommended O
. O
Intravenous O
Pentamidine B-DRUG
: O
Treatment O
with O
HIVID B-DRUG
should O
be O
interrupted O
when O
the O
use O
of O
a O
drug O
that O
has O
the O
potential O
to O
cause O
pancreatitis O
is O
required O
. O
Death O
due O
to O
fulminant O
pancreatitis O
possibly O
related O
to O
intravenous O
pentamidine B-DRUG
and O
HIVID B-DRUG
has O
been O
reported O
. O
If O
intravenous O
pentamidine B-DRUG
is O
required O
to O
treat O
Pneumocystis O
carinii O
pneumonia O
, O
treatment O
with O
HIVID B-DRUG
should O
be O
interrupted O
. O
Amphotericin B-DRUG
, O
Foscarnet B-DRUG
, O
and O
Aminoglycosides B-GROUP
: O
Drugs O
such O
as O
amphotericin B-DRUG
, O
foscarnet B-DRUG
, O
and O
aminoglycosides B-GROUP
may O
increase O
the O
risk O
of O
developing O
peripheral O
neuropathy O
or O
other O
HIVID B-DRUG
- O
associated O
adverse O
events O
by O
interfering O
with O
the O
renal O
clearance O
of O
zalcitabine B-DRUG
( O
thereby O
raising O
systemic O
exposure O
) O
. O
Patients O
who O
require O
the O
use O
of O
one O
of O
these O
drugs O
with O
HIVID B-DRUG
should O
have O
frequent O
clinical O
and O
laboratory O
monitoring O
with O
dosage O
adjustment O
for O
any O
significant O
change O
in O
renal O
function O
. O
Probenecid B-DRUG
or O
Cimetidine B-DRUG
: O
Concomitant O
administration O
of O
probenecid B-DRUG
or O
cimetidine B-DRUG
decreases O
the O
elimination O
of O
zalcitabine B-DRUG
, O
most O
likely O
by O
inhibition O
of O
renal O
tubular O
secretion O
of O
zalcitabine B-DRUG
. O
Patients O
receiving O
these O
drugs O
in O
combination O
with O
zalcitabine B-DRUG
should O
be O
monitored O
for O
signs O
of O
toxicity O
and O
the O
dose O
of O
zalcitabine B-DRUG
reduced O
if O
warranted O
. O
Magnesium B-DRUG
/ O
Aluminum B-DRUG
- O
containing O
Antacid B-GROUP
Products I-GROUP
: O
Absorption O
of O
zalcitabine B-DRUG
is O
moderately O
reduced O
( O
approximately O
25 O
% O
) O
when O
coadministered O
with O
magnesium B-DRUG
/ O
aluminum B-DRUG
- O
containing O
antacid B-GROUP
products I-GROUP
. O
The O
clinical O
significance O
of O
this O
reduction O
is O
not O
known O
, O
hence O
zalcitabine B-DRUG
is O
not O
recommended O
to O
be O
ingested O
simultaneously O
with O
magnesium B-DRUG

/ O
aluminum B-DRUG
- O
containing O
antacids B-GROUP
. O
Metoclopramide B-DRUG
: O
Bioavailability O
is O
mildly O
reduced O
( O
approximately O
10 O
% O
) O
when O
zalcitabine B-DRUG
and O
metoclopramide B-DRUG
are O
coadministered O
. O
Doxorubicin B-DRUG
: O
Doxorubicin B-DRUG
caused O
a O
decrease O
in O
zalcitabine B-DRUG
phosphorylation O
( O
50 O
% O
inhibition O
of O
total O
phosphate O
formation O
) O
in O
U937 O
/ O
Molt O
4 O
cells O
. O
Although O
there O
may O
be O
decreased O
zalcitabine B-DRUG
activity O
because O
of O
lessened O
active O
metabolite O
formation O
, O
the O
clinical O
relevance O
of O
these O
in O
vitro O
results O
are O
not O
known O
. O

As O
with O
all O
drugs O
, O
the O
potential O
exists O
for O
interaction O
with O
other O
drugs O
by O
a O
variety O
of O
mechanisms O
. O
CNS O
- O
Active O
Drugs O
Ethanol B-DRUG
: O
Sonata B-BRAND
10 O
mg O
potentiated O
the O
CNS O
- O
impairing O
effects O
of O
ethanol B-DRUG
0 O
. O
75 O
g O
/ O
kg O
on O
balance O
testing O
and O
reaction O
time O
for O
1 O
hour O
after O
ethanol B-DRUG
administration O
and O
on O
the O
digit O
symbol O
substitution O
test O
( O
DSST O
) O
, O
symbol O
copying O
test O
, O
and O
the O
variability O
component O
of O
the O
divided O
attention O
test O
for O
2 O
. O
5 O
hours O
after O
ethanol B-DRUG
administration O
. O
The O
potentiation O
resulted O
from O
a O
CNS O
pharmacodynamic O
interaction O
; O
zaleplon B-DRUG
did O
not O
affect O
the O
pharmacokinetics O
of O
ethanol B-DRUG
. O
Imipramine B-DRUG
: O
Coadministration O
of O
single O
doses O
of O
Sonata B-BRAND
20 O
mg O
and O
imipramine B-DRUG
75 O
mg O
produced O
additive O
effects O
on O
decreased O
alertness O
and O
impaired O
psychomotor O
performance O
for O
2 O
to O
4 O
hours O
after O
administration O
. O
The O
interaction O
was O
pharmacodynamic O
with O
no O
alteration O
of O
the O
pharmacokinetics O
of O
either O
drug O
. O
Paroxetine B-DRUG
: O
Coadministration O
of O
a O
single O
dose O
of O
Sonata B-BRAND
20 O
mg O
and O
paroxetine B-DRUG
20 O
mg O
daily O
for O
7 O
days O
did O
not O
produce O
any O
interaction O
on O
psychomotor O
performance O
. O
Additionally O
, O
paroxetine B-DRUG
did O
not O
alter O
the O
pharmacokinetics O
of O
Sonata B-BRAND
, O
reflecting O
the O
absence O
of O
a O
role O
of O
CYP2D6 O
in O
zaleplon B-DRUG
s O
metabolism O
. O
Thioridazine B-DRUG
: O
Coadministration O
of O
single O
doses O
of O
Sonata B-BRAND
20 O
mg O
and O
thioridazine B-DRUG
50 O
mg O
produced O
additive O
effects O
on O
decreased O
alertness O
and O
impaired O
psychomotor O
performance O
for O
2 O
to O
4 O
hours O
after O
administration O
. O
The O
interaction O
was O
pharmacodynamic O
with O
no O
alteration O
of O
the O
pharmacokinetics O
of O
either O
drug O
. O
Venlafaxine B-DRUG
: O
Coadministration O
of O
a O
single O
dose O
of O
zaleplon B-DRUG
10 O
mg O
and O
multiple O
doses O
of O
venlafaxine B-DRUG
ER O
( O
extended O
release O
) O
150 O
mg O
did O
not O
result O
in O
any O
significant O
changes O
in O
the O
pharmacokinetics O
of O
either O
zaleplon B-DRUG
or O
venlafaxine B-DRUG
. O
In O
addition O
, O
there O
was O
no O
pharmacodynamic O
interaction O
as O
a O
result O
of O
coadministration O
of O
zaleplon B-DRUG
and O
venlafaxine B-DRUG
ER O
. O
Promethazine B-DRUG
: O
Coadministration O
of O
a O
single O
dose O
of O
zaleplon B-DRUG
and O
promethazine B-DRUG
( O
10 O
and O
25 O
mg O
, O
respectively O
) O
resulted O
in O
a O
15 O
% O
decrease O
in O
maximal O
plasma O
concentrations O
of O
zaleplon B-DRUG
, O
but O
no O
change O
in O
the O
area O

under O
the O
plasma O
concentration O
- O
time O
curve O
. O
However O
, O
the O
pharmacodynamics O
of O
coadministration O
of O
zaleplon B-DRUG
and O
promethazine B-DRUG
have O
not O
been O
evaluated O
. O
Caution O
should O
be O
exercised O
when O
these O
2 O
agents O
are O
coadministered O
. O
Drugs O
That O
Induce O
CYP3A4 O
Rifampin B-DRUG
: O
CYP3A4 O
is O
ordinarily O
a O
minor O
metabolizing O
enzyme O
of O
zaleplon B-DRUG
. O
Multiple O
- O
dose O
administration O
of O
the O
potent O
CYP3A4 O
inducer O
rifampin B-DRUG
( O
600 O
mg O
every O
24 O
hours O
, O
q24h O
, O
for O
14 O
days O
) O
, O
however O
, O
reduced O
zaleplon B-DRUG
Cmax O
and O
AUC O
by O
approximately O
80 O
% O
. O
The O
coadministration O
of O
a O
potent O
CYP3A4 O
enzyme O
inducer O
, O
although O
not O
posing O
a O
safety O
concern O
, O
thus O
could O
lead O
to O
ineffectiveness O
of O
zaleplon B-DRUG
. O
An O
alternative O
non O
- O
CYP3A4 O
substrate O
hypnotic B-GROUP
agent I-GROUP
may O
be O
considered O
in O
patients O
taking O
CYP3A4 O
inducers O
such O
as O
rifampin B-DRUG
, O
phenytoin B-DRUG
, O
carbamazepine B-DRUG
, O
and O
phenobarbital B-DRUG
. O
Drugs O
That O
Inhibit O
CYP3A4 O
CYP3A4 O
is O
a O
minor O
metabolic O
pathway O
for O
the O
elimination O
of O
zaleplon B-DRUG
because O
the O
sum O
of O
desethylzaleplon O
( O
formed O
via O
CYP3A4 O
in O
vitro O
) O
and O
its O
metabolites O
, O
5 B-DRUG_N
- I-DRUG_N
oxo I-DRUG_N
- I-DRUG_N
desethylzaleplon I-DRUG_N
and O
5 B-DRUG_N
- I-DRUG_N
oxo I-DRUG_N
- I-DRUG_N
desethylzaleplon I-DRUG_N
glucuronide I-DRUG_N
, O
account O
for O
only O
9 O
% O
of O
the O
urinary O
recovery O
of O
a O
zaleplon B-DRUG
dose O
. O
Coadministration O
of O
single O
, O
oral O
doses O
of O
zaleplon B-DRUG
with O
erythromycin B-DRUG
( O
10 O
mg O
and O
800 O
mg O
, O
respectively O
) O
, O
a O
strong O
, O
selective O
CYP3A4 O
inhibitor O
produced O
a O
34 O
% O
increase O
in O
zaleplons B-DRUG
maximal O
plasma O
concentrations O
and O
a O
20 O
% O
increase O
in O
the O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
. O
The O
magnitude O
of O
interaction O
with O
multiple O
doses O
of O
erythromycin B-DRUG
is O
unknown O
. O
Other O
strong O
selective O
CYP3A4 O
inhibitors O
such O
as O
ketoconazole B-DRUG
can O
also O
be O
expected O
to O
increase O
the O
exposure O
of O
zaleplon B-DRUG
. O
A O
routine O
dosage O
adjustment O
of O
zaleplon B-DRUG
is O
not O
considered O
necessary O
. O
Drugs O
That O
Inhibit O
Aldehyde O
Oxidase O
The O
aldehyde O
oxidase O
enzyme O
system O
is O
less O
well O
studied O
than O
the O
cytochrome O
P450 O
enzyme O

system O
. O
Diphenhydramine B-DRUG
: O
Diphenhydramine B-DRUG
is O
reported O
to O
be O
a O
weak O
inhibitor O
of O
aldehyde O
oxidase O
in O
rat O
liver O
, O
but O
its O
inhibitory O
effects O
in O
human O
liver O
are O
not O
known O
. O
There O
is O
no O
pharmacokinetic O
interaction O
between O
zaleplon B-DRUG
and O
diphenhydramine B-DRUG
following O
the O
administration O
of O
a O
single O
dose O
( O
10 O
mg O
and O
50 O
mg O
, O
respectively O
) O
of O
each O
drug O
. O
However O
, O
because O
both O
of O
these O
compounds O
have O
CNS O
effects O
, O
an O
additive O
pharmacodynamic O
effect O
is O
possible O
. O
Drugs O
That O
Inhibit O
Both O
Aldehyde O
Oxidase O
and O
CYP3A4 O
Cimetidine B-DRUG
: O
Cimetidine B-DRUG
inhibits O
both O
aldehyde O
oxidase O
( O
in O
vitro O
) O
and O
CYP3A4 O
( O
in O
vitro O
and O
in O
vivo O
) O
, O
the O
primary O
and O
secondary O
enzymes O
, O
respectively O
, O
responsible O
for O
zaleplon B-DRUG
metabolism O
. O
Concomitant O
administration O
of O
Sonata B-BRAND
( O
10 O
mg O
) O
and O
cimetidine B-DRUG
( O
800 O
mg O
) O
produced O
an O
85 O
% O
increase O
in O
the O
mean O
Cmax O
and O
AUC O
of O
zaleplon B-DRUG
. O
An O
initial O
dose O
of O
5 O
mg O
should O
be O
given O
to O
patients O
who O
are O
concomitantly O
being O
treated O
with O
cimetidine B-DRUG
. O
Drugs O
Highly O
Bound O
to O
Plasma O
Protein O
Zaleplon B-DRUG
is O
not O
highly O
bound O
to O
plasma O
proteins O
( O
fraction O
bound O
60 O
% O
15 O
% O
) O
; O
therefore O
, O
the O
disposition O
of O
zaleplon B-DRUG
is O
not O
expected O
to O
be O
sensitive O
to O
alterations O
in O
protein O
binding O
. O
In O
addition O
, O
administration O
of O
Sonata B-BRAND
to O
a O
patient O
taking O
another O
drug O
that O
is O
highly O
protein O
bound O
should O
not O
cause O
transient O
increase O
in O
free O
concentrations O
of O
the O
other O
drug O
. O
Drugs O
with O
a O
Narrow O
Therapeutic O
Index O
Digoxin B-DRUG
: O
Sonata B-BRAND
( O
10 O
mg O
) O
did O
not O
affect O
the O
pharmacokinetic O
or O
pharmacodynamic O
profile O
of O
digoxin B-DRUG
( O
0 O
. O
375 O
mg O
q24h O
for O
8 O
days O
) O
. O
Warfarin B-DRUG
: O
Multiple O
oral O
doses O
of O
Sonata B-BRAND
( O
20 O
mg O
q24h O
for O
13 O
days O
) O
did O
not O
affect O
the O
pharmacokinetics O
of O
warfarin B-DRUG
( O
R O
+ O
) O
- O
or O
( O
S O
- O
) O
- O
enantiomers O
or O
the O
pharmacodynamics O
( O
prothrombin O
time O
) O
following O
a O
single O
25 O
- O
mg O
oral O
dose O
of O
warfarin B-DRUG
. O
Drugs O
That O
Alter O
Renal O
Excretion O
Ibuprofen B-DRUG
: O
Ibuprofen B-DRUG
is O
known O
to O
affect O
renal O
function O
and O
, O
consequently O
, O
alter O
the O
renal O
excretion O
of O
other O
drugs O
. O
There O

was O
no O
apparent O
pharmacokinetic O
interaction O
between O
zaleplon B-DRUG
and O
ibuprofen B-DRUG
following O
single O
dose O
administration O
( O
10 O
mg O
and O
600 O
mg O
, O
respectively O
) O
of O
each O
drug O
. O
This O
was O
expected O
because O
zaleplon B-DRUG
is O
primarily O
metabolized O
and O
renal O
excretion O
of O
unchanged O
zaleplon B-DRUG
accounts O
for O
less O
than O
1 O
% O
of O
the O
administered O
dose O
. O

